"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B1,US 8607680 B1,113-667-721-138-871,2013-12-17,2013,US 201213424774 A,2012-03-20,US 201213424774 A,2012-03-20,Combined dual bevel miter and radial arm saw device,"The combined dual bevel miter and radial arm saw device provides the advantages of both a radial arm saw and a miter saw. The device thereby provides for cross cuts, rip cuts and angle cuts, all simultaneously if desired.",CARR STEVEN,CARR STEVEN,,https://lens.org/113-667-721-138-871,Granted Patent,yes,21,6,1,1,0,B23D45/025;;B23D45/025;;B27B5/201;;B27B5/201;;B27B5/22;;B27B5/22;;Y10T83/7697;;Y10T83/7697;;Y10T83/7734;;Y10T83/7734;;Y10T83/7772;;Y10T83/7772;;Y10T83/8763;;Y10T83/8763,B27B5/20;;B27B5/00,83/486.1;;83/471.3;;83/478;;83/574,0,0,,,,INACTIVE
2,EP,A2,EP 1735168 A2,078-361-663-590-472,2006-12-27,2006,EP 05731602 A,2005-04-08,US 2005/0011847 W;;US 82083304 A,2004-04-08,VEHICLE TRACTION IMPROVEMENT SYSTEM,,VOLVO TRUCKS NORTH AMERICA INC,CARR STEVEN,,https://lens.org/078-361-663-590-472,Patent Application,yes,0,7,4,4,0,B60B39/02;;B60B39/02;;B60B39/04;;B60B39/04,B60S9/00;;B60B39/00;;B60B39/04;;B60C27/00;;B60D1/28;;B60K28/16;;B60R21/00,,1,0,,,See references of WO 2005100054A3,DISCONTINUED
3,WO,A2,WO 2005/100054 A2,040-216-751-689-288,2005-10-27,2005,US 2005/0011847 W,2005-04-08,US 82083304 A,2004-04-08,VEHICLE TRACTION IMPROVEMENT SYSTEM,A traction improvement system for an over-the-road vehicle includes a traction improvement module that sense vehicle hydroplaning and activates ultra-sound wave emitters to disrupt water surface tension in proximity to the tire when hydroplaning is sensed. The emitters direct ultra-sound waves onto the road surface as well as on the tire tread. An optional traction enhancing agent dispenser dispenses deicing solution or grit in proximity to the tire to further enhance traction.,VOLVO TRUCKS NORTH AMERICA INC;;CARR STEVEN,CARR STEVEN,,https://lens.org/040-216-751-689-288,Patent Application,yes,0,1,4,4,0,B60B39/02;;B60B39/02;;B60B39/04;;B60B39/04,B60B39/00;;B60B39/04;;B60C27/00;;B60R21/00,,0,0,,,,PENDING
4,WO,A3,WO 2005/100054 A3,146-786-634-103-522,2007-08-23,2007,US 2005/0011847 W,2005-04-08,US 82083304 A,2004-04-08,VEHICLE TRACTION IMPROVEMENT SYSTEM,A traction improvement system for an over-the-road vehicle includes a traction improvement module that sense vehicle hydroplaning and activates ultra-sound wave emitters to disrupt water surface tension in proximity to the tire when hydroplaning is sensed. The emitters direct ultra-sound waves onto the road surface as well as on the tire tread. An optional traction enhancing agent dispenser dispenses deicing solution or grit in proximity to the tire to further enhance traction.,VOLVO TRUCKS NORTH AMERICA INC;;CARR STEVEN,CARR STEVEN,,https://lens.org/146-786-634-103-522,Search Report,yes,3,0,4,4,0,B60B39/02;;B60B39/02;;B60B39/04;;B60B39/04,B60S9/00;;B60B39/00;;B60B39/04;;B60C27/00;;B60D1/28;;B60K28/16;;B60R21/00,,0,0,,,,PENDING
5,US,S,US D0399716 S,003-158-982-805-421,1998-10-20,1998,US 7707597 F,1997-09-26,US 7707597 F,1997-09-26,Universal wrench,,VALLEY POWER INC,CARR STEVEN H,VALLEY POWER INC (1997-09-25),https://lens.org/003-158-982-805-421,Design Right,yes,6,12,1,1,0,,,D 8 21;;0805,0,0,,,,EXPIRED
6,US,S,US D0935798 S,180-473-175-457-422,2021-11-16,2021,US 201929701885 F,2019-08-15,US 201929701885 F,2019-08-15,Pet waste bag dispenser,,CARR STEVEN CALDWELL,CARR STEVEN CALDWELL,,https://lens.org/180-473-175-457-422,Design Right,no,9,0,1,1,0,,,2002;;D 6518,2,0,,,"Rosetylerr, Dog Poop Bag Barrell, thingiverse.com, Jan. 22, 2014.;;Derringer, Doggie Barrell, dog-milk.com, Jan. 24, 2012.",ACTIVE
7,US,B2,US 6850943 B2,063-011-789-677-19X,2005-02-01,2005,US 24980303 A,2003-05-08,US 24980303 A;;US 41979802 P,2002-10-18,Security system and methodology for providing indirect access control,"A system providing methods for indirect access control is described. When an attempt to access a network by a first application is detected, a determination is made as to whether at least one other application is attempting indirect network access through the first application. If at least one other application is determined to be attempting indirect network access, each such other application is evaluated to determine if it is approved for network access. If each such other application is approved for network access, access to the network is permitted. Otherwise, access to the network is denied.",CHECK POINT SOFTWARE TECH LTD,TEIXEIRA STEVEN L;;CARR CHRISTOPHER,CHECK POINT SOFTWARE TECHNOLOGIES INC (2004-08-05);;ZONE LABS INC (2003-04-25);;ZONE LABS L.L.C (2004-04-13),https://lens.org/063-011-789-677-19X,Granted Patent,yes,74,117,2,2,0,G06F21/554;;G06F21/554;;G06F2221/2145;;G06F2221/2145;;H04L63/0227;;H04L63/0227;;H04L63/0272;;H04L63/0272;;H04L63/08;;H04L63/08;;H04L63/10;;H04L63/10;;H04L63/20;;H04L63/20,G06F21/00;;H04L29/06,707/10;;709/219,3,0,,,"http://home.no.net/svgub/emner/dcomcnfg_side 1, Using Dcomcnfg, May 22-2001, no publisher, pp. 1-5.*;;http://www.software.rockwell.com, Security Server, Dec. 2000, Rockwell Software Products. pp. 1-3.*;;http://www.sei.cmu.edu/str/descriptions/com, Component Object Model (COM), DCOM and related capabilities, 1997-3-2001, pp. 1-11.",EXPIRED
8,US,A1,US 2004/0078591 A1,004-639-529-017-228,2004-04-22,2004,US 24980303 A,2003-05-08,US 24980303 A;;US 41979802 P,2002-10-18,Security System And Methodology For Providing Indirect Access Control,"
   A system providing methods for indirect access control is described. When an attempt to access a network by a first application is detected, a determination is made as to whether at least one other application is attempting indirect network access through the first application. If at least one other application is determined to be attempting indirect network access, each such other application is evaluated to determine if it is approved for network access. If each such other application is approved for network access, access to the network is permitted. Otherwise, access to the network is denied. 
",ZONE LABS INC,TEIXEIRA STEVEN L;;CARR CHRISTOPHER,CHECK POINT SOFTWARE TECHNOLOGIES INC (2004-08-05);;ZONE LABS INC (2003-04-25);;ZONE LABS L.L.C (2004-04-13),https://lens.org/004-639-529-017-228,Patent Application,yes,74,155,2,2,0,G06F21/554;;G06F21/554;;G06F2221/2145;;G06F2221/2145;;H04L63/0227;;H04L63/0227;;H04L63/0272;;H04L63/0272;;H04L63/08;;H04L63/08;;H04L63/10;;H04L63/10;;H04L63/20;;H04L63/20,G06F21/00;;H04L29/06,713/201;;709/225,0,0,,,,EXPIRED
9,US,A1,US 2023/0173356 A1,111-160-096-720-288,2023-06-08,2023,US 202217727291 A,2022-04-22,US 202217727291 A;;US 202117544033 A,2021-12-07,GOLF CLUB HEAD WITH VORTEX GENERATORS,"Golf club heads with improved aerodynamic properties. The golf club head may include a striking face, a sole, a crown, and a plurality of vortex generators positioned in an aft half of the sole or an aft half of the crown. The vortex generators may be positioned on an inlay that is received by a recess of the crown or the sole. The inlay may be manufactured separately from the remainder of the club head body, such as the crown and the sole.",ACUSHNET CO,OGG STEVEN S;;CARR KYLE A,ACUSHNET COMPANY (2022-04-25),https://lens.org/111-160-096-720-288,Patent Application,yes,0,1,1,13,0,A63B60/006;;A63B53/0408;;A63B53/0433;;A63B53/0437;;A63B53/0466;;A63B60/006;;A63B53/0466;;A63B53/0408;;A63B53/0437;;A63B53/0433,A63B60/00;;A63B53/04,,0,0,,,,PENDING
10,KR,A,KR 20230150742 A,116-319-089-708-639,2023-10-31,2023,KR 20230051863 A,2023-04-20,US 202217727291 A,2022-04-22,GOLF CLUB HEAD WITH VORTEX GENERATORS,"공기 역학적 특성이 개선된 골프 클럽 헤드. 골프 클럽 헤드는 타격 페이스, 솔, 크라운, 및 솔의 후미 절반부 또는 크라운의 후미 절반부에 위치 설정된 복수의 와류 발생부를 포함할 수 있다. 와류 발생부는 크라운 또는 솔의 리세스에 의해 수용되는 인레이 상에 위치 설정될 수 있다. 인레이는 크라운 및 솔과 같은 클럽 헤드 본체의 나머지 부분과 별개로 제조될 수 있다.",ACUSHNET CO,OGG STEVEN S;;CARR KYLE A,,https://lens.org/116-319-089-708-639,Patent Application,no,0,0,2,13,0,A63B53/0466;;A63B53/0433;;A63B53/0437;;A63B53/0408;;A63B2225/01,A63B53/04,,0,0,,,,PENDING
11,US,A1,US 2013/0198326 A1,166-557-568-017-314,2013-08-01,2013,US 201313734759 A,2013-01-04,US 201313734759 A;;US 11344905 A;;US 65893705 P,2005-03-04,PERSONALIZED PRELOADING OF DIGITAL CONTENT,"Techniques are described regarding providing consumers with devices on which digital content appropriate for those consumers has been loaded, such as digital media player devices or other consumer devices that are able to play or otherwise present digital media loaded on those devices. In some situations, when a consumer orders such a digital media player or other consumer device from a merchant (or other distributor of the device), the merchant preloads a copy of the device with digital media content before delivering that device to the consumer or other specified recipient, such as digital media items that are automatically selected in a personalized manner for the recipient to whom the device will be sent. This abstract is provided to comply with rules requiring an abstract, and is submitted with the intention that it will not be used to interpret or limit the scope or meaning of the claims.",AMAZON TECH INC;;AMAZON TECH INC,KESSEL STEVEN;;CARR BILL;;HEYWORTH SAMUEL,AMAZON TECHNOLOGIES INC (2013-03-20),https://lens.org/166-557-568-017-314,Patent Application,yes,8,4,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,H04L29/08;;H04N21/24;;H04N21/6332,709/217,2,0,,,"""Join the Capitol Record Club & get 7 stereo albums! (1966) - Click Americana"" (retrieved from http://clickamericana.com/eras/1960s/join-the-capitol-record-club-get-7-stereo-albums-1966, on July 21, 2015, 6 pages);;""The rise and fall of the Columbia House record club - and how we learned to steal music"" (Retrieved from https://steveleeds.wordpress.com/2011/11/17/the-rise-and-fall-of-the-columbia-house-record-club-and-how-we-learned-to-steal-music on July 21, 2015, 7 pages, Brockman et al.)",ACTIVE
12,DE,T2,DE 69016384 T2,082-635-978-181-569,1995-05-24,1995,DE 69016384 T,1990-11-22,US 45130689 A,1989-12-15,Hydrodynamischer Rauchgaswäscher.,,VECTOR TECH GROUP INC,CARR WILLIAM JAMES;;KRUMMEN RAYMOND STEVEN,"ATMI ECOSYS CORP., SAN JOSE, CALIF., US (1998-09-03)",https://lens.org/082-635-978-181-569,Granted Patent,no,0,0,9,9,0,B01D47/08;;B01D53/38;;B01D53/74;;Y10S261/54;;B01D53/18;;B01D53/74;;B01D47/08;;B01D53/38;;Y10S261/54,B01D53/18;;B01D47/08;;B01D53/38;;B01D53/74,,0,0,,,,EXPIRED
13,EP,A2,EP 1866864 A2,054-924-286-478-957,2007-12-19,2007,EP 06769766 A,2006-02-22,US 2006/0006270 W;;US 11344905 A;;US 65893705 P,2005-03-04,PERSONALIZED PRELOADING OF DIGITAL CONTENT,,AMAZON TECH INC,KESSEL STEVEN;;CARR BILL;;HEYWORTH SAMUEL,,https://lens.org/054-924-286-478-957,Patent Application,yes,0,0,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,G06Q99/00;;H04N21/24;;H04N21/6332,,0,0,,,,DISCONTINUED
14,WO,B1,WO 2006/112945 B1,105-772-228-965-78X,2007-06-07,2007,US 2006/0006270 W,2006-02-22,US 65893705 P;;US 11344905 A,2005-03-04,PERSONALIZED PRELOADING OF DIGITAL CONTENT,"Techniques are described regarding providing consumers with devices on which digital content appropriate for those consumers has been loaded, such as digital media player devices or other consumer devices that are able to play or otherwise present digital media loaded on those devices. In some situations, when a consumer orders such a digital media player or other consumer device from a merchant (or other distributor of the device), the merchant preloads a copy of the device with digital media content before delivering that device to the consumer or other specified recipient, such as digital media items that are automatically selected in a personalized manner for the recipient to whom the device will be sent. This abstract is provided to comply with rules requiring an abstract, and is submitted with the intention that it will not be used to interpret or limit the scope or meaning of the claims.",AMAZON TECH INC,KESSEL STEVEN;;CARR BILL;;HEYWORTH SAMUEL,,https://lens.org/105-772-228-965-78X,Patent Application,no,0,0,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,G06Q99/00;;H04N21/24;;H04N21/6332,,0,0,,,,PENDING
15,WO,A3,WO 2006/112945 A3,150-991-035-842-742,2007-04-26,2007,US 2006/0006270 W,2006-02-22,US 65893705 P;;US 11344905 A,2005-03-04,PERSONALIZED PRELOADING OF DIGITAL CONTENT,"Techniques are described regarding providing consumers with devices on which digital content appropriate for those consumers has been loaded, such as digital media player devices or other consumer devices that are able to play or otherwise present digital media loaded on those devices. In some situations, when a consumer orders such a digital media player or other consumer device from a merchant (or other distributor of the device), the merchant preloads a copy of the device with digital media content before delivering that device to the consumer or other specified recipient, such as digital media items that are automatically selected in a personalized manner for the recipient to whom the device will be sent. This abstract is provided to comply with rules requiring an abstract, and is submitted with the intention that it will not be used to interpret or limit the scope or meaning of the claims.",AMAZON TECH INC,KESSEL STEVEN;;CARR BILL;;HEYWORTH SAMUEL,,https://lens.org/150-991-035-842-742,Search Report,yes,3,0,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,G06Q99/00;;H04N21/24;;H04N21/6332,,1,0,,,"""Digital Rights Management"", WIKIPEDIA, 2005, XP008123809, Retrieved from the Internet <URL:http://www.answers.com/topic/digital-rights-management-1>",PENDING
16,US,A,US 4802161 A,015-799-150-761-45X,1989-01-31,1989,US 90805586 A,1986-09-16,US 90805586 A,1986-09-16,Packet bus interface,"The Arbitrated Bus Interface (ABI) is a set of custom LSI circuits which sends and receives minipackets of binary information to and from a data bus. The ABI performs arbitration, address recognition, and buffering required for transmitting and receiving mini-packets of information between the local packet bus and a microprocessor.",GTE COMMUNICATION SYST,BYARS STEVEN J;;CARR WILLIAM N,,https://lens.org/015-799-150-761-45X,Granted Patent,yes,7,48,1,1,0,H04L12/56;;H04L12/56,H04L12/56,370/94,0,0,,,,EXPIRED
17,CA,A1,CA 2599942 A1,038-475-211-806-513,2006-10-26,2006,CA 2599942 A,2006-02-22,US 65893705 P;;US 11344905 A;;US 2006/0006270 W,2005-03-04,PERSONALIZED PRELOADING OF DIGITAL CONTENT,,AMAZON TECH INC,CARR BILL;;HEYWORTH SAMUEL;;KESSEL STEVEN,,https://lens.org/038-475-211-806-513,Patent Application,no,0,0,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,G06Q99/00;;H04N21/24;;H04N21/6332,,0,0,,,,DISCONTINUED
18,JP,A,JP 2011108248 A,144-599-103-019-552,2011-06-02,2011,JP 2010271658 A,2010-12-06,US 65893705 P;;US 11344905 A,2005-03-04,PERSONALIZED PRELOADING OF DIGITAL CONTENT,"<P>PROBLEM TO BE SOLVED: To provide techniques regarding providing consumers with devices on which digital content appropriate for those consumers has been loaded, such as digital media player devices or other consumer devices that are able to play or otherwise present digital media loaded on those devices. <P>SOLUTION: In some situations, when a consumer orders such a digital media player or other consumer device from a merchant (or other distributor of the device), the merchant preloads a copy of the device with digital media content before delivering that device to the consumer or other specified recipient, such as digital media items that are automatically selected in a personalized manner for the recipient to whom the device will be sent. <P>COPYRIGHT: (C)2011,JPO&INPIT",AMAZON TECH INC,KESSEL STEVEN;;CARR BILL;;HEYWORTH SAMUEL,,https://lens.org/144-599-103-019-552,Patent Application,no,5,2,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,G06Q30/00;;G06F17/30;;G10K15/02;;H04N7/173;;H04N21/24;;H04N21/6332,,2,0,,,"JPN6012036377; '特集１ ＰＣ購入サイトを徹底比較する' 日経パソコン ３７３号, 20001113, ｐｐ．１２６-１４７;;JPN6012036377; '特集１ ＰＣ購入サイトを徹底比較する' 日経パソコン ３７３号, 20001113, ｐｐ．１２６-１４７",ACTIVE
19,EP,A4,EP 1866864 A4,162-831-852-568-125,2010-07-07,2010,EP 06769766 A,2006-02-22,US 2006/0006270 W;;US 11344905 A;;US 65893705 P,2005-03-04,PERSONALIZED PRELOADING OF DIGITAL CONTENT,,AMAZON TECH INC,KESSEL STEVEN;;CARR BILL;;HEYWORTH SAMUEL,,https://lens.org/162-831-852-568-125,Search Report,no,4,0,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,G06Q99/00;;H04N21/24;;H04N21/6332,,0,0,,,,DISCONTINUED
20,US,A1,US 2006/0200413 A1,178-744-994-692-696,2006-09-07,2006,US 11344905 A,2005-04-22,US 11344905 A;;US 65893705 P,2005-03-04,Personalized preloading of digital content,"Techniques are described regarding providing consumers with devices on which digital content appropriate for those consumers has been loaded, such as digital media player devices or other consumer devices that are able to play or otherwise present digital media loaded on those devices. In some situations, when a consumer orders such a digital media player or other consumer device from a merchant (or other distributor of the device), the merchant preloads a copy of the device with digital media content before delivering that device to the consumer or other specified recipient, such as digital media items that are automatically selected in a personalized manner for the recipient to whom the device will be sent. This abstract is provided to comply with rules requiring an abstract, and is submitted with the intention that it will not be used to interpret or limit the scope or meaning of the claims.",KESSEL STEVEN;;CARR BILL;;HEYWORTH SAMUEL,KESSEL STEVEN;;CARR BILL;;HEYWORTH SAMUEL,AMAZON TECHNOLOGIES INC (2005-07-22),https://lens.org/178-744-994-692-696,Patent Application,yes,8,63,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,G06Q99/00;;H04N21/24;;H04N21/6332,705/50,0,0,,,,INACTIVE
21,US,A1,US 2014/0244517 A1,030-281-045-451-465,2014-08-28,2014,US 201414221545 A,2014-03-21,US 201414221545 A;;US 201314142204 A;;US 201361769188 P,2013-02-25,Incremental Batch Method for Transforming Event-driven Metrics and Measures within a Map/Reduce Data Center,"A method for a plurality of processors configured to perform steps in a map/reduce network operation adds incremental batch transformation of sequential measures recorded by time periods and uploaded asynchronously from their capture on mobile devices. The method creates and tracks measure states for each measure. The current recurrence of a measure is a transformation of selected past recurrences and measures. Measure state is propagated according to rules. The ID for a current measure is derived from the IDs of its cache measures and the IDs of its trigger measures. A batch incremental enrichment transforms one or more measures from one or more recurrences into at least one output measure that may be transformed again by the same or another batch incremental enrichment. The apparatus determines if the value needs to be overwritten with a newer value by the type of transformation, the recurrence id and the state.",CARR STEVEN R;;LACEY BRUCE BLAINE;;CARRIER IQ INC,CARR STEVEN R;;LACEY BRUCE BLAINE,CARRIER IQ INC (2016-09-03);;AT&T MOBILITY IP LLC (2015-11-18),https://lens.org/030-281-045-451-465,Patent Application,yes,4,0,1,5,0,H04M2201/18;;H04M3/5175;;H04M3/5175;;H04M2201/18,H04M3/51;;G06Q30/00,705/304,2,0,,,"Peng et al, ""Large-scale Incremental Processing using Distributed Transactions and Notifications"" 2010;;Peng et al, ""Large-scale Incremental Processing using Distributed Transactions and Notifications"" 2010",DISCONTINUED
22,US,A1,US 2011/0185842 A1,138-700-339-397-994,2011-08-04,2011,US 71742210 A,2010-03-04,US 71742210 A;;US 30109010 P,2010-02-03,FLYWHEEL LOCKING TOOL KIT,"A flywheel locking tool kit comprises unitary body blocks designed to fit through and respectively compatible with the opening of a bell housing of a transmission so that teeth provided on one sector of the tool may be engaged with the flywheel teeth and projections and elements of the opposite end of the tool may be engaged with the sides or edges of the opening through the bell housing to retain the tool in a fixed, desired position.",LISLE CORP,WHITEHEAD MICHAEL L;;CARR STEVEN J,LISLE CORPORATION (2010-04-09),https://lens.org/138-700-339-397-994,Patent Application,yes,0,2,1,1,0,G05G5/06;;Y10T74/20636;;Y10T74/20636;;G05G5/06,G05G5/06,74/527,0,0,,,,DISCONTINUED
23,US,A1,US 2012/0011083 A1,104-543-077-638-697,2012-01-12,2012,US 83242310 A,2010-07-08,US 83242310 A,2010-07-08,Product-Centric Automatic Software Identification in z/OS Systems,"A software identification manager selects a unique software module that corresponds to a single knowledge base software product. Next, the software identification manager determines that one or more software modules included in a raw inventory corresponds to the unique software module and, in turn, the software identification manager includes the single knowledge base software product into a refined group of knowledge base software products. The software identification manager then matches one of the knowledge base software products included in the refined group of knowledge base software products to one of the related raw inventory software modules. Once the software identification manager identifies a match, the software identification manager stores a module identification entry in a storage area and associates the matched raw inventory software module to the matched knowledge base software product.",STORMS THOMAS CARR;;YOUCHNOW STEVEN R;;IBM,STORMS THOMAS CARR;;YOUCHNOW STEVEN R,INTERNATIONAL BUSINESS MACHINES CORPORATION (2010-07-07),https://lens.org/104-543-077-638-697,Patent Application,yes,4,6,1,1,0,G06N5/02;;G06N5/022;;G06N5/02;;G06N5/022,G06N5/02;;G06F15/18,706/12;;706/54,5,4,003-121-499-547-937;;119-512-016-225-576;;143-063-466-206-558;;003-182-041-034-40X,10.1002/cpe.670;;10.1109/mahc.2008.29;;10.1007/bfb0095343;;10.1016/j.diin.2006.08.010,"Moore et al., ""NetBuild: transparent cross-platform access to computational software libraries"", Concurrency and Computation: Practice and Experience, Volume 14, Pages 1445-1456, 2002, John Wiley & Sons, LTD;;Grosse et al., ""NetBuild: Automated Installation and Use of Network-Accessible Software Libraries"" Publisher and Date of Publication Unknown;;Dongarra et al., ""Netlib and NA-Net: Building a Scientific Computing Community"", IEEE Annals of the History of Computing, Pages 30-41, 2008, IEEE;;Holmqvist et al., ""NetLink: A Modern Data Distribution Approach Applied to Transparent Access of High Performance Software Libraries"", Applied Parallel Computing Large Scale Scientific and Industrial Problems, Lecture Notes in Computer Science, Volume 1541, Pages 248-254, 1998, Springer Berlin Heidelberg;;Mead , ""Unique file identification in the National Software Reference Library"", Digital Investigation 3, Pages 138-150, Elsevier Ltd., 2006",DISCONTINUED
24,US,B2,US 8370216 B2,188-131-354-504-053,2013-02-05,2013,US 11344905 A,2005-04-22,US 11344905 A;;US 65893705 P,2005-03-04,Personalized preloading of digital content,"Techniques are described regarding providing consumers with devices on which digital content appropriate for those consumers has been loaded, such as digital media player devices or other consumer devices that are able to play or otherwise present digital media loaded on those devices. In some situations, when a consumer orders such a digital media player or other consumer device from a merchant (or other distributor of the device), the merchant preloads a copy of the device with digital media content before delivering that device to the consumer or other specified recipient, such as digital media items that are automatically selected in a personalized manner for the recipient to whom the device will be sent. This abstract is provided to comply with rules requiring an abstract, and is submitted with the intention that it will not be used to interpret or limit the scope or meaning of the claims.",AMAZON TECH INC;;KESSEL STEVEN;;CARR BILL;;HEYWORTH SAMUEL,KESSEL STEVEN;;CARR BILL;;HEYWORTH SAMUEL,AMAZON TECHNOLOGIES INC (2005-07-22),https://lens.org/188-131-354-504-053,Granted Patent,yes,18,11,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,G06Q30/00;;H04N21/24;;H04N21/6332,705/26.7;;705/26.5;;705/50;;705/57,34,0,,,"Apple-iTunes-Store, http://web.archive.org/web/20040202103547/www.apple.com/itunes/store/, 3 pages.;;Napster-terms, http://web.archive.org/web/20040405153036/www.napster.com/terms.html (1 of 8)May 29, 2009 10:57:37 AM, 8 pages.;;Napster | Membership Service Preview, http://web.archive.org/web/20011130122914/www.napster.com/preview/howitworks.html, 2 pages.;;Napster.com, http://web.archive.org/web/20040207143455/http://www.napster.com, 1 page.;;Apple-iTunes-Music Store, The #I music download store. http://www.apple.com/iTunes/store, 2 pages.;;Napster terms (http://web.archive.org/web/20040405153036/www.napster.com/terms.html, 8 pages).;;Apple-iTunes-Store (http://web.archive.org/web/20040202103547/www.apple.com/itunes/store/, 3 pages).;;""Connect With the Future of Medicine Today!,"" Handheldmed®, retrieved Feb. 24, 2005, from http://www.handheldmed.com/, 2 pages.;;""Digital Juke Boxes,"" ADEC, retrieved Feb. 24, 2005, from http://www.adecmusic.com/adecshop/full-size-jukeboxes.htm, 3 pages.;;""HP and Apple Partner to Deliver Digital Music Player and iTunes to HP Customers,"" Apple Computer, Inc., retrieved Feb. 24, 2005, from http://www.apple.com/pr/library/2004/jan/08hp.html, 3 pages.;;""IRiver IFP-790T MP3 Player,"" Tweeter, retrieved Feb. 24, 2005, from http://www.tweeter.com/sm-iriver-ifp-790t-mp3-player--pi-1876379.html, 1 page.;;""Jukebox C,"" Neversoft, retrieved Feb. 17, 2006, from http://neversoft.com.au/nomadc.htm, 2 pages.;;""Ministry Bundles Album with MP3 Player,"" Tech Digest, Nov. 3, 2003, retrieved Feb. 24, 2005, from http://techdigestik.typepad.com/tech-digest/2003/11/ministry-bundle.html, 2 pages.;;""Napster to Go Launches,"" Engadget, Feb. 3, 2005, retrieved Feb. 24, 2005, from http://www.engadget.com/entry/1234000567030228, 19 pages.;;""Napster to Go,"" Napster, retrieved Feb. 24, 2005, from http://www.napster.com/ntg.html, 2 pages.;;""PalmOne MP3 Audio Kit,"" Ascént, retrieved Feb. 24, 2005, from http://www.ascent.co.nz/mn-product-spec.asp?pid=222221, 2 pages.;;""Portable Music,"" Hypebot, retrieved Feb. 24, 2005, from http://hypebot.ypepad.com/hypebot/portable-music/, 47 pages.;;""Preloaded iPods,"" MacSlash, retrieved Feb. 24, 2005, from http://macslash.org/article.pl?sid=04/01/13/0841239, 5 pages.;;""The #1 Music Download Store,"" Apple Computer, Inc., retrieved Feb. 24, 2005, from http://www.apple.com/itunes/store/ 2 pages.;;""TomTom TomTom GO (maps preloaded),"" Vann's, retrieved Feb. 24, 2005, from http://www.vans.com/shop/servlet/item/features/405026789, 2 pages.;;""UNCW Launches First Multi-Campus Peer-to-Peer File Sharing Initiative-UNCW One of Four Test Sites,"" UNCW News, Oct. 14, 2004, retrieved Feb. 24, 2005, from http://appserv02.uncw.edu/news/article.asp?ID=1386, 3 pages.;;""Virgin Player Review,"" MP3 Player Blog, Jan. 5, 2005, retrieved Feb. 24, 2005, from http://www.playerblog.com/archives/000481.shtml, 2 pages.;;""www.AudioBooksForFree.com Entrypoint,"" retrieved Feb. 24, 2005, from http://www.audiobooksforfree.com/, 1 page.;;Bishop, T., ""Microsoft Notebook: Making Music Subscriptions Portable,"" Seattlepi.com, May 3, 2004, retrieved Feb. 24, 2005, from http://seattlepi.nwsource.com/business/171589-msftnotebook03.html, 3 pages.;;Cassavoy, L., ""Listen.com Adds CD Burning to Service-Rhapsody Subscription Service Now Lets Users Transfer Some Tracks to Disc-For a Price,"" PC World Oct. 25, 2002, retrieved Feb. 17, 2006, from http://www.pcworld.com/news/article/0,aid,106380,00.asp, 4 pages.;;Lasky, M., ""100-Plus Hours of Digital Music on the Go-The nomad jukebox has robust features and large storage capacity,"" PC World, Nov. 2000, retrieved Feb. 17, 2006, from http://www.pcworld.com/reviews/article.asp?aid=18591 , 3 pages.;;Naraine, R., ""Windows Media Player on the Fly with 'Janus' DRM-Janus DRM Technology Debuts in WMP 10 Beta,"" Winplanet, retrieved Feb. 24, 2005, from http://www.winplanet.com/article/2367-.htm, 2 pages.;;Rohde, L., ""Gateway sends digital tunes directly to your PC-PC Maker and Pressplay Team for Gateway Music Vault, Which Offers 2,000 Songs Preloaded on Your Hard Drive,"" PC World, Dec. 6, 2002, retrieved Feb. 17, 2006, from http://www.pcworld.com/news/article/0,aid,107735,00.asp, 3 pages.;;Viksnins, R., ""Napster 2.0,"" CNET Reviews, retrieved Feb. 24, 2005, from http://reviews.cnet.com/Napster-2-0/4514-9240-7-30974729.html, 4 pages.;;Wiseman, T., ""The Current Consumer Obsession With a New Generation of Personal Entertainment and Communication Devices Is Causing Airlines to Rethink Their IFE Strategies,"" Ultimate Ears, Nov. 2004, retrieved Feb. 24, 2005, from http://www.ultimateears.com/press-aircraft-interiors.htm, 4 pages.;;Worthington, D., ""Microsoft Remakes DRM for MSN Music Service,"" BetaNews, Mar. 29, 2004, retrieved Feb. 24, 2005, from http://www.betanews.com/article/1080606040, 26 pages.;;Zhang, K., et al., ""FluidMedia: An Offline Peer-to-Peer Media Transaction System,"" HP Laboratories Palo Alto, HPL-2002-342, Dec. 11, 2002, 7 pages.;;""Digital Rights Management"", Wikipedia, Retrieved Nov. 9, 2006, from http://www.answers.com/topic/digital-rights-management-1, 16 pages.;;""Special Topic 1; Thoroughly Comparing PC Purchase Sites,"" Nikkei Personal Computing, No. 373, Nov. 13, 2000, pp. 126-147.",INACTIVE
25,CN,A,CN 101180649 A,194-838-415-684-999,2008-05-14,2008,CN 200680014818 A,2006-02-22,US 2006/0006270 W;;US 65893705 P;;US 11344905 A,2005-03-04,Personalized preloading of digital content,,AMAZON TECH INC,STEVEN KESSEL;;BILL CARR;;SAMUEL HEYWORTH,,https://lens.org/194-838-415-684-999,Patent Application,no,0,6,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,G06Q99/00;;H04N21/24;;H04N21/6332,,0,0,,,,ACTIVE
26,EP,B1,EP 0432538 B1,025-297-272-295-576,1995-01-25,1995,EP 90122315 A,1990-11-22,US 45130689 A,1989-12-15,Hydrodynamic fume scrubber.,,VECTOR TECH GROUP INC,CARR WILLIAM JAMES;;KRUMMEN RAYMOND STEVEN,,https://lens.org/025-297-272-295-576,Granted Patent,yes,3,0,9,9,0,B01D47/08;;B01D53/38;;B01D53/74;;Y10S261/54;;B01D53/18;;B01D53/74;;B01D47/08;;B01D53/38;;Y10S261/54,B01D53/18;;B01D47/08;;B01D53/38;;B01D53/74,,1,0,,,"PATENT ABSTRACTS OF JAPAN, vol. 12, no. 279 (C-517)[3126], 1st August 1988;& JP-A-63 59 337 (FURUKAWA ELECTRIC CO.) 15-03-1988",EXPIRED
27,US,S,US D0441690 S,070-976-567-774-722,2001-05-08,2001,US 11860400 F,2000-02-11,GB 2085746 F;;GB 2085747 F,1999-08-11,Four wheeled vehicle body,,LOTUS CAR,CARR RUSSELL;;HILL MATTHEW;;CRIJNS STEVEN,LOTUS CARS LIMITED (2000-04-10),https://lens.org/070-976-567-774-722,Design Right,yes,4,0,1,1,0,,,D12/87,0,0,,,,EXPIRED
28,WO,A2,WO 2012/058313 A2,026-074-454-538-944,2012-05-03,2012,US 2011/0057894 W,2011-10-26,US 40734510 P,2010-10-27,NOVEL BIOMARKERS FOR CARDIOVASCULAR INJURY,The invention provides methods for the early detection of cardiovascular injury using one or more cardiac injury biomarkers identified herein.,BROAD INST OF MIT AND HARVARD;;GEN HOSPITAL CORPORATIONS D B A MASSACHUSETTS GENERAL HOSPITAL;;GERSZTEN ROBERT;;FIFER MICHAEL;;CARR STEVEN,GERSZTEN ROBERT;;FIFER MICHAEL;;CARR STEVEN,,https://lens.org/026-074-454-538-944,Patent Application,yes,0,7,3,3,0,G01N33/6893;;G01N2800/324;;G01N2800/325;;G01N2800/52;;G01N2800/60;;G01N33/6893;;G01N2800/60;;G01N2800/324;;G01N2800/52;;G01N2800/325;;G01N33/6887,G01N33/53,,0,0,,,,PENDING
29,GB,A,GB 2495738 A,118-779-897-585-075,2013-04-24,2013,GB 201118018 A,2011-10-19,GB 201118018 A,2011-10-19,A vinyl floor edge strip,"The strip comprises an elongate strip 3, 4 having a channel in its upper face in use, characterised in that the channel holds a section of vinyl flooring 1 so to match the vinyl flooring 6 installed in the surrounding area. The strip 3, 4 will be made from clear or transparent plastic, which in use will make the desired floor finish visible through the vinyl floor edge strip along its length, which is intended to therefore minimise the visibility of the vinyl floor edge strip itself. The section of vinyl flooring 1 is held securely in use by wings 2. The edge strip may further comprise a plurality of pieces 3, 4 having complimentary profiles 5, such that in use variation in height may be achieved when joining different floor heights.",CARR STEVEN LAWRENCE;;WYNN SIMON LEE,CARR STEVEN LAWRENCE;;WYNN SIMON LEE,,https://lens.org/118-779-897-585-075,Patent Application,no,4,0,4,4,0,E04F19/02;;E04F19/062;;E04F19/065;;E04F19/061;;E04F19/062;;E04F19/063,E04F19/06;;E04F19/02,,0,0,,,,DISCONTINUED
30,WO,A3,WO 2012/058313 A3,053-824-064-661-647,2012-06-28,2012,US 2011/0057894 W,2011-10-26,US 40734510 P,2010-10-27,NOVEL BIOMARKERS FOR CARDIOVASCULAR INJURY,Described herein are methods for the early detection of cardiovascular injury using one or more cardiac injury biomarkers.,BROAD INST INC;;GEN HOSPITAL CORPORATIONS D B A MASSACHUSETTS GENERAL HOSPITAL;;GERSZTEN ROBERT;;FIFER MICHAEL;;CARR STEVEN,GERSZTEN ROBERT;;FIFER MICHAEL;;CARR STEVEN,,https://lens.org/053-824-064-661-647,Search Report,yes,1,0,3,3,0,G01N33/6893;;G01N2800/324;;G01N2800/325;;G01N2800/52;;G01N2800/60;;G01N33/6893;;G01N2800/60;;G01N2800/324;;G01N2800/52;;G01N2800/325;;G01N33/6887,C12P19/34;;C12Q1/68;;G01N33/53,,2,2,174-888-253-750-171;;000-353-138-882-418,15611012;;pmc1665562;;10.1113/jphysiol.2004.080473;;10.1161/circulationaha.104.482570;;16702488,"ANDERSON: ""Candidate-based proteomics in the search for biomarkers of cardiovascular disease"", J. PHYSIOL., vol. 563.1, 2005, pages 23 - 60, XP003008393, DOI: doi:10.1113/jphysiol.2004.080473;;VASAN: ""Biomarkers of Cardiovascular Disease : Molecular Basis and Practical Considerations"", CIRCULATION, vol. 113, 2006, pages 2335 - 2362",PENDING
31,WO,A8,WO 2013/057522 A8,198-275-396-421-040,2013-06-20,2013,GB 2012053194 W,2012-12-19,GB 201118018 A,2011-10-19,FLOOR EDGE STRIP,"A vinyl floor edge strip is provided with a channel in its uppermost face in use. The channel has a means of holding and bending a section of vinyl flooring so as to match the vinyl flooring installed in the surrounding area. The section of vinyl flooring is held securely in use via wings, and held in such a way as to cover a substantial portion of the floor edge strip with the section of vinyl flooring. The vinyl floor edge strip may be made from clear/transparent plastic so as to make a desired floor finish visible through the vinyl floor edge strip along its length to therefore minimise the visibility of the vinyl floor edge strip itself.",CARR STEVEN LAWRENCE;;WYNN SIMON LEE,CARR STEVEN LAWRENCE;;WYNN SIMON LEE,,https://lens.org/198-275-396-421-040,Amended Application,yes,0,0,4,4,0,E04F19/02;;E04F19/062;;E04F19/065;;E04F19/061;;E04F19/062;;E04F19/063,E04F19/06,,0,0,,,,PENDING
32,DE,D1,DE 69016384 D1,058-038-635-260-446,1995-03-09,1995,DE 69016384 T,1990-11-22,US 45130689 A,1989-12-15,Hydrodynamischer Rauchgaswäscher.,,VECTOR TECH GROUP INC,CARR WILLIAM JAMES;;KRUMMEN RAYMOND STEVEN,"ATMI ECOSYS CORP., SAN JOSE, CALIF., US (1998-09-03)",https://lens.org/058-038-635-260-446,Granted Patent,no,0,0,9,9,0,B01D47/08;;B01D53/38;;B01D53/74;;Y10S261/54;;B01D53/18;;B01D53/74;;B01D47/08;;B01D53/38;;Y10S261/54,B01D53/18;;B01D47/08;;B01D53/38;;B01D53/74,,0,0,,,,EXPIRED
33,WO,A2,WO 2006/112945 A2,156-366-733-879-125,2006-10-26,2006,US 2006/0006270 W,2006-02-22,US 65893705 P;;US 11344905 A,2005-03-04,PERSONALIZED PRELOADING OF DIGITAL CONTENT,"Techniques are described regarding providing consumers with devices on which digital content appropriate for those consumers has been loaded, such as digital media player devices or other consumer devices that are able to play or otherwise present digital media loaded on those devices. In some situations, when a consumer orders such a digital media player or other consumer device from a merchant (or other distributor of the device), the merchant preloads a copy of the device with digital media content before delivering that device to the consumer or other specified recipient, such as digital media items that are automatically selected in a personalized manner for the recipient to whom the device will be sent. This abstract is provided to comply with rules requiring an abstract, and is submitted with the intention that it will not be used to interpret or limit the scope or meaning of the claims.",AMAZON TECH INC,KESSEL STEVEN;;CARR BILL;;HEYWORTH SAMUEL,,https://lens.org/156-366-733-879-125,Patent Application,yes,0,6,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,G06Q99/00;;H04N21/24;;H04N21/6332,,0,0,,,,PENDING
34,JP,A,JP 2023160812 A,134-793-430-198-11X,2023-11-02,2023,JP 2023070388 A,2023-04-21,US 202217727291 A,2022-04-22,GOLF CLUB HEAD WITH VORTEX GENERATORS,"To provide golf club heads with improved aerodynamic properties.SOLUTION: The golf club head may include a striking face, a sole, a crown, and a plurality of vortex generators positioned in an aft half of the sole or an aft half of the crown. The vortex generators may be positioned on an inlay that is received by a recess of the crown or sole. The inlay may be manufactured separately from remaining portions of the club head body, such as the crown and the sole.SELECTED DRAWING: Figure 9",ACUSHNET CO,STEVEN S OGG;;KYLE A CARR,,https://lens.org/134-793-430-198-11X,Patent Application,no,0,0,2,13,0,A63B53/0466;;A63B53/0433;;A63B53/0437;;A63B53/0408;;A63B2225/01,A63B53/04,,0,0,,,,PENDING
35,WO,A3,WO 2006/112945 A3,067-018-071-012-524,2007-06-07,2007,US US2006/006270,2006-02-22,"US 60/6/058,937;;US 11/1/013,449",2005-03-04,PERSONALIZED PRELOADING OF DIGITAL CONTENT,"Techniques are described regarding providing consumers with devices on which digital content appropriate for those consumers has been loaded, such as digital media player devices or other consumer devices that are able to play or otherwise present digital media loaded on those devices. In some situations, when a consumer orders such a digital media player or other consumer device from a merchant (or other distributor of the device), the merchant preloads a copy of the device with digital media content before delivering that device to the consumer or other specified recipient, such as digital media items that are automatically selected in a personalized manner for the recipient to whom the device will be sent. This abstract is provided to comply with rules requiring an abstract, and is submitted with the intention that it will not be used to interpret or limit the scope or meaning of the claims.","AMAZON TECHNOLOGIES, INC.","KESSEL, Steven;;CARR, Bill;;HEYWORTH, Samuel",,https://lens.org/067-018-071-012-524,Search Report,yes,0,0,1,1,0,,G06Q99/00,,0,0,,,,UNKNOWN
36,WO,A1,WO 2013/057522 A1,113-843-010-887-26X,2013-04-25,2013,GB 2012053194 W,2012-12-19,GB 201118018 A,2011-10-19,FLOOR EDGE STRIP,"A vinyl floor edge strip is provided with a channel in its uppermost face in use. The channel has a means of holding and bending a section of vinyl flooring so as to match the vinyl flooring installed in the surrounding area. The section of vinyl flooring is held securely in use via wings, and held in such a way as to cover a substantial portion of the floor edge strip with the section of vinyl flooring. The vinyl floor edge strip may be made from clear/transparent plastic so as to make a desired floor finish visible through the vinyl floor edge strip along its length to therefore minimise the visibility of the vinyl floor edge strip itself.",CARR STEVEN LAWRENCE;;WYNN SIMON LEE,CARR STEVEN LAWRENCE;;WYNN SIMON LEE,,https://lens.org/113-843-010-887-26X,Patent Application,yes,2,0,4,4,0,E04F19/061;;E04F19/062;;E04F19/065;;E04F19/063;;E04F19/02;;E04F19/062,E04F19/06,,0,0,,,,PENDING
37,WO,A1,WO 2013/148178 A1,142-364-318-204-035,2013-10-03,2013,US 2013/0030718 W,2013-03-13,US 201261618518 P,2012-03-30,QUANTIFICATION OF POST-TRANSLATIONAL MODIFICATIONS ON HISTONE PROTEINS WITH MASS SPECTROMETRY,Provided is a highly sensitive mass spectrometry based quantitative assay for detecting histone modifications suitable for high throughput use. Also provided is a peptide reference set containing synthetic reference peptides that are direct equivalents of endogenously produced post-translationally modified histone peptides to quantify individual or a combination of histone modifications in a multiplexed manner in biological samples.,BROAD INST INC,CARR STEVEN A;;JAFFE JACOB D,,https://lens.org/142-364-318-204-035,Patent Application,yes,0,12,1,1,629,G01N33/6848;;G01N33/6875;;G01N2440/00,C12Q1/37,,19,18,057-722-115-487-991;;016-673-505-871-635;;024-396-826-800-034;;093-701-738-495-536;;021-103-320-657-380;;060-748-794-887-420;;049-093-633-636-716;;046-789-426-519-011;;054-628-542-928-907;;022-416-799-781-052;;025-721-435-531-01X;;008-142-751-730-392;;017-988-476-564-97X;;043-094-889-380-749;;042-873-603-983-779;;069-777-463-218-37X;;052-378-596-292-607;;001-073-259-897-958,12450536;;10.1016/s1570-0232(02)00631-1;;18957203;;10.1016/j.cell.2008.09.055;;pmc2579750;;22910205;;pmc3741997;;10.1016/b978-0-12-391940-3.00006-8;;10.2174/1875397301005010106;;21966350;;pmc3178935;;10.1586/epr.11.47;;pmc3249422;;21999833;;2074824;;10.1016/0076-6879(90)93423-i;;10.1002/mas.1280070403;;10224676;;10.1002/(sici)1098-2787(1998)17:4<255::aid-mas1>3.3.co;2-w;;10.1002/(sici)1098-2787(1998)17:4<255::aid-mas1>3.0.co;2-4;;10.1016/s1044-0305(01)00211-2;;11322186;;7949336;;10.1002/rcm.1290080916;;10.1016/s0168-1176(97)00218-8;;10.1002/1097-0231(20001230)14:24<2348::aid-rcm175>3.0.co;2-8;;11114049;;10.1021/a1980023+;;9726172;;10.1002/0471721980;;10.1021/pr050266a;;16457588;;22442256;;pmc3418838;;10.1074/mcp.m111.015941;;20147306;;10.1093/bioinformatics/btq054;;pmc2844992;;17446892;;pmc4627699;;10.1038/nprot.2007.106,"ZHANG K ET AL: ""Analysis of core histones by liquid chromatography-mass spectrometry and peptide mapping"", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 783, no. 1, 5 January 2003 (2003-01-05), pages 173 - 179, XP004394192, ISSN: 1570-0232, DOI: 10.1016/S1570-0232(02)00631-1;;DUNCAN ELIZABETH M ET AL: ""Cathepsin L Proteolytically Processes Histone H3 During Mouse Embryonic Stem Cell Differentiation"", October 2008, CELL, VOL. 135, NR. 2, PAGE(S) 284-294, ISSN: 0092-8674, XP002711275;;FORNÉ, I. ET AL.: ""Quantifying histone modifications using mass spectrometry (Prot 51)"", 20 January 2012 (2012-01-20), XP002711276, Retrieved from the Internet <URL:http://www.epigenesys.eu/index.php/en/protcols/histone-modifications-antibodies/251-quantifying-histone-modifications-using-mass-spectrometry> [retrieved on 20130813];;ROTHBART SCOTT B ET AL: ""Peptide microarrays to interrogate the histone code"", METHODS IN ENZYMOLOGY, ACADEM. PRESS, USA, vol. 512, 1 January 2012 (2012-01-01), pages 107 - 135, XP009171346, ISSN: 1557-7988, DOI: 10.1016/B978-0-12-391940-3.00006-8;;ZEE BARRY M ET AL: ""Quantitative proteomic approaches to studying histone modifications."", 2011, CURRENT CHEMICAL GENOMICS 2011, VOL. 5, NR. SUPPL 1, PAGE(S) 106 - 114, ISSN: 1875-3973, XP002711277;;BRITTON LAURA-MAE P ET AL: ""Breaking the histone code with quantitative mass spectrometry"", EXPERT REVIEW OF PROTEOMICS, FUTURE DRUGS, LONDON, GB, vol. 8, no. 5, 1 October 2011 (2011-10-01), pages 631 - 643, XP009171333, ISSN: 1744-8387, DOI: 10.1586/EPR.11.47;;KNAPP, D. R., METHODS ENZYMOLOGY, vol. 193, 1990, pages 314 - 329;;ANDEREGG, R. J., MASS SPECTROM. REV., vol. 7, 1988, pages 395 - 424;;ROTH, K. D. W.; HUANG, Z-H.; SADAGOPAN N; WATSON J. T., MASS SPECTROM. REV., vol. 17, 1998, pages 255 - 274;;SADAGOPAN, N.; WATSON J. T., J. AM. SOC. MASS. SPECTROM., vol. 12, 2001, pages 399 - 409;;JONES, M. B.; JEFFREY, W. A.; HANSEN, H. F.; PAPPIN, D. J. C., RAPID COMMUN. MASS SPECTROM., vol. 8, 1994, pages 737 - 42;;SPENGLER, B.; LUETZENKIRCHEN, F.; METZGER, S.; CHAURAND, P.; KAUFINANN, R.; JEFFERY, W.; BARTLET-JONES, M.; PAPPIN, D. J. C., INT. J MASS SPECTROM. ION PROC., vol. 169/170, 1997, pages 127 - 140;;KEOGH, T.; L,ACEY, M. P.; YOUNGQUIST, R. S., RAPID. COMMUM. MASS SPECTROM., vol. 14, 2000, pages 2348;;BURLINGAME ET AL., ANAL. CHEM., vol. 70, 1998, pages 647 R - 716R;;KINTER; SHERMAN: ""Protein Sequencing and Identification Using Tandem Mass Spectrometry"", 2000, WILEY-INTERSCIENCE;;THOMAS ET AL., JOURNAL OF PROTEOME RESEARCH, vol. 5, 2006, pages 240 - 7;;PEACH, SE ET AL., MOL CELL PROTEOMICS, vol. 11, no. 5, 2012, pages 128 - 37;;MACLEAN ET AL., BIOINFORMATICS, vol. 26, no. 7, 2010, pages 966 - 968;;GARCIA ET AL., NATURE PROTOCOLS, vol. 2, 2007, pages 933 - 938",PENDING
38,KR,A,KR 20080021584 A,177-777-055-491-882,2008-03-07,2008,KR 20077022709 A,2006-02-22,US 11344905 A;;US 65893705 P;;US 2006/0006270 W,2005-03-04,PERSONALIZED PRELOADING OF DIGITAL CONTENT,"Techniques are described regarding providing consumers with devices on which digital content appropriate for those consumers has been loaded, such as digital media player devices or other consumer devices that are able to play or otherwise present digital media loaded on those devices. In some situations, when a consumer orders such a digital media player or other consumer device from a merchant (or other distributor of the device), the merchant preloads a copy of the device with digital media content before delivering that device to the consumer or other specified recipient, such as digital media items that are automatically selected in a personalized manner for the recipient to whom the device will be sent. This abstract is provided to comply with rules requiring an abstract, and is submitted with the intention that it will not be used to interpret or limit the scope or meaning of the claims. ® KIPO & WIPO 2008",AMAZON TECH INC,KESSEL STEVEN;;CARR BILL;;HEYWORTH SAMUEL,,https://lens.org/177-777-055-491-882,Patent Application,no,0,0,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,H04N21/24;;H04N21/6332,,0,0,,,,ACTIVE
39,EP,A1,EP 0432538 A1,176-164-409-120-627,1991-06-19,1991,EP 90122315 A,1990-11-22,US 45130689 A,1989-12-15,Hydrodynamic fume scrubber.,"A self-cleaning, hydrodynamic fume scrubber for scrubbing a gaseous phase effluent with a scrubbing liquid, such as water or a liquid phase scrubbing chemical, includes an inlet stage (18) for receiving the gaseous effluent, a negative pressure generating stage (20) which creates a negative pressure (suction) by spraying a first pressurized component of the scrubbing liquid into a stream of the effluent passing from the inlet device through a tube. A main scrubbing chamber (22) includes one or more hydrodynamic spray assemblies driven by a second pressurized component of the scrubbing liquid for hydrodynamically spraying the scrubbing liquid through an upper region of the chamber; a filter media layer (124) disposed in a central region of the chamber for filtering and mixing the effluent gas and scrubbing liquid thereby to promote dissolution of components within the effluent which are soluble in the scrubbing liquid; a scrubbing liquid, scrubbed gas separation region (126) within the chamber below the filter media means for separating and discharging scrubbed gas effluent collected therein; a splash plate or diverter plate (128) at the lower boundary of the separation region (126) for further breaking up particle masses formed within the scrubbing liquid as it drips from a lower surface of the filter media through the separation region; and, a scrubbing liquid reservoir (130) below the splash plate means in a lowermost region of the chamber for receiving excess scrubbing liquid. The fume scrubber further comprises a scrubbing liquid supply for supplying scrubbing liquid to the scrubber from a source thereof, and a discharge for discharging scrubbing liquid from the reservoir at a flow rate approximating the flow rate of scrubbing liquid incoming from the supply.",VECTOR TECH GROUP INC,CARR WILLIAM JAMES;;KRUMMEN RAYMOND STEVEN,,https://lens.org/176-164-409-120-627,Patent Application,yes,3,4,9,9,0,B01D47/08;;B01D53/38;;B01D53/74;;Y10S261/54;;B01D53/18;;B01D53/74;;B01D47/08;;B01D53/38;;Y10S261/54,B01D53/18;;B01D47/08;;B01D53/38;;B01D53/74,,1,0,,,"PATENT ABSTRACTS OF JAPAN, vol. 12, no. 279 (C-517)[3126], 1st August 1988; & JP-A-63 59 337 (FURUKAWA ELECTRIC CO.) 15-03-1988",EXPIRED
40,US,A1,US 2005/0278270 A1,160-386-679-571-148,2005-12-15,2005,US 86843404 A,2004-06-14,US 86843404 A,2004-06-14,Data services handler,"A data services handler comprises an interface between a data store and applications that supply and consume data, and a real time information director (RTID) that transforms data under direction of polymorphic metadata that defines a security model and data integrity rules for application to the data.",HEWLETT PACKARD DEVELOPMENT CO,CARR STEVEN R;;MUTHUSWAMY VENKATAKRISHNAN;;HAR TUDOR,VALTRUS INNOVATIONS LIMITED (2021-01-21);;HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2004-06-08),https://lens.org/160-386-679-571-148,Patent Application,yes,17,224,2,2,0,G06Q10/10;;G06Q10/10;;Y10S707/99945;;Y10S707/99942;;Y10S707/99943;;Y10S707/99948,G06F17/00,706/25,0,0,,,,ACTIVE
41,US,A1,US 2007/0082898 A1,059-070-118-595-623,2007-04-12,2007,US 55336104 A,2004-04-13,GB 0308511 A;;GB 2004001589 W,2003-04-14,5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases,"The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition mediated by a p38 MAP kinase; the compound being defined by formula (I): wherein: R 1 and R 2 are the same or different and each is selected from hydrogen, C 1-4 hydrocarbyl, halogen and cyano; X is selected from C═O, C═S, C(═O)NH, C(═S)NH, C(═O)O, C(═O)S, C(═S)O and C(═S)S; R 3 is selected from aryl and hetcroaryl groups each having from 5 to 12 ring members, the aryl and heteroaryl groups each being unsubstituted or substituted by one or more substituent groups R 7 selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R a —R b wherein R a is a bond, 0, CO, X 1 C(X 2 ), C(X 2 )X 1 , X 1 C(X 2 )X 1 , S, SO, SO 2 , NR c , SO 2 NR c or NR c SO 2 ; and R b is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 7 ring members, and a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C 1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C 1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO 2 , NR c , X 1 C(X 2 ), C(X 2 )X 1 or X 1 C(X 2 )X 1 ; X 1 is O, S or NR c and X 2 is ═O, ═S or ═NR c ; R c is hydrogen or C 1-4 hydrocarbyl; R 4 is a group YR 5 or a group R 6 ; Y is is NH, O or S; R 5 is selected from (a) carbocyclic and heterocyclic groups having from 3 to 12 ring members; and (b) C 1-8 hydrocarbyl groups optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, amino, mono- or di- C 1-4 hydrocarbylamino, and carbocyclic and heterocyclic groups having from 3 to 12 ring members, wherein one or more carbon atoms of the C 1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO 2 , NR c , X 1 C(X 2 ), C(X 2 )X 1 or X 1 C(X 2 )X 1 , provided that when Y is O, a carbon atom adjacent to the group Y is not replaced by O; and R 6 is a heterocyclic group having from 4 to 12 ring members and containing at least one ring nitrogen atom through which R 6 is linked to the adjacent carbonyl group; wherein the carbocyclic and heterocyclic groups of substituents R 5 and R 6 are each unsubstituted or substituted by one or more substituent groups R 7 as hereinbefore defined. Also provided are novel compounds, pharmaceutical compositions containing the compounds and methods for their preparation.",ASTEX THERAPEUTICS LTD,GILL ADRIAN L;;WOODHEAD STEVEN;;CARR MARIA,ASTEX THERAPEUTICS LTD (2006-10-20),https://lens.org/059-070-118-595-623,Patent Application,yes,3,0,5,5,0,A61P1/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/16;;A61P17/00;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/06;;A61P31/18;;A61P33/06;;A61P37/02;;A61P43/00;;C07D409/12;;C07D409/12;;C07D333/38;;C07D333/38;;C07D409/14;;C07D409/14;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14,A61K31/538;;A61K31/416;;A61K31/4178;;A61K31/4709;;A61K31/4745;;A61K31/496;;A61K31/517;;A61K31/52;;A61K31/522;;A61P29/00;;C07D333/38;;C07D409/02;;C07D409/12;;C07D409/14;;C07D413/02;;C07D417/02;;C07D417/12;;C07D417/14,514/230.5;;514/248;;514/249;;514/263.23;;514/266.2;;514/300;;514/241;;514/256;;514/307;;514/314;;514/362;;514/374;;514/365;;514/397;;514/381;;514/406;;514/372;;514/364;;514/447;;544/105;;544/276;;544/277;;544/236;;544/238;;544/314;;544/331;;544/353;;544/284;;546/122;;546/148;;546/159;;549/68;;548/190;;544/209;;548/215;;548/311.1,0,0,,,,DISCONTINUED
42,US,A1,US 2008/0180656 A1,095-286-471-651-989,2008-07-31,2008,US 62767707 A,2007-01-26,US 62767707 A,2007-01-26,SURFACE CHARACTERISTIC ANALYSIS,"In one embodiment, a system to measure defects on a surface of a wafer and an edge of the wafer using a single tool comprises a scatterometer to identify at least one defect region on the surface and a surface profile height measuring tool to measure one or more characteristics of the surface in the defect region with a surface profile height measuring tool.",KLA TENCOR TECH CORP,MEEKS STEVEN W;;SAPPEY ROMAIN;;CARR TOM,KLA-TENCOR TECHNOLOGIES CORPORATION (2007-02-23),https://lens.org/095-286-471-651-989,Patent Application,yes,95,13,2,2,0,G01B11/306;;G01N21/9501;;G01N21/9503;;G01B11/306;;G01N21/9503;;G01N21/9501,G01B11/30,356/73,0,0,,,,ACTIVE
43,US,B2,US 7313575 B2,108-298-213-211-380,2007-12-25,2007,US 86843404 A,2004-06-14,US 86843404 A,2004-06-14,Data services handler,"A data services handler comprises an interface between a data store and applications that supply and consume data, and a real time information director (RTID) that transforms data under direction of polymorphic metadata that defines a security model and data integrity rules for application to the data.",HEWLETT PACKARD DEVELOPMENT CO,CARR STEVEN R;;MUTHUSWAMY VENKATAKRISHNAN;;HAR TUDOR,VALTRUS INNOVATIONS LIMITED (2021-01-21);;HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2004-06-08),https://lens.org/108-298-213-211-380,Granted Patent,yes,17,390,2,2,0,G06Q10/10;;G06Q10/10;;Y10S707/99945;;Y10S707/99942;;Y10S707/99943;;Y10S707/99948,G06F7/00;;G06F17/00;;G06F15/16,707/104.1;;707/101;;707/102;;709/201,0,0,,,,ACTIVE
44,US,A1,US 2015/0148247 A1,051-161-217-020-289,2015-05-28,2015,US 201314402727 A,2013-05-24,US 201314402727 A;;US 201261651510 P;;US 201361780121 P;;US 2013/0042620 W,2012-05-24,METHODS AND DEVICES FOR TUBERCULOSIS DIAGNOSIS USING BIOMARKER PROFILES,The invention relates to tuberculosis diagnostic methods and devices that measure particular biomarker profiles in subjects and identify a subject having tuberculosis based on such profiles.,BROAD INST INC;;GEN HOSPITAL CORP;;GEN HOSPITAL CORPORATI D B A MASSACHUSETTS GENERAL HOSPITAL,AHMAD RUSHDY;;GILLETTE MICHAEL;;CARR STEVEN A,THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (2013-05-21);;THE BROAD INSTITUTE INC (2013-05-15),https://lens.org/051-161-217-020-289,Patent Application,yes,0,0,3,3,0,G01N33/5695;;A61K39/04;;G01N33/5695;;G01N33/6869;;G01N33/6893;;G01N33/74;;G01N2333/475;;G01N2333/54;;G01N2333/5412;;G01N2333/5421;;G01N2333/7155;;G01N2800/26,G01N33/68;;G01N33/74,506/9;;506/18,0,0,,,,ACTIVE
45,US,A1,US 2014/0045714 A1,039-162-953-950-484,2014-02-13,2014,US 201113881327 A,2011-10-26,US 201113881327 A;;US 40734510 P;;US 2011/0057894 W,2010-10-27,Novel Biomarkers For Cardiovascular Injury,The invention provides methods for the early detection of cardiovascular injury using one or more cardiac injury biomarkers identified herein.,GERSZTEN ROBERT;;FIFER MICHAEL;;CARR STEVEN A,GERSZTEN ROBERT;;FIFER MICHAEL;;CARR STEVEN A,THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (2013-08-16);;THE BROAD INSTITUTE INC (2013-08-07),https://lens.org/039-162-953-950-484,Patent Application,yes,0,11,3,3,54,G01N33/6893;;G01N2800/324;;G01N2800/325;;G01N2800/52;;G01N2800/60;;G01N33/6893;;G01N2800/60;;G01N2800/324;;G01N2800/52;;G01N2800/325;;G01N33/6887,G01N33/68,506/9;;506/12;;435/7.92;;435/7.4;;435/6.11;;435/6.12;;435/287.2;;506/18,1,1,174-888-253-750-171,15611012;;pmc1665562;;10.1113/jphysiol.2004.080473,Anderson. The Journal of physiology 563.1 (2005): 23-60,DISCONTINUED
46,US,B2,US 7554654 B2,067-590-607-458-709,2009-06-30,2009,US 62767707 A,2007-01-26,US 62767707 A,2007-01-26,Surface characteristic analysis,"In one embodiment, a system to measure defects on a surface of a wafer and an edge of the wafer using a single tool comprises a scatterometer to identify at least one defect region on the surface and a surface profile height measuring tool to measure one or more characteristics of the surface in the defect region with a surface profile height measuring tool.",KLA TENCOR CORP,MEEKS STEVEN W;;SAPPEY ROMAIN;;CARR TOM,KLA-TENCOR TECHNOLOGIES CORPORATION (2007-02-23),https://lens.org/067-590-607-458-709,Granted Patent,yes,99,10,2,2,0,G01B11/306;;G01N21/9501;;G01N21/9503;;G01B11/306;;G01N21/9503;;G01N21/9501,G01N21/00,356/237.2;;356/237.3;;356/237.4;;356/237.5;;356/237.6;;356/237.1,0,0,,,,ACTIVE
47,WO,A1,WO 2004/089929 A1,077-396-262-687-541,2004-10-21,2004,GB 2004001589 W,2004-04-13,GB 0308511 A,2003-04-14,5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES,"The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition mediated by a p38 MAP kinase; the compound being defined by formula (I): wherein: R1 and R2 are the same or different and each is selected from hydrogen, C1-4 hydrocarbyl, halogen and cyano; X is selected from C=O, C=S, C(=O)NH, C(=S)NH, C(=O)O, C(=O)S, C(=S)O and C(=S)S; R3 is selected from aryl and heteroaryl groups each having from 5 to 12 ring members, the aryl and heteroaryl groups each being unsubstituted or substituted by one or more substituent groups R7 selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group Ra-Rb wherein Ra is a bond, 0, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2; and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 7 ring members, and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by 0, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; X1 is 0, S or NRc and X2 is =0, =S or =NRc; Rc is hydrogen or C1-4 hydrocarbyl; R4 is a group YR5 or a group R6; Y is is NH, 0 or S; R5 is selected from (a) carbocyclic and heterocyclic groups having from 3 to 12 ring members; and (b) C1-8 hydrocarbyl groups optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, amino, mono- or di- C1-4 hydrocarbylamino, and carbocyclic and heterocyclic groups having from 3 to 12 ring members, wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by 0, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1, provided that when Y is 0, a carbon atom adjacent to the group Y is not replaced by 0; and R6 is a heterocyclic group having from 4 to 12 ring members and containing at least one ring nitrogen atom through which R6 is linked to the adjacent carbonyl group; wherein the carbocyclic and heterocyclic groups of substituents R5 and R6 are each unsubstituted or substituted by one or more substituent groups R7 as hereinbefore defined. Also provided are novel compounds, pharmaceutical compositions containing the compounds and methods for their preparation.",ASTEX TECHNOLOGY LTD;;GILL ADRIAN LIAM;;WOODHEAD STEVEN;;CARR MARIA,GILL ADRIAN LIAM;;WOODHEAD STEVEN;;CARR MARIA,,https://lens.org/077-396-262-687-541,Patent Application,yes,3,31,5,5,0,A61P1/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/16;;A61P17/00;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/06;;A61P31/18;;A61P33/06;;A61P37/02;;A61P43/00;;C07D409/12;;C07D409/12;;C07D333/38;;C07D333/38;;C07D409/14;;C07D409/14;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14,A61P29/00;;C07D333/38;;C07D409/12;;C07D409/14;;C07D417/12;;C07D417/14,,2,2,018-876-077-255-117;;061-322-850-971-749,11992781;;10.1016/s0960-894x(02)00161-0;;10.1002/ardp.19813140905,"U.E.W. LANGE ET AL.: ""Synthesis of Highly potent and Selective Hetaryl Ureas as Integrin avb3-Receptor Antagonists"", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 1379 - 1382, XP002289253;;D. BINDER ET AL.: ""Substituierte 3-Alkoxy-4,5,6,7-tetrahydro-8H-thieno[2,3-b]indole"", ARCH. PHARM., vol. 314, 1981, pages 751 - 757, XP009033934",PENDING
48,US,A1,US 2019/0241880 A1,027-523-024-052-896,2019-08-08,2019,US 201716333185 A,2017-09-13,US 201716333185 A;;US 201662394133 P;;US 2017/0051428 W,2016-09-13,PROXIMITY-DEPENDENT BIOTINYLATION AND USES THEREOF,"The present invention provides fusion proteins, polynucleotides, kits, as well as TALE- or CRISPR-Cas based systems and methods. The present invention relies on proximity-dependent biotinylation, which allows site-directed protein or DNA purification and identification. The present invention provides tools for delineating the genetics of disease mechanism and for the identification of therapeutic targets and markers.",WRIGHT JASON;;BROAD INST INC,CARR STEVEN A;;WRIGHT JASON;;MYERS SAM,THE BROAD INSTITUTE INC (2018-08-15),https://lens.org/027-523-024-052-896,Patent Application,yes,0,0,2,2,201,C12N15/63;;C12Y603/04015;;C12N9/0065;;C12N9/93;;C12N15/102;;C07K2319/09;;C07K2319/85;;C12Y111/01011;;C12N2740/16043;;G16B20/00;;C12N9/22;;G16B15/30;;C12Y603/04015;;C12N9/93;;C12N15/102;;C12N15/63;;C12Y111/01011;;C07K2319/85;;C12N9/0065;;C07K2319/09;;C12N2740/16043;;G16B20/00;;G16B15/30;;C12N9/22;;C12N2310/20;;C12N15/11,C12N9/22;;C12N9/00;;C12N15/10;;C12N15/11;;G16B15/30,,1,1,008-398-997-808-355,pmc7606464;;10.1038/s41467-020-19344-1;;33139742,"Gasiunas, Giedrius, et al. ""A catalogue of biochemically diverse CRISPR-Cas9 orthologs."" Nature communications 11.1 (2020): 5512",PENDING
49,EP,A1,EP 1615907 A1,067-579-190-667-152,2006-01-18,2006,EP 04727048 A,2004-04-13,GB 2004001589 W;;GB 0308511 A,2003-04-14,5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES,,ASTEX THERAPEUTICS LTD,GILL ADRIAN LIAM;;WOODHEAD STEVEN;;CARR MARIA,,https://lens.org/067-579-190-667-152,Patent Application,yes,0,0,5,5,0,A61P1/00;;A61P7/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P11/16;;A61P17/00;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/28;;A61P29/00;;A61P31/00;;A61P31/06;;A61P31/18;;A61P33/06;;A61P37/02;;A61P43/00;;C07D409/12;;C07D409/12;;C07D333/38;;C07D333/38;;C07D409/14;;C07D409/14;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14,A61P29/00;;C07D333/38;;C07D409/12;;C07D409/14;;C07D417/12;;C07D417/14,,1,0,,,See references of WO 2004089929A1,DISCONTINUED
50,WO,A1,WO 2013/177502 A1,148-917-406-462-857,2013-11-28,2013,US 2013/0042620 W,2013-05-24,US 201261651510 P;;US 201361780121 P,2012-05-24,METHODS AND DEVICES FOR TUBERCULOSIS DIAGNOSIS USING BIOMARKER PROFILES,The invention relates to tuberculosis diagnostic methods and devices that measure particular biomarker profiles in subjects and identify a subject having tuberculosis based on such profiles.,BROAD INST INC;;GEN HOSPITAL CORP,AHMAD RUSHDY;;GILLETTE MICHAEL;;CARR STEVEN A,,https://lens.org/148-917-406-462-857,Patent Application,yes,2,8,3,3,0,G01N33/5695;;A61K39/04;;G01N33/5695;;G01N33/6869;;G01N33/6893;;G01N33/74;;G01N2333/475;;G01N2333/54;;G01N2333/5412;;G01N2333/5421;;G01N2333/7155;;G01N2800/26,G01N33/68;;G01N33/58;;G01N35/00,,5,4,014-834-630-627-289;;140-872-851-101-50X;;068-461-162-546-620;;084-207-833-565-985,10.1097/qai.0b013e31822e0d15;;pmc3196770;;21826013;;8073625;;10.1016/0378-1135(94)90055-8;;12150484;;10.1111/j.1365-2249.1993.tb08228.x;;7504602;;pmc1534426,"F. CONRADIE ET AL.: ""Natural Killer cell activation distinguishes M. tuberculosis- mediated Immune reconstitution syndrome (IRIS) from chronic HIV and HIV-MTB co-infection"", J ACQUIR IMMUNE DEFIC SYNDR., vol. 58, no. 3, 1 November 2011 (2011-11-01), pages 309 - 318;;MUHAMMAD JUBAYER RAHMAN.: ""Mucosal immunity against mycobacterial infection"", DOCTORAL THESIS, vol. 4, 2010, STOCKHOLM UNIVERSITY, STOCKHOLM, pages 54 - 55;;J.F.T. GRIFFIN ET AL.: ""Aetiology, pathogenesis and diagnosis of Mycobacterium bovis in deer"", VETERINARY MICROBIOLOGY, vol. 40, 1994, pages 193 - 205;;E. HRABEC ET AL.: ""Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients"", INT J TUBERC LUNG DIS, vol. 6, no. 8, 2002, pages 7, PP. 713 - 719;;C. K. W. LAI ET AL.: ""Circulating adhesion molecules in tuberculosis"", CLIN EXP IMMUNOL, vol. 94, 1993, pages 522 - 526",PENDING
51,WO,A1,WO 2018/053053 A1,136-852-310-914-513,2018-03-22,2018,US 2017/0051428 W,2017-09-13,US 201662394133 P,2016-09-13,PROXIMITY-DEPENDENT BIOTINYLATION AND USES THEREOF,"The present invention provides fusion proteins, polynucleotides, kits, as well as TALE- or CRISPR-Cas based systems and methods. The present invention relies on proximity-dependent biotinylation, which allows site-directed protein or DNA purification and identification. The present invention provides tools for delineating the genetics of disease mechanism and for the identification of therapeutic targets and markers.",BROAD INST INC;;CARR STEVEN A;;WRIGHT JASON;;MYERS SAM,CARR STEVEN A;;WRIGHT JASON;;MYERS SAM,,https://lens.org/136-852-310-914-513,Patent Application,yes,4,20,2,2,201,C12N15/63;;C12Y603/04015;;C12N9/0065;;C12N9/93;;C12N15/102;;C07K2319/09;;C07K2319/85;;C12Y111/01011;;C12N2740/16043;;G16B20/00;;C12N9/22;;G16B15/30;;C12Y603/04015;;C12N9/93;;C12N15/102;;C12N15/63;;C12Y111/01011;;C07K2319/85;;C12N9/0065;;C07K2319/09;;C12N2740/16043;;G16B20/00;;G16B15/30;;C12N9/22;;C12N2310/20;;C12N15/11,A61K48/00;;C12N9/22;;C12N15/63;;C12N15/79;;G16B15/30,,1,1,040-529-381-429-987,10.1080/19491034.2016.1239000;;27676121;;pmc5120596,"SCHMIDTMANN ET AL.: ""Determination of local chromatin composition by CasID"", NUCLEUS, vol. 7, 27 September 2016 (2016-09-27), pages 476 - 484, XP055498312",PENDING
52,US,B2,US 9702886 B2,144-292-517-630-822,2017-07-11,2017,US 201314402727 A,2013-05-24,US 201314402727 A;;US 201261651510 P;;US 201361780121 P;;US 2013/0042620 W,2012-05-24,Methods and devices for tuberculosis diagnosis using biomarker profiles,The invention relates to tuberculosis diagnostic methods and devices that measure particular biomarker profiles in subjects and identify a subject having tuberculosis based on such profiles.,BROAD INST INC;;MASSACHUSETTS GEN HOSPITAL,AHMAD RUSHDY;;GILLETTE MICHAEL;;CARR STEVEN A,THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (2013-05-21);;THE BROAD INSTITUTE INC (2013-05-15),https://lens.org/144-292-517-630-822,Granted Patent,yes,6,1,3,3,0,G01N33/5695;;A61K39/04;;G01N33/5695;;G01N33/6869;;G01N33/6893;;G01N33/74;;G01N2333/475;;G01N2333/54;;G01N2333/5412;;G01N2333/5421;;G01N2333/7155;;G01N2800/26,A61K39/04;;A61K39/00;;G01N33/53;;G01N33/569;;G01N33/68;;G01N33/74,,10,6,014-834-630-627-289;;140-872-851-101-50X;;068-461-162-546-620;;084-207-833-565-985;;090-413-991-610-766;;088-858-720-387-670,10.1097/qai.0b013e31822e0d15;;pmc3196770;;21826013;;8073625;;10.1016/0378-1135(94)90055-8;;12150484;;10.1111/j.1365-2249.1993.tb08228.x;;7504602;;pmc1534426;;19064929;;10.1073/pnas.0810903105;;pmc2604941;;pmc2997816;;20614087;;10.1039/c0an00204f,"International Search Report and Written Opinion for Application No. PCT/US2013/042620 mailed Sep. 12, 2013.;;International Preliminary Report on Patentability for Application No. PCT/US2013/042620 mailed Dec. 4, 2014.;;[No Author Listed], Human Inflammation MAP® v1.0. Myriad RBM. http://rbm.myriad.com/products-services/humanmap-services/human-inflammationmap/ [last accessed Feb. 5, 2015]. 3 pages.;;Conradie et al., Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. Nov. 1, 2011;58(3):309-18. doi: 10.1097/QAI.0b013e31822e0d15. Epub Nov. 1, 2011. 18 pages.;;Griffin et al., Aetiology, pathogenesis and diagnosis of Mycobacterium bovis in deer. Vet Microbiol. May 1994;40(1-2):193-205. Review.;;Hrabec et al., Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int J Tuberc Lung Dis. Aug. 2002;6(8):713-9.;;Lai et al., Circulating adhesion molecules in tuberculosis. Clin Exp Immunol. Dec. 1993;94(3):522-6.;;Martinez et al., Three-dimensional microfluidic devices fabricated in layered paper and tape. Proc Natl Acad Sci U S A. Dec. 16, 2008;105(50):19606-11. doi: 10.1073/pnas.0810903105. Epub Dec. 8, 2008.;;Rahman, Mucosal immunity against mycobacterial infection. Thesis. Stockholm University. 2010;4,54-5.;;Rusling et al., Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. Analyst. Oct. 2010;135(10):2496-511. doi: 10.1039/c0an00204f. Epub Dec. 6, 2010. 31 pages.",ACTIVE
53,EP,A1,EP 3349439 A1,059-994-674-919-262,2018-07-18,2018,EP 17210589 A,2008-12-31,EP 08870076 A;;US 2008/0014136 W;;US 1005008 P,2008-01-04,SYSTEMS AND METHODS FOR SELECTING MEDIA ASSETS FOR DISPLAY IN A SCREEN OF AN INTERACTIVE MEDIA GUIDANCE APPLICATION,"A method and system of selecting assets for display in an interactive media guidance application includes receiving a user input indicating interest in a media item; generating a list of media assets related to the media item, selecting, based on priority rules, a subset of the media assets to display in an interactive media guidance application, and displaying an identifier for each of the subset of media assets in the interactive media guidance application screen. The priority rules may assign a first priority to one type of media asset and a second priority to a second type of media asset, and may be based on: whether the media asset has been viewed, and a respective time associated with the media asset.
",ROVI GUIDES INC,CARR STEVEN;;WHITE CHARLES;;AARON KYLE;;KUNKEL GERALD,,https://lens.org/059-994-674-919-262,Patent Application,yes,6,0,15,15,0,H04N7/163;;H04N7/17318;;H04N21/4532;;H04N21/47202;;H04N21/482;;H04N21/47;;H04N5/445;;H04N21/472;;H04N21/482;;H04N7/173;;H04N7/163;;H04N21/47202;;H04N21/4532;;H04N7/17318;;H04N21/47;;H04N21/482,H04N7/173;;G06F3/0482;;H04N5/445,,0,0,,,,DISCONTINUED
54,CN,B,CN 102046243 B,079-734-984-809-055,2012-11-28,2012,CN 200980119185 A,2009-04-08,GB 2009050346 W;;GB 0806359 A,2008-04-08,Carrying system for breathing apparatus,"A carrying system adapted for use with breathing apparatus suitable for carrying one or more air cylinders for use in emergency situations by people such as fire-fighters and others who may be exposed to contaminated and hostile environments. The carrying system comprises a backplate (11) and a pair of straps (12) adapted to hold the backplate (11) on the back of a user when the carrying system is worn. The backplate (11) comprises at least one plate of a plastics material adapted both to provide impact protection to a user during use by at least partially absorbing and / or dispersing impactforces, and to deform resiliently in response to external forces imposed by bending and / or twisting of a user during use and then return substantially to its predetermined shape when not subjected to an external force.",SCOTT HEALTH & SAFETY LTD,ROBERT CARR;;STEVEN THURGOOD;;BARRY LEWIN;;TONY PICKETT,,https://lens.org/079-734-984-809-055,Granted Patent,no,0,0,16,16,0,A62B9/04;;A62B9/04;;A45F3/10;;A45F3/10;;A45F2003/045;;A45F2003/045;;A62B25/00;;A62B25/00;;B63C11/02;;B63C11/02;;B63C2011/026;;B63C2011/026,A62B25/00,,0,0,,,,INACTIVE
55,NO,A1,NO 20131070 A1,175-537-543-243-014,2013-08-23,2013,NO 20131070 A,2013-08-06,US 201161444419 P;;US 201213398333 A;;US 2012/0025643 W,2011-02-18,Interferometrisk transduser med bredt dynamisk omrade og divergerende stralebunt,"En anordning og en fremgangsmåte for å estimere en parameter av interesse ved bruk av verdier av en strålebuntegenskap fra to eller flere elektromagnetisk strålebunter som begge passerer gjennom i det minste en del av en optisk forskyvningsanordning, er beskrevet. Anordningen kan innbefatte et Fabry-Perot-interferometer, en kollimert lyskilde og en detektorgruppe. Minst ett speil i interferometeret kan være operativt koplet til et element som mottar en ytre stimulus, slik som trykk, kraft og/eller akselerasjon. Fremgangsmåten innbefatter bruk av anordningen.",BAKER HUGHES INC,EDWARDS CARL M;;CARR DUSTIN;;PATTERSON STEVEN R,,https://lens.org/175-537-543-243-014,Patent Application,no,0,0,10,10,0,G01V8/02;;G01V8/02;;G01V8/02,G01V8/10;;G01V3/18,,0,0,,,,DISCONTINUED
56,EP,B1,EP 3346703 B1,189-142-122-309-574,2022-03-16,2022,EP 17210588 A,2008-12-31,EP 08870076 A;;US 2008/0014136 W;;US 1005008 P,2008-01-04,SYSTEMS AND METHODS FOR SELECTING MEDIA ASSETS FOR DISPLAY IN A SCREEN OF AN INTERACTIVE MEDIA GUIDANCE APPLICATION,,ROVI GUIDES INC,CARR STEVEN;;WHITE CHARLES;;AARON KYLE;;KUNKEL GERALD,,https://lens.org/189-142-122-309-574,Granted Patent,yes,6,0,15,15,0,H04N7/163;;H04N7/17318;;H04N21/4532;;H04N21/47202;;H04N21/482;;H04N21/47;;H04N5/445;;H04N21/472;;H04N21/482;;H04N7/173;;H04N7/163;;H04N21/47202;;H04N21/4532;;H04N7/17318;;H04N21/47;;H04N21/482,H04N21/482;;G06F3/0482,,0,0,,,,ACTIVE
57,MX,A,MX 2010010958 A,037-309-069-085-54X,2011-02-22,2011,MX 2010010958 A,2009-04-08,GB 0806359 A;;GB 2009050346 W,2008-04-08,CARRYING SYSTEM FOR BREATHING APPARATUS.,"A carrying system adapted for use with breathing apparatus suitable for carrying one or more air cylinders for use in emergency situations by people such as fire- fighters and others who may be exposed to contaminated and hostile environments. The carrying system comprises a backplate (11) and a pair of straps(12) adapted to hold the backplate (11)on the back of a user when the carrying system is worn. The backplate (11)comprises at least one plate of a plastics material adapted both to provide impact protection to a user during use by at least partially absorbing and / or dispersing impact forces, and to deform resiliently in response to external forces imposed by bending and / or twisting of a user during use and then return substantially to its predetermined shape when not subjected to an external force.",SCOTT HEALTH & SAFETY LTD,CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY,,https://lens.org/037-309-069-085-54X,Patent Application,no,0,0,16,16,0,A62B9/04;;A62B9/04;;A45F3/10;;A45F3/10;;A45F2003/045;;A45F2003/045;;A62B25/00;;A62B25/00;;B63C11/02;;B63C11/02;;B63C2011/026;;B63C2011/026,A62B25/00,,0,0,,,,ACTIVE
58,WO,A1,WO 2009/125223 A1,168-455-881-473-493,2009-10-15,2009,GB 2009050346 W,2009-04-08,GB 0806359 A,2008-04-08,CARRYING SYSTEM FOR BREATHING APPARATUS,"A carrying system adapted for use with breathing apparatus suitable for carrying one or more air cylinders for use in emergency situations by people such as fire- fighters and others who may be exposed to contaminated and hostile environments. The carrying system comprises a backplate (11) and a pair of straps(12) adapted to hold the backplate (11)on the back of a user when the carrying system is worn. The backplate (11)comprises at least one plate of a plastics material adapted both to provide impact protection to a user during use by at least partially absorbing and / or dispersing impact forces, and to deform resiliently in response to external forces imposed by bending and / or twisting of a user during use and then return substantially to its predetermined shape when not subjected to an external force.",SCOTT HEALTH & SAFETY LTD;;CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY,CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY,,https://lens.org/168-455-881-473-493,Patent Application,yes,7,1,16,16,0,A45F3/10;;A45F2003/045;;A62B25/00;;B63C11/02;;B63C2011/026;;A62B9/04;;A45F3/10;;A45F2003/045;;A62B25/00;;B63C11/02;;B63C2011/026;;A62B9/04,A62B25/00,,0,0,,,,PENDING
59,US,B2,US 9344499 B2,151-805-441-287-62X,2016-05-17,2016,US 201313734759 A,2013-01-04,US 201313734759 A;;US 11344905 A;;US 65893705 P,2005-03-04,Personalized preloading of digital content,"Techniques are described regarding providing consumers with devices on which digital content appropriate for those consumers has been loaded, such as digital media player devices or other consumer devices that are able to play or otherwise present digital media loaded on those devices. In some situations, when a consumer orders such a digital media player or other consumer device from a merchant (or other distributor of the device), the merchant preloads a copy of the device with digital media content before delivering that device to the consumer or other specified recipient, such as digital media items that are automatically selected in a personalized manner for the recipient to whom the device will be sent. This abstract is provided to comply with rules requiring an abstract, and is submitted with the intention that it will not be used to interpret or limit the scope or meaning of the claims.",AMAZON TECH INC,KESSEL STEVEN;;CARR WILLIAM DUGALD;;HEYWORTH SAMUEL STEVENS,AMAZON TECHNOLOGIES INC (2013-03-20),https://lens.org/151-805-441-287-62X,Granted Patent,yes,27,1,17,17,0,G06Q30/02;;G06Q30/06;;G06Q30/0621;;G06Q50/10;;G06Q30/06;;G06Q20/123;;G06Q20/1235;;G06Q30/0621;;G06Q30/02;;G06Q30/06;;H04L67/1097,G06Q99/00;;G06Q20/12;;G06Q30/02;;G06Q30/06;;H04L29/08;;H04N21/24;;H04N21/6332,,35,1,101-943-455-541-774,10.1145/957013.957040,"""Join the Capitol Record Club & get 7 stereo albums! (1966)-Click Americana"" (retrieved from http://clickamericana.com/eras/1960s/join-the-capitol-record-club-get-7-stereo-albums-1966, on Jul. 21, 2015, 6 pages).;;""The rise and fall of the Columbia House record club-and how we learned to steal music"" (Retrieved from https://steveleeds.wordpress.com/2011/11/17/the-rise-and-fall-of-the-columbia-house-record-club-and-how-we-learned-to-steal-music on Jul. 21, 2015, 7 pages, Brockman et al.).;;""Connect With the Future of Medicine Today!,"" Handheldmed®, retrieved Feb. 24, 2005, from http://www.handheldmed.com/, 2 pages.;;""Digital Juke Boxes,"" ADEC, retrieved Feb. 24, 2005, from http://www.adecmusic.com/adecshop/full-size-jukeboxes.htm, 3 pages.;;""HP and Apple Partner to Deliver Digital Music Player and iTunes to HP Customers,"" Apple Computer, Inc., Jan. 8, 2004, retrieved Feb. 24, 2005, from http://www.apple.com/pr/library/2004/jan/08hp.html, 3 pages.;;""IRiver IFP-790T MP3 Player,"" Tweeter, retrieved Feb. 24, 2005, from http://www.tweeter.com/sm-iriver-ifp-790t-mp3-player--pi-1876379.html, 1 page.;;""Jukebox C,"" Neversoft, retrieved Feb. 17, 2006, from http://neversoft.com.au/nomadc.htm, 2 pages.;;""Ministry Bundles Album with MP3 Player,"" Tech Digest, Nov. 3, 2003, retrieved Feb. 24, 2005, from http://techdigestik.typepad.com/tech-digest/2003/11/ministry-bundle.html, 2 pages.;;""Napster to Go Launches,"" Engadget, Feb. 3, 2005, retrieved Feb. 24, 2005, from http://www.engadget.com/entry/1234000567030228, 19 pages.;;""Napster to Go,"" Napster, retrieved Feb. 24, 2005, from http://www.napster.com/ntg.html, 2 pages.;;""PalmOne MP3 Audio Kit,"" Ascént, retrieved Feb. 24, 2005, from http://www.ascent.co.nz/mn-product-spec.asp?pid=222221, 2 pages.;;""Portable Music,"" Hypebot, retrieved Feb. 24, 2005, from http://hypebot.ypepad.com/hypebot/portable-music/, 47 pages.;;""Preloaded iPods,"" MacSlash, retrieved Feb. 24, 2005, from http://macslash.org/article.pl?sid=04/01/13/0841239, 5 pages.;;""The #1 Music Download Store,"" Apple Computer, Inc., retrieved Feb. 24, 2005, from http://www.apple.com/itunes/store/ 2 pages.;;""TomTom TomTom Go (maps preloaded),"" Vann's, retrieved Feb. 24, 2005, from http://www.vans.com/shop/servlet/item/features/405026789, 2 pages.;;""UNCW Launches First Multi-Campus Peer-to-Peer File Sharing Initiative-UNCW One of Four Test Sites,"" UNCW News, Oct. 14, 2004, retrieved Feb. 24, 2005, from http://appserv02.uncw.edu/news/article.asp?ID=1386, 3 pages.;;""Virgin Player Review,"" MP3 Player Blog, Jan. 5, 2005, retrieved Feb. 24, 2005, from http://www.playerblog.com/archives/000481.shtml, 2 pages.;;""www.AudioBooksForFree.com Entrypoint,"" retrieved Feb. 24, 2005, from http://www.audiobooksforfree.com/, 1 page.;;Bishop, T., ""Microsoft Notebook: Making Music Subscriptions Portable,"" Seattlepi.com, May 3, 2004, retrieved Feb. 24, 2005, from http://seattlepi.nwsource.com/business/171589-msftnotebook03.html, 3 pages.;;Cassavoy, L., ""Listen.com Adds CD Burning to Service-Rhapsody Subscription Service Now Lets Users Transfer Some Tracks to Disc-for a Price,"" PC World, Oct. 25, 2002 retrieved Feb. 17, 2006, from http://www.pcworld.com/news/article/0,aid,106380,00.asp, 4 pages.;;Lasky, M., ""100-Plus Hours of Digital Music on the Go-The nomad jukebox has robust features and large storage capacity,"" PC World, Nov. 2000, retrieved Feb. 17, 2006, from http://www.pcworld.com/reviews/article.asp?aid=18591, 3 pages.;;Naraine, R., ""Windows Media Player on the Fly with 'Janus' DRM-Janus DRM Technology Debuts in WMP 10 Beta,"" Winplanet, retrieved Feb. 24, 2005, from http://www.winplanet.com/article/2367-.htm, 2 pages.;;Rohde, L., ""Gateway sends digital tunes directly to your PC-PC Maker and Pressplay Team for Gateway Music Vault, Which Offers 2,000 Songs Preloaded on Your Hard Drive,"" PC World, Dec. 6, 2002, retrieved Feb. 17, 2006, from http://www.pcworld.com/news/article/0,aid,107735,00.asp, 3 pages.;;Viksnins, R., ""Napster 2.0,"" CNET Reviews, retrieved Feb. 24, 2005, from http://reviews.cnet.com/Napster-2-0/4514-9240-7-30974729.html, 4 pages.;;Wiseman, T., ""The Current Consumer Obsession With a New Generation of Personal Entertainment and Communication Devices is Causing Airlines to Rethink Their IFE Strategies,"" Ultimate Ears, Nov. 2004, retrieved Feb. 24, 2005, from http://www.ultimateears.com/press-aircraft-interiors.htm, 4 pages.;;Worthington, D., ""Microsoft Remakes DRM for MSN Music Service,"" BetaNews, Mar. 29, 2004, retrieved Feb. 24, 2005, from http://www.betanews.com/article/1080606040, 26 pages.;;Zhang, K., et al., ""FluidMedia: An Offline Peer-to-Peer Media Transaction System,"" HP Laboratories Palo Alto, HPL-2002-342, Dec. 11, 2002, http://www.hpl.hp.com/techreports/2002/HPL-2002-342.pdf, 7 pages.;;""Special Topic 1; Thoroughly Comparing PC Purchase Sites,"" Nikkei Personal Computing, No. 373, Nov. 13, 2000, pp. 126-147.;;""Digital Rights Management"", Wikipedia, Retrieved Nov. 9, 2006, from http://www.answers.com/topic/digital-rights-management-1, 16 pages.;;Apple-iTunes-Store, http://web.archive.org/web/20040202103547/www.apple.come/itunes/store, accessed May 29, 2009, 3 pages.;;Napster-Terms and Conditions, http://web.archive.org/web/20040405153036/www.napster.com/terms.html, accessed May 29, 2009, 8 pages.;;Napster-Membership Service Preview, http://web.archive.org/web/20011130122914/www.napster.com/preview/howitworks.html, accessed May 29, 2009, 2 pages.;;Napster.com, http://web.archive.org/web/20040207143455/http://www.napster.com, accessed May 29, 2009, 1 page.;;Apple-iTunes-Music Store, various pages, Apple Computer, Inc., 2004, retrieved Sep. 27, 2013, from www.apple.com/itunes/store, 6 pages.;;Hoashi et al., ""Personalization of User Profiles for Content-based Music Retrieval Based on Relevance Feedback,"" Proceedings of the Eleventh ACM International Conference on Multimedia, Berkeley, CA, Nov. 2-8, 2003, pp. 110-119.",ACTIVE
60,DE,T2,DE 3883015 T2,195-035-118-438-369,1994-03-24,1994,DE 3883015 T,1988-11-16,US 8804088 W;;US 24518688 A,1988-09-16,VERFAHREN UND VORRICHTUNG ZUR MESSUNG VON VERBRENNUNGSVORGÄNGEN IN EINER BRENNKRAFTMASCHINE.,,CATERPILLAR INC,MCCOY STEVEN;;STEVENSON THOMAS;;CARR DOUGLAS;;KING KEVIN,,https://lens.org/195-035-118-438-369,Granted Patent,no,0,0,10,10,0,F02P5/152;;G01L23/225;;Y02T10/40;;F02P5/152;;G01L23/225;;Y02T10/40,F02D45/00;;F02P5/04;;F02P5/152;;F02P5/153;;F02P5/155;;G01L23/22,,0,0,,,,EXPIRED
61,US,B2,US 8464293 B2,085-218-492-617-627,2013-06-11,2013,US 34748108 A,2008-12-31,US 34748108 A;;US 1005008 P,2008-01-04,Systems and methods for selecting media assets for display in a screen of an interactive media guidance application,"A method and system of selecting assets for display in an interactive media guidance application includes receiving a user input indicating interest in a media item; generating a list of media assets related to the media item, selecting, based on priority rules, a subset of the media assets to display in an interactive media guidance application, and displaying an identifier for each of the subset of media assets in the interactive media guidance application screen. The priority rules may assign a first priority to one type of media asset and a second priority to a second type of media asset, and may be based on: whether the media asset has been viewed, and a respective time associated with the media asset.",CARR STEVEN;;WHITE CHARLES;;KUNKEL GERARD;;AARON KYLE;;ROVI GUIDES INC,CARR STEVEN;;WHITE CHARLES;;KUNKEL GERARD;;AARON KYLE,ROVI GUIDES INC (2010-02-26);;GUIDEWORKS LLC (2009-01-28),https://lens.org/085-218-492-617-627,Granted Patent,yes,34,2,15,15,0,H04N7/163;;H04N7/17318;;H04N21/4532;;H04N21/47202;;H04N21/482;;H04N21/47;;H04N5/445;;H04N21/472;;H04N21/482;;H04N7/173;;H04N7/163;;H04N21/47202;;H04N21/4532;;H04N7/17318;;H04N21/47;;H04N21/482,G06F3/00;;G06F3/0482,725/47;;725/44;;725/45;;725/46;;725/61,12,3,002-807-137-852-600;;021-787-012-170-239;;112-324-970-921-348,10.1109/tce.1979.273227;;10.5594/j01427;;10.1109/tce.1979.273220,"Antonofs, M., ""Stay Tuned for Smart TV,"" Popular Science, Nov. 1990, pp. 62-65.;;Brugliera, Vito, ""Digital On-Screen Display-A New Technology for the Consumer Interface"", Symposium Record Cable Sessions. Jun. 11, 1993, pp. 571-586.;;Compuvid Sales Manual (date unknown).;;Fassihi, Theresa & Bishop, Nancy, ""Cable Guide Courting National Advertisers,"" Adweek, Aug. 8, 1988.;;Manners, George, ""Smart Screens; Development of Personal Navigation Systems for TV Viewers,"" Video Magazine, Dec. 1993.;;Prevue Guide Brochure , Spring, 1994.;;Robinson, G., and Loveless, W., ""Touch-Tone' Teletext-A Combined Teletext-Viewdata System,"" IEEE Transactions on Consumer Electronics, vol. CE-25, No. 3, Jul. 1979, pp. 298-303.;;Roizen, Joseph, ""Teletext in the USA,"" SMPTE Journal, Jul. 1981, pp. 602-610. . Advertisement for ""TV Decision,"" CableVision, Aug. 4, 1986.;;Tanton, N. E., ""UK Teletext-Evolution and Potential,"" IEEE Transactions on Consumer Electronics, vol. CE-25, No. 3, Jul. 1979, pp. 246-250.;;TV Communications Advertisement for MSI Datacasting Systems, Jan. 1973.;;Advertisement for ""TV Decision"", Cablevision, Aug. 4, 1986.;;International Search Report and Written Opinion for PCT/US2008/014136 dated Jul. 4, 2009.",ACTIVE
62,JP,A,JP 2013225917 A,119-965-024-510-352,2013-10-31,2013,JP 2013136377 A,2013-06-28,US 1005008 P,2008-01-04,SYSTEMS AND METHODS FOR SELECTING MEDIA ASSETS DISPLAYED ON SCREEN OF INTERACTIVE MEDIA GUIDANCE APPLICATION,"PROBLEM TO BE SOLVED: To provide systems and methods for selecting media assets displayed on a screen of an interactive media guidance application.SOLUTION: A method and system of selecting assets for display in an interactive media guidance application includes: receiving a user input indicating interest in a media item; generating a list of media assets related to the media item; selecting, based on priority rules, a subset of the media assets to display in an interactive media guidance application; and displaying an identifier for each of the subset of media assets in the interactive media guidance application screen. The priority rules may assign a first priority to one type of media asset and a second priority to a second type of media asset, and may be based at least in part on: whether the media asset has been viewed, and a corresponding time associated with the media asset.",UNITED VIDEO PROPERTIES INC,STEVEN CARR;;CHARLES WHITE;;KYLE AARON;;GERARD KUNKEL,,https://lens.org/119-965-024-510-352,Patent Application,no,8,0,15,15,0,H04N7/163;;H04N7/17318;;H04N21/4532;;H04N21/47202;;H04N21/482;;H04N21/47;;H04N5/445;;H04N21/472;;H04N21/482;;H04N7/173;;H04N7/163;;H04N21/47202;;H04N21/4532;;H04N7/17318;;H04N21/47;;H04N21/482,H04N21/482;;G06F3/0482;;H04N5/445;;H04N21/475,,0,0,,,,PENDING
63,EP,A1,EP 2259846 A1,111-803-636-584-317,2010-12-15,2010,EP 09729495 A,2009-04-08,GB 2009050346 W;;GB 0806359 A,2008-04-08,CARRYING SYSTEM FOR BREATHING APPARATUS,,SCOTT HEALTH & SAFETY LTD,CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY,,https://lens.org/111-803-636-584-317,Patent Application,yes,2,0,16,16,0,A62B9/04;;A62B9/04;;A45F3/10;;A45F3/10;;A45F2003/045;;A45F2003/045;;A62B25/00;;A62B25/00;;B63C11/02;;B63C11/02;;B63C2011/026;;B63C2011/026,A62B25/00,,1,0,,,See also references of WO 2009125223A1,DISCONTINUED
64,US,A1,US 2011/0048421 A1,145-617-924-777-417,2011-03-03,2011,US 93617709 A,2009-04-08,GB 0806359 A;;GB 2009050346 W,2008-04-08,CARRYING SYSTEM FOR BREATHING APPARATUS,"A carrying system is provided for use with breathing apparatus. The carrying system includes a backplate and a plurality of straps adapted to hold the backplate on the back of a user when the carrying system is worn. The backplate includes at least one plate of a plastics material. The at least one plate having a predetermined shape and the at least one plate being adapted to provide impact protection to a user during use by at least partially absorbing and/or dispersing impact forces, and to deform resiliency in response to external forces imposed by bending and/or twisting of a user during use and return substantially to its predetermined shape when not subjected to an external force.",CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY,CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY,SCOTT HEALTH & SAFETY LTD (2010-11-01),https://lens.org/145-617-924-777-417,Patent Application,yes,15,16,16,16,0,A62B9/04;;A62B9/04;;A45F3/10;;A45F3/10;;A45F2003/045;;A45F2003/045;;A62B25/00;;A62B25/00;;B63C11/02;;B63C11/02;;B63C2011/026;;B63C2011/026,A62B9/04;;A45F3/08,128/205.22;;224/633,0,0,,,,ACTIVE
65,ZA,B,ZA 201007167 B,031-295-273-118-078,2011-12-28,2011,ZA 201007167 A,2010-10-07,GB 0806359 A;;GB 2009050346 W,2008-04-08,CARRYING SYSTEM FOR BREATHING APPRATUS,,SCOTT HEALTH & SAFETY LTD,CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY,,https://lens.org/031-295-273-118-078,Granted Patent,no,0,0,16,16,0,A62B9/04;;A62B9/04;;A45F3/10;;A45F3/10;;A45F2003/045;;A45F2003/045;;A62B25/00;;A62B25/00;;B63C11/02;;B63C11/02;;B63C2011/026;;B63C2011/026,A62B/,,0,0,,,,ACTIVE
66,AU,B2,AU 2009/235237 B2,048-098-676-741-571,2014-07-24,2014,AU 2009/235237 A,2009-04-08,GB 0806359 A;;GB 2009050346 W,2008-04-08,Carrying system for breathing apparatus,"A carrying system adapted for use with breathing apparatus suitable for carrying one or more air cylinders for use in emergency situations by people such as fire- fighters and others who may be exposed to contaminated and hostile environments. The carrying system comprises a backplate (11) and a pair of straps(12) adapted to hold the backplate (11)on the back of a user when the carrying system is worn. The backplate (11)comprises at least one plate of a plastics material adapted both to provide impact protection to a user during use by at least partially absorbing and / or dispersing impact forces, and to deform resiliently in response to external forces imposed by bending and / or twisting of a user during use and then return substantially to its predetermined shape when not subjected to an external force.",SCOTT HEALTH & SAFETY LTD,PICKETT TONY;;THURGOOD STEVEN;;LEWIN BARRY;;CARR ROBERT,,https://lens.org/048-098-676-741-571,Granted Patent,no,5,0,16,16,0,A45F3/10;;A45F2003/045;;A62B25/00;;B63C11/02;;B63C2011/026;;A62B9/04;;A45F3/10;;A45F2003/045;;A62B25/00;;B63C11/02;;B63C2011/026;;A62B9/04,A62B25/00,,0,0,,,,INACTIVE
67,KR,A,KR 20100101690 A,199-109-535-490-138,2010-09-17,2010,KR 20107017319 A,2008-12-31,US 1005008 P,2008-01-04,SYSTEMS AND METHODS FOR SELECTING MEDIA ASSETS FOR DISPLAY IN A SCREEN OF AN INTERACTIVE MEDIA GUIDANCE APPLICATION,,UNITED VIDEO PROPERTIES INC,CARR STEVEN;;WHITE CHARLES;;AARON KYLE;;KUNKEL GERARD,,https://lens.org/199-109-535-490-138,Patent Application,no,2,0,15,15,0,H04N7/163;;H04N7/17318;;H04N21/4532;;H04N21/47202;;H04N21/482;;H04N21/47;;H04N5/445;;H04N21/472;;H04N21/482;;H04N7/173;;H04N7/163;;H04N21/47202;;H04N21/4532;;H04N7/17318;;H04N21/47;;H04N21/482,H04N7/173;;G06F3/0482;;H04N5/445,,0,0,,,,ACTIVE
68,US,S,US D0632021 S,087-262-589-985-97X,2011-02-01,2011,US 32593208 F,2008-10-08,EM 09154910000 F,2008-04-09,Harness for carrying breathing apparatus,,SCOTT HEALTH & SAFETY LTD,CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY,SCOTT HEALTH & SAFETY LTD (2008-11-12),https://lens.org/087-262-589-985-97X,Design Right,no,0,1,1,1,0,,,2902;;D29/124,0,0,,,,ACTIVE
69,US,B2,US 10137319 B2,190-439-656-240-324,2018-11-27,2018,US 93617709 A,2009-04-08,GB 0806359 A;;GB 2009050346 W,2008-04-08,Carrying system for breathing apparatus,"A carrying system is provided for use with breathing apparatus. The carrying system includes a backplate and a plurality of straps adapted to hold the backplate on the back of a user when the carrying system is worn. The backplate includes at least one plate of a plastics material. The at least one plate having a predetermined shape and the at least one plate being adapted to provide impact protection to a user during use by at least partially absorbing and/or dispersing impact forces, and to deform resiliency in response to external forces imposed by bending and/or twisting of a user during use and return substantially to its predetermined shape when not subjected to an external force.",CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY;;SCOTT HEALTH & SAFETY LTD,CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY,SCOTT HEALTH & SAFETY LTD (2010-11-01),https://lens.org/190-439-656-240-324,Granted Patent,yes,18,5,16,16,0,A62B9/04;;A62B9/04;;A45F3/10;;A45F3/10;;A45F2003/045;;A45F2003/045;;A62B25/00;;A62B25/00;;B63C11/02;;B63C11/02;;B63C2011/026;;B63C2011/026,A61M16/00;;A45F3/04;;A45F3/10;;A62B9/04;;A62B25/00;;B63C11/02,,0,0,,,,ACTIVE
70,DE,D1,DE 3883015 D1,195-463-631-467-778,1993-09-09,1993,DE 3883015 T,1988-11-16,US 8804088 W;;US 24518688 A,1988-09-16,VERFAHREN UND VORRICHTUNG ZUR MESSUNG VON VERBRENNUNGSVORGAENGEN IN EINER BRENNKRAFTMASCHINE.,,CATERPILLAR INC,MCCOY STEVEN;;STEVENSON THOMAS;;CARR DOUGLAS;;KING KEVIN,,https://lens.org/195-463-631-467-778,Granted Patent,no,0,0,10,10,0,F02P5/152;;G01L23/225;;Y02T10/40;;F02P5/152;;G01L23/225;;Y02T10/40,F02D45/00;;F02P5/04;;F02P5/152;;F02P5/153;;F02P5/155;;G01L23/22,,0,0,,,,EXPIRED
71,EP,A1,EP 2238756 A1,030-544-865-785-761,2010-10-13,2010,EP 08870076 A,2008-12-31,US 2008/0014136 W;;US 1005008 P,2008-01-04,SYSTEMS AND METHODS FOR SELECTING MEDIA ASSETS FOR DISPLAY IN A SCREEN OF AN INTERACTIVE MEDIA GUIDANCE APPLICATION,,UNITED VIDEO PROPERTIES INC,CARR STEVEN;;WHITE CHARLES;;AARON KYLE;;KUNKEL GERARD,"ROVI GUIDES, INC. (2018-01-03);;UNITED VIDEO PROPERTIES, INC. (2011-06-29)",https://lens.org/030-544-865-785-761,Patent Application,yes,0,0,15,15,0,H04N7/163;;H04N7/17318;;H04N21/4532;;H04N21/47202;;H04N21/482;;H04N21/47;;H04N5/445;;H04N21/472;;H04N21/482;;H04N7/173;;H04N7/163;;H04N21/47202;;H04N21/4532;;H04N7/17318;;H04N21/47;;H04N21/482,H04N7/173;;G06F3/0482;;H04N5/445,,0,0,,,,DISCONTINUED
72,US,A1,US 2023/0248814 A1,055-702-435-853-304,2023-08-10,2023,US 202117928649 A,2021-06-01,US 202117928649 A;;US 202063033191 P;;US 2021/0035196 W,2020-06-01,COMPOSITIONS AND METHODS FOR TREATING MERKEL CELL CARCINOMA (MCC) USING HLA CLASS I SPECIFIC EPITOPES,The subject matter disclosed herein is generally directed to epitopes that specifically bind to subject specific HLA class I molecules in MCC. The epitope identified is specific for MCC and is encoded for in the Merkel Cell Polyomavirus (MCPyV) large T antigen (MCPyV LT).,BROAD INST INC;;DANA FARBER CANCER INST INC,WU CATHERINE;;CARR STEVEN;;KLAEGER SUSAN;;KESKIN DERIN,DANA-FARBER CANCER INSTITUTE INC (2022-11-18);;THE BROAD INSTITUTE INC (2021-08-16),https://lens.org/055-702-435-853-304,Patent Application,yes,0,0,3,3,27,A61K39/12;;C12N2710/22034;;A61K2039/585;;A61K2039/876;;Y02A50/30;;A61K39/12;;A61K2039/5154;;C07K14/7051;;C07K16/084,A61K39/12;;C07K14/725;;C07K16/08,,0,0,,,,PENDING
73,CA,A1,CA 2711054 A1,147-114-962-531-467,2009-07-16,2009,CA 2711054 A,2008-12-31,US 1005008 P;;US 2008/0014136 W,2008-01-04,SYSTEMS AND METHODS FOR SELECTING MEDIA ASSETS FOR DISPLAY IN A SCREEN OF AN INTERACTIVE MEDIA GUIDANCE APPLICATION,"A method and system of selecting assets for display in an interactive media guidance application includes receiving a user input indicating interest in a media item; generating a list of media assets related to the media item, selecting, based on priority rules, a subset of the media assets to display in an interactive media guidance application, and displaying an identifier for each of the subset of media assets in the interactive media guidance application screen. The priority rules may assign a first priority to one type of media asset and a second priority to a second type of media asset, and may be based on: whether the media asset has been viewed, and a respective time associated with the media asset.",UNITED VIDEO PROPERTIES INC,CARR STEVEN;;WHITE CHARLES;;AARON KYLE;;KUNKEL GERARD,,https://lens.org/147-114-962-531-467,Patent Application,no,0,0,15,15,0,H04N7/163;;H04N7/17318;;H04N21/4532;;H04N21/47202;;H04N21/482;;H04N21/47;;H04N5/445;;H04N21/472;;H04N21/482;;H04N7/173;;H04N7/163;;H04N21/47202;;H04N21/4532;;H04N7/17318;;H04N21/47;;H04N21/482,H04N7/173;;G06F3/0482;;H04N5/445,,0,0,,,,DISCONTINUED
74,WO,A1,WO 2009/088481 A1,136-904-925-858-169,2009-07-16,2009,US 2008/0014136 W,2008-12-31,US 1005008 P,2008-01-04,SYSTEMS AND METHODS FOR SELECTING MEDIA ASSETS FOR DISPLAY IN A SCREEN OF AN INTERACTIVE MEDIA GUIDANCE APPLICATION,"A method and system of selecting assets for display in an interactive media guidance application includes receiving a user input indicating interest in a media item; generating a list of media assets related to the media item, selecting, based on priority rules, a subset of the media assets to display in an interactive media guidance application, and displaying an identifier for each of the subset of media assets in the interactive media guidance application screen. The priority rules may assign a first priority to one type of media asset and a second priority to a second type of media asset, and may be based on: whether the media asset has been viewed, and a respective time associated with the media asset.",UNITED VIDEO PROPERTIES INC,CARR STEVEN;;WHITE CHARLES;;AARON KYLE;;KUNKEL GERARD,,https://lens.org/136-904-925-858-169,Patent Application,yes,6,0,15,15,0,H04N7/163;;H04N7/17318;;H04N21/4532;;H04N21/47202;;H04N21/482;;H04N21/47;;H04N5/445;;H04N21/472;;H04N21/482;;H04N7/173;;H04N7/163;;H04N21/47202;;H04N21/4532;;H04N7/17318;;H04N21/47;;H04N21/482,H04N7/173;;G06F3/0482;;H04N5/445,,0,0,,,,PENDING
75,CA,C,CA 2720221 C,158-187-089-679-585,2016-09-06,2016,CA 2720221 A,2009-04-08,GB 0806359 A;;GB 2009050346 W,2008-04-08,CARRYING SYSTEM FOR BREATHING APPARATUS,"A carrying system adapted for use with breathing apparatus suitable for carrying one or more air cylinders for use in emergency situations by people such as fire- fighters and others who may be exposed to contaminated and hostile environments. The carrying system comprises a backplate (11) and a pair of straps(12) adapted to hold the backplate (11)on the back of a user when the carrying system is worn. The backplate (11)comprises at least one plate of a plastics material adapted both to provide impact protection to a user during use by at least partially absorbing and / or dispersing impact forces, and to deform resiliently in response to external forces imposed by bending and / or twisting of a user during use and then return substantially to its predetermined shape when not subjected to an external force.",SCOTT HEALTH & SAFETY LTD,CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY,,https://lens.org/158-187-089-679-585,Granted Patent,no,0,0,16,16,0,A62B9/04;;A62B9/04;;A45F3/10;;A45F3/10;;A45F2003/045;;A45F2003/045;;A62B25/00;;A62B25/00;;B63C11/02;;B63C11/02;;B63C2011/026;;B63C2011/026,A62B25/00,,0,0,,,,INACTIVE
76,EP,A1,EP 3346703 A1,083-695-390-882-074,2018-07-11,2018,EP 17210588 A,2008-12-31,EP 08870076 A;;US 2008/0014136 W;;US 1005008 P,2008-01-04,SYSTEMS AND METHODS FOR SELECTING MEDIA ASSETS FOR DISPLAY IN A SCREEN OF AN INTERACTIVE MEDIA GUIDANCE APPLICATION,"A method and system of selecting assets for display in an interactive media guidance application includes receiving a user input indicating interest in a media item; generating a list of media assets related to the media item, selecting, based on priority rules, a subset of the media assets to display in an interactive media guidance application, and displaying an identifier for each of the subset of media assets in the interactive media guidance application screen. The priority rules may assign a first priority to one type of media asset and a second priority to a second type of media asset, and may be based on: whether the media asset has been viewed, and a respective time associated with the media asset.
",ROVI GUIDES INC,CARR STEVEN;;WHITE CHARLES;;AARON KYLE;;KUNKEL GERALD,,https://lens.org/083-695-390-882-074,Patent Application,yes,6,0,15,15,0,H04N7/163;;H04N7/17318;;H04N21/4532;;H04N21/47202;;H04N21/482;;H04N21/47;;H04N5/445;;H04N21/472;;H04N21/482;;H04N7/173;;H04N7/163;;H04N21/47202;;H04N21/4532;;H04N7/17318;;H04N21/47;;H04N21/482,H04N7/173;;G06F3/0482;;H04N5/445,,0,0,,,,ACTIVE
77,US,A1,US 2009/0178083 A1,120-900-001-789-221,2009-07-09,2009,US 34748108 A,2008-12-31,US 34748108 A;;US 1005008 P,2008-01-04,SYSTEMS AND METHODS FOR SELECTING MEDIA ASSETS FOR DISPLAY IN A SCREEN OF AN INTERACTIVE MEDIA GUIDANCE APPLICATION,"A method and system of selecting assets for display in an interactive media guidance application includes receiving a user input indicating interest in a media item; generating a list of media assets related to the media item, selecting, based on priority rules, a subset of the media assets to display in an interactive media guidance application, and displaying an identifier for each of the subset of media assets in the interactive media guidance application screen. The priority rules may assign a first priority to one type of media asset and a second priority to a second type of media asset, and may be based on: whether the media asset has been viewed, and a respective time associated with the media asset.",GUIDEWORKS LLC,WHITE CHARLES;;AARON KYLE;;KUNKEL GERARD;;CARR STEVEN,ROVI GUIDES INC (2010-02-26);;GUIDEWORKS LLC (2009-01-28),https://lens.org/120-900-001-789-221,Patent Application,yes,22,67,15,15,0,H04N7/163;;H04N7/17318;;H04N21/4532;;H04N21/47202;;H04N21/482;;H04N21/47;;H04N5/445;;H04N21/472;;H04N21/482;;H04N7/173;;H04N7/163;;H04N21/47202;;H04N21/4532;;H04N7/17318;;H04N21/47;;H04N21/482,H04N5/445;;G06F3/0482,725/61,0,0,,,,ACTIVE
78,CN,A,CN 1235366 A,120-186-415-658-939,1999-11-17,1999,CN 99107626 A,1999-05-09,GB 9809821 A,1998-05-09,Electron gun arrangements,,EEV LTD,THWAITES ALFRED CHRISTOPHER;;CARR DAVID WARD;;BARDELL STEVEN,E2V TECHNOLOGY (UK) LIMITED (2005-08-10),https://lens.org/120-186-415-658-939,Patent Application,no,0,3,9,9,0,H01J23/065;;H01J23/065;;H01J2225/04;;H01J2225/04,H01J23/065,,0,0,,,,EXPIRED
79,CN,C,CN 1188890 C,011-770-939-137-668,2005-02-09,2005,CN 99107626 A,1999-05-09,GB 9809821 A,1998-05-09,Electron gun arrangements,,EEV LTD,THWAITES ALFRED CHRISTOPHER;;CARR DAVID WARD;;BARDELL STEVEN,E2V TECHNOLOGY (UK) LIMITED (2005-08-10),https://lens.org/011-770-939-137-668,Granted Patent,no,0,0,9,9,0,H01J23/065;;H01J23/065;;H01J2225/04;;H01J2225/04,H01J23/065,,0,0,,,,EXPIRED
80,BR,A2,BR PI0911628 A2,036-968-941-165-685,2015-10-06,2015,BR PI0911628 A,2009-04-08,GB 2009050346 W;;GB 0806359 A,2008-04-08,sistema de transporte para aparelho respiratórios,,SCOTT HEALTH & SAFETY LTD,LEWIN BARRY;;CARR ROBERT;;THURGOOD STEVEN;;PICKETT TONY,,https://lens.org/036-968-941-165-685,Patent Application,no,0,0,16,16,0,A62B9/04;;A62B9/04;;A45F3/10;;A45F3/10;;A45F2003/045;;A45F2003/045;;A62B25/00;;A62B25/00;;B63C11/02;;B63C11/02;;B63C2011/026;;B63C2011/026,A62B25/00,,0,0,,,,PENDING
81,KR,A,KR 20130133918 A,067-256-347-722-900,2013-12-09,2013,KR 20137031262 A,2008-12-31,US 1005008 P;;US 2008/0014136 W,2008-01-04,SYSTEMS AND METHODS FOR SELECTING MEDIA ASSETS FOR DISPLAY IN A SCREEN OF AN INTERACTIVE MEDIA GUIDANCE APPLICATION,,UNITED VIDEO PROPERTIES INC,CARR STEVEN;;WHITE CHARLES;;AARON KYLE;;KUNKEL GERARD,,https://lens.org/067-256-347-722-900,Patent Application,no,0,0,15,15,0,H04N7/163;;H04N7/17318;;H04N21/4532;;H04N21/47202;;H04N21/482;;H04N21/47;;H04N5/445;;H04N21/472;;H04N21/482;;H04N7/173;;H04N7/163;;H04N21/47202;;H04N21/4532;;H04N7/17318;;H04N21/47;;H04N21/482,H04N21/472;;G06F3/0482;;H04N5/445;;H04N21/482,,0,0,,,,DISCONTINUED
82,AU,A1,AU 2009/235237 A1,068-126-829-756-688,2009-10-15,2009,AU 2009/235237 A,2009-04-08,GB 0806359 A;;GB 2009050346 W,2008-04-08,Carrying system for breathing apparatus,,SCOTT HEALTH & SAFETY LTD,CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY,,https://lens.org/068-126-829-756-688,Patent Application,no,0,0,16,16,0,A62B9/04;;A62B9/04;;A45F3/10;;A45F3/10;;A45F2003/045;;A45F2003/045;;A62B25/00;;A62B25/00;;B63C11/02;;B63C11/02;;B63C2011/026;;B63C2011/026,A62B25/00,,0,0,,,,INACTIVE
83,CA,A1,CA 2720221 A1,054-083-642-935-023,2009-10-15,2009,CA 2720221 A,2009-04-08,GB 0806359 A;;GB 2009050346 W,2008-04-08,CARRYING SYSTEM FOR BREATHING APPARATUS,"A carrying system adapted for use with breathing apparatus suitable for carrying one or more air cylinders for use in emergency situations by people such as fire- fighters and others who may be exposed to contaminated and hostile environments. The carrying system comprises a backplate (11) and a pair of straps(12) adapted to hold the backplate (11)on the back of a user when the carrying system is worn. The backplate (11)comprises at least one plate of a plastics material adapted both to provide impact protection to a user during use by at least partially absorbing and / or dispersing impact forces, and to deform resiliently in response to external forces imposed by bending and / or twisting of a user during use and then return substantially to its predetermined shape when not subjected to an external force.",SCOTT HEALTH & SAFETY LTD,CARR ROBERT;;THURGOOD STEVEN;;LEWIN BARRY;;PICKETT TONY,,https://lens.org/054-083-642-935-023,Patent Application,no,0,0,16,16,0,A62B9/04;;A62B9/04;;A45F3/10;;A45F3/10;;A45F2003/045;;A45F2003/045;;A62B25/00;;A62B25/00;;B63C11/02;;B63C11/02;;B63C2011/026;;B63C2011/026,A62B25/00,,0,0,,,,INACTIVE
84,CN,A,CN 102046243 A,144-202-921-939-782,2011-05-04,2011,CN 200980119185 A,2009-04-08,GB 2009050346 W;;GB 0806359 A,2008-04-08,Carrying system for breathing apparatus,"A carrying system adapted for use with breathing apparatus suitable for carrying one or more air cylinders for use in emergency situations by people such as fire-fighters and others who may be exposed to contaminated and hostile environments. The carrying system comprises a backplate (11) and a pair of straps (12) adapted to hold the backplate (11) on the back of a user when the carrying system is worn. The backplate (11) comprises at least one plate of a plastics material adapted both to provide impact protection to a user during use by at least partially absorbing and / or dispersing impact forces, and to deform resiliently in response to external forces imposed by bending and / or twisting of a user during use and then return substantially to its predetermined shape when not subjected to an external force.",SCOTT HEALTH & SAFETY LTD,ROBERT CARR;;STEVEN THURGOOD;;BARRY LEWIN;;TONY PICKETT,,https://lens.org/144-202-921-939-782,Patent Application,no,0,11,16,16,0,A62B9/04;;A62B9/04;;A45F3/10;;A45F3/10;;A45F2003/045;;A45F2003/045;;A62B25/00;;A62B25/00;;B63C11/02;;B63C11/02;;B63C2011/026;;B63C2011/026,A62B25/00,,0,0,,,,INACTIVE
85,AU,A,AU 2002/030484 A,016-913-744-805-424,2002-05-27,2002,AU 2002/030484 A,2001-11-16,US 24914200 P;;US 0144244 W,2000-11-16,System and method of managing documents,,INTERLEGIS INC,MEIER STEVEN E;;CARR KEVIN B;;KEDIDI LEYTH M,,https://lens.org/016-913-744-805-424,Patent Application,no,0,0,4,4,0,G06F16/93;;G06F16/93,G06F17/30;;G06F40/00,,0,0,,,,PENDING
86,CA,A1,CA 2156732 A1,093-446-553-113-970,1995-07-13,1995,CA 2156732 A,1995-01-09,US 18001894 A,1994-01-11,METHOD FOR IMPLANTING TISSUE IN A HOST,"A method for implanting cells into a host tissue is provided. The method comprises the steps of: creating an implant assembly for holding cells including wall means for forming a porous boundary between the host tissue and the implanted cells in the device, the pore size of the boundary being sufficient to isolate the implanted cells from the immune response; implanting the assembly without the cells into a host tissue; and accessing an interior of the assembly to add the cells thereto.",BAXTER INT,NEUENFELDT STEVEN;;BRAUKER JAMES;;CLARKE ROBERT;;CARR-BRENDEL VICTORIA,,https://lens.org/093-446-553-113-970,Patent Application,no,0,0,6,6,0,A61F2/022;;A61K9/0024;;A61L27/38;;Y10S623/902;;A61K9/0024;;A61L27/38;;A61F2/022,C12M1/00;;A61F2/02;;A61K9/00;;A61L27/00;;A61L27/38;;C12N5/07;;C12N5/071,,0,0,,,,DISCONTINUED
87,WO,A2,WO 2002/041170 A2,107-004-615-602-648,2002-05-23,2002,US 0144244 W,2001-11-16,US 24914200 P,2000-11-16,SYSTEM AND METHOD OF MANAGING DOCUMENTS,"A system and method of managing documents wherein after document preparation, documents may be scanned to form a digital document image. After optical character recognition, a compressed digital image file with a test layer is created so that a separate text file may be extracted from the document image and tethered together by a unique identifier. The compressed digital image file and its corresponding extracted text file may be sent to a server and where an inventory of each word of every document is created. The images and text inventory are then inserted into a database such that users manipulating the system may use Boolean searches and/or activate hyperlinks tethered to document images for the purposes of navigation or the creation of index entries that may contain additional information about the documents. In the preferred method, the system allows the management of a plurality of documents over a wide area network such as the Internet.",INTERLEGIS INC,MEIER STEVEN E;;CARR KEVIN B;;KEDIDI LEYTH M,,https://lens.org/107-004-615-602-648,Patent Application,yes,0,12,4,4,0,G06F16/93;;G06F16/93,G06F17/30;;G06F40/00,,0,0,,,,PENDING
88,EP,A1,EP 0692952 A1,152-921-335-921-812,1996-01-24,1996,EP 95906805 A,1995-01-09,US 9500321 W;;US 18001894 A,1994-01-11,METHOD FOR IMPLANTING TISSUE IN A HOST,,BAXTER INT,NEUENFELDT STEVEN;;BRAUKER JAMES;;CLARKE ROBERT;;CARR-BRENDEL VICTORIA,,https://lens.org/152-921-335-921-812,Patent Application,yes,0,0,6,6,0,A61F2/022;;A61K9/0024;;A61L27/38;;Y10S623/902;;A61K9/0024;;A61L27/38;;A61F2/022,C12M1/00;;A61F2/02;;A61K9/00;;A61L27/00;;A61L27/38;;C12N5/07;;C12N5/071,,0,0,,,,DISCONTINUED
89,US,A1,US 2013/0247103 A1,180-063-256-998-157,2013-09-19,2013,US 201313887916 A,2013-05-06,US 201313887916 A;;US 34748108 A;;US 1005008 P,2008-01-04,SYSTEMS AND METHODS FOR SELECTING MEDIA ASSETS FOR DISPLAY IN A SCREEN OF AN INTERACTIVE MEDIA GUIDANCE APPLICATION,"A method and system of selecting assets for display in an interactive media guidance application includes receiving a user input indicating interest in a media item; generating a list of media assets related to the media item, selecting, based on priority rules, a subset of the media assets to display in an interactive media guidance application, and displaying an identifier for each of the subset of media assets in the interactive media guidance application screen. The priority rules may assign a first priority to one type of media asset and a second priority to a second type of media asset, and may be based on: whether the media asset has been viewed, and a respective time associated with the media asset.",ROVI GUIDES INC,WHITE CHARLES D;;AARON KYLE;;KUNKEL GERARD;;CARR STEVEN,ROVI GUIDES INC (2010-02-26);;GUIDEWORKS LLC (2009-01-28),https://lens.org/180-063-256-998-157,Patent Application,yes,3,4,15,15,0,H04N7/163;;H04N7/17318;;H04N21/4532;;H04N21/47202;;H04N21/482;;H04N21/47;;H04N5/445;;H04N21/472;;H04N21/482;;H04N7/173;;H04N7/163;;H04N21/47202;;H04N21/4532;;H04N7/17318;;H04N21/47;;H04N21/482,H04N21/482;;G06F3/0482,725/44,0,0,,,,DISCONTINUED
90,US,A1,US 2005/0074863 A1,046-539-922-715-132,2005-04-07,2005,US 49709104 A,2004-05-28,EP 01128519 A;;EP 02001778 A;;EP 02020634 A;;EP 0213351 W,2001-11-29,T-cell epitodes in carboxypeptidase g2,The invention in particular relates to the modification of a bacterial enzyme carboxypeptidease G2 (CPG2) to result in CPG2 proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo. The present invention relates also to T-cell epitope peptides derived from said non-modified protein by means of which it is possible to create modified CPG2 variants with reduced immunogenicity. These polypeptides are suitable particularly for therapeutic use in humans.,HELLENDOORN KOEN;;BAKER MATTHEW;;WILLIAMS STEVEN;;CARR FRANCIS J.,HELLENDOORN KOEN;;BAKER MATTHEW;;WILLIAMS STEVEN;;CARR FRANCIS J,MERCK PATENT GMBH (2004-03-19),https://lens.org/046-539-922-715-132,Patent Application,yes,0,5,13,15,312,A61K38/00;;A61K39/00;;C12N9/48;;A61P43/00;;C12N9/48;;C12N15/52;;C12N9/48;;A61K38/00;;A61K39/00,A61K38/00;;A61K38/46;;A61K38/48;;C12N15/09;;A61K39/00;;A61K47/42;;A61P43/00;;C07K7/08;;C12N9/48;;C12N9/52;;C12N15/57,435/212;;435/69.1;;435/252.3;;435/471;;536/23.2,0,0,,,,DISCONTINUED
91,WO,A1,WO 2003/045426 A1,066-068-634-671-793,2003-06-05,2003,EP 0213351 W,2002-11-27,EP 01128519 A;;EP 02001778 A;;EP 02020634 A,2001-11-29,T-CELL EPITODES IN CARBOXYPEPTIDASE G2,The invention in particular relates to the modification of a bacterial enzyme carboxypeptidease G2 (CPG2) to result in CPG2 proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo. The present invention relates also to T-cell epitope peptides derived from said non-modified protein by means of which it is possible to create modified CPG2 variants with reduced immunogenicity. These polypeptides are suitable particularly for therapeutic use in humans.,MERCK PATENT GMBH;;HELLENDOORN KOEN;;BAKER MATTHEW;;WILLIAMS STEVEN;;CARR FRANCIS J,HELLENDOORN KOEN;;BAKER MATTHEW;;WILLIAMS STEVEN;;CARR FRANCIS J,,https://lens.org/066-068-634-671-793,Patent Application,yes,2,0,13,15,409,A61K38/00;;A61K39/00;;C12N9/48;;A61P43/00;;C12N9/48;;C12N15/52;;C12N9/48;;A61K38/00;;A61K39/00,A61K38/00;;A61K38/46;;A61K38/48;;C12N15/09;;A61K39/00;;A61K47/42;;A61P43/00;;C07K7/08;;C12N9/48;;C12N9/52;;C12N15/57,,3,3,015-922-111-951-753;;043-954-931-570-464;;010-210-890-724-121,10.1002/1615-9861(200203)2:3<271::aid-prot271>3.0.co;2-w;;11921443;;10741695;;pmc1137318;;7945221;;10.1042/bj3020921,"SPENCER DANIEL I R ET AL: ""A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics."", PROTEOMICS. GERMANY MAR 2002, vol. 2, no. 3, March 2002 (2002-03-01), pages 271 - 279, XP009009265, ISSN: 1615-9853;;NAPIER M P ET AL: ""Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma."", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES MAR 2000, vol. 6, no. 3, March 2000 (2000-03-01), pages 765 - 772, XP002238264, ISSN: 1078-0432;;MOOLA Z B ET AL: ""Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes."", THE BIOCHEMICAL JOURNAL. ENGLAND 15 SEP 1994, vol. 302 ( Pt 3), 15 September 1994 (1994-09-15), pages 921 - 927, XP000918634, ISSN: 0264-6021",PENDING
92,HU,A2,HU P0402160 A2,180-910-106-809-431,2005-01-28,2005,HU P0402160 A,2002-11-27,EP 01128519 A;;EP 02001778 A;;EP 02020634 A;;EP 0213351 W,2001-11-29,T-CELL EPITODES IN CARBOXYPEPTIDASE G2,"A találmány tárgyát elsősorban embereknek történő beadásra alkalmasterápiás hatású polipeptidek képezik. A találmány szerintipolipeptidek olyan módosított polipeptidek, ahol a módosítás azteredményezi, hogy a polipeptid csökkent mértékben hajlamosimmunválaszt kiváltani emberi alanynak való beadás esetén. A találmánytárgyát különösen bakteriális karboxipeptidáz-G2 (CPG2) enzimmódosítása képezi olyan CPG2-fehérjék előállítása céljából, melyeklényegében nem immunegének vagy kevésbé immunegének, mint bármelymegfelelő nem módosított enzim, ha in vivo alkalmazzuk azokat. Atalálmány tárgyát képezik továbbá az említett módosítatlan fehérjébőlszármazó T-sejt-epitóp-peptidek; amelyeket eszközként lehet használnicsökkent mértékben immunegén, módosított CPG2-variánsok előállítására. Ó",MERCK PATENT GMBH,HELLENDOORN KOEN;;BAKER MATTHEW;;WILLIAMS STEVEN;;CARR FRANCIS J,,https://lens.org/180-910-106-809-431,Patent Application,no,0,0,13,15,0,A61K38/00;;A61K39/00;;C12N9/48;;A61P43/00;;C12N9/48;;C12N15/52;;C12N9/48;;A61K38/00;;A61K39/00,A61K38/00;;C12N15/09;;A61K38/46;;A61K38/48;;A61K39/00;;A61K47/42;;A61P43/00;;C07K7/08;;C12N9/48;;C12N9/52;;C12N15/57,,0,0,,,,DISCONTINUED
93,WO,A2,WO 2008/149060 A2,119-920-613-240-312,2008-12-11,2008,GB 2008001791 W,2008-05-27,GB 0710670 A,2007-06-05,TURBOCHARGER,"A turbocharger comprises a turbine wheel (5) mounted within a housing assembly (1, 3) for rotation about a turbine axis, a gas flow inlet passage (8) upstream of the turbine wheel (5), and a gas flow control mechanism (10, 16, 32) located within the housing assembly (1, 3) upstream of the turbine wheel (5) and operable to control gas flow through said gas flow inlet passage (9). An actuator assembly is mounted to the housing assembly and comprises: A lead screw including a lead screw shaft (37) defining a lead screw axis, and a lead screw nut (36) threadedly engaged on a threaded portion of the lead screw shaft (37). The lead screw (36, 37) being arranged so that rotation of one of said shaft and nut relative to the housing assembly produces linear movement in the other of said shaft and nut in the direction of the lead screw axis: The lead screw (36, 37) engages the gas flow control mechanism (10, 16, 32) at a location within a housing cavity defined within said housing assembly (1, 3).",CUMMINS TURBO TECH LTD;;BYWATER JOHN MICHAEL;;GARRETT STEVEN;;CARR HENRY DAVID LAMBTON,BYWATER JOHN MICHAEL;;GARRETT STEVEN;;CARR HENRY DAVID LAMBTON,,https://lens.org/119-920-613-240-312,Patent Application,yes,0,21,7,7,0,F02C6/12;;F02C6/12;;F01D17/143;;F01D17/143;;F01D17/167;;F01D17/167;;F02B37/24;;F02B37/24;;F05D2220/40;;F05D2220/40;;F05D2250/41;;F05D2250/41;;F05D2250/411;;F05D2250/411;;F05D2260/40;;F05D2260/40;;F05D2260/50;;F05D2260/50;;F05D2260/56;;F05D2260/56;;Y02T10/12;;Y02T10/12,,,0,0,,,,PENDING
94,TW,U,TW 573545 U,118-761-981-331-54X,2004-01-21,2004,TW 90214939 U,2001-08-29,TW 90214939 U,2001-08-29,The grip is to prevent slippery and to increase stable grasp,,MING HSING LEATHER CO LTD;;FERRARI IMP ING COMPANY,ZHANG CHUN-FU;;CARR RONALD H;;FAGAN STEVEN MR,,https://lens.org/118-761-981-331-54X,Limited Patent,no,0,0,1,1,0,,A63B49/08;;A63B53/14,,0,0,,,,EXPIRED
95,US,A1,US 2021/0406915 A1,035-660-104-010-304,2021-12-30,2021,US 202117468918 A,2021-09-08,US 202117468918 A;;US 201816143333 A;;US 201314142204 A;;US 201361769188 P,2013-02-25,MOBILE WIRELESS CUSTOMER MICRO-CARE APPARATUS AND METHOD,"In one example, a data package created by a particular wireless mobile device, and comprising metrics collected by the wireless mobile device, is retrieved. The metrics concern performance of the wireless mobile device in a wireless communication network, and are transformed into measures that enable derivation of a key performance indicator concerning the performance of the wireless mobile device. An enriched measure is generated by processing the measures based on correlations of wireless mobile device events in a time sequence, and the enriched measure is transformed into a KPI that is specific to the performance of the wireless mobile device. The KPI of the wireless mobile device is compared to a KPI of the population of wireless mobile devices, and results of the comparison of KPIs serve as a basis to resolve a problem regarding operation of the wireless mobile device.",AT&T MOBILITY IP LLC,LACEY BRUCE BLAINE;;WONG ELLIS L;;CARR STEVEN R,,https://lens.org/035-660-104-010-304,Patent Application,yes,5,0,4,5,0,G06Q30/016;;G06Q30/016,G06Q30/00,,0,0,,,,DISCONTINUED
96,AU,A,AU 1995/015260 A,184-373-020-910-955,1995-08-01,1995,AU 1995/015260 A,1995-01-09,US 18001894 A;;US 9500321 W,1994-01-11,Method for implanting tissue in a host,,BAXTER INT,NEUENFELDT STEVEN;;BRAUKER JAMES;;CLARKE ROBERT;;CARR-BRENDEL VICTORIA,,https://lens.org/184-373-020-910-955,Patent Application,no,0,0,6,6,0,A61F2/022;;A61K9/0024;;A61L27/38;;Y10S623/902;;A61K9/0024;;A61L27/38;;A61F2/022,C12M1/00;;A61F2/02;;A61K9/00;;A61L27/00;;A61L27/38;;C12N5/07;;C12N5/071,,0,0,,,,PENDING
97,US,B2,US 11144931 B2,001-526-967-228-957,2021-10-12,2021,US 201816143333 A,2018-09-26,US 201816143333 A;;US 201314142204 A;;US 201361769188 P,2013-02-25,Mobile wireless customer micro-care apparatus and method,"In one example, a data package created by a particular wireless mobile device, and comprising metrics collected by the wireless mobile device, is retrieved. The metrics concern performance of the wireless mobile device in a wireless communication network, and are transformed into measures that enable derivation of a key performance indicator concerning the performance of the wireless mobile device. An enriched measure is generated by processing the measures based on correlations of wireless mobile device events in a time sequence, and the enriched measure is transformed into a KPI that is specific to the performance of the wireless mobile device. The KPI of the wireless mobile device is compared to a KPI of the population of wireless mobile devices, and results of the comparison of KPIs serve as a basis to resolve a problem regarding operation of the wireless mobile device.",AT&T MOBILITY IP LLC,LACEY BRUCE BLAINE;;WONG ELLIS L;;CARR STEVEN R,CARRIER IQ INC (2016-09-03);;AT&T MOBILITY IP LLC (2019-06-13),https://lens.org/001-526-967-228-957,Granted Patent,yes,23,0,4,5,0,G06Q30/016;;G06Q30/016,G06Q30/00,,16,1,108-216-580-470-18X,10.1109/icpads.2008.21,"16143333 EIC 3600 Search Report—dated Aug. 18, 2020 (Year: 2020).;;16143333 EIC 3600 Search Report—dated Mar. 22, 2021 (Year: 2021).;;U.S. Appl. No. 61/769,188, filed Feb. 25, 2013, Steven R. Carr, et al.;;U.S. Appl. No. 14/142,204, filed Dec. 27, 2013, Bruce Blaine Lacey, et al.;;U.S. Appl. No. 14/221,545, filed Mar. 21, 2014, Steven R. Carr, et al.;;Peng et al, “Large-scale Incremental Processing using Distributed Transactions and Notifications” 2010.;;Carrier IQ, “Understanding Carrier IQ Technology: What Carrier IQ Does and Does Not Do.” Dec. 12, 2011. https://www.franken.senate.gov/?p=press_release&id=1891.;;Ngamsuriyaroj, “Optimal Placement of Pipeline Applications on Grid.” 14th IEEE International Conference on Parallel and Distributed Systems (2008). pp. 245-251. http://ieeexplore.ieee.org/stamp/stamp.jsp?arnumber=4724326.;;U.S. Appl. No. 14/221,545, Oct. 6, 2016, Restriction Requirement.;;U.S. Appl. No. 14/221,545, Jan. 4, 2017, Office Action.;;U.S. Appl. No. 14/142,204, Sep. 20, 2017, Office Action.;;U.S. Appl. No. 14/221,545, Jul. 25, 2017, Final Office Action.;;U.S. Appl. No. 14/221,545, Oct. 23, 2017, Office Action.;;U.S. Appl. No. 14/142,204, May 3, 2018, Final Office Action.;;U.S. Appl. No. 14/221,545, Jun. 15, 2018, Final Office Action.;;Final Office action received for U.S. Appl. No. 14/221,545 dated Oct. 3, 2019, 14 Pages.",ACTIVE
98,WO,A3,WO 2008/032024 A3,012-449-563-059-651,2008-05-08,2008,GB 2007003382 W,2007-09-07,GB 0618228 A;;GB 0706804 A,2006-09-15,MOBILE TELEVISION SIGNAL TESTING APPARATUS,"A mobile television signal testing apparatus comprising receiving means for receiving a television signal; generating means for generating a video signal comprising an image generated from the received television signal; detection means for detecting at least a part of the image; and output means for outputting a signal obtained using the detection means, said signal providing a measure of the reception quality of the received television signal. The detection means may be a photodetector for detecting light from a television screen displaying the image. The mobile television receiver may also comprise a mask for shielding the photodetector from extraneous light. The mask may be removable from the mobile television receiver, and the photodetector may be attached to the mask.",NAT GRID WIRELESS LTD;;INMAN RUSSELL;;OSBORNE PHILIP;;CARR STEVEN;;MASON RICHARD ASHLEY,INMAN RUSSELL;;OSBORNE PHILIP;;CARR STEVEN;;MASON RICHARD ASHLEY,,https://lens.org/012-449-563-059-651,Search Report,yes,6,0,2,6,0,H04N17/00;;H04N17/04,H04N17/00;;H04B17/00,,0,0,,,,PENDING
99,US,A,US 5108401 A,094-403-187-664-698,1992-04-28,1992,US 68545291 A,1991-04-12,US 68545291 A,1991-04-12,Patella cutting clamp,A patella cutting clamp comprises a pair of jaw members joined together in scissors-like relation for pivotal movement relative to each other about a pivot axis intermediate their ends. Each jaw member has a handle portion extending in one direction from the pivot axis and a jaw portion extending in the other direction. The jaw portions have edges facing each other that are shaped for engagement with opposite borders of a patella. Teeth along the patella-gripping edges grip and hold the patella firmly. Saw guide slots in the jaw portions lying in a common plane guide the saw when the saw cut is made. A patella elevator member is attached to the jaw members for movement along the pivot axis and has a platform portion adapted to engage the anterior aspect of the patella. A mechanism is provided for establishing and maintaining a predetermined position of the elevator member relative to the jaw members and thereby positioning the patella at a predetermined position relative to the saw guide slots. Another mechanism holds the jaw members in an adjusted position relative to each other with the jaw portions engaging and holding the patella.,NEW YORK SOCIETY,INSALL JOHN N;;HAAS STEVEN B;;CARR JAMES M,NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY 535 EAST 70TH STREET NEW YORK NY 10021 A NOT-FOR-PROFIT CORP. OF NY (1991-04-10),https://lens.org/094-403-187-664-698,Granted Patent,yes,8,79,1,1,0,A61B17/158;;A61B17/2812;;A61F2/3877;;A61B17/2812;;A61F2/3877;;A61B17/158,A61B17/15;;A61B17/28;;A61F2/38,606/79;;606/82;;606/87,0,0,,,,EXPIRED
100,WO,A1,WO 1995/018584 A1,163-877-027-859-272,1995-07-13,1995,US 9500321 W,1995-01-09,US 18001894 A,1994-01-11,METHOD FOR IMPLANTING TISSUE IN A HOST,"A method for implanting cells into a host tissue is provided. The method comprises the steps of: creating an implant assembly for holding cells including wall means for forming a porous boundary between the host tissue and the implanted cells in the device, the pore size of the boundary being sufficient to isolate the implanted cells from the immune response; implanting the assembly without the cells into a host tissue; and accessing an interior of the assembly to add the cells thereto.",BAXTER INT,NEUENFELDT STEVEN;;BRAUKER JAMES;;CLARKE ROBERT;;CARR-BRENDEL VICTORIA,,https://lens.org/163-877-027-859-272,Patent Application,no,8,4,6,6,0,A61F2/022;;A61K9/0024;;A61L27/38;;Y10S623/902;;A61K9/0024;;A61L27/38;;A61F2/022,C12M1/00;;A61F2/02;;A61K9/00;;A61L27/00;;A61L27/38;;C12N5/07;;C12N5/071,,1,1,126-335-537-104-998,8123923;;10.1097/00002480-199310000-00013,"CHOA ET AL.: ""Histologic appearance of the Islet Organoid"", ASAIO JOURNAL, vol. 39, no. 4, 15 October 1993 (1993-10-15), HAGERSTOWN, pages 893 - 898",PENDING
101,GB,A,GB 2501834 A,182-571-628-003-477,2013-11-06,2013,GB 201313254 A,2012-02-17,US 2012/0025643 W;;US 201161444419 P;;US 201213398333 A,2011-02-18,Wide dynamic range interferometric transducer with divergent beam,"An apparatus and method for estimating a parameter of interest using values of a beam property from two or more electromagnetic beams that both pass through at least part of an optical displacement device. The apparatus may include a Fabry-Perot interferometer, a collimated light source, and a detection array. At least one mirror of the interferometer may be operably coupled to an element receiving an external stimulus, such as pressure, force, and/or acceleration. The method includes using the apparatus.",BAKER HUGHES INC,EDWARDS CARL M;;CARR DUSTIN W;;PATTERSON STEVEN R,,https://lens.org/182-571-628-003-477,Patent Application,no,4,0,10,10,0,G01V8/02;;G01V8/02;;G01V8/02,G01V8/02,,0,0,,,,INACTIVE
102,PL,A1,PL 369735 A1,009-822-194-690-994,2005-05-02,2005,PL 36973502 A,2002-11-27,EP 01128519 A;;EP 02001778 A;;EP 02020634 A,2001-11-29,T-CELL EPITODES IN CARBOXYPEPTIDASE G2,,MERCK PATENT GMBH,HELLENDOORN KOEN;;BAKER MATTHEW;;WILLIAMS STEVEN;;CARR FRANCIS J,,https://lens.org/009-822-194-690-994,Patent Application,no,0,0,13,15,0,A61K38/00;;A61K39/00;;C12N9/48;;A61P43/00;;C12N9/48;;C12N15/52;;C12N9/48;;A61K38/00;;A61K39/00,A61K38/00;;A61K38/46;;A61K38/48;;C12N15/09;;A61K39/00;;A61K47/42;;A61P43/00;;C07K7/08;;C12N9/48;;C12N9/52;;C12N15/57,,0,0,,,,DISCONTINUED
103,WO,A2,WO 2021/247534 A2,045-210-105-957-633,2021-12-09,2021,US 2021/0035196 W,2021-06-01,US 202063033191 P,2020-06-01,COMPOSITIONS AND METHODS FOR TREATING MERKEL CELL CARCINOMA (MCC) USING HLA CLASS I SPECIFIC EPITOPES,The subject matter disclosed herein is generally directed to epitopes that specifically bind to subject specific HLA class I molecules in MCC. The epitope identified is specific for MCC and is encoded for in the Merkel Cell Polyomavirus (MCPyV) large T antigen (MCPyV LT).,BROAD INST INC;;DANA FARBER CANCER INST INC,WU CATHERINE J;;CARR STEVEN;;KLAEGER SUSAN;;KESKIN DERIN,,https://lens.org/045-210-105-957-633,Patent Application,yes,0,0,3,3,27,A61K39/12;;C12N2710/22034;;A61K2039/585;;A61K2039/876;;Y02A50/30;;A61K39/12;;A61K2039/5154;;C07K14/7051;;C07K16/084,,,0,0,,,,PENDING
104,CA,A1,CA 2468501 A1,059-877-517-306-718,2003-06-05,2003,CA 2468501 A,2002-11-27,EP 01128519 A;;EP 02001778 A;;EP 02020634 A;;EP 0213351 W,2001-11-29,T-CELL EPITODES IN CARBOXYPEPTIDASE G2,The invention in particular relates to the modification of a bacterial enzym e carboxypeptidease G2 (CPG2) to result in CPG2 proteins that are substantiall y non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo. The present invention relates also to T-cell epitope peptides derived from said non-modified protein by means of which it is possible to create modified CPG2 variants with reduced immunogenicity. These polypeptide s are suitable particularly for therapeutic use in humans.,MERCK PATENT GMBH,CARR FRANCIS J;;WILLIAMS STEVEN;;BAKER MATTHEW;;HELLENDOORN KOEN,,https://lens.org/059-877-517-306-718,Patent Application,no,0,0,13,15,312,A61K38/00;;A61K39/00;;C12N9/48;;A61P43/00;;C12N9/48;;C12N15/52;;C12N9/48;;A61K38/00;;A61K39/00,C12N15/09;;A61K38/00;;A61K38/46;;A61K38/48;;A61K39/00;;A61K47/42;;A61P43/00;;C07K7/08;;C12N9/48;;C12N9/52;;C12N15/57,,0,0,,,,DISCONTINUED
105,US,A1,US 2002/0139076 A1,172-719-567-410-276,2002-10-03,2002,US 81799501 A,2001-03-27,US 81799501 A,2001-03-27,"Single-ply roofing membrane with laminated, skinned nonwoven","
   This invention is directed to a membrane laminate for a roofing system comprising a membrane sheet and a nonwoven material laminated to said sheet. The nonwoven material has a semi-permeable, skinned layer formed therein. 
",CARR RICHARD W.;;CLARKE STEVEN R.;;MITCHELL JOHN G.,CARR RICHARD W;;CLARKE STEVEN R;;MITCHELL JOHN G,NICOLON CORPORATION (2006-02-17);;CARLISLE MANAGEMENT CO (2001-07-25);;THANTEX SPECIALTIES INC (2001-08-27);;THANTEX INC (2006-02-16),https://lens.org/172-719-567-410-276,Patent Application,yes,0,3,11,11,0,E04D5/12;;E04D5/12;;E04D5/10;;E04D5/10;;Y10T428/149;;Y10T428/149,B32B11/10;;E04D5/10;;E04D5/12,52/409;;156/71,0,0,,,,EXPIRED
106,BR,A,BR 0214567 A,196-965-813-349-090,2004-12-28,2004,BR 0214567 A,2002-11-27,EP 01128519 A;;EP 02001778 A;;EP 02020634 A;;EP 0213351 W,2001-11-29,Epìtopos de célula t em carboxipeptidase g2,"""EPìTOPOS DE CéLULA T EM CARBOXIPEPTIDASE G2"". A invenção refere-se em particular à modificação da enzima bactedana carboxipeptidase G2 (CPG2) para resultar em proteínas CPG2 que são substancialmente não-imunogênicas ou menos imunogênicas do que qualquer par não-modificado quando usadas in vivo. A presente invenção referese também a peptídeos de epítopo de célula T derivados da dita proteína não-modificada através da qual é possível criar variantes de CPG2 modificadas com imunogenicidade reduzida. Esses polipeptídeos são adequados particularmente para uso terapêutico em seres humanos.",MERCK PATENT GMBH,HELLENDOORN KOEN;;BAKER MATTHEW;;WILLIAMS STEVEN;;CARR FRANCIS J,,https://lens.org/196-965-813-349-090,Patent Application,no,0,0,13,15,0,A61K38/00;;A61K39/00;;C12N9/48;;A61P43/00;;C12N9/48;;C12N15/52;;C12N9/48;;A61K38/00;;A61K39/00,C12N15/09;;A61K38/00;;A61K38/46;;A61K38/48;;A61K39/00;;A61K47/42;;A61P43/00;;C07K7/08;;C12N9/48;;C12N9/52;;C12N15/57,,0,0,,,,DISCONTINUED
107,US,A,US 5462741 A,054-590-576-964-358,1995-10-31,1995,US 23445794 A,1994-04-28,US 23445794 A;;US 92661492 A,1992-08-06,High agent loaded controlled release dispenser,"A fluid-activated delivery device is disclosed comprising a housing defining an internal compartment, a beneficial agent formulation in the compartment, exit means in the housing for delivering the beneficial agent formulation from the delivery device, and wherein the formulation comprises an active agent in an amount of 50 wt % or greater blended with a glyceride or a mixture of glycerides of a fatty acid.",ALZA CORP,CARR JOHN P;;LARSEN STEVEN D;;ECKENHOFF JAMES B,ALZA CORPORATION (1994-04-20),https://lens.org/054-590-576-964-358,Granted Patent,yes,25,13,1,1,0,A61K9/0004;;A61K9/0004,A61K9/00,424/438;;424/413,4,2,037-403-513-223-218;;023-031-275-918-643,13672840;;10.1002/jps.3030480808;;10.1002/jps.3030490208;;13855441,"Grafton, P., General Principles for Designing with Plastics, 1969 1970 Modern Plastics Encyclopedia pp. 62 to 71.;;Wurster, Dale E. Air Suspension Technique of Coating Drug Particles, J. of Amer, Phar Assoc. vol. XLVIII, No. 8. pp. 451 to 454, 1959.;;Wurster, Dale E., Preparation of Compressed Tablet Granulations by the Air Suspension Technique II, pp. 82 to 84, J. of Amer. Phar. V. 49, No. 2.;;Felmeister, Alvin, Powders, pp. 1626 1680, Remington s 14th Ed. 1970, Mack Publishing Co.",EXPIRED
108,US,A,US 5552078 A,058-596-438-198-248,1996-09-03,1996,US 36031294 A,1994-12-21,US 36031294 A;;US 8500893 A,1993-06-29,Carbonate built laundry detergent composition,"A powdered laundry detergent composition comprising an active surfactant, at least about 70 wt. % of a water soluble alkaline carbonate salt, e.g., sodium carbonate, about 0.1 to 2 wt. % of a phosphorus-containing sequestering agent, e.g., sodium tripolyphosphate (STPP), about 0.1 to 2 wt. % of a polymeric polycarboxylate, e.g., a polyacrylate or a polymaleate, and about 1-12 wt. % water. Use of the foregoing detergent composition provides excellent cleaning and whitening of fabrics while avoiding the problem of eutrophication which occurs when a substantial amount of a phosphorus containing builder such as STPP is present in the composition, and while minimizing the problem of fabric encrustation often present when the composition contains a large amount of carbonate builder.",CHURCH & DWIGHT CO INC,CARR CHARLES D;;BOLKAN STEVEN A;;BECKER JOSEPH G,CHURCH & DWIGHT CO. INC (1994-12-14),https://lens.org/058-596-438-198-248,Granted Patent,yes,19,27,4,4,0,C11D3/10;;C11D3/3761;;C11D1/83;;C11D3/06;;C11D3/364;;C11D3/3761;;C11D3/10;;C11D1/83;;C11D3/06;;C11D3/364,C11D3/075;;C11D3/10;;C11D3/37,510/351;;510/359;;510/361;;510/476;;510/469,0,0,,,,EXPIRED
109,US,A1,US 2002/0083079 A1,107-766-642-517-466,2002-06-27,2002,US 99391501 A,2001-11-16,US 99391501 A;;US 24914200 P,2000-11-16,System and method of managing documents,"
   A system and method of managing documents wherein after document preparation, documents may be scanned to form a digital document image. After optical character recognition, a compressed digital image file with a text layer is created so that a separate text file may be extracted from the document image and tethered together by a unique identifier. The compressed digital image file and its corresponding extracted text file may be sent to a server and where an inventory of each word of every document is created. The images and text inventory are then inserted into a database such that users manipulating the system may use Boolean searches and/or activate hyperlinks tethered to document images for the purposes of navigation or the creation of index entries that may contain additional information about the documents. In the preferred method, the system allows the management of a plurality of documents over a wide area network such as the Internet. 
",INTERLEGIS INC,MEIER STEVEN E;;CARR KEVIN B;;KEDIDI LEYTH M,INTERLEGIS INC (2002-02-12),https://lens.org/107-766-642-517-466,Patent Application,yes,23,287,4,4,0,G06F16/93;;G06F16/93,G06F17/30;;G06F40/00,707/104.1,0,0,,,,DISCONTINUED
110,US,A1,US 2012/0212745 A1,136-601-773-223-798,2012-08-23,2012,US 201213398333 A,2012-02-16,US 201213398333 A;;US 201161444419 P,2011-02-18,WIDE DYNAMIC RANGE INTERFEROMETRIC TRANSDUCER WITH DIVERGENT BEAM,"An apparatus and method for estimating a parameter of interest using values of a beam property from two or more electromagnetic beams that both pass through at least part of an optical displacement device. The apparatus may include a Fabry-Perot interferometer, a collimated light source, and a detection array. At least one mirror of the interferometer may be operably coupled to an element receiving an external stimulus, such as pressure, force, and/or acceleration. The method includes using the apparatus.",EDWARDS CARL M;;CARR DUSTIN W;;PATTERSON STEVEN R;;BAKER HUGHES INC,EDWARDS CARL M;;CARR DUSTIN W;;PATTERSON STEVEN R,BAKER HUGHES INCORPORATED (2012-02-17),https://lens.org/136-601-773-223-798,Patent Application,yes,1,5,10,10,0,G01V8/02;;G01V8/02;;G01V8/02,G01B11/02,356/498,0,0,,,,INACTIVE
111,TW,S,TW D227174 S,122-243-409-137-142,2023-08-21,2023,TW 111306402 F,2022-12-20,US 202229843429 F,2022-06-21,SOUNDBAR,﻿【物品用途】;本設計係關於一種長條喇叭。;【設計說明】,美商伯斯公司 美國;;BOSE CORP,SILVERSTEIN STEVEN A;;CARR ADAM A;;EVA BRENTON HARRY,,https://lens.org/122-243-409-137-142,Design Right,no,0,0,2,2,0,,,14-01,0,0,,,,ACTIVE
112,CA,A1,CA 2827264 A1,020-754-514-119-882,2012-08-23,2012,CA 2827264 A,2012-02-17,US 201161444419 P;;US 201213398333 A;;US 2012/0025643 W,2011-02-18,WIDE DYNAMIC RANGE INTERFEROMETRIC TRANSDUCER WITH DIVERGENT BEAM,"An apparatus and method for estimating a parameter of interest using values of a beam property from two or more electromagnetic beams that both pass through at least part of an optical displacement device. The apparatus may include a Fabry-Perot interferometer, a collimated light source, and a detection array. At least one mirror of the interferometer may be operably coupled to an element receiving an external stimulus, such as pressure, force, and/or acceleration. The method includes using the apparatus.",BAKER HUGHES INC,EDWARDS CARL M;;CARR DUSTIN W;;PATTERSON STEVEN R,,https://lens.org/020-754-514-119-882,Patent Application,no,0,0,10,10,0,G01V8/02;;G01V8/02;;G01V8/02,G01V8/10;;G01V3/18,,0,0,,,,INACTIVE
113,EP,A1,EP 1501540 A1,153-763-026-414-628,2005-02-02,2005,EP 02787840 A,2002-11-27,EP 02787840 A;;EP 0213351 W;;EP 01128519 A;;EP 02001778 A;;EP 02020634 A,2001-11-29,T-CELL EPITODES IN CARBOXYPEPTIDASE G2,,MERCK PATENT GMBH,ELLENDOORN KOEN;;BAKER MATTHEW;;WILLIAMS STEVEN;;CARR FRANCIS J,,https://lens.org/153-763-026-414-628,Patent Application,yes,0,1,13,15,0,A61K38/00;;A61K39/00;;C12N9/48;;A61P43/00;;C12N9/48;;C12N15/52;;C12N9/48;;A61K38/00;;A61K39/00,A61K38/00;;A61K38/46;;A61K38/48;;C12N15/09;;A61K39/00;;A61K47/42;;A61P43/00;;C07K7/08;;C12N9/48;;C12N9/52;;C12N15/57,,0,0,,,,DISCONTINUED
114,ZA,B,ZA 200405149 B,197-497-491-243-470,2005-06-17,2005,ZA 200405149 A,2004-06-28,EP 01128519 A,2001-11-29,T-cell epitodes in carboxypeptidase G2.,,MERCK PATENT GMBH,HELLENDOORN KOEN;;BAKER MATTHEW;;WILLIAMS STEVEN;;CARR FRANCIS J,,https://lens.org/197-497-491-243-470,Granted Patent,no,0,0,1,15,0,,A61K/;;C12N/,,0,0,,,,ACTIVE
115,WO,A3,WO 2012/112887 A3,017-671-031-840-825,2012-12-13,2012,US 2012/0025643 W,2012-02-17,US 201161444419 P;;US 201213398333 A,2011-02-18,WIDE DYNAMIC RANGE INTERFEROMETRIC TRANSDUCER WITH DIVERGENT BEAM,"An apparatus and method for estimating a parameter of interest using values of a beam property from two or more electromagnetic beams that both pass through at least part of an optical displacement device. The apparatus may include a Fabry-Perot interferometer, a collimated light source, and a detection array. At least one mirror of the interferometer may be operably coupled to an element receiving an external stimulus, such as pressure, force, and/or acceleration. The method includes using the apparatus.",BAKER HUGHES INC;;EDWARDS CARL M;;CARR DUSTIN W;;PATTERSON STEVEN R,EDWARDS CARL M;;CARR DUSTIN W;;PATTERSON STEVEN R,,https://lens.org/017-671-031-840-825,Search Report,yes,4,0,10,10,0,G01V8/02;;G01V8/02;;G01V8/02,G01V8/10;;G01V3/18,,0,0,,,,PENDING
116,CN,B,CN 101743381 B,133-425-089-699-651,2013-05-08,2013,CN 200880024727 A,2008-05-27,GB 2008001791 W;;GB 0710670 A,2007-06-05,Turbocharger,,CUMMINS TURBO TECH LTD,BYWATER JOHN MICHAEL;;GARRETT STEVEN;;CARR HENRY DAVID LAMBTON,,https://lens.org/133-425-089-699-651,Granted Patent,no,0,0,7,7,0,F02C6/12;;F02C6/12;;F01D17/143;;F01D17/143;;F01D17/167;;F01D17/167;;F02B37/24;;F02B37/24;;F05D2220/40;;F05D2220/40;;F05D2250/41;;F05D2250/41;;F05D2250/411;;F05D2250/411;;F05D2260/40;;F05D2260/40;;F05D2260/50;;F05D2260/50;;F05D2260/56;;F05D2260/56;;Y02T10/12;;Y02T10/12,F01D17/14;;F02C6/12,,0,0,,,,ACTIVE
117,US,B2,US 8797548 B2,145-463-806-348-399,2014-08-05,2014,US 201213398333 A,2012-02-16,US 201213398333 A;;US 201161444419 P,2011-02-18,Wide dynamic range interferometric transducer with divergent beam,"An apparatus and method for estimating a parameter of interest using values of a beam property from two or more electromagnetic beams that both pass through at least part of an optical displacement device. The apparatus may include a Fabry-Perot interferometer, a collimated light source, and a detection array. At least one mirror of the interferometer may be operably coupled to an element receiving an external stimulus, such as pressure, force, and/or acceleration. The method includes using the apparatus.",EDWARDS CARL M;;CARR DUSTIN W;;PATTERSON STEVEN R;;BAKER HUGHES INC,EDWARDS CARL M;;CARR DUSTIN W;;PATTERSON STEVEN R,BAKER HUGHES INCORPORATED (2012-02-17),https://lens.org/145-463-806-348-399,Granted Patent,yes,15,3,10,10,0,G01V8/02;;G01V8/02;;G01V8/02,G01B11/02,356/506,0,0,,,,INACTIVE
118,AU,A1,AU 2002/352162 A1,174-202-831-122-881,2003-06-10,2003,AU 2002/352162 A,2002-11-27,EP 01128519 A;;EP 02001778 A;;EP 02020634 A;;EP 0213351 W,2001-11-29,T-CELL EPITODES IN CARBOXYPEPTIDASE G2,,MERCK PATENT GMBH,HELLENDOORN KOEN;;BAKER MATTHEW;;WILLIAMS STEVEN;;CARR FRANCIS J,,https://lens.org/174-202-831-122-881,Patent Application,no,0,0,13,15,0,A61K38/00;;A61K39/00;;C12N9/48;;A61P43/00;;C12N9/48;;C12N15/52;;C12N9/48;;A61K38/00;;A61K39/00,C12N15/09;;A61K38/00;;A61K38/46;;A61K38/48;;A61K39/00;;A61K47/42;;A61P43/00;;C07K7/08;;C12N9/48;;C12N9/52;;C12N15/57,,0,0,,,,DISCONTINUED
119,CA,C,CA 2827264 C,014-415-122-640-835,2017-02-14,2017,CA 2827264 A,2012-02-17,US 201161444419 P;;US 201213398333 A;;US 2012/0025643 W,2011-02-18,WIDE DYNAMIC RANGE INTERFEROMETRIC TRANSDUCER WITH DIVERGENT BEAM,"An apparatus and method for estimating a parameter of interest using values of a beam property from two or more electromagnetic beams that both pass through at least part of an optical displacement device. The apparatus may include a Fabry-Perot interferometer, a collimated light source, and a detection array. At least one mirror of the interferometer may be operably coupled to an element receiving an external stimulus, such as pressure, force, and/or acceleration. The method includes using the apparatus.",BAKER HUGHES INC,EDWARDS CARL M;;CARR DUSTIN W;;PATTERSON STEVEN R,,https://lens.org/014-415-122-640-835,Granted Patent,no,0,0,10,10,0,G01V8/02;;G01V8/02;;G01V8/02,G01V8/10;;G01V3/18,,0,0,,,,INACTIVE
120,WO,A3,WO 2008/149060 A3,036-044-107-053-892,2009-06-25,2009,GB 2008001791 W,2008-05-27,GB 0710670 A,2007-06-05,TURBOCHARGER,"A turbocharger comprises a turbine wheel (5) mounted within a housing assembly (1, 3) for rotation about a turbine axis, a gas flow inlet passage (8) upstream of the turbine wheel (5), and a gas flow control mechanism (10, 16, 32) located within the housing assembly (1, 3) upstream of the turbine wheel (5) and operable to control gas flow through said gas flow inlet passage (9). An actuator assembly is mounted to the housing assembly and comprises: A lead screw including a lead screw shaft (37) defining a lead screw axis, and a lead screw nut (36) threadedly engaged on a threaded portion of the lead screw shaft (37). The lead screw (36, 37) being arranged so that rotation of one of said shaft and nut relative to the housing assembly produces linear movement in the other of said shaft and nut in the direction of the lead screw axis: The lead screw (36, 37) engages the gas flow control mechanism (10, 16, 32) at a location within a housing cavity defined within said housing assembly (1, 3).",CUMMINS TURBO TECH LTD;;BYWATER JOHN MICHAEL;;GARRETT STEVEN;;CARR HENRY DAVID LAMBTON,BYWATER JOHN MICHAEL;;GARRETT STEVEN;;CARR HENRY DAVID LAMBTON,,https://lens.org/036-044-107-053-892,Search Report,yes,8,0,7,7,0,F02C6/12;;F02C6/12;;F01D17/143;;F01D17/143;;F01D17/167;;F01D17/167;;F02B37/24;;F02B37/24;;F05D2220/40;;F05D2220/40;;F05D2250/41;;F05D2250/41;;F05D2250/411;;F05D2250/411;;F05D2260/40;;F05D2260/40;;F05D2260/50;;F05D2260/50;;F05D2260/56;;F05D2260/56;;Y02T10/12;;Y02T10/12,F01D17/14;;F02C6/12,,0,0,,,,PENDING
121,CN,A,CN 1592633 A,059-477-587-115-631,2005-03-09,2005,CN 02823301 A,2002-11-27,EP 01128519 A;;EP 02001778 A;;EP 02020634 A,2001-11-29,T-cell epitodes in carboxypeptidase G2,,MERCK PATENT GMBH,KOEN HELLENDOORN;;MATTHEW BAKER;;STEVEN WILLIAMS;;CARR FRANCIS J,,https://lens.org/059-477-587-115-631,Patent Application,no,0,0,13,15,0,A61K38/00;;A61K39/00;;C12N9/48;;A61P43/00;;C12N9/48;;C12N15/52;;C12N9/48;;A61K38/00;;A61K39/00,C12N15/09;;A61K38/00;;A61K38/46;;A61K38/48;;A61K39/00;;A61K47/42;;A61P43/00;;C07K7/08;;C12N9/48;;C12N9/52;;C12N15/57,,0,0,,,,DISCONTINUED
122,US,A,US 5549675 A,048-978-084-770-024,1996-08-27,1996,US 18001894 A,1994-01-11,US 18001894 A,1994-01-11,Method for implanting tissue in a host,"A method for implanting cells into a host tissue is provided. The method comprises the steps of: creating an implant assembly for holding cells including wall means for forming a porous boundary between the host tissue and the implanted cells in the device, the pore size of the boundary being sufficient to isolate the implanted cells from the immune response; implanting the assembly without the cells into a host tissue; and accessing an interior of the assembly to add the cells thereto.",BAXTER INT,NEUENFELDT STEVEN;;BRAUKER JAMES;;CLARKE ROBERT;;CARR-BRENDEL VICTORIA,BAXTER INTERNATIONAL INC (1994-02-28),https://lens.org/048-978-084-770-024,Granted Patent,yes,1,121,6,6,0,A61F2/022;;A61K9/0024;;A61L27/38;;Y10S623/902;;A61K9/0024;;A61L27/38;;A61F2/022,C12M1/00;;A61F2/02;;A61K9/00;;A61L27/00;;A61L27/38;;C12N5/07;;C12N5/071,623/11;;623/66;;424/93.7,1,0,,,"Webster s New World Dictionary 3rd College edition, 1988 p. 441.",EXPIRED
123,GB,A,GB 2441805 A,032-614-903-305-399,2008-03-19,2008,GB 0618228 A,2006-09-15,GB 0618228 A,2006-09-15,Testing Television Signals using a Mobile Device,"A mobile television signal testing apparatus comprising receiving means for receiving a television signal; a screen for displaying an image generated from the received television signal; a detector for detecting at least a part of the image; and output means for outputting a signal derived from the detector, for providing a measure of the reception quality of the received television signal. The detector may be a photodetector, and the mobile television receiver may also comprise a mask for shielding the photodetector from extraneous light. The mask may be removable from the mobile television receiver, and the photodetector may be attached to the mask. Alternatively, the detector may be an internal detector which directly detects an electronic signal from the video decoder output.",NAT GRID WIRELESS LTD,INMAN RUSSELL;;OSBORNE PHILLIP;;CARR STEVEN;;MASON RICHARD ASHLEY,,https://lens.org/032-614-903-305-399,Patent Application,no,5,3,4,6,0,H04N17/02;;H04N17/04;;H04N17/045;;H04N17/004,H04N17/04;;H04N17/02,H4F FEG           EG,0,0,,,,DISCONTINUED
124,WO,A2,WO 2012/112887 A2,085-768-995-197-392,2012-08-23,2012,US 2012/0025643 W,2012-02-17,US 201161444419 P;;US 201213398333 A,2011-02-18,WIDE DYNAMIC RANGE INTERFEROMETRIC TRANSDUCER WITH DIVERGENT BEAM,"An apparatus and method for estimating a parameter of interest using values of a beam property from two or more electromagnetic beams that both pass through at least part of an optical displacement device. The apparatus may include a Fabry-Perot interferometer, a collimated light source, and a detection array. At least one mirror of the interferometer may be operably coupled to an element receiving an external stimulus, such as pressure, force, and/or acceleration. The method includes using the apparatus.",BAKER HUGHES INC;;EDWARDS CARL M;;CARR DUSTIN W;;PATTERSON STEVEN R,EDWARDS CARL M;;CARR DUSTIN W;;PATTERSON STEVEN R,,https://lens.org/085-768-995-197-392,Patent Application,yes,0,0,10,10,0,G01V8/02;;G01V8/02;;G01V8/02,G01V8/10;;G01V3/18,,0,0,,,,PENDING
125,WO,A3,WO 2021/247534 A3,108-675-265-621-745,2022-01-13,2022,US 2021/0035196 W,2021-06-01,US 202063033191 P,2020-06-01,COMPOSITIONS AND METHODS FOR TREATING MERKEL CELL CARCINOMA (MCC) USING HLA CLASS I SPECIFIC EPITOPES,The subject matter disclosed herein is generally directed to epitopes that specifically bind to subject specific HLA class I molecules in MCC. The epitope identified is specific for MCC and is encoded for in the Merkel Cell Polyomavirus (MCPyV) large T antigen (MCPyV LT).,BROAD INST INC;;DANA FARBER CANCER INST INC,WU CATHERINE J;;CARR STEVEN;;KLAEGER SUSAN;;KESKIN DERIN,,https://lens.org/108-675-265-621-745,Search Report,yes,4,0,3,3,27,A61K39/12;;C12N2710/22034;;A61K2039/585;;A61K2039/876;;Y02A50/30;;A61K39/12;;A61K2039/5154;;C07K14/7051;;C07K16/084,A61K39/12;;C07K16/08,,0,0,,,,PENDING
126,US,A1,US 2019/0026748 A1,152-514-144-676-107,2019-01-24,2019,US 201816143333 A,2018-09-26,US 201816143333 A;;US 201314142204 A;;US 201361769188 P,2013-02-25,MOBILE WIRELESS CUSTOMER MICRO-CARE APPARATUS AND METHOD,"In one example, a data package created by a particular wireless mobile device, and comprising metrics collected by the wireless mobile device, is retrieved. The metrics concern performance of the wireless mobile device in a wireless communication network, and are transformed into measures that enable derivation of a key performance indicator concerning the performance of the wireless mobile device. An enriched measure is generated by processing the measures based on correlations of wireless mobile device events in a time sequence, and the enriched measure is transformed into a KPI that is specific to the performance of the wireless mobile device. The KPI of the wireless mobile device is compared to a KPI of the population of wireless mobile devices, and results of the comparison of KPIs serve as a basis to resolve a problem regarding operation of the wireless mobile device.",CARRIER IQ INC,LACEY BRUCE BLAINE;;WONG ELLIS L;;CARR STEVEN R,CARRIER IQ INC (2016-09-03);;AT&T MOBILITY IP LLC (2019-06-13),https://lens.org/152-514-144-676-107,Patent Application,yes,0,0,4,5,0,G06Q30/016;;G06Q30/016,G06Q30/00,,0,0,,,,ACTIVE
127,WO,A3,WO 2002/041170 A3,013-942-183-499-335,2003-08-14,2003,US 0144244 W,2001-11-16,US 24914200 P,2000-11-16,SYSTEM AND METHOD OF MANAGING DOCUMENTS,"A system and method of managing documents wherein after document preparation, documents may be scanned to form a digital document image. After optical character recognition, a compressed digital image file with a test layer is created so that a separate text file may be extracted from the document image and tethered together by a unique identifier. The compressed digital image file and its corresponding extracted text file may be sent to a server and where an inventory of each word of every document is created. The images and text inventory are then inserted into a database such that users manipulating the system may use Boolean searches and/or activate hyperlinks tethered to document images for the purposes of navigation or the creation of index entries that may contain additional information about the documents. In the preferred method, the system allows the management of a plurality of documents over a wide area network such as the Internet.",INTERLEGIS INC,MEIER STEVEN E;;CARR KEVIN B;;KEDIDI LEYTH M,,https://lens.org/013-942-183-499-335,Search Report,yes,5,0,4,4,0,G06F16/93;;G06F16/93,G06F17/30;;G06F40/00,,0,0,,,,PENDING
128,GB,B,GB 2501834 B,071-718-613-641-723,2016-08-03,2016,GB 201313254 A,2012-02-17,US 2012/0025643 W;;US 201161444419 P;;US 201213398333 A,2011-02-18,Wide dynamic range interferometric transducer with divergent beam,,BAKER HUGHES INC,CARL M EDWARDS;;DUSTIN W CARR;;STEVEN R PATTERSON,,https://lens.org/071-718-613-641-723,Granted Patent,no,5,0,10,10,0,G01V8/02;;G01V8/02;;G01V8/02,G01V8/02,,0,0,,,,INACTIVE
129,GB,A,GB 2441837 A,095-275-463-910-959,2008-03-19,2008,GB 0706804 A,2007-04-05,GB 0618228 A,2006-09-15,Mobile television signal testing apparatus,"A mobile television signal testing apparatus comprises means such as a photo-detector 155 for detecting at least part of an image displayed on the screen 152 of a mobile television receiver 150. The apparatus may also comprise an opaque mask 154 which prevents other ambient light from reaching the detector. The output from the detector is provided to a signal conditioning unit 160 where is is filtered and digitised. Comparator 163 performs comparison with a test signal in order to determine a measure of the reception quality for the mobile television in any given location. Also disclosed is a mobile television signal testing apparatus which is able to report whether or not a picture freeze is detected by comparing the duration of a non-variant scene with a predetermined time limit. The detector 155 may be attached to the mask, whilst in turn the mask may be attached securely to the screen using hook and loop fastener strip.",NAT GRID WIRELESS LTD,INMAN RUSSELL;;OSBORNE PHILLIP;;CARR STEVEN;;MASON RICHARD ASHLEY,,https://lens.org/095-275-463-910-959,Patent Application,no,2,0,4,6,0,H04N17/02;;H04N17/04;;H04N17/045;;H04N17/004,H04N17/04,,0,0,,,,DISCONTINUED
130,WO,A2,WO 2008/032024 A2,102-821-640-478-675,2008-03-20,2008,GB 2007003382 W,2007-09-07,GB 0618228 A;;GB 0706804 A,2006-09-15,MOBILE TELEVISION SIGNAL TESTING APPARATUS,"A mobile television signal testing apparatus comprising receiving means for receiving a television signal; generating means for generating a video signal comprising an image generated from the received television signal; detection means for detecting at least a part of the image; and output means for outputting a signal obtained using the detection means, said signal providing a measure of the reception quality of the received television signal. The detection means may be a photodetector for detecting light from a television screen displaying the image. The mobile television receiver may also comprise a mask for shielding the photodetector from extraneous light. The mask may be removable from the mobile television receiver, and the photodetector may be attached to the mask.",NAT GRID WIRELESS LTD;;INMAN RUSSELL;;OSBORNE PHILIP;;CARR STEVEN;;MASON RICHARD ASHLEY,INMAN RUSSELL;;OSBORNE PHILIP;;CARR STEVEN;;MASON RICHARD ASHLEY,,https://lens.org/102-821-640-478-675,Patent Application,yes,0,3,2,6,0,H04N17/00;;H04N17/04,H04N17/00;;H04B17/00,,0,0,,,,PENDING
131,CN,A,CN 101743381 A,170-366-334-081-068,2010-06-16,2010,CN 200880024727 A,2008-05-27,GB 2008001791 W;;GB 0710670 A,2007-06-05,Turbocharger,"A turbocharger comprises a turbine wheel (5) mounted within a housing assembly (1, 3) for rotation about a turbine axis, a gas flow inlet passage (8) upstream of the turbine wheel (5), and a gas flow control mechanism (10, 16, 32) located within the housing assembly (1, 3) upstream of the turbine wheel (5) and operable to control gas flow through said gas flow inlet passage (9). An actuator assembly is mounted to the housing assembly and comprises: A lead screw including a lead screw shaft (37) defining a lead screw axis, and a lead screw nut (36) threadedly engaged on a threaded portion of the lead screw shaft (37). The lead screw (36, 37) being arranged so that rotation of one of said shaft and nut relative to the housing assembly produces linear movement in the other of said shaft and nut in the direction of the lead screw axis: The lead screw (36, 37) engages the gas flow control mechanism (10, 16, 32) at a location within a housing cavity defined within said housing assembly (1, 3).",CUMMINS TURBO TECH LTD,MICHAEL BYWATER JOHN;;STEVEN GARRETT;;LAMBTON CARR HENRY DAVID,,https://lens.org/170-366-334-081-068,Patent Application,no,0,5,7,7,0,F02C6/12;;F02C6/12;;F01D17/143;;F01D17/143;;F01D17/167;;F01D17/167;;F02B37/24;;F02B37/24;;F05D2220/40;;F05D2220/40;;F05D2250/41;;F05D2250/41;;F05D2250/411;;F05D2250/411;;F05D2260/40;;F05D2260/40;;F05D2260/50;;F05D2260/50;;F05D2260/56;;F05D2260/56;;Y02T10/12;;Y02T10/12,F01D17/14;;F02C6/12,,0,0,,,,ACTIVE
132,DE,T2,DE 69832622 T2,006-935-729-900-92X,2006-08-03,2006,DE 69832622 T,1998-09-03,GB 9718552 A;;GB 9719834 A;;GB 9720184 A;;GB 9720522 A;;GB 9720525 A;;GB 9720523 A;;GB 9720524 A;;US 7006397 P;;US 7006297 P;;US 7003797 P;;GB 9802649 W,1997-09-03,METHODEN ZUR DURCHFORSTUNG (SCREENEN) VON PROTEINEN,,BIOVATION LTD,CARR FRANCIS;;CARTER GRAHAM;;HAMILTON ANITA;;ADAIR FIONA;;WILLIAMS STEVEN,"MERCK PATENT GMBH, 64293 DARMSTADT, DE (2008-05-15)",https://lens.org/006-935-729-900-92X,Granted Patent,no,0,0,2,26,0,,C12N15/10;;C07K17/00;;C12N11/14;;C12P21/00;;C12Q1/68,,0,0,,,,EXPIRED
133,DE,T2,DE 60224129 T2,105-767-313-625-281,2008-12-11,2008,DE 60224129 T,2002-02-28,US 81799501 A,2001-03-27,"Mit einem Vliesstoff beschichtete, einlagige Dachbahn",,CARLISLE MAN COMPANY;;NICOLON CORP,CARR RICHARD W III;;CLARKE STEVEN R;;MITCHELL JOHN G,,https://lens.org/105-767-313-625-281,Granted Patent,no,0,0,11,11,0,E04D5/12;;E04D5/12;;E04D5/10;;E04D5/10;;Y10T428/149;;Y10T428/149,E04D5/10;;B32B11/10;;E04D5/12,,0,0,,,,EXPIRED
134,EP,A2,EP 1245753 A2,190-863-043-413-619,2002-10-02,2002,EP 02004589 A,2002-02-28,US 81799501 A,2001-03-27,"Singe-ply roofing membrane with laminated, skinned nonwoven","This invention is directed to a membrane laminate (20) for a roofing system comprising a membrane sheet (22) and a nonwoven material (24) laminated to said sheet. The nonwoven material (24) has a semipermeable, skinned layer formed therein.",THANTEX SPECIALTIES INC;;CARLISLE MAN COMPANY,CARR RICHARD W III;;CLARKE STEVEN R;;MITCHELL JOHN G,NICOLON CORPORATION (2007-12-05);;CARLISLE MANAGEMENT COMPANY (2007-12-05),https://lens.org/190-863-043-413-619,Patent Application,yes,4,0,11,11,0,E04D5/12;;E04D5/12;;E04D5/10;;E04D5/10;;Y10T428/149;;Y10T428/149,B32B11/10;;E04D5/10;;E04D5/12,,0,0,,,,EXPIRED
135,EP,A3,EP 1245753 A3,008-818-909-406-574,2002-10-09,2002,EP 02004589 A,2002-02-28,US 81799501 A,2001-03-27,"Singe-ply roofing membrane with laminated, skinned nonwoven","This invention is directed to a membrane laminate (20) for a roofing system comprising a membrane sheet (22) and a nonwoven material (24) laminated to said sheet. The nonwoven material (24) has a semipermeable, skinned layer formed therein.",THANTEX SPECIALTIES INC;;CARLISLE MAN COMPANY,CARR RICHARD W III;;CLARKE STEVEN R;;MITCHELL JOHN G,NICOLON CORPORATION (2007-12-05);;CARLISLE MANAGEMENT COMPANY (2007-12-05),https://lens.org/008-818-909-406-574,Search Report,yes,4,0,11,11,0,E04D5/10;;E04D5/12;;Y10T428/149;;Y10T428/149;;E04D5/12;;E04D5/10,B32B11/10;;E04D5/10;;E04D5/12,,0,0,,,,EXPIRED
136,JP,A,JP 2002339522 A,063-476-804-770-246,2002-11-27,2002,JP 2002077790 A,2002-03-20,US 81799501 A,2001-03-27,SINGLE-PLY ROOFING MEMBRANE HAVING LAMINATED AND SKIN ATTACHED NONWOVEN FABRIC,"PROBLEM TO BE SOLVED: To provide a membrane laminate capable of being used by an asphalt adhesive single-ply laminate roofing system and eliminating or decreasing the occurrence of 'INFILTRATION'. SOLUTION: The membrane laminate formed of a membrane sheet and a nonwoven fabric is used for a roofing system, the nonwoven fabric is laminated together with the membrane, and the nonwoven fabric forms a translucent skin attached layer therein.",THANTEX SPECIALTIES INC;;CARLYLE MAN CO,CARR RICHARD W III;;CLARKE STEVEN R;;MITCHELL JOHN G,,https://lens.org/063-476-804-770-246,Patent Application,no,1,0,11,11,0,E04D5/12;;E04D5/12;;E04D5/10;;E04D5/10;;Y10T428/149;;Y10T428/149,B32B11/10;;E04D5/10;;E04D5/12,,0,0,,,,EXPIRED
137,EP,B1,EP 1245753 B1,073-948-527-241-949,2007-12-19,2007,EP 02004589 A,2002-02-28,US 81799501 A,2001-03-27,"Singe-ply roofing membrane with laminated, skinned nonwoven",,NICOLON CORP;;CARLISLE MAN COMPANY,CARR RICHARD W III;;CLARKE STEVEN R;;MITCHELL JOHN G,NICOLON CORPORATION (2007-12-05);;CARLISLE MANAGEMENT COMPANY (2007-12-05),https://lens.org/073-948-527-241-949,Granted Patent,yes,4,0,11,11,0,E04D5/12;;E04D5/12;;E04D5/10;;E04D5/10;;Y10T428/149;;Y10T428/149,E04D5/10;;B32B11/10;;E04D5/12,,0,0,,,,EXPIRED
138,CA,C,CA 2366769 C,132-160-464-390-262,2009-12-15,2009,CA 2366769 A,2002-01-07,US 81799501 A,2001-03-27,"SINGLE-PLY ROOFING MEMBRANE WITH LAMINATED, SKINNED NONWOVEN","This invention is directed to a membrane laminate for a roofing system comprising a membrane sheet and a nonwoven material laminated to said sheet. The nonwoven material has a semi--permeable, skinned layer formed therein.",CARLISLE MAN COMPANY;;THANTEX SPECIALTIES INC,MITCHELL JOHN G;;CLARKE STEVEN R;;CARR RICHARD W III,,https://lens.org/132-160-464-390-262,Granted Patent,no,0,0,11,11,0,E04D5/12;;E04D5/12;;E04D5/10;;E04D5/10;;Y10T428/149;;Y10T428/149,E04B7/22;;B32B11/10;;E04D5/10;;E04D5/12;;E04D7/00,,0,0,,,,EXPIRED
139,DE,D1,DE 69832622 D1,030-544-553-464-045,2006-01-05,2006,DE 69832622 T,1998-09-03,GB 9718552 A;;GB 9719834 A;;GB 9720184 A;;GB 9720522 A;;GB 9720525 A;;GB 9720523 A;;GB 9720524 A;;US 7006397 P;;US 7006297 P;;US 7003797 P;;GB 9802649 W,1997-09-03,METHODEN ZUR DURCHFORSTUNG (SCREENEN) VON PROTEINEN,,BIOVATION LTD,CARR FRANCIS;;CARTER GRAHAM;;HAMILTON ANITA;;ADAIR FIONA;;WILLIAMS STEVEN,"MERCK PATENT GMBH, 64293 DARMSTADT, DE (2008-05-15)",https://lens.org/030-544-553-464-045,Granted Patent,no,0,0,2,26,0,,C07K17/00;;C12N11/14;;C12N15/10;;C12P21/00;;C12Q1/68,,0,0,,,,EXPIRED
140,EP,A1,EP 1003853 A1,137-392-813-267-604,2000-05-31,2000,EP 98940471 A,1998-09-03,GB 9802649 W;;GB 9718552 A;;GB 9719834 A;;GB 9720184 A;;GB 9720522 A;;GB 9720525 A;;GB 9720523 A;;GB 9720524 A;;GB 9801255 A;;GB 9803828 A;;GB 9807760 A;;GB 9811130 A;;US 7006397 P;;US 7006297 P;;US 7003797 P;;US 7005097 P,1997-09-03,METHODS FOR PROTEIN SCREENING,"The present invention provides novel methods of protein/polypeptide screening based on the provision of libraries of individual proteins/polypeptides, which in turn can be screened for cell binding, biological activity etc. Methods for recovering genes encoding such proteins/polypeptides are also provided.",BIOVATION LTD,CARR FRANCIS;;CARTER GRAHAM;;HAMILTON ANITA;;ADAIR FIONA;;WILLIAMS STEVEN,,https://lens.org/137-392-813-267-604,Patent Application,yes,0,0,8,26,0,C07K16/00;;C07K2319/00;;C12N15/1037;;C12N15/1041;;C40B40/02,C12N15/09;;C07K14/16;;C07K14/54;;C07K16/00;;C07K17/00;;C12N11/14;;C12N15/10;;C12P21/00;;C12Q1/68;;C40B40/02;;G01N37/00,,0,0,,,,EXPIRED
141,US,B2,US 6502360 B2,031-540-108-525-848,2003-01-07,2003,US 81799501 A,2001-03-27,US 81799501 A,2001-03-27,"Single-ply roofing membrane with laminated, skinned nonwoven","
    This invention is directed to a membrane laminate for a roofing system comprising a membrane sheet and a nonwoven material laminated to said sheet. The nonwoven material has a semi-permeable, skinned layer formed therein. 
",THANTEX SPECIALTIES INC;;CARLISLE MAN CO,CARR III RICHARD W;;CLARKE STEVEN R;;MITCHELL JOHN G,NICOLON CORPORATION (2006-02-17);;CARLISLE MANAGEMENT CO (2001-07-25);;THANTEX SPECIALTIES INC (2001-08-27);;THANTEX INC (2006-02-16),https://lens.org/031-540-108-525-848,Granted Patent,yes,9,143,11,11,0,E04D5/12;;E04D5/12;;E04D5/10;;E04D5/10;;Y10T428/149;;Y10T428/149,B32B11/10;;E04D5/10;;E04D5/12,52/408;;52/409;;52/746.11;;428/42.2,4,0,,,"U.S. patent application Ser. No. 09/238,678, Clarke, filed Jan. 26, 1999.;;Carlisle Syntec Incorporated, ""855119-FB-FA System Submittal Sheet"" Product Bulletin, (1999).;;Carlisle Syntec Incorporated, ""600545-FB System Components Briefolio"" Product Bulletin, (2000).;;Carlisle Syntec Incorporated, ""Sure-Seal(R) HM ""Hot Mopped"" Roofing System"", (Aug. 2000).",EXPIRED
142,DE,D1,DE 60224129 D1,060-932-163-366-362,2008-01-31,2008,DE 60224129 T,2002-02-28,US 81799501 A,2001-03-27,"Mit einem Vliesstoff beschichtete, einlagige Dachbahn",,CARLISLE MAN COMPANY;;NICOLON CORP,CARR RICHARD W III;;CLARKE STEVEN R;;MITCHELL JOHN G,,https://lens.org/060-932-163-366-362,Granted Patent,no,0,0,11,11,0,E04D5/12;;E04D5/12;;E04D5/10;;E04D5/10;;Y10T428/149;;Y10T428/149,E04D5/10;;B32B11/10;;E04D5/12,,0,0,,,,EXPIRED
143,US,A,US 5926148 A,128-106-468-597-04X,1999-07-20,1999,US 93401397 A,1997-08-25,US 93401397 A,1997-08-25,Three dimensional reconfigurable photoconductive antenna array element,"First and second tandemly positioned electrically biased semiconductor members radiate microwave energy in response to the receipt of an excitation light beam having two wavelengths related to the bandgaps of the members. The projected microwave beam may be made more narrow and directional if two of the members are electrically biased at the same time. An inefficient frequency doubler generates the two wavelength beam enabling a single light beam to excite both members in a simple, rugged photoconductive antenna element.",US AIR FORCE,LIU DAVID DA-WEI;;CARR PAUL H;;MITTLEMAN STEVEN D,AIR FORCE UNITED STATES (1997-08-08),https://lens.org/128-106-468-597-04X,Granted Patent,yes,3,2,1,1,0,H01Q3/2676;;H01Q3/2676;;H01Q13/24;;H01Q13/24,H01Q3/26;;H01Q13/24,343/785;;343/721;;342/368;;250/551,0,0,,,,EXPIRED
144,EP,B1,EP 1003853 B1,048-624-521-224-358,2005-11-30,2005,EP 98940471 A,1998-09-03,GB 9802649 W;;GB 9718552 A;;GB 9719834 A;;GB 9720184 A;;GB 9720522 A;;GB 9720525 A;;GB 9720523 A;;GB 9720524 A;;GB 9801255 A;;GB 9803828 A;;GB 9807760 A;;GB 9811130 A;;US 7006397 P;;US 7006297 P;;US 7003797 P;;US 7005097 P,1997-09-03,METHODS FOR PROTEIN SCREENING,"The present invention provides novel methods of protein/polypeptide screening based on the provision of libraries of individual proteins/polypeptides, which in turn can be screened for cell binding, biological activity etc. Methods for recovering genes encoding such proteins/polypeptides are also provided.",BIOVATION LTD,CARR FRANCIS;;CARTER GRAHAM;;HAMILTON ANITA;;ADAIR FIONA;;WILLIAMS STEVEN,,https://lens.org/048-624-521-224-358,Granted Patent,yes,8,1,8,26,0,C07K16/00;;C07K2319/00;;C12N15/1037;;C12N15/1041;;C40B40/02,C12N15/09;;C07K14/16;;C07K14/54;;C07K16/00;;C07K17/00;;C12N11/14;;C12N15/10;;C12P21/00;;C12Q1/68;;C40B40/02;;G01N37/00,,3,0,,,"HANES J & PL CKTHUN A: ""In vitro selection and evolution of functional proteins by using ribosome display"" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, no. 94, page 4937 4937 XP002077149 cited in the application;;MATTHEAKIS L C ET AL: ""AN IN VITRO POLYSOME DISPLAY SYSTEM FOR IDENTIFYING LIGANDS FROM VERY LARGE PEPTIDE LIBRARIES"" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, September 1994, pages 9022-9026, XP002043737 cited in the application;;S. JUNG AND A. PLÜCKTHUN: ""Improving in vivo folding and stability of a single-chain-Fv antibody fragmnet by loop grafting"" PROTEIN ENGINEERING, vol. 10, no. 8, August 1997, pages 959-966, XP002085709 IRL PRESS LIMITED OXFORD, ENGLAND",EXPIRED
145,US,A1,US 2005/0125401 A1,160-518-066-859-618,2005-06-09,2005,US 72868603 A,2003-12-05,US 72868603 A,2003-12-05,Wizard for usage in real-time aggregation and scoring in an information handling system,"An information handling method includes constructing aggregates for a case set, computing aggregates from detailed in-memory data that is dynamically cached, and iteratively mining data during an entity transaction to define new aggregates and refine existing aggregates based on entity responses. The aggregates are defined and refined using a wizard.",HEWLETT PACKARD DEVELOPMENT CO,CARR STEVEN R;;MUTHUSWAMY VENKATAKRISHNAN;;HAR TUDOR;;BOSINOFF PHILIP R,,https://lens.org/160-518-066-859-618,Patent Application,yes,4,65,1,1,0,G06Q30/02;;G06Q30/02,G06Q30/00,707/5,0,0,,,,DISCONTINUED
146,CA,A1,CA 2366769 A1,083-743-805-558-596,2002-09-27,2002,CA 2366769 A,2002-01-07,US 81799501 A,2001-03-27,"SINGLE-PLY ROOFING MEMBRANE WITH LAMINATED, SKINNED NONWOVEN","This invention is directed to a membrane laminate for a roofing system comprising a membrane sheet and a nonwoven material laminated to said sheet. The nonwoven material has a semi- permeable, skinned layer formed therein.",CARLISLE MAN COMPANY;;THANTEX SPECIALTIES INC,CARR RICHARD W III;;CLARKE STEVEN R;;MITCHELL JOHN G,,https://lens.org/083-743-805-558-596,Patent Application,no,0,0,11,11,0,E04D5/12;;E04D5/12;;E04D5/10;;E04D5/10;;Y10T428/149;;Y10T428/149,B32B11/10;;E04D5/10;;E04D5/12,,0,0,,,,EXPIRED
147,US,A1,US 2005/0125280 A1,014-219-678-552-867,2005-06-09,2005,US 72870803 A,2003-12-05,US 72870803 A,2003-12-05,Real-time aggregation and scoring in an information handling system,An information handling method comprises a recommender with an aggregation engine capable of computing aggregates in from in-memory data that is dynamically cached during a transaction with an entity.,HEWLETT PACKARD DEVELOPMENT CO,CARR STEVEN R;;MUTHUSWAMY VENKATAKRISHNAN;;HAR TUDOR;;BOSINOFF PHILIP R,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2004-05-10),https://lens.org/014-219-678-552-867,Patent Application,yes,10,12,1,1,0,G06Q30/02;;G06Q30/0631;;G06Q30/02;;G06Q30/0631,G06Q30/00,705/10,0,0,,,,DISCONTINUED
148,US,A,US 4796256 A,042-685-948-285-759,1989-01-03,1989,US 90805686 A,1986-09-16,US 90805686 A,1986-09-16,(MPRT) Mini packet receiver transmitter,"The Mini Packet Receiver Transmitter Circuit (MPRT) provides an interface between one or two eight bit microprocessors and a digital subscriber loop interface circuit. The bi-directional communication on a single wire pair is accomplished by alternating the subscriber loop receive and transmit frames controlled by a ""Ping-Pong Protocol"" using fixed frame format and bipolar alternate mark inversion (AMI) line encoding. There are two microprocessor ports within the MPRT, a transparent port for voice transmission and a non-transparent port for data trasmission. The MPRT implements the Mini Packet Protocol frame format as a mini packet (MP) of information, for both transparent and non-transparent data.",GTE COMMUNICATION SYST,OPDERBECK HOLGER;;SENCER GULAY;;CARR WILLIAM N;;BYARS STEVEN J,GTE COMMUNICATION SYSTEMS CORPORATION NORTHLAKE ILL. A CORP. OF DE (1986-10-28);;AG COMMUNICATION SYSTEMS CORPORATION 2500 W. UTOPIA RD. PHOENIX AZ 85027 A DE CORP (1988-12-28),https://lens.org/042-685-948-285-759,Granted Patent,yes,4,15,1,1,0,H04L5/1492;;H04L7/042;;H04L7/10;;H04L7/10;;H04L7/042;;H04L5/1492,H04L5/14;;H04L7/04;;H04L7/10,370/110.1;;370/29,0,0,,,,EXPIRED
149,US,A1,US 2003/0220901 A1,173-558-549-552-897,2003-11-27,2003,US 40228303 A,2003-03-27,US 40228303 A;;US 38249602 P;;US 41318602 P,2002-05-21,Interaction manager,"
   An interaction manager (IM) is provided which is designed for gathering information associated with customer interactions, loading customer-related data at the beginning of each session, enriching the customer interactions with offers from a rules service, and performing data caching for more efficient customer interaction data retrieval and processing, including caching a session context with the gathered information and customer-related data after each interaction and restoring the session context at the beginning of each interaction. Offers to the customers are based on a comprehensive real-time view of the customer-related data and are augmented by rules and/or data mining, wherein the rules include enterprise rules and/or policies. The data caching includes saving data in denormalized form. The denormalized form is fashioned by taking the data in the normalized form and caching it lined up flatly and serially, end-to-end, in a long record so that it can be quickly retrieved in subsequent interactions and forwarded to the rules service. The long record with the data in denormalized form is cached along with a session identification key for easy association of the data in the denormalized form with a particular session. 
",HEWLETT PACKARD DEVELOPMENT CO,CARR STEVEN R;;GENTILOZZI HARRY V;;HAR TUDOR I;;MUTHUSWAMY VENKATAKRISHNAN,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2003-03-18),https://lens.org/173-558-549-552-897,Patent Application,yes,14,158,2,2,0,G06Q30/02;;G06Q30/02;;G06F16/217;;G06F16/217;;G06F16/2465;;G06F16/2465,G06F7/00;;G06F9/00;;G06F9/44;;G06F17/30;;G06Q30/02,707/1,0,0,,,,DISCONTINUED
150,AU,A,AU 1998/088792 A,047-691-911-594-059,1999-03-22,1999,AU 1998/088792 A,1998-09-03,GB 9811130 A;;US 7005097 P,1997-12-30,Methods for protein screening,,MERCK PATENT GMBH,CARR FRANCIS JOSEPH;;CARTER GRAHAM;;HAMILTON ANITA;;ADAIR FIONA;;WILLIAMS STEVEN,,https://lens.org/047-691-911-594-059,Patent Application,no,0,1,2,26,0,H04B1/7093;;C07K16/00;;C12N15/1037;;C12N15/1041;;C40B40/02;;C07K2319/00,C12N15/09;;C07K14/16;;C07K14/54;;C07K16/00;;C07K17/00;;C12N11/14;;C12N15/10;;C12P21/00;;C12Q1/68;;C40B40/02;;G01N37/00;;G01S1/04;;G01S5/14;;H04B1/7093,,0,0,,,,EXPIRED
151,US,A1,US 2003/0101099 A1,067-444-110-610-722,2003-05-29,2003,US 99663701 A,2001-11-29,US 99663701 A,2001-11-29,Computerized method for the solicitation and sales of transactions,"
   A computerized method for managing electronic data configured to enable the generation of paper and electronic solicits for effectuating consumer service transactions between a consumer and a service center. The method allows for selecting populations for receiving paper and/or electronic solicits for purchase of extended warranties generated as a function of consumer and product related data. The method also allows for the consumer and product data to be copied to Web based solicit response tables and for the scheduling and generation of electronic solicits via email delivery. Each email also contains a unique and personalized link that permits the consumer to link directly to a Web page menu that includes data indicative of warranty services that may be purchased by that consumer. Warranty service data of the paper solicit, the electronic solicit and the Web based solicit are synchronized so the consumer will receive the same data in each medium. Feedback is provided to the service center to suppress further solicits once the consumer has made a purchase. 
",SHELTZ STEVEN PETER;;HEALEY MICHAEL;;CARR REBECCA LEANN;;FISCUS KRISTI HARBERTS,SHELTZ STEVEN PETER;;HEALEY MICHAEL;;CARR REBECCA LEANN;;FISCUS KRISTI HARBERTS,GENERAL ELECTRIC COMPANY (2001-11-15),https://lens.org/067-444-110-610-722,Patent Application,yes,18,26,2,2,0,G06Q30/02;;G06Q30/0621;;G06Q30/0635;;G06Q30/0641;;G06Q30/02;;G06Q30/0641;;G06Q30/0635;;G06Q30/0621,G06Q30/02;;G06Q30/06,705/26,0,0,,,,DISCONTINUED
152,US,A1,US 2003/0229884 A1,069-580-302-746-359,2003-12-11,2003,US 40248203 A,2003-03-27,US 40248203 A;;US 38249602 P;;US 41318602 P,2002-05-21,Interaction manager template,"
   A template for deployment of enterprise applications one example of which is an interaction manager. For deployment of the interaction manager, the template is configured with a class framework for building source code of the interaction manager and a test driver. The template is further configured with wizards. An application wizard provides for building a base class portion of the class framework. Interaction and attribute wizards provide for extending or modifying the class framework once the base class portion is built so as to provide for enterprise-specific deployment of the interaction manager along with the test driver. In addition, test driver script is provided through which the test driver is to be used for validating and measuring the performance of the interaction manager once their source code is converted to executable code. 
",HEWLETT PACKARD DEVELOPMENT CO,CARR STEVEN R;;GENTILOZZI HARRY V;;HAR TUDOR I;;MUTHUSWAMY VENKATAKRISHNAN,HEWLETT-PACKARD COMPANY (2003-04-03);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2005-09-22),https://lens.org/069-580-302-746-359,Patent Application,yes,6,76,2,2,0,G06Q30/02;;G06Q30/02;;G06F16/217;;G06F16/217;;G06F16/2465;;G06F16/2465,G06F7/00;;G06F9/00;;G06F9/44;;G06F17/30;;G06Q30/02,717/101;;709/106,0,0,,,,DISCONTINUED
153,CN,A,CN 115697219 A,156-389-400-123-84X,2023-02-03,2023,CN 202180039050 A,2021-07-23,US 202063055585 P;;US 2021/0042898 W,2020-07-23,Surgical saw blade bracket and coupler therefor,"A saw blade carrier includes a saw blade and a cartridge. The cartridge is disposed on a proximal portion of the saw blade and includes a first cartridge portion and a second cartridge portion opposite each other across the proximal portion. Each portion includes a housing and a damper. The housing has a first stiffness and has an outer side. The damper has a second stiffness less than the first stiffness and is disposed on an inner side of the housing. The cartridge portions are substantially fixed relative to the proximal portion and substantially aligned with each other. The housings are secured to each other. The damper contacts the proximal portion. A handpiece coupler for engaging either a saw blade carrier or a saw blade includes a release button, where a lock button is slidably disposed in the handpiece coupler to prevent accidental opening.",STRYKER CORP,KOVAL WAYNE S;;CARR JAMES G;;CULVER GIDEON;;CARUSILLO STEVEN J,,https://lens.org/156-389-400-123-84X,Patent Application,no,0,0,7,7,0,A61B17/142;;A61B17/162;;A61B17/142;;A61B2017/00477,A61B17/14,,0,0,,,,PENDING
154,AU,B2,AU 754377 B2,047-062-739-790-573,2002-11-14,2002,AU 1998/087560 A,1998-04-14,GB 9801255 A;;GB 9803828 A;;GB 9807760 A;;GB 9718552 A;;GB 9719834 A;;GB 9720184 A;;GB 9720522 A;;GB 9720525 A;;GB 9720523 A;;GB 9720524 A;;GB 9802649 W;;US 7006397 P;;US 7006297 P;;US 7003797 P,1997-09-03,Methods for protein screening,,BIOVATION LTD,CARR FRANCIS JOSEPH;;CARTER GRAHAM;;HAMILTON ANITA;;ADAIR FIONA;;WILLIAMS STEVEN,,https://lens.org/047-062-739-790-573,Granted Patent,no,2,0,2,26,0,G01S5/0036;;G01S5/0054;;G01S19/09;;G01S19/30;;G01S19/37;;H04B1/7077;;H04B1/7077;;H04B1/708;;H04B1/7093;;H04B2201/70707;;H04B2201/70715,C07K14/16;;C07K14/54;;C07K16/00;;C07K17/00;;C12N11/14;;C12N15/10;;C12N15/12;;C12N15/24;;C12N15/49;;C12P21/00;;C12Q1/68;;G01S1/00;;G01S5/00;;G01S19/09;;G01S19/24;;G01S19/30;;G01S19/37;;H04B1/707,,1,1,059-349-671-883-389,pmc24609;;9144168;;10.1073/pnas.94.10.4937,PNAS VOL94 PP 4937-4942,EXPIRED
155,US,A,US 6016875 A,002-638-228-904-459,2000-01-25,2000,US 2143398 A,1998-02-10,US 2143398 A,1998-02-10,Gain adaptation control for hydraulic systems,"A system or method for controlling the position of an implement coupled to a work vehicle. The implement is moveable by a hydraulic positioning assembly including an actuator and a valve assembly which control the flow of fluid to the actuator in response to control signals. The valve assembly includes raise and lower valves, each valve requiring a control signal equal to a threshold value before the valve opens and fluid begins to flow. The system includes a sensor to detect the position of the implement and a control circuit. In response to a change in a position command, the control circuit applies a control signal to the appropriate raise or lower valve based upon the respective threshold value. The control signal is generated by using a predetermined gain. When undesirable implement movement such as an overshoot condition is detected, the control circuit modifies the gain value. The modified gain value is used to generate subsequent control signals for actuating the implement.",CASE CORP,ORBACH ABRAHAM;;SCHUBERT WILLIAM L;;SEYMOUR STEVEN W;;CARR DONALD D,CASE CORPORATION (1998-02-03);;CNH AMERICA LLC (2006-06-06);;BLUE LEAF I.P. INC (2006-06-06),https://lens.org/002-638-228-904-459,Granted Patent,yes,10,39,1,1,0,A01B63/1117;;G05B13/024;;G05B13/024;;A01B63/1117,A01B63/111;;G05B13/02,172/2;;701/50,0,0,,,,EXPIRED
156,WO,A1,WO 2023/196083 A1,036-651-525-718-396,2023-10-12,2023,US 2023/0015049 W,2023-03-12,US 202263328623 P;;US 202217840156 A,2022-04-07,LOCATION ADJUSTMENT WITH NON-VISUAL LOCATION FEEDBACK,"Generally discussed herein are devices, systems, and methods for location adjustment with non-visual location feedback. A method can include providing, by a visual map program, an indication of an initial selected location of a user-selected location, detecting, by data provided by an input component, an audio or tactile trigger by a user, responsive to the detecting, altering, by a first distance and a first direction, the initial selected location to a new location on the visual map program, and responsive to the altering, causing an output component to provide an audio or tactile indication of the new location.",MICROSOFT TECHNOLOGY LICENSING LLC,KNEISEL MELANIE JO;;MILLER AMOS;;CARR FRAZIER ROBERT;;ABRAMS STEVEN RICHARD,,https://lens.org/036-651-525-718-396,Patent Application,yes,2,0,1,2,0,G06F3/016;;G01C21/3664;;G06F2203/014,G01C21/36;;G06F3/01,,0,0,,,,PENDING
157,US,A1,US 2005/0177457 A1,133-853-370-414-444,2005-08-11,2005,US 6331705 A,2005-02-22,US 6331705 A;;US 99663701 A,2001-11-29,Computerized method for the solicitation and sales of transactions,"A computerized method for managing electronic data configured to enable the generation of paper and electronic solicits for effectuating consumer service transactions between a consumer and a service center. The method allows for selecting populations for receiving paper and/or electronic solicits for purchase of extended warranties generated as a function of consumer and product related data. The method also allows for the consumer and product data to be copied to Web based solicit response tables and for the scheduling and generation of electronic solicits via email delivery. Each email also contains a unique and personalized link that permits the consumer to link directly to a Web page menu that includes data indicative of warranty services that may be purchased by that consumer. Warranty service data of the paper solicit, the electronic solicit and the Web based solicit are synchronized so the consumer will receive the same data in each medium. Feedback is provided to the service center to suppress further solicits once the consumer has made a purchase.",SHELTZ STEVEN P.;;HEALEY MICHAEL;;CARR REBECCA L.;;FISCUS KRISTI H.,SHELTZ STEVEN P;;HEALEY MICHAEL;;CARR REBECCA L;;FISCUS KRISTI H,GENERAL ELECTRIC COMPANY (2001-11-15),https://lens.org/133-853-370-414-444,Patent Application,yes,28,15,2,2,0,G06Q30/02;;G06Q30/0621;;G06Q30/0635;;G06Q30/0641;;G06Q30/02;;G06Q30/0641;;G06Q30/0635;;G06Q30/0621,G06Q30/02;;G06Q30/06,705/26,0,0,,,,DISCONTINUED
158,WO,A1,WO 1999/011777 A1,036-356-466-841-893,1999-03-11,1999,GB 9802649 W,1998-09-03,GB 9718552 A;;GB 9719834 A;;GB 9720184 A;;GB 9720522 A;;GB 9720525 A;;GB 9720523 A;;GB 9720524 A;;GB 9801255 A;;GB 9803828 A;;GB 9807760 A;;GB 9811130 A;;US 7006397 P;;US 7006297 P;;US 7003797 P;;US 7005097 P,1997-09-03,METHODS FOR PROTEIN SCREENING,"The present invention provides novel methods of protein/polypeptide screening based on the provision of libraries of individual proteins/polypeptides, which in turn can be screened for cell binding, biological activity etc. Methods for recovering genes encoding such proteins/polypeptides are also provided.",BIOVATION LTD;;CARR FRANCIS JOSEPH;;CARTER GRAHAM;;HAMILTON ANITA;;ADAIR FIONA;;WILLIAMS STEVEN,CARR FRANCIS JOSEPH;;CARTER GRAHAM;;HAMILTON ANITA;;ADAIR FIONA;;WILLIAMS STEVEN,,https://lens.org/036-356-466-841-893,Patent Application,yes,8,25,8,26,57,C07K16/00;;C07K2319/00;;C12N15/1037;;C12N15/1041;;C40B40/02,C07K14/16;;C07K14/54;;C07K16/00;;C07K17/00;;C12N11/14;;C12N15/10;;C12P21/00;;C12Q1/68;;C40B40/02;;G01N37/00;;C12N15/09,,3,3,059-349-671-883-389;;116-821-682-892-530;;049-973-174-679-084,pmc24609;;9144168;;10.1073/pnas.94.10.4937;;7522328;;10.1073/pnas.91.19.9022;;pmc44739;;10.1093/protein/10.8.959;;9415446,"HANES J & PL CKTHUN A: ""In vitro selection and evolution of functional proteins by using ribosome display"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, no. 94, pages 4937 4937, XP002077149;;MATTHEAKIS L C ET AL: ""AN IN VITRO POLYSOME DISPLAY SYSTEM FOR IDENTIFYING LIGANDS FROM VERY LARGE PEPTIDE LIBRARIES"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, September 1994 (1994-09-01), pages 9022 - 9026, XP002043737;;S. JUNG AND A. PLÜCKTHUN: ""Improving in vivo folding and stability of a single-chain-Fv antibody fragmnet by loop grafting"", PROTEIN ENGINEERING, vol. 10, no. 8, August 1997 (1997-08-01), IRL PRESS LIMITED OXFORD, ENGLAND, pages 959 - 966, XP002085709",PATENTED
159,US,A,US 6058343 A,081-846-782-023-116,2000-05-02,2000,US 7359098 A,1998-05-06,US 7359098 A;;US 68581796 A,1996-07-25,Threshold current control system for hydraulic valves,"A system or method for controlling the position of an implement coupled to a work vehicle. The implement is moveable by a hydraulic positioning assembly including an actuator and a valve assembly which control the flow of fluid to the actuator in response to control signals. The valve assembly includes raise and lower valves, each valve requiring a control signal equal to a threshold value before the valve opens and fluid begins to flow. The system includes a sensor to detect the position of the implement and a control circuit. In response to a change in a position command, the control circuit applies a control signal to the appropriate raise or lower valve based upon the respective threshold value. The control signal may include a component for moving the implement at a desired rate of movement. After undesirable implement movement is detected, the control circuit modifies the threshold value. The modification may occur when the control circuit detects that the implement is moving at an excessive rate due to the effects of valve hysteresis and implement weight. The control circuit may detect the undesirable movement by determining that the position error value is more negative than a predetermined value. The modified threshold value then replaces the threshold value for subsequent implement movement. The new threshold value prevents the undesirable movement in subsequent implement movement.",CASE CORP,ORBACH ABRAHAM;;SCHUBERT WILLIAM L;;SEYMOUR STEVEN W;;CARR DONALD D,CASE CORPORATION (1998-04-24);;CNH AMERICA LLC (2006-06-06);;BLUE LEAF I.P. INC (2006-06-06),https://lens.org/081-846-782-023-116,Granted Patent,yes,6,43,1,2,0,A01B63/1006;;E02F9/2029;;E02F9/2203;;E02F9/2207;;A01B63/1006;;E02F9/2207;;E02F9/2203;;E02F9/2029,A01B63/10;;E02F9/20;;E02F9/22,701/50;;172/2;;172/4.5,0,0,,,,EXPIRED
160,US,A1,US 2023/0326368 A1,183-187-737-978-791,2023-10-12,2023,US 202217840156 A,2022-06-14,US 202217840156 A;;US 202263328623 P,2022-04-07,LOCATION ADJUSTMENT WITH NON-VISUAL LOCATION FEEDBACK,"Generally discussed herein are devices, systems, and methods for location adjustment with non-visual location feedback. A method can include providing, by a visual map program, an indication of an initial selected location of a user-selected location, detecting, by data provided by an input component, an audio or tactile trigger by a user, responsive to the detecting, altering, by a first distance and a first direction, the initial selected location to a new location on the visual map program, and responsive to the altering, causing an output component to provide an audio or tactile indication of the new location.",MICROSOFT TECHNOLOGY LICENSING LLC,KNEISEL MELANIE JO;;MILLER AMOS;;CARR FRAZIER ROBERT;;ABRAMS STEVEN RICHARD,MICROSOFT TECHNOLOGY LICENSING LLC (2022-04-13),https://lens.org/183-187-737-978-791,Patent Application,yes,8,0,1,2,0,G09B21/006;;G09B21/003;;G06F3/016;;G06F3/165;;G06F3/167;;G09B21/003;;G06F3/04842;;G06F3/167;;G01C21/3626;;G06F3/0346;;G09B21/006;;G01C21/3664;;G06F3/016,G09B21/00;;G01C21/36;;G06F3/01;;G06F3/0346;;G06F3/04842;;G06F3/16,,0,0,,,,PENDING
161,EP,A3,EP 0957504 A3,031-349-020-548-951,2001-12-05,2001,EP 99303554 A,1999-05-06,GB 9809821 A,1998-05-09,Electron gun arrangements,"An electron gun arrangement includes a cathode 1 having a front surface 2 and control grid 3 located in front of it. The control grid 3 is mounted via a cylindrical support 8 on a Kovar mount 12. The cathode 1 is supported by a cylindrical support 6 mounted on a Kovar support 10. Ceramic material 11 being located between the two supports 10 and 12. The vacuum envelope within which the electron gun is contained includes the Kovar support 12 and a flexible member 13 with which it makes a vacuum seal, this member 13 being of copper. The copper member 13 is sealed to a ceramic cylinder 16 via metal flanges 17 and 18. The assembly permits the spacing between the cathode and grid 3 to be maintained whilst the copper member 13 permits thermal expansion to occur to maintain vacuum integrity.",EEV LTD,THWAITES ALFRED CRISTOPHER;;CARR DAVID WARD;;BARDELL STEVEN;;COX PETER ROBERT JOHN,E2V TECHNOLOGIES (UK) LIMITED (2004-10-20),https://lens.org/031-349-020-548-951,Search Report,yes,3,0,9,9,0,H01J23/065;;H01J23/065;;H01J2225/04;;H01J2225/04,H01J23/065,,0,0,,,,DISCONTINUED
162,CA,A1,CA 2271250 A1,193-183-660-136-952,1999-11-09,1999,CA 2271250 A,1999-05-07,GB 9809821 A,1998-05-09,ELECTRON GUN ARRANGEMENTS,"An electron gun arrangement includes a cathode 1 having a front surface 2 and control grid 3 located in front of it. The control grid 3 is mounted via a cylindrical support 8 on a Kovar mount 12. The cathode 1 is supported by a cylindrical support 6 mounted on a Kovar support 10, Ceramic material 11 being located between the two supports 14 and 12. The vacuum envelope within which the electron gun is contained includes the Kovar support 12 and a flexible member 13 with which it makes a vacuum seal, this member 13 being of copper. The copper member 13 is staled to a ceramic cylinder 16 via metal flanges 17 and 18. The assembly permits the spacing between the cathode and grid 3 to be maintained whilst the copper member 13 permits thermal expansion to occur to maintain vacuum integrity.",EEV LTD,CARR DAVID WARD;;THWAITES ALFRED CHRISTOPHER;;BARDELL STEVEN;;COX PETER ROBERT JOHN,,https://lens.org/193-183-660-136-952,Patent Application,no,0,0,9,9,0,H01J23/065;;H01J23/065;;H01J2225/04;;H01J2225/04,H01J23/065,,0,0,,,,DISCONTINUED
163,US,A1,US 2019/0231856 A1,016-935-113-861-435,2019-08-01,2019,US 201816157194 A,2018-10-11,US 201816157194 A;;US 201615112088 A;;IB 2015050313 W;;US 201461931071 P,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.,PFIZER,ARKIN STEVEN;;CARR MARCUS;;FRUEBIS JOACHIM;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA,,https://lens.org/016-935-113-861-435,Patent Application,yes,0,1,27,27,2,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48,,0,0,,,,DISCONTINUED
164,BR,A,BR 8807799 A,074-803-309-873-197,1990-10-23,1990,BR 8807799 A,1988-11-16,US 24518688 A;;US 8804088 W,1988-09-16,METODO E APARELHO DE MEDIR MAGNITUDE DE BATIDA DE MOTOR DE COMBUSTAO INTERNA,,CATERPILLAR INC,MCCOY STEVEN R;;STEVENSON THOMAS T;;CARR DOUGLAS E;;KING KEVIN D,,https://lens.org/074-803-309-873-197,Patent Application,no,0,0,10,10,0,F02P5/152;;G01L23/225;;Y02T10/40;;F02P5/152;;G01L23/225;;Y02T10/40,F02D45/00;;F02P5/04;;F02P5/152;;F02P5/153;;F02P5/155;;G01L23/22,,0,0,,,,EXPIRED
165,GB,B,GB 2337151 B,160-183-270-104-050,2002-08-28,2002,GB 9809821 A,1998-05-09,GB 9809821 A,1998-05-09,Electron gun arrangements,,EEV LTD;;MARCONI APPLIED TECHN LTD,COX PETER ROBERT JOHN;;THWAITES ALFRED CHRISTOPHER;;BARDELL STEVEN;;CARR DAVID WARD,,https://lens.org/160-183-270-104-050,Granted Patent,no,1,0,9,9,0,H01J23/065;;H01J23/065;;H01J2225/04;;H01J2225/04,H01J23/065,H1D DKDF          KDF;;H1D D17AY         KDF;;H1D D17A1Y        KDF;;H1D D17A2B        KDF;;H1D D17A2Y        KDF;;H1D D46A          KDF;;H1D D46Y          KDF;;H1D D9CY          KDF;;H1D D9C1X         KDF;;H1D D9C1Y         KDF;;H1D D9C2          KDF;;H1D D9FX          KDF;;H1D D9FY          KDF;;H1D D9Y           KDF,0,0,,,,EXPIRED
166,US,A1,US 2009/0299586 A1,184-242-215-458-364,2009-12-03,2009,US 12715208 A,2008-05-27,US 12715208 A,2008-05-27,METHOD TO AUTOSTART AN INTERNAL COMBUSTION ENGINE IN A HYBRID POWERTRAIN SYSTEM,"Internal combustion engine autostarting includes selecting from among several autostart processes in accordance with desired input torque from the engine to the transmission, cranking the engine, and fueling the engine during the engine cranking based upon the selected engine autostart process.",GM GLOBAL TECH OPERATIONS INC,MILLER JON C;;JOZEFOWICZ KELLY T;;CARR MARK D;;SHEPHERD STEVEN J,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2008-05-28),https://lens.org/184-242-215-458-364,Patent Application,yes,4,18,6,6,0,B60K1/02;;B60K6/365;;B60K6/445;;B60K6/547;;B60L2240/486;;B60W10/06;;B60W10/08;;B60W10/115;;B60W20/00;;B60W2540/10;;B60W2540/12;;B60W2540/16;;B60W2710/0616;;B60W2710/0644;;F02N11/04;;F02N99/006;;F02N2300/104;;Y02T10/62;;B60K2006/268;;B60W20/10;;B60W10/06;;B60W10/08;;B60K6/365;;B60W2540/12;;F02N2300/104;;F02N11/04;;B60W2710/0616;;B60W2710/0644;;B60W2540/10;;B60K1/02;;B60K6/445;;F02N99/006;;B60K6/547;;B60W2540/16;;B60W10/115;;B60L2240/486;;Y02T10/62,G06F19/00,701/54,0,0,,,,ACTIVE
167,US,A1,US 2015/0086565 A1,162-033-088-235-803,2015-03-26,2015,US 201314389080 A,2013-03-14,US 201314389080 A;;US 201261616981 P;;US 201261616987 P;;US 2013/0031492 W,2012-03-28,CANCER-RELATED EXTRACELLULAR MATRIX SIGNATURES AND RELATED METHODS AND PRODUCTS,"Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.",MASSACHUSETTS INST TECHNOLOGY;;GEN HOSPITAL CORPORAITON D B A MASSACHUSETTS GENERAL HOSPITAL;;BROAD INST INC,HYNES RICHARD O;;NABA ALEXANDRA;;CLAUSER KARL;;CARR STEVEN A;;TANABE KENNETH,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2014-09-23);;THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (2014-09-23);;THE BROAD INSTITUTE INC (2014-09-24),https://lens.org/162-033-088-235-803,Patent Application,yes,3,4,3,6,0,G01N33/57419;;G01N33/57484;;G01N33/57488;;G01N2800/56;;A61K47/6851;;A61K47/6855;;A61K47/6863;;A61K31/138;;A61K31/192;;A61K31/197;;A61K31/215;;A61K31/727;;A61K38/4833;;A61K38/486;;A61K38/488;;A61P35/00;;G01N33/57419;;G01N33/57484;;G01N33/57488;;G01N2800/56;;A61K47/6851;;A61K47/6855;;A61K47/6863;;A61K31/138;;A61K31/192;;A61K31/197;;A61K31/215;;A61K31/727;;A61K38/4833;;A61K38/486;;A61K38/488;;C07K16/40;;C12N15/1138;;C12N2310/14;;C12N2310/141;;C12N2320/00;;G01N33/57492;;G01N2333/705,A61K47/48;;A61K31/138;;A61K31/192;;A61K31/197;;A61K31/215;;A61K31/727;;A61K38/48;;C07K16/40;;C12N15/113;;G01N33/574,424/158.1;;424/178.1;;435/7.23;;514/570;;X514 44  A;;514/510;;514/561;;424/94.64;;424/94.66;;514/648;;514/56,3,2,027-613-931-714-40X;;024-769-771-423-284,10.1200/jco.2005.05.4569;;16877732;;10502355;;10.1021/bc990040w,"Mamelak et al. Phase I single-dose study of intracavitary-admininstered 131I-TM601 in adults with recurrent high-grade Glioma. J. Clin. Onc. 24, 3644-3650, 2006.;;Foulon et al., Preparation and Characterization of Anti-Tenascin Monoclonal Antibody-Streptavidin Conjugates for Pretargeting Applications, Bioconj. Chemistry, 10,867-876, 1999.;;Lo et al., huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol. Immunother. 56, 447-457, 2007.",ACTIVE
168,US,A,US 5431836 A,019-043-456-961-660,1995-07-11,1995,US 13639493 A,1993-10-13,US 13639493 A,1993-10-13,Carbonate built laundry detergent composition,"A laundry detergent composition, wherein the solids content comprises an active surfactant, at least about 70 wt. % of a water soluble alkaline carbonate, e.g., sodium carbonate, up to about 12 wt. % of elemental magnesium in the form of a water soluble salt, e.g., magnesium sulfate or magnesium chloride, and about 0.05 to 5 wt. % of a polymeric polycarboxylate, e.g., an acrylic acid polymer, based on the total weight of solids in the composition. Incorporation of magnesium ions in the foregoing laundry detergent composition containing carbonate ions is intended to minimize negative interactions that will occur between the precipitation of calcium carbonate and the surfaces of the fabric being cleaned, e.g., fabric encrustation, with an enhancement of this effect due to the presence of the polymeric polycarboxylate.",CHURCH & DWIGHT CO INC,CARR CHARLES D;;BECKER JOSEPH G;;FALOTICO ANTHONY J;;BOLKAN STEVEN A,CHURCH & DWIGHT CO. INC (1993-10-06),https://lens.org/019-043-456-961-660,Granted Patent,yes,17,35,1,1,0,C11D3/046;;C11D3/10;;C11D3/2075;;C11D3/3761;;C11D3/046;;C11D3/2075;;C11D3/10;;C11D3/3761,C11D3/02;;C11D3/10;;C11D3/37,252/174.14;;252/174.21;;252/174.23;;252/174.24;;134/42,1,1,062-449-510-052-943,10.1016/0022-0248(80)90095-0,"M. M. Reddy et al., Crystallization of Calcium Carbonate in the Presence of Metal Ions, Journal of Crystal Growth 50 (1980) 470 480.",EXPIRED
169,US,A1,US 2016/0375109 A1,121-633-679-242-660,2016-12-29,2016,US 201515112088 A,2015-01-15,US 201515112088 A;;US 201461931071 P;;IB 2015050313 W,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.,PFIZER,ARKIN STEVEN;;CARR MARCUS;;FRUEBIS JOACHIM;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA,,https://lens.org/121-633-679-242-660,Patent Application,yes,0,1,27,27,2,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48,,0,0,,,,DISCONTINUED
170,US,B2,US 9526800 B2,055-039-316-152-160,2016-12-27,2016,US 201314389080 A,2013-03-14,US 201314389080 A;;US 201261616981 P;;US 201261616987 P;;US 2013/0031492 W,2012-03-28,Cancer-related extracellular matrix signatures and related methods and products,"Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyzes of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.",MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL;;BROAD INST INC,HYNES RICHARD O;;NABA ALEXANDRA;;CLAUSER KARL;;CARR STEVEN A;;TANABE KENNETH,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2014-09-23);;THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (2014-09-23);;THE BROAD INSTITUTE INC (2014-09-24),https://lens.org/055-039-316-152-160,Granted Patent,yes,14,1,3,6,0,G01N33/57419;;G01N33/57484;;G01N33/57488;;G01N2800/56;;A61K47/6851;;A61K47/6855;;A61K47/6863;;A61K31/138;;A61K31/192;;A61K31/197;;A61K31/215;;A61K31/727;;A61K38/4833;;A61K38/486;;A61K38/488;;A61P35/00;;G01N33/57419;;G01N33/57484;;G01N33/57488;;G01N2800/56;;A61K47/6851;;A61K47/6855;;A61K47/6863;;A61K31/138;;A61K31/192;;A61K31/197;;A61K31/215;;A61K31/727;;A61K38/4833;;A61K38/486;;A61K38/488;;C07K16/40;;C12N15/1138;;C12N2310/14;;C12N2310/141;;C12N2320/00;;G01N33/57492;;G01N2333/705,A61K47/48;;A61K31/138;;A61K31/192;;A61K31/197;;A61K31/215;;A61K31/727;;A61K38/48;;C07K16/00;;C07K16/40;;C12N15/113;;G01N33/574,,14,14,027-613-931-714-40X;;024-769-771-423-284;;067-438-409-984-701;;104-120-226-895-618;;065-684-269-783-203;;080-360-276-571-359;;111-535-015-904-092;;067-484-019-294-673;;019-055-424-431-057;;039-157-453-013-834;;025-860-316-360-991;;044-462-212-309-599;;018-527-264-097-737;;027-613-931-714-40X,10.1200/jco.2005.05.4569;;16877732;;10502355;;10.1021/bc990040w;;10.1007/s00262-006-0203-1;;16874486;;10.1002/0470867302.ch14;;1727373;;637870;;10.1016/0006-291x(78)91322-0;;10.1016/j.tips.2012.04.002;;22633092;;pmc3322572;;22159717;;10.1074/mcp.m111.014647;;3317828;;10.1126/science.3317828;;10.1002/path.2278;;18044827;;pmc3025826;;10.1186/1755-8794-4-3;;21214954;;10.1089/cbr.2007.351;;18454694;;20565704;;pmc2895582;;10.1186/1756-9966-29-71;;10.1200/jco.2005.05.4569;;16877732,"Mamelak et al. Phase I single-dose study of intracavitary-admininstered 131I-TM601 in adults with recurrent high-grade Glioma. J. Clin. Onc. 24, 3644-3650, 2006.;;Foulon et al., Preparation and Characterization of Anti-Tenascin Monoclonal Antibody-Streptavidin Conjugates for Pretargeting Applications, Bioconj. Chemistry, 10,867-876, 1999.;;Lo et al., huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol. Immunother. 56, 447-457, 2007.;;Betts et al., Chapter 14: Amino Acid Properties and Consequences of Substitutions. Biolnformatics for Geneticists. John Wiley & Sons, Ltd. 2003;289-316.;;Chari et al., Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. Jan. 1, 1992;52(1):127-31.;;Fraker et al., Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. Feb. 28, 1978;80(4):849-57.;;Goodman et al., Integrins as therapeutic targets. Trends Pharmacol Sci. Jul. 2012;33(7):405-12. doi: 10.1016/j.tips.2012.04.002. Epub May 25, 2012. Review. 8 pages.;;Naba et al., The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics. Apr. 2012;11(4):M111.014647. doi: 10.1074/mcp.M111.014647. Epub Dec 9, 2011. 18 pages.;;Vitetta et al., Redesigning nature's poisons to create anti-tumor reagents. Science. Nov. 20, 1987;238(4830):1098-104. Review.;;Bergamaschi et al., Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. Feb. 2008;214(3):357-67.;;Fan et al., Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics. Jan. 9, 2011;4:3. doi: 10.1186/1755-8794-4-3.;;Han et al., Selective gene transfer to endometrial cancer cells by a polymer against matrix metalloproteinase 2 (MMP-2). Cancer Biother Radiopharm. Apr. 2008;23(2):247-58. doi: 10.1089/cbr.2007.351.;;Liang et al., Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res. Jun. 16, 2010;29:71. doi: 10.1186/1756-9966-29-71.;;Mamelak et al., Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol. Aug. 1, 2006;24(22):3644-50.",ACTIVE
171,US,B2,US 10024860 B2,100-086-083-308-276,2018-07-17,2018,US 201615272870 A,2016-09-22,US 201615272870 A;;US 201414389080 A;;US 2013/0031492 W;;US 201261616981 P;;US 201261616987 P,2012-03-28,Cancer-related extracellular matrix signatures and related methods and products,"Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyzes of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.",MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL;;BROAD INST INC,HYNES RICHARD O;;NABA ALEXANDRA;;CLAUSER KARL;;CARR STEVEN A;;TANABE KENNETH,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2014-09-23);;THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (2014-09-23);;THE BROAD INSTITUTE INC (2014-09-24),https://lens.org/100-086-083-308-276,Granted Patent,yes,16,1,3,6,0,A61K47/6855;;A61K49/0002;;A61K49/0002;;A61K51/1051;;A61K51/1051;;A61K51/1063;;A61K51/1063;;A61K51/1093;;A61K51/1093;;G01N33/57492;;G01N33/57492;;G01N33/57415;;G01N33/57415;;G01N2333/705;;G01N2333/705,G01N33/574;;A61K47/68;;A61K49/00;;A61K51/00;;A61K51/10,,14,14,028-360-729-242-756;;039-157-453-013-834;;104-120-226-895-618;;065-684-269-783-203;;025-860-316-360-991;;024-769-771-423-284;;080-360-276-571-359;;111-535-015-904-092;;044-462-212-309-599;;018-527-264-097-737;;067-438-409-984-701;;027-613-931-714-40X;;067-484-019-294-673;;019-055-424-431-057,pmc3092194;;21779449;;10.1177/1947601910365896;;10.1002/path.2278;;18044827;;10.1002/0470867302.ch14;;1727373;;pmc3025826;;10.1186/1755-8794-4-3;;21214954;;10502355;;10.1021/bc990040w;;637870;;10.1016/0006-291x(78)91322-0;;10.1016/j.tips.2012.04.002;;22633092;;10.1089/cbr.2007.351;;18454694;;20565704;;pmc2895582;;10.1186/1756-9966-29-71;;10.1007/s00262-006-0203-1;;16874486;;10.1200/jco.2005.05.4569;;16877732;;pmc3322572;;22159717;;10.1074/mcp.m111.014647;;3317828;;10.1126/science.3317828,"Rezaul et al. Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics. Genes & Cancer, 1, 251-271, 2010 (Year: 2010).;;Bergamaschi et al., Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. Feb. 2008;214(3):357-67.;;Betts et al., Chapter 14: Amino Acid Properties and Consequences of Substitutions. BioInformatics for Geneticists. John Wiley & Sons, Ltd. 2003;289-316.;;Chari et al., Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. Jan. 1, 1992;52(1):127-31.;;Fan et al., Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics. Jan. 9, 2011;4:3. doi: 10.1186/1755-8794-4-3.;;Foulon et al., Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications. Bioconjug Chem. Sep.-Oct. 1999;10(5):867-76.;;Fraker et al., Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun. Feb. 28, 1978;80(4):849-57.;;Goodman et al., Integrins as therapeutic targets. Trends Pharmacol Sci. Jul. 2012;33(7):405-12. doi: 10.1016/j.tips.2012.04.002. Epub May 25, 2012. Review. 8 pages.;;Han et al., Selective gene transfer to endometrial cancer cells by a polymer against matrix metalloproteinase 2 (MMP-2). Cancer Biother Radiopharm. Apr. 2008;23(2):247-58. doi: 10.1089/cbr.2007.351.;;Liang et al., Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res. Jun. 16, 2010;29:71. doi: 10.1186/1756-9966-29-71.;;Lo et al., huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol Immunother. Apr. 2007;56(4):447-57.;;Mamelak et al., Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol. Aug. 1, 2006;24(22):3644-50.;;Naba et al., The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics. Apr. 2012;11(4):M111.014647. doi: 10.1074/mcp.M111.014647. Epub Dec. 9, 2011. 18 pages.;;Vitetta et al., Redesigning nature's poisons to create anti-tumor reagents. Science. Nov. 20, 1987;238(4830):1098-104. Review.",ACTIVE
172,DE,A1,DE 102009020805 A1,112-285-896-983-014,2010-03-04,2010,DE 102009020805 A,2009-05-11,US 12715208 A,2008-05-27,Verfahren für den Autostart einer Brennkraftmaschine in einem Hybrid-Antriebsstrangsystem,"Ein Brennkraftmaschinen-Autostart umfasst das Wählen unter mehreren Autostartprozessen in Übereinstimmung mit dem Soll-Eingangsdrehmoment von der Maschine in das Getriebe, das Anlassen der Maschine und das Versorgen der Maschine mit Kraftstoff während des Anlassens der Maschine anhand des gewählten Maschinenautostartprozesses.",GM GLOBAL TECH OPERATIONS INC,MILLER JON C;;JOZEFOWICZ KELLY T;;CARR MARK D;;SHEPHERD STEVEN J,"GM GLOBAL TECHNOLOGY OPERATIONS LLC (N. D. GES, US (2011-03-23);;GM GLOBAL TECHNOLOGY OPERATIONS LLC , ( N. D. , US (2011-05-26)",https://lens.org/112-285-896-983-014,Patent Application,no,0,0,6,6,0,B60K1/02;;B60K6/365;;B60K6/445;;B60K6/547;;B60L2240/486;;B60W10/06;;B60W10/08;;B60W10/115;;B60W20/00;;B60W2540/10;;B60W2540/12;;B60W2540/16;;B60W2710/0616;;B60W2710/0644;;F02N11/04;;F02N99/006;;F02N2300/104;;Y02T10/62;;B60K2006/268;;B60W20/10;;B60W10/06;;B60W10/08;;B60K6/365;;B60W2540/12;;F02N2300/104;;F02N11/04;;B60W2710/0616;;B60W2710/0644;;B60W2540/10;;B60K1/02;;B60K6/445;;F02N99/006;;B60K6/547;;B60W2540/16;;B60W10/115;;B60L2240/486;;Y02T10/62,F02N99/00,,0,0,,,,ACTIVE
173,WO,A1,WO 1990/002932 A1,163-473-632-771-198,1990-03-22,1990,US 8804088 W,1988-11-16,US 24518688 A,1988-09-16,METHOD AND APPARATUS FOR MEASURING DETONATION IN AN INTERNAL COMBUSTION ENGINE,"A method and apparatus is provided for measuring detonation in an internal combustion engine (14). Vibration sensors (12) located on the engine (14) send signals through a filter (34) which is tuned to the cavity resonance frequency (f) of the engine's cylinders (16, 18, 20, 22, 24, 26). The peaks (A) and valleys (B) of the filtered signals are detected and ratiometrically compared one with another to determine the magnitude of detonation. The detonation information may be used by an engine control (44) to retard timing in response to a predetermined level of detonation.",CATERPILLAR INC,MCCOY STEVEN R;;STEVENSON THOMAS T;;CARR DOUGLAS E;;KING KEVIN D,,https://lens.org/163-473-632-771-198,Patent Application,yes,7,1,10,10,0,F02P5/152;;G01L23/225;;Y02T10/40;;F02P5/152;;G01L23/225;;Y02T10/40,F02D45/00;;F02P5/04;;F02P5/152;;F02P5/153;;F02P5/155;;G01L23/22,,0,0,,,,PATENTED
174,IN,B,IN 175816 B,166-127-699-838-323,1995-09-09,1995,IN 224MA1990 A,1990-03-27,CA 609578 A,1989-08-28,An apparatus for measuring the magnitude of knock in an internal combustion engine,,CATERPILLAR INC,MCCOY STEVEN R;;STEVENSON THOMAS T;;CARR DOUGLAS E;;KING KEVIN D,,https://lens.org/166-127-699-838-323,Granted Patent,no,0,0,1,1,0,,G01L23/22,,0,0,,,,EXPIRED
175,US,B2,US 10895090 B2,186-488-667-702-375,2021-01-19,2021,US 201816175198 A,2018-10-30,US 201816175198 A,2018-10-30,Anchoring umbrella stand with manually extendable drill bit,"Disclosed is an anchoring umbrella stand with a manually extendable drill bit. In certain exemplary embodiments disclosed herein, the anchoring umbrella stand includes a drill bit that can be manually extendable from and manually retractable into an elongate housing body by use of a crank handle. Manual operation of the crank handle rotates and translates the drill bit between a retracted position within the elongate housing body and an extended position outside the elongate housing body. In certain embodiments, the anchoring umbrella stand further includes a gear train assembly and/or a stabilizing plate to further aid a user in anchoring the umbrella stand. The anchoring umbrella stand facilitates umbrella anchoring by providing a more stable anchoring mechanism that requires less strength, less coordination, and no electric power to operate.",JOSEPH WESTON CAPITAL MAN LLC,WORM STEVEN LEE;;CARR WILLIAM BRYAN;;HILTON RYAN JOSEPH;;HILTON CURRY WESTON,JOSEPH WESTON CAPITAL MANAGEMENT LLC (2018-10-28),https://lens.org/186-488-667-702-375,Granted Patent,yes,44,2,2,2,0,A45B23/00;;A45B23/00;;A45B2023/0012;;A45B2023/0012;;A45B2025/003;;A45B2200/1009;;E04H12/2223;;E04H12/2223;;F16H25/20;;F16H2025/2084;;F16H2025/2084,E04H12/22;;A45B23/00;;A45B25/00;;F16H25/20,,3,0,,,"Author Unknown, “Beach umbrella sand anchor,” eurekaweb.fr/wp/beach-umbrella-sand-anchor-es/, accessed on Mar. 21, 2018, EurekaWEB, 5 pages.;;Author Unknown, “DrillBeach: An Electric Beach Umbrella That Scews Into the Sand,” odditymall.com/drillbeach-electric-beach-umbrella, Jul. 24, 2015, Odditymall, 9 pages.;;Author Unknown, “Power Driver,” www.aughog.com/products-page/power-driver/, accessed Mar. 23, 2018, Aughog Products, LLC, 5 pages.",ACTIVE
176,US,B1,US 6614158 B1,190-556-092-388-122,2003-09-02,2003,US 30681199 A,1999-05-07,GB 9809821 A,1998-05-09,Electron gun arrangements having closely spaced cathode and electrode and a vacuum seal,"
    An electron gun arrangement includes a cathode having a front surface and control grid located in front of it. The control grid is mounted via a cylindrical support on a Kovar mount. The cathode is supported by a cylindrical support mounted on a Kovar support. Ceramic material being located between the two supports. The vacuum envelope within which the electron gun is contained includes the Kovar support and a flexible member with which it makes a vacuum seal, this member being of copper. The copper member is sealed to a ceramic cylinder via metal flanges. The assembly permits the spacing between the cathode and grid to be maintained while the copper member permits thermal expansion to occur to maintain vacuum integrity. 
",EEV LTD,THWAITES ALFRED CHRISTOPHER;;CARR DAVID WARD;;BARDELL STEVEN;;COX PETER ROBERT JOHN,E2V TECHNOLOGIES (UK) LIMITED (1999-06-25),https://lens.org/190-556-092-388-122,Granted Patent,yes,14,1,9,9,0,H01J23/065;;H01J23/065;;H01J2225/04;;H01J2225/04,H01J23/065,313/446;;313/447;;313/451;;313/456,0,0,,,,EXPIRED
177,US,A9,US 2017/0343553 A9,034-132-731-074-352,2017-11-30,2017,US 201615272870 A,2016-09-22,US 201615272870 A;;US 201414389080 A;;US 2013/0031492 W;;US 201261616981 P;;US 201261616987 P,2012-03-28,CANCER-RELATED EXTRACELLULAR MATRIX SIGNATURES AND RELATED METHODS AND PRODUCTS,"Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.",MASSACHUSETTS INST TECHNOLOGY;;THE GENERAL HOSPITAL CORP D/B/A MASSACHUSETTES GENERAL HOSPITAL;;BROAD INST INC,HYNES RICHARD O;;NABA ALEXANDRA;;CLAUSER KARL;;CARR STEVEN A;;TANABE KENNETH,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2014-09-23);;THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (2014-09-23);;THE BROAD INSTITUTE INC (2014-09-24),https://lens.org/034-132-731-074-352,Amended Application,yes,0,2,3,6,0,A61K47/6855;;A61K49/0002;;A61K49/0002;;A61K51/1051;;A61K51/1051;;A61K51/1063;;A61K51/1063;;A61K51/1093;;A61K51/1093;;G01N33/57492;;G01N33/57492;;G01N33/57415;;G01N33/57415;;G01N2333/705;;G01N2333/705,G01N33/574;;A61K47/68;;A61K49/00;;A61K51/10,,0,0,,,,ACTIVE
178,US,B2,US 8099203 B2,081-694-427-850-934,2012-01-17,2012,US 12715208 A,2008-05-27,US 12715208 A,2008-05-27,Method to autostart an internal combustion engine in a hybrid powertrain system,"Internal combustion engine autostarting includes selecting from among several autostart processes in accordance with desired input torque from the engine to the transmission, cranking the engine, and fueling the engine during the engine cranking based upon the selected engine autostart process.",MILLER JON C;;JOZEFOWICZ KELLY T;;CARR MARK D;;SHEPHERD STEVEN J;;GM GLOBAL TECH OPERATIONS INC,MILLER JON C;;JOZEFOWICZ KELLY T;;CARR MARK D;;SHEPHERD STEVEN J,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2008-05-28),https://lens.org/081-694-427-850-934,Granted Patent,yes,4,12,6,6,0,B60K1/02;;B60K6/365;;B60K6/445;;B60K6/547;;B60L2240/486;;B60W10/06;;B60W10/08;;B60W10/115;;B60W20/00;;B60W2540/10;;B60W2540/12;;B60W2540/16;;B60W2710/0616;;B60W2710/0644;;F02N11/04;;F02N99/006;;F02N2300/104;;Y02T10/62;;B60K2006/268;;B60W20/10;;B60W10/06;;B60W10/08;;B60K6/365;;B60W2540/12;;F02N2300/104;;F02N11/04;;B60W2710/0616;;B60W2710/0644;;B60W2540/10;;B60K1/02;;B60K6/445;;F02N99/006;;B60K6/547;;B60W2540/16;;B60W10/115;;B60L2240/486;;Y02T10/62,B60K1/00;;B60L11/00;;B60W10/06,701/22;;180/65.28;;180/65.265,0,0,,,,ACTIVE
179,US,A,US 6052415 A,001-818-616-239-739,2000-04-18,2000,US 92283597 A,1997-08-26,US 92283597 A,1997-08-26,Early error detection within an MPEG decoder,"An MPEG digital video decoder system, method and computer program product are presented for monitoring decoding of an encoded digital video signal for one or more predefined illegal conditions. Error detection logic is coupled to the variable length (VLC) decoder, inverse quantizer (IQ), inverse discrete cosine transformer (IDCT) and motion compensator (MC) of the decoder for detecting an illegal condition within at least one of the VLC decoder, IQ, IDCT and MC during decoding of the encoded digital video signal. The monitored illegal conditions can include a VLC/IQ control error, an IQ level overrun, and IQ/IDCT buffer error, an MC idle error and an MC macroblock start error. Error signals are reported to a central error register which is monitored periodically by the decoder's control processor. The control processor initiates recovery within the decoder system prior to stoppage of the system due to the illegal condition.",IBM,CARR JEFFERY DEAN;;NGAI CHUCK HONG;;STEIN CHARLES JOHN;;SVEC RONALD STEVEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (1997-08-25);;RIGHT CHANCE INC (2006-06-30);;MEDIATEK INC (2013-11-30),https://lens.org/001-818-616-239-739,Granted Patent,yes,9,54,3,3,0,H04N19/89;;H04N19/89;;H04N19/89,H04N19/89,375/240;;348/402,0,0,,,,EXPIRED
180,EP,A1,EP 0423130 A1,023-583-146-253-134,1991-04-24,1991,EP 89904719 A,1988-11-16,US 24518688 A,1988-09-16,METHOD AND APPARATUS FOR MEASURING DETONATION IN AN INTERNAL COMBUSTION ENGINE.,"Sont décrits un procédé et un appareil pour mesurer le cognement dans un moteur à combustion interne (14). Des capteurs (12) de vibrations situés sur le moteur (14) envoient des signaux à travers un filtre (34) qui est syntonisé sur la fréquence de résonance de cavité (f) des cylindres (16, 18, 20, 22, 24, 26) du moteur. Les valeurs maximales (A) et minimales (B) des signaux filtrés sont détectées et comparées les unes avec les autres au moyen d'un logomètre afin de déterminer l'ampleur du cognement. Les données de cognement sont utilisables par une commande (44) du moteur afin de retarder la distribution lorsque le cognement atteint un niveau prédéterminé.",CATERPILLAR INC,MCCOY STEVEN R;;STEVENSON THOMAS T;;CARR DOUGLAS E;;KING KEVIN D,,https://lens.org/023-583-146-253-134,Patent Application,yes,0,0,10,10,0,F02P5/152;;G01L23/225;;Y02T10/40;;F02P5/152;;G01L23/225;;Y02T10/40,F02D45/00;;F02P5/04;;F02P5/152;;F02P5/153;;F02P5/155;;G01L23/22,,0,0,,,,EXPIRED
181,WO,A1,WO 2013/148259 A1,032-752-926-715-783,2013-10-03,2013,US 2013/0031492 W,2013-03-14,US 201261616981 P;;US 201261616987 P,2012-03-28,CANCER-RELATED EXTRACELLULAR MATRIX SIGNATURES AND RELATED METHODS AND PRODUCTS,"Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.",MASSACHUSETTS INST TECHNOLOGY;;GEN HOSPITAL CORP;;BROAD INST INC,HYNES RICHARD O;;NABA ALEXANDRA;;CLAUSER KARL;;CARR STEVEN A;;TANABE KENNETH,,https://lens.org/032-752-926-715-783,Patent Application,yes,1,0,3,6,0,G01N33/57419;;G01N33/57484;;G01N33/57488;;G01N2800/56;;A61K47/6851;;A61K47/6855;;A61K47/6863;;A61K31/138;;A61K31/192;;A61K31/197;;A61K31/215;;A61K31/727;;A61K38/4833;;A61K38/486;;A61K38/488;;A61P35/00;;G01N33/57419;;G01N33/57484;;G01N33/57488;;G01N2800/56;;A61K47/6851;;A61K47/6855;;A61K47/6863;;A61K31/138;;A61K31/192;;A61K31/197;;A61K31/215;;A61K31/727;;A61K38/4833;;A61K38/486;;A61K38/488;;C07K16/40;;C12N15/1138;;C12N2310/14;;C12N2310/141;;C12N2320/00;;G01N33/57492;;G01N2333/705,A61K47/48;;A61P35/00;;G01N33/50,,5,5,018-527-264-097-737;;039-157-453-013-834;;025-860-316-360-991;;027-613-931-714-40X;;044-462-212-309-599,20565704;;pmc2895582;;10.1186/1756-9966-29-71;;10.1002/path.2278;;18044827;;pmc3025826;;10.1186/1755-8794-4-3;;21214954;;10.1200/jco.2005.05.4569;;16877732;;10.1089/cbr.2007.351;;18454694,"LIANG, J-F ET AL.: ""Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer."", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH., vol. 29, 2010, pages 71, XP021083477, DOI: doi:10.1186/1756-9966-29-71;;BERGAMASCHI, A ET AL.: ""Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome."", JOURNAL OF PATHOLOGY., vol. 214, 2008, pages 357 - 367;;FAN, C ET AL.: ""Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures."", BMC MEDICAL GENOMICS., vol. 4, 2011, pages 3, XP021090978, DOI: doi:10.1186/1755-8794-4-3;;MAMELAK, AN ET AL.: ""Phase I Single-Dose Study of Intracavitary-Administered Iodine-13 1-TM-601 in Adults With Recurrent High-Grade Glioma."", JOURNAL OF CLINICAL ONCOLOGY., vol. 24, 2006, pages 3644 - 3650, XP002590948, DOI: doi:10.1200/JCO.2005.05.4569;;HAN, JY ET AL.: ""Selective gene transfer to endometrial cancer cells by a polymer against matrix metalloproteinase 2 (MMP-2)."", CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol. 23, no. 2, 2008, pages 247 - 258",PENDING
182,US,A,US 5863877 A,054-814-423-604-466,1999-01-26,1999,US 64998896 A,1996-05-17,US 64998896 A;;US 13639793 A,1993-10-13,Carbonate built cleaning composition containing added magnesium,"A non-bleaching cleaning composition, e.g. laundry detergent, wherein the solids content comprises at least about 70 wt. % of sodium carbonate, and up to about 12 wt. % of elemental magnesium in the form of a water soluble salt, e.g., magnesium sulfate or magnesium chloride, based on the total weight of the solids composition. Preferably the composition also contains an active surfactant and, when used as a laundry detergent, a polymeric polycarboxylate, e.g., an acrylic acid polymer. Incorporation of magnesium ions in the foregoing cleaning composition containing carbonate ions is intended to minimize negative interactions that will occur between the precipitation of calcium carbonate and the substrate being cleaned, e.g., fabric encrustation when the composition is used as a laundry detergent.",CHURCH & DWIGHT CO INC,CARR CHARLES D;;BECKER JOSEPH G;;FALOTICO ANTHONY J;;BOLKAN STEVEN A,CHURCH & DWIGHT CO. INC (1996-09-05),https://lens.org/054-814-423-604-466,Granted Patent,yes,14,50,1,1,0,C11D3/046;;C11D3/046;;C11D1/29;;C11D1/29;;C11D1/72;;C11D1/72;;C11D1/83;;C11D1/83;;C11D3/048;;C11D3/048;;C11D3/10;;C11D3/10;;C11D17/06;;C11D17/06,C11D1/29;;C11D1/72;;C11D1/83;;C11D3/02;;C11D3/10;;C11D17/06,510/348;;510/351,0,0,,,,EXPIRED
183,AT,T1,AT E311443 T1,104-674-343-457-742,2005-12-15,2005,AT 98940471 T,1998-09-03,GB 9718552 A;;GB 9719834 A;;GB 9720184 A;;GB 9720522 A;;GB 9720525 A;;GB 9720523 A;;GB 9720524 A;;US 7006397 P;;US 7006297 P;;US 7003797 P;;US 7005097 P;;GB 9801255 A;;GB 9803828 A;;GB 9807760 A;;GB 9811130 A;;GB 9802649 W,1997-09-03,METHODEN ZUR DURCHFORSTUNG (SCREENEN) VON PROTEINEN,"The present invention provides novel methods of protein/polypeptide screening based on the provision of libraries of individual proteins/polypeptides, which in turn can be screened for cell binding, biological activity etc. Methods for recovering genes encoding such proteins/polypeptides are also provided.",BIOVATION LTD,CARR FRANCIS;;BALGOWNIE DRIVE;;CARTER GRAHAM;;HAMILTON ANITA;;ADAIR FIONA;;WILLIAMS STEVEN,,https://lens.org/104-674-343-457-742,Granted Patent,no,0,0,8,26,0,C07K16/00;;C07K2319/00;;C12N15/1037;;C12N15/1041;;C40B40/02,C12N15/09;;C07K14/16;;C07K14/54;;C07K16/00;;C07K17/00;;C12N11/14;;C12N15/10;;C12P21/00;;C12Q1/68;;C40B40/02;;G01N37/00,,0,0,,,,EXPIRED
184,CN,B,CN 101592093 B,062-575-844-054-68X,2013-01-23,2013,CN 200910141816 A,2009-05-26,US 12715208 A,2008-05-27,Method for autostarting internal combustion engine in hybrid powertrain system,,GM GLOBAL TECH OPERATIONS INC,MILLER JON C;;JOZEFOWICZ KELLY T;;CARR MARK D;;SHEPHERD STEVEN J,,https://lens.org/062-575-844-054-68X,Granted Patent,no,0,0,6,6,0,B60K1/02;;B60K6/365;;B60K6/445;;B60K6/547;;B60L2240/486;;B60W10/06;;B60W10/08;;B60W10/115;;B60W20/00;;B60W2540/10;;B60W2540/12;;B60W2540/16;;B60W2710/0616;;B60W2710/0644;;F02N11/04;;F02N99/006;;F02N2300/104;;Y02T10/62;;B60K2006/268;;B60W20/10;;B60W10/06;;B60W10/08;;B60K6/365;;B60W2540/12;;F02N2300/104;;F02N11/04;;B60W2710/0616;;B60W2710/0644;;B60W2540/10;;B60K1/02;;B60K6/445;;F02N99/006;;B60K6/547;;B60W2540/16;;B60W10/115;;B60L2240/486;;Y02T10/62,F02D41/06,,0,0,,,,ACTIVE
185,EP,B1,EP 0423130 B1,105-011-267-439-903,1993-08-04,1993,EP 89904719 A,1988-11-16,US 24518688 A,1988-09-16,METHOD AND APPARATUS FOR MEASURING DETONATION IN AN INTERNAL COMBUSTION ENGINE,,CATERPILLAR INC.,"MCCOY, STEVEN, R.;;STEVENSON, THOMAS, T.;;CARR, DOUGLAS, E.;;KING, KEVIN, D.",,https://lens.org/105-011-267-439-903,Granted Patent,yes,7,1,10,10,0,F02P5/152;;G01L23/225;;Y02T10/40;;F02P5/152;;G01L23/225;;Y02T10/40,F02D45/00;;F02P5/04;;F02P5/152;;F02P5/153;;F02P5/155;;G01L23/22,,0,0,,,,EXPIRED
186,CA,C,CA 1330593 C,127-900-585-740-687,1994-07-05,1994,CA 609578 A,1989-08-28,US 8804088 W;;US 24518688 A,1988-09-16,METHOD AND APPARATUS FOR MEASURING DETONATION IN AN INTERNAL COMBUSTION ENGINE,Method and Apparatus for Measuring Detonation in an Internal Combustion Engine A method and apparatus is provided for measuring detonation in an internal combustion engine. Vibration sensors located on the engine send signals through a filter which is tuned to the cavity resonance of the engine's cylinders. The peaks and valleys of the filtered signals are detected and ratiometrically compared one with another to determine the magnitude of detonation. The detonation information may be used by an engine control to retard timing in response to a predetermined level of detonation.,CATERPILLAR INC,MCCOY STEVEN R;;STEVENSON THOMAS T;;CARR DOUGLAS E;;KING KEVIN D,,https://lens.org/127-900-585-740-687,Granted Patent,no,0,0,10,10,0,F02P5/152;;G01L23/225;;Y02T10/40;;F02P5/152;;G01L23/225;;Y02T10/40,F02D45/00;;F02P5/04;;F02P5/152;;F02P5/153;;F02P5/155;;G01L23/22,D23540024    M,0,0,,,,EXPIRED
187,US,A,US 4895121 A,158-630-470-060-451,1990-01-23,1990,US 24518688 A,1988-09-16,US 24518688 A,1988-09-16,Method and apparatus for measuring detonation in an internal combustion engine,A method and apparatus is provided for measuring detonation in an internal combustion engine. Vibration sensors located on the engine send signals through a filter which is turned to the cavity resonance of the engine's cylinders. The peaks and valleys of the filtered signals are detected and ratiometrically compared one with another to determine the magnitude of detonation. The detonation information may be used by an engine control to retard timing in response to a predetemined level of detonation.,CATERPILLAR INC,MCCOY STEVEN R;;STEVENSON THOMAS T;;CARR DOUGLAS E;;KING KEVIN D,CATERPILLAR INC. A DE. CORP (1988-08-25),https://lens.org/158-630-470-060-451,Granted Patent,yes,19,19,10,10,0,F02P5/152;;G01L23/225;;Y02T10/40;;F02P5/152;;G01L23/225;;Y02T10/40,F02D45/00;;F02P5/04;;F02P5/152;;F02P5/153;;F02P5/155;;G01L23/22,123/425;;73/35,0,0,,,,EXPIRED
188,US,A1,US 2003/0220860 A1,170-481-561-465-647,2003-11-27,2003,US 42367803 A,2003-04-24,US 42367803 A;;US 38336702 P,2002-05-24,Knowledge discovery through an analytic learning cycle,"
   Knowledge discovery through analytic learning cycles is founded on a coherent, real-time view of data from across an enterprise, the data having been captured and aggregated and is available in real-time at a central repository. Knowledge discovery is an iterative process where each cycle of analytic learning employs data mining. Thus, an analytic learning cycle includes defining a problem, exploring the data at the central repository in relation to the problem, preparing a modeling data set from the explored data, building a model from the modeling data set, assessing the model, deploying the model back to the central repository, and applying the model to a set of inputs associated with the problem. Application of the model produces results and, in turn, creates historic data that is saved at the central repository. Subsequent iterations of the analytic learning cycle use the historic data, as well as current data accumulated in the central repository, thereby creating up-to-date knowledge for evaluating and refreshing the model. 
",HEWLETT PACKARD DEVELOPMENT CO,HEYTENS MICHAEL L;;CARR STEVEN R;;BATTAS GREGORY S;;BOSINOFF PHILIP R,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2002-10-01),https://lens.org/170-481-561-465-647,Patent Application,yes,7,155,1,1,0,G06N5/022;;G06Q30/02;;G06Q30/0201;;G06Q40/00;;G06Q30/02;;G06Q30/0201;;G06N5/022;;G06Q40/00,G06N5/02;;G06Q30/02;;G06Q40/00,705/35;;706/12;;707/3;;706/47;;705/7,0,0,,,,DISCONTINUED
189,US,A1,US 2020/0131795 A1,011-662-026-213-015,2020-04-30,2020,US 201816175198 A,2018-10-30,US 201816175198 A,2018-10-30,ANCHORING UMBRELLA STAND WITH MANUALLY EXTENDABLE DRILL BIT,"Disclosed is an anchoring umbrella stand with a manually extendable drill bit. In certain exemplary embodiments disclosed herein, the anchoring umbrella stand includes a drill bit that can be manually extendable from and manually retractable into an elongate housing body by use of a crank handle. Manual operation of the crank handle rotates and translates the drill bit between a retracted position within the elongate housing body and an extended position outside the elongate housing body. In certain embodiments, the anchoring umbrella stand further includes a gear train assembly and/or a stabilizing plate to further aid a user in anchoring the umbrella stand. The anchoring umbrella stand facilitates umbrella anchoring by providing a more stable anchoring mechanism that requires less strength, less coordination, and no electric power to operate.",JOSEPH WESTON CAPITAL MAN LLC,WORM STEVEN LEE;;CARR WILLIAM BRYAN;;HILTON RYAN JOSEPH;;HILTON CURRY WESTON,JOSEPH WESTON CAPITAL MANAGEMENT LLC (2018-10-28),https://lens.org/011-662-026-213-015,Patent Application,yes,8,4,2,2,0,A45B23/00;;A45B23/00;;A45B2023/0012;;A45B2023/0012;;A45B2025/003;;A45B2200/1009;;E04H12/2223;;E04H12/2223;;F16H25/20;;F16H2025/2084;;F16H2025/2084,E04H12/22;;F16H25/20,,0,0,,,,ACTIVE
190,US,A1,US 2017/0051073 A1,063-345-834-768-753,2017-02-23,2017,US 201615272870 A,2016-09-22,US 201615272870 A;;US 201414389080 A;;US 2013/0031492 W;;US 201261616981 P;;US 201261616987 P,2012-03-28,CANCER-RELATED EXTRACELLULAR MATRIX SIGNATURES AND RELATED METHODS AND PRODUCTS,"Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.",MASSACHUSETTS INST TECHNOLOGY;;THE GENERAL HOSPITAL CORP D/B/A MASSACHUSETTES GENERAL HOSPITAL;;BROAD INST INC,HYNES RICHARD O;;NABA ALEXANDRA;;CLAUSER KARL;;CARR STEVEN A;;TANABE KENNETH,,https://lens.org/063-345-834-768-753,Patent Application,yes,0,3,3,6,0,A61K47/6855;;A61K49/0002;;A61K49/0002;;A61K51/1051;;A61K51/1051;;A61K51/1063;;A61K51/1063;;A61K51/1093;;A61K51/1093;;G01N33/57492;;G01N33/57492;;G01N33/57415;;G01N33/57415;;G01N2333/705;;G01N2333/705,C07K16/30;;G01N33/574,,0,0,,,,ACTIVE
191,EP,A2,EP 0957504 A2,177-574-232-745-143,1999-11-17,1999,EP 99303554 A,1999-05-06,GB 9809821 A,1998-05-09,Electron gun arrangements,"An electron gun arrangement includes a cathode 1 having a front surface 2 and control grid 3 located in front of it. The control grid 3 is mounted via a cylindrical support 8 on a Kovar mount 12. The cathode 1 is supported by a cylindrical support 6 mounted on a Kovar support 10. Ceramic material 11 being located between the two supports 10 and 12. The vacuum envelope within which the electron gun is contained includes the Kovar support 12 and a flexible member 13 with which it makes a vacuum seal, this member 13 being of copper. The copper member 13 is sealed to a ceramic cylinder 16 via metal flanges 17 and 18. The assembly permits the spacing between the cathode and grid 3 to be maintained whilst the copper member 13 permits thermal expansion to occur to maintain vacuum integrity.",EEV LTD,THWAITES ALFRED CRISTOPHER;;CARR DAVID WARD;;BARDELL STEVEN;;COX PETER ROBERT JOHN,E2V TECHNOLOGIES (UK) LIMITED (2004-10-20),https://lens.org/177-574-232-745-143,Patent Application,yes,0,2,9,9,0,H01J23/065;;H01J23/065;;H01J2225/04;;H01J2225/04,H01J23/065,,0,0,,,,DISCONTINUED
192,GB,A,GB 2337151 A,177-098-271-442-247,1999-11-10,1999,GB 9809821 A,1998-05-09,GB 9809821 A,1998-05-09,Electron gun arrangements,"An electron gun arrangement, e.g. for an IOT, includes a cathode 1 having a front surface 2 and control grid 3 located in front of it. The control grid 3 is mounted via a cylindrical member 8 on a support 12 of low thermal expansivity. The cathode 1 is supported by a cylindrical member 6 mounted on a similar support 10. Ceramic material 11 is located between the two supports 10 and 12 as a microwave window. The vacuum envelope within which the electron gun is contained includes the support 12 and a flexible member 13 with which it makes a vacuum seal, this member 13 being of copper for example. The copper member 13 is sealed to a ceramic cylinder 16 via metal flanges 17 and 18. The assembly permits the spacing between the cathode 1 and grid 3 to be maintained whilst the copper member 13 permits thermal expansion to occur to maintain vacuum integrity. A focus electrode 4 may also be mounted via the member 8.",EEV LTD,COX PETER ROBERT JOHN;;THWAITES ALFRED CHRISTOPHER;;BARDELL STEVEN;;CARR DAVID WARD,,https://lens.org/177-098-271-442-247,Patent Application,no,1,3,9,9,0,H01J23/065;;H01J23/065;;H01J2225/04;;H01J2225/04,H01J23/065,H1D DKDF          KDF;;H1D D17AY         KDF;;H1D D17A1Y        KDF;;H1D D17A2B        KDF;;H1D D17A2Y        KDF;;H1D D46A          KDF;;H1D D46Y          KDF;;H1D D9CY          KDF;;H1D D9C1X         KDF;;H1D D9C1Y         KDF;;H1D D9C2          KDF;;H1D D9FX          KDF;;H1D D9FY          KDF;;H1D D9Y           KDF,0,0,,,,EXPIRED
193,DE,B4,DE 102009020805 B4,112-274-953-864-051,2018-09-27,2018,DE 102009020805 A,2009-05-11,US 12715208 A,2008-05-27,Verfahren für den Autostart einer Brennkraftmaschine in einem Hybrid-Antriebsstrangsystem,"Verfahren zum Steuern eines Antriebsstrangs, der eine Brennkraftmaschine (14) enthält, die mit einem Getriebe (10) mechanisch verbunden ist, um Traktionsleistung an einen Endantrieb (90) zu übertragen, wobei das Verfahren umfasst:Befehlen eines Maschinenautostartereignisses während des laufenden Betriebs des Antriebsstrangs;Bestimmen eines Soll-Eingangsdrehmoments von der Maschine (14) in das Getriebe (10) anhand einer Bedienerdrehmomentanforderung und eines Ladezustands einer Batterie, die elektrisch angeschlossen ist, um an den Antriebsstrang Leistung zu übertragen;Auswählen eines Maschinenautostartprozesses, der einen ruhigen Maschinenautostartprozess, einen normalen Maschinenautostartprozess oder einen aggressiven Maschinenautostartprozess umfasst, anhand des Soll-Eingangsdrehmoments;gekennzeichnet durchein Anlassen der Maschine (14) bis zu einer durch den Maschinenautostartprozess definierten Drehzahl, die erreicht sein muss, bis die Kraftstoffversorgung der Maschine (14) beginnt; undein Versorgen der Maschine (14) mit Kraftstoff während des Anlassens der Maschine (14) anhand eines Anlass-Kraftstoffmassenprofils, das für den ausgewählten Maschinenautostartprozess vorgegeben ist.",GM GLOBAL TECH OPERATIONS LLC,MILLER JON C;;JOZEFOWICZ KELLY T;;CARR MARK D;;SHEPHERD STEVEN J,"GM GLOBAL TECHNOLOGY OPERATIONS LLC (N. D. GES, US (2011-03-23);;GM GLOBAL TECHNOLOGY OPERATIONS LLC , ( N. D. , US (2011-05-26)",https://lens.org/112-274-953-864-051,Granted Patent,no,5,0,6,6,0,B60K1/02;;B60K6/365;;B60K6/445;;B60K6/547;;B60L2240/486;;B60W10/06;;B60W10/08;;B60W10/115;;B60W20/00;;B60W2540/10;;B60W2540/12;;B60W2540/16;;B60W2710/0616;;B60W2710/0644;;F02N11/04;;F02N99/006;;F02N2300/104;;Y02T10/62;;B60K2006/268;;B60W20/10;;B60W10/06;;B60W10/08;;B60K6/365;;B60W2540/12;;F02N2300/104;;F02N11/04;;B60W2710/0616;;B60W2710/0644;;B60W2540/10;;B60K1/02;;B60K6/445;;F02N99/006;;B60K6/547;;B60W2540/16;;B60W10/115;;B60L2240/486;;Y02T10/62,F02D29/00,,0,0,,,,ACTIVE
194,US,A1,US 2019/0274292 A1,064-432-149-200-619,2019-09-12,2019,US 201916408792 A,2019-05-10,US 201916408792 A;;US 201815955073 A;;US 201615074920 A;;US 2014/0064629 W;;US 201361915439 P;;US 201361902066 P,2013-11-08,KNOCK-IN RODENT COMPRISING A MUTATION IN AN ENDOGENOUS CRBN LOCUS AND METHODS OF USE THEREOF,The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.,BROAD INST INC;;BRIGHAM & WOMENS HOSPITAL INC,EBERT BENJAMIN LEVINE;;KRÖNKE JAN;;CARR STEVEN A;;UDESHI NAMRATA D;;FINK EMMA,THE BRIGHAM AND WOMEN'S HOSPITAL INC (2016-08-16);;THE BROAD INSTITUTE INC (2018-03-14),https://lens.org/064-432-149-200-619,Patent Application,yes,1,1,9,9,69,C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;G01N33/5011;;G01N33/5088;;G01N33/57496;;G01N33/94;;G01N2333/47;;A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/03;;C12Q1/6876;;C12Q2600/136,A01K67/027;;C12Q1/6876;;C12Q1/6886;;G01N33/50;;G01N33/574;;G01N33/94,,0,0,,,,ACTIVE
195,WO,A1,WO 2021/030460 A1,143-176-176-930-223,2021-02-18,2021,US 2020/0045962 W,2020-08-12,US 201962885709 P;;US 201962889373 P,2019-08-12,PROTEOGENOMIC METHODS FOR DIAGNOSING CANCER,"Methods disclosed herein concern cancer proteogenomics, which integrates genomics, transcriptomics and mass spectrometry (MS)-based proteomics to gain insights into cancer biology and treatment efficacy. To promote clinical utility of embodiments herein, proteogenomics approaches were developed for frozen core needle biopsies using tissue-sparing specimen processing with or without a microscaled proteomics workflow.",BAYLOR COLLEGE MEDICINE;;BROAD INST INC;;MASSACHUSETTS GEN HOSPITAL,ELLIS MATTHEW J;;ZHANG BING;;JAEHNIG ERIC;;CARR STEVEN;;SATPATHY SHANKHA;;GILLETTE MICHAEL,,https://lens.org/143-176-176-930-223,Patent Application,yes,3,2,4,4,66,C12Q1/6886;;C12Q2600/158;;C12Q2600/106;;G01N33/574;;G01N33/6848;;G01N33/6842;;G01N2440/14;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158;;G01N33/57415;;G01N33/6848;;G01N2440/14,C12Q1/6886,,9,9,027-191-399-117-192;;108-555-431-425-269;;057-834-381-946-800;;046-223-380-340-936;;031-359-685-845-669;;003-792-470-014-042;;073-065-525-657-220;;048-120-341-468-874;;050-623-241-122-119,10.1038/nprot.2013.141;;24136348;;pmc4211643;;30736982;;10.1016/j.tips.2019.01.006;;29279356;;pmc5837062;;10.1158/0008-5472.can-17-2129;;10.18632/oncotarget.24418;;pmc5862596;;29568375;;10.3390/ijms16023537;;25664860;;pmc4346912;;30758755;;10.1007/s12105-019-01016-2;;pmc6854128;;23386926;;10.1089/bio.2011.0034;;pmc3558729;;pmc4822694;;10.1586/14789450.2016.1122529;;26581546;;10.1093/jxb/erz104;;30838411;;pmc6460961,"PENA-LLOPIS ET AL.: ""Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications"", NAT PROTOC., vol. 8, no. 11, 2013, pages 2240 - 2255, XP055678000, DOI: 10.1038/nprot.2013.141;;DE RUBIS GABRIELE, RAJEEV KRISHNAN SABNA, BEBAWY MARY: ""Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis"", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 40, no. 3, March 2019 (2019-03-01), pages 172 - 186, XP055792893;;CHEN PAN-YU, MUZUMDAR MANDAR DEEPAK, DORANS KIMBERLY JUDITH, ROBBINS REBECCA, BHUTKAR ARJUN, DEL ROSARIO AMANDA, MERTINS PHILIPP, : ""Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells"", CANCER RESEARCH, vol. 78, no. 4, 15 February 2018 (2018-02-15), pages 985 - 1002, XP055792895;;ATAK APURVA, KHURANA SAMIKSHA, GOLLAPALLI KISHORE, REDDY PANGA JAIPAL, LEVY ROEI, BEN-SALMON STAV, HOLLANDER DROR, DONYO MAYA, HEI: ""Quantitative mass spectrometry analysis reveals a panel of nine proteins as diagnostic markers for colon adenocarcinomas"", ONCOTARGET, vol. 9, no. 17, 5 February 2018 (2018-02-05), pages 13530 - 13544, XP055792896;;FEIST ET AL.: ""Proteomic Challenges: Sample Preparation Techniques for Microgram-Quantity Protein Analysis from Biological Samples"", INT J MOL SCI., vol. 16, no. 2, 2015, pages 3537 - 3563, XP055270464, DOI: 10.3390/ijms16023537;;SAAB-CHALHOUB ET AL.: ""Utility and Practicality of Multi-level Sectioning and Upfront Unstained Slide Cutting in Head and Neck Biopsies: A Critical Analysis"", HEAD NECK PATHOL., vol. 13, no. 4, 13 February 2019 (2019-02-13), pages 613 - 617, XP036941489, DOI: 10.1007/s12105-019-01016-2;;MEE BLANAID C., CARROLL PAUL, DONATELLO SIMONA, CONNOLLY ELIZABETH, GRIFFIN MAIREAD, DUNNE BARBARA, BURKE LOUISE, FLAVIN RICHARD, : ""Maintaining Breast Cancer Specimen Integrity and Individual or Simultaneous Extraction of Quality DNA, RNA, and Proteins from All protect-Stabilized and Nonstabilized Tissue Samples"", BIOPRESERVATION AND BIOBANKING, vol. 9, no. 4, December 2011 (2011-12-01), pages 389 - 398, XP055792897;;WANG ET AL.: ""The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification"", EXPERT REV PROTEOMICS, vol. 13, no. 1, 2016, pages 99 - 114, XP055894584;;PERRAR ANDREAS, DISSMEYER NICO, HUESGEN PITTER F: ""New beginnings and new ends: methods for large-scale characterization of protein termini and their use in plant biology"", JOURNAL OF EXPERIMENTAL BOTANY, vol. 70, no. 7, 15 March 2019 (2019-03-15), pages 2021 - 2038, XP055792898",PENDING
196,DE,T2,DE 68921131 T2,160-406-675-245-949,1995-06-01,1995,DE 68921131 T,1989-10-06,US 25747988 A,1988-10-13,Verfahren zur Herstellung von Bis(aminopropoxy)alkanen.,,AIR PROD & CHEM,VAN COURT CARR RICHARD;;JOHNSON THOMAS ALBERT;;GALATON STEVEN MARC;;ALBANESE THOMAS ARCHIE,,https://lens.org/160-406-675-245-949,Granted Patent,no,0,0,9,9,0,C07C217/08;;C07C217/08;;C07C213/02;;C07C213/02;;C07C253/34;;C07C253/34;;Y02P20/52;;Y02P20/52,B01J23/04;;C07B61/00;;C07C213/02;;C07C217/08;;C07C253/34,,0,0,,,,EXPIRED
197,US,B2,US 6996930 B2,186-874-043-136-155,2006-02-14,2006,US 64899703 A,2003-08-27,US 64899703 A,2003-08-27,Retractable face safety for a firearm,"An improved muzzleloading firearm having a novel safety system. The safety system utilizes a spool coupled to a compression spring to maintain an ignition system such as a primer out of potential contact with a firing pin, even in the event of unintentional actuation of a hammer or sear. The safety system is automatic in operation, automatically placing the ignition system within reach of the firing pin when the firearm is placed into battery.",KNIGHT RIFLE INC,HENGSTENBERG ERIC;;CARR HOWARD D;;WINTER STEVEN J;;VOGEL JERALD M;;DAYAL VINAY,KNIGHT RIFLE INC (2003-07-22);;NISUS TECHNOLOGIES LLC (2003-07-22);;MODERN MUZZLELOADING INC (2018-05-02);;P.I. INC (2010-03-15),https://lens.org/186-874-043-136-155,Granted Patent,yes,24,8,2,2,0,F41A19/57;;F41A19/57;;F41C9/08;;F41C9/08,F41C9/08;;F41A19/57,42/51;;42/69.03;;89/27.13,0,0,,,,EXPIRED
198,EP,A3,EP 0353599 A3,018-774-391-675-569,1991-01-16,1991,EP 89113698 A,1989-07-25,US 22664188 A,1988-08-01,PROCESS FOR THE PREPARATION OF BIS(AMINOPROPYL)ALIPHATIC GLYCOLS,"This invention relates to a process for the separation of acrylonitrile used in the cyanoethylation of glycols to produce a bis(cyanoethylated) aliphatic glycol from the resulting glycol which is then reduced with hydrogen to produce the corresponding bis(aminopropyl) aliphatic glycol. In this process, acrylonitrile is reacted with an aliphatic glycol in stoichiometric excess and the acrylonitrile removed from the cyanoethylated glycol by reaction with aliphatic primary or secondary amine prior to effecting the hydrogenation of the cyanoethylated aliphatic glycol in the presence of the acrylonitrlle-amine reaction product. The reaction product then can be separated by conventional techniques such as distillation.  ","AIR PRODUCTS AND CHEMICALS, INC.","VAN COURT CARR, RICHARD;;JOHNSON, THOMAS ALBERT;;GALATON, STEVEN MARC;;ALBANESE, THOMAS ARCHIE",,https://lens.org/018-774-391-675-569,Search Report,yes,4,0,5,5,0,C07C213/02;;C07C213/06;;C07C217/08;;C07C253/34;;C07C217/08;;C07C253/34;;C07C213/06;;C07C213/02,C07C213/02;;C07C213/06;;C07C217/08;;C07C253/34,,0,0,,,,DISCONTINUED
199,US,A1,US 2023/0098182 A1,125-791-066-969-196,2023-03-30,2023,US 202117449320 A,2021-09-29,US 202117449320 A,2021-09-29,NETWORK DEVICE INTERFACE FOR SUPPORTING CENTRALIZED ADDRESS POOL MANAGEMENT,"A first device may establish a connection with a second device, and may provide a connection check RPC message to the second device. The first device may receive a verification RPC message from the second device, and may provide, to the second device, a sync domains RPC request that includes a first list of active domains with associated address pools. The first device may receive, from the second device, a sync domains RPC response that includes threshold values for the active domains included in the first list of active domains, and may provide, to the second device, a sync pools RPC request that includes a first list of address pools associated with the active domains. The first device may receive, from the second device, a sync pools RPC response that includes confirmation of the first list of address pools, and may allocate addresses of an address pool to a CPE.",JUNIPER NETWORKS INC,RAISON PAUL;;AZEVEDO JONATHAN;;ONISHI STEVEN P;;CABECA LINDA M;;CARR MICHAEL D,JUNIPER NETWORKS INC (2021-09-29),https://lens.org/125-791-066-969-196,Patent Application,yes,19,0,2,2,0,H04L61/5007;;H04L61/5061;;H04L61/5061;;H04L61/5007,H04W76/10,,2,1,186-106-405-683-85X,10.1109/mcom.2017.1601001,"Xie, Chongfeng, et al. ""ARPIM: IP address resource pooling and intelligent management system for broadband IP networks."" IEEE Communications Magazine 55.6 (2017): 55-61. (Year: 2017);;Wikipedia contributors. ""NETCONF."" Wikipedia, The Free Encyclopedia. Wikipedia, The Free Encyclopedia, 21 Dec. 2021. Web. 12 Jan. 2023. (Year: 2021)",ACTIVE
200,CA,C,CA 1319706 C,155-876-012-272-685,1993-06-29,1993,CA 606710 A,1989-07-26,US 22664188 A,1988-08-01,PROCESS FOR THE PREPARATION OF BIS(AMINOPROPYL) ALIPHATIC GLYCOLS,173PUS03798 ABSTRACT This invention relates to a process for the separation of acrylonitrile used in the cyanoethylation of glycols to produce a bis(cyanoethylated) aliphatic glycol from the resulting glycol which is then reduced with hydrogen to produce the corresponding bis(aminopropyl) aliphatic glycol. In this process acrylonitrile is reacted with an aliphatic glycol in stoichiometric excess and the acrylonitrile removed from the cyanoethylated glycol by reaction with aliphatic primary or secondary amine prior to effecting the hydrogenation of the cyanoethylated aliphatic glycol in the presence of the acrylonitrile-amine reaction product. The reaction product then can be separated by conventional techniques such as distillation.,AIR PROD & CHEM,VAN COURT CARR RICHARD;;JOHNSON THOMAS A;;GALATON STEVEN M;;ALBANESE THOMAS A,,https://lens.org/155-876-012-272-685,Granted Patent,no,0,0,5,5,0,C07C213/02;;C07C213/06;;C07C217/08;;C07C253/34;;C07C217/08;;C07C253/34;;C07C213/06;;C07C213/02,C07C213/02;;C07C213/06;;C07C217/08;;C07C253/34,D126006075   M,0,0,,,,EXPIRED
201,US,A1,US 2004/0128899 A1,177-011-864-951-077,2004-07-08,2004,US 64899603 A,2003-08-27,US 64899603 A,2003-08-27,Firing system for a firearm,"
   An improved action for a muzzleloading firearm which allows loading an ignition system from above, and completely releasing the action from below. The system covers the ignition system during firing to shield the user and the line of sight. The action may be removed in the field for inspection, cleaning or repair, without the need for tools. 
",HENGSTENBERG ERIC;;CARR HOWARD D.;;WINTER STEVEN J.;;VOGEL JERALD M.;;DAYAL VINAY,HENGSTENBERG ERIC;;CARR HOWARD D;;WINTER STEVEN J;;VOGEL JERALD M;;DAYAL VINAY,KNIGHT RIFLE INC (2003-07-22);;NISUS TECHNOLOGIES LLC (2003-07-22);;MODERN MUZZLELOADING INC (2018-05-02);;P.I. INC (2010-03-15),https://lens.org/177-011-864-951-077,Patent Application,yes,24,1,2,2,0,F41C9/08;;F41C9/08,B05D1/18;;C07D207/404;;F41C9/08;;G01N33/543,42/51,0,0,,,,EXPIRED
202,WO,A3,WO 2015/077058 A3,183-247-565-550-968,2015-11-05,2015,US 2014/0064629 W,2014-11-07,US 201361902066 P;;US 201361915439 P,2013-11-08,COMPOSITIONS AND METHODS FOR SELECTING A TREATMENT FOR B-CELL NEOPLASIAS,The present invention features compositions and methods for identifying a subject having a B cell neoplasia or related condition responsive to treatment with lenalidomide and lenalidoinide-related compounds.,BROAD INST INC;;BRIGHAM & WOMENS HOSPITAL,EBERT BENJAMIN LEVINE;;CARR STEVEN A;;KRONKE JAN;;UDESHI NAMRATA D;;FINK EMMA,,https://lens.org/183-247-565-550-968,Search Report,yes,7,0,9,9,0,C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;G01N33/5011;;G01N33/5088;;G01N33/57496;;G01N33/94;;G01N2333/47;;A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/03;;C12Q1/6876;;C12Q2600/136,G01N33/574,,5,5,014-347-919-911-928;;008-585-270-074-796;;031-403-238-398-698;;153-029-134-050-570;;037-369-297-813-419,pmc3919793;;10.1038/ng.2532;;23334668;;10.1038/sj.onc.1209133;;16205638;;10.1038/leu.2012.119;;pmc3496085;;22552008;;10.1016/j.bbrc.2011.02.062;;21329675;;23349485;;10.2337/db12-1030;;pmc3661653,"HOLMFELDT ET AL.: ""The genomic landscape of hypodiploid acute lymphoblastic leukemia"", NATURE GENETICS, vol. 45, no. 3, 20 January 2013 (2013-01-20), pages 242 - 254., XP055234866, ISSN: 1061-4036;;KLEIN ET AL.: ""BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells"", ONCOGENE, vol. 25, no. 7, 3 October 2005 (2005-10-03), pages 1118 - 1124, XP002516649, ISSN: 0950-9232;;CHOPRA ET AL.: ""Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide"", LEUKEMIA, vol. 26, no. 11, 3 May 2012 (2012-05-03), pages 2326 - 2335, XP055087163, ISSN: 0887-6924;;HE ET AL.: ""lkaros is degraded by proteasome-dependent mechanism in the early phase of apoptosis induction"", BIOCHEM AND BIOPHYS RES COMM, vol. 406, no. 3, 15 February 2011 (2011-02-15), pages 430 - 434, XP028166943, ISSN: 0006-291x;;MIN LEE ET AL.: ""Disruption of the Cereblon Gene Enhances Hepatic AMPK Activity and Prevents High-Fat Diet-Induced Obesity and Insulin Resistance in Mice"", DIABETES, vol. 62, no. 6, 1 June 2013 (2013-06-01), pages 1855 - 1864, XP055234872, ISSN: 0012-1797",PENDING
203,SG,G,SG 133994 G,037-521-143-927-732,1995-01-13,1995,SG 133994 A,1994-09-21,SG 133994 A;;US 13781187 A,1987-12-28,Composition chromatographic article .,,MINNESOTA MINING & MFG,HAGEN DONALD F;;MARY ST STEVEN J;;ERREDE LOUIS A;;CARR PETER W,,https://lens.org/037-521-143-927-732,Granted Patent,no,0,0,1,16,0,,B01D15/08;;B01J20/28,,0,0,,,,EXPIRED
204,EP,A3,EP 0363843 A3,047-312-271-046-982,1991-01-16,1991,EP 89118609 A,1989-10-06,US 25747988 A,1988-10-13,PROCESS FOR THE PREPARATION OF BIS(AMINOPROXY)ALKANES,"This invention relates to a process for the separation of acrylonitrile used in the cyanoethylation of glycols to produce a bis(cyanoethylated) aliphatic glycol from the resulting glycol which is then reduced with hydrogen to produce the corresponding bis(aminopropyl) alkoxy glycol. In this process, acrylonitrile or methacrylonitrile is reacted with an aliphatic glycol in stoichiometric excess and the acrylonitrile removed from the cyanoethylated glycol by reaction with aliphatic primary or secondary alcohol prior to effecting the hydrogenation of the cyanoethylated aliphatic glycol in the presence of the acrylonitrile-amine reaction product. The reaction product then can be separated by conventional techniques such as distillation.  ","AIR PRODUCTS AND CHEMICALS, INC.","VAN COURT CARR, RICHARD;;JOHNSON, THOMAS ALBERT;;GALATON, STEVEN MARC;;ALBANESE, THOMAS ARCHIE",,https://lens.org/047-312-271-046-982,Search Report,yes,4,0,9,9,0,C07C217/08;;C07C217/08;;C07C213/02;;C07C213/02;;C07C253/34;;C07C253/34;;Y02P20/52;;Y02P20/52,B01J23/04;;C07B61/00;;C07C213/02;;C07C217/08;;C07C253/34,,0,0,,,,EXPIRED
205,US,A1,US 2005/0066565 A1,056-354-240-192-778,2005-03-31,2005,US 64895803 A,2003-08-27,US 64895803 A,2003-08-27,ACTION RELEASE FOR A MUZZLELOADER,"A firearm having an improved action for a muzzleloading firearm which allows the toolless field removal of the firing system for inspection, cleaning and repair. The system provides for quick release, removal and reinsertion of the firing system while maintaining safe and secure operation of the firearm during firing.",HENGSTENBERG ERIC;;CARR HOWARD D.;;WINTER STEVEN J.;;VOGEL JERALD M.;;DAYAL VINAY,HENGSTENBERG ERIC;;CARR HOWARD D;;WINTER STEVEN J;;VOGEL JERALD M;;DAYAL VINAY,KNIGHT RIFLE INC (2003-07-22);;NISUS TECHNOLOGIES LLC (2003-07-22);;MODERN MUZZLELOADING INC (2018-05-02);;P.I. INC (2010-03-15),https://lens.org/056-354-240-192-778,Patent Application,yes,23,0,2,2,0,F41A19/49;;F41A19/49;;F41A3/06;;F41A3/06;;F41A19/15;;F41A19/15;;F41C9/08;;F41C9/08,F41A3/06;;F41A19/15;;F41A19/49;;F41C9/08,42/51;;42/69.03,0,0,,,,EXPIRED
206,US,A1,US 2016/0282354 A1,189-382-213-846-407,2016-09-29,2016,US 201415034490 A,2014-11-07,US 201415034490 A;;US 201361902066 P;;US 201361915439 P;;US 2014/0064629 W,2013-11-08,COMPOSITIONS AND METHODS FOR SELECTING A TREATMENT FOR B-CELL NEOPLASIAS,The present invention features compositions and methods for identifying a subject having a B cell neoplasia or related condition responsive to treatment with lenalidomide and lenalidoinide-related compounds.,BROAD INST INC;;BRIGHAM & WOMENS HOSPITAL INC;;THE BRIGHAM & WOMEN'S HOSPITAL INC,EBERT BENJAMIN LEVINE;;CARR STEVEN A;;KRÖNKE JAN;;UDESHI NAMRATA D;;FINK EMMA,THE BRIGHAM AND WOMEN'S HOSPITAL INC (2016-06-29),https://lens.org/189-382-213-846-407,Patent Application,yes,0,13,9,9,33,C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;G01N33/5011;;G01N33/5088;;G01N33/57496;;G01N33/94;;G01N2333/47;;A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/03;;C12Q1/6876;;C12Q2600/136,G01N33/574;;G01N33/50;;G01N33/94,,0,0,,,,DISCONTINUED
207,WO,A2,WO 2015/077058 A2,143-343-128-231-87X,2015-05-28,2015,US 2014/0064629 W,2014-11-07,US 201361902066 P;;US 201361915439 P,2013-11-08,COMPOSITIONS AND METHODS FOR SELECTING A TREATMENT FOR B-CELL NEOPLASIAS,The present invention features compositions and methods for identifying a subject having a B cell neoplasia or related condition responsive to treatment with lenalidomide and lenalidoinide-related compounds.,BROAD INST INC;;BRIGHAM & WOMENS HOSPITAL,EBERT BENJAMIN LEVINE;;CARR STEVEN A;;KRONKE JAN;;UDESHI NAMRATA D;;FINK EMMA,,https://lens.org/143-343-128-231-87X,Patent Application,yes,0,57,9,9,0,C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;G01N33/5011;;G01N33/5088;;G01N33/57496;;G01N33/94;;G01N2333/47;;A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/03;;C12Q1/6876;;C12Q2600/136,C12Q1/68;;C12N15/70,,0,0,,,,PENDING
208,US,B2,US 6922932 B2,009-513-534-530-26X,2005-08-02,2005,US 64895803 A,2003-08-27,US 64895803 A,2003-08-27,Action release for a muzzleloader,"A firearm having an improved action for a muzzleloading firearm which allows the toolless field removal of the firing system for inspection, cleaning and repair. The system provides for quick release, removal and reinsertion of the firing system while maintaining safe and secure operation of the firearm during firing.",HENGSTENBERG ERIC;;CARR HOWARD D.;;WINTER STEVEN J.;;VOGEL JERALD M.;;DAYAL VINAY,HENGSTENBERG ERIC;;CARR HOWARD D;;WINTER STEVEN J;;VOGEL JERALD M;;DAYAL VINAY,KNIGHT RIFLE INC (2003-07-22);;NISUS TECHNOLOGIES LLC (2003-07-22);;MODERN MUZZLELOADING INC (2018-05-02);;P.I. INC (2010-03-15),https://lens.org/009-513-534-530-26X,Granted Patent,yes,23,8,2,2,0,F41A19/49;;F41A19/49;;F41A3/06;;F41A3/06;;F41A19/15;;F41A19/15;;F41C9/08;;F41C9/08,F41A3/06;;F41A19/15;;F41A19/49;;F41C9/08,42/51;;42/69.03,0,0,,,,EXPIRED
209,US,A,US 4810381 A,152-689-845-668-657,1989-03-07,1989,US 13781187 A,1987-12-28,US 13781187 A,1987-12-28,Composite chromatographic article,"A composite chromatographic article comprising: (a) a polytetrafluoroethylene fibril matrix, and (b) non-swellable sorptive particles enmeshed in said matrix, the ration of non-swellable sorptive particles to polytetrafluoroethylene being in the range of 19:1 to 4:1 by weight, said composite article having a net surface energy in the range of 20 to 300 milliNewtons per meter.",MINNESOTA MINING & MFG,HAGEN DONALD F;;ST MARY STEVEN J;;ERREDE LOUIS A;;CARR PETER W,MINNESOTA MINING AND MANUFACTURING COMPANY A CORP. OF DE (1987-12-23),https://lens.org/152-689-845-668-657,Granted Patent,yes,9,153,13,16,0,B01J20/28028;;B01J20/28033;;Y10S435/803;;Y10T428/249986;;Y10T428/249954;;Y10T428/249986;;Y10T428/249954;;B01J20/28028;;B01J20/28033;;Y10S435/803,B01D15/08;;B01J20/28;;B01J20/285;;G01N30/88;;B01J20/281;;G01N30/92,210/502.1;;210/635;;210/657;;428/305.5;;428/317.9;;435/803,0,0,,,,EXPIRED
210,US,A1,US 2018/0343839 A1,193-770-502-966-789,2018-12-06,2018,US 201815955073 A,2018-04-17,US 201815955073 A;;US 201615074920 A;;US 2014/0064629 W;;US 201361902066 P;;US 201361915439 P,2013-11-08,KNOCK-IN RODENT COMPRISING A MUTATION IN AN ENDOGENOUS CRBN LOCUS AND METHODS OF USE THEREOF,The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.,EBERT BENJAMIN LEVINE;;KROENKE JAN;;FINK EMMA;;CARR STEVEN A;;UDESHI NAMRATA D;;BROAD INST INC;;BRIGHAM & WOMENS HOSPITAL INC,EBERT BENJAMIN LEVINE;;KRÖNKE JAN;;CARR STEVEN A;;UDESHI NAMRATA D;;FINK EMMA,THE BRIGHAM AND WOMEN'S HOSPITAL INC (2016-08-16);;THE BROAD INSTITUTE INC (2018-03-14),https://lens.org/193-770-502-966-789,Patent Application,yes,0,7,9,9,69,C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;G01N33/5011;;G01N33/5088;;G01N33/57496;;G01N33/94;;G01N2333/47;;A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/03;;C12Q1/6876;;C12Q2600/136,A01K67/027;;C12Q1/6876;;C12Q1/6886;;G01N33/50;;G01N33/574;;G01N33/94,,0,0,,,,ACTIVE
211,US,B2,US 7076902 B2,019-646-805-686-138,2006-07-18,2006,US 64899603 A,2003-08-27,US 64899603 A,2003-08-27,Firing system for a firearm,"An improved action for a muzzleloading firearm which allows loading an ignition system from above, and completely releasing the action from below. The system covers the ignition system during firing to shield the user and the line of sight. The action may be removed in the field for inspection, cleaning or repair, without the need for tools.",KNIGHT RIFLE INC,HENGSTENBERG ERIC;;CARR HOWARD D;;WINTER STEVEN J;;VOGEL JERALD M;;DAYAL VINAY,KNIGHT RIFLE INC (2003-07-22);;NISUS TECHNOLOGIES LLC (2003-07-22);;MODERN MUZZLELOADING INC (2018-05-02);;P.I. INC (2010-03-15),https://lens.org/019-646-805-686-138,Granted Patent,yes,24,15,2,2,0,F41C9/08;;F41C9/08,F41C7/00;;B05D1/18;;C07D207/404;;F41C9/08;;G01N33/543,42/51;;42/69.01;;42/69.03,0,0,,,,EXPIRED
212,US,B2,US 9974289 B2,028-848-935-907-789,2018-05-22,2018,US 201615074920 A,2016-03-18,US 201615074920 A;;US 2014/0064629 W;;US 201361902066 P;;US 201361915439 P,2013-11-08,Knock-in rodent comprising a mutation in an endogenous CRBN locus and methods of use thereof,The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.,BROAD INST INC;;BRIGHAM & WOMENS HOSPITAL INC,EBERT BENJAMIN LEVINE;;KRÖNKE JAN;;CARR STEVEN A;;UDESHI NAMRATA D;;FINK EMMA,THE BRIGHAM AND WOMEN'S HOSPITAL INC (2016-08-16);;THE BROAD INSTITUTE INC (2018-03-14),https://lens.org/028-848-935-907-789,Granted Patent,yes,8,2,9,9,69,C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;G01N33/5011;;G01N33/5088;;G01N33/57496;;G01N33/94;;G01N2333/47;;A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/03;;C12Q1/6876;;C12Q2600/136,A01K67/027;;C12Q1/68;;G01N33/00;;G01N33/50;;G01N33/574;;G01N33/94,,26,19,005-654-188-739-004;;031-403-238-398-698;;014-732-105-086-413;;086-329-095-564-726;;081-789-604-294-249;;037-369-297-813-419;;039-337-750-255-109;;010-971-530-112-814;;032-568-192-050-38X;;056-072-812-092-997;;158-134-792-322-490;;101-481-896-960-735;;025-349-822-800-031;;012-400-907-533-488;;014-347-919-911-928;;008-585-270-074-796;;031-403-238-398-698;;153-029-134-050-570;;037-369-297-813-419,10.1126/science.1177319;;20223979;;10.1038/leu.2012.119;;pmc3496085;;22552008;;10.1016/j.bbr.2011.09.039;;21995942;;pmc5864115;;23434730;;10.1038/leu.2013.59;;10.1111/bjh.12291;;23480694;;pmc3655110;;23349485;;10.2337/db12-1030;;pmc3661653;;24166296;;10.1038/leu.2013.315;;pmc4017253;;26188093;;10.1016/j.bbrc.2015.07.068;;10.1016/j.bbrc.2015.01.054;;25619137;;26131937;;pmc4853910;;10.1038/nature14610;;26410577;;10.1016/j.bbadis.2015.09.014;;24292625;;10.1126/science.1244851;;pmc4077049;;10.1182/blood-2014-02-557819;;24914135;;pmc4110660;;10.4161/21624011.2014.941742;;pmc4292522;;25610725;;pmc3919793;;10.1038/ng.2532;;23334668;;10.1038/sj.onc.1209133;;16205638;;10.1038/leu.2012.119;;pmc3496085;;22552008;;10.1016/j.bbrc.2011.02.062;;21329675;;23349485;;10.2337/db12-1030;;pmc3661653,"Ito (Science, Mar. 12, 2010, vol. 327, No. 5971, p. 1345-1350).;;Lopez-Girona (Leukemia, 2012, vol. 26, p. 2326-2335).;;Rajadhyaksha (Behavioral Brain Res., 2012, available Oct. 4, 2011, vol. 226, p. 428-434).;;Zhu (Blood, Nov. 16, 2012, vol. 120, No. 21, p. 1807, abstract).;;Sardnal (Leukemia, Apr. 26, 2013, vol. 27, p. 1610-1613).;;Egan (British Journal of Haematology, (Jun. 2013) vol. 161, No. 5, pp. 748-751).;;Lee (Diabetes, Jun. 2013, vol. 62, p. 1855-1864).;;Thakurta (Blood, (Nov. 15, 2013) vol. 122, No. 21, pp. 3139. Meeting Info.: 55th Annual Meeting of the American-Society-of-Hematology. New Orleans, LA, USA. Dec. 7-10, 2013. Amer Soc Hematol.).;;Gouri (J. Hematol Thrombo Dis 2014, 2:3, p. 1).;;Maity, Blood, Dec. 6, 2014, vol. 124, No. 21, Meeting Info.: 56th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA, USA. Dec. 6-9, 2014. Amer Soc Hematol.).;;Thakurta (Leukemia, 2014, vol. 28, p. 1129-1131, available online Oct. 29, 2013).;;Sawamura (Biochem. & Biophys. Res. Comm., 2015, vol. 464, p. 1054-1059).;;Lee (Biochemical and Biophysical Res. Comm., Jan. 22, 2015, vol. 458, p. 34-39).;;Kronke (Nature, Jul. 9, 2015, vol. 523, No. 7559, p. 183-188).;;Kim (Biochimica et Biophysica Acta, Sep. 26, 2015, vol. 1852, p. 2662-2670).;;Neri (Dec. 3, 2016, Blood, (Dec. 2, 2016) vol. 128, No. 22, pp. 120. Meeting Info.: 58th Annual Meeting and Exposition of the American-Society-of-Hematology. San Diego, CA, USA. Dec. 3-6, 2016. Amer Soc Hematol.).;;Kronke (Science, Jan. 17, 2014, vol. 343, p. 301-305).;;Zhu (Blood, Jul. 24, 2014, prepublished online Jun. 9, 2014, vol. 124, No. 4, p. 536-545).;;Kronke (Oncolmmunology, Jul. 1, 2014, vol. 3, No. 7, e941742).;;Gandhi (British J. Haematology, 2014 (first published Dec. 13, 2013), vol. 164, p. 811-821).;;Holmfelt et al., “The genomic landscape of hypodiploid acute lymphoblastic leukemia,” Nature Genetics, vol. 45, No. 3, pp. 242-254 (2013).;;Klein et al., “BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells,” Oncogene, vol. 25, pp. 1118-1124 (2005).;;Chopra et al., “Cereblon is a direct protein target, for immunomoldulatory and antiproliferative activities of lenalidomide and pomalidomide,” Leukemia, vol. 26, pp. 2326-2335 (2012).;;He et al., “Ikaros is degraded by proteasome-dependent mechanism in the early phase of apoptosis induction,” Biochem and Biophys. Res. Comm., vol. 409, pp. 430-434 (2011).;;Min, Lee et al., Disruption of the Cereblon Gene Enhances Hepatic AMPK Activity and Prevents High-Fat Diet-Induced Obesity and Insulin Resistance in Mice, Diabetes, vol. 62, pp. 1855-1864 (2013).;;International Search Report and Written Opinion, for corresponding PCT/US2014/064629, dated Mar. 24, 2015 (17 pages).",ACTIVE
213,EP,A2,EP 0363843 A2,080-679-097-917-398,1990-04-18,1990,EP 89118609 A,1989-10-06,US 25747988 A,1988-10-13,Process for the preparation of bis(aminoproxy)alkanes.,"This invention relates to a process for the separation of acrylonitrile used in the cyanoethylation of glycols to produce a bis(cyanoethylated) aliphatic glycol from the resulting glycol which is then reduced with hydrogen to produce the corresponding bis(aminopropyl) alkoxy glycol. In this process, acrylonitrile or methacrylonitrile is reacted with an aliphatic glycol in stoichiometric excess and the acrylonitrile removed from the cyanoethylated glycol by reaction with aliphatic primary or secondary alcohol prior to effecting the hydrogenation of the cyanoethylated aliphatic glycol in the presence of the acrylonitrile-amine reaction product. The reaction product then can be separated by conventional techniques such as distillation.  ",AIR PROD & CHEM,VAN COURT CARR RICHARD;;JOHNSON THOMAS ALBERT;;GALATON STEVEN MARC;;ALBANESE THOMAS ARCHIE,,https://lens.org/080-679-097-917-398,Patent Application,yes,0,4,9,9,0,C07C217/08;;C07C217/08;;C07C213/02;;C07C213/02;;C07C253/34;;C07C253/34;;Y02P20/52;;Y02P20/52,B01J23/04;;C07B61/00;;C07C213/02;;C07C217/08;;C07C253/34,,0,0,,,,EXPIRED
214,EP,A1,EP 4013896 A1,190-407-680-642-95X,2022-06-22,2022,EP 20852344 A,2020-08-12,US 201962885709 P;;US 201962889373 P;;US 2020/0045962 W,2019-08-12,PROTEOGENOMIC METHODS FOR DIAGNOSING CANCER,,BAYLOR COLLEGE MEDICINE;;BROAD INST INC;;MASSACHUSETTS GEN HOSPITAL,ELLIS MATTHEW J;;ZHANG BING;;JAEHNIG ERIC;;CARR STEVEN;;SATPATHY SHANKHA;;GILLETTE MICHAEL,,https://lens.org/190-407-680-642-95X,Patent Application,yes,0,0,4,4,66,C12Q1/6886;;C12Q2600/158;;C12Q2600/106;;G01N33/574;;G01N33/6848;;G01N33/6842;;G01N2440/14;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158;;G01N33/57415;;G01N33/6848;;G01N2440/14,C12Q1/6886,,0,0,,,,PENDING
215,EP,A2,EP 0353599 A2,054-908-527-251-99X,1990-02-07,1990,EP 89113698 A,1989-07-25,US 22664188 A,1988-08-01,Process for the preparation of bis(aminopropyl)aliphatic glycols.,"This invention relates to a process for the separation of acrylonitrile used in the cyanoethylation of glycols to produce a bis(cyanoethylated) aliphatic glycol from the resulting glycol which is then reduced with hydrogen to produce the corresponding bis(aminopropyl) aliphatic glycol. In this process, acrylonitrile is reacted with an aliphatic glycol in stoichiometric excess and the acrylonitrile removed from the cyanoethylated glycol by reaction with aliphatic primary or secondary amine prior to effecting the hydrogenation of the cyanoethylated aliphatic glycol in the presence of the acrylonitrlle-amine reaction product. The reaction product then can be separated by conventional techniques such as distillation.  ",AIR PROD & CHEM,VAN COURT CARR RICHARD;;JOHNSON THOMAS ALBERT;;GALATON STEVEN MARC;;ALBANESE THOMAS ARCHIE,,https://lens.org/054-908-527-251-99X,Patent Application,yes,0,0,5,5,0,C07C213/02;;C07C213/06;;C07C217/08;;C07C253/34;;C07C217/08;;C07C253/34;;C07C213/06;;C07C213/02,C07C213/02;;C07C213/06;;C07C217/08;;C07C253/34,,0,0,,,,DISCONTINUED
216,US,B2,US 11757833 B2,153-540-868-232-910,2023-09-12,2023,US 202117449320 A,2021-09-29,US 202117449320 A,2021-09-29,Network device interface for supporting centralized address pool management,"A first device may establish a connection with a second device, and may provide a connection check RPC message to the second device. The first device may receive a verification RPC message from the second device, and may provide, to the second device, a sync domains RPC request that includes a first list of active domains with associated address pools. The first device may receive, from the second device, a sync domains RPC response that includes threshold values for the active domains included in the first list of active domains, and may provide, to the second device, a sync pools RPC request that includes a first list of address pools associated with the active domains. The first device may receive, from the second device, a sync pools RPC response that includes confirmation of the first list of address pools, and may allocate addresses of an address pool to a CPE.",JUNIPER NETWORKS INC,RAISON PAUL;;AZEVEDO JONATHAN;;ONISHI STEVEN P;;CABECA LINDA M;;CARR MICHAEL D,JUNIPER NETWORKS INC (2021-09-29),https://lens.org/153-540-868-232-910,Granted Patent,yes,22,0,2,2,0,H04L61/5007;;H04L61/5061;;H04L61/5061;;H04L61/5007,H04L61/5061;;H04L61/5007,,2,1,186-106-405-683-85X,10.1109/mcom.2017.1601001,"Xie, Chongfeng, et al. “ARPIM: IP address resource pooling and intelligent management system for broadband IP networks.” IEEE Communications Magazine 55.6 (2017): 55-61. (Year: 2017).;;Wikipedia contributors. “NETCONF.” Wikipedia, The Free Encyclopedia. Wikipedia, The Free Encyclopedia, Dec. 21, 2021. Web. Jan. 12, 2023. (Year: 2021).",ACTIVE
217,WO,A1,WO 2006/009663 A1,171-429-762-659-542,2006-01-26,2006,US 2005/0020790 W,2005-06-13,US 58228004 P;;US 58291404 P;;US 65664205 P;;US 67302205 P,2004-06-22,"DIGITAL ASSET MANAGEMENT, TARGETED SEARCHING AND DESKTOP SEARCHING USING DIGITAL WATERMARKS","The present invention provides methods and systems to improve network searching for watermarked content. In some implementations we employ keyword searching to narrow the universe of possible URL candidates. A resulting URL list is searched for digital watermarking. A system is provided to allow customer input. For example, a customer enters keywords or network locations. The keywords or network locations are provided to a watermark-enabled web browser which accesses locations associated with the keywords or network locations. Some implementations of the present invention employ a plurality of distributed watermark-enabled web browsers. Other aspects of the invention provide methods and system to facilitate desktop searching and automated metadata gathering and generating. In one implementation a digital watermark is used to determine whether metadata associated with an image or audio file is current or fresh. The metadata is updated when it is out of date. Watermarks can also be used to link to or facilitate so-called on-line 'blogs' (or online conversations).",DIGIMARC CORP;;RODRIGUEZ TONY F;;CALHOON SEAN;;CARR SCOTT J;;GRAY STEVEN;;REED ALASTAIR M,RODRIGUEZ TONY F;;CALHOON SEAN;;CARR SCOTT J;;GRAY STEVEN;;REED ALASTAIR M,,https://lens.org/171-429-762-659-542,Patent Application,yes,1,22,5,1547,0,G06F16/68;;G06F16/683;;G06F16/951;;G06F16/58;;G06F16/951;;G06F16/48,H04N21/232;;H04N21/4728;;H04N21/84,,0,0,,,,PENDING
218,US,A1,US 2005/0066566 A1,031-392-353-607-458,2005-03-31,2005,US 64899703 A,2003-08-27,US 64899703 A,2003-08-27,Retractable face safety for a firearm,"An improved muzzleloading firearm having a novel safety system. The safety system utilizes a spool coupled to a compression spring to maintain an ignition system such as a primer out of potential contact with a firing pin, even in the event of unintentional actuation of a hammer or sear. The safety system is automatic in operation, automatically placing the ignition system within reach of the firing pin when the firearm is placed into battery.",HENGSTENBERG ERIC;;CARR HOWARD D.;;WINTER STEVEN J.;;VOGEL JERALD M.;;DAYAL VINAY,HENGSTENBERG ERIC;;CARR HOWARD D;;WINTER STEVEN J;;VOGEL JERALD M;;DAYAL VINAY,KNIGHT RIFLE INC (2003-07-22);;NISUS TECHNOLOGIES LLC (2003-07-22);;MODERN MUZZLELOADING INC (2018-05-02);;P.I. INC (2010-03-15),https://lens.org/031-392-353-607-458,Patent Application,yes,23,3,2,2,0,F41A19/57;;F41A19/57;;F41C9/08;;F41C9/08,F41A19/57;;F41C9/08,42/51;;42/69.03;;89/27.13,0,0,,,,EXPIRED
219,KR,B1,KR 970007075 B1,128-382-469-210-215,1997-05-02,1997,KR 880017561 A,1988-12-27,US 13781187 A,1987-12-28,HROMATOGRAPHIC ARTICLE COMPOSITION,내용없음,MINNESOTA MINING & MFG,DONALD FREDRICK HAGEN;;STEVEN JAMES ST MARY;;LOUIS ANTONY ERREDE;;PETER WILLIAM CARR,,https://lens.org/128-382-469-210-215,Granted Patent,no,0,0,13,16,0,B01J20/28028;;B01J20/28033;;Y10S435/803;;Y10T428/249986;;Y10T428/249954;;Y10T428/249986;;Y10T428/249954;;B01J20/28028;;B01J20/28033;;Y10S435/803,B01D15/08;;B01J20/281;;B01J20/28;;B01J20/285;;G01N30/88;;G01N30/92,,0,0,,,,EXPIRED
220,CA,C,CA 1330073 C,186-348-825-364-582,1994-06-07,1994,CA 584533 A,1988-11-30,US 13781187 A,1987-12-28,COMPOSITE CHROMATOGRAPHIC ARTICLE,"ABSTRACT OF THE DISCLOSURE A composite chromatographic article comprising: a) a polytetrafluoroethylene fibril matrix, and b) non-swellable sorptive particles enmeshed in said matrix, the ratio of non-swellable sorptive particles to polytetrafluoroethylene being in the range of 19:1 to 4: 1 by weight, said composite article having a net surface energy in the range of 20 to 300 milliNewtons per meter.",MINNESOTA MINING & MFG,HAGEN DONALD F;;ST MARY STEVEN J;;ERREDE LOUIS A;;CARR PETER W,,https://lens.org/186-348-825-364-582,Granted Patent,no,0,0,13,16,0,B01J20/28028;;B01J20/28033;;Y10S435/803;;Y10T428/249986;;Y10T428/249954;;Y10T428/249986;;Y10T428/249954;;B01J20/28028;;B01J20/28033;;Y10S435/803,B01J20/281;;B01D15/08;;B01J20/28;;B01J20/285;;G01N30/88;;G01N30/92,D22520031    M;;18200025   S,0,0,,,,EXPIRED
221,US,B2,US 10334829 B2,156-651-718-294-80X,2019-07-02,2019,US 201815955073 A,2018-04-17,US 201815955073 A;;US 201615074920 A;;US 2014/0064629 W;;US 201361902066 P;;US 201361915439 P,2013-11-08,IMiD screening methods IMiD-sensitive cells with mutant CRBN,The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.,BROAD INST INC;;BRIGHAM & WOMENS HOSPITAL INC,EBERT BENJAMIN LEVINE;;KRÖNKE JAN;;CARR STEVEN A;;UDESHI NAMRATA D;;FINK EMMA,THE BRIGHAM AND WOMEN'S HOSPITAL INC (2016-08-16);;THE BROAD INSTITUTE INC (2018-03-14),https://lens.org/156-651-718-294-80X,Granted Patent,yes,10,2,9,9,69,C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;G01N33/5011;;G01N33/5088;;G01N33/57496;;G01N33/94;;G01N2333/47;;A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/03;;C12Q1/6876;;C12Q2600/136,G01N33/00;;A01K67/027;;C12Q1/6876;;C12Q1/6886;;G01N33/50;;G01N33/574;;G01N33/94,,30,20,005-654-188-739-004;;031-403-238-398-698;;014-732-105-086-413;;086-329-095-564-726;;081-789-604-294-249;;037-369-297-813-419;;039-337-750-255-109;;010-971-530-112-814;;032-568-192-050-38X;;056-072-812-092-997;;158-134-792-322-490;;101-481-896-960-735;;025-349-822-800-031;;012-400-907-533-488;;014-347-919-911-928;;008-585-270-074-796;;031-403-238-398-698;;153-029-134-050-570;;037-369-297-813-419;;010-971-530-112-814,10.1126/science.1177319;;20223979;;10.1038/leu.2012.119;;pmc3496085;;22552008;;10.1016/j.bbr.2011.09.039;;21995942;;pmc5864115;;23434730;;10.1038/leu.2013.59;;10.1111/bjh.12291;;23480694;;pmc3655110;;23349485;;10.2337/db12-1030;;pmc3661653;;24166296;;10.1038/leu.2013.315;;pmc4017253;;26188093;;10.1016/j.bbrc.2015.07.068;;10.1016/j.bbrc.2015.01.054;;25619137;;26131937;;pmc4853910;;10.1038/nature14610;;26410577;;10.1016/j.bbadis.2015.09.014;;24292625;;10.1126/science.1244851;;pmc4077049;;10.1182/blood-2014-02-557819;;24914135;;pmc4110660;;10.4161/21624011.2014.941742;;pmc4292522;;25610725;;pmc3919793;;10.1038/ng.2532;;23334668;;10.1038/sj.onc.1209133;;16205638;;10.1038/leu.2012.119;;pmc3496085;;22552008;;10.1016/j.bbrc.2011.02.062;;21329675;;23349485;;10.2337/db12-1030;;pmc3661653;;26188093;;10.1016/j.bbrc.2015.07.068,"Ito (Science, Mar. 12, 2010, vol. 327, No. 5971, p. 1345-1350).;;Lopez-Girona (Leukemia, 2012, vol. 26, p. 2326-2335).;;Rajadhyaksha (Behavioral Brain Res., 2012, available Oct. 4, 2011, vol. 226, p. 428-434).;;Zhu (Blood, Nov. 16, 2012, vol. 120, No. 21, p. 1807, abstar.;;Sardnal (Leukemia, Apr. 26, 2013, vol. 27, p. 1610-1613).;;Egan (British Journal of Haematology, (Jun. 2013) vol. 161, No. 5, pp. 748-751).;;Lee (Diabetes, Jun. 2013, vol. 62, p. 1855-1864).;;Thakurta (Blood, (Nov. 15, 2013) vol. 122, No. 21, pp. 3139. Meeting Info.: 55th Annual Meeting of the American-Society-of-Hematology. New Orleans, LA, USA. Dec. 7-10, 2013. Amer Soc Hematol.).;;Gouri (J. Hematol Thrombo Dis 2014, 2:3, p. 1).;;Maity, Blood, Dec. 6, 2014, vol. 124, No. 21, Meeting Info.: 56th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA, USA. Dec. 6-9, 2014. Amer Soc Hematol.).;;Thakurta (Leukemia, 2014, vol. 28, p. 1129-1131, available online Oct. 29, 2013).;;Sawamura (Biochem. & Biophys. Res. Comm., 2015, vol. 464, p. 1054-1059).;;Lee (Biochemical and Biophysical Res. Comm., Jan. 22, 2015, vol. 458, p. 34-39).;;Kronke (Nature, Jul. 9, 2015, vol. 523, No. 7559, p. 183-188).;;Kim (Biochimica et Biophysica Acta, Sep. 26, 2015, vol. 1852, p. 2662-2670).;;Neri (Dec. 3, 2016, Blood, (Dec. 2 2016) vol. 128, No. 22, pp. 120. Meeting Info.: 58th Annual Meeting and Exposition of the American-Society-of-Hematology. San Diego, CA, USA. Dec. 3-6, 2016. Amer Soc Hematol.).;;Kronke (Science, Jan. 17, 2014, vol. 343, p. 301-305).;;Zhu (Blood, Jul. 24, 2014, prepublished online Jun. 9, 2014, vol. 124, No. 4, p. 536-545).;;Kronke (Oncolmmunology, Jul. 1, 2014, vol. 3, No. 7, e941742).;;Gandhi (British J. Haematology, 2014 (first published Dec. 13, 2013), vol. 164, p. 811-821).;;Holmfelt et al., “The genomic landscape of hypodiploid acute lymphoblastic leukemia,” Nature Genetics, vol. 45, No. 3, pp. 242-254 (2013).;;Klein et al., “BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells,” Oncogene, vol. 25, pp. 1118-1124 (2005).;;Chopra et al., “Cereblon is a direct protein target for immunomoldulatory and antiproliferative activities of lenalidomide and pomalidomide,” Leukemia, vol. 26, pp. 2326-2335 (2012).;;He et al., “Ikaros is degraded by proteasome-dependent mechanism in the early phase of apoptosis induction,” Biochem and Biophys. Res. Comm., vol. 409, pp. 430-434 (2011).;;Min, Lee et al., Disruption of the Cereblon Gene Enhances Hepatic AMPK Activity and Prevents High-Fat Diet-Induced Obesity and Insulin Resistance in Mice, Diabetes, vol. 62, pp. 1855-1864 (2013).;;International Search Report and Written Opinion, for corresponding PCT/US2014/064629, dated Mar. 24, 2015 (17 pages).;;Zhu (Blood, Nov. 16, 2012, vol. 120, No. 21, p. 1807, abstract).;;R. Maity et al., Blood, Dec. 6, 2014, vol. 124, No. 21, p. 639, Meeting Info: 56th Annual Meeting of the American-Society-of-Hematology, San Francisco, CA, USA, Dec. 6-9, 2014, Amer. Soc. Hematol.).;;Sawamura (Biochm. & Biophys. Res. Comm., 2015, vol. 464, p. 1054-1059).;;P. Neri (Dec. 3, 2016, Blood, (Dec. 2, 2016), vol. 128, No. 22, p. 120, Meeting Info.: 58th Annual Meeting and Exposition of the American-Society-of-Hematology, San Diego, CA, USA, Dec. 3-6, 2016. Amer. Soc. Hematol).",ACTIVE
222,CA,C,CA 1328282 C,181-249-760-510-941,1994-04-05,1994,CA 615125 A,1989-09-29,US 25747988 A,1988-10-13,PROCESS FOR THE PREPARATION OF BIS(AMINOPROPOXY) ALKANES,"ABSTRACT This invention relates to a process for the separation of acrylonitrile used in the cyanoethylation of glycols to produce a bis(cyanoethylated) aliphatic glycol from the resulting glycol which is then reduced with hydrogen to produce the corresponding bis(aminopropyl) alkoxy glycol. In this process, acrylonitrile or methacrylonitrile is reacted with an aliphatic glycol in stoichiometric excess and the acrylonitrile removed from the cyanoethylated glycol by reaction with aliphatic primary or secondary alcohol prior to effecting the hydrogenation of the cyanoethylated aliphatic glycol in the presence of the acrylonitrile-amine reaction product. The reaction product then can be separated by conventional techniques such as distillation.",AIR PROD & CHEM,CARR RICHARD V C;;JOHNSON THOMAS A;;GALATON STEVEN M;;ALBANESE THOMAS A,,https://lens.org/181-249-760-510-941,Granted Patent,no,0,0,9,9,0,C07C213/02;;C07C217/08;;C07C253/34;;Y02P20/52;;C07C217/08;;C07C253/34;;C07C213/02;;Y02P20/52,B01J23/04;;C07B61/00;;C07C213/02;;C07C217/08;;C07C253/34,D126006075   M,0,0,,,,EXPIRED
223,US,A1,US 2016/0338326 A1,067-685-250-288-736,2016-11-24,2016,US 201615074920 A,2016-03-18,US 201615074920 A;;US 2014/0064629 W;;US 201361902066 P;;US 201361915439 P,2013-11-08,KNOCK-IN RODENT COMPRISING A MUTATION IN AN ENDOGENOUS CRBN LOCUS AND METHODS OF USE THEREOF,The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.,BROAD INST INC;;BRIGHAM & WOMENS HOSPITAL INC,EBERT BENJAMIN LEVINE;;KRÖNKE JAN;;CARR STEVEN A;;UDESHI NAMRATA D;;FINK EMMA,THE BRIGHAM AND WOMEN'S HOSPITAL INC (2016-08-16);;THE BROAD INSTITUTE INC (2018-03-14),https://lens.org/067-685-250-288-736,Patent Application,yes,1,3,9,9,69,C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;G01N33/5011;;G01N33/5088;;G01N33/57496;;G01N33/94;;G01N2333/47;;A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/03;;C12Q1/6876;;C12Q2600/136,A01K67/027;;C12Q1/68;;G01N33/50,,20,14,005-654-188-739-004;;031-403-238-398-698;;014-732-105-086-413;;086-329-095-564-726;;081-789-604-294-249;;037-369-297-813-419;;039-337-750-255-109;;010-971-530-112-814;;032-568-192-050-38X;;056-072-812-092-997;;158-134-792-322-490;;101-481-896-960-735;;025-349-822-800-031;;012-400-907-533-488,10.1126/science.1177319;;20223979;;10.1038/leu.2012.119;;pmc3496085;;22552008;;10.1016/j.bbr.2011.09.039;;21995942;;pmc5864115;;23434730;;10.1038/leu.2013.59;;10.1111/bjh.12291;;23480694;;pmc3655110;;23349485;;10.2337/db12-1030;;pmc3661653;;24166296;;10.1038/leu.2013.315;;pmc4017253;;26188093;;10.1016/j.bbrc.2015.07.068;;10.1016/j.bbrc.2015.01.054;;25619137;;26131937;;pmc4853910;;10.1038/nature14610;;26410577;;10.1016/j.bbadis.2015.09.014;;24292625;;10.1126/science.1244851;;pmc4077049;;10.1182/blood-2014-02-557819;;24914135;;pmc4110660;;10.4161/21624011.2014.941742;;pmc4292522;;25610725,"Ito (Science, March 12, 2010, Vol. 327, No. 5971, pg 1345-1350);;Lopez-Girona (Leukemia, 2012, Vol. 26, pg 2326-2335);;Rajadhyaksha (Behavioral Brain Res., 2012, available Oct. 4, 2011, Vol. 226, pg 428-434);;Zhu (Blood, Nov. 16, 2012, Vol. 120, No. 21, pg 1807, abstract);;Sardnal (Leukemia, April 26, 2013, Vol. 27, pg 1610-1613);;Egan (British Journal of Haematology, (JUN 2013) Vol. 161, No. 5, pp. 748-751);;Lee (Diabetes, June 2013, Vol. 62, pg 1855-1864);;Thakurta (Blood, (NOV 15 2013) Vol. 122, No. 21, pp. 3139. Meeting Info.: 55th Annual Meeting of the American-Society-of-Hematology. New Orleans, LA, USA. December 07 -10, 2013. Amer Soc Hematol.);;Gouri (J. Hematol Thrombo Dis 2014, 2:3, pg 1);;Maity, Blood, DEC 6 2014, Vol. 124, No. 21, Meeting Info.: 56th Annual Meeting of the American-Society-of-Hematology. San Francisco, CA, USA. December 06 -09, 2014. Amer Soc Hematol.);;Thakurta (Leukemia, 2014, Vol. 28, pg 1129-1131, available online Oct. 29, 2013);;Sawamura (Biochem. & Biophys. Res. Comm., 2015, Vol. 464, pg 1054-1059);;Lee (Biochemical and Biophysical Res. Comm., Jan. 22, 2015, Vol. 458, pg 34-39);;Kronke (Nature, July 9, 2015, Vol. 523, No. 7559, pg 183-188);;Kim (Biochimica et Biophysica Acta, Sept. 26, 2015, Vol. 1852, pg 2662-2670);;Neri (Dec. 3, 2016, Blood, (DEC 2 2016) Vol. 128, No. 22, pp. 120. Meeting Info.: 58th Annual Meeting and Exposition of the American-Society-of-Hematology. San Diego, CA, USA. December 03 -06, 2016. Amer Soc Hematol.);;Kronke (Science, Jan. 17, 2014, Vol. 343, pg 301-305);;Zhu (Blood, July 24, 2014, prepublished online June 9, 2014, Vol. 124, No. 4, pg 536-545);;Kronke (OncoImmunology, July 1, 2014, Vol. 3, No. 7, e941742);;Gandhi (British J. Haematology, 2014 (first published Dec 13, 2013), Vol. 164, pg 811-821)",ACTIVE
224,US,A,US 5081305 A,063-423-247-270-003,1992-01-14,1992,US 25747988 A,1988-10-13,US 25747988 A,1988-10-13,PROCESS FOR THE PREPARATION OF BIS(AMINOPROPOXY)ALKANES,"This invention relates to a process for the separation of acrylonitrile used in the cyanoethylation of glycols to produce a bis(cyanoethylated) aliphatic glycol from the resulting glycol which is then reduced with hydrogen to produce the corresponding bis(aminopropoxy) alkane. In this process, acrylonitrile or methacrylonitrile is reacted with an aliphatic glycol in stoichiometric excess and the acrylonitrile removed from the cyanoethylated glycol by reaction with aliphatic primary or secondary alcohol prior to effecting the hydrogenation of the cyanoethylated aliphatic glycol in the presence of the acrylonitrile-amine reaction product. The reaction product then can be separated by conventional techniques such as distillation.",AIR PROD & CHEM,CARR RICHARD V C;;GALATON STEVEN M;;JOHNSON THOMAS A;;ALBANESE THOMAS A,AIR PRODUCTS AND CHEMICALS INC. A CORP. OF DE (1988-09-30),https://lens.org/063-423-247-270-003,Granted Patent,yes,3,8,9,9,0,C07C217/08;;C07C217/08;;C07C213/02;;C07C213/02;;C07C253/34;;C07C253/34;;Y02P20/52;;Y02P20/52,B01J23/04;;C07B61/00;;C07C213/02;;C07C217/08;;C07C253/34,564/490;;564/491;;558/450,0,0,,,,EXPIRED
225,EP,B1,EP 0363843 B1,193-301-401-200-002,1995-02-15,1995,EP 89118609 A,1989-10-06,US 25747988 A,1988-10-13,Process for the preparation of bis(aminopropoxy)alkanes.,,AIR PROD & CHEM,VAN COURT CARR RICHARD;;JOHNSON THOMAS ALBERT;;GALATON STEVEN MARC;;ALBANESE THOMAS ARCHIE,,https://lens.org/193-301-401-200-002,Granted Patent,yes,4,0,9,9,0,C07C217/08;;C07C217/08;;C07C213/02;;C07C213/02;;C07C253/34;;C07C253/34;;Y02P20/52;;Y02P20/52,B01J23/04;;C07B61/00;;C07C213/02;;C07C217/08;;C07C253/34,,0,0,,,,EXPIRED
226,HK,A,HK 136794 A,068-580-297-314-466,1994-12-09,1994,HK 136794 A,1994-12-01,US 13781187 A,1987-12-28,Composition chromatographic article,,MINNESOTA MINING & MFG,HAGEN DONALD F;;ST MARY STEVEN J;;ERREDE LOUIS A;;CARR PETER W,,https://lens.org/068-580-297-314-466,Granted Patent,no,0,0,13,16,0,B01J20/28028;;B01J20/28033;;Y10S435/803;;Y10T428/249986;;Y10T428/249954;;Y10T428/249986;;Y10T428/249954;;B01J20/28028;;B01J20/28033;;Y10S435/803,B01D15/08;;B01J20/28;;B01J20/285;;B01J20/281;;G01N30/88;;G01N30/92,,0,0,,,,EXPIRED
227,DE,D1,DE 68921131 D1,033-546-172-136-767,1995-03-23,1995,DE 68921131 T,1989-10-06,US 25747988 A,1988-10-13,Verfahren zur Herstellung von Bis(aminopropoxy)alkanen.,,AIR PROD & CHEM,VAN COURT CARR RICHARD;;JOHNSON THOMAS ALBERT;;GALATON STEVEN MARC;;ALBANESE THOMAS ARCHIE,,https://lens.org/033-546-172-136-767,Granted Patent,no,0,0,9,9,0,C07C217/08;;C07C217/08;;C07C213/02;;C07C213/02;;C07C253/34;;C07C253/34;;Y02P20/52;;Y02P20/52,B01J23/04;;C07B61/00;;C07C213/02;;C07C217/08;;C07C253/34,,0,0,,,,EXPIRED
228,US,B2,US 11785925 B2,146-086-474-965-686,2023-10-17,2023,US 201916408792 A,2019-05-10,US 201916408792 A;;US 201815955073 A;;US 201615074920 A;;US 2014/0064629 W;;US 201361915439 P;;US 201361902066 P,2013-11-08,Disease biomarkers and treatment methods related thereto,The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.,BROAD INST INC;;BRIGHAM & WOMENS HOSPITAL INC,EBERT BENJAMIN LEVINE;;KRÖNKE JAN;;CARR STEVEN A;;UDESHI NAMRATA D;;FINK EMMA,THE BRIGHAM AND WOMEN'S HOSPITAL INC (2016-08-16);;THE BROAD INSTITUTE INC (2018-03-14),https://lens.org/146-086-474-965-686,Granted Patent,yes,29,0,9,9,69,C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;C12Q1/6886;;C12Q2600/106;;C12Q2600/156;;C12Q2600/158;;G01N33/5011;;G01N33/5088;;G01N33/57496;;G01N33/94;;G01N2333/47;;A01K67/0278;;A01K2217/072;;A01K2227/105;;A01K2267/03;;C12Q1/6876;;C12Q2600/136,C12Q1/6876;;A01K67/027;;C12Q1/6886;;G01N33/50;;G01N33/574;;G01N33/94,,54,46,031-403-238-398-698;;081-789-604-294-249;;153-029-134-050-570;;014-347-919-911-928;;005-654-188-739-004;;158-134-792-322-490;;008-585-270-074-796;;056-072-812-092-997;;101-481-896-960-735;;012-400-907-533-488;;032-568-192-050-38X;;037-369-297-813-419;;031-403-238-398-698;;037-369-297-813-419;;014-732-105-086-413;;086-329-095-564-726;;010-971-530-112-814;;039-337-750-255-109;;025-349-822-800-031;;033-883-676-575-63X;;079-647-329-595-809;;047-254-938-968-625;;025-757-799-244-024;;130-680-203-388-320;;090-408-538-433-304;;072-017-105-744-341;;153-029-134-050-570;;032-568-192-050-38X;;011-887-472-938-873;;048-907-502-780-72X;;026-298-963-986-297;;163-744-684-695-31X;;120-092-289-181-465;;057-245-151-208-065;;070-534-354-748-776;;031-987-314-603-297;;013-502-354-686-401;;017-560-097-056-628;;027-477-313-726-928;;007-285-616-513-629;;084-658-537-586-450;;018-368-672-735-253;;044-508-973-698-489;;112-236-803-511-827;;057-962-361-692-766;;104-084-369-554-874,10.1038/leu.2012.119;;pmc3496085;;22552008;;10.1111/bjh.12291;;23480694;;pmc3655110;;10.1016/j.bbrc.2011.02.062;;21329675;;pmc3919793;;10.1038/ng.2532;;23334668;;10.1126/science.1177319;;20223979;;26410577;;10.1016/j.bbadis.2015.09.014;;10.1038/sj.onc.1209133;;16205638;;26131937;;pmc4853910;;10.1038/nature14610;;24292625;;10.1126/science.1244851;;pmc4077049;;10.4161/21624011.2014.941742;;pmc4292522;;25610725;;10.1016/j.bbrc.2015.01.054;;25619137;;23349485;;10.2337/db12-1030;;pmc3661653;;10.1038/leu.2012.119;;pmc3496085;;22552008;;23349485;;10.2337/db12-1030;;pmc3661653;;10.1016/j.bbr.2011.09.039;;21995942;;pmc5864115;;23434730;;10.1038/leu.2013.59;;26188093;;10.1016/j.bbrc.2015.07.068;;24166296;;10.1038/leu.2013.315;;pmc4017253;;10.1182/blood-2014-02-557819;;24914135;;pmc4110660;;19059307;;pmc3420066;;10.1016/j.mce.2008.10.050;;23489099;;10.1517/17460441.3.4.441;;18487603;;pmc2556023;;10.1074/mcp.m800113-mcp200;;10.1038/nsmb.2874;;25108355;;10.1038/nbt0394-320;;10.1038/nbt.3026;;25184501;;pmc4262738;;10521338;;10.1126/science.286.5439.487;;10.1016/j.bbrc.2011.02.062;;21329675;;10.1016/j.bbrc.2015.01.054;;25619137;;10.1056/nejmoa041668;;15703420;;24292623;;10.1126/science.1244917;;pmc4070318;;10.3791/51719;;25177895;;pmc4364389;;10.1182/blood.v122.21.3107.3107;;23749302;;pmc3943163;;10.1038/nmeth.2518;;10.1038/nature05690;;17344859;;11734846;;10.1038/35107009;;10.1038/nprot.2006.427;;17406521;;16118317;;pmc1895238;;10.1182/blood-2005-07-2817;;17703201;;10.1038/nprot.2007.261;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;25075903;;10.1101/006726;;pmc4486245;;10.1038/nmeth.3047;;10.1136/annrheumdis-2015-eular.3498;;pmc2542904;;18568025;;10.1038/nature07064;;11733746;;10.1038/35103535;;7585946;;10.1016/0092-8674(95)90170-1;;22698399;;pmc4059833;;10.1016/j.ccr.2012.05.024;;21860026;;pmc3208291;;10.1182/blood-2011-05-356063,"Chopra et al., “Cereblon is a direct protein target for immunomoldulatory and antiproliferative activities of lenalidomide and pomalidomide,” Leukemia, vol. 26, pp. 2326-2335 (2012).;;Egan (British Journal of Haematology, (Jun. 2013), vol. 161, No. 5, pp. 748-751.;;Gandhi (British J. Haematology, 2014 (first published Dec. 13, 2013), vol. 164, p. 811-821.;;Gouri (J. Hematol Thrombo Dis. 2014, 2:3, p. 1).;;He et al., “Ikaros is degraded by proteasome-dependent mechanism in the early phase of apoptosis induction,” Biochem and Biophys. Res. Comm., vol. 409, pp. 430-434 (2011).;;Holmfelt et al., “The genomic landscape of hypodiploid acute lymphoblastic leukemia,” Nature Genetics, vol. 45, No. 3, pp. 242-254 (2013).;;Ito (Science, Mar. 12, 2010, vol. 327, No. 5971, p. 1345-1350).;;Kim (Biochimica et Biophysica Acta, Sep. 26, 2015, vol. 1852, p. 2662-2670).;;Klein et al., “BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells,” Oncogene, vol. 25, pp. 1118-1124 (2005).;;Kronke (Nature, Jul. 9, 2015, vol. 523, No. 7559, p. 183-188).;;Kronke (Science, Jan. 17, 2014, vol. 343, p. 301-305).;;Kronke, (Oncolmmunology, Jul. 1, 2014, vol. 3, No. 7, e941742).;;Lee (Biochemical and Biophysical Res. Comm, Jan. 22, 2015, vol. 458, p. 34-39).;;Lee (Diabetes, Jun. 2013, vol. 62, p. 1855-1864).;;Lopez-Girona (Leukemia, 2012, vol. 26, p. 2326-2335).;;Min, Lee et al., Disruption of the Cereblon Gene Enhances Hepatic AMPK Activity and Prevents High-Fat Diet-Induced Obesity and Insulin Resistance in Mice, Diabetes, vol. 62, pp. 1855-1864 (2013).;;P. Neri (Dec. 3, 2016, Blood, (Dec. 2, 2016), vol. 128, No. 22, p. 120, Meeting Info.: 58th Annual Meeting and Exposition of the American-Society-of-Hematology, San Diego, CA, USA, Dec. 3-6, 2016. Amer. Soc. Hematol).;;R. Maity et al., Blood, Dec. 6, 2014, vol. 124, No. 21, p. 639, Meeting Info: 56th Annual Meeting of the American-Society-of-Hematology, San Francisco, CA, USA, Dec. 6-9, 2014, Amer. Soc. Hematol.).;;Rajadhyaksha (Behavioral Brain Res., 2012, available Oct. 4, 2011, vol. 226, p. 428-434).;;Sardnal (Leukemia, Apr. 26, 2013, vol. 27, p. 1610-1613).;;Sawamura (Biochm. & Biophys. Res. Comm., 2015, vol. 464, p. 1054-1059).;;Thakurta (Blood, (Nov. 15, 2013), vol. 122, No. 21, p. 3139, Meeting Info.: 55th Annual Meeting of the American-Society-of-Hematology, New Orleans, LA, USA, Dec. 7-10, 2013, Amer. Soc. Hematol).;;Thakurta (Leukemia, 2014, vol. 28, p. 1129-1131, available online Oct. 29, 2013).;;Zhu (Blood, Jul. 24, 2014, prepublished online Jun. 9, 2014, vol. 124, No. 4, p. 536-545).;;Zhu (Blood, Nov. 16, 2012, vol. 120, No. 21, p. 1807, abstract).;;Office Action dated Nov. 7, 2018 in U.S. Appl. No. 15/034,490 (44 pages).;;International Search Report and Written Opinion, for corresponding PCT/US2014/064629, dated Mar. 24, 2015 (17 pages).;;Ball et al., “Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements,” Molecular and Cellular Endocrinology, 2009, vol. 299, pp. 204-211.;;Baxevanis, Constantin N., “Antibody-based cancer therapy,” Expert Opinion on Drug Discovery, 2008, vol. 3, No. 4, pp. 441-452.;;Bendall et al., “Prevention of Amino Acid Conversion in SILAC Experiments with Embryonic Stem Cells,” Molecular & Cellular Proteomics, 2008, vol. 7, No. 9, pp. 1587-1597.;;Chamberlain et al., “Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs,” Nature Structural & Molecular Biology, 2014, vol. 21, pp. 803-809.;;Dermer, Gerald B., “Another Anniversary for the War on Cancer,” Biotechnology, Mar. 12, 1994, vol. 12, p. 320.;;Doench et al., “Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation,” Nature Biotechnology, 2014, vol. 32, No. 12, pp. 1262-1267.;;Evans et al., “Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics,” Science, Oct. 15, 1999, vol. 286, pp. 487-491.;;He et al., “Ikaros is degraded by proteasome-dependent mechanism in the early phase of apoptosis induction,” Biochemical and Biophysical Research Communications, 2011, vol. 406, pp. 430-434.;;Lee et al., “Depletion of the cereblon gene activates the unfolded protein response and protects cells from ER stress-induced cell death,” Biochemical and Biophysical Research Communications, 2015, vol. 458, pp. 34-39.;;List et al., “Efficacy of Lenalidomide in Myelodysplastic Syndromes,” The New England Journal of Medicine, Feb. 10, 2005, vol. 352, No. 6, pp. 549-557.;;Lu et al., “The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins,” Science, Jan. 17, 2014, vol. 343, pp. 305-309.;;Melnikov et al., “Massively Parallel Reporter Assays in Cultured Mammalian Cells,” Journal of Visualized Experiments (joVE), Aug. 2014, vol. 90, e51719, pp. 1-8.;;Menard et al., “Cereblon (CRBN) Splicing Could Influence Response To IMiDs: A New PCR Strategy to Easily Detect and Semi-Quantify Loss Of The IMiDs Binding Domain,” Blood, 2013, vol. 122, No. 21, p. 3107.;;Mertins et al., “Integrated proteomic analysis of post-translational modifications by serial enrichment,” Nature Methods, 2013, vol. 10, pp. 634-637.;;Mullighan et al., “Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia,” Nature, Apr. 12, 2007, vol. 446, pp. 758-764.;;Nash et al., “Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication,” Nature, Nov. 29, 2001, vol. 414, pp. 514-521.;;Ong et al., “A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC),” Nature Protocols, 2006, vol. 1, No. 6, pp. 2650-2660.;;Rajkumar et al., “Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma,” Blood, Dec. 15, 2005, vol. 106, No. 13, pp. 4050-4053.;;Rappsilber et al., “Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips,” Nature Protocols, 2007, vol. 2, No. 8, pp. 1896-1906.;;Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proceedings of the National Academy of Sciences of the United States of America, Mar. 1982, vol. 79, pp. 1979-1983.;;Sanjana et al., “Improved vectors and genome-wide libraries for CRISPR screening,” Nature Methods, Aug. 2014, vol. 11, No. 8, pp. 783-784.;;Schafer et al., “The CUL4 (CRBN) E3 Ubiquitin Ligase Modulator CC-220 Induces Degradation of the Transcription Factors Ikaros and Aiolos: Immunomodulation in Healthy Volunteers and Relevance to Systemic Lupus Erythematosus,” Arthritis & Rheumatology, Oct. 2014, vol. 66, Suppl. 10, pp. S1176-S1177.;;Shaffer et al., “IRF4 addiction in multiple myeloma,” Nature, Jul. 10, 2008, vol. 454, No. 7201, pp. 226-231.;;Syvanen, Ann-Christine, “Accessing genetic variation: genotyping single nucleotide polymorphisms,” Nature Reviews Genetics, Dec. 2001, vol. 2, pp. 930-942.;;Winandy et al., “A Dominant Mutation in the Ikaros Gene Leads to Rapid Development of Leukemia and Lymphoma,” Cell, Oct. 20, 1995, vol. 83, pp. 289-299.;;Yang et al., “Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma,” Cancer Cell, Jun. 12, 2012, vol. 21, pp. 723-737.;;Zhu et al., “Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide,” Blood, Nov. 3, 2011, vol. 118, No. 18, pp. 4771-4779.",ACTIVE
229,US,A1,US 2022/0326241 A1,080-126-470-374-943,2022-10-13,2022,US 202017634218 A,2020-08-12,US 202017634218 A;;US 201962885709 P;;US 201962889373 P;;US 2020/0045962 W,2019-08-12,PROTEOGENOMIC METHODS FOR DIAGNOSING CANCER,"Methods disclosed herein concern cancer proteogenomics, which integrates genomics, transcriptomics and mass spectrometry (MS)-based proteomics to gain insights into cancer biology and treatment efficacy. To promote clinical utility of embodiments herein, proteogenomics approaches were developed for frozen core needle biopsies using tissue-sparing specimen processing with or without a microscaled proteomics workflow.",BAYLOR COLLEGE MEDICINE;;BROAD INST INC;;MASSACHUSETTS GEN HOSPITAL,ELLIS MATTHEW J;;ZHANG BING;;JAEHNIG ERIC;;CARR STEVEN;;SATPATHY SHANKHA;;GILLETTE MICHAEL,BAYLOR COLLEGE OF MEDICINE (2020-03-11);;THE BROAD INSTITUTE INC (2020-03-11);;THE GENERAL HOSPITAL CORPORATION (2020-03-11),https://lens.org/080-126-470-374-943,Patent Application,yes,0,0,4,4,66,C12Q1/6886;;C12Q2600/158;;C12Q2600/106;;G01N33/574;;G01N33/6848;;G01N33/6842;;G01N2440/14;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158;;G01N33/57415;;G01N33/6848;;G01N2440/14,G01N33/574;;C12Q1/6886;;G01N33/68,,0,0,,,,PENDING
230,US,A,US 5075507 A,159-364-149-740-140,1991-12-24,1991,US 22664188 A,1988-08-01,US 22664188 A,1988-08-01,PROCESS FOR THE PREPARATION OF BIS(AMINOPROPYL)ALIPHATIC GLYCOLS,"This invention relates to a process for the separation of acrylonitrile used in the cyanoethylation of glycols to produce a bis(cyanoethylated) aliphatic glycol from the resulting glycol which is then reduced with hydrogen to produce the corresponding bis(aminopropyl) aliphatic glycol. In this process, acrylonitrile is reacted with an aliphatic glycol in stoichiometric excess and the acrylonitrile removed from the cyanoethylated glycol by reaction with aliphatic primary or secondary amine prior to effecting the hydrogenation of the cyanoethylated aliphatic glycol in the presence of the acrylonitrile-amine reaction product. The reaction product then can be separated by conventional techniques such as distillation.",AIR PROD & CHEM,CARR RICHARD V C;;JOHNSON THOMAS A;;GALATON STEVEN M;;ALBANESE THOMAS A,AIR PRODUCTS AND CHEMICALS INC. ALLENTOWN PENNSYLVANIA 18195 A CORP. OF DE (1988-06-29),https://lens.org/159-364-149-740-140,Granted Patent,yes,6,12,5,5,0,C07C213/02;;C07C213/06;;C07C217/08;;C07C253/34;;C07C217/08;;C07C253/34;;C07C213/06;;C07C213/02,C07C213/02;;C07C213/06;;C07C217/08;;C07C253/34,564/491;;564/490,1,0,,,"Adams et al., Organic Reactions , vol. IV, pp. 82 85, and 89 92 (1949).",EXPIRED
231,JP,A,JP 2010267292 A,132-816-929-086-922,2010-11-25,2010,JP 2010158011 A,2010-07-12,US 58228004 P;;US 58291404 P;;US 65664205 P;;US 67302205 P,2004-06-22,"DIGITAL ASSET MANAGEMENT, TARGETED SEARCHING AND DESKTOP SEARCHING USING DIGITAL WATERMARK","<P>PROBLEM TO BE SOLVED: To provide methods and systems to improve network searching for watermarked content. <P>SOLUTION: Keyword searching is employed to narrow the universe of URL candidates, and a resulting URL list is searched for digital watermarking. A customer inputs keywords or network locations. The keywords or the network location information are provided to a watermark-enabled web browser, which accesses locations associated with the keywords or network locations. In this case, a plurality of distributed watermark-enabled web browsers are employed. Thus, methods and system to facilitate desktop searching and automated metadata gathering and generating are provided. <P>COPYRIGHT: (C)2011,JPO&INPIT",DIGIMARC CORP,RODRIGUEZ TONY F;;CALHOON SEAN;;CARR SCOTT J;;GRAY STEVEN;;REED ALASTAIR M,,https://lens.org/132-816-929-086-922,Patent Application,no,18,1,5,1547,0,G06F16/68;;G06F16/683;;G06F16/951;;G06F16/58;;G06F16/951;;G06F16/48,G06F17/30;;G06T1/00;;H04N1/387;;H04N21/232;;H04N21/4728;;H04N21/84,,3,0,,,"JPN6012030141; 渋井 晋平: 'ＭＳソフト一朝一夕講座' Ｓｏｆｍａｐ ＷＯＲＬＤ ＨＹＰＥＲ 第３８巻, 19981001, ｐ．１２２-１２５, 株式会社デジタルコミュニケーション;;JPN6012030141; 渋井 晋平: 'ＭＳソフト一朝一夕講座' Ｓｏｆｍａｐ ＷＯＲＬＤ ＨＹＰＥＲ 第３８巻, 19981001, ｐ．１２２-１２５, 株式会社デジタルコミュニケーション;;CSND199801050003; 渋井 晋平: 'ＭＳソフト一朝一夕講座' Ｓｏｆｍａｐ ＷＯＲＬＤ ＨＹＰＥＲ 第３８巻, 19981001, ｐ．１２２-１２５, 株式会社デジタルコミュニケーション",ACTIVE
232,EP,A4,EP 4013896 A4,146-714-215-306-090,2023-09-20,2023,EP 20852344 A,2020-08-12,US 201962885709 P;;US 201962889373 P;;US 2020/0045962 W,2019-08-12,PROTEOGENOMIC METHODS FOR DIAGNOSING CANCER,,BAYLOR COLLEGE MEDICINE;;BROAD INST INC;;MASSACHUSETTS GEN HOSPITAL,ELLIS MATTHEW J;;ZHANG BING;;JAEHNIG ERIC;;CARR STEVEN;;SATPATHY SHANKHA;;GILLETTE MICHAEL,,https://lens.org/146-714-215-306-090,Search Report,no,8,0,4,4,0,C12Q1/6886;;C12Q2600/158;;C12Q2600/106;;G01N33/574;;G01N33/6848;;G01N33/6842;;G01N2440/14;;C12Q1/6886;;C12Q2600/156;;C12Q2600/158;;G01N33/57415;;G01N33/6848;;G01N2440/14,G01N33/574;;C12Q1/6886;;G01N33/68,,7,7,027-191-399-117-192;;108-555-431-425-269;;057-834-381-946-800;;046-223-380-340-936;;067-544-556-845-313;;067-408-141-567-167;;073-065-525-657-220,10.1038/nprot.2013.141;;24136348;;pmc4211643;;30736982;;10.1016/j.tips.2019.01.006;;29279356;;pmc5837062;;10.1158/0008-5472.can-17-2129;;10.18632/oncotarget.24418;;pmc5862596;;29568375;;20011662;;pmc2789530;;10.1155/2009/574398;;7692896;;23386926;;10.1089/bio.2011.0034;;pmc3558729,"PEÑA-LLOPIS SAMUEL ET AL: ""Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications"", NATURE PROTOCOLS, vol. 8, no. 11, 17 October 2013 (2013-10-17), GB, pages 2240 - 2255, XP093072274, ISSN: 1754-2189, DOI: 10.1038/nprot.2013.141;;DE RUBIS GABRIELE ET AL: ""Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis"", TRENDS IN PHARMACOLOGICAL SCIENCES., vol. 40, no. 3, 1 March 2019 (2019-03-01), GB, pages 172 - 186, XP055792893, ISSN: 0165-6147, DOI: 10.1016/j.tips.2019.01.006;;CHEN PAN-YU ET AL: ""Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells"", CANCER RESEARCH, vol. 78, no. 4, 26 December 2017 (2017-12-26), US, pages 985 - 1002, XP055792895, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-17-2129;;ATAK APURVA ET AL: ""Quantitative mass spectrometry analysis reveals a panel of nine proteins as diagnostic markers for colon adenocarcinomas"", ONCOTARGET, vol. 9, no. 17, 5 February 2018 (2018-02-05), pages 13530 - 13544, XP055792896, DOI: 10.18632/oncotarget.24418;;SIUN CHEE TAN ET AL: ""DNA, RNA, and Protein Extraction: The Past and The Present"", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, vol. 295, no. 5554, 1 January 2009 (2009-01-01), pages 517 - 10, XP055131453, ISSN: 1110-7243, DOI: 10.1155/2009/574398;;CHOMCZYNSKI P: ""A REAGENT FOR THE SINGLE-STEP SIMULTANEOUS ISOLATION OF RNA, DNA AND PROTEINS FROM CELL AND TISSUE SAMPLES"", BIOTECHNIQUES, INFORMA HEALTHCARE, US, vol. 15, no. 3, 1 September 1993 (1993-09-01), pages 532 - 536, XP000604677, ISSN: 0736-6205;;MEE BLANAID C. ET AL: ""Maintaining Breast Cancer Specimen Integrity and Individual or Simultaneous Extraction of Quality DNA, RNA, and Proteins from Allprotect-Stabilized and Nonstabilized Tissue Samples"", BIOPRESERVATION TODAY, vol. 9, no. 4, 1 December 2011 (2011-12-01), United States, pages 389 - 398, XP055792897, ISSN: 1947-5535, DOI: 10.1089/bio.2011.0034",PENDING
233,US,A1,US 2002/0117446 A1,014-602-883-523-514,2002-08-29,2002,US 94535401 A,2001-08-31,US 94535401 A;;US 22969600 P,2000-09-01,Chromatography and other adsorptions using modified carbon clad metal oxide particles,"
   Separation devices and systems are described which have a stationary phase and a mobile phase, wherein the stationary phase contains carbon-clad zirconium dioxide particles having attached at least one organic group. The stationary phase which is used in the present invention has the ability to dial in the selectivity by attaching the proper organic groups onto the carbon-clad zirconium dioxide particles in order to achieve the desired separation. Various separation processes are described such as chromatography, electrophoresis, magnetic separations, membrane separations, and the like. The processes to accomplish these types of separations are also described. 
",KYRLIDIS AGATHAGELOS;;REZNEK STEVEN R.;;BELMONT JAMES A.;;CARR PETER W.;;MCNEFF CLAYTON V.,KYRLIDIS AGATHAGELOS;;REZNEK STEVEN R;;BELMONT JAMES A;;CARR PETER W;;MCNEFF CLAYTON V,CABOT CORPORATION (2002-06-21);;ZIRCHROM SEPARATIONS INC (2002-06-21),https://lens.org/014-602-883-523-514,Patent Application,yes,25,6,7,7,0,B01D15/08;;B01D57/02;;B01D67/0093;;B01D69/141;;B01D71/021;;B01D71/024;;B01D71/82;;B01J20/06;;B01J20/20;;B01J20/286;;B01J20/3204;;B01J20/3244;;B01J20/3272;;B01J2220/52;;B01J2220/54;;G01N27/44747;;B01J2220/825;;B01J20/287;;B01J20/29;;B01J20/3227;;B01J20/3246;;B01J20/3253;;B01J20/3255;;B01J20/3285;;B01J2220/42;;B01J20/3092;;B01J2220/58;;B01J20/3204;;B01D71/024;;B01J20/06;;B01J20/286;;G01N27/44747;;B01D71/82;;B01J2220/54;;B01J2220/52;;B01D71/021;;B01D15/08;;B01J20/20;;B01D57/02;;B01J20/3244;;B01J20/3272;;B01J2220/825;;B01J20/3255;;B01J20/3285;;B01J20/29;;B01J20/3246;;B01J20/3227;;B01J20/3092;;B01J2220/42;;B01J20/287;;B01J20/3253;;B01J2220/58;;B01D69/1411;;B01D67/00931,B01D15/08;;B01D57/02;;B01D67/00;;B01D69/14;;B01D71/02;;B01D71/82;;B01J20/20;;B01J20/281;;B01J20/291;;B01J20/32;;G01N27/447;;G01N30/02;;G01N30/26;;G01N30/74;;G01N30/88,210/635;;210/656;;210/198.2,0,0,,,,DISCONTINUED
234,WO,A2,WO 2002/018928 A2,098-874-727-966-74X,2002-03-07,2002,US 0127060 W,2001-08-31,US 22969600 P,2000-09-01,CHROMATOGRAPHY AND OTHER ADSORPTIONS USING MODIFIED CARBON-CLAD METAL OXIDE PARTICLES,"Separation devices and systems are described which have a stationary phase and a mobile phase, wherein the stationary phase contains carbon-clad zirconium dioxide particles having attached at least one organic group. The stationary phase which is used in the present invention has the ability to dial in the selectivity by attaching the proper organic groups onto the carbon-clad zirconium dioxide particles in order to achieve the desired separation. Various separation processes are described such as chromatography, electrophoresis, magnetic separations, membrane separations, and the like. The processes to accomplish these types of separations are also described.",CABOT CORP;;ZIRCHROM SEPARATIONS INC,KYRLIDIS AGATHAGELOS;;REZNEK STEVEN R;;BELMONT JAMES A;;CARR PETER W;;MCNEFF CLAYTON V,,https://lens.org/098-874-727-966-74X,Patent Application,yes,0,2,7,7,0,B01D15/08;;B01D57/02;;B01D67/0093;;B01D69/141;;B01D71/021;;B01D71/024;;B01D71/82;;B01J20/06;;B01J20/20;;B01J20/286;;B01J20/3204;;B01J20/3244;;B01J20/3272;;B01J2220/52;;B01J2220/54;;G01N27/44747;;B01J2220/825;;B01J20/287;;B01J20/29;;B01J20/3227;;B01J20/3246;;B01J20/3253;;B01J20/3255;;B01J20/3285;;B01J2220/42;;B01J20/3092;;B01J2220/58;;B01J20/3204;;B01D71/024;;B01J20/06;;B01J20/286;;G01N27/44747;;B01D71/82;;B01J2220/54;;B01J2220/52;;B01D71/021;;B01D15/08;;B01J20/20;;B01D57/02;;B01J20/3244;;B01J20/3272;;B01J2220/825;;B01J20/3255;;B01J20/3285;;B01J20/29;;B01J20/3246;;B01J20/3227;;B01J20/3092;;B01J2220/42;;B01J20/287;;B01J20/3253;;B01J2220/58;;B01D69/1411;;B01D67/00931,B01D15/08;;B01D57/02;;B01D67/00;;B01D69/14;;B01D71/02;;B01D71/82;;B01J20/20;;B01J20/281;;B01J20/291;;B01J20/32;;G01N27/447;;G01N30/02;;G01N30/26;;G01N30/74;;G01N30/88,,0,0,,,,PENDING
235,KR,A,KR 20160093731 A,141-055-950-930-756,2016-08-08,2016,KR 20167019778 A,2015-01-15,US 201461931071 P;;IB 2015050313 W,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,본 개시내용은 FXa의 변이체를 투여하는 것에 의해 대상체에서 뇌내 출혈 (ICH)을 치료하거나 예방하기 위한 조성물 및 방법을 제공한다.,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/141-055-950-930-756,Patent Application,no,0,0,27,27,4,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K9/00,,0,0,,,,DISCONTINUED
236,CN,A,CN 105934250 A,152-445-077-683-860,2016-09-07,2016,CN 201580005696 A,2015-01-15,US 201461931071 P;;IB 2015050313 W,2014-01-24,Compositions and methods for treating intracerebral hemorrhage,The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/152-445-077-683-860,Patent Application,no,2,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,2,0,,,"LACRAMIOARA IVANCIU等: ""A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia"", 《NATURE BIOTECHNOLOGY》;;ERIC SANDLER等: ""Prevention of Recurrent Intracranial Hemorrhage in a Factor X-Deficient Infant"", 《THE AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY》",DISCONTINUED
237,US,B2,US 10990515 B2,174-257-894-983-505,2021-04-27,2021,US 201916700261 A,2019-12-02,US 201916700261 A;;US 201815913159 A;;US 201862623760 P,2018-01-30,Automated unit testing in a mainframe environment,"An automated system is presented for unit testing an application in a mainframe execution environment. The system includes a test configurator, a stub setup routine and an interceptor routine. The test configurator is configured to receive and parse a test input file, where the test input file includes a record for a particular file accessed by the application using the given type of file system. Upon reading the record, the test configurator calls the stub setup routine. The stub setup routine is associated with the given type of file system and creates an object for the particular file in the mainframe execution environment, such that the object is instantiated from a class representing the given type of file system. The interceptor routine is accessible by the application. In response to a given command issued by the application for the given type of file system, the interceptor routine operates to interact with methods provided by the object.",COMPUWARE CORP;;BMC SOFTWARE INC,EVERITT GLENN;;WATKINS DOUGLAS MCLEOD;;WALBECK LORETTA ANN;;SPURRELL SHELDON JOHN;;CARR STEVEN JAMES,BMC SOFTWARE INC (2021-03-31);;COMPUWARE CORPORATION (2018-03-19),https://lens.org/174-257-894-983-505,Granted Patent,yes,6,1,4,4,0,G06F11/3684;;G06F11/3688;;G06F11/3664;;G06F11/3688;;G06F11/3684;;G06F11/3664;;G06F11/362;;G06F16/188;;G06F16/252;;G06F40/205;;B32B25/04;;C08K3/38;;C08K2003/387;;F16F1/36,G06F9/44;;B32B25/04;;C08K3/38;;F16F1/36;;G06F11/36;;G06F16/188;;G06F16/25;;G06F40/205,,0,0,,,,ACTIVE
238,CA,A1,CA 2420916 A1,167-561-253-551-094,2002-03-07,2002,CA 2420916 A,2001-08-31,US 22969600 P;;US 0127060 W,2000-09-01,CHROMATOGRAPHY AND OTHER ADSORPTIONS USING MODIFIED CARBON-CLAD METAL OXIDE PARTICLES,"Separation devices and systems are described which have a stationary phase a nd a mobile phase, wherein the stationary phase contains carbon-clad zirconium dioxide particles having attached at least one organic group. The stationary phase which is used in the present invention has the ability to dial in the selectivity by attaching the proper organic groups onto the carbon-clad zirconium dioxide particles in order to achieve the desired separation. Various separation processes are described such as chromatography, electrophoresis, magnetic separations, membrane separations, and the like. T he processes to accomplish these types of separations are also described.</SDOA B>",CABOT CORP;;ZIRCHROM SEPARATIONS INC,CARR PETER W;;MCNEFF CLAYTON V;;BELMONT JAMES A;;REZNEK STEVEN R;;KYRLIDIS AGATHAGELOS,,https://lens.org/167-561-253-551-094,Patent Application,no,0,0,7,7,0,B01D15/08;;B01D57/02;;B01D67/0093;;B01D69/141;;B01D71/021;;B01D71/024;;B01D71/82;;B01J20/06;;B01J20/20;;B01J20/286;;B01J20/3204;;B01J20/3244;;B01J20/3272;;B01J2220/52;;B01J2220/54;;G01N27/44747;;B01J2220/825;;B01J20/287;;B01J20/29;;B01J20/3227;;B01J20/3246;;B01J20/3253;;B01J20/3255;;B01J20/3285;;B01J2220/42;;B01J20/3092;;B01J2220/58;;B01J20/3204;;B01D71/024;;B01J20/06;;B01J20/286;;G01N27/44747;;B01D71/82;;B01J2220/54;;B01J2220/52;;B01D71/021;;B01D15/08;;B01J20/20;;B01D57/02;;B01J20/3244;;B01J20/3272;;B01J2220/825;;B01J20/3255;;B01J20/3285;;B01J20/29;;B01J20/3246;;B01J20/3227;;B01J20/3092;;B01J2220/42;;B01J20/287;;B01J20/3253;;B01J2220/58;;B01D69/1411;;B01D67/00931,B01D15/08;;B01D57/02;;B01D67/00;;B01D69/14;;B01D71/02;;B01D71/82;;B01J20/20;;B01J20/281;;B01J20/291;;B01J20/32;;G01N27/447;;G01N30/02;;G01N30/26;;G01N30/74;;G01N30/88,,0,0,,,,DISCONTINUED
239,US,A1,US 2020/0104249 A1,107-649-477-579-918,2020-04-02,2020,US 201916700261 A,2019-12-02,US 201916700261 A;;US 201815913159 A;;US 201862623760 P,2018-01-30,Automated Unit Testing In A Mainframe Environment,"An automated system is presented for unit testing an application in a mainframe execution environment. The system includes a test configurator, a stub setup routine and an interceptor routine. The test configurator is configured to receive and parse a test input file, where the test input file includes a record for a particular file accessed by the application using the given type of file system. Upon reading the record, the test configurator calls the stub setup routine. The stub setup routine is associated with the given type of file system and creates an object for the particular file in the mainframe execution environment, such that the object is instantiated from a class representing the given type of file system. The interceptor routine is accessible by the application. In response to a given command issued by the application for the given type of file system, the interceptor routine operates to interact with methods provided by the object.",COMPUWARE CORP,EVERITT GLENN;;WATKINS DOUGLAS MCLEOD;;WALBECK LORETTA ANN;;SPURRELL SHELDON JOHN;;CARR STEVEN JAMES,BMC SOFTWARE INC (2021-03-31);;COMPUWARE CORPORATION (2018-03-19),https://lens.org/107-649-477-579-918,Patent Application,yes,0,0,4,4,0,G06F11/3684;;G06F11/3688;;G06F11/3664;;G06F11/3688;;G06F11/3684;;G06F11/3664;;G06F11/362;;G06F16/188;;G06F16/252;;G06F40/205;;B32B25/04;;C08K3/38;;C08K2003/387;;F16F1/36,G06F11/36;;G06F16/188;;G06F16/25,,0,0,,,,ACTIVE
240,US,A1,US 2005/0003893 A1,140-949-083-987-899,2005-01-06,2005,US 70539203 A,2003-11-12,US 70539203 A;;US 37119703 A;;US 35838702 P,2002-02-22,System and method for interactive wagering from a remote location,"A system and method for interactive wagering from a remote location. The invention may preferably be implemented on a multi-purpose device, and preferably uses a multi-purpose communication means, such that a dedicated terminal and/or dedicated line are not required. Various customizable features may be provided, allowing for user-friendly, interactive wagering and related communications between the remote location and an event location over a network, which may further include content locations and server locations, among others.",HOGWOOD WILLIAM EDWARD;;DIXON ARTHUR JOHN;;CARR PETER JOHN;;DAVIS JAMES;;BOFFO STEVEN LUIGI,HOGWOOD WILLIAM EDWARD;;DIXON ARTHUR JOHN;;CARR PETER JOHN;;DAVIS JAMES;;BOFFO STEVEN LUIGI,,https://lens.org/140-949-083-987-899,Patent Application,yes,24,152,5,5,0,G06Q50/34;;G07F17/3288;;G06Q50/34;;G07F17/3288,G06Q50/34,463/42,0,0,,,,DISCONTINUED
241,AU,B2,AU 2015/208819 B2,137-122-255-630-666,2020-01-23,2020,AU 2015/208819 A,2015-01-15,US 201461931071 P;;IB 2015050313 W,2014-01-24,Compositions and methods for treating intracerebral hemorrhage,The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/137-122-255-630-666,Granted Patent,no,1,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,0,0,,,,INACTIVE
242,SI,T1,SI 3096779 T1,022-207-740-933-663,2020-03-31,2020,SI 201531081 T,2015-01-15,US 201461931071 P;;IB 2015050313 W;;EP 15708578 A,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/022-207-740-933-663,Granted Patent,no,0,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/00;;A61P7/00,,0,0,,,,ACTIVE
243,AU,A1,AU 2015/208819 A1,123-147-736-716-519,2016-06-30,2016,AU 2015/208819 A,2015-01-15,US 201461931071 P;;IB 2015050313 W,2014-01-24,Compositions and methods for treating intracerebral hemorrhage,The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/123-147-736-716-519,Patent Application,no,0,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,0,0,,,,INACTIVE
244,CA,A1,CA 2937418 A1,162-913-010-272-36X,2015-07-30,2015,CA 2937418 A,2015-01-15,US 201461931071 P;;IB 2015050313 W,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/162-913-010-272-36X,Patent Application,no,0,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,0,0,,,,DISCONTINUED
245,PL,T3,PL 3096779 T3,057-785-360-506-226,2020-05-18,2020,PL 15708578 T,2015-01-15,US 201461931071 P;;EP 15708578 A;;IB 2015050313 W,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/057-785-360-506-226,Patent Application,no,0,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,0,0,,,,PENDING
246,KR,A,KR 20210008177 A,084-638-379-594-480,2021-01-20,2021,KR 20217001254 A,2015-01-15,US 201461931071 P;;IB 2015050313 W,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,본 개시내용은 FXa의 변이체를 투여하는 것에 의해 대상체에서 뇌내 출혈 (ICH)을 치료하거나 예방하기 위한 조성물 및 방법을 제공한다.,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/084-638-379-594-480,Patent Application,no,0,0,27,27,4,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61K9/00,,0,0,,,,DISCONTINUED
247,US,S,US D0317071 S,063-814-468-755-854,1991-05-21,1991,US 19281688 F,1988-05-11,US 19281688 F,1988-05-11,Self service terminal or similar article,,NCR CORP,MCFADDEN FRANCIS J A;;CARR DONALD W;;SWAINE STEVEN W;;ROHAN CHARLES G V,NCR CORPORATION A CORP. OF MD (1988-04-15),https://lens.org/063-814-468-755-854,Design Right,yes,17,6,1,1,0,,,D99/28,0,0,,,,EXPIRED
248,HU,T2,HU E047588 T2,178-385-999-759-43X,2020-04-28,2020,HU E15708578 A,2015-01-15,US 201461931071 P,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/178-385-999-759-43X,Amended Patent,no,0,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,0,0,,,,PENDING
249,WO,A1,WO 2015/110939 A1,036-178-569-189-034,2015-07-30,2015,IB 2015050313 W,2015-01-15,US 201461931071 P,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/036-178-569-189-034,Patent Application,yes,7,3,27,27,2,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,49,37,038-896-746-633-861;;030-384-649-303-780;;007-838-219-314-762;;159-461-089-358-541;;104-875-894-618-945;;093-860-533-702-069;;005-571-045-261-45X;;041-990-622-589-079;;000-840-587-385-28X;;073-983-191-380-075;;024-054-201-490-339;;079-085-027-953-082;;001-416-221-564-893;;007-838-219-314-762;;093-860-533-702-069;;055-034-166-241-009;;104-875-894-618-945;;104-875-894-618-945;;034-211-797-058-553;;006-291-183-805-769;;049-880-421-840-902;;005-778-712-776-392;;022-813-159-255-539;;012-105-572-357-846;;071-366-379-338-841;;007-561-495-470-551;;036-829-873-123-538;;040-512-694-784-989;;019-193-678-407-562;;073-519-958-503-407;;001-076-193-891-919;;033-926-300-995-449;;041-015-735-803-883;;086-174-713-061-939;;063-454-411-649-106;;107-697-191-729-833;;005-447-346-908-386,10.1053/j.seminhematol.2005.11.020;;16427389;;15901870;;15906433;;10.1056/nejm200505193522017;;10.1056/nejmoa0707534;;18480205;;10.4103/0972-5229.16262;;pmc4157830;;10.1038/nbt.1995;;22020385;;18460471;;pmc2441561;;10.1074/jbc.m802205200;;pmc3702044;;10.1016/s1474-4422(13)70049-8;;23518332;;10.1056/nejm200105103441907;;11346811;;10.1161/strokeaha.107.183689;;17478736;;8322400;;10.1161/01.str.24.7.987;;16636233;;10.1212/01.wnl.0000208408.98482.99;;22744655;;10.1212/wnl.0b013e318260cbba;;pmc2646334;;19108704;;10.1186/cc7092;;10.1056/nejmoa0707534;;18480205;;18460471;;pmc2441561;;10.1074/jbc.m802205200;;20864578;;10.1182/blood-2010-08-300756;;pmc3037750;;pmc4157830;;10.1038/nbt.1995;;22020385;;pmc4157830;;10.1038/nbt.1995;;22020385;;8412817;;10.1016/0076-6879(93)22009-5;;2583108;;10.2210/pdb1ppb/pdb;;10.1002/j.1460-2075.1989.tb08511.x;;pmc401503;;1141218;;10.1016/s0021-9258(19)41330-6;;10.1161/strokeaha.111.623165;;pmc3202076;;21852615;;10.3171/foc.2008.25.10.e2;;18828700;;10.1037/t02366-000;;14258950;;10.1161/strokeaha.111.618611;;21737803;;23466430;;pmc3743539;;10.1159/000346599;;10.1212/wnl.0b013e3182143317;;21346218;;pmc3068004;;22878870;;10.1007/s12028-012-9765-2;;pmc3707619;;17322083;;10.1161/01.str.0000259633.59404.f3;;pmc3508322;;10.1161/strokeaha.112.664003;;23132779;;10.1016/s1474-4422(12)70038-8;;22405630;;pmc3498504;;10.1161/strokeaha.109.554667;;19574553;;10.1016/j.jstrokecerebrovasdis.2011.10.018;;22244714;;pmc3426364;;22621984;;10.1161/strokeaha.112.659094;;18078021;;pmc2291314;;21998055;;10.1161/strokeaha.111.629360;;pmc3722613;;10.1161/strokeaha.108.517482;;18772448;;pmc3712841,"MAYER S A ET AL: ""Ultra-early hemostatic therapy for acute intracerebral hemorrhage"", SEMINARS IN HEMATOLOGY, PHILADELPHIA, PA, US, vol. 43, no. Suppl. 1, 1 January 2006 (2006-01-01), pages S70 - S76, XP009120241, ISSN: 0037-1963, DOI: 10.1053/J.SEMINHEMATOL.2005.11.020;;STEPHAN A MAYER ET AL: ""n Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage for the Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators* From the background"", N ENGL J MED, 1 January 2005 (2005-01-01), pages 777 - 85, XP055184485, Retrieved from the Internet <URL:http://www.nejm.org/doi/pdf/10.1056/NEJMoa042991> [retrieved on 20150421];;MAYER STEPHAN A ET AL: ""Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage"", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 358, no. 20, 15 May 2008 (2008-05-15), pages 2127 - 2137, XP002537672, ISSN: 1533-4406, DOI: 10.1056/NEJMOA0707534;;SUDHIR KUMAR: ""Recombinant activated factor VII for acute intracerebral hemorrhage"", INDIAN JOURNAL OF CRITICAL CARE MEDICINE, vol. 9, no. 1, 1 January 2005 (2005-01-01), pages 11, XP055184291, ISSN: 0972-5229, DOI: 10.4103/0972-5229.16262;;LU G ET AL: ""Reconstructed recombinant factor Xa as an 5 antidote to reverse anticoagulation by factor Xa inhibitors"", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, vol. 7, no. suppl. 2, 1 July 2009 (2009-07-01), pages 309/OC - TH, XP009177312, ISSN: 1538-7933;;HOLLENBACH S ET AL: ""Bolus administration of PRT064445, a recombinant Factor Xa inhibitor antidote, reverses blood loss and PD markers in a rat model following enoxaparin induced anticoagulation"", EUROPEAN HEART JOURNAL, OXFORD UNIVERSITY PRESS, GB, vol. 33, no. Suppl, 1 January 2012 (2012-01-01), pages 309 - 310, XP009177324, ISSN: 0195-668X;;LACRAMIOARA IVANCIU ET AL: ""A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia"", NATURE BIOTECHNOLOGY, vol. 29, no. 11, 23 October 2011 (2011-10-23), US, pages 1028 - 1033, XP055111224, ISSN: 1087-0156, DOI: 10.1038/nbt.1995;;NABIL K THALJI ET AL: ""Reversal of Direct Factor Xa Inhibitors Using Factor Xa Zymogen-Like Variants"", 28TH ANNUAL MD/PHD STUDENT CONFERENCE, KEYSTONE, COLORADO, JULY 26-28, 2013,, 27 July 2013 (2013-07-27), pages 16, XP009177338;;NABIL K THALJI ET AL: ""Zymogen-Like FXa Is An Effective Pro-Hemostatic To Reverse The Anticoagulant Effects Of Direct FXa Inhibitors"", INTERNET CITATION, pages 1, XP002722746, Retrieved from the Internet <URL:https://ash.confex.com/ash/2013/webprogram/Paper63599.html> [retrieved on 20140401];;TOSO RAFFAELLA ET AL: ""The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly"", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 283, no. 27, 1 July 2008 (2008-07-01), pages 18627 - 18635, XP002526299, ISSN: 0021-9258, DOI: 10.1074/JBC.M802205200;;ARNE LAUER ET AL: ""Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies"", THE LANCET NEUROLOGY, vol. 12, no. 4, 1 April 2013 (2013-04-01), pages 394 - 405, XP055184564, ISSN: 1474-4422, DOI: 10.1016/S1474-4422(13)70049-8;;QURESHI ET AL., N ENGL J MED, vol. 344, no. 19, 2001, pages 1450 - 1460;;ROGER ET AL., CIRCULATION, vol. 125, 2012, pages E2 - 220;;BRODERICK ET AL., STROKE, vol. 38, 2007, pages 2001 - 2023;;BRODERICK ET AL., STROKE, vol. 24, 1993, pages 987 - 993;;BROTT ET AL., STROKE, vol. 28, 1997, pages 1 - 5;;DAVIS ET AL., NEUROLOGY, vol. 66, 2006, pages 1175 - 1181;;DELCOURT ET AL., NEUROLOGY, vol. 79, 2012, pages 314 - 319;;RINCON; MAYER, CRITICAL CARE, vol. 12, 2008, pages 237 - 250;;MAYER ET AL., NEJM, vol. 358, 2008, pages 2127 - 2137;;TOSO ET AL., J. BIOL. CHEM., vol. 283, 2008, pages 18627 - 18635;;BUNCE ET AL., BLOOD, vol. 117, 2011, pages 290 - 298;;IVANCIU ET AL., NAT. BIOTECHNOL., vol. 29, 2011, pages 1028 - 1033;;IVANCIU ET AL., NAT. BIOTECHNOL., vol. 29, 2011, pages 1028 - 1033;;BAJAJ; BIRKTOFT, METHODS ENZYMOL., vol. 222, 1993, pages 96 - 128;;BODE W; MAYR I; BAUMAN Y ET AL.: ""The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Trp insertion segment"", EMBO J, vol. 8, no. 11, 1989, pages 3467 - 3475;;JESTY ET AL., J BIOL CHEM., vol. 250, no. 12, 25 June 1975 (1975-06-25), pages 4497 - 504;;ML FLAHERTY ET AL.: ""Intracerebral Hemorrhage"", 2010, CAMBRIDGE UNIVERSITY PRESS, article ""The epidemiology of intracerebral hemorrhage"";;S.-B. KO ET AL., STROKE, vol. 42, 2011, pages 3087 - 3092;;C. ZWEIFEL ET AL., NEUROSURG. FOCUS, vol. 25, no. 10, 2008, pages E2;;MAHONEY F.; BARTHEL D.: ""Functional evaluation: the Barthel Index."", MD MED J., vol. 14, 1965, pages 61 - 65;;D. STAYKOV ET AL., STROKE, vol. 42, 2011, pages 2625 - 2629;;H. ARIMA ET AL., NEUROLOGY, vol. 73, 2009, pages 1963 - 1968;;BROUWERS; GREENBERG, CEREBROVASC. DIS., vol. 35, 2013, pages 195 - 201;;DOWLATSHAHI ET AL., NEUROLOGY, vol. 76, 2011, pages 1238 - 1244;;BROUWERS ET AL., NEUROCRIT CARE, vol. 17, 2012, pages 421 - 428;;WADA ET AL., STROKE, vol. 38, 2007, pages 1257 - 1262;;BROUWERS ET AL., STROKE, vol. 43, 2012, pages 3427 - 3432;;DEMCHUK ET AL., LANCET NEUROL, vol. 11, 2012, pages 307 - 314;;DELGADO ET AL., STROKE, vol. 40, 2009, pages 2994 - 3000;;APPELBOOM ET AL., J. STROKE CEREB DIS., vol. 22, 2013, pages 713 - 717;;BROUWERS ET AL., STROKE, vol. 43, 2012, pages 2120 - 2125;;R. SAHNI; J. WEINBERGER, VASC HEALTH RISK MANAG, vol. 3, 2007, pages 701 - 709;;F. SCHLUNK ET AL., STROKE, vol. 43, 2012, pages 246 - 249;;C. FOERCH ET AL., STROKE, vol. 39, 2008, pages 3397 - 3404;;SAMBROOK J.; RUSSELL D.: ""Molecular Cloning: A Laboratory Manual"", 2000, COLD SPRING HARBOR LABORATORY PRESS;;AUSUBEL ET AL.: ""Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology"", 2002, WILEY, JOHN & SONS, INC.;;HARLOW; LANE: ""Using Antibodies: A Laboratory Manual"", 1998, COLD SPRING HARBOR LABORATORY PRESS;;COLIGAN ET AL.: ""Short Protocols in Protein Science"", 2003, WILEY, JOHN & SONS, INC.",PENDING
250,WO,A3,WO 2002/018928 A3,123-556-433-343-791,2002-10-10,2002,US 0127060 W,2001-08-31,US 22969600 P,2000-09-01,CHROMATOGRAPHY AND OTHER ADSORPTIONS USING MODIFIED CARBON-CLAD METAL OXIDE PARTICLES,"Separation devices and systems are described which have a stationary phase and a mobile phase, wherein the stationary phase contains carbon-clad zirconium dioxide particles having attached at least one organic group. The stationary phase which is used in the present invention has the ability to dial in the selectivity by attaching the proper organic groups onto the carbon-clad zirconium dioxide particles in order to achieve the desired separation. Various separation processes are described such as chromatography, electrophoresis, magnetic separations, membrane separations, and the like. The processes to accomplish these types of separations are also described.",CABOT CORP;;ZIRCHROM SEPARATIONS INC,KYRLIDIS AGATHAGELOS;;REZNEK STEVEN R;;BELMONT JAMES A;;CARR PETER W;;MCNEFF CLAYTON V,,https://lens.org/123-556-433-343-791,Search Report,yes,7,0,7,7,0,B01D15/08;;B01D57/02;;B01D67/0093;;B01D69/141;;B01D71/021;;B01D71/024;;B01D71/82;;B01J20/06;;B01J20/20;;B01J20/286;;B01J20/3204;;B01J20/3244;;B01J20/3272;;B01J2220/52;;B01J2220/54;;G01N27/44747;;B01J2220/825;;B01J20/287;;B01J20/29;;B01J20/3227;;B01J20/3246;;B01J20/3253;;B01J20/3255;;B01J20/3285;;B01J2220/42;;B01J20/3092;;B01J2220/58;;B01J20/3204;;B01D71/024;;B01J20/06;;B01J20/286;;G01N27/44747;;B01D71/82;;B01J2220/54;;B01J2220/52;;B01D71/021;;B01D15/08;;B01J20/20;;B01D57/02;;B01J20/3244;;B01J20/3272;;B01J2220/825;;B01J20/3255;;B01J20/3285;;B01J20/29;;B01J20/3246;;B01J20/3227;;B01J20/3092;;B01J2220/42;;B01J20/287;;B01J20/3253;;B01J2220/58;;B01D69/1411;;B01D67/00931,B01D15/08;;B01D57/02;;B01D67/00;;B01D69/14;;B01D71/02;;B01D71/82;;B01J20/20;;B01J20/281;;B01J20/291;;B01J20/32;;G01N27/447;;G01N30/02;;G01N30/26;;G01N30/74;;G01N30/88,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 017, no. 200 (C - 1050) 20 April 1993 (1993-04-20);;DATABASE WPI Section Ch Week 199036, Derwent World Patents Index; Class J04, AN 1990-272346, XP002192133",PENDING
251,CN,A,CN 112156176 A,027-443-629-053-605,2021-01-01,2021,CN 202011260045 A,2015-01-15,US 201461931071 P;;CN 201580005696 A,2014-01-24,Compositions and methods for treating intracerebral hemorrhage,The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/027-443-629-053-605,Patent Application,no,1,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61K9/00;;A61P7/04;;A61P9/00;;A61P9/10,,2,0,,,"ERIC SANDLER等: ""Prevention of Recurrent Intracranial Hemorrhage in a Factor X-Deficient Infant"", 《THE AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY》, vol. 14, no. 2, pages 163 - 165;;LACRAMIOARA IVANCIU等: ""A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia"", 《NATURE BIOTECHNOLOGY》, vol. 29, no. 11, pages 1028 - 1035",PENDING
252,DK,T3,DK 3096779 T3,056-176-809-761-180,2020-02-24,2020,DK 15708578 T,2015-01-15,US 201461931071 P;;IB 2015050313 W,2014-01-24,Sammensætninger og fremgangsmåder til behandling af intracerebral blødning,,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/056-176-809-761-180,Granted Patent,no,0,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,0,0,,,,ACTIVE
253,MX,A,MX 2016009665 A,033-759-910-553-87X,2016-11-14,2016,MX 2016009665 A,2015-01-15,US 201461931071 P;;IB 2015050313 W,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE.,The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.,PFIZER,PITTMAN DEBRA D;;JOACHIM FRUEBIS;;STEVEN ARKIN;;MARCUS E CARR;;SUNITA HETT;;REEMA JASUJA,,https://lens.org/033-759-910-553-87X,Patent Application,no,0,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,0,0,,,,ACTIVE
254,EP,B1,EP 3096779 B1,194-032-343-077-483,2019-12-18,2019,EP 15708578 A,2015-01-15,US 201461931071 P;;IB 2015050313 W,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/194-032-343-077-483,Granted Patent,yes,6,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,11,0,,,"MAYER S A ET AL: ""Ultra-early hemostatic therapy for acute intracerebral hemorrhage"", SEMINARS IN HEMATOLOGY, PHILADELPHIA, PA, US, vol. 43, no. Suppl. 1, 1 January 2006 (2006-01-01), pages S70-S76, XP009120241, ISSN: 0037-1963, DOI: 10.1053/J.SEMINHEMATOL.2005.11.020;;Stephan A Mayer ET AL: ""n Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage for the Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators* From the background"", N Engl J Med, 1 January 2005 (2005-01-01), pages 777-85, XP55184485, Retrieved from the Internet: URL:http://www.nejm.org/doi/pdf/10.1056/NE JMoa042991 [retrieved on 2015-04-21];;MAYER STEPHAN A ET AL: ""Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage"", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 358, no. 20, 15 May 2008 (2008-05-15) , pages 2127-2137, XP002537672, ISSN: 1533-4406, DOI: 10.1056/NEJMOA0707534;;SUDHIR KUMAR: ""Recombinant activated factor VII for acute intracerebral hemorrhage"", INDIAN JOURNAL OF CRITICAL CARE MEDICINE, vol. 9, no. 1, 1 January 2005 (2005-01-01) , page 11, XP55184291, ISSN: 0972-5229, DOI: 10.4103/0972-5229.16262;;LU G ET AL: ""Reconstructed recombinant factor Xa as an 5 antidote to reverse anticoagulation by factor Xa inhibitors"", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, vol. 7, no. suppl. 2, 1 July 2009 (2009-07-01), pages 309/OC-TH, XP009177312, ISSN: 1538-7933;;HOLLENBACH S ET AL: ""Bolus administration of PRT064445, a recombinant Factor Xa inhibitor antidote, reverses blood loss and PD markers in a rat model following enoxaparin induced anticoagulation"", EUROPEAN HEART JOURNAL, OXFORD UNIVERSITY PRESS, GB, vol. 33, no. Suppl, 1 January 2012 (2012-01-01), pages 309-310, XP009177324, ISSN: 0195-668X;;LACRAMIOARA IVANCIU ET AL: ""A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia"", NATURE BIOTECHNOLOGY, vol. 29, no. 11, 23 October 2011 (2011-10-23), pages 1028-1033, XP055111224, US ISSN: 1087-0156, DOI: 10.1038/nbt.1995;;NABIL K THALJI ET AL: ""Reversal of Direct Factor Xa Inhibitors Using Factor Xa Zymogen-Like Variants"", 28TH ANNUAL MD/PHD STUDENT CONFERENCE, KEYSTONE, COLORADO, JULY 26-28, 2013,, 27 July 2013 (2013-07-27), page 16, XP009177338,;;NABIL K THALJI ET AL: ""Zymogen-Like FXa Is An Effective Pro-Hemostatic To Reverse The Anticoagulant Effects Of Direct FXa Inhibitors"", INTERNET CITATION, [Online] page 1, XP002722746, Retrieved from the Internet: URL:https://ash.confex.com/ash/2013/webpro gram/Paper63599.html> [retrieved on 2014-04-01];;TOSO RAFFAELLA ET AL: ""The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly"", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 283, no. 27, 1 July 2008 (2008-07-01) , pages 18627-18635, XP002526299, ISSN: 0021-9258, DOI: 10.1074/JBC.M802205200;;ARNE LAUER ET AL: ""Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies"", THE LANCET NEUROLOGY, vol. 12, no. 4, 1 April 2013 (2013-04-01), pages 394-405, XP055184564, ISSN: 1474-4422, DOI: 10.1016/S1474-4422(13)70049-8",ACTIVE
255,JP,A,JP 2015147764 A,003-507-508-083-110,2015-08-20,2015,JP 2015011332 A,2015-01-23,US 201461931071 P,2014-01-24,COMPOSITION AND METHOD FOR TREATING INTRACEREBRAL HEMORRHAGE,"PROBLEM TO BE SOLVED: To provide effective therapies to prevent intracerebral hemorrhage (ICH) in susceptible patients and to treat patients with ICH, in order to reduce mortality and improve functional neurologic outcomes.SOLUTION: The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.",PFIZER,STEVEN ARKIN;;JOACHIM FRUEBIS;;MARCUS E CARR;;SUNITA HETT;;REEMA JASUJA;;DEBRA D PITTMAN,,https://lens.org/003-507-508-083-110,Patent Application,no,5,0,27,27,2,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/43;;A61P9/00,,2,1,104-875-894-618-945,pmc4157830;;10.1038/nbt.1995;;22020385,"IVANCIU, LACRAMIOARA ET AL.: ""A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia"", NATURE BIOTECHNOLOGY, vol. VOL. 29, NO. 11, JPN6018051354, 2011, pages p. 1028-1033;;松田保, Ｔ−ＰＡ, vol. 第１版第１刷, JPN6018051355, 25 October 1991 (1991-10-25), pages 第５−１１頁",INACTIVE
256,AU,A,AU 2001/086936 A,026-220-384-948-616,2002-03-13,2002,AU 2001/086936 A,2001-08-31,US 22969600 P;;US 0127060 W,2000-09-01,Chromatography and other adsorptions using modified carbon-clad metal oxide particles,,CABOT CORP;;ZIRCHROM SEPARATIONS INC,KYRLIDIS AGATHAGELOS;;REZNEK STEVEN R;;BELMONT JAMES A;;CARR PETER W;;MCNEFF CLAYTON V,,https://lens.org/026-220-384-948-616,Patent Application,no,0,0,7,7,0,B01D15/08;;B01D57/02;;B01D67/0093;;B01D69/141;;B01D71/021;;B01D71/024;;B01D71/82;;B01J20/06;;B01J20/20;;B01J20/286;;B01J20/3204;;B01J20/3244;;B01J20/3272;;B01J2220/52;;B01J2220/54;;G01N27/44747;;B01J2220/825;;B01J20/287;;B01J20/29;;B01J20/3227;;B01J20/3246;;B01J20/3253;;B01J20/3255;;B01J20/3285;;B01J2220/42;;B01J20/3092;;B01J2220/58;;B01J20/3204;;B01D71/024;;B01J20/06;;B01J20/286;;G01N27/44747;;B01D71/82;;B01J2220/54;;B01J2220/52;;B01D71/021;;B01D15/08;;B01J20/20;;B01D57/02;;B01J20/3244;;B01J20/3272;;B01J2220/825;;B01J20/3255;;B01J20/3285;;B01J20/29;;B01J20/3246;;B01J20/3227;;B01J20/3092;;B01J2220/42;;B01J20/287;;B01J20/3253;;B01J2220/58;;B01D69/1411;;B01D67/00931,B01D15/08;;B01D57/02;;B01D67/00;;B01D69/14;;B01D71/02;;B01D71/82;;B01J20/20;;B01J20/281;;B01J20/291;;B01J20/32;;G01N27/447;;G01N30/02;;G01N30/26;;G01N30/74;;G01N30/88,,0,0,,,,PENDING
257,EP,A2,EP 1328327 A2,085-333-670-683-621,2003-07-23,2003,EP 01966421 A,2001-08-31,US 0127060 W;;US 22969600 P,2000-09-01,CHROMATOGRAPHY AND OTHER ADSORPTIONS USING MODIFIED CARBON-CLAD METAL OXIDE PARTICLES,,CABOT CORP;;ZIRCHROM SEPARATIONS INC,KYRLIDIS AGATHAGELOS;;REZNEK STEVEN R;;BELMONT JAMES A;;CARR PETER W;;MCNEFF CLAYTON V,,https://lens.org/085-333-670-683-621,Patent Application,yes,0,0,7,7,0,B01D15/08;;B01D57/02;;B01D67/0093;;B01D69/141;;B01D71/021;;B01D71/024;;B01D71/82;;B01J20/06;;B01J20/20;;B01J20/286;;B01J20/3204;;B01J20/3244;;B01J20/3272;;B01J2220/52;;B01J2220/54;;G01N27/44747;;B01J2220/825;;B01J20/287;;B01J20/29;;B01J20/3227;;B01J20/3246;;B01J20/3253;;B01J20/3255;;B01J20/3285;;B01J2220/42;;B01J20/3092;;B01J2220/58;;B01J20/3204;;B01D71/024;;B01J20/06;;B01J20/286;;G01N27/44747;;B01D71/82;;B01J2220/54;;B01J2220/52;;B01D71/021;;B01D15/08;;B01J20/20;;B01D57/02;;B01J20/3244;;B01J20/3272;;B01J2220/825;;B01J20/3255;;B01J20/3285;;B01J20/29;;B01J20/3246;;B01J20/3227;;B01J20/3092;;B01J2220/42;;B01J20/287;;B01J20/3253;;B01J2220/58;;B01D69/1411;;B01D67/00931,B01D15/08;;B01D57/02;;B01D67/00;;B01D69/14;;B01D71/02;;B01D71/82;;B01J20/20;;B01J20/281;;B01J20/291;;B01J20/32;;G01N27/447;;G01N30/02;;G01N30/26;;G01N30/74;;G01N30/88,,0,0,,,,DISCONTINUED
258,US,B2,US 10528457 B2,192-554-239-749-222,2020-01-07,2020,US 201815913159 A,2018-03-06,US 201815913159 A;;US 201862623760 P,2018-01-30,Automated unit testing in a mainframe environment,"An automated system is presented for unit testing an application in a mainframe execution environment. The system includes a test configurator, a stub setup routine and an interceptor routine. The test configurator is configured to receive and parse a test input file, where the test input file includes a record for a particular file accessed by the application using the given type of file system. Upon reading the record, the test configurator calls the stub setup routine. The stub setup routine is associated with the given type of file system and creates an object for the particular file in the mainframe execution environment, such that the object is instantiated from a class representing the given type of file system. The interceptor routine is accessible by the application. In response to a given command issued by the application for the given type of file system, the interceptor routine operates to interact with methods provided by the object.",COMPUWARE CORP,EVERITT GLENN;;WATKINS DOUGLAS MCLEOD;;WALBECK LORETTA ANN;;SPURRELL SHELDON JOHN;;CARR STEVEN JAMES,BMC SOFTWARE INC (2021-03-31);;COMPUWARE CORPORATION (2018-03-19),https://lens.org/192-554-239-749-222,Granted Patent,yes,5,2,4,4,0,G06F11/3684;;G06F11/3688;;G06F11/3664;;G06F11/3688;;G06F11/3684;;G06F11/3664;;G06F11/362;;G06F16/188;;G06F16/252;;G06F40/205;;B32B25/04;;C08K3/38;;C08K2003/387;;F16F1/36,G06F9/44;;G06F11/36;;G06F16/188;;G06F16/25,,0,0,,,,ACTIVE
259,US,A1,US 2019/0235999 A1,046-000-092-153-708,2019-08-01,2019,US 201815913159 A,2018-03-06,US 201815913159 A;;US 201862623760 P,2018-01-30,Automated Unit Testing In A Mainframe Environment,"An automated system is presented for unit testing an application in a mainframe execution environment. The system includes a test configurator, a stub setup routine and an interceptor routine. The test configurator is configured to receive and parse a test input file, where the test input file includes a record for a particular file accessed by the application using the given type of file system. Upon reading the record, the test configurator calls the stub setup routine. The stub setup routine is associated with the given type of file system and creates an object for the particular file in the mainframe execution environment, such that the object is instantiated from a class representing the given type of file system. The interceptor routine is accessible by the application. In response to a given command issued by the application for the given type of file system, the interceptor routine operates to interact with methods provided by the object.",COMPUWARE CORP,EVERITT GLENN;;WATKINS DOUGLAS MCLEOD;;WALBECK LORETTA ANN;;SPURRELL SHELDON JOHN;;CARR STEVEN JAMES,BMC SOFTWARE INC (2021-03-31);;COMPUWARE CORPORATION (2018-03-19),https://lens.org/046-000-092-153-708,Patent Application,yes,5,6,4,4,0,G06F11/3684;;G06F11/3688;;G06F11/3664;;G06F11/3688;;G06F11/3684;;G06F11/3664;;G06F11/362;;G06F16/188;;G06F16/252;;G06F40/205;;B32B25/04;;C08K3/38;;C08K2003/387;;F16F1/36,G06F11/36;;G06F17/27,,0,0,,,,ACTIVE
260,EP,A1,EP 3096779 A1,033-484-597-951-58X,2016-11-30,2016,EP 15708578 A,2015-01-15,US 201461931071 P;;IB 2015050313 W,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/033-484-597-951-58X,Patent Application,yes,0,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,0,0,,,,ACTIVE
261,KR,A,KR 20180014221 A,106-109-026-660-019,2018-02-07,2018,KR 20187002632 A,2015-01-15,US 201461931071 P;;IB 2015050313 W,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,본 개시내용은 FXa의 변이체를 투여하는 것에 의해 대상체에서 뇌내 출혈 (ICH)을 치료하거나 예방하기 위한 조성물 및 방법을 제공한다.,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/106-109-026-660-019,Patent Application,no,0,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61K9/00,,0,0,,,,DISCONTINUED
262,HU,T4,HU E047588 T4,157-101-155-608-616,2020-06-29,2020,HU E15708578 A,2015-01-15,US 201461931071 P,2014-01-24,COMPOSITIONS AND METHODS FOR TREATING INTRACEREBRAL HEMORRHAGE,,PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/157-101-155-608-616,Unknown,no,0,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,0,0,,,,PENDING
263,BR,A2,BR 112016014617 A2,145-300-991-124-963,2017-09-19,2017,BR 112016014617 A,2015-01-15,IB 2015050313 W;;US 201461931071 P,2014-01-24,VARIANTE DO FATOR XA (FXA) E USOS DA REFERIDA VARIANTE,COMPOSIÇÕES E MÉTODOS PARA O TRATAMENTO DE HEMORRAGIA INTRACEREBRAL. A presente invenção refere-se a composições e métodos para o tratamento ou para a prevenção de hemorragia intracerebral (ICH) em um sujeito por administração de uma variante do FXa.,PFIZER,STEVEN ARKIN;;JOACHIM FRUEBIS;;MARCUS E CARR;;SUNITA HETT;;REEMA JASUJA;;DEBRA D PITTMAN,,https://lens.org/145-300-991-124-963,Patent Application,no,0,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,0,0,,,,DISCONTINUED
264,ES,T3,ES 2772802 T3,113-394-837-131-507,2020-07-08,2020,ES 15708578 T,2015-01-15,US 201461931071 P;;IB 2015050313 W,2014-01-24,Composiciones y procedimientos para tratar la hemorragia intracerebral,"Una variante del Factor Xa (FXa) para su uso en el tratamiento de la hemorragia intracerebral (ICH), en la que la variante del Factor Xa (FXa) incluye al menos una mutación de sustitución seleccionada del grupo que consiste en: a) el aminoácido en la posición correspondiente a 235 en SEQ ID NO: 1 está sustituido con Thr, Leu, Phe, Asp o Gly; y b) el aminoácido en la posición correspondiente a 236 en SEQ ID NO: 1 está sustituido con Leu, Ala o Gly.",PFIZER,ARKIN STEVEN;;FRUEBIS JOACHIM;;CARR MARCUS E;;HETT SUNITA;;JASUJA REEMA;;PITTMAN DEBRA D,,https://lens.org/113-394-837-131-507,Granted Patent,no,0,0,27,27,0,A61K38/4846;;C12Y304/21006;;A61P7/04;;A61P9/00;;A61K9/0019;;A61K9/0021;;A61K38/4846;;A61K38/4846;;C12Y304/21006,A61K38/48;;A61P7/04,,0,0,,,,ACTIVE
265,EP,B1,EP 2405954 B1,012-832-893-900-425,2017-06-07,2017,EP 10751302 A,2010-03-09,US 2010/0026698 W;;US 15857409 P,2009-03-09,SURGICAL FLUID MANAGEMENT SYSTEM,,THERMEDX LLC,WILLIAMS JEFFREY B;;PYLES KENNETH R;;CARR DOUGLAS L;;TORER STEVEN J;;DONATH EDWARD R,,https://lens.org/012-832-893-900-425,Granted Patent,yes,9,1,17,27,0,A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M3/022;;A61M2205/502;;A61M1/777;;A61M3/0245;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M1/72;;G01G17/04;;G01G19/414;;A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M2205/502;;A61M3/022;;A61M1/777;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M3/0245;;A61M5/142;;A61M5/172,A61M1/00;;A61M3/02;;A61M5/36;;A61M5/44,,0,0,,,,ACTIVE
266,WO,A1,WO 2010/104878 A1,168-484-435-037-694,2010-09-16,2010,US 2010/0026698 W,2010-03-09,US 15857409 P,2009-03-09,SURGICAL FLUID MANAGEMENT SYSTEM,"Surgical fluid management systems and methods of operating surgical fluid management systems which may provide one or more functions associated with suction, irrigation, distention, deficit monitoring, infusion, fluid warming, and the like. Some example embodiments may include infra-red lamps arranged to heat fluid flowing through a disposable cartridge. Some example embodiments may provide a three-dimensional fluid path through the cartridge and/or multi-stage heating capabilities. Some example fluid management systems may be selectable between pressure control and flow control modes.",THERMEDX LLC;;WILLIAMS JEFFREY B;;PYLES KENNETH R;;CARR DOUGLAS L;;TORER STEVEN J;;DONATH EDWARD R,WILLIAMS JEFFREY B;;PYLES KENNETH R;;CARR DOUGLAS L;;TORER STEVEN J;;DONATH EDWARD R,,https://lens.org/168-484-435-037-694,Patent Application,yes,6,16,17,27,0,A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M3/022;;A61M2205/502;;A61M1/777;;A61M3/0245;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M1/72;;G01G17/04;;G01G19/414;;A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M2205/502;;A61M3/022;;A61M1/777;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M3/0245;;A61M5/142;;A61M5/172,A61M1/00,,1,0,,,See also references of EP 2405954A4,PENDING
267,CA,A1,CA 2754773 A1,145-699-177-741-50X,2010-09-16,2010,CA 2754773 A,2010-03-09,US 15857409 P;;US 2010/0026698 W,2009-03-09,SURGICAL FLUID MANAGEMENT SYSTEM,"Surgical fluid management systems and methods of operating surgical fluid management systems which may provide one or more functions associated with suction, irrigation, distention, deficit monitoring, infusion, fluid warming, and the like. Some example embodiments may include infra-red lamps arranged to heat fluid flowing through a disposable cartridge. Some example embodiments may provide a three-dimensional fluid path through the cartridge and/or multi-stage heating capabilities. Some example fluid management systems may be selectable between pressure control and flow control modes.",THERMEDX LLC,WILLIAMS JEFFREY B;;PYLES KENNETH R;;CARR DOUGLAS L;;TORER STEVEN J;;DONATH EDWARD R,,https://lens.org/145-699-177-741-50X,Patent Application,no,0,0,17,27,0,A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M3/022;;A61M2205/502;;A61M1/777;;A61M3/0245;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M1/72;;G01G17/04;;G01G19/414;;A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M2205/502;;A61M3/022;;A61M1/777;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M3/0245;;A61M5/142;;A61M5/172,A61M1/00,,0,0,,,,INACTIVE
268,WO,A3,WO 2005/118961 A3,135-886-991-797-824,2007-04-19,2007,US 2005/0018764 W,2005-05-27,US 85505104 A,2004-05-27,MOUNTAIN CLOUDWATER,"A method and apparatus for completing a natural solar distillation cycle (comprised of maritime trade winds being elevated over mountain formations to form orographic clouds) includes enabling the low cost harvesting of freshwater during time periods when weather conditions permit, despite the absence of rain. The cloud-catching wind management structures preferably incorporate minimal pressure drop gas cyclones to centrifuge condensate particles out of the air stream, and jet pump-like flow guide structures to help overcome pressure drop, for efficient, energy-passive production of freshwater utilizing only the stagnation pressure of natural wind velocity. The permanence (design and anchoring against natural disasters) of the structures provides for incorporation of water treatment means, and connection with permanent collection reservoirs and distribution systems, for large volume supply of potage freshwater for pub is and industrial use.",KILLION DAVID L;;CARR JAMES E;;KILLION JESSE D;;KILLION JOAN A;;BRUNO STEVEN L,KILLION DAVID L;;CARR JAMES E;;KILLION JESSE D;;KILLION JOAN A;;BRUNO STEVEN L,,https://lens.org/135-886-991-797-824,Search Report,yes,1,0,4,4,0,E03B3/28;;E03B3/28,B01D50/00;;E01H13/00;;E03B3/28,,0,0,,,,PENDING
269,EP,A1,EP 3248625 A1,177-850-068-589-342,2017-11-29,2017,EP 17174579 A,2010-03-09,US 15857409 P;;EP 10751302 A,2009-03-09,SURGICAL FLUID MANAGEMENT SYSTEM,"According to the specification there is provided a fluid management system comprising: a cartridge having a plurality of fluid channels, including first, second, third and fourth fluid channels defining a three-dimensional fluid path for fluid flowing therethrough, said cartridge having a main wall dividing the cartridge between first and second sides. The first fluid channel and the fourth fluid channel are separated by a first separation wall and are located on the first side of the cartridge. The second fluid channel and the third fluid channel are separated by a second separation wall and are located on the second side of the cartridge. The cartridge including an inlet in fluid communication with said first fluid channel and an outlet in fluid communication with said fourth fluid channel, and the fluid flowing through the three-dimensional fluid path of the cartridge from the inlet to the outlet in order of: first fluid channel, second fluid channel, third fluid channel, and fourth fluid channel. There is further provided a heater assembly including: a housing having a slot dimensioned to receive the cartridge, and a plurality of infrared lamps, including first, second, third and fourth infrared lamps mounted within the housing generally adjacent to the slot and a control system operatively connected to the plurality of infrared lamps to adjust power to the plurality of infrared lamps to heat the fluid in the three-dimensional fluid path to a desired temperature.
",THERMEDX LLC,WILLIAMS JEFFREY B;;PYLES KENNETH R;;CARR DOUGLAS L;;TORER STEVEN J;;DONATH EDWARD R,,https://lens.org/177-850-068-589-342,Patent Application,yes,7,0,17,27,0,A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M3/022;;A61M2205/502;;A61M1/777;;A61M3/0245;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M1/72;;G01G17/04;;G01G19/414;;A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M2205/502;;A61M3/022;;A61M1/777;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M3/0245;;A61M5/142;;A61M5/172,A61M1/00;;A61M3/02;;A61M5/44,,0,0,,,,DISCONTINUED
270,EP,A4,EP 2405954 A4,195-492-845-678-661,2014-03-19,2014,EP 10751302 A,2010-03-09,US 2010/0026698 W;;US 15857409 P,2009-03-09,SURGICAL FLUID MANAGEMENT SYSTEM,,THERMEDX LLC,WILLIAMS JEFFREY B;;PYLES KENNETH R;;CARR DOUGLAS L;;TORER STEVEN J;;DONATH EDWARD R,,https://lens.org/195-492-845-678-661,Search Report,no,5,0,17,27,0,A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M3/022;;A61M2205/502;;A61M1/777;;A61M3/0245;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M1/72;;G01G17/04;;G01G19/414;;A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M2205/502;;A61M3/022;;A61M1/777;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M3/0245;;A61M5/142;;A61M5/172,A61M1/00;;A61M3/02;;A61M5/36;;A61M5/44,,1,0,,,See also references of WO 2010104878A1,ACTIVE
271,US,A1,US 2021/0382068 A1,116-963-933-919-632,2021-12-09,2021,US 201917280380 A,2019-10-02,US 201917280380 A;;US 201862740324 P;;US 201962852924 P;;US 2019/0054365 W,2018-10-02,HLA SINGLE ALLELE LINES,"Adaptive immune responses rely on the ability of cytotoxic T cells to identify and eliminate cells displaying disease-specific antigens on human leukocyte antigen (HLA) class I molecules. Investigations into antigen processing and display have immense implications in human health, disease and therapy. To extend understanding of the rules governing antigen processing and presentation, immunopurified peptides from B cells, each expressing a single HLA class I allele, were profiled. A resource dataset containing thousands of peptides bound to distinct class I HLA-A, -B, and -C alleles was generated by implementing a novel allele-specific database search strategy. Applicants discovered new binding motifs, established the role of gene expression in peptide presentation and improved prediction of HLA-peptide binding by using these data to train machine-learning models. These streamlined experimental and analytic workflows enable direct identification and analysis of endogenously processed and presented antigens.",DANA FARBER CANCER INST INC;;MASSACHUSETTS GEN HOSPITAL;;BROAD INST INC,KESKIN DERIN;;SARKIZOVA SIRANUSH;;KLAEGER SUSAN;;CLAUSER KARL;;CARR STEVEN;;HACOHEN NIR;;WU CATHERINE J,DANA-FARBER CANCER INSTITUTE INC (2020-07-21);;THE BROAD INSTITUTE INC (2019-12-10);;THE GENERAL HOSPITAL CORPORATION (2020-03-06),https://lens.org/116-963-933-919-632,Patent Application,yes,0,0,2,2,173477,G01N33/56977;;A61K39/0011;;A61K39/00;;A61K2039/572;;G01N33/6878;;A61K39/001114;;G16B30/10;;G16B40/00;;G01N33/56977;;G01N33/6878;;G01N2333/70539;;G01N2500/04,G01N33/68;;A61K39/00;;G01N33/569;;G16B30/10;;G16B40/00,,0,0,,,,PENDING
272,US,A1,US 2005/0223719 A1,159-490-303-774-064,2005-10-13,2005,US 85505104 A,2004-05-27,US 85505104 A;;US 47353103 P,2003-05-27,Mountain cloudwater,"A method and apparatus for completing a natural solar distillation cycle (comprised of maritime trade winds being elevated over mountain formations to form orographic clouds) includes enabling the low cost harvesting of freshwater during time periods when weather conditions permit, despite the absence of rain. The cloud-catching wind management structures preferably incorporate minimal pressure drop gas cyclones to centrifuge condensate particles out of the air stream, and jet pump-like flow guide structures to help overcome pressure drop, for efficient, energy-passive production of freshwater utilizing only the stagnation pressure of natural wind velocity. The permanence (design and anchoring against natural disasters) of the structures provides for incorporation of water treatment means, and connection with permanent collection reservoirs and distribution systems, for large volume supply of potable freshwater for public and industrial use.",KILLION DAVID L;;CARR JAMES E;;KILLION JESSE D;;KILLION JOAN A;;BRUNO STEVEN L,KILLION DAVID L;;CARR JAMES E;;KILLION JESSE D;;KILLION JOAN A;;BRUNO STEVEN L,,https://lens.org/159-490-303-774-064,Patent Application,yes,1,13,4,4,0,E03B3/28;;E03B3/28,E01H13/00;;E03B3/28,62/93,0,0,,,,INACTIVE
273,EP,A1,EP 2405954 A1,110-131-540-902-485,2012-01-18,2012,EP 10751302 A,2010-03-09,US 2010/0026698 W;;US 15857409 P,2009-03-09,SURGICAL FLUID MANAGEMENT SYSTEM,,THERMEDX LLC,WILLIAMS JEFFREY B;;PYLES KENNETH R;;CARR DOUGLAS L;;TORER STEVEN J;;DONATH EDWARD R,,https://lens.org/110-131-540-902-485,Patent Application,yes,0,0,17,27,0,A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M3/022;;A61M2205/502;;A61M1/777;;A61M3/0245;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M1/72;;G01G17/04;;G01G19/414;;A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M2205/502;;A61M3/022;;A61M1/777;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M3/0245;;A61M5/142;;A61M5/172,A61M1/00;;A61M3/02;;A61M5/36;;A61M5/44,,0,0,,,,ACTIVE
274,CA,A1,CA 2964741 A1,185-929-996-629-644,2010-09-16,2010,CA 2964741 A,2010-03-09,US 15857409 P;;CA 2754773 A,2009-03-09,SURGICAL FLUID MANAGEMENT SYSTEM,,THERMEDX LLC,WILLIAMS JEFFREY B;;PYLES KENNETH R;;CARR DOUGLAS L;;TORER STEVEN J;;DONATH EDWARD R,,https://lens.org/185-929-996-629-644,Patent Application,no,0,0,17,27,0,A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M3/022;;A61M2205/502;;A61M1/777;;A61M3/0245;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M1/72;;G01G17/04;;G01G19/414;;A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M2205/502;;A61M3/022;;A61M1/777;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M3/0245;;A61M5/142;;A61M5/172,A61M1/00;;A61M5/142;;A61M5/172;;A61M5/36;;A61M5/44,,0,0,,,,INACTIVE
275,CA,C,CA 2964741 C,013-737-986-412-763,2019-10-29,2019,CA 2964741 A,2010-03-09,US 15857409 P;;CA 2754773 A,2009-03-09,SURGICAL FLUID MANAGEMENT SYSTEM,"A fluid management system comprising: a cartridge having a plurality of fluid channels, including first, second, third and fourth fluid channels defining a three- dimensional fluid path for fluid flowing therethrough, said cartridge having a main wall dividing the cartridge between first and second sides, wherein the first fluid channel and the fourth fluid channel are separated by a first separation wall and are located on the first side of the cartridge, the second fluid channel and the third fluid channel are separated by a second separation wall and are located on the second side of the cartridge, said cartridge includes an inlet in fluid communication with said first fluid channel and an outlet in fluid communication with said fourth fluid channel, and said fluid flowing through the three-dimensional fluid path of the cartridge from the inlet to the outlet in order of: first fluid channel, second fluid channel, third fluid channel, and fourth fluid channel; a heater assembly including: a housing having a slot dimensioned to receive the cartridge, a plurality of infrared lamps, including first, second, third and fourth infrared lamps mounted within the housing generally adjacent to the slot, wherein the first and fourth infrared lamps are respectively located proximate to the first and fourth fluid channels on the first side of the cartridge when received in the slot, and the second and third infrared lamps are respectively located proximate to the second and third fluid channels on the second side of the cartridge when said cartridge is received in the slot; and a control system operatively connected to the plurality of infrared lamps to adjust power to the plurality of infrared lamps to heat the fluid in the three- dimensional fluid path to a desired temperature.",THERMEDX LLC,WILLIAMS JEFFREY B;;PYLES KENNETH R;;CARR DOUGLAS L;;TORER STEVEN J;;DONATH EDWARD R,,https://lens.org/013-737-986-412-763,Granted Patent,no,0,0,17,27,0,A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M3/022;;A61M2205/502;;A61M1/777;;A61M3/0245;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M1/72;;G01G17/04;;G01G19/414;;A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M2205/502;;A61M3/022;;A61M1/777;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M3/0245;;A61M5/142;;A61M5/172,A61M1/00;;A61M5/142;;A61M5/172;;A61M5/36;;A61M5/44,,0,0,,,,INACTIVE
276,US,A1,US 2014/0205988 A1,095-635-319-695-971,2014-07-24,2014,US 201313748828 A,2013-01-24,US 201313748828 A,2013-01-24,"SYSTEM, SOFTWARE AND ASSOCIATED METHOD OF USE THEREOF FOR THE TRANSFER OF INFORMATION BETWEEN A MODERATOR ADN RECIPIENTS","The present invention relates to a web-based computer system, a web-based computer software, and a method of use thereof for the transfer of information between a moderator and a plurality of recipients either in a face-to-face environment or in a remote environment, and more specifically the use of a moderator station, a projector display, and a plurality of user web-enabled devices connected to a network in a group and team competitive environment.",CHANG PAUL JOSEPH;;KALBFLEISCH BRIAN JOSEPH;;DREW STEVEN THOMAS;;CARR CHRISTOPHER DANIEL;;PEDE DAVID RICHARD;;RADIOLOGICAL SOC OF NORTH AMERICA,CHANG PAUL JOSEPH;;KALBFLEISCH BRIAN JOSEPH;;DREW STEVEN THOMAS;;CARR CHRISTOPHER DANIEL;;PEDE DAVID RICHARD,,https://lens.org/095-635-319-695-971,Patent Application,yes,5,2,1,1,0,G09B7/02;;G09B7/02,G09B5/00,434/350,0,0,,,,DISCONTINUED
277,WO,A1,WO 2020/072700 A1,148-835-079-563-722,2020-04-09,2020,US 2019/0054365 W,2019-10-02,US 201862740324 P;;US 201962852924 P,2018-10-02,HLA SINGLE ALLELE LINES,"Adaptive immune responses rely on the ability of cytotoxic T cells to identify and eliminate cells displaying disease-specific antigens on human leukocyte antigen (HLA) class I molecules. Investigations into antigen processing and display have immense implications in human health, disease and therapy. To extend understanding of the rules governing antigen processing and presentation, immunopurified peptides from B cells, each expressing a single HLA class I allele, were profiled. A resource dataset containing thousands of peptides bound to distinct class I HLA- A, -B, and -C alleles was generated by implementing a novel allele-specific database search strategy. Applicants discovered new binding motifs, established the role of gene expression in peptide presentation and improved prediction of HLA-peptide binding by using these data to train machine-learning models. These streamlined experimental and analytic workflows enable direct identification and analysis of endogenously processed and presented antigens.",DANA FARBER CANCER INST INC;;MASSACHUSETTS GEN HOSPITAL;;BROAD INST INC;;KESKIN DERIN;;SARKIZOVA SIRANUSH;;CARR STEVEN;;WU CATHERINE J;;CLAUSER KARL,KESKIN DERIN;;SARKIZOVA SIRANUSH;;CARR STEVEN;;WU CATHERINE J;;CLAUSER KARL;;KLAEGER SUSAN;;HACOHEN NIR,,https://lens.org/148-835-079-563-722,Patent Application,yes,258,13,2,2,173477,G01N33/56977;;A61K39/0011;;A61K39/00;;A61K2039/572;;G01N33/6878;;A61K39/001114;;G16B30/10;;G16B40/00;;G01N33/56977;;G01N33/6878;;G01N2333/70539;;G01N2500/04,A61K35/15;;A61K39/00;;G01N33/569,,294,250,056-937-846-565-908;;016-545-787-663-386;;080-812-133-067-23X;;074-116-122-329-453;;074-116-122-329-453;;003-610-988-711-248;;000-171-862-284-243;;071-256-710-186-001;;074-116-122-329-453;;141-167-705-529-48X;;085-876-354-611-31X;;086-314-396-456-567;;043-132-461-941-255;;080-812-133-067-23X;;105-571-956-647-527;;072-983-585-843-582;;040-345-923-870-253;;022-225-349-299-937;;092-667-724-840-965;;035-019-404-496-12X;;079-889-760-145-612;;086-660-693-292-847;;048-156-676-293-513;;134-565-035-294-633;;048-419-629-020-848;;016-499-149-910-093;;019-528-408-419-565;;003-667-059-981-03X;;090-327-557-741-105;;095-849-513-154-961;;016-229-772-022-557;;026-944-353-804-488;;024-392-972-050-341;;017-216-732-209-839;;059-400-780-458-227;;002-882-009-745-691;;004-724-173-477-122;;037-904-735-240-537;;120-176-283-549-095;;093-423-744-136-655;;082-887-373-158-244;;040-277-381-986-160;;067-423-318-569-025;;125-645-965-899-165;;031-039-129-088-844;;020-178-335-962-88X;;066-916-220-868-595;;033-600-295-094-741;;079-874-646-887-645;;057-353-589-104-357;;084-280-558-764-322;;028-333-567-010-894;;007-260-298-056-037;;003-264-306-643-657;;031-807-821-140-812;;151-747-107-866-762;;065-427-040-070-857;;009-706-535-362-887;;001-738-886-327-915;;064-133-645-690-020;;028-696-271-645-551;;086-507-133-163-907;;001-135-488-035-957;;086-469-414-422-958;;015-839-900-804-759;;033-517-475-734-956;;004-528-067-817-471;;057-353-589-104-357;;041-737-949-940-597;;001-684-791-731-05X;;047-796-156-303-991;;015-752-955-256-76X;;015-005-537-927-250;;073-390-485-598-068;;067-768-558-783-008;;014-630-446-453-288;;000-426-165-109-927;;020-178-779-477-981;;104-877-511-857-009;;114-442-739-618-020;;114-700-871-180-280;;011-463-146-073-65X;;000-078-232-627-567;;020-781-137-201-736;;032-464-541-034-729;;089-310-781-933-578;;061-708-359-767-416;;024-311-781-677-427;;026-411-645-167-642;;007-261-999-134-784;;096-012-584-064-893;;001-634-188-074-328;;048-055-110-364-340;;034-835-564-577-980;;125-237-538-945-224;;013-223-611-540-656;;055-061-574-892-808;;064-682-744-872-69X;;135-277-134-797-957;;041-501-254-191-787;;087-286-239-620-774;;091-509-047-035-538;;042-913-591-104-522;;018-065-511-380-65X;;089-443-554-843-061;;063-009-450-995-217;;059-910-245-294-03X;;014-491-792-527-932;;038-228-972-634-164;;129-580-616-064-283;;061-542-637-203-585;;095-894-960-349-974;;065-268-854-361-113;;014-188-174-852-197;;033-059-065-421-652;;105-045-276-085-540;;018-041-187-164-982;;005-198-548-268-394;;067-344-233-099-751;;090-522-587-795-474;;077-295-979-222-239;;066-872-003-079-846;;091-806-773-741-403;;009-939-788-857-914;;089-942-491-393-839;;004-992-481-487-884;;013-559-502-235-993;;037-780-185-187-88X;;029-373-120-748-203;;093-806-058-071-01X;;124-408-451-056-317;;088-971-131-416-01X;;071-978-992-443-516;;079-902-257-271-084;;002-955-370-415-401;;045-714-831-915-963;;112-871-461-451-205;;086-268-955-647-163;;046-289-867-375-85X;;152-279-674-137-242;;086-575-237-486-844;;113-118-416-348-870;;046-289-867-375-85X;;099-372-009-770-60X;;012-522-132-362-171;;103-736-007-949-11X;;019-202-837-544-006;;033-473-897-919-959;;020-366-451-479-738;;023-024-890-895-871;;020-289-144-251-278;;060-824-980-876-559;;010-901-227-513-259;;007-041-645-879-370;;088-156-513-960-044;;023-784-290-990-164;;002-085-775-109-916;;010-152-833-378-258;;020-579-657-226-196;;053-783-298-552-453;;083-694-793-270-14X;;032-942-121-304-562;;047-798-771-039-642;;045-728-526-507-231;;094-554-724-588-44X;;068-210-720-709-636;;002-658-040-691-779;;044-454-305-666-245;;115-853-993-617-472;;009-820-952-967-579;;103-168-089-019-035;;136-929-781-463-029;;138-064-957-580-062;;068-655-416-231-860;;098-135-152-864-70X;;038-874-519-022-238;;010-679-857-763-16X;;033-916-697-838-388;;009-647-298-610-949;;028-982-532-025-930;;032-075-442-654-704;;051-326-039-695-605;;057-165-601-966-358;;081-374-000-676-84X;;031-575-623-752-48X;;023-784-290-990-164;;041-982-926-028-887;;000-021-137-125-270;;073-493-217-484-744;;144-725-849-679-447;;100-917-703-348-75X;;044-254-945-915-100;;001-889-138-393-421;;020-750-167-506-977;;041-161-089-834-866;;031-103-391-280-149;;024-271-538-787-93X;;080-812-133-067-23X;;125-702-184-945-681;;089-804-744-587-493;;028-053-759-834-584;;113-227-143-558-84X;;033-060-549-025-363;;067-936-483-188-019;;056-072-812-092-997;;055-015-731-698-797;;020-080-307-999-663;;019-050-851-092-659;;007-895-184-496-578;;016-545-787-663-386;;080-812-133-067-23X;;011-489-316-586-155;;085-807-604-889-957;;046-244-724-273-929;;041-557-178-255-226;;083-694-793-270-14X;;046-591-246-444-59X;;083-986-864-561-054;;028-973-226-410-051;;093-939-233-498-395;;147-200-064-427-482;;057-130-806-124-031;;074-592-384-030-23X;;160-431-554-919-542;;033-557-609-586-925;;038-886-779-344-792;;021-589-751-977-872;;114-391-871-363-54X;;062-220-645-265-457;;125-449-120-736-331;;085-644-716-529-231;;108-223-978-674-639;;052-411-138-378-990;;020-687-928-733-922;;138-892-507-425-536;;039-537-460-734-773;;056-352-601-588-569;;100-278-802-415-454;;015-635-391-873-726;;006-051-218-299-26X;;074-116-122-329-453;;126-858-335-833-271;;039-046-502-367-312;;011-085-779-195-045;;034-207-794-611-075;;040-500-330-459-87X;;037-647-818-359-766;;085-644-716-529-231;;071-256-710-186-001;;018-161-126-719-119,10.2174/138161209789105180;;19860672;;10.1101/149518;;10.4049/jimmunol.1700893;;28978689;;pmc5679736;;pmc5405381;;28228285;;10.1016/j.immuni.2017.02.007;;10.1093/nar/gku1075;;10.1093/nar/gku1235;;10.1093/nar/gku1056;;25300482;;pmc4383874;;10.1093/nar/gku1003;;pmc4288154;;25352553;;pmc4384014;;10.1093/nar/gku938;;25505164;;10.1093/nar/gku1075;;10.1093/nar/gku1235;;10.1093/nar/gku1056;;25300482;;pmc4383874;;10.1093/nar/gku1003;;pmc4288154;;25352553;;pmc4384014;;10.1093/nar/gku938;;25505164;;25414341;;10.1093/nar/gku1161;;pmc4383959;;10.1126/science.1546328;;1546328;;7890324;;10.1007/bf00172063;;10.1093/nar/gku1075;;10.1093/nar/gku1235;;10.1093/nar/gku1056;;25300482;;pmc4383874;;10.1093/nar/gku1003;;pmc4288154;;25352553;;pmc4384014;;10.1093/nar/gku938;;25505164;;pmc3319061;;10.1007/s00251-008-0341-z;;19002680;;pmc2447772;;10.1093/nar/gkn202;;18463140;;25717196;;pmc4481849;;10.1093/bioinformatics/btv123;;pmc5378011;;28096240;;10.1101/cshperspect.a026740;;pmc5405381;;28228285;;10.1016/j.immuni.2017.02.007;;22318521;;pmc3874809;;10.1038/nature10755;;10.1099/0022-1317-68-10-2587;;2822841;;7636255;;10.4049/jimmunol.155.4.2039;;10.1016/j.vaccine.2013.03.042;;pmc3755097;;23583893;;18715801;;pmc6731373;;10.1016/j.smim.2008.07.003;;10.1073/pnas.91.21.9866;;7937907;;pmc44918;;10.1073/pnas.1019266108;;21502532;;pmc3088639;;11325844;;pmc1266037;;10.1073/pnas.0500090102;;16247014;;10.1038/nature10803;;pmc3288744;;22318517;;20921459;;pmc3020702;;10.1200/jco.2010.28.6963;;10.3410/f.6040956.6344054;;29588069;;10.1016/j.tibtech.2018.02.008;;10.1038/nrrheum.2017.107;;28701761;;10.3791/57637;;pmc6101271;;29863666;;2936651;;10.1016/0378-1119(85)90022-8;;pmc386907;;3095831;;10.1073/pnas.83.21.8258;;10.1016/j.ijpharm.2005.06.007;;16046256;;10.1021/ja00897a025;;10.1016/0264-410x(89)90266-1;;2609722;;10.1016/0196-8858(81)90046-4;;4058585;;10.1038/317813a0;;6260373;;10.1016/0092-8674(81)90282-8;;10.1016/s0065-308x(08)60152-9;;10050276;;11050940;;10.1016/s0065-3527(00)55001-5;;8690928;;10.1016/0022-1759(96)00035-x;;pmc4395260;;25875117;;10.1371/journal.pone.0118803;;9498786;;10.1126/science.270.5234.299;;7569980;;8265577;;10.1073/pnas.90.24.11478;;pmc48007;;23125444;;pmc3532831;;10.1093/infdis/jis670;;10.1128/jvi.63.5.2374-2378.1989;;2784836;;pmc250661;;pmc240569;;10.1128/jvi.65.5.2220-2224.1991;;1850008;;1727603;;10.1016/0042-6822(92)90082-z;;22777090;;pmc3495727;;10.4161/hv.21080;;10.1038/302490a0;;6835382;;7616101;;10.1002/jlb.58.1.1;;10.1038/354520a0;;1758494;;6095272;;10.1073/pnas.81.22.7194;;pmc392104;;10.1073/pnas.83.20.7947;;3464010;;pmc386841;;17227690;;10.1016/j.vaccine.2006.11.066;;10.1016/j.vaccine.2009.09.033;;19925953;;10.1038/330259a0;;3118219;;pmc247729;;10.1128/jvi.63.2.600-606.1989;;2783466;;10.1016/0042-6822(90)90119-c;;2154895;;219640;;10.1006/viro.1998.9397;;9837798;;pmc228399;;10.1128/jvi.77.19.10606-10622.2003;;12970445;;10.1016/0042-6822(90)90294-2;;2219722;;16731942;;pmc1472566;;10.1128/jvi.02108-05;;10.1099/vir.0.83018-0;;17698656;;10.1128/jvi.02216-07;;18184713;;pmc2258966;;10.2174/156652311795684731;;21453284;;8337851;;10.1006/viro.1993.1442;;7616101;;10.1002/jlb.58.1.1;;9603331;;10.1099/0022-1317-79-5-1159;;11393868;;11283352;;10.1126/science.1058915;;11739541;;10.4049/jimmunol.167.12.7180;;15308364;;10.1016/j.vaccine.2004.02.025;;10.1086/421266;;15227622;;15014500;;10.1038/nature02331;;15708987;;10.1128/jvi.79.5.2678-2688.2005;;pmc548443;;17900219;;10.1016/j.vaccine.2007.04.002;;17499893;;17434244;;10.1016/j.vaccine.2007.02.084;;10.1016/j.vaccine.2007.12.059;;18336966;;10.1073/pnas.0705191105;;18270165;;pmc2538878;;10.1200/jco.2004.08.083;;15169798;;10.1158/1078-0432.ccr-08-0668;;19010868;;10.1007/s10637-008-9187-3;;18931824;;10.1200/jco.2009.25.0597;;20100959;;pmc2834462;;20881001;;10.1158/1078-0432.ccr-10-2082;;20975327;;10.4161/hv.6.10.13144;;pmc9491320;;21069322;;10.1007/s00262-010-0935-9;;15242542;;10.1089/0889222041217428;;15325077;;10.1016/j.virusres.2004.04.008;;10.1073/pnas.0406381102;;15781866;;pmc555695;;10.4161/hv.9693;;19786840;;18393831;;10.2174/156652308784049363;;10.1002/eji.200939754;;pmc3044835;;20017188;;pmc2885029;;19008384;;10.1099/vir.0.2008/004440-0;;19944151;;pmc2814951;;10.1016/j.vaccine.2009.11.030;;10.1097/coh.0b013e32833d1e87;;20978379;;10.1016/s0952-7915(97)80104-5;;9287173;;10.1007/s002620000146;;11092617;;10873071;;10.4049/jimmunol.171.2.1094;;12847284;;pmc38060;;10.1073/pnas.93.21.11349;;8876138;;10.1200/jco.1999.17.1.332;;10458251;;10.1007/bf01641272;;2033387;;10.1099/0022-1317-72-5-1031;;20413326;;10.1016/j.smim.2010.03.004;;20693851;;pmc2922045;;10.1097/ppo.0b013e3181eaca65;;pmc3256967;;10.1084/jem.20111171;;22065672;;10.1016/s0264-410x(00)00498-9;;11257407;;10.1007/bf01025492;;10566139;;10.1111/j.1600-065x.1999.tb01326.x;;17908809;;10.1128/iai.00828-07;;pmc2168343;;10.4049/jimmunol.1300097;;23585680;;pmc3647383;;pmc3815523;;10.1021/cb400264n;;23683494;;10477547;;pmc2195611;;10.1084/jem.190.5.617;;7573360;;pmc1871000;;pmc1475951;;10.1200/jco.2005.00.240;;15800326;;12663709;;10.1200/jco.2003.06.100;;16491401;;10.1007/s00262-006-0145-7;;9637761;;10.1006/cimm.1998.1283;;9554254;;10.1097/00002371-199611000-00005;;9041460;;16763660;;10.1038/nrd2059;;18499419;;10.1016/j.coi.2008.04.011;;pmc2538913;;17975151;;10.1158/1078-0432.ccr-07-0486;;10.1038/nature14567;;26040715;;10.1172/jci68395;;pmc3726168;;23867552;;pmc3846695;;23928481;;10.3791/50085;;19136947;;pmc2684978;;10.1038/nmat2357;;8977634;;10.1002/(sici)1097-0045(199612)29:6<371::aid-pros5>3.0.co;2-b;;10.1002/(sici)1097-0045(199612)29:6<371::aid-pros5>3.3.co;2-3;;9288186;;10.1002/(sici)1097-0045(19970901)32:4<272::aid-pros7>3.0.co;2-l;;10.1084/jem.20100223;;pmc2882835;;20479118;;10.1038/nm0810-854;;20689546;;1690918;;10.1126/science.1690918;;2856201;;23159882;;10.1038/nbt.2436;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;10.1002/eji.200324804;;14991590;;20563707;;10.1007/82_2010_49;;pmc4060248;;10.1038/nri2216;;18097448;;10.1002/cncr.24988;;20187092;;22842478;;10.1038/nm.2883;;10.3410/f.717954402.793461338;;16960692;;10.1007/s00262-006-0225-8;;10.1038/nri2216;;18097448;;16984371;;10.1111/j.1349-7006.2006.00272.x;;23307859;;10.1158/1078-0432.ccr-12-1630;;pmc3752683;;pmc3232304;;10.1002/ijc.26219;;21633954;;10.1158/1078-0432.ccr-07-5212;;18927310;;pmc2972555;;21050422;;10.1186/bcr2572;;10.1158/1078-0432.ccr-11-0184;;21586625;;21149254;;pmc3064599;;10.1093/neuonc/noq157;;20406835;;10.1158/1078-0432.ccr-10-0041;;10.1126/science.1076514;;pmc1764179;;12242449;;pmc2929689;;19451549;;10.1182/blood-2009-03-211714;;10.1126/science.1129003;;pmc2267026;;16946036;;21832238;;pmc3393096;;10.1126/scitranslmed.3002842;;pmc5413401;;10.1158/1078-0432.ccr-16-1300;;27815355;;pmc4533835;;10.1146/annurev-immunol-032713-120136;;24423116;;pmc6295668;;10.1126/science.aaa4967;;25838374;;22437939;;10.1038/nri3191;;pmc6292222;;10.1111/imr.12139;;24329794;;pmc3991306;;10.1182/blood-2014-04-567933;;24891321;;pmc4102716;;pmc2747302;;19561539;;10.1097/cji.0b013e3181ac6138;;10.1016/s0161-5890(97)00144-2;;9566763;;12393484;;10.1182/blood-2002-07-1989;;pmc1476695;;10.1089/hum.2005.16.457;;15871677;;11753365;;10.1038/nbt0102-70;;29496042;;10.1016/j.oraloncology.2018.01.024;;pmc5836804;;10.1093/neuonc/nox116;;pmc5761579;;28651374;;10.4049/jimmunol.174.10.6212;;15879118;;pmc2292990;;18256142;;10.1128/jvi.02013-07;;15879877;;10.1097/01.ju.0000158121.49085.ba;;15958592;;10.1158/0008-5472.can-04-4395;;15210797;;10.4049/jimmunol.173.1.384;;29114389;;pmc5671987;;10.1038/cti.2017.37;;18354038;;10.1182/blood-2007-11-120998;;pmc2442746;;10.1016/j.immuni.2009.09.014;;pmc2787786;;19879162;;pmc6134179;;29456158;;10.1016/j.stem.2018.01.016;;10.3389/fimmu.2017.00267;;pmc5376574;;28421069;;10.1111/imr.12132;;pmc3920180;;24329789;;10.1158/2326-6066.cir-15-0190;;26438444;;10.3389/fonc.2017.00064;;28459041;;pmc5394116;;pmc4419602;;25999859;;10.3389/fphar.2015.00095;;10.1182/blood-2014-01-551671;;24753538;;pmc4064331;;20506146;;pmc3290395;;10.1002/stem.433;;26183927;;10.1158/0008-5472.can-14-3321;;pmc5413401;;10.1158/1078-0432.ccr-16-1300;;27815355;;28123068;;10.1126/scitranslmed.aaj2013;;pmc5774207;;29122757;;10.1182/blood-2017-05-787598;;10.1016/j.ymthe.2018.02.025;;pmc5993944;;29605708;;28678778;;pmc5577644;;10.1038/nature22991;;18799724;;pmc2597140;;10.1182/blood-2008-07-169797;;pmc5264497;;27068940;;10.1042/bst20150251;;26347741;;pmc4544156;;10.3389/fimmu.2015.00418;;10.1126/science.274.5284.94;;8810254;;22498709;;10.1038/nprot.2012.037;;8254189;;10.4049/jimmunol.152.1.163;;10.1186/1476-9433-5-1;;16674822;;pmc1559620;;pmc5405381;;28228285;;10.1016/j.immuni.2017.02.007;;19948066;;pmc2790471;;10.1186/1471-2105-10-394;;10.1038/nmeth.1923;;22388286;;pmc3322381;;pmc3163565;;10.1201/b16589-5;;21816040;;10.1186/1471-2105-12-323;;2075190;;10.1093/protein/4.2.155;;23203878;;pmc3531159;;10.1093/nar/gks1226;;10.1111/tan.12413;;25154780;;26131937;;pmc4853910;;10.1038/nature14610;;10.1074/mcp.m111.016857;;22505724;;pmc3418844;;pmc2901998;;10.1038/nature09204;;20562859;;10.1186/1745-7580-6-7;;21044289;;pmc2990731;;pmc3956658;;10.1038/nri3370;;23334245;;10.1101/149518;;10.4049/jimmunol.1700893;;28978689;;pmc5679736;;pmc5405381;;28228285;;10.1016/j.immuni.2017.02.007;;10.1016/j.cels.2018.05.014;;29960884;;10.4049/jimmunol.1800914;;30429286;;10.1038/nbt.4313;;30556813;;pmc4812631;;27029192;;10.1186/s13073-016-0288-x;;10.1182/blood-2014-04-567933;;24891321;;pmc4102716;;21057081;;10.4049/jimmunol.1002629;;pmc5746078;;29296176;;10.18632/oncotarget.22487;;11119299;;10.1002/1098-2272(200101)20:1<87::aid-gepi8>3.0.co;2-r;;23806270;;10.1016/j.humimm.2013.06.025;;18638659;;10.1016/j.humimm.2008.05.001;;pmc2632948;;10.1172/jci88590;;pmc5127664;;27841757;;9722926;;10.1016/s0952-7915(98)80124-6;;10.1034/j.1399-0039.2000.550314.x;;10777106;;pmc1949492;;17726526;;10.1371/journal.pone.0000796;;10.4049/jimmunol.1300292;;23749632;;10.4049/jimmunol.165.6.3260;;10975842;;pmc5490200;;28649982;;10.1038/ncomms15924;;10.1007/s00251-018-1058-2;;pmc6061458;;29602958;;pmc6387973;;30833945;;10.3389/fimmu.2019.00141;;pmc4349985;;10.1074/mcp.m114.042812;;25576301;;27846572;;10.1126/science.aaf4384;;10.1126/sciimmunol.aar3947;;30315122;;30171158;;10.1074/mcp.ra118.000877;;pmc6283289;;30346791;;pmc6465104;;10.1021/acs.jproteome.8b00651;;10.4049/jimmunol.1700938;;28904123;;27869121;;10.1038/ncomms13404;;pmc5121339;;10.1073/pnas.1707658114;;pmc5699044;;29093164;;10.1016/s0171-2985(11)80548-6;;8530148;;10.1074/mcp.tir117.000383;;29242379;;pmc5836376;;10.1093/nar/gku1075;;10.1093/nar/gku1235;;10.1093/nar/gku1056;;25300482;;pmc4383874;;10.1093/nar/gku1003;;pmc4288154;;25352553;;pmc4384014;;10.1093/nar/gku938;;25505164;;pmc6546179;;10.1038/s41586-018-0792-9;;30568305;;pmc6211289;;29988108;;10.1038/s41596-018-0006-9;;10.1074/mcp.m500061-mcp200;;15958392;;10.21105/joss.00861;;10.1177/1087057108329453;;19196700;;26771021;;10.1016/j.cels.2015.12.004;;pmc4707969;;pmc4349985;;10.1074/mcp.m114.042812;;25576301;;7890324;;10.1007/bf00172063;;10602881;;10.1007/s002510050595,"FELIX KLUG ET AL: ""Characterization of MHC Ligands for Peptide Based Tumor Vaccination"", CURRENT PHARMACEUTICAL DESIGN, vol. 15, no. 28, 1 October 2009 (2009-10-01), pages 3221 - 3236, XP055006049, ISSN: 1381-6128, DOI: 10.2174/138161209789105180;;VANESSA JURTZ ET AL: ""NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data"", THE JOURNAL OF IMMUNOLOGY, vol. 199, no. 9, 4 October 2017 (2017-10-04), US, pages 3360 - 3368, XP055634914, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1700893;;ABELIN JENNIFER G ET AL: ""Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction"", IMMUNITY, CELL PRESS, US, vol. 46, no. 2, 24 February 2017 (2017-02-24), pages 315 - 326, XP029929858, ISSN: 1074-7613, DOI: 10.1016/J.IMMUNI.2017.02.007;;RANDI VITA ET AL: ""The immune epitope database (IEDB) 3.0"", NUCLEIC ACIDS RESEARCH, vol. 43, no. D1, 9 October 2014 (2014-10-09), pages D405 - D412, XP055645090, ISSN: 0305-1048, DOI: 10.1093/nar/gku938;;LEFRANC, M.-P. ET AL.: ""IMGT@, the international ImMunoGeneTics information system® 25 years on"", NUCLEIC ACIDS RES., vol. 43, 2015, pages D413 - 22;;ROBINSON, J. ET AL.: ""The IPD and IMGT/HLA database: allele variant databases"", NUCLEIC ACIDS RES., vol. 43, 2015, pages D423 - 31;;HUNT DFHENDERSON RASHABANOWITZ JSAKAGUCHI KMICHEL HSEVILIR NCOX ALAPPELLA EENGELHARD VH: ""Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry"", SCIENCE, vol. 255, 1992, pages 1261 - 1263, XP002970509, DOI: 10.1126/science.1546328;;RAMMENSEE HG: ""Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing"", IMMUNOGENETICS, vol. 41, 1995, pages 178 - 228;;VITA ROVERTON JAGREENBAUM JAPONOMARENKO JCLARK JDCANTRELL JRWHEELER DKGABBARD JLHIX DSETTE A: ""The immune epitope database (IEDB) 3.0"", NUCLEIC ACIDS RES., vol. 43, 2015, pages D405 - D412;;HOOF IPETERS BSIDNEY JPEDERSEN LESETTE ALUND OBUUS S: ""Nielsen M. NetMHCpan, a method for MHC class I binding prediction beyond humans"", IMMUNOGENETICS, vol. 61, 2009, pages 1 - 13, XP019705355;;LUNDEGAARD CLAMBERTH KHARNDAHL MBUUS SLUND ONIELSEN M: ""NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11"", NUCLEIC ACIDS RES., vol. 36, 2008, pages W509 - 12, XP055252573, DOI: 10.1093/nar/gkn202;;TROLLE TMETUSHI IGGREENBAUM JAKIM YSIDNEY JLUND OSETTE APETERS BNIELSEN M: ""Automated benchmarking of peptide-MHC class I binding predictions"", BIOINFORMATICS, vol. 31, 2015, pages 2174 - 2181;;PURROY N ET AL., COLD SPRING HARB PERSPECT MED, 2017;;ABELIN JGKESKIN DBSARKIZOVA SHARTIGAN CRZHANG WSIDNEY JSTEVENS JLANE WZHANG GLEISENHAURE TM: ""Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction"", IMMUNITY, vol. 46, 2017, pages 315 - 26, XP029929858, DOI: 10.1016/j.immuni.2017.02.007;;MATSUSHITA ET AL.: ""Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting"", NATURE, vol. 482, 2012, pages 400, XP055355530, DOI: 10.1038/nature10755;;SULLIVAN VJ., GEN. VIR., vol. 68, 1987, pages 2587 - 98;;MOR ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 155, no. 4, 1995, pages 2039 - 2046;;LUCKOWSUMMERS, BIO/TECHNOLOGY, vol. 6, 1988, pages 47;;MOSS, VACCINE, vol. 31, no. 39, 2013, pages 4220 - 4222;;SEMINARS IN IMMUNOLOGY, vol. 20, 2008, pages 296 - 300;;SEDEGAH ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 91, no. 21, 1994, pages 9866 - 9870;;BUCHSCHER ET AL., J. VIROL., vol. 188, no. 1, 1992, pages 1635 - 1640;;T. LINDHOUT ET AL., PNAS, vol. 108, no. 18, 2011, pages 7397 - 7402;;MEDZIHRADSZKY KFCHALKLEY RJ, MASS SPECTROM REV., vol. 34, no. l, January 2015 (2015-01-01), pages 43 - 63;;KARANIKAS ET AL.: ""High frequency of cytolytic T lymphocytes directed against a tumor- specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival"", CANCER RES., vol. 61, 2001, pages 3718 - 3724, XP055111384;;LENNERZ ET AL.: ""The response of autologous T cells to a human melanoma is dominated by mutated neoantigens"", PROC NATL ACAD SCI U S A., vol. 102, 2005, pages 16013, XP002408502, DOI: 10.1073/pnas.0500090102;;DUPAGE ET AL.: ""Expression of tumor-specific antigens underlies cancer immunoediting"", NATURE, vol. 482, 2012, pages 405;;SAMPSON ET AL.: ""Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma"", J CLIN ONCOL., vol. 28, 2010, pages 4722 - 4729, XP055111559, DOI: 10.1200/JCO.2010.28.6963;;SHAKYANANDAKUMAR: ""Antigen-Specific Tolerization and Targeted Delivery as Therapeutic Strategies for Autoimmune Diseases"", TRENDS BIOTECHNOL., vol. 36, no. 7, July 2018 (2018-07-01), pages 686 - 699;;POZSGAY ET AL.: ""Antigen-specific immunotherapies in rheumatic diseases"", NAT REV RHEUMATOL., vol. 13, no. 9, September 2017 (2017-09-01), pages 525 - 537;;WEI ET AL.: ""Development and Functional Characterization of Murine Tolerogenic Dendritic Cells"", J VIS EXP., vol. 135, 18 May 2018 (2018-05-18);;MARATEA ET AL., GENE, vol. 40, 1985, pages 39 - 46;;MURPHY ET AL., PROC. NAT'L. ACAD. SCI. USA, vol. 83, 1986, pages 8258 - 62;;G. GREGORIADIS ET AL., INT. J. PHARMACEUTICS, vol. 300, no. 1-2, pages 125 - 30;;MERRIFIELD RB: ""Solid phase peptide synthesis. I. The synthesis of a tetrapeptide"", J. AM. CHEM. SOC., vol. 85, 1963, pages 2149 - 54, XP002257754, DOI: 10.1021/ja00897a025;;YILMA TD, VACCINE, vol. 7, 1989, pages 484 - 485;;SMITHWATERMAN, ADVANCES IN APPLIED MATHEMATICS, vol. 2, 1981, pages 482 - 489;;ZOELLER ET AL., PROC. NAT'L. ACAD. SCI. USA, vol. 81, 1984, pages 5662 - 5066;;BULLER, RM NATURE, vol. 317, no. 6040, 1985, pages 813 - 5;;GLUZMAN, CELL, vol. 23, 1981, pages 175;;LEITNER ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 159, no. 12, 1997, pages 1945 - 1952;;ALARCON ET AL., ADV. PARASITOL. ADVANCES IN PARASITOLOGY, vol. 42, 1999, pages 343 - 410;;ROBINSON ET AL., ADV. VIRUS RES. ADVANCES IN VIRUS RESEARCH, vol. 55, 2000, pages 1 - 74;;BOHMET, JOURNAL OF IMMUNOLOGICAL METHODS, vol. 193, no. 1, 1996, pages 29 - 40;;WEINER ET AL., SCIENTIFIC AMERICAN, vol. 281, no. 1, 1999, pages 129 - 41;;SHAREI ET AL.: ""Ex Vivo Cytosolic Delivery of Functional Macromolecules to Immune Cells"", PLOS ONE, 13 April 2015 (2015-04-13);;CHEN ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 160, no. 5, 1998, pages 2425 - 2432;;SIZEMORE, SCIENCE, vol. 270, no. 5234, 1995, pages 299 - 302;;FYNAN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, no. 24, 1993, pages 11478 - 82;;BADEN ET AL.: ""First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001"", J INFECT DIS., vol. 207, no. 2, 15 January 2013 (2013-01-15), pages 240 - 7, XP055190590, DOI: 10.1093/infdis/jis670;;SOMMNERFELT ET AL., VIROL., vol. 176, 1990, pages 58 - 59;;WILSON ET AL., J. VIROL., vol. 63, 1998, pages 2374 - 2378;;MILLER ET AL., J. VIROL., vol. 65, 1991, pages 2220 - 2224;;BALAGAAN: ""J Gene Med"", vol. 8, 21 November 2005, WILEY INTERSCIENCE, pages: 275 - 285;;CHROBOCZEK, J.BIEBER, F.JACROT, B.: ""The Sequence of the Genome of Adenovirus Type 5 and Its Comparison with the Genome of Adenovirus Type 2"", VIROLOGY, vol. 186, 1992, pages 280 - 285, XP023049327, DOI: 10.1016/0042-6822(92)90082-Z;;VERARDIET, HUM VACCIN IMMUNOTHER., vol. 8, no. 7, July 2012 (2012-07-01), pages 961 - 70;;PANICALI, D., PROC. NATL. ACAD. SCI., vol. 79, 1982, pages 7415 - 7419;;PANICALI D., PROC. NATL. ACAD. SCI., vol. 80, no. 23, 1983, pages 7155 - 9;;SMITH GL., NATURE, vol. 302, 1983, pages 490 - 5;;PERKUS M, JOURNAL OF LEUKOCYTE BIOLOGY, vol. 58, 1995, pages 1 - 13;;BROCHIER B., NATURE, vol. 354, 1991, pages 520 - 22;;WIKTOR, TJ., PROC. NATL ACD. SCI., vol. 81, 1984, pages 7194 - 8;;RUPPRECHT, CE, PROC. NATL ACD. SCI., vol. 83, 1986, pages 7947 - 50;;POULET, H, VACCINE, 25 July 2007 (2007-07-25), pages 5606 - 12;;WEYER J., VACCINE, 27 November 2009 (2009-11-27), pages 7198 - 201;;BULLER RM., J. VIROL., vol. 62, no. 12, 1988, pages 4474 - 80;;FLEXNER, C., NATURE, vol. 330, no. 6145, 1987, pages 259 - 62;;KOTWAL, GJ., J. VIROL., vol. 63, no. 2, 1989, pages 600 - 6;;CHILD, SJ., VIROLOGY, vol. 174, no. 2, 1990, pages 625 - 9;;MAYR A., ZENTRALBL BAKTERIOL, vol. 167, no. 5,6, 1978, pages 375 - 9;;WYATT, LS., VIROLOGY, vol. 251, no. 2, 1998, pages 334 - 42;;SANCHO, MC, J. VIROL., vol. 76, no. 16, 2002, pages 8313 - 34;;GALLEGO-GOMEZ, JC., J. VIROL., vol. 77, no. 19, 2003, pages 10606 - 57;;GOEBEL S, J. VIROLOGY, vol. 179, 1990, pages 247 - 66;;NAJERA, JL., J. VIROL., vol. 80, no. 12, 2006, pages 6033 - 6047;;GOMEZ, CE., J. GEN. VIROL., vol. 88, 2007, pages 2473 - 78;;MOOIJ, P., JOUR. OF VIROL., vol. 82, 2008, pages 2975 - 2988;;GOMEZ, CE., CURR. GENE THER., vol. 11, 2011, pages 189 - 217;;COX,W., VIROLOGY, vol. 195, 1993, pages 845 - 50;;PERKUS, M., JOUR. OF LEUKOCYTE BIOLOGY, vol. 58, 1995, pages 1 - 13;;BLANCHARD TJ., J GEN VIROLOGY, vol. 79, no. 5, 1998, pages 1159 - 67;;AMARA R., SCIENCE, vol. 292, 2001, pages 69 - 74;;HEL, Z., J. IMMUNOL., vol. 167, 2001, pages 7180 - 9;;DIDIERLAURENT, A., VACCINE, vol. 22, 2004, pages 3395 - 3403;;BISSHT H., PROC. NAT. ACA. SCI., vol. 101, 2004, pages 6641 - 46;;MCCURDY LH., CLIN. INF. DIS, vol. 38, 2004, pages 1749 - 53;;EARL PL, NATURE, vol. 428, 2004, pages 182 - 85;;CHEN Z., J. VIROL., vol. 79, 2005, pages 2678 - 2688;;NAM JH, ACTA. VIROL., vol. 51, 2007, pages 125 - 30;;ANTONIS AF, VACCINE, vol. 25, 2007, pages 2863 - 4827;;B WEYER, J. VACCINE, vol. 25, 2007, pages 4213 - 22;;FERRIER-REMBERT A, VACCINE, vol. 26, no. 14, 2008, pages 1794 - 804;;CORBETT, M., PROC. NATL. ACAD. SCI., vol. 105, no. 6, 2008, pages 2046 - 2051;;KAUFMAN HL., J. CLIN. ONCOL., vol. 22, 2004, pages 2122 - 32;;AMATO, RJ., CLIN. CANCER RES., vol. 14, no. 22, 2008, pages 7504 - 10;;DREICER R., INVEST NEW DRUGS, vol. 27, no. 4, 2009, pages 379 - 86;;KANTOFFPW., J. CLIN. ONCOL., vol. 28, 2010, pages 1099 - 1 105;;AMATO RJ., J. CLIN. CAN. RES., vol. 16, no. 22, 2010, pages 5539 - 47;;KIM, DW., HUM. VACCINE, vol. 6, 2010, pages 784 - 791;;OUDARD, S., CANCER IMMUNOL. IMMUNOTHER, vol. 60, 2011, pages 261 - 71;;WYATT, LS., AIDS RES. HUM. RETROVIRUSES, vol. 20, 2004, pages 645 - 53;;GOMEZ, CE., VIRUS RESEARCH, vol. 105, 2004, pages 11 - 22;;WEBSTER, DP, PROC. NATL. ACAD. SCI., vol. 102, 2005, pages 4836 - 4;;ESTEBAN M, HUM. VACCINE, vol. 5, 2009, pages 867 - 871;;GOMEZ, CE, CURR. GENE THERAPY, vol. 8, no. 2, 2008, pages 97 - 120;;WHELAN, KT, PLOS ONE, vol. 4, no. 6, 2009, pages 5934;;SCRIBA, TJ, EUR. JOUR. IMMUNO., vol. 40, no. 1, 2010, pages 279 - 90;;MIDGLEY, CM, J. GEN. VIROL., vol. 89, 2008, pages 2992 - 97;;VON KREMPELHUBER, A, VACCINE, vol. 28, 2010, pages 1209 - 16;;PERREAU, M, J. OF VIROL., October 2011 (2011-10-01), pages 9854 - 62;;PANTALEO, G., CURR OPIN HIV-AIDS, vol. 5, 2010, pages 391 - 396;;ROLPH ET AL.: ""Recombinant viruses as vaccines and immunological tools"", CURR OPIN IMMUNOL, vol. 9, 1997, pages 517 - 524, XP004313548, DOI: 10.1016/S0952-7915(97)80104-5;;HORIG HLEE DSCONKRIGHT W ET AL.: ""Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule"", CANCER IMMUNOL IMMUNOTHER, vol. 49, 2000, pages 504 - 14, XP002194114, DOI: 10.1007/s002620000146;;VON MEHREN MARLEN PTSANG KY ET AL.: ""Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas"", CLIN CANCER RES, vol. 6, 2000, pages 2219 - 28, XP002327290;;MUSEY LDING YELIZAGA M ET AL.: ""HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1 -uninfected individuals"", J IMMUNOL, vol. 171, 2003, pages 1094 - 101;;PAOLETTI E: ""Applications of pox virus vectors to vaccination: an update"", PROC NATL ACAD SCI U S A, vol. 93, 1996, pages 11349 - 53, XP002135943, DOI: 10.1073/pnas.93.21.11349;;MARSHALL JLHAWKINS MJTSANG KY ET AL.: ""Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen"", J CLIN ONCOL, vol. 17, 1999, pages 332 - 7, XP001084702;;MAYR, A. ET AL., INFECTION, vol. 3, 1975, pages 6 - 14;;MEYER, H. ET AL., J. GEN. VIROL., vol. 72, 1991, pages 1031 - 1038;;MANDL ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 61, no. 1, January 2012 (2012-01-01), pages 19 - 29;;SPEISERROMERO, MOLECULARLY DEFINED VACCINES FOR CANCER IMMUNOTHERAPY, AND PROTECTIVE T CELL IMMUNITY SEMINARS IN IMMUNOL, vol. 22, 2010, pages 144;;BHARDWAJGNJATIC: ""TLR AGONISTS: Are They Good Adjuvants?"", CANCER J., vol. 16, 2010, pages 382 - 391;;CASKEY ET AL.: ""Synthetic double- stranded RNA induces innate immune responses similar to a live viral vaccine in humans"", J EXP MED, vol. 208, 2011, pages 2357;;AUCOUTURIER ET AL., VACCINE, vol. 19, 2001, pages 2666 - 2672;;KIDERA, A.KONISHI, Y.OKA, M.OOI, T.SCHERAGA, H. A.: ""Statistical analysis of the physical properties of the 20 naturally occurring amino acids"", J. PROTEIN CHEM., vol. 4, 1985, pages 1418 - 55;;SCHNEIDER ET AL.: ""Induction of CD8+ T cells using heterologous prime-boost immunisation strategies"", IMMUNOLOGICAL REVIEWS, vol. 170, no. 1, August 1999 (1999-08-01), pages 29 - 38, XP000981910, DOI: 10.1111/j.1600-065X.1999.tb01326.x;;HUTCHINGS ET AL.: ""Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge"", INFECT IMMUN., vol. 75, no. 12, December 2007 (2007-12-01), pages 5819 - 26;;CONLON ET AL.: ""Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid"", JOURNAL OF IMMUNOLOGY, vol. 190, 2013, pages 5216 - 25, XP055367377, DOI: 10.4049/jimmunol.1300097;;KIM ET AL., ANTICANCER FLAVONOIDS ARE MOUSE-SELECTIVE STING AGONISTS, vol. 8, 2013, pages 1396 - 1401;;NISHIMURA ET AL.: ""Distinct role of antigen-specific T helper type 1 (TH1) and Th2 cells in tumor eradication in vivo"", J EX MED, vol. 190, 1999, pages 617 - 27;;AGATHANGGELOU ET AL., AM.J.PATHOL., vol. 147, 1995, pages 1152 - 1160;;DUDLEY ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 10, 2005, pages 2346 - 57;;HALABI ET AL., J CLIN ONCOL, vol. 21, 2003, pages 1232 - 1237;;BRUNSVIG P F ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 55, no. 12, 2006, pages 1553 - 1564;;M. STAEHLER ET AL., ASCO MEETING 2007;;DUPUIS M ET AL., CELL IMMUNOL., vol. 186, no. 1, 1998, pages 18 - 27;;ALLISON A C, DEV BIOL STAND., vol. 92, 1998, pages 3 - 11;;GABRILOVICH D I ET AL., J IMMUNOTHER EMPHASI S TUMOR IMMUNOL ., vol. 6, 1996, pages 414 - 418;;PLOS PATHOGENS, vol. 5, no. 4, April 2009 (2009-04-01);;ARTHUR M., KRIEG, NATURE REVIEWS, DRUG DISCOVERY, 5 June 2006 (2006-06-05), pages 471 - 484;;KOBAYASHI ET AL., CURRENT OPINION IN IMMUNOLOGY, vol. 20, 2008, pages 221 - 27;;SLINGLUFF ET AL.: ""Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting"", CLINICAL CANCER RESEARCH, vol. 13, no. 21, 2007, pages 6386 - 95, XP009144705, DOI: 10.1158/1078-0432.CCR-07-0486;;KREITER ET AL.: ""Mutant MHC Class II epitopes drive therapeutic immune responses to cancer"", NATURE, 2015;;CARRENO ET AL.: ""L-12p70-producing patient DC vaccine elicits Tel -polarized immunity"", JOURNAL OF CLINICAL INVESTIGATION, vol. 123, no. 8, 2013, pages 33 83 - 94;;ALI ET AL.: ""situ regulation of DC subsets and T cells mediates tumor regression in mice"", CANCER IMMUNOTHERAPY, vol. 1, no. 8, 2009, pages 1 - 10, XP009165920, DOI: 10.1126/scitranslmed.3000359;;SABADO ET AL.: ""Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy"", J. VIS EXP., vol. 1, August 2013 (2013-08-01), pages 78;;ALI ET AL.: ""situ regulation of DC subsets and T cells mediates tumor regression in mice"", CANCER IMMUNOTHERAPY, vol. 1, no. 8, pages 1 - 10;;ALI ET AL.: ""Infection-mimicking materials to program dendritic cells in situ"", NAT MATER, vol. 8, 2009, pages 151 - 8;;SHAREI ET AL., PLOS ONE, 2015;;MURPHY ET AL., THE PROSTATE, vol. 29, 1996, pages 371 - 380;;TJUA ET AL., THE PROSTATE, vol. 32, 1997, pages 272 - 278;;CROZAT ET AL., J. EXP. MED., vol. 207, 2010, pages 1283 - 1292;;GALLOISBHARDWAJ, NATURE MED., vol. 16, 2010, pages 854 - 856;;WOLFF ET AL., SCIENCE, vol. 247, 1990, pages 1465 - 1468;;MANNINOGOULD-FOGERITE, BIOTECHNIQUES, vol. 6, no. 7, 1988, pages 682 - 691;;FEIGNER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413 - 7414;;PETSCH ET AL., NATURE BIOTECHNOLOGY, vol. 30, no. 12, 7 December 2012 (2012-12-07), pages 1210 - 6;;SAMBROOK: ""Molecular Cloning: A Laboratory Manual"", 1989;;GAIT, OLIGONUCLEOTIDE SYNTHESIS, 1984;;FRESHNEY, ANIMAL CELL CULTURE, 1987;;WEI: ""Handbook of Experimental Immunology"", 1996, article ""Methods in Enzymology"";;MILLERCALOS, GENE TRANSFER VECTORS FOR MAMMALIAN CELLS, 1987;;AUSUBEL, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 1987;;MULLIS, PCR: THE POLYMERASE CHAIN REACTION, 1994;;COLIGAN, CURRENT PROTOCOLS IN IMMUNOLOGY, 1991;;NOCENTINI ET AL., PROC NATL ACAD SCI USA, vol. 94, 1997, pages 6216 - 6221;;RONCHETTI ET AL., EUR J IMMUNOL, vol. 34, 2004, pages 613 - 622;;AVOGADRI ET AL., CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 344, 2011;;PAGE, ANNUAL REVIEW OF MEDICINE, vol. 65, 2014, pages 27;;ZITVOGEL ET AL.: ""Immunological aspects of cancer chemotherapy"", NAT REV IMMUNOL., vol. 8, no. l, January 2008 (2008-01-01), pages 59 - 73, XP055008389, DOI: 10.1038/nri2216;;PEREZ ET AL.: ""A new era in anticancer peptide vaccines"", CANCER, May 2010 (2010-05-01);;WALTER ET AL.: ""Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival"", NATURE MEDICINE, vol. 18, 2012, pages 8;;GHIRINGHELLI ET AL.: ""Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients"", CANCER IMMUNOL IMMUNOTHER, vol. 56, 2007, pages 641 - 648, XP019489789;;ZITVOGEL ET AL., NAT. REV. IMMUNOL., vol. 8, no. 1, 2008, pages 59 - 73;;ITOH ET AL.: ""Personalized peptide vaccines: A new therapeutic modality for cancer"", CANCER SCI, vol. 97, 2006, pages 970 - 976, XP002538826, DOI: 10.1111/j.1349-7006.2006.00272.x;;FREDERICK ET AL.: ""BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma"", CLIN CANCER RES., vol. 19, 2013, pages 1225 - 1231, XP055568357, DOI: 10.1158/1078-0432.CCR-12-1630;;FARSACI ET AL.: ""Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy"", INT J CANCER, vol. 130, pages 1948 - 1959;;FINKE ET AL.: ""Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients"", CLIN CANCER RES, vol. 14, no. 20, 2008;;ALVAREZ: ""Present and future evolution of advanced breast cancer therapy"", BREAST CANCER RESEARCH, vol. 12, no. 2, 2010, pages S 1;;KYTE ET AL.: ""Tel om erase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients"", CLIN CANCER RES, vol. 17, no. 13, pages 2011;;SAMPSON ET AL.: ""Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma"", NEURO-ONCOLOGY, vol. 13, no. 3, 2011, pages 324 - 333;;METTANANDA ET AL.: ""Editing an a-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia"", NAT COMMUN., vol. 8, no. 1, 4 September 2017 (2017-09-04), pages 424;;BESSER ET AL., CLIN. CANCER RES, vol. 16, no. 9, 2010, pages 2646 - 55;;DUDLEY ET AL., SCIENCE, vol. 298, no. 5594, 2002, pages 850 - 4;;JOHNSON ET AL., BLOOD, vol. 114, no. 3, 2009, pages 535 - 46;;MORGAN ET AL., SCIENCE, vol. 314, no. 5796, 2006, pages 126 - 9;;KALOS ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 3, no. 95, 2011, pages 95ra73;;REN ET AL., CLIN CANCER RES, vol. 23, no. 9, 2017, pages 2255 - 2266;;MAUS ET AL., ADOPTIVE IMMUNOTHERAPY FOR CANCER OR VIRUSES, ANNUAL REVIEW OF IMMUNOLOGY, vol. 32, 2014, pages 189 - 225;;ROSENBERGRESTIFO: ""Adoptive cell transfer as personalized immunotherapy for human cancer"", SCIENCE, vol. 348, no. 6230, 2015, pages 62 - 68, XP055256712, DOI: 10.1126/science.aaa4967;;RESTIFO ET AL.: ""Adoptive immunotherapy for cancer: harnessing the T cell response"", NAT. REV. IMMUNOL., vol. 12, no. 4, 2015, pages 269 - 281, XP055034896, DOI: 10.1038/nri3191;;JENSONRIDDELL: ""Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells"", IMMUNOL REV., vol. 257, no. 1, 2014, pages 127 - 144;;RAJASAGI ET AL.: ""Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia"", BLOOD, vol. 124, no. 3, 17 July 2014 (2014-07-17), pages 453 - 62, XP055322841, DOI: 10.1182/blood-2014-04-567933;;FRIEDMAN ET AL.: ""Effective Targeting of Multiple BCMA-Expressing Hematological Malignancies by Anti-BCMA CAR T Cells"", HUM GENE THER., 8 March 2018 (2018-03-08);;BERDEJA JG ET AL.: ""Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-Bcma CAR T cell therapy"", BLOOD, vol. 130, 2017, pages 740;;MOUHIEDDINEGHOBRIAL, IMMUNOTHERAPY IN MULTIPLE MYELOMA: THE ERA OF CAR T CELL THERAPY, HEMATOLOGIST, vol. 15, no. 3, May 2018 (2018-05-01);;""Genbank"", Database accession no. NM 006139;;KOCHENDERFER ET AL., J IMMUNOTHER., vol. 32, no. 7, 2009, pages 689 - 702;;NICHOLSON ET AL., MOLECULAR IMMUNOLOGY, vol. 34, 1997, pages 1157 - 1165;;COOPER ET AL., BLOOD, vol. 101, 2003, pages 1637 - 1644;;HUGHES ET AL., HUMAN GENE THERAPY, vol. 16, 2005, pages 457 - 472;;MAHER ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 70 - 75;;PARK ET AL.: ""CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma"", ORAL ONCOL., vol. 78, March 2018 (2018-03-01), pages 145 - 150, XP085353974, DOI: 10.1016/j.oraloncology.2018.01.024;;JIN ET AL.: ""CD70, a novel target of CAR T-cell therapy for gliomas"", NEURO ONCOL., vol. 20, no. 1, 10 January 2018 (2018-01-10), pages 55 - 65, XP055464384, DOI: 10.1093/neuonc/nox116;;HUNTER ET AL., BLOOD, vol. 104, no. 4881, 2004, pages 26;;LENS ET AL., J IMMUNOL., vol. 174, 2005, pages 6212 - 6219;;BABA ET AL., J VIROL., vol. 82, 2008, pages 3843 - 3852;;JUNKER ET AL., J UROL., vol. 173, 2005, pages 2150 - 2153;;CHAHLAVI ET AL., CANCER RES, vol. 65, 2005, pages 5428 - 5438;;VON ESSEN, M. ET AL., J. IMMUNOL., vol. 173, 2004, pages 384 - 393;;YUNG ET AL., SCIENCE, 2015;;BUDDEE ET AL., PLOS ONE, 2013;;LI ET AL.: ""Adoptive cell therapy with CD4+ T helper 1 cells and CD8+ cytotoxic T cells enhances complete rejection of an established tumour, leading to generation of endogenous memory responses to non-targeted tumour epitopes"", CLIN TRANSL IMMUNOLOGY, vol. 6, no. 10, October 2017 (2017-10-01), pages el60;;MURANSKI P ET AL.: ""Tumor-specific Thl7-polarized cells eradicate large established melanoma"", BLOOD, vol. 112, no. 2, 15 July 2008 (2008-07-15), pages 362 - 73, XP055503075, DOI: 10.1182/blood-2007-11-120998;;MARTIN-OROZCO N ET AL.: ""T helper 17 cells promote cytotoxic T cell activation in tumor immunity"", IMMUNITY, vol. 31, no. 5, 20 November 2009 (2009-11-20), pages 787 - 98;;KOOREMANNIGEL G ET AL.: ""Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses"", VIVO, CELL STEM CELL, vol. 22, 2018, pages 1 - 13;;IRVING ET AL.: ""Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel"", FRONT. IMMUNOL., 3 April 2017 (2017-04-03);;HINRICHS CS: ""Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer"", IMMUNOL REV, vol. 257, no. 1, 2014, pages 56 - 71, XP055249662, DOI: 10.1111/imr.12132;;HOUOT ET AL.: ""T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition"", CANCER IMMUNOL RES, vol. 3, no. 10, 2015, pages 1115 - 22, XP055437818, DOI: 10.1158/2326-6066.CIR-15-0190;;KAMTA ET AL.: ""dvancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches"", FRONT. ONCOL., vol. 7, 2017, pages 64;;GRECO ET AL.: ""Improving the safety of cell therapy with the TK-suicide gene"", FRONT. PHARMACOL., vol. 6, 2015, pages 95;;ZHOU ET AL., BLOOD, vol. 123/25, 2014, pages 3895 - 3905;;DI STASI ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 365, 2011, pages 1735 - 1683;;RAMOS ET AL., STEM CELLS, vol. 28, no. 6, 2010, pages 1107 - 15;;POIROT ET AL.: ""Multiplex genome edited T-cell manufacturing platform for ''off-the-shelf'' adoptive T-cell immunotherapies"", CANCER RES, vol. 75, no. 18, 2015, pages 3853, XP055568648, DOI: 10.1158/0008-5472.CAN-14-3321;;REN ET AL.: ""Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition"", CLIN CANCER RES., vol. 23, no. 9, 1 May 2017 (2017-05-01), pages 2255 - 2266, XP055565027, DOI: 10.1158/1078-0432.CCR-16-1300;;QASIM ET AL.: ""Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells"", SCI TRANSL MED., vol. 9, no. 374, 25 January 2017 (2017-01-25), XP055498786, DOI: 10.1126/scitranslmed.aaj2013;;LEGUT ET AL.: ""CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells"", BLOOD, vol. 131, no. 3, 2018, pages 311 - 322, XP055536727, DOI: 10.1182/blood-2017-05-787598;;GEORGIADIS ET AL.: ""Long Terminal Repeat CRISPR-CAR-Coupled ''Universal'' T Cells Mediate Potent Anti-leukemic Effects, Molecular Therapy"", PRESS, CORRECTED PROOF, AVAILABLE ONLINE, 6 March 2018 (2018-03-06);;OTT, P. A. ET AL.: ""An immunogenic personal neoantigen vaccine for patients with melanoma"", NATURE, vol. 547, 2017, pages 217 - 221;;BONI, MURANSKI ET AL., BLOOD, vol. 112, no. 12, 2008, pages 4746 - 54;;WATSON HA ET AL.: ""SHP-1: the next checkpoint target for cancer immunotherapy?"", BIOCHEM SOC TRANS., vol. 44, no. 2, 15 April 2016 (2016-04-15), pages 356 - 62, XP055469547, DOI: 10.1042/BST20150251;;LE MERCIER I ET AL.: ""Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators"", FRONT. IMMUNOL., vol. 6, 2015, pages 418;;ALTMAN ET AL., SCIENCE, vol. 274, no. 5284, 4 October 1996 (1996-10-04), pages 94 - 6;;ANDERSEN ET AL., NAT PROTOC., vol. 7, 2012, pages 891 - 902;;PARKER ET AL., J. IMMUNOL., vol. 152, 1994, pages 163;;RECHE PAKESKIN DBHUSSEY REANCUTA PGABUZDA DREINHERZ EL: ""Elicitation from virus-naive individuals of cytotoxic T lymphocytes directed against conserved HIV-1 epitopes"", MED IMMUNOL., vol. 5, 2006, pages 1, XP021018435, DOI: 10.1186/1476-9433-5-1;;ABELIN ET AL.: ""Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction"", IMMUNITY, vol. 46, no. 2, 21 February 2017 (2017-02-21), pages 315 - 326, XP029929858, DOI: 10.1016/j.immuni.2017.02.007;;KIM, Y.SIDNEY, J.PINILLA, C.SETTE, A.PETERS, B.: ""Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior"", BMC BIOINFORMATICS, vol. 10, 2009, pages 394, XP021061918, DOI: 10.1186/1471-2105-10-394;;SIDNEY JSOUTHWOOD SOSEROFF CDEL GUERCIO MFSETTE AGREY HM: ""Measurement of MHC/peptide interactions by gel filtration"", CURR PROTOC IMMUNOL CHAPTER, vol. 18, 2001, pages 3;;LANGMEAD BSALZBERG SL: ""Fast gapped-read alignment with Bowtie 2"", NAT METHODS., vol. 9, 2012, pages 357 - 359, XP002715401, DOI: 10.1038/nmeth.1923;;LI BDEWEY CN: ""RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome"", BMC BIOINFORMATICS, vol. 12, 2011, pages 323, XP021104619, DOI: 10.1186/1471-2105-12-323;;GURUPRASAD KREDDY BVBPANDIT MW: ""Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence"", PROTEIN ENG., vol. 4, 1990, pages 155 - 161;;OATES MEROMERO PISHIDA TGHALWASH MMIZIANTY MJXUE BDOSZTANYI ZUVERSKY VNOBRADOVIC ZKURGAN L ET AL.: ""D2P2: Database of disordered protein predictions"", NUCLEIC ACIDS RES., vol. 41, 2013, pages D508 - D516;;EICHMANN MDE RU AVAN VEELEN PAPEAKMAN MKRONENBERG-VERSTEEG D: ""Identification and characterisation of peptide binding motifs of six autoimmune disease-associated human leukocyte antigen-class I molecules including HLA-B*39:06"", TISSUE ANTIGENS, vol. 84, 2014, pages 378 - 388;;KRONKE JFINK ECHOLLENBACH PWMACBETH KJHURST SNUDESHI NDCHAMBERLAIN PPMANI DRMAN HWGANDHI AK ET AL.: ""Lenalidomide induces ubiquitination and degradation of CKla in del(5q) MDS"", NATURE, vol. 523, 2015, pages 183 - 188, XP055336278, DOI: 10.1038/nature14610;;UDESHI NDMANI DREISENHAURE TMERTINS PJAFFE JDCLAUSER KRHACOHEN N: ""Carr SA. Methods for quantification of in vivo changes in protein ubiquitination following proteasome and deubiquitinase inhibition"", MOL CELL PROTEOMICS, vol. 11, 2012, pages 148 - 159;;BEHRENDS CSOWA MEGYGI SPHARPER JW: ""Network organization of the human autophagy system"", NATURE, vol. 466, 2010, pages 68 - 76;;BREMEL, R. D.HOMAN, E. J.: ""An integrated approach to epitope analysis I: Dimensional reduction, visualization and prediction of MHC binding using amino acid principal components and regression approaches"", IMMUNOME RES., vol. 6, 2010, pages 7, XP021080935, DOI: 10.1186/1745-7580-6-7;;OSORIO DRONDON-VILLARREAL PTORRES R: ""Peptides: Calculate indices and theoretical physicochemical properties of peptides and protein sequences"", CRAN.R-PROJECT.ORG/PACKAGE=PEPTIDES. R PACKAGE VERSION 1.1.0, 2014;;PARHAM, P.MOFFETT, A.: ""Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution"", NAT. REV. IMMUNOL., vol. 13, 2013, pages 133 - 144;;JURTZ, V. ET AL.: ""NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data"", THE JOURNAL OF IMMUNOLOGY, vol. 199, 2017, pages 3360 - 3368, XP055634914, DOI: 10.4049/jimmunol.1700893;;ABELIN, J. G. ET AL.: ""Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction"", IMMUNITY, vol. 46, 2017, pages 315 - 326, XP029929858, DOI: 10.1016/j.immuni.2017.02.007;;O'DONNELL, T. J. ET AL.: ""MHCflurry: Open-Source Class I MHC Binding Affinity Prediction"", CELL SYST, vol. 7, 2018, pages 129 - 132;;GFELLER, D. ET AL.: ""The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands"", J. IMMUNOL., vol. 201, 2018, pages 3705 - 3716;;BULIK-SULLIVAN, B. ET AL.: ""Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification"", NAT. BIOTECHNOL., 2018;;NIELSEN, M.ANDREATTA, M.: ""NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets"", GENOME MED., vol. 8, 2016, pages 33, XP055571478, DOI: 10.1186/s13073-016-0288-x;;RAJASAGI, M. ET AL.: ""Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia"", BLOOD, vol. 124, 2014, pages 453 - 462, XP055322841, DOI: 10.1182/blood-2014-04-567933;;DE KRUIJF, E. M. ET AL.: ""HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients"", J. IMMUNOL., vol. 185, 2010, pages 7452 - 7459;;ZHANG, R.-L. ET AL.: ""Predictive value of different proportion of lesion HLA-G expression in colorectal cancer"", ONCOTARGET, vol. 8, 2017, pages 107441 - 107451;;DAWSON, D. V.OZGUR, M.SARI, K.GHANAYEM, M.KOSTYU, D. D.: ""Ramifications of HLA class I polymorphism and population genetics for vaccine development"", GENET. EPIDEMIOL., vol. 20, 2001, pages 87 - 106;;GRAGERT, L.MADBOULY, A.FREEMAN, J.MAIERS, M.: ""Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry"", HUM. IMMUNOL., vol. 74, 2013, pages 1313 - 1320;;SOLBERG, O. D. ET AL.: ""Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies"", HUM. IMMUNOL., vol. 69, 2008, pages 443 - 464, XP022930390, DOI: 10.1016/j.humimm.2008.05.001;;PEARSON, H. ET AL.: ""MHC class I-associated peptides derive from selective regions of the human genome"", J. CLIN. INVEST., vol. 126, 2016, pages 4690 - 4701;;SETTE, A.SIDNEY, J.: ""HLA supertypes and supermotifs: a functional perspective on HLA polymorphism"", CURR. OPIN. IMMUNOL., vol. 10, 1998, pages 478 - 482, XP004327132, DOI: 10.1016/S0952-7915(98)80124-6 et al.",PENDING
278,US,B2,US 7404837 B2,174-578-375-707-311,2008-07-29,2008,US 85505104 A,2004-05-27,US 85505104 A;;US 47353103 P,2003-05-27,Mountain cloudwater,"A method and apparatus for completing a natural solar distillation cycle (comprised of maritime trade winds being elevated over mountain formations to form orographic clouds) includes enabling the low cost harvesting of freshwater during time periods when weather conditions permit, despite the absence of rain. The cloud-catching wind management structures preferably incorporate minimal pressure drop gas cyclones to centrifuge condensate particles out of the air stream, and jet pump-like flow guide structures to help overcome pressure drop, for efficient, energy-passive production of freshwater utilizing only the stagnation pressure of natural wind velocity. The permanence (design and anchoring against natural disasters) of the structures provides for incorporation of water treatment means, and connection with permanent collection reservoirs and distribution systems, for large volume supply of potable freshwater for public and industrial use.",KILLION DAVID L;;CARR JAMES E;;KILLION JESSE D;;KILLION JOAN A;;BRUNO STEVEN L,KILLION DAVID L;;CARR JAMES E;;KILLION JESSE D;;KILLION JOAN A;;BRUNO STEVEN L,,https://lens.org/174-578-375-707-311,Granted Patent,yes,1,8,4,4,0,E03B3/28;;E03B3/28,B01D47/00;;E01H13/00;;E03B3/28,55/421;;55/423;;55/466;;55/468;;55/495,4,0,,,"Mukerji, Sitoo, et al., Fogwater Collection System, International Development Research Centre, Canada website, 1997, Ottawa, Canada.;;U.S. Department of the Interior, Standard Fog Collector, U.S: Geological Survey website, Reston, Virginia, Apr. 23, 2002.;;U.S. Department of the Interior, ""Harp"" type Fog Collector, U.S. Geological Survey website, Reston, Virginia, Nov. 13, 2001.;;Patrick Wilson, News Release, University of East London website, May 27, 2002.",INACTIVE
279,WO,A2,WO 2005/118961 A2,017-640-181-131-053,2005-12-15,2005,US 2005/0018764 W,2005-05-27,US 85505104 A,2004-05-27,MOUNTAIN CLOUDWATER,"A method and apparatus for completing a natural solar distillation cycle (comprised of maritime trade winds being elevated over mountain formations to form orographic clouds) includes enabling the low cost harvesting of freshwater during time periods when weather conditions permit, despite the absence of rain. The cloud-catching wind management structures preferably incorporate minimal pressure drop gas cyclones to centrifuge condensate particles out of the air stream, and jet pump-like flow guide structures to help overcome pressure drop, for efficient, energy-passive production of freshwater utilizing only the stagnation pressure of natural wind velocity. The permanence (design and anchoring against natural disasters) of the structures provides for incorporation of water treatment means, and connection with permanent collection reservoirs and distribution systems, for large volume supply of potage freshwater for pub is and industrial use.",KILLION DAVID L;;CARR JAMES E;;KILLION JESSE D;;KILLION JOAN A;;BRUNO STEVEN L,KILLION DAVID L;;CARR JAMES E;;KILLION JESSE D;;KILLION JOAN A;;BRUNO STEVEN L,,https://lens.org/017-640-181-131-053,Patent Application,yes,0,3,4,4,0,E03B3/28;;E03B3/28,E01H13/00;;E03B3/28,,0,0,,,,PENDING
280,CA,C,CA 2754773 C,144-548-406-115-592,2017-06-13,2017,CA 2754773 A,2010-03-09,US 15857409 P;;US 2010/0026698 W,2009-03-09,SURGICAL FLUID MANAGEMENT SYSTEM HAVING DEFAULT OPERATING PARAMETERS ASSOCIATED WITH A PLURALITY OF MEDICAL PROCEDURES,"A fluid management system comprising: a pump to deliver a fluid from a fluid supply container to a surgical site or a patient; and a control system for operating the fluid management system according to operating parameters with a user interface to select one of a plurality of medical procedures. The control system has default operating parameters associated with each of the medical procedures, the default operating parameters associated with selection of a first medical procedure include: (a) a target pressure, and (b) a pressure control mode, wherein said control system controls the pump to deliver fluid to the site at approximately the target pressure, and wherein the default operating parameters associated with selection of a second medical procedure include: (a) a target flow rate, and (b) a flow control mode, wherein said control system controls the pump to deliver fluid to the site at approximately the target flow rate.",THERMEDX LLC,WILLIAMS JEFFREY B;;PYLES KENNETH R;;CARR DOUGLAS L;;TORER STEVEN J;;DONATH EDWARD R,,https://lens.org/144-548-406-115-592,Granted Patent,no,0,0,17,27,0,A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M3/022;;A61M2205/502;;A61M1/777;;A61M3/0245;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M1/72;;G01G17/04;;G01G19/414;;A61M5/36;;A61M5/44;;A61M2205/123;;A61M2205/127;;A61M2205/368;;A61M2205/505;;A61M3/0258;;A61M2205/3331;;A61M2205/3334;;A61M2205/3344;;A61M3/0208;;A61M3/0216;;A61M2205/502;;A61M3/022;;A61M1/777;;A61M3/0201;;A61M1/77;;A61M3/0202;;A61M3/0245;;A61M5/142;;A61M5/172,A61M1/00;;A61M5/44,,0,0,,,,INACTIVE
281,AU,A1,AU 2010/247145 A1,107-547-253-766-573,2011-12-08,2011,AU 2010/247145 A,2010-05-11,GB 0908148 A;;GB 2010050768 W,2009-05-12,Mask for breathing apparatus,"A mask (10) for breathing apparatus has a seal (13) for sealing against and around the face of a user. The mask further includes a mask inlet (15) adapted to be placed in fluid communication with a supply of air, and a mask outlet (16) through which a user's exhaled breath is emitted, the mask outlet (16) including a one-way exhalation valve (22) including a valve closure member (23) mounted on a valve seat (25). An oronasal mask (14) in fluid communication with the mask inlet (15) and mask outlet (16) and positioned to engage, in use, over the nose and mouth of the wearer. The oronasal mask (14) is at least partially formed of material which is at least partially translucent, and an Illuminating LED (42) is in optical communication with the oronasal mask (14) so as to illuminate said oronasal mask (14).",SCOTT HEALTH & SAFETY LTD,CHRISTOPHER SUMNER;;STEVEN THURGOOD;;BARRY LEWIN;;PAUL HENSEY;;PICKETT ANTHONY W;;ROBERT CARR;;MARSHALL RICHARD D,,https://lens.org/107-547-253-766-573,Patent Application,no,0,0,12,12,0,A62B18/08;;A61M39/24;;A61M2205/583;;A62B18/10;;A62B18/00;;A62B18/02;;A62B18/08;;A61M39/24;;A62B9/02;;A62B18/10,A62B18/08,,0,0,,,,ACTIVE
282,GB,A,GB 2470199 A,186-666-445-861-126,2010-11-17,2010,GB 0908148 A,2009-05-12,GB 0908148 A,2009-05-12,Full-face breathing mask with illuminated oronasal mask,"A mask 10 for breathing apparatus incorporates an oronasal mask 40, that is at least partially translucent and is preferably transparent, and a light source to illuminate it. The light source may be one or more LEDs which may be carried on a plug that is removably connectable to a port formed in the mask. Also disclosed is a mask in which the exhalation valve (23, figure 2; 22, figure 3a) operates at a higher pressure when a pressurised air supply is attached to the mask. A spring 27 is normally prevented from opposing operation of the exhalation valve by the tip 31 of lever arm 30. However, connecting a pressurised air supply brings an adaptor to bear on a cam surface 30a of the lever arm and releases the biasing spring to bear on the exhalation valve.",SCOTT HEALTH & SAFETY LTD,SUMNER CHRISTOPHER;;THURGOOD STEVEN;;LEWIN BARRY;;HENSEY PAUL;;PICKETT ANTHONY W;;CARR ROBERT;;MARSHALL RICHARD D,,https://lens.org/186-666-445-861-126,Patent Application,no,2,0,12,12,0,A62B18/08;;A61M39/24;;A61M2205/583;;A62B18/10;;A62B18/00;;A62B18/02;;A62B18/08;;A61M39/24;;A62B9/02;;A62B18/10,A62B18/02;;A62B18/00,,0,0,,,,ACTIVE
283,US,A1,US 2020/0117826 A1,087-910-370-021-343,2020-04-16,2020,US 201916654630 A,2019-10-16,US 201916654630 A;;US 201862746141 P,2018-10-16,DATA ACCESS POLICY MANAGEMENT,"A method for automated data access management can include creating a project that manages data access to data sources by a plurality of users, wherein each user has user attributes indicating data access policies for the data sources. The method can also include performing project equalization for the project, wherein the project equalization determines a set of user attributes shared by the users. Additionally, the method can include modifying the user attributes of each user for the project, wherein the user attributes of each user are modified to conform to the set of user attributes determined by the project equalization, and detecting a query to retrieve data from the data source. The method can include modifying the query to produce a modified query by applying the modified user attributes associated with the project to the query and retrieving the data from the data source based on the modified query.",IMMUTA INC,LILLY JR KYLE THOMAS;;PERRY ERIC JAMES;;TOUW STEVEN WILLIAM;;HAMMEN BARRY RAY;;HAMLIN ADAM CARR,IMMUTA INC (2019-10-21),https://lens.org/087-910-370-021-343,Patent Application,yes,0,10,2,2,0,G06F16/21;;G06F16/2453;;G06F21/6227;;G06F21/6254;;G06F21/6227;;G06F21/31;;G06F16/2457;;G06F16/2455;;G06F16/24539;;G06F16/10;;G06F16/24;;G06F16/2471;;H04L67/1001,G06F21/62;;G06F16/2453;;G06F16/2455;;G06F16/2457;;G06F21/31,,0,0,,,,ACTIVE
284,US,B2,US 11556666 B2,019-890-744-159-450,2023-01-17,2023,US 201916654630 A,2019-10-16,US 201916654630 A;;US 201862746141 P,2018-10-16,Data access policy management,"A method for automated data access management can include creating a project that manages data access to data sources by a plurality of users, wherein each user has user attributes indicating data access policies for the data sources. The method can also include performing project equalization for the project, wherein the project equalization determines a set of user attributes shared by the users. Additionally, the method can include modifying the user attributes of each user for the project, wherein the user attributes of each user are modified to conform to the set of user attributes determined by the project equalization, and detecting a query to retrieve data from the data source. The method can include modifying the query to produce a modified query by applying the modified user attributes associated with the project to the query and retrieving the data from the data source based on the modified query.",IMMUTA INC,LILLY JR KYLE THOMAS;;PERRY ERIC JAMES;;TOUW STEVEN WILLIAM;;HAMMEN BARRY RAY;;HAMLIN ADAM CARR,IMMUTA INC (2019-10-21),https://lens.org/019-890-744-159-450,Granted Patent,yes,11,1,2,2,0,G06F16/21;;G06F16/2453;;G06F21/6227;;G06F21/6254;;G06F21/6227;;G06F21/31;;G06F16/2457;;G06F16/2455;;G06F16/24539;;G06F16/10;;G06F16/24;;G06F16/2471;;H04L67/1001,G06F21/62;;G06F16/10;;G06F16/24;;G06F16/2453;;G06F16/2455;;G06F16/2457;;G06F16/2458;;G06F21/31;;H04L67/1001,,0,0,,,,ACTIVE
285,WO,A8,WO 2017/184590 A8,096-982-938-621-00X,2018-10-25,2018,US 2017/0028122 W,2017-04-18,US 201662324228 P;;US 201662345556 P;;US 201762458954 P,2016-04-18,IMPROVED HLA EPITOPE PREDICTION,"Adaptive immune responses rely on the ability of cytotoxic T cells to identify and eliminate cells displaying disease-specific antigens on human leukocyte antigen (HLA) class I molecules. Investigations into antigen processing and display have immense implications in human health, disease and therapy. To extend understanding of the rules governing antigen processing and presentation, immunopurified peptides from B cells, each expressing a single HLA class I allele, were profiled using accurate mass, high-resolution liquid chromatography- mass spectrometry (LC-MS/MS). A resource dataset containing thousands of peptides bound to 28 distinct class I HLA-A, -B, and -C alleles was generated by implementing a novel allele-specific database search strategy. Applicants discovered new binding motifs, established the role of gene expression in peptide presentation and improved prediction of HLA-peptide binding by using these data to train machine-learning models. These streamlined experimental and analytic workflows enable direct identification and analysis of endogenously processed and presented antigens.",BROAD INST INC;;MASSACHUSETTS INST TECHNOLOGY;;HARVARD COLLEGE;;DANA FARBER CANCER INST INC;;MASSACHUSETTS GEN HOSPITAL;;CARR STEVEN A;;HACOHEN NIR;;WU CATHERINE J;;ABELIN JENNIFER G;;SARKIZOVA SIRANUSH;;KESKIN DERIN B;;CLAUSER KARL R;;ROONEY MICHAEL S,CARR STEVEN;;HACOHEN NIR;;WU CATHERINE;;ABELIN JENNIFER;;SARKIZOVA SIRANUSH;;KESKIN DERIN;;CLAUSER KARL;;ROONEY MICHAEL,,https://lens.org/096-982-938-621-00X,Amended Application,yes,0,1,5,5,0,A61K39/0011;;A61K2039/5158;;C12Q1/6881;;C12Q1/6886;;G01N33/56977;;G01N33/56977;;G01N2560/00;;G16B25/10;;G16B30/00;;G16B40/10,G01N33/569,,0,0,,,,PENDING
286,WO,A2,WO 2010/131031 A2,193-004-885-739-950,2010-11-18,2010,GB 2010050768 W,2010-05-11,GB 0908148 A,2009-05-12,MASK FOR BREATHING APPARATUS,"A mask (10) for breathing apparatus has a seal (13) for sealing against and around the face of a user. The mask further includes a mask inlet (15) adapted to be placed in fluid communication with a supply of air, and a mask outlet (16) through which a user's exhaled breath is emitted, the mask outlet (16) including a one-way exhalation valve (22) including a valve closure member (23) mounted on a valve seat (25). An oronasal mask (14) in fluid communication with the mask inlet (15) and mask outlet (16) and positioned to engage, in use, over the nose and mouth of the wearer. The oronasal mask (14) is at least partially formed of material which is at least partially translucent, and an Illuminating LED (42) is in optical communication with the oronasal mask (14) so as to illuminate said oronasal mask (14).",SCOTT HEALTH & SAFETY LTD;;SUMNER CHRISTOPHER;;THURGOOD STEVEN;;LEWIN BARRY;;HENSEY PAUL;;PICKETT ANTHONY W;;CARR ROBERT;;MARSHALL RICHARD D,SUMNER CHRISTOPHER;;THURGOOD STEVEN;;LEWIN BARRY;;HENSEY PAUL;;PICKETT ANTHONY W;;CARR ROBERT;;MARSHALL RICHARD D,,https://lens.org/193-004-885-739-950,Patent Application,yes,3,8,12,12,0,A62B18/08;;A61M39/24;;A61M2205/583;;A62B18/10;;A62B18/00;;A62B18/02;;A62B18/08;;A61M39/24;;A62B9/02;;A62B18/10,A62B18/08,,0,0,,,,PENDING
287,AU,B2,AU 2010/247145 B2,057-875-055-082-999,2015-02-19,2015,AU 2010/247145 A,2010-05-11,GB 0908148 A;;GB 2010050768 W,2009-05-12,Mask for breathing apparatus,"A mask (10) for breathing apparatus has a seal (13) for sealing against and around the face of a user. The mask further includes a mask inlet (15) adapted to be placed in fluid communication with a supply of air, and a mask outlet (16) through which a user's exhaled breath is emitted, the mask outlet (16) including a one-way exhalation valve (22) including a valve closure member (23) mounted on a valve seat (25). An oronasal mask (14) in fluid communication with the mask inlet (15) and mask outlet (16) and positioned to engage, in use, over the nose and mouth of the wearer. The oronasal mask (14) is at least partially formed of material which is at least partially translucent, and an Illuminating LED (42) is in optical communication with the oronasal mask (14) so as to illuminate said oronasal mask (14).",SCOTT HEALTH & SAFETY LTD,SUMNER CHRISTOPHER;;THURGOOD STEVEN;;LEWIN BARRY;;HENSEY PAUL;;PICKETT ANTHONY W;;CARR ROBERT;;MARSHALL RICHARD D,,https://lens.org/057-875-055-082-999,Granted Patent,no,2,0,12,12,0,A62B18/08;;A61M39/24;;A61M2205/583;;A62B18/10;;A62B18/00;;A62B18/02;;A62B18/08;;A61M39/24;;A62B9/02;;A62B18/10,A62B18/08,,0,0,,,,ACTIVE
288,EP,A2,EP 2429661 A2,060-889-368-806-025,2012-03-21,2012,EP 10735309 A,2010-05-11,GB 2010050768 W;;GB 0908148 A,2009-05-12,MASK FOR BREATHING APPARATUS,,SCOTT HEALTH & SAFETY LTD,SUMNER CHRISTOPHER;;THURGOOD STEVEN;;LEWIN BARRY;;HENSEY PAUL;;PICKETT ANTHONY W;;CARR ROBERT;;MARSHALL RICHARD D,,https://lens.org/060-889-368-806-025,Patent Application,yes,0,0,12,12,0,A62B18/08;;A61M39/24;;A61M2205/583;;A62B18/10;;A62B18/00;;A62B18/02;;A62B18/08;;A61M39/24;;A62B9/02;;A62B18/10,A62B18/08,,0,0,,,,ACTIVE
289,US,B2,US 8204420 B2,167-947-192-293-053,2012-06-19,2012,US 20015608 A,2008-08-28,US 20015608 A,2008-08-28,Fuser with end caps having protuberances for reducing belt skew,A fuser has a heater housing extending through an endless belt with end caps on the housing adjacent to opposite lateral sides of the belt. The end caps have inner flanges spaced radially outward from a center portion and radially inward from the opposite marginal side edge portions of the belt so as to define clearance therebetween. Protuberances on the inner flanges of the end caps project toward opposite marginal edge portions of the belt and are circumferentially spaced apart to reduce belt skew relative to the end caps by either decreasing the surface area of contact of the inner flanges with the opposite marginal side edge portions of the belt to reduced surface areas of contact of protuberances therewith or decreasing the radial height of the clearance between the inner flanges and opposite side edge portions of the belt to the reduced radial height between the latter and the protuberances.,CARR JR PATRICK WAYNE;;CRETEAU GREGORY DANIEL;;GOGATE HNSHIKESH PRAMOD;;FOSTER LARRY STEVEN;;RANNICK DAVID ERWIN;;LEXMARK INT INC,CARR JR PATRICK WAYNE;;CRETEAU GREGORY DANIEL;;GOGATE HNSHIKESH PRAMOD;;FOSTER LARRY STEVEN;;RANNICK DAVID ERWIN,LEXMARK INTERNATIONAL INC (2008-08-26),https://lens.org/167-947-192-293-053,Granted Patent,yes,1,0,2,2,0,G03G15/2064;;G03G15/2064;;G03G2215/00151;;G03G2215/00151,G03G15/20,399/329,0,0,,,,ACTIVE
290,US,A1,US 2010/0054827 A1,159-974-770-578-055,2010-03-04,2010,US 20015608 A,2008-08-28,US 20015608 A,2008-08-28,FUSER WITH END CAPS HAVING PROTUBERANCES FOR REDUCING BELT SKEW,A fuser has a heater housing extending through an endless belt with end caps on the housing adjacent to opposite lateral sides of the belt. The end caps have inner flanges spaced radially outward from a center portion and radially inward from the opposite marginal side edge portions of the belt so as to define clearance therebetween. Protuberances on the inner flanges of the end caps project toward opposite marginal edge portions of the belt and are circumferentially spaced apart to reduce belt skew relative to the end caps by either decreasing the surface area of contact of the inner flanges with the opposite marginal side edge portions of the belt to reduced surface areas of contact of protuberances therewith or decreasing the radial height of the clearance between the inner flanges and opposite side edge portions of the belt to the reduced radial height between the latter and the protuberances.,CARR JR PATRICK WAYNE;;CRETEAU GREGORY DANIEL;;GOGATE HNSHIKESH PRAMOD;;FOSTER LARRY STEVEN;;RANNICK DAVID ERWIN,CARR JR PATRICK WAYNE;;CRETEAU GREGORY DANIEL;;GOGATE HNSHIKESH PRAMOD;;FOSTER LARRY STEVEN;;RANNICK DAVID ERWIN,LEXMARK INTERNATIONAL INC (2008-08-26),https://lens.org/159-974-770-578-055,Patent Application,yes,1,5,2,2,0,G03G15/2064;;G03G15/2064;;G03G2215/00151;;G03G2215/00151,G03G15/20,399/329,0,0,,,,ACTIVE
291,GB,B,GB 2470199 B,131-071-395-392-713,2013-08-14,2013,GB 0908148 A,2009-05-12,GB 0908148 A,2009-05-12,Mask for breathing apparatus,,SCOTT HEALTH & SAFETY LTD,SUMNER CHRISTOPHER;;THURGOOD STEVEN;;LEWIN BARRY;;HENSEY PAUL;;PICKETT ANTHONY W;;CARR ROBERT;;MARSHALL RICHARD D,,https://lens.org/131-071-395-392-713,Granted Patent,no,2,0,12,12,0,A62B18/08;;A61M39/24;;A61M2205/583;;A62B18/10;;A62B18/00;;A62B18/02;;A62B18/08;;A61M39/24;;A62B9/02;;A62B18/10,A62B18/02;;A62B18/00;;A62B18/08,,0,0,,,,ACTIVE
292,WO,A3,WO 2010/131031 A3,014-828-186-096-483,2011-04-14,2011,GB 2010050768 W,2010-05-11,GB 0908148 A,2009-05-12,MASK FOR BREATHING APPARATUS,"A mask (10) for breathing apparatus has a seal (13) for sealing against and around the face of a user. The mask further includes a mask inlet (15) adapted to be placed in fluid communication with a supply of air, and a mask outlet (16) through which a user's exhaled breath is emitted, the mask outlet (16) including a one-way exhalation valve (22) including a valve closure member (23) mounted on a valve seat (25). An oronasal mask (14) in fluid communication with the mask inlet (15) and mask outlet (16) and positioned to engage, in use, over the nose and mouth of the wearer. The oronasal mask (14) is at least partially formed of material which is at least partially translucent, and an Illuminating LED (42) is in optical communication with the oronasal mask (14) so as to illuminate said oronasal mask (14).",SCOTT HEALTH & SAFETY LTD;;SUMNER CHRISTOPHER;;THURGOOD STEVEN;;LEWIN BARRY;;HENSEY PAUL;;PICKETT ANTHONY W;;CARR ROBERT;;MARSHALL RICHARD D,SUMNER CHRISTOPHER;;THURGOOD STEVEN;;LEWIN BARRY;;HENSEY PAUL;;PICKETT ANTHONY W;;CARR ROBERT;;MARSHALL RICHARD D,,https://lens.org/014-828-186-096-483,Search Report,yes,3,0,12,12,0,A62B18/08;;A61M39/24;;A61M2205/583;;A62B18/10;;A62B18/00;;A62B18/02;;A62B18/08;;A61M39/24;;A62B9/02;;A62B18/10,A62B18/08,,0,0,,,,PENDING
293,EP,B1,EP 2429661 B1,053-132-895-109-784,2019-12-18,2019,EP 10735309 A,2010-05-11,GB 2010050768 W;;GB 0908148 A,2009-05-12,MASK FOR BREATHING APPARATUS,,SCOTT HEALTH & SAFETY LTD,SUMNER CHRISTOPHER;;THURGOOD STEVEN;;LEWIN BARRY;;HENSEY PAUL;;PICKETT ANTHONY W;;CARR ROBERT;;MARSHALL RICHARD D,,https://lens.org/053-132-895-109-784,Granted Patent,yes,2,0,12,12,0,A62B18/08;;A61M39/24;;A61M2205/583;;A62B18/10;;A62B18/00;;A62B18/02;;A62B18/08;;A61M39/24;;A62B9/02;;A62B18/10,A62B18/08,,0,0,,,,ACTIVE
294,NZ,A,NZ 739020 A,042-515-002-157-72X,2019-06-28,2019,NZ 73902016 A,2016-08-04,US 2016/0045563 W;;US 201562211410 P,2015-08-28,"Thixotropic suspension agent for plant nutrients or animal feed supplements: composition, method of making, and use thereof","A composition, in the form of an aqueous suspension. The composition comprises at least one form of attapulgite present in a solid weight fraction (SWF) amount ranging from 0.065% to 0.30%. The composition comprises kaolin present in a percent solids by weight (w/w%) amount ranging from 0.80% to 2.80%. The composition comprises one or more main plant nutrients or major animal mineral nutrient supplements. In the composition, the total percent solids by weight (w/w%) amount in the composition ranges from 45% to 90%. Although usable for other purposes, the composition is usable as a fertilizer. Although makeable in other ways, the composition is makeable by mixing the ingredients with agitation sufficient enough to form an aqueous suspension.",ACTIVE MINERALS INT LLC,FELDMAN STEVEN B;;CARR JEFFERY;;LYMAN MATTHEW J;;KITCHENS JOHN;;FUHRMANN LUKE;;PURCELL JR;;PARKER DENNIS C,,https://lens.org/042-515-002-157-72X,Patent Application,no,0,0,9,9,0,A01C21/005;;C05D5/00;;C05D5/00;;C05B9/00;;C05B9/00;;C05D9/02;;C05D9/02;;C05F11/02;;C05F11/02;;C05G1/00;;C05G1/00;;C05G5/27;;C05G5/27,C05B9/00;;C05F11/02;;C05G1/00;;C05G3/00,,0,0,,,,DISCONTINUED
295,US,B1,US 6188699 B1,060-203-997-648-067,2001-02-13,2001,US 98916297 A,1997-12-11,US 98916297 A,1997-12-11,Multi-channel encoder/decoder,"A multi-channel network device for interfacing between a plurality of physical data links and a control processor, where each physical data link is characterized by a data stream of data packets communicated according to a data link control protocol. The multi-channel network device includes a plurality of receive-side line interfaces, with each with each receive-side line interface having at least one channel associated therewith. Each receive-side line interface is operative to receive incoming data packets from one of the physical data links such that each incoming data packet is received in at least one incoming data segment. Each receive-side line interface is also operative to determine a time-slot number for each incoming data segment arriving thereon.",PMC SIERRA LTD,LANG STEVEN FORBES;;MOK WINSTON KI-CHEONG;;CARR LARRIE SIMON;;STEEDMAN RICHARD ARTHUR JOHN;;BINDLEY GLENN KENNETH,PMC-SIERRA LTD (1997-12-05),https://lens.org/060-203-997-648-067,Granted Patent,yes,5,156,1,1,0,H04L69/14;;H04L9/40;;H04L69/14;;H04L9/40,H04J3/12;;H04L29/06,370/463;;370/400;;370/419;;370/439;;370/458,3,1,129-619-891-611-654,10.3403/00254062,"American National Standards Institute, Inc. T1.107-1995 ""Digital Hierarchy-Formats Specifications"" 1995: pp. 1-98.;;ITU-T Recommendation G.704 ""Synchronous Frame Structures Used at 1544,6312, 2048, 8488 and 44 736 kbit/s Hierarchical Levels"" Jul., 1995: pp. 1-33.;;ISO/IEC 3309-1993 (E) ""Information Technology-Telecommunications and Information Exchange Between Systems-High-level Data Link Control (HDLC) Procedures-Frame Structure"" Dec. 15, 1993: pp. 1-8.",EXPIRED
296,TW,B,TW I637933 B,135-095-812-255-632,2018-10-11,2018,TW 105125516 A,2016-08-10,US 201562211410 P,2015-08-28,"Thixotropic suspension agent for plant nutrients or animal feed supplements: composition, method of making, and use thereof",,,FELDMAN STEVEN B;;CARR JEFFERY;;LYMAN MATTHEW J;;KITCHENS JOHN;;FUHRMANN LUKE;;PURCELL JR;;PARKER DENNIS C,,https://lens.org/135-095-812-255-632,Granted Patent,no,1,0,9,9,0,A01C21/005;;C05D5/00;;C05D5/00;;C05B9/00;;C05B9/00;;C05D9/02;;C05D9/02;;C05F11/02;;C05F11/02;;C05G1/00;;C05G1/00;;C05G5/27;;C05G5/27,,,0,0,,,,INACTIVE
297,CA,A1,CA 2224392 A1,168-012-331-947-065,1999-06-09,1999,CA 2224392 A,1997-12-09,CA 2224392 A,1997-12-09,MULTI-CHANNEL ENCODER/DECODER,"A multi-channel network device, for interfacing between a plurality of physical data links and a control processor, with each physical data link characterized by a data stream of data packets communicated according to a data link control protocol. The device includes a receive section where incoming data packets are each received in at least one data segment on one of a plurality of receive-side line interfaces. A receive-side priority encoder circuit services incoming data segments arriving on the receive-side line interfaces and pipelines the incoming data segments to a receive-side channel assigner circuit for channel assignment. A receive-side data processor coupled to the receive-side channel assigner circuit decodes ones of the incoming data segments. A receive-side packet buffer processor coupled to the receive-side data processor stores incoming data segments in receive-side channel FIFO buffers. A receive-side packet management circuit coupled to the receive-side packet buffer processor transfers incoming data segments from the receive-side channel FIFO buffers to an external control processor via a control processor interface. In a transmit section of the device, a transmit-side packet management circuit sorts blocks of outgoing data, each having at least one outgoing data segment and awaiting transmission from the control processor to ones of the physical data links, into linked lists. Each linked list is associated with one of a plurality of outgoing data channels in the transmit section. The transmit-side packet management circuit is operative to communicate each block of outgoing data from the control processor to a transmit-side packet buffer processor based on requests for outgoing data transmitted by transmit-side line interfaces. The transmit-side packet buffer processor is operative to store outgoing data segments of each block of outgoing data received from the transmit-side packet management circuit in transmit-side channel FIFO buffers. The transmit-side line interfaces are operative to communicate with the physical data links and are monitored for requests for outgoing data by a transmit-side priority encoder circuit. The transmit-side packet buffer processor retrieves outgoing data segments stored in the transmit-side channel FIFO buffers according to the order of the requests for outgoing data, for subsequent transmission by the associated transmit-side line interfaces to ones of the physical data links. A transmit-side data processor encodes ones of the outgoing data segments retrieved from the transmit-side channel FIFO buffers. Retrieved outgoing data segments are pipelined to a transmit-side channel assigner for channel assignment prior to transmission on the appropriate transmit-side line interfaces.",PMC SIERRA INC,CARR LARRIE SIMON;;STEEDMAN RICHARD ARTHUR JOHN;;MOK WINSTON KI-CHEONG;;LANG STEVEN FORBES;;BINDLEY GLENN KENNETH,,https://lens.org/168-012-331-947-065,Patent Application,no,0,0,2,2,0,H04L47/6215;;H04L49/90;;H04L49/901;;H04L49/9047;;H04L49/9073;;H04L69/12;;H04L69/324,H04L12/56;;H04L29/06;;H04L29/08,,0,0,,,,EXPIRED
298,AU,B2,AU 2016/317298 B2,174-622-882-591-785,2018-11-15,2018,AU 2016/317298 A,2016-08-04,US 201562211410 P;;US 2016/0045563 W,2015-08-28,"Thixotropic suspension agent for plant nutrients or animal feed supplements: composition, method of making, and use thereof","A composition, in the form of an aqueous suspension. The composition comprises at least one form of attapulgite present in a solid weight fraction (SWF) amount ranging from 0.065% to 0.30%. The composition comprises kaolin present in a percent solids by weight (w/w%) amount ranging from 0.80% to 2.80%. The composition comprises one or more main plant nutrients or major animal mineral nutrient supplements. In the composition, the total percent solids by weight (w/w%) amount in the composition ranges from 45% to 90%. Although usable for other purposes, the composition is usable as a fertilizer. Although makeable in other ways, the composition is makeable by mixing the ingredients with agitation sufficient enough to form an aqueous suspension.",ACTIVE MINERALS INTERNATIONAL LLC,FELDMAN STEVEN B;;CARR JEFFERY;;LYMAN MATTHEW J;;KITCHENS JOHN;;FUHRMANN LUKE;;PURCELL JR;;PARKER DENNIS C,,https://lens.org/174-622-882-591-785,Granted Patent,no,3,0,9,9,0,C05B9/00;;C05F11/02;;C05G1/00;;C05D5/00;;C05D9/02;;C05G5/27;;C05B9/00;;C05G1/00;;C05F11/02;;C05G5/27;;A01C21/005;;C05D5/00;;C05D9/02,C05B9/00;;C05F11/02;;C05G1/00;;C05G3/00,,0,0,,,,ACTIVE
299,TW,A,TW 201711985 A,187-097-080-972-577,2017-04-01,2017,TW 105125516 A,2016-08-10,US 201562211410 P,2015-08-28,"Thixotropic suspension agent for plant nutrients or animal feed supplements: composition, method of making, and use thereof","A composition, in the form of an aqueous suspension. The composition comprises at least one form of attapulgite present in a solid weight fraction (SWF) amount ranging from 0.065% to 0.30%. The composition comprises kaolin present in a percent solids by weight (w/w%) amount ranging from 0.80% to 2.80%. The composition comprises one or more main plant nutrients or major animal mineral nutrient supplements. In the composition, the total percent solids by weight (w/w%) amount in the composition ranges from 45% to 90%. Although usable for other purposes, the composition is usable as a fertilizer. Although makeable in other ways, the composition is makeable by mixing the ingredients with agitation sufficient enough to form an aqueous suspension.",ACTIVE MINERALS INTERNATIONAL LLC,FELDMAN STEVEN B;;CARR JEFFERY;;LYMAN MATTHEW J;;KITCHENS JOHN;;FUHRMANN LUKE;;PURCELL JR;;PARKER DENNIS C,,https://lens.org/187-097-080-972-577,Patent of Addition,no,0,0,9,9,0,A01C21/005;;C05D5/00;;C05D5/00;;C05B9/00;;C05B9/00;;C05D9/02;;C05D9/02;;C05F11/02;;C05F11/02;;C05G1/00;;C05G1/00;;C05G5/27;;C05G5/27,C05D1/00;;C05D3/00;;C05D5/00;;C05D9/00;;C05G5/00,,0,0,,,,INACTIVE
300,CA,C,CA 2224392 C,103-441-118-920-952,2001-12-04,2001,CA 2224392 A,1997-12-09,CA 2224392 A,1997-12-09,MULTI-CHANNEL ENCODER/DECODER,"A multi-channel network device, for interfacing between a plurality of physical data links and a control processor, with each physical data link characterized by a data stream of data packets communicated according to a data link control protocol. The device includes a receive section where incoming data packets are each received in at least one data segment on one of a plurality of receive-side line interfaces. A receive-side priority encoder circuit services incoming data segments arriving on the receive-side line interfaces and pipelines the incoming data segments to a receive-side channel assigner circuit for channel assignment. A receive-side data processor coupled to the receive-side channel assigner circuit decodes ones of the incoming data segments. A receive-side packet buffer processor coupled to the receive-side data processor stores incoming data segments in receive-side channel FIFO buffers. A receive-side packet management circuit coupled to the receive-side packet buffer processor transfers incoming data segments from the receive-side channel FIFO buffers to an external control processor via a control processor interface. In a transmit section of the device, a transmit-side packet management circuit sorts blocks of outgoing data, each having at least one outgoing data segment and awaiting transmission from the control processor to ones of the physical data links, into linked lists. Each linked list is associated with one of a plurality of outgoing data channels in the transmit section. The transmit-side packet management circuit is operative to communicate each block of outgoing data from the control processor to a transmit-side packet buffer processor based on requests for outgoing data transmitted by transmit-side line interfaces. The transmit-side packet buffer processor is operative to store outgoing data segments of each block of outgoing data received from the transmit-side packet management circuit in transmit-side channel FIFO buffers. The transmit-side line interfaces are operative to communicate with the physical data links and are monitored for requests for outgoing data by a transmit-side priority encoder circuit. The transmit-side packet buffer processor retrieves outgoing data segments stored in the transmit-side channel FIFO buffers according to the order of the requests for outgoing data, for subsequent transmission by the associated transmit-side line interfaces to ones of the physical data links. A transmit-side data processor encodes ones of the outgoing data segments retrieved from the transmit-side channel FIFO buffers. Retrieved outgoing data segments are pipelined to a transmit-side channel assigner for channel assignment prior to transmission on the appropriate transmit-side line interfaces.",PMC SIERRA INC,MOK WINSTON KI-CHEONG;;LANG STEVEN FORBES;;BINDLEY GLENN KENNETH;;STEEDMAN RICHARD ARTHUR JOHN;;CARR LARRIE SIMON,,https://lens.org/103-441-118-920-952,Granted Patent,no,0,0,2,2,0,H04L47/6215;;H04L49/90;;H04L49/901;;H04L49/9047;;H04L49/9073;;H04L69/12;;H04L69/324,H04L12/56;;H04L29/06;;H04L29/08,,0,0,,,,EXPIRED
301,AU,A1,AU 2016/317298 A1,099-861-191-989-217,2018-02-01,2018,AU 2016/317298 A,2016-08-04,US 201562211410 P;;US 2016/0045563 W,2015-08-28,"Thixotropic suspension agent for plant nutrients or animal feed supplements: composition, method of making, and use thereof","A composition, in the form of an aqueous suspension. The composition comprises at least one form of attapulgite present in a solid weight fraction (SWF) amount ranging from 0.065% to 0.30%. The composition comprises kaolin present in a percent solids by weight (w/w%) amount ranging from 0.80% to 2.80%. The composition comprises one or more main plant nutrients or major animal mineral nutrient supplements. In the composition, the total percent solids by weight (w/w%) amount in the composition ranges from 45% to 90%. Although usable for other purposes, the composition is usable as a fertilizer. Although makeable in other ways, the composition is makeable by mixing the ingredients with agitation sufficient enough to form an aqueous suspension.",ACTIVE MINERALS INTERNATIONAL LLC,FELDMAN STEVEN B;;CARR JEFFERY;;LYMAN MATTHEW J;;KITCHENS JOHN;;FUHRMANN LUKE;;PURCELL JR;;PARKER DENNIS C,,https://lens.org/099-861-191-989-217,Patent Application,no,0,0,9,9,0,A01C21/005;;C05D5/00;;C05D5/00;;C05B9/00;;C05B9/00;;C05D9/02;;C05D9/02;;C05F11/02;;C05F11/02;;C05G1/00;;C05G1/00;;C05G5/27;;C05G5/27,C05B9/00;;C05F11/02;;C05G1/00;;C05G3/00,,0,0,,,,ACTIVE
302,EP,A1,EP 1169271 A1,164-043-493-492-178,2002-01-09,2002,EP 00926914 A,2000-04-12,EP 0003336 W;;US 12932899 P,1999-04-14,METHOD OF AQUIFER REMEDIATION,,SHELL INT RESEARCH,JOHNSON PAUL CARR;;SALANITRO JOSEPH PATRICK;;STEARNS STEVEN MERLE;;MANER PAUL MICHAEL;;MILLER JAMES HENRY;;SPINNLER GERARD EUGENE,,https://lens.org/164-043-493-492-178,Patent Application,yes,0,0,18,18,0,B09C1/002;;B09C1/10;;B09C2101/00;;E21B43/00;;E21B43/30;;Y10S210/908;;E21B43/00;;E21B43/30;;B09C1/002;;B09C1/10;;B09C2101/00;;Y10S210/908,B09C1/00;;B09C1/10;;E21B43/00;;E21B43/30,,0,0,,,,EXPIRED
303,WO,A2,WO 2020/131586 A2,080-635-476-521-567,2020-06-25,2020,US 2019/0066104 W,2019-12-12,US 201862780832 P;;US 201962820042 P,2018-12-17,METHODS FOR IDENTIFYING NEOANTIGENS,"Disclosed herein are polypeptides and compositions comprising one or more neoantigens, methods of identifying neoantigens, and methods for preparing a neoantigen for an immunogenic pharmaceutical composition. The neoantigen can be specific to a subject that has a cancer, disease, or other disorder.",BROAD INST INC;;MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL;;DANA FARBER CANCER INST INC;;OUSPENSKAIA TAMARA;;LAW TRAVIS;;CARR STEVEN;;CLAUSER KARL;;KLAEGER SUSAN;;WU CATHERINE;;KESKIN DERIN,OUSPENSKAIA TAMARA;;LAW TRAVIS;;CARR STEVEN;;CLAUSER KARL;;KLAEGER SUSAN;;WU CATHERINE;;KESKIN DERIN;;REGEV AVIV;;HACOHEN NIR,,https://lens.org/080-635-476-521-567,Patent Application,yes,505,3,3,3,83,A61K39/0011;;G01N33/56972;;C12Q1/6869;;A61K39/0005;;A61K45/06;;C12Q1/6869;;G01N33/6848,A61K39/00;;C12Q1/68;;C12Q1/6869;;G01N33/569,,289,242,101-619-608-539-575;;001-903-296-280-551;;144-725-849-679-447;;105-571-956-647-527;;072-983-585-843-582;;040-345-923-870-253;;015-839-900-804-759;;035-019-404-496-12X;;079-889-760-145-612;;001-889-138-393-421;;016-229-772-022-557;;026-944-353-804-488;;024-392-972-050-341;;069-098-080-911-332;;017-216-732-209-839;;059-400-780-458-227;;002-882-009-745-691;;004-724-173-477-122;;037-904-735-240-537;;120-176-283-549-095;;093-423-744-136-655;;082-887-373-158-244;;040-277-381-986-160;;067-423-318-569-025;;125-645-965-899-165;;031-039-129-088-844;;020-178-335-962-88X;;001-135-488-035-957;;066-916-220-868-595;;033-600-295-094-741;;022-225-349-299-937;;079-874-646-887-645;;057-353-589-104-357;;084-280-558-764-322;;028-333-567-010-894;;007-260-298-056-037;;003-264-306-643-657;;031-807-821-140-812;;006-083-496-103-526;;151-747-107-866-762;;065-427-040-070-857;;086-507-133-163-907;;001-738-886-327-915;;064-133-645-690-020;;028-696-271-645-551;;086-469-414-422-958;;033-517-475-734-956;;004-528-067-817-471;;057-353-589-104-357;;041-737-949-940-597;;001-684-791-731-05X;;047-796-156-303-991;;015-752-955-256-76X;;015-005-537-927-250;;073-390-485-598-068;;067-768-558-783-008;;014-630-446-453-288;;000-426-165-109-927;;020-178-779-477-981;;104-877-511-857-009;;114-442-739-618-020;;114-700-871-180-280;;011-463-146-073-65X;;000-078-232-627-567;;020-781-137-201-736;;032-464-541-034-729;;089-310-781-933-578;;061-708-359-767-416;;024-311-781-677-427;;026-411-645-167-642;;007-261-999-134-784;;096-012-584-064-893;;001-634-188-074-328;;048-055-110-364-340;;034-835-564-577-980;;125-237-538-945-224;;013-223-611-540-656;;055-061-574-892-808;;064-682-744-872-69X;;135-277-134-797-957;;041-501-254-191-787;;087-286-239-620-774;;091-509-047-035-538;;042-913-591-104-522;;018-065-511-380-65X;;013-157-557-283-421;;006-448-546-680-292;;115-651-104-503-761;;072-714-803-299-875;;013-157-557-283-421;;182-509-955-763-417;;079-335-206-483-53X;;010-062-796-785-17X;;092-667-724-840-965;;086-660-693-292-847;;048-156-676-293-513;;134-565-035-294-633;;048-419-629-020-848;;041-161-089-834-866;;031-103-391-280-149;;015-473-954-917-712;;081-043-582-448-428;;020-289-144-251-278;;060-824-980-876-559;;105-045-276-085-540;;010-901-227-513-259;;007-041-645-879-370;;088-156-513-960-044;;023-784-290-990-164;;002-085-775-109-916;;010-152-833-378-258;;020-579-657-226-196;;053-783-298-552-453;;083-694-793-270-14X;;032-942-121-304-562;;047-798-771-039-642;;045-728-526-507-231;;094-554-724-588-44X;;068-210-720-709-636;;002-658-040-691-779;;044-454-305-666-245;;033-059-065-421-652;;115-853-993-617-472;;009-820-952-967-579;;103-168-089-019-035;;136-929-781-463-029;;138-064-957-580-062;;068-655-416-231-860;;098-135-152-864-70X;;038-874-519-022-238;;010-679-857-763-16X;;033-916-697-838-388;;009-647-298-610-949;;028-982-532-025-930;;032-075-442-654-704;;051-326-039-695-605;;057-165-601-966-358;;081-374-000-676-84X;;031-575-623-752-48X;;023-784-290-990-164;;041-982-926-028-887;;000-021-137-125-270;;073-493-217-484-744;;100-917-703-348-75X;;044-254-945-915-100;;017-988-476-564-97X;;116-006-026-994-001;;034-027-320-616-482;;019-935-207-779-386;;023-823-789-911-612;;019-935-207-779-386;;057-140-619-721-980;;039-979-283-814-649;;025-914-055-206-101;;085-572-237-487-038;;007-831-674-897-689;;125-980-003-853-48X;;049-453-156-162-576;;029-876-751-016-505;;124-885-937-444-127;;180-157-749-310-434;;082-835-678-745-138;;029-409-793-996-772;;090-471-371-814-464;;058-626-148-407-368;;030-362-081-995-720;;044-920-384-051-702;;063-930-236-516-908;;139-035-880-523-441;;090-408-538-433-304;;045-152-488-303-852;;066-494-081-508-460;;045-213-195-045-219;;018-549-244-814-02X;;121-487-526-617-027;;059-422-987-872-246;;052-681-741-362-942;;044-670-788-454-71X;;042-656-289-635-213;;005-417-999-880-598;;155-284-518-841-057;;009-802-337-761-385;;003-371-450-234-667;;040-426-590-534-706;;034-174-292-681-665;;031-296-631-582-212;;129-580-616-064-283;;061-542-637-203-585;;095-894-960-349-974;;065-268-854-361-113;;014-188-174-852-197;;005-198-548-268-394;;067-344-233-099-751;;090-522-587-795-474;;077-295-979-222-239;;089-839-991-684-282;;066-872-003-079-846;;091-806-773-741-403;;009-939-788-857-914;;089-942-491-393-839;;004-992-481-487-884;;013-559-502-235-993;;037-780-185-187-88X;;029-373-120-748-203;;093-806-058-071-01X;;124-408-451-056-317;;088-971-131-416-01X;;071-978-992-443-516;;079-902-257-271-084;;018-041-187-164-982;;002-955-370-415-401;;089-443-554-843-061;;063-009-450-995-217;;059-910-245-294-03X;;014-491-792-527-932;;045-714-831-915-963;;112-871-461-451-205;;086-268-955-647-163;;046-289-867-375-85X;;152-279-674-137-242;;086-575-237-486-844;;113-118-416-348-870;;099-372-009-770-60X;;012-522-132-362-171;;103-736-007-949-11X;;019-202-837-544-006;;020-366-451-479-738;;023-024-890-895-871;;080-812-133-067-23X;;003-557-113-880-882;;032-919-736-284-099;;115-651-104-503-761;;004-754-590-497-690;;009-703-336-646-103;;141-167-705-529-48X;;015-976-536-925-925;;044-024-797-432-33X;;064-941-422-859-613;;126-858-335-833-271;;001-823-119-905-442;;062-711-160-177-156;;019-159-262-627-554,10.1126/science.1251102;;24812403;;pmc6686185;;28408606;;10.1126/science.aak9510;;pmc6295311;;28678778;;pmc5577644;;10.1038/nature22991;;22318521;;pmc3874809;;10.1038/nature10755;;10.1099/0022-1317-68-10-2587;;2822841;;7636255;;10.4049/jimmunol.155.4.2039;;10.1128/jvi.02216-07;;18184713;;pmc2258966;;10.1073/pnas.91.21.9866;;7937907;;pmc44918;;10.1073/pnas.1019266108;;21502532;;pmc3088639;;26347741;;pmc4544156;;10.3389/fimmu.2015.00418;;10.1016/j.ijpharm.2005.06.007;;16046256;;10.1021/ja00897a025;;10.1016/0264-410x(89)90266-1;;2609722;;21261958;;pmc3038947;;10.1186/1743-422x-8-36;;10.1016/0196-8858(81)90046-4;;4058585;;10.1038/317813a0;;6260373;;10.1016/0092-8674(81)90282-8;;10.1016/s0065-308x(08)60152-9;;10050276;;11050940;;10.1016/s0065-3527(00)55001-5;;8690928;;10.1016/0022-1759(96)00035-x;;pmc4395260;;25875117;;10.1371/journal.pone.0118803;;9498786;;10.1126/science.270.5234.299;;7569980;;8265577;;10.1073/pnas.90.24.11478;;pmc48007;;23125444;;pmc3532831;;10.1093/infdis/jis670;;10.1128/jvi.63.5.2374-2378.1989;;2784836;;pmc250661;;pmc240569;;10.1128/jvi.65.5.2220-2224.1991;;1850008;;16731942;;pmc1472566;;10.1128/jvi.02108-05;;1727603;;10.1016/0042-6822(92)90082-z;;22777090;;pmc3495727;;10.4161/hv.21080;;10.1016/j.vaccine.2013.03.042;;pmc3755097;;23583893;;10.1038/302490a0;;6835382;;7616101;;10.1002/jlb.58.1.1;;10.1038/354520a0;;1758494;;6095272;;10.1073/pnas.81.22.7194;;pmc392104;;10.1073/pnas.83.20.7947;;3464010;;pmc386841;;17227690;;10.1016/j.vaccine.2006.11.066;;10.1016/j.vaccine.2009.09.033;;19925953;;3184271;;pmc253556;;10.1128/jvi.62.12.4474-4480.1988;;10.1038/330259a0;;3118219;;pmc247729;;10.1128/jvi.63.2.600-606.1989;;2783466;;10.1016/0042-6822(90)90294-2;;2219722;;219640;;10.1006/viro.1998.9397;;9837798;;pmc228399;;10.1128/jvi.77.19.10606-10622.2003;;12970445;;10.1099/vir.0.83018-0;;17698656;;10.2174/156652311795684731;;21453284;;8337851;;10.1006/viro.1993.1442;;7616101;;10.1002/jlb.58.1.1;;9603331;;10.1099/0022-1317-79-5-1159;;11393868;;11283352;;10.1126/science.1058915;;11739541;;10.4049/jimmunol.167.12.7180;;15308364;;10.1016/j.vaccine.2004.02.025;;10.1086/421266;;15227622;;15014500;;10.1038/nature02331;;15708987;;10.1128/jvi.79.5.2678-2688.2005;;pmc548443;;17900219;;10.1016/j.vaccine.2007.04.002;;17499893;;17434244;;10.1016/j.vaccine.2007.02.084;;10.1016/j.vaccine.2007.12.059;;18336966;;10.1073/pnas.0705191105;;18270165;;pmc2538878;;10.1200/jco.2004.08.083;;15169798;;10.1158/1078-0432.ccr-08-0668;;19010868;;10.1007/s10637-008-9187-3;;18931824;;10.1200/jco.2009.25.0597;;20100959;;pmc2834462;;20881001;;10.1158/1078-0432.ccr-10-2082;;20975327;;10.4161/hv.6.10.13144;;pmc9491320;;21069322;;10.1007/s00262-010-0935-9;;15242542;;10.1089/0889222041217428;;15325077;;10.1016/j.virusres.2004.04.008;;10.1073/pnas.0406381102;;15781866;;pmc555695;;10.4161/hv.9693;;19786840;;18393831;;10.2174/156652308784049363;;10.1002/eji.200939754;;pmc3044835;;20017188;;pmc2885029;;19008384;;10.1099/vir.0.2008/004440-0;;19944151;;pmc2814951;;10.1016/j.vaccine.2009.11.030;;10.1097/coh.0b013e32833d1e87;;20978379;;10.1016/s0952-7915(97)80104-5;;9287173;;10.1007/s002620000146;;11092617;;10873071;;10.4049/jimmunol.171.2.1094;;12847284;;pmc38060;;10.1073/pnas.93.21.11349;;8876138;;10.1200/jco.1999.17.1.332;;10458251;;10.1007/bf01641272;;2033387;;10.1099/0022-1317-72-5-1031;;10.1038/nrg3645;;24468696;;pmc6939389;;30542152;;10.1038/s41586-018-0794-7;;pmc6152898;;29529017;;10.1038/nmeth.4631;;19213877;;10.1126/science.1168978;;pmc2746483;;10.1038/nrg3645;;24468696;;pmc4006352;;24766808;;10.1016/j.cell.2014.02.033;;10.1007/978-1-60327-367-1_12;;20238084;;19182786;;10.1038/nbt.1523;;pmc2663421;;18715801;;pmc6731373;;10.1016/j.smim.2008.07.003;;11325844;;pmc1266037;;10.1073/pnas.0500090102;;16247014;;10.1038/nature10803;;pmc3288744;;22318517;;20921459;;pmc3020702;;10.1200/jco.2010.28.6963;;10.3410/f.6040956.6344054;;22498709;;10.1038/nprot.2012.037;;8254189;;10.4049/jimmunol.152.1.163;;10.1038/s41467-017-00479-7;;28871148;;pmc5583283;;pmc6348479;;29867227;;10.1038/s41591-018-0040-8;;20406835;;10.1158/1078-0432.ccr-10-0041;;10.1126/science.1076514;;pmc1764179;;12242449;;pmc1475951;;10.1200/jco.2005.00.240;;15800326;;pmc2929689;;19451549;;10.1182/blood-2009-03-211714;;10.1126/science.1129003;;pmc2267026;;16946036;;21832238;;pmc3393096;;10.1126/scitranslmed.3002842;;pmc5413401;;10.1158/1078-0432.ccr-16-1300;;27815355;;pmc4533835;;10.1146/annurev-immunol-032713-120136;;24423116;;pmc6295668;;10.1126/science.aaa4967;;25838374;;22437939;;10.1038/nri3191;;pmc6292222;;10.1111/imr.12139;;24329794;;pmc3991306;;10.1182/blood-2014-04-567933;;24891321;;pmc4102716;;pmc2747302;;19561539;;10.1097/cji.0b013e3181ac6138;;10.1016/s0161-5890(97)00144-2;;9566763;;12393484;;10.1182/blood-2002-07-1989;;pmc1476695;;10.1089/hum.2005.16.457;;15871677;;11753365;;10.1038/nbt0102-70;;29496042;;10.1016/j.oraloncology.2018.01.024;;pmc5836804;;10.1093/neuonc/nox116;;pmc5761579;;28651374;;7573360;;pmc1871000;;10.4049/jimmunol.174.10.6212;;15879118;;pmc2292990;;18256142;;10.1128/jvi.02013-07;;15879877;;10.1097/01.ju.0000158121.49085.ba;;15958592;;10.1158/0008-5472.can-04-4395;;15210797;;10.4049/jimmunol.173.1.384;;29114389;;pmc5671987;;10.1038/cti.2017.37;;18354038;;10.1182/blood-2007-11-120998;;pmc2442746;;10.1016/j.immuni.2009.09.014;;pmc2787786;;19879162;;pmc6134179;;29456158;;10.1016/j.stem.2018.01.016;;10.3389/fimmu.2017.00267;;pmc5376574;;28421069;;10.1111/imr.12132;;pmc3920180;;24329789;;10.1158/2326-6066.cir-15-0190;;26438444;;10.3389/fonc.2017.00064;;28459041;;pmc5394116;;pmc4419602;;25999859;;10.3389/fphar.2015.00095;;10.1182/blood-2014-01-551671;;24753538;;pmc4064331;;20506146;;pmc3290395;;10.1002/stem.433;;26183927;;10.1158/0008-5472.can-14-3321;;pmc5413401;;10.1158/1078-0432.ccr-16-1300;;27815355;;28123068;;10.1126/scitranslmed.aaj2013;;pmc5774207;;29122757;;10.1182/blood-2017-05-787598;;10.1016/j.ymthe.2018.02.025;;pmc5993944;;29605708;;18799724;;pmc2597140;;10.1182/blood-2008-07-169797;;pmc5264497;;27068940;;10.1042/bst20150251;;10.1021/a1980023+;;9726172;;28759029;;10.1038/nmeth.4380;;pmc5669064;;10.1101/113068;;10.1038/protex.2017.068;;10.1016/j.cell.2015.05.002;;26000488;;pmc4481139;;28099430;;10.1038/nmeth.4177;;pmc5334791;;10.1101/083774;;10.1016/j.cell.2015.05.002;;26000488;;pmc4481139;;26000487;;pmc4441768;;10.1016/j.cell.2015.04.044;;10.1038/nbt.3432;;pmc4786454;;26829319;;22318506;;10.1039/c2lc21147e;;10.1039/b805456h;;18651066;;pmc2570196;;29605858;;10.1007/978-1-4939-7768-0_15;;10.1126/science.1231143;;pmc3795411;;23287718;;23360965;;10.1038/nbt.2508;;pmc3748948;;23643243;;pmc3969854;;10.1016/j.cell.2013.04.025;;pmc3856241;;23877069;;10.1038/nature12466;;10.1016/j.cell.2013.09.040;;10.1038/nbt.2647;;23873081;;pmc3969858;;24157548;;10.1038/nprot.2013.143;;pmc3969860;;pmc4089965;;10.1126/science.1247005;;24336571;;24529477;;10.1016/j.cell.2014.02.001;;pmc4139937;;24752079;;pmc4145672;;10.1038/nbt.2889;;pmc4265475;;25263330;;10.1016/j.cell.2014.09.014;;10.1016/j.cell.2014.05.010;;24906146;;pmc4343198;;pmc3972032;;10.1126/science.1246981;;24336569;;10.1038/nbt.3026;;25184501;;pmc4262738;;10.1038/nbt.3055;;pmc4492112;;25326897;;pmc4420636;;10.1038/nature14136;;25494202;;10.1038/nbt.3149;;pmc4503468;;25643054;;25748654;;pmc4380877;;10.1016/j.cell.2015.02.038;;pmc4393360;;25830891;;10.1038/nature14299;;10.1038/nrg3899;;25854182;;pmc4503232;;pmc4509999;;10.1101/gr.191452.115;;26063738;;pmc4522370;;26189680;;10.1016/j.cell.2015.06.059;;pmc4649911;;26035283;;10.1038/srep10833;;pmc4670267;;10.1016/j.cell.2015.08.007;;26317473;;26375006;;pmc4644101;;10.1038/nature15521;;pmc4638220;;26422227;;10.1016/j.cell.2015.09.038;;pmc4660269;;26593719;;10.1016/j.molcel.2015.10.008;;pmc4714946;;10.1126/science.aad5227;;26628643;;27272385;;10.1038/nbt.3596;;10.1101/046417;;10566139;;10.1111/j.1600-065x.1999.tb01326.x;;17908809;;10.1128/iai.00828-07;;pmc2168343;;10.4049/jimmunol.1300097;;23585680;;pmc3647383;;pmc3815523;;10.1021/cb400264n;;23683494;;10477547;;pmc2195611;;10.1084/jem.190.5.617;;16491401;;10.1007/s00262-006-0145-7;;9637761;;10.1006/cimm.1998.1283;;9554254;;10.1097/00002371-199611000-00005;;9041460;;pmc2660151;;19360120;;10.1371/journal.ppat.1000373;;16763660;;10.1038/nrd2059;;18499419;;10.1016/j.coi.2008.04.011;;pmc2538913;;17975151;;10.1158/1078-0432.ccr-07-0486;;10.1038/nature14567;;26040715;;10.1172/jci68395;;pmc3726168;;23867552;;pmc3846695;;23928481;;10.3791/50085;;19136947;;pmc2684978;;10.1038/nmat2357;;8977634;;10.1002/(sici)1097-0045(199612)29:6<371::aid-pros5>3.0.co;2-b;;10.1002/(sici)1097-0045(199612)29:6<371::aid-pros5>3.3.co;2-3;;9288186;;10.1002/(sici)1097-0045(19970901)32:4<272::aid-pros7>3.0.co;2-l;;10.1084/jem.20100223;;pmc2882835;;20479118;;10.1038/nm0810-854;;20689546;;1690918;;10.1126/science.1690918;;2856201;;12663709;;10.1200/jco.2003.06.100;;23159882;;10.1038/nbt.2436;;20413326;;10.1016/j.smim.2010.03.004;;20693851;;pmc2922045;;10.1097/ppo.0b013e3181eaca65;;pmc3256967;;10.1084/jem.20111171;;22065672;;10.1016/s0264-410x(00)00498-9;;11257407;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;10.1002/eji.200324804;;14991590;;20563707;;10.1007/82_2010_49;;pmc4060248;;10.1038/nri2216;;18097448;;10.1002/cncr.24988;;20187092;;22842478;;10.1038/nm.2883;;10.3410/f.717954402.793461338;;16960692;;10.1007/s00262-006-0225-8;;16984371;;10.1111/j.1349-7006.2006.00272.x;;23307859;;10.1158/1078-0432.ccr-12-1630;;pmc3752683;;pmc3232304;;10.1002/ijc.26219;;21633954;;10.1158/1078-0432.ccr-07-5212;;18927310;;10.1158/1078-0432.ccr-11-0184;;21586625;;21149254;;pmc3064599;;10.1093/neuonc/noq157;;pmc5405381;;28228285;;10.1016/j.immuni.2017.02.007;;25640239;;pmc4356254;;10.1016/j.cell.2015.01.009;;29710410;;10.1002/pmic.201700218;;pmc6152898;;29529017;;10.1038/nmeth.4631;;26638175;;10.1016/j.molcel.2015.11.013;;pmc4720255;;10.1093/nar/gky955;;30357393;;pmc6323946;;pmc3319061;;10.1007/s00251-008-0341-z;;19002680;;25599403;;10.1038/ng.3192;;pmc4417758;;10.7554/elife.08890.029;;26687005;;pmc4739776;;10.7554/elife.08890;;26638776;;pmc4686820;;10.1038/ncomms9866;;pmc6546179;;10.1038/s41586-018-0792-9;;30568305;;28528987;;10.1016/j.tcb.2017.04.006;;pmc5565689;;28678784;;10.1038/nature23003;;pmc5287289;;10.1038/nature21036;;28077873,"TRAN ET AL.: ""Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer"", SCIENCE, vol. 344, no. 6184, 9 May 2014 (2014-05-09), pages 641 - 645, XP055547527, DOI: 10.1126/science.1251102;;STEVANOVIC ET AL.: ""Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer"", SCIENCE, vol. 356, no. 6334, 14 April 2016 (2016-04-14), pages 200 - 205, XP055659875, DOI: 10.1126/science.aak9510;;OTT ET AL.: ""An immunogenic personal neoantigen vaccine or patients with melanoma"", NATURE, vol. 547, no. 7662, 13 July 2017 (2017-07-13), pages 217 - 221, XP002785348;;MATSUSHITA ET AL.: ""Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting"", NATURE, vol. 482, 2012, pages 400, XP055355530, DOI: 10.1038/nature10755;;SULLIVAN VJ., GEN. VIR., vol. 68, 1987, pages 2587 - 98;;MOR ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 155, no. 4, 1995, pages 2039 - 2046;;LUCKOWSUMMERS, BIO/TECHNOLOGY, vol. 6, 1988, pages 47;;MOOIJ, P., JOUR. OF VIROL., vol. 82, 2008, pages 2975 - 2988;;SEDEGAH ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 91, no. 21, 1994, pages 9866 - 9870;;BUCHSCHER ET AL., J. VIROL., vol. 188, no. 1, 1992, pages 1635 - 1640;;T. LINDHOUT ET AL., PNAS, vol. 108, no. 18, 2011, pages 7397 - 7402;;LE MERCIER I ET AL.: ""Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators"", FRONT. IMMUNOL., vol. 6, 2015, pages 418;;G. GREGORIADIS ET AL., INT. J. PHARMACEUTICS, vol. 300, no. 1-2, pages 125 - 30;;MERRIFIELD RB: ""Solid phase peptide synthesis. I. The synthesis of a tetrapeptide"", J. AM. CHEM. SOC., vol. 85, 1963, pages 2149 - 54, XP002257754, DOI: 10.1021/ja00897a025;;YILMA TD., VACCINE, vol. 7, 1989, pages 484 - 485;;NASLUND ET AL., VIROLOGY JOURNAL, vol. 8, 2011, pages 36;;SMITHWATERMAN, ADVANCES IN APPLIED MATHEMATICS, vol. 2, 1981, pages 482 - 489;;ZOELLER ET AL., PROC. NAT'L. ACAD. SCI. USA, vol. 81, 1984, pages 5662 - 5066;;BULLER, RM, NATURE, vol. 317, no. 6040, 1985, pages 813 - 5;;GLUZMAN, CELL, vol. 23, 1981, pages 175;;DAHESHIA ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 159, no. 12, 1997, pages 1945 - 1952;;ALARCON ET AL., ADV. PARASITOL. ADVANCES IN PARASITOLOGY, vol. 42, 1999, pages 343 - 410;;ROBINSON ET AL., ADV. VIRUS RES. ADVANCES IN VIRUS RESEARCH, vol. 55, 2000, pages 1 - 74;;BOHMET, JOURNAL OF IMMUNOLOGICAL METHODS, vol. 193, no. 1, 1996, pages 29 - 40;;WEINER ET AL., SCIENTIFIC AMERICAN, vol. 281, no. 1, 1999, pages 129 - 41;;SHAREI ET AL.: ""Ex Vivo Cytosolic Delivery of Functional Macromolecules to Immune Cells"", PLOS ONE, 13 April 2015 (2015-04-13);;CHEN ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 160, no. 5, 1998, pages 2425 - 2432;;SIZEMORE, SCIENCE, vol. 270, no. 5234, 1995, pages 299 - 302;;FYNAN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, no. 24, 1993, pages 11478 - 82;;BADEN ET AL.: ""First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001"", J INFECT DIS., vol. 207, no. 2, 15 January 2013 (2013-01-15), pages 240 - 7, XP055190590, DOI: 10.1093/infdis/jis670;;SOMMNERFELT ET AL., VIROL., vol. 176, 1990, pages 58 - 59;;WILSON ET AL., J. VIROL., vol. 63, 1998, pages 2374 - 2378;;MILLER ET AL., J. VIROL., vol. 65, 1991, pages 2220 - 2224;;NAJERA JL., J. VIROL., vol. 80, no. 12, 2006, pages 6033 - 6047;;CHROBOCZEK, J.BIEBER, F.JACROT, B.: ""The Sequence of the Genome of Adenovirus Type 5 and Its Comparison with the Genome of Adenovirus Type 2"", VIROLOGY, vol. 186, 1992, pages 280 - 285, XP023049327, DOI: 10.1016/0042-6822(92)90082-Z;;VERARDIET, HUM VACCIN IMMUNOTHER., vol. 8, no. 7, July 2012 (2012-07-01), pages 961 - 70;;MOSS, VACCINE, vol. 31, no. 39, 2013, pages 4220 - 4222;;PANICALI, D., PROC. NATL. ACAD. SCI., vol. 79, 1982, pages 7415 - 7419;;PANICALI D., PROC. NATL. ACAD. SCI., vol. 80, no. 23, 1983, pages 7155 - 9;;SMITH GL, NATURE, vol. 302, 1983, pages 490 - 5;;PERKUS M, JOURNAL OF LEUKOCYTE BIOLOGY, vol. 58, 1995, pages 1 - 13;;BROCHIER B., NATURE, vol. 354, 1991, pages 520 - 22;;WIKTOR, TJ, PROC. NATL ACD. SCI., vol. 81, 1984, pages 7194 - 8;;RUPPRECHT, CE, PROC. NATL ACD. SCI., vol. 83, 1986, pages 7947 - 50;;POULET, H, VACCINE, vol. 25, July 2007 (2007-07-01), pages 5606 - 12;;WEYER J., VACCINE, vol. 27, November 2009 (2009-11-01), pages 7198 - 201;;SHIDA, H., J. VIROL., vol. 62, no. 12, 1988, pages 4474 - 80;;FLEXNER, C., NATURE, vol. 330, no. 6145, 1987, pages 259 - 62;;KOTWAL, GJ, J. VIROL., vol. 63, no. 2, 1989, pages 600 - 6;;GOEBEL SJ., VIROLOGY, vol. 179, no. 2, 1990, pages 247 - 66;;MAYR A., ZENTRALBL BAKTERIOL, vol. 167, no. 5,6, 1978, pages 375 - 9;;WYATT, LS., VIROLOGY, vol. 251, no. 2, 1998, pages 334 - 42;;SANCHO, MC., J. VIROL., vol. 76, no. 16, 2002, pages 8313 - 34;;GALLEGO-GOMEZ, JC., J. VIROL., vol. 77, no. 19, 2003, pages 10606 - 57;;GOMEZ, CE, J. GEN. VIROL., vol. 88, 2007, pages 2473 - 78;;GOMEZ, CE., CURR. GENE THER., vol. 11, 2011, pages 189 - 217;;COX,W., VIROLOGY, vol. 195, 1993, pages 845 - 50;;PERKUS, M., JOUR. OF LEUKOCYTE BIOLOGY, vol. 58, 1995, pages 1 - 13;;BLANCHARD TJ, J GEN VIROLOGY, vol. 79, no. 5, 1998, pages 1159 - 67;;AMARA R., SCIENCE, vol. 292, 2001, pages 69 - 74;;HEL, Z., J. IMMUNOL., vol. 167, 2001, pages 7180 - 9;;DIDIERLAURENT, A., VACCINE, vol. 22, 2004, pages 3395 - 3403;;BISSHT H., PROC. NAT. ACA. SCI., vol. 101, 2004, pages 6641 - 46;;MCCURDY LH, CLIN. INF. DIS, vol. 38, 2004, pages 1749 - 53;;EARL PL, NATURE, vol. 428, 2004, pages 182 - 85;;CHEN Z., J. VIROL., vol. 79, 2005, pages 2678 - 2688;;NAM JH, ACTA. VIROL., vol. 51, 2007, pages 125 - 30;;ANTONIS AF, VACCINE, vol. 25, 2007, pages 2863 - 4827;;B WEYER, J. VACCINE, vol. 25, 2007, pages 4213 - 22;;FERRIER-REMBERT A., VACCINE, vol. 26, no. 14, 2008, pages 1794 - 804;;CORBETT, M., PROC. NATL. ACAD. SCI., vol. 105, no. 6, 2008, pages 2046 - 2051;;KAUFMAN HL., J. CLIN. ONCOL., vol. 22, 2004, pages 2122 - 32;;AMATO, RJ, CLIN. CANCER RES., vol. 14, no. 22, 2008, pages 7504 - 10;;DREICER R., INVEST NEW DRUGS, vol. 27, no. 4, 2009, pages 379 - 86;;KANTOFF PW, J. CLIN. ONCOL., vol. 28, 2010, pages 1099 - 1105;;AMATO RJ, J. CLIN. CAN. RES., vol. 16, no. 22, 2010, pages 5539 - 47;;KIM, DW, HUM. VACCINE, vol. 6, 2010, pages 784 - 791;;OUDARD, S., CANCER IMMUNOL. IMMUNOTHER, vol. 60, 2011, pages 261 - 71;;WYATT, LS, AIDS RES. HUM. RETROVIRUSES, vol. 20, 2004, pages 645 - 53;;GOMEZ, CE, VIRUS RESEARCH, vol. 105, 2004, pages 11 - 22;;WEBSTER, DP, PROC. NATL. ACAD. SCI., vol. 102, 2005, pages 4836 - 4;;ESTEBAN M., HUM. VACCINE, vol. 5, 2009, pages 867 - 871;;GOMEZ, CE, CURR. GENE THERAPY, vol. 8, no. 2, 2008, pages 97 - 120;;WHELAN, KT., PLOS ONE, vol. 4, no. 6, 2009, pages 5934;;SCRIBA, TJ, EUR. JOUR. IMMUNO., vol. 40, no. 1, 2010, pages 279 - 90;;MIDGLEY, CM, J. GEN. VIROL., vol. 89, 2008, pages 2992 - 97;;VON KREMPELHUBER, A. VACCINE, vol. 28, 2010, pages 1209 - 16;;PERREAU, M., J. OF VIROL., October 2011 (2011-10-01), pages 9854 - 62;;PANTALEO, G., CURR OPIN HIV-AIDS, vol. 5, 2010, pages 391 - 396;;ROLPH ET AL.: ""Recombinant viruses as vaccines and immunological tools"", CURR OPIN IMMUNOL, vol. 9, 1997, pages 517 - 524, XP004313548, DOI: 10.1016/S0952-7915(97)80104-5;;HORIG HLEE DSCONKRIGHT W ET AL.: ""Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule"", CANCER IMMUNOL IMMUNOTHER, vol. 49, 2000, pages 504 - 14, XP002194114, DOI: 10.1007/s002620000146;;MEHREN MARLEN PTSANG KY ET AL.: ""Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas"", CLIN CANCER RES, vol. 6, 2000, pages 2219 - 28, XP002327290;;MUSEY LDING YELIZAGA M ET AL.: ""HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals"", J IMMUNOL, vol. 171, 2003, pages 1094 - 101;;PAOLETTI E: ""Applications of pox virus vectors to vaccination: an update"", PROC NATL ACAD SCI U S A, vol. 93, 1996, pages 11349 - 53, XP002135943, DOI: 10.1073/pnas.93.21.11349;;MARSHALL JLHAWKINS MJTSANG KY ET AL.: ""Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen"", J CLIN ONCOL, vol. 17, 1999, pages 332 - 7, XP001084702;;MAYR, A. ET AL., INFECTION, vol. 3, 1975, pages 6 - 14;;MEYER, H. ET AL., J. GEN. VIROL., vol. 72, 1991, pages 1031 - 1038;;MANDL ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 61, no. 1, January 2012 (2012-01-01), pages 19 - 29;;INGOLIA NT: ""Ribosome profiling: new views of translation, from single codons to genome scale"", NATURE REVIEWS. GENETICS, vol. 15, no. 3, pages 205 - 13;;JACKSON ET AL.: ""The translation of non-canonical open reading frames controls mucosal immunity"", NATURE, 12 December 2018 (2018-12-12);;JI ET AL., ELIFE, vol. 4, 2015;;ERHARD ET AL., NAT. METHODS, vol. 15, no. 5, May 2018 (2018-05-01), pages 363 - 366;;INGOLIA, N. T.S. GHAEMMAGHAMIJ. R. NEWMANJ. S. WEISSMAN: ""Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling"", SCIENCE, vol. 324, 2009, pages 218 - 223, XP007918278, DOI: 10.1126/science.1168978;;INGOLIA, N. T.: ""Ribosome profiling: new views of translation, from single codons to genome scale"", NAT. REV. GENET, vol. 15, 2014, pages 205 - 213;;LI, G. W.D. BURKHARDTC. GROSSJ. S. WEISSMAN: ""Quantifying absolute protein synthesis rates reveals principles underlying allocation of cellular resources"", CELL, vol. 157, 2014, pages 624 - 635;;KIRKNESS, METHODS MOL. BIOL., vol. 628, 2010, pages 215 - 26;;GNIRKE ET AL., NATURE BIOTECHNOLOGY, vol. 27, 2009, pages 182 - 189;;MYLLYKANGASJI, BIOTECHNOL GENET ENG REV., vol. 27, 2010, pages 135 - 58;;BUCKWALTERSRIVASTAVA PK: ""It is the antigen(s), stupid'' and other lessons from over a decade of vaccitherapy of human cancer"", SEMINARS IN IMMUNOLOGY, vol. 20, 2008, pages 296 - 300, XP025646569, DOI: 10.1016/j.smim.2008.07.003;;KARANIKAS ET AL.: ""High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival"", CANCER RES., vol. 61, 2001, pages 3718 - 3724, XP055111384;;LENNERZ ET AL.: ""The response of autologous T cells to a human melanoma is dominated by mutated neoantigens"", PROC NATL ACAD SCI U S A., vol. 102, 2005, pages 16013, XP002408502, DOI: 10.1073/pnas.0500090102;;DUPAGE ET AL.: ""Expression of tumor-specific antigens underlies cancer immunoediting"", NATURE, vol. 482, 2012, pages 405;;SAMPSON ET AL.: ""Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma"", J CLIN ONCOL., vol. 28, 2010, pages 4722 - 4729, XP055111559, DOI: 10.1200/JCO.2010.28.6963;;CARRENO ET AL., SCIENCE, vol. 274, no. 5284, 4 October 1996 (1996-10-04), pages 803 - 808;;ANDERSEN ET AL., NAT PROTOC., vol. 7, 2012, pages 891 - 902;;PARKER ET AL., J. IMMUNOL., vol. 152, 1994, pages 163;;METTANANDA ET AL.: ""Editing an a-globin enhancer in primary human hematopoietic stem cells as a treatment for 0-thalassemia"", NAT COMMUN., vol. 8, no. 1, 4 September 2017 (2017-09-04), pages 424;;ZACHARAKIS ET AL., NAT MED., vol. 24, no. 6, June 2018 (2018-06-01), pages 724 - 730;;BESSER ET AL., CLIN. CANCER RES, vol. 16, no. 9, 2010, pages 2646 - 55;;DUDLEY ET AL., SCIENCE, vol. 298, no. 5594, 2002, pages 850 - 4;;DUDLEY ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 10, 2005, pages 2346 - 57;;JOHNSON ET AL., BLOOD, vol. 114, no. 3, 2009, pages 535 - 46;;MORGAN ET AL., SCIENCE, vol. 314, no. 5796, 2006, pages 126 - 9;;KALOS ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 3, no. 95, 2011, pages 95ra73;;REN ET AL., CLIN CANCER RES, vol. 23, no. 9, 2017, pages 2255 - 2266;;MAUS ET AL., ADOPTIVE IMMUNOTHERAPY FOR CANCER OR VIRUSES, ANNUAL REVIEW OF IMMUNOLOGY, vol. 32, 2014, pages 189 - 225;;ROSENBERGRESTIFO: ""Adoptive cell transfer as personalized immunotherapy for human cancer"", SCIENCE, vol. 348, no. 6230, 2015, pages 62 - 68, XP055256712, DOI: 10.1126/science.aaa4967;;RESTIFO ET AL.: ""Adoptive immunotherapy for cancer: harnessing the T cell response"", NAT. REV. IMMUNOL., vol. 12, no. 4, 2015, pages 269 - 281, XP055034896, DOI: 10.1038/nri3191;;JENSONRIDDELL: ""Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells"", IMMUNOL REV., vol. 257, no. 1, 2014, pages 127 - 144;;RAJASAGI ET AL.: ""Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia"", BLOOD, vol. 124, no. 3, 17 July 2014 (2014-07-17), pages 453 - 62, XP055322841, DOI: 10.1182/blood-2014-04-567933;;KOCHENDERFER ET AL., J IMMUNOTHER., vol. 32, no. 7, 2009, pages 689 - 702;;NICHOLSON ET AL., MOLECULAR IMMUNOLOGY, vol. 34, 1997, pages 1157 - 1165;;COOPER ET AL., BLOOD, vol. 101, 2003, pages 1637 - 1644;;HUGHES ET AL., HUMAN GENE THERAPY, vol. 16, 2005, pages 457 - 472;;MAHER ET AL., NATURE BIOTECHNOLOGY, vol. 20, 2002, pages 70 - 75;;PARK ET AL.: ""CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma"", ORAL ONCOL., vol. 78, March 2018 (2018-03-01), pages 145 - 150, XP085353974, DOI: 10.1016/j.oraloncology.2018.01.024;;JIN ET AL.: ""CD70, a novel target of CAR T-cell therapy for gliomas"", NEURO ONCOL., vol. 20, no. 1, 10 January 2018 (2018-01-10), pages 55 - 65, XP055464384, DOI: 10.1093/neuonc/nox116;;AGATHANGGELOU ET AL., AM.J.PATHOL., vol. 147, 1995, pages 1152 - 1160;;HUNTER ET AL., BLOOD, vol. 104, no. 4881, 2004, pages 26;;LENS ET AL., J IMMUNOL., vol. 174, 2005, pages 6212 - 6219;;BABA ET AL., J VIROL., vol. 82, 2008, pages 3843 - 3852;;JUNKER ET AL., J UROL., vol. 173, 2005, pages 2150 - 2153;;CHAHLAVI ET AL., CANCER RES, vol. 65, 2005, pages 5428 - 5438;;VON ESSEN, M. ET AL., J. IMMUNOL., vol. 173, 2004, pages 384 - 393;;YUNG ET AL., SCIENCE, 2015;;BUDDEE ET AL., PLOS ONE, 2013;;LI ET AL.: ""Adoptive cell therapy with CD4+ T helper 1 cells and CD8+ cytotoxic T cells enhances complete rejection of an established tumour, leading to generation of endogenous memory responses to non-targeted tumour epitopes"", CLIN TRANSL IMMUNOLOGY, vol. 6, no. 10, October 2017 (2017-10-01), pages el60;;MURANSKI P ET AL.: ""Tumor-specific Thl7-polarized cells eradicate large established melanoma"", BLOOD, vol. 112, no. 2, 15 July 2008 (2008-07-15), pages 362 - 73, XP055503075, DOI: 10.1182/blood-2007-11-120998;;MARTIN-OROZCO N ET AL.: ""T helper 17 cells promote cytotoxic T cell activation in tumor immunity"", IMMUNITY, vol. 31, no. 5, 20 November 2009 (2009-11-20), pages 787 - 98;;KOOREMANNIGEL G. ET AL.: ""Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses"", IN VIVO, CELL STEM CELL, vol. 22, 13 January 2018 (2018-01-13);;IRVING ET AL.: ""Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel"", FRONT. IMMUNOL., 3 April 2017 (2017-04-03);;HINRICHS CS: ""Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer"", IMMUNOL REV, vol. 257, no. 1, 2014, pages 56 - 71, XP055249662, DOI: 10.1111/imr.12132;;HOUOT ET AL.: ""T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition"", CANCER IMMUNOL RES, vol. 3, no. 10, 2015, pages 1115 - 22, XP055437818, DOI: 10.1158/2326-6066.CIR-15-0190;;KAMTA ET AL.: ""Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches"", FRONT. ONCOL., vol. 7, 2017, pages 64;;GRECO ET AL.: ""Improving the safety of cell therapy with the TK-suicide gene"", FRONT. PHARMACOL., vol. 6, 2015, pages 95;;ZHOU ET AL., BLOOD, vol. 123/25, 2014, pages 3895 - 3905;;DI STASI ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 365, 2011, pages 1735 - 1683;;RAMOS ET AL., STEM CELLS, vol. 28, no. 6, 2010, pages 1107 - 15;;POIROT ET AL.: ""Multiplex genome edited T-cell manufacturing platform for ''off-the-shelf'' adoptive T-cell immunotherapies"", CANCER RES, vol. 75, no. 18, 2015, pages 3853, XP055568648, DOI: 10.1158/0008-5472.CAN-14-3321;;REN ET AL.: ""Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition"", CLIN CANCER RES., vol. 23, no. 9, 1 May 2017 (2017-05-01), pages 2255 - 2266, XP055565027, DOI: 10.1158/1078-0432.CCR-16-1300;;QASIM ET AL.: ""Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells"", SCI TRANSL MED., vol. 9, no. 374, 25 January 2017 (2017-01-25), XP055498786, DOI: 10.1126/scitranslmed.aaj2013;;LEGUT ET AL.: ""CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells"", BLOOD, vol. 131, no. 3, 2018, pages 311 - 322, XP055536727, DOI: 10.1182/blood-2017-05-787598;;GEORGIADIS ET AL.: ""Molecular Therapy"", 6 March 2018, PRESS, CORRECTED PROOF, article ""Long Terminal Repeat CRISPR-CAR-Coupled ''Universal'' T Cells Mediate Potent Anti-leukemic Effects"";;OTT, P.A.HU, Z.KESKIN, D.B.SHUKLA, S.A.SUN, J.BOZYM, D.JZHANG, W.LUOMA, A.GIOBBIE-HURDER, A.PETER, L. ET AL.: ""An immunogenic personal neoantigen vaccine for patients with melanoma"", NATURE, vol. 543, 2017, pages 113 - 117;;BONI, MURANSKI ET AL., BLOOD, vol. 112, no. 12, 2008, pages 4746 - 54;;WATSON HA ET AL.: ""SHP-1: the next checkpoint target for cancer immunotherapy?"", BIOCHEM SOC TRANS., vol. 44, no. 2, 15 April 2016 (2016-04-15), pages 356 - 62, XP055469547, DOI: 10.1042/BST20150251;;BURLINGAME ET AL., ANAL. CHEM., vol. 70, 1998, pages 647 R - 716R;;STOECKIUS M ET AL.: ""Simultaneous epitope and transcriptome measurement in single cells"", NATURE METHODS, vol. 9, 31 July 2017 (2017-07-31), pages 2579 - 10;;STOECKIUS, M.SMIBERT, CITE-SEQ, PROTOCOL EXCHANGE, 31 July 2017 (2017-07-31);;MACOSKO ET AL., CELL, vol. 161, no. 5, 21 May 2015 (2015-05-21), pages 1202 - 1214;;NATURE METHODS, vol. 14, no. 3, pages 297 - 301;;DAHLMAN ET AL., NATURE BIOTECHNOLOGY, 2015;;MACOSKO ET AL.: ""Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets"", CELL, vol. 161, 2015, pages 1202 - 1214, XP055586617, DOI: 10.1016/j.cell.2015.05.002;;KLEIN ET AL.: ""Droplet Barcoding for Single-Cell Transcriptomics Applied to Embryonic Stem Cells"", CELL, vol. 161, 2015, pages 1187 - 1201, XP055569619, DOI: 10.1016/j.cell.2015.04.044;;ZHENG ET AL.: ""Haplotyping germline and cancer genomes with high-throughput linked-read sequencing"", NATURE BIOTECHNOLOGY, vol. 34, 2016, pages 303 - 311, XP055486933, DOI: 10.1038/nbt.3432;;GUO ET AL., LAB CHIP, vol. 12, 2012, pages 2146 - 2155;;EDD ET AL.: ""Controlled encapsulation of single-cells into monodisperse picolitre drops"", LAB CHIP, vol. 8, no. 8, 2008, pages 1262 - 1264;;RANU ET AL., NUCLEIC ACIDS RES., 26 September 2018 (2018-09-26);;SCIENCE, vol. 356, no. 6335, 21 April 2017 (2017-04-21), pages eaah4573;;SAGAR ET AL., METHODS MOL BIOL, vol. 1766, 2018, pages 257 - 283;;HAN ET AL., GENOME BIOL., vol. 19, 2018, pages 47;;CONG, L.RAN, F.A.COX, D.LIN, S.BARRETTO, R.HABIB, N.HSU, P.D.WU, X.JIANG, W.MARRAFFINI, L.A.: ""Multiplex genome engineering using CRISPR/Cas systems"", SCIENCE, vol. 339, no. 6121, 15 February 2013 (2013-02-15), pages 819 - 23, XP055458249, DOI: 10.1126/science.1231143;;JIANG W.BIKARD D.COX D.ZHANG FMARRAFFINI LA: ""RNA-guided editing of bacterial genomes using CRISPR-Cas systems"", NAT BIOTECHNOL, vol. 31, no. 3, March 2013 (2013-03-01), pages 233 - 9, XP055249123, DOI: 10.1038/nbt.2508;;WANG H.YANG H.SHIVALILA CS.DAWLATY MM.CHENG AW.ZHANG F.JAENISCH R.: ""One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering"", CELL, vol. 153, no. 4, 9 May 2013 (2013-05-09), pages 910 - 8, XP028538358, DOI: 10.1016/j.cell.2013.04.025;;KONERMANN SBRIGHAM MDTREVINO AEHSU PDHEIDENREICH MCONG LPLATT RJSCOTT DACHURCH GMZHANG F: ""Optical control of mammalian endogenous transcription and epigenetic states"", NATURE, vol. 500, no. 7463, 22 August 2013 (2013-08-22), pages 472 - 6;;RAN, FA.HSU, PD.LIN, CY.GOOTENBERG, JS.KONERMANN, S.TREVINO, AE.SCOTT, DA.INOUE, A.MATOBA, S.ZHANG, Y.: ""Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity"", CELL, vol. 0092-8674, no. 13, 28 August 2013 (2013-08-28), pages 01015 - 5;;HSU, P.SCOTT, D.WEINSTEIN, J.RAN, FA.KONERMANN, S.AGARWALA, V.LI, Y.FINE, E.WU, X.SHALEM, O.: ""DNA targeting specificity of RNA-guided Cas9 nucleases"", NAT BIOTECHNOL, 2013;;RAN, FA.HSU, PD.WRIGHT, J.AGARWALA, V.SCOTT, DA.ZHANG, F.: ""Genome engineering using the CRISPR-Cas9 system"", NATURE PROTOCOLS, vol. 8, no. 11, November 2013 (2013-11-01), pages 2281 - 308, XP009174668, DOI: 10.1038/nprot.2013.143;;SHALEM, O.SANJANA, NE.HARTENIAN, E.SHI, X.SCOTT, DA.MIKKELSON, T.HECKL, D.EBERT, BL.ROOT, DE.DOENCH, JG.: ""Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells"", SCIENCE, 12 December 2013 (2013-12-12);;NISHIMASU, H.RAN, FA.HSU, PD.KONERMANN, S.SHEHATA, SI.DOHMAE, N.ISHITANI, R.ZHANG, F.NUREKI, O.: ""Crystal structure of cas9 in complex with guide RNA and target DNA"", CELL, vol. 156, no. 5, 27 February 2014 (2014-02-27), pages 935 - 49, XP028667665, DOI: 10.1016/j.cell.2014.02.001;;WU X.SCOTT DA.KRIZ AJ.CHIU AC.HSU PD.DADON DB.CHENG AW.TREVINO AE.KONERMANN S.CHEN S.: ""Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells"", NAT BIOTECHNOL., 20 April 2014 (2014-04-20);;PLATT RJCHEN SZHOU YYIM MJSWIECH LKEMPTON HRDAHLMAN JEPARNAS OEISENHAURE TMJOVANOVIC M: ""CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling"", CELL, vol. 159, no. 2, 2014, pages 440 - 455, XP055523070, DOI: 10.1016/j.cell.2014.09.014;;HSU PDLANDER ESZHANG F.: ""Development and Applications of CRISPR-Cas9 for Genome Engineering"", CELL, vol. 157, no. 6, 5 June 2014 (2014-06-05), pages 1262 - 78, XP055529223, DOI: 10.1016/j.cell.2014.05.010;;WANG TWEI JJSABATINI DMLANDER ES.: ""Genetic screens in human cells using the CRISPR/Cas9 system"", SCIENCE, vol. 343, no. 6166, 3 January 2014 (2014-01-03), pages 80 - 84, XP055294787, DOI: 10.1126/science.1246981;;DOENCH JGHARTENIAN EGRAHAM DBTOTHOVA ZHEGDE MSMITH ISULLENDER MEBERT BLXAVIER RJROOT DE.: ""Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation"", NAT BIOTECHNOL., vol. 32, no. 12, 3 September 2014 (2014-09-03), pages 1262 - 7, XP055376169, DOI: 10.1038/nbt.3026;;SWIECH LHEIDENREICH MBANERJEE AHABIB NLI YTROMBETTA JSUR MZHANG F.: ""In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9"", NAT BIOTECHNOL., vol. 33, no. 1, 19 October 2014 (2014-10-19), pages 102 - 6, XP055176807, DOI: 10.1038/nbt.3055;;KONERMANN SBRIGHAM MDTREVINO AEJOUNG JABUDAYYEH 00BARCENA CHSU PDHABIB NGOOTENBERG JSNISHIMASU H: ""Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex"", NATURE, vol. 517, no. 7536, 29 January 2015 (2015-01-29), pages 583 - 8, XP055585957, DOI: 10.1038/nature14136;;ZETSCHE BVOLZ SEZHANG F.: ""A split-Cas9 architecture for inducible genome editing and transcription modulation"", NAT BIOTECHNOL., vol. 33, no. 2, 2 February 2015 (2015-02-02), pages 139 - 42, XP055227889, DOI: 10.1038/nbt.3149;;CHEN SSANJ ANA NEZHENG KSHALEM OLEE KSHI XSCOTT DASONG JPAN JQWEISSLEDER R: ""Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis"", CELL, vol. 160, 12 March 2015 (2015-03-12), pages 1246 - 1260, XP029203797, DOI: 10.1016/j.cell.2015.02.038;;IN VIVO GENOME EDITING USING STAPHYLOCOCCUS AUREUS CAS9RAN FACONG LYAN WXSCOTT DAGOOTENBERG JSKRIZ AJZETSCHE BSHALEM OWU X, NATURE, vol. 520, no. 7546, 1 April 2015 (2015-04-01), pages 186 - 91;;SHALEM ET AL.: ""High-throughput functional genomics using CRISPR-Cas9"", NATURE REVIEWS GENETICS, vol. 16, May 2015 (2015-05-01), pages 299 - 311, XP055207968, DOI: 10.1038/nrg3899;;XU ET AL.: ""Sequence determinants of improved CRISPR sgRNA design"", GENOME RESEARCH, vol. 25, August 2015 (2015-08-01), pages 1147 - 1157, XP055321186, DOI: 10.1101/gr.191452.115;;PARNAS ET AL.: ""A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks"", CELL, vol. 162, 30 July 2015 (2015-07-30), pages 675 - 686, XP029248090, DOI: 10.1016/j.cell.2015.06.059;;RAMANAN ET AL.: ""CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus"", SCIENTIFIC REPORTS, vol. 5, 2 June 2015 (2015-06-02), pages 10833, XP055305966, DOI: 10.1038/srep10833;;NISHIMASU ET AL.: ""Crystal Structure of Staphylococcus aureus Cas9"", CELL, vol. 162, 27 August 2015 (2015-08-27), pages 1113 - 1126, XP055304450, DOI: 10.1016/j.cell.2015.08.007;;CANVER ET AL.: ""BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis"", NATURE, vol. 527, no. 7577, 12 November 2015 (2015-11-12), pages 192 - 7, XP055274680, DOI: 10.1038/nature15521;;ZETSCHE ET AL.: ""Cpfl Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System,"", CELL, vol. 163, 25 September 2015 (2015-09-25), pages 759 - 71;;SHMAKOV ET AL.: ""Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems"", MOLECULAR CELL, vol. 60, no. 3, 22 October 2015 (2015-10-22), pages 385 - 397, XP055482679, DOI: 10.1016/j.molcel.2015.10.008;;SLAYMAKER ET AL.: ""Rationally engineered Cas9 nucleases with improved specificity"", SCIENCE, vol. 351, no. 6268, 1 January 2016 (2016-01-01), pages 84 - 88, XP055551663, DOI: 10.1126/science.aad5227;;GAO ET AL.: ""Engineered Cpfl Enzymes with Altered PAM Specificities"", BIORXIV, vol. 091611, 4 December 2016 (2016-12-04);;ABUDAYEH ET AL., SCIENCE, vol. 5, no. 353, 2016, pages 6299;;HUR, J.K. ET AL.: ""Targeted mutagenesis in mice by electroporation of Cpfl ribonucleoproteins"", NAT BIOTECHNOL., 6 June 2016 (2016-06-06);;KIM, D. ET AL.: ""Genome-wide analysis reveals specificities of Cpfl endonucleases in human cells"", NAT BIOTECHNOL., 6 June 2016 (2016-06-06);;PORT, F. ET AL., EXPANSION OF THE CRISPR TOOLBOX IN AN ANIMAL WITH TRNA-FLANKED CAS9 AND CPFL GRNAS;;SHENGDAR Q. TSAINICOLAS WYVEKENSCYD KHAYTERJENNIFER A. FODENVISHAL THAPARDEEPAK REYONMATHEW J. GOODWINMARTIN J. ARYEEJ. KEITH JOUN: ""Dimeric CRISPR RNA-guided Fokl nucleases for highly specific genome editing"", NATURE BIOTECHNOLOGY, vol. 32, no. 6, 2014, pages 569 - 77, XP055378307;;SCHNEIDER ET AL.: ""Induction of CD8+ T cells using heterologous prime-boost immunization strategies"", IMMUNOLOGICAL REVIEWS, vol. 170, no. 1, August 1999 (1999-08-01), pages 29 - 38, XP000981910, DOI: 10.1111/j.1600-065X.1999.tb01326.x;;HUTCHINGS ET AL.: ""Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge"", INFECT IMMUN., vol. 75, no. 12, December 2007 (2007-12-01), pages 5819 - 26;;CONLON ET AL.: ""Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid"", JOURNAL OF IMMUNOLOGY, vol. 190, 2013, pages 5216 - 25, XP055367377, DOI: 10.4049/jimmunol.1300097;;KIM ET AL., ANTICANCER FLAVONOIDS ARE MOUSE-SELECTIVE STING AGONISTS, vol. 8, 2013, pages 1396 - 1401;;NISHIMURA ET AL.: ""Distinct role of antigen-specific T helper type 1 (TH1) and Th2 cells in tumor eradication in vivo"", J EX MED, vol. 190, 1999, pages 617 - 27;;""Encyclopedia of Reagents for Organic Synthesis"", 1995, JOHN WILEY AND SONS;;BRUNSVIG P F ET AL., CANCER IMMUNOL IMMUNOTHER., vol. 55, no. 12, 2006, pages 1553 - 1564;;M. STAEHLER ET AL., ASCO MEETING, 2007;;DUPUIS M ET AL., CELL IMMUNOL., vol. 186, no. 1, 1998, pages 18 - 27;;ALLISON A C, DEV BIOL STAND., vol. 92, 1998, pages 3 - 11;;GABRILOVICH D I ET AL., J IMMUNOTHER EMPHASIS TUMOR IMMUNOL., vol. 6, 1996, pages 414 - 418;;STAHL-HENNIG CEISENBLATTER MJASNY E ET AL.: ""Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques"", PLOS PATHOGENS, vol. 5, no. 4, April 2009 (2009-04-01);;ARTHUR M. KRIEG, NATURE REVIEWS, DRUG DISCOVERY, 5 June 2006 (2006-06-05), pages 471 - 484;;KOBAYASHI ET AL., CURRENT OPINION IN IMMUNOLOGY, vol. 20, 2008, pages 221 - 27;;SLINGLUFF ET AL.: ""Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting"", CLINICAL CANCER RESEARCH, vol. 13, no. 21, 2007, pages 6386 - 95, XP009144705, DOI: 10.1158/1078-0432.CCR-07-0486;;KREITER ET AL.: ""Mutant MHC Class II epitopes drive therapeutic immune responses to cancer"", NATURE, 2015;;CARRENO ET AL.: ""L-12p70-producing patient DC vaccine elicits Tel-polarized immunity"", JOURNAL OF CLINICAL INVESTIGATION, vol. 123, no. 8, 2013, pages 33 83 - 94;;ALI ET AL.: ""situ regulation of DC subsets and T cells mediates tumor regression in mice"", CANCER IMMUNOTHERAPY, vol. 1, no. 8, 2009, pages 1 - 10, XP009165920, DOI: 10.1126/scitranslmed.3000359;;SABADO ET AL.: ""Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy"", J. VIS EXP., vol. 1, no. 78, August 2013 (2013-08-01);;ALI ET AL.: ""In situ regulation of DC subsets and T cells mediates tumor regression in mice"", CANCER IMMUNOTHERAPY, vol. 1, no. 8, pages 1 - 10;;ALI ET AL.: ""Infection-mimicking materials to program dendritic cells in situ"", NAT MATER, vol. 8, 2009, pages 151 - 8;;SHAREI ET AL., PLOS ONE, 2015;;MURPHY ET AL., THE PROSTATE, vol. 29, 1996, pages 371 - 380;;TJUA ET AL., THE PROSTATE, vol. 32, 1997, pages 272 - 278;;CROZAT ET AL., J. EXP. MED., vol. 207, 2010, pages 1283 - 1292;;GALLOISBHARDWAJ, NATURE MED., vol. 16, 2010, pages 854 - 856;;WOLFF ET AL., SCIENCE, vol. 247, 1990, pages 1465 - 1468;;MANNINOGOULD-FOGERITE, BIOTECHNIQUES, vol. 6, no. 7, 1988, pages 682 - 691;;FEIGNER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413 - 7414;;HALABI ET AL., J CLIN ONCOL, vol. 21, 2003, pages 1232 - 1237;;PETSCH ET AL., NATURE BIOTECHNOLOGY, vol. 30, no. 12, 7 December 2012 (2012-12-07), pages 1210 - 6;;SAMBROOK: ""Transdermal Drug Delivery: Developmental Issues and Research Initiatives"", 1989, MARCEL DEKKER INC.;;GAIT, OLIGONUCLEOTIDE SYNTHESIS, 1984;;FRESHNEY, ANIMAL CELL CULTURE, 1987;;WEI: ""Handbook of Experimental Immunology"", 1996, article ""Methods in Enzymology"";;MILLERCALOS, GENE TRANSFER VECTORS FOR MAMMALIAN CELLS, 1987;;AUSUBEL, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 1987;;MULLIS, PCR: THE POLYMERASE CHAIN REACTION, 1994;;COLIGAN, CURRENT PROTOCOLS IN IMMUNOLOGY, 1991;;SPEISERROMERO: ""Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity Seminars"", IMMUNOL, vol. 22, 2010, pages 144, XP027080489, DOI: 10.1016/j.smim.2010.03.004;;BHARDWAJGNJATIC: ""TLR AGONISTS: Are They Good Adjuvants?"", CANCER J., vol. 16, 2010, pages 382 - 391, XP055641509, DOI: 10.1097/PPO.0b013e3181eaca65;;CASKEY ET AL.: ""Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans"", J EXP MED, vol. 208, 2011, pages 2357;;AUCOUTURIER ET AL., VACCINE, vol. 19, 2001, pages 2666 - 2672;;GOODMANGILMAN ET AL.: ""The Pharmacological Basis of Therapeutics"", 2005, MCGRAW-HILL;;""Remington: The Science and Practice of Pharmacy"", 2003, LIPPINCOTT WILLIAMS & WILKINS;;NOCENTINI ET AL., PROC NATL ACAD SCI USA, vol. 94, 1997, pages 6216 - 6221;;RONCHETTI ET AL., EUR J IMMUNOL, vol. 34, 2004, pages 613 - 622;;AVOGADRI ET AL., CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 344, 2011;;PAGE, ANNUAL REVIEW OF MEDICINE, vol. 65, 2014, pages 27;;ZITVOGEL ET AL.: ""Immunological aspects of cancer chemotherapy"", NAT REV IMMUNOL., vol. 8, no. 1, January 2008 (2008-01-01), pages 59 - 73, XP055008389, DOI: 10.1038/nri2216;;PEREZ ET AL.: ""A new era in anticancer peptide vaccines"", CANCER, May 2010 (2010-05-01);;WALTER ET AL.: ""Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival"", NATURE MEDICINE, vol. 18, 2012, pages 8;;GHIRINGHELLI ET AL.: ""Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients"", CANCER IMMUNOL IMMUNOTHER, vol. 56, 2007, pages 641 - 648, XP019489789;;ITOH ET AL.: ""Personalized peptide vaccines: A new therapeutic modality for cancer"", CANCER SCI, vol. 97, 2006, pages 970 - 976, XP002538826, DOI: 10.1111/j.1349-7006.2006.00272.x;;FREDERICK ET AL.: ""BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma"", CLIN CANCER RES., vol. 19, 2013, pages 1225 - 1231, XP055568357, DOI: 10.1158/1078-0432.CCR-12-1630;;FARSACI ET AL.: ""Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy"", INT J CANCER, vol. 130, pages 1948 - 1959 et al.",PENDING
304,WO,A1,WO 2019/240943 A1,067-349-129-896-710,2019-12-19,2019,US 2019/0034236 W,2019-05-29,US 201816006793 A,2018-06-12,INTACT PEA PROTEIN-BASED NUTRIENT COMPOSITION,"The present invention discloses a nutritional composition and method of using and making the nutritional composition. The nutritional composition is an intact pea protein based nutrient composition for use in both enteral and oral feeding, and provides a nonallergenic diet for providing optimal nutrition to users. The nutritional composition is made from organic and plant-based ingredients. The nutritional composition has pea protein, phytochemical extracts, fatty acids, organic ingredients free of the top eight allergens and corn, and prebiotic fiber. The nutritional composition is provided in liquid form for enteral and/or oral feeding.",KATE FARMS INC,LAVER RICHARD;;LAVER MICHELLE;;MATTHEWS BRETT;;PICKAR WILLIAM;;COLE DAVID;;WITHERLY STEVEN;;WITHERLY CAROLINE;;CARR VANESSA;;PHREANER CHRISTINA,,https://lens.org/067-349-129-896-710,Patent Application,yes,8,2,11,11,0,A61K31/202;;A61K31/733;;A61K36/53;;A61K36/898;;A61K36/88;;A61K36/899;;A23L33/105;;A23L33/12;;A23L33/10;;A23L33/21;;A23L33/185;;A61K33/06;;A61K33/14;;A61P3/02;;A23V2002/00;;A23J3/14;;A23L33/10;;A23L33/105;;A23L33/12;;A23L33/135;;A23L33/15;;A23L33/16;;A23J3/16;;A61K36/53;;A61K36/88;;A61K36/898;;A61K36/899;;A61K31/202;;A61K31/733;;A61K33/06;;A61K33/14;;A61P3/02;;A23V2250/1874;;A23V2250/5062;;A23V2200/32;;A23V2002/00;;A23V2250/21;;A23V2250/1944;;A23V2250/1868;;A23V2250/187;;A61K31/733;;A23L33/185;;A23L33/105;;A23L33/12;;A23L33/15;;A23V2002/00;;A23L33/26;;A61K36/53;;A61K31/202;;A61K36/898;;A23L33/16;;A23L33/135;;A23J3/14,A23C9/156,,3,0,,,"GUNNARS, K. ET AL.: ""Avoid Vegetable Oils High In Omega-6"", HOW TO OPTIMIZE YOUR OMEGA-6 TO OMEGA-3 RATIO, 11 June 2018 (2018-06-11), pages 7 - 9, XP055669028, Retrieved from the Internet <URL:https://www.healthline.com/nutrition/optimize-omega-6-omega-3-ratio>;;ANONYMOUS: ""Sunflower Oil"", 8 October 2010 (2010-10-08), pages 1 - 1, XP055755909, Retrieved from the Internet <URL:https://web.archive.org/web/20101008154453/https://www.sunflowernsa.com/oil/linoleic-sunflower-oil/>;;TEXTRON: ""Sunflower Oil, Organic"", TEXTRON PRODUCT DATA SHEET, 31 December 2007 (2007-12-31), XP055669046, Retrieved from the Internet <URL:https://www.brenntag.com/media/documents/bsi/product-data-sheets/life-science/textron-natural-oils/sunflower-oil-refined-tx008081_pds.pdf>",PENDING
305,AU,A,AU 2000/045487 A,013-875-989-330-654,2000-11-02,2000,AU 2000/045487 A,2000-04-12,EP 0003336 W;;US 12932899 P,1999-04-14,Method of aquifer remediation,,SHELL INT RESEARCH,JOHNSON PAUL CARR;;SALANITRO JOSEPH PATRICK;;STEARNS STEVEN MERLE;;MANER PAUL MICHAEL;;MILLER JAMES HENRY;;SPINNLER GERARD EUGENE,,https://lens.org/013-875-989-330-654,Patent Application,no,0,0,18,18,0,B09C1/002;;B09C1/10;;B09C2101/00;;E21B43/00;;E21B43/30;;Y10S210/908;;E21B43/00;;E21B43/30;;B09C1/002;;B09C1/10;;B09C2101/00;;Y10S210/908,B09C1/00;;B09C1/10;;E21B43/00;;E21B43/30,,0,0,,,,DISCONTINUED
306,PT,E,PT 1169271 E,057-444-199-285-491,2004-08-31,2004,PT 00926914 T,2000-04-12,US 12932899 P,1999-04-14,METODO DE DESCONTAMINACAO DUMA CAMADA AQUIFERA,,SHELL INT RESEARCH,JOHNSON PAUL CARR;;SALANITRO JOSEPH PATRICK;;STEARNS STEVEN MERLE;;MANER PAUL MICHAEL;;MILLER JAMES HENRY;;SPINNLER GERARD EUGENE,,https://lens.org/057-444-199-285-491,Granted Patent,no,0,0,18,18,0,B09C1/002;;B09C1/10;;B09C2101/00;;E21B43/00;;E21B43/30;;Y10S210/908;;E21B43/00;;E21B43/30;;B09C1/002;;B09C1/10;;B09C2101/00;;Y10S210/908,B09C1/00;;B09C1/10;;E21B43/00;;E21B43/30,,0,0,,,,EXPIRED
307,EP,B1,EP 1169271 B1,085-439-004-111-862,2004-03-24,2004,EP 00926914 A,2000-04-12,EP 0003336 W;;US 12932899 P,1999-04-14,METHOD OF AQUIFER REMEDIATION,,SHELL INT RESEARCH,JOHNSON PAUL CARR;;SALANITRO JOSEPH PATRICK;;STEARNS STEVEN MERLE;;MANER PAUL MICHAEL;;MILLER JAMES HENRY;;SPINNLER GERARD EUGENE,,https://lens.org/085-439-004-111-862,Granted Patent,yes,4,2,18,18,0,B09C1/002;;B09C1/10;;B09C2101/00;;E21B43/00;;E21B43/30;;Y10S210/908;;E21B43/00;;E21B43/30;;B09C1/002;;B09C1/10;;B09C2101/00;;Y10S210/908,B09C1/00;;B09C1/10;;E21B43/00;;E21B43/30,,0,0,,,,EXPIRED
308,CN,A,CN 112118748 A,097-595-370-569-734,2020-12-22,2020,CN 201980032571 A,2019-05-08,US 201815980355 A;;US 2019/0031362 W,2018-05-15,HYDROLYZED PEA PROTEIN-BASED NUTRIENT COMPOSITION,"The present invention discloses a nutritional composition and method of using and making the nutritional composition. The nutritional composition is a hydrolyzed pea protein based nutrient compositionfor use in both enteral and oral feeding, and provides a non-allergenic diet for providing optimal nutrition to users. The nutritional composition is made from organic and plant-based ingredients. The nutritional composition has pea protein hydrolysates, phytochemical extracts, fatty acids, organic ingredients free of the top eight allergens and corn, and prebiotic fiber. The nutritional composition is provided in liquid form for enteral and/or oral feeding.",KATE FARMS INC,LAVER RICHARD;;LAVER MICHELLE;;MATTHEWS BRETT;;PICKAR WILLIAM;;COLE DAVID;;WITHERLY STEVEN;;WITHERLY CAROLINE;;CARR VANESSA;;PHREANER CHRISTINA,,https://lens.org/097-595-370-569-734,Patent Application,no,14,1,12,12,0,A61K31/01;;A61K31/015;;A61K31/198;;A61K31/216;;A61K31/23;;A61K31/255;;A61K31/353;;A61K31/375;;A61K31/7028;;A61K31/733;;A61K33/00;;A61K33/06;;A61K33/14;;A61K38/168;;A61K36/53;;A61K36/898;;A61K36/899;;A61K36/537;;A61K36/21;;A61K36/48;;A61K36/88;;A23L33/105;;A23L33/16;;A23L33/15;;A23L33/115;;A23L33/21;;A23L33/18;;A23L33/185;;A23L33/40;;A23L33/105;;A23L33/185;;A23L33/115;;A23L33/135;;A23L33/15;;A23L33/16;;A23L3/01;;A61K38/011;;A61K36/28;;A61K36/53;;A61K31/194;;A61K33/14;;A61K31/202;;A61K31/201;;A61P3/02;;A23V2002/00;;A23V2250/21;;A23V2250/194;;A23V2200/262;;A23V2200/30;;A61K2300/00;;A23L33/18;;A23V2002/00;;A23L33/105;;A23L33/12;;A23L33/16;;A23L33/15;;A23L33/21;;A61K31/353;;A61K31/216;;A61K31/375;;A61K31/7028;;A61K31/01;;A61K31/198;;A61K31/255;;A61K31/015;;A61K9/0019;;A61K36/55;;A61K36/28;;A61K38/168;;A61K31/733;;A61K31/23;;A61K36/537;;A61K36/21;;A61K36/53;;A61K33/00;;A61K33/06;;A61K33/14;;A23L33/185,A23L33/00;;A23L2/66;;A23L33/105;;A23L33/12;;A23L33/18,,0,0,,,,PENDING
309,AT,T1,AT E262491 T1,125-422-138-702-551,2004-04-15,2004,AT 00926914 T,2000-04-12,EP 0003336 W;;US 12932899 P,1999-04-14,VERFAHREN ZUR GRUNDWASSERSANIERUNG,,SHELL INT RESEARCH,JOHNSON PAUL CARR;;SALANITRO JOSEPH PATRICK;;STEARNS STEVEN MERLE;;MANER PAUL MICHAEL;;MILLER JAMES HENRY;;SPINNLER GERARD EUGENE,,https://lens.org/125-422-138-702-551,Granted Patent,no,0,0,18,18,0,B09C1/002;;B09C1/10;;B09C2101/00;;E21B43/00;;E21B43/30;;Y10S210/908;;E21B43/00;;E21B43/30;;B09C1/002;;B09C1/10;;B09C2101/00;;Y10S210/908,B09C1/00;;B09C1/10;;E21B43/00;;E21B43/30,,0,0,,,,DISCONTINUED
310,ES,T3,ES 2218155 T3,036-689-363-134-841,2004-11-16,2004,ES 00926914 T,2000-04-12,US 12932899 P,1999-04-14,METODO PARA LA DESCONTAMINACION DE ACUIFEROS.,"Un método para la descontaminación in situ de un acuífero que tiene una zona a través de la cual pasa agua contaminada con al menos un contaminante que es un producto químico recalcitrante el metil t-butileter (MTBE) y/o el alcohol butílico terciario (TBA), cuyo método comprende, a) proveer a la zona en el acuífero un gas que contiene oxígeno, a una presión de al menos 5 psi (0, 35 bar) mayor que la presión hidrostática en el punto de provisión por inyección por pulsos, a una frecuencia en la gama de desde una vez por semana a 10 veces por día, y b) proveer a la zona en el acuífero un cultivo microbiano capaz de degradar el al menos un contaminante químico.",SHELL INT RESEARCH,JOHNSON PAUL CARR;;SALANITRO JOSEPH PATRICK;;STEARNS STEVEN MERLE;;MANER PAUL MICHAEL;;MILLER JAMES HENRY;;SPINNLER GERARD EUGENE,,https://lens.org/036-689-363-134-841,Granted Patent,no,0,0,18,18,0,B09C1/002;;B09C1/10;;B09C2101/00;;E21B43/00;;E21B43/30;;Y10S210/908;;E21B43/00;;E21B43/30;;B09C1/002;;B09C1/10;;B09C2101/00;;Y10S210/908,B09C1/00;;B09C1/10;;E21B43/00;;E21B43/30,,0,0,,,,EXPIRED
311,WO,A3,WO 2020/131586 A3,100-230-535-597-827,2020-07-23,2020,US 2019/0066104 W,2019-12-12,US 201862780832 P;;US 201962820042 P,2018-12-17,METHODS FOR IDENTIFYING NEOANTIGENS,"Disclosed herein are polypeptides and compositions comprising one or more neoantigens, methods of identifying neoantigens, and methods for preparing a neoantigen for an immunogenic pharmaceutical composition. The neoantigen can be specific to a subject that has a cancer, disease, or other disorder.",BROAD INST INC;;MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL;;DANA FARBER CANCER INST INC;;OUSPENSKAIA TAMARA;;LAW TRAVIS;;CARR STEVEN;;CLAUSER KARL;;KLAEGER SUSAN;;WU CATHERINE;;KESKIN DERIN,KESKIN DERIN;;REGEV AVIV;;HACOHEN NIR;;OUSPENSKAIA TAMARA;;LAW TRAVIS;;CARR STEVEN;;CLAUSER KARL;;KLAEGER SUSAN;;WU CATHERINE,,https://lens.org/100-230-535-597-827,Search Report,yes,2,0,3,3,0,A61K39/0011;;G01N33/56972;;C12Q1/6869;;A61K39/0005;;A61K45/06;;C12Q1/6869;;G01N33/6848,A61K39/00;;C12Q1/68;;C12Q1/6869;;G01N33/569,,1,1,025-866-577-884-248,29459023;;10.1016/j.lfs.2018.01.025,"SHEN YING ET AL: ""Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma"", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 196, 3 February 2018 (2018-02-03), pages 133 - 142, XP085351309, ISSN: 0024-3205, DOI: 10.1016/J.LFS.2018.01.025",PENDING
312,US,A1,US 2019/0374569 A1,188-530-081-375-919,2019-12-12,2019,US 201816006793 A,2018-06-12,US 201816006793 A,2018-06-12,INTACT PEA PROTEIN-BASED NUTRIENT COMPOSITION,"The present invention discloses a nutritional composition and method of using and making the nutritional composition. The nutritional composition is an intact pea protein based nutrient composition for use in both enteral and oral feeding, and provides a non-allergenic diet for providing optimal nutrition to users. The nutritional composition is made from organic and plant-based ingredients. The nutritional composition has pea protein, phytochemical extracts, fatty acids, organic ingredients free of the top eight allergens and corn, and prebiotic fiber. The nutritional composition is provided in liquid form for enteral and/or oral feeding.",LAVER RICHARD;;LAVER MICHELLE;;MATTHEWS BRETT;;PICKAR BILL;;COLE DAVID;;WITHERLY STEVEN;;WITHERLY CAROLINE;;CARR VANESSA;;PHREANER CHRISTINA,LAVER RICHARD;;LAVER MICHELLE;;MATTHEWS BRETT;;PICKAR BILL;;COLE DAVID;;WITHERLY STEVEN;;WITHERLY CAROLINE;;CARR VANESSA;;PHREANER CHRISTINA,KATE FARMS INC (2020-04-02),https://lens.org/188-530-081-375-919,Patent Application,yes,19,6,11,11,0,A61K31/202;;A61K31/733;;A61K36/53;;A61K36/898;;A61K36/88;;A61K36/899;;A23L33/105;;A23L33/12;;A23L33/10;;A23L33/21;;A23L33/185;;A61K33/06;;A61K33/14;;A61P3/02;;A23V2002/00;;A23J3/14;;A23L33/10;;A23L33/105;;A23L33/12;;A23L33/135;;A23L33/15;;A23L33/16;;A23J3/16;;A61K36/53;;A61K36/88;;A61K36/898;;A61K36/899;;A61K31/202;;A61K31/733;;A61K33/06;;A61K33/14;;A61P3/02;;A23V2250/1874;;A23V2250/5062;;A23V2200/32;;A23V2002/00;;A23V2250/21;;A23V2250/1944;;A23V2250/1868;;A23V2250/187;;A61K31/733;;A23L33/185;;A23L33/105;;A23L33/12;;A23L33/15;;A23V2002/00;;A23L33/26;;A61K36/53;;A61K31/202;;A61K36/898;;A23L33/16;;A23L33/135;;A23J3/14,A61K31/733;;A23L33/105;;A23L33/12;;A23L33/15;;A23L33/16;;A23L33/185;;A23L33/26;;A61K31/202;;A61K36/53;;A61K36/898,,0,0,,,,PENDING
313,WO,A1,WO 2000/063127 A1,034-471-839-093-236,2000-10-26,2000,EP 0003336 W,2000-04-12,US 12932899 P,1999-04-14,METHOD OF AQUIFER REMEDIATION,"The invention provides a method for the in situ remediation of an aquifer having a zone through which passes water contaminated with at least one contaminant which method comprises: a) delivering to the zone in the aquifer an oxygen-containing gas at a pressure of at least 5 psi(0.35 Bar) above hydrostatic pressure at point of delivery by pulsed injection at a frequency in the range of from once per week to 10 times per day, and b) delivering to the zone in the aquifer a microbial culture capable of degrading the at least one chemical contaminant.",SHELL INT RESEARCH,JOHNSON PAUL CARR;;SALANITRO JOSEPH PATRICK;;STEARNS STEVEN MERLE;;MANER PAUL MICHAEL;;MILLER JAMES HENRY;;SPINNLER GERARD EUGENE,,https://lens.org/034-471-839-093-236,Patent Application,yes,4,5,18,18,0,B09C1/002;;B09C1/10;;B09C2101/00;;E21B43/00;;E21B43/30;;Y10S210/908;;E21B43/00;;E21B43/30;;B09C1/002;;B09C1/10;;B09C2101/00;;Y10S210/908,B09C1/00;;B09C1/10;;E21B43/00;;E21B43/30,,0,0,,,,PATENTED
314,CN,A,CN 112203531 A,034-937-202-315-008,2021-01-08,2021,CN 201980036532 A,2019-05-29,US 201816006793 A;;US 2019/0034236 W,2018-06-12,INTACT PEA PROTEIN-BASED NUTRIENT COMPOSITION,"The present invention discloses a nutritional composition and method of using and making the nutritional composition. The nutritional composition is an intact pea protein based nutrient composition for use in both enteral and oral feeding, and provides a nonallergenic diet for providing optimal nutrition to users. The nutritional composition is made from organic and plant-based ingredients. The nutritional composition has pea protein, phytochemical extracts, fatty acids, organic ingredients free of the top eight allergens and corn, and prebiotic fiber. The nutritional composition is provided in liquid form for enteral and/or oral feeding.",KATE FARMS INC,LAVER RICHARD;;LAVER MICHELLE;;MATTHEWS BRETT;;PICKAR WILLIAM;;COLE DAVID;;WITHERLY STEVEN;;WITHERLY CAROLINE;;CARR VANESSA;;PHREANER CHRISTINA,,https://lens.org/034-937-202-315-008,Patent Application,no,5,0,11,11,0,A61K31/202;;A61K31/733;;A61K36/53;;A61K36/898;;A61K36/88;;A61K36/899;;A23L33/105;;A23L33/12;;A23L33/10;;A23L33/21;;A23L33/185;;A61K33/06;;A61K33/14;;A61P3/02;;A23V2002/00;;A23J3/14;;A23L33/10;;A23L33/105;;A23L33/12;;A23L33/135;;A23L33/15;;A23L33/16;;A23J3/16;;A61K36/53;;A61K36/88;;A61K36/898;;A61K36/899;;A61K31/202;;A61K31/733;;A61K33/06;;A61K33/14;;A61P3/02;;A23V2250/1874;;A23V2250/5062;;A23V2200/32;;A23V2002/00;;A23V2250/21;;A23V2250/1944;;A23V2250/1868;;A23V2250/187;;A61K31/733;;A23L33/185;;A23L33/105;;A23L33/12;;A23L33/15;;A23V2002/00;;A23L33/26;;A61K36/53;;A61K31/202;;A61K36/898;;A23L33/16;;A23L33/135;;A23J3/14,A23L33/185;;A23L33/105;;A23L33/12;;A23L33/15;;A23L33/155;;A23L33/16;;A23L33/175;;A23L33/21,,0,0,,,,PENDING
315,WO,A1,WO 2019/222000 A1,087-904-642-844-650,2019-11-21,2019,US 2019/0031362 W,2019-05-08,US 201815980355 A,2018-05-15,HYDROLYZED PEA PROTEIN-BASED NUTRIENT COMPOSITION,"The present invention discloses a nutritional composition and method of using and making the nutritional composition. The nutritional composition is a hydrolyzed pea protein based nutrient composition for use in both enteral and oral feeding, and provides a non-allergenic diet for providing optimal nutrition to users. The nutritional composition is made from organic and plant-based ingredients. The nutritional composition has pea protein hydrolysates, phytochemical extracts, fatty acids, organic ingredients free of the top eight allergens and corn, and prebiotic fiber. The nutritional composition is provided in liquid form for enteral and/or oral feeding.",KATE FARMS INC,LAVER RICHARD;;LAVER MICHELLE;;MATTHEWS BRETT;;PICKAR WILLIAM;;COLE DAVID;;WITHERLY STEVEN;;WITHERLY CAROLINE;;CARR VANESSA;;PHREANER CHRISTINA,,https://lens.org/087-904-642-844-650,Patent Application,yes,9,0,12,12,0,A61K31/01;;A61K31/015;;A61K31/198;;A61K31/216;;A61K31/23;;A61K31/255;;A61K31/353;;A61K31/375;;A61K31/7028;;A61K31/733;;A61K33/00;;A61K33/06;;A61K33/14;;A61K38/168;;A61K36/53;;A61K36/898;;A61K36/899;;A61K36/537;;A61K36/21;;A61K36/48;;A61K36/88;;A23L33/105;;A23L33/16;;A23L33/15;;A23L33/115;;A23L33/21;;A23L33/18;;A23L33/185;;A23L33/40;;A23L33/105;;A23L33/185;;A23L33/115;;A23L33/135;;A23L33/15;;A23L33/16;;A23L3/01;;A61K38/011;;A61K36/28;;A61K36/53;;A61K31/194;;A61K33/14;;A61K31/202;;A61K31/201;;A61P3/02;;A23V2002/00;;A23V2250/21;;A23V2250/194;;A23V2200/262;;A23V2200/30;;A61K2300/00;;A23L33/18;;A23V2002/00;;A23L33/105;;A23L33/12;;A23L33/16;;A23L33/15;;A23L33/21;;A61K31/353;;A61K31/216;;A61K31/375;;A61K31/7028;;A61K31/01;;A61K31/198;;A61K31/255;;A61K31/015;;A61K9/0019;;A61K36/55;;A61K36/28;;A61K38/168;;A61K31/733;;A61K31/23;;A61K36/537;;A61K36/21;;A61K36/53;;A61K33/00;;A61K33/06;;A61K33/14;;A23L33/185,A23L2/66,,3,0,,,"""Dietary fiber"", WIKIPEDIA, 30 November 2017 (2017-11-30), XP055655802, Retrieved from the Internet <URL:https://en.wikipedia.org/w/index.php?title=Dietary_fiber&oldid=812822101> [retrieved on 20190708];;""Agave Inulin: All You Need to Know"", NATUREL, 23 December 2016 (2016-12-23), XP055655805, Retrieved from the Internet <URL:https://www.naturelwest.eu/agave-inulin-need-know> [retrieved on 20190708];;E. PHILLIPS ET AL., PEPTIDE-BASED FORMULAS: THE NUTRACEUTICALS OF ENTERAL FEEDING?, 2005",PENDING
316,US,A1,US 2019/0350245 A1,119-234-686-999-16X,2019-11-21,2019,US 201815980355 A,2018-05-15,US 201815980355 A,2018-05-15,HYDROLYZED PEA PROTEIN-BASED NUTRIENT COMPOSITION,"The present invention discloses a nutritional composition and method of using and making the nutritional composition. The nutritional composition is a hydrolyzed pea protein based nutrient composition for use in both enteral and oral feeding, and provides a non-allergenic diet for providing optimal nutrition to users. The nutritional composition is made from organic and plant-based ingredients. The nutritional composition has pea protein hydrolysates, phytochemical extracts, fatty acids, organic ingredients free of the top eight allergens and corn, and prebiotic fiber. The nutritional composition is provided in liquid form for enteral and/or oral feeding.",LAVER RICHARD;;LAVER MICHELLE;;MATTHEWS BRETT;;PICKAR WILLIAM;;COLE DAVID;;WITHERLY STEVEN;;WITHERLY CAROLINE;;CARR VANESSA;;PHREANER CHRISTINA,LAVER RICHARD;;LAVER MICHELLE;;MATTHEWS BRETT;;PICKAR WILLIAM;;COLE DAVID;;WITHERLY STEVEN;;WITHERLY CAROLINE;;CARR VANESSA;;PHREANER CHRISTINA,KATE FARMS INC (2020-04-02),https://lens.org/119-234-686-999-16X,Patent Application,yes,11,3,12,12,0,A61K31/01;;A61K31/015;;A61K31/198;;A61K31/216;;A61K31/23;;A61K31/255;;A61K31/353;;A61K31/375;;A61K31/7028;;A61K31/733;;A61K33/00;;A61K33/06;;A61K33/14;;A61K38/168;;A61K36/53;;A61K36/898;;A61K36/899;;A61K36/537;;A61K36/21;;A61K36/48;;A61K36/88;;A23L33/105;;A23L33/16;;A23L33/15;;A23L33/115;;A23L33/21;;A23L33/18;;A23L33/185;;A23L33/40;;A23L33/105;;A23L33/185;;A23L33/115;;A23L33/135;;A23L33/15;;A23L33/16;;A23L3/01;;A61K38/011;;A61K36/28;;A61K36/53;;A61K31/194;;A61K33/14;;A61K31/202;;A61K31/201;;A61P3/02;;A23V2002/00;;A23V2250/21;;A23V2250/194;;A23V2200/262;;A23V2200/30;;A61K2300/00;;A23L33/18;;A23V2002/00;;A23L33/105;;A23L33/12;;A23L33/16;;A23L33/15;;A23L33/21;;A61K31/353;;A61K31/216;;A61K31/375;;A61K31/7028;;A61K31/01;;A61K31/198;;A61K31/255;;A61K31/015;;A61K9/0019;;A61K36/55;;A61K36/28;;A61K38/168;;A61K31/733;;A61K31/23;;A61K36/537;;A61K36/21;;A61K36/53;;A61K33/00;;A61K33/06;;A61K33/14;;A23L33/185,A23L33/18;;A23L33/105;;A23L33/12;;A23L33/15;;A23L33/16;;A23L33/185;;A23L33/21;;A61K9/00;;A61K31/01;;A61K31/015;;A61K31/198;;A61K31/216;;A61K31/23;;A61K31/255;;A61K31/353;;A61K31/375;;A61K31/7028;;A61K31/733;;A61K33/00;;A61K33/06;;A61K33/14;;A61K36/21;;A61K36/28;;A61K36/53;;A61K36/537;;A61K36/55;;A61K38/16,,0,0,,,,ACTIVE
317,DK,T3,DK 1169271 T3,065-510-104-648-61X,2004-07-26,2004,DK 00926914 T,2000-04-12,EP 0003336 W;;US 12932899 P,1999-04-14,Fremgangsmåde til remediering af vandförende lag,,SHELL INT RESEARCH,JOHNSON PAUL CARR;;SALANITRO JOSEPH PATRICK;;STEARNS STEVEN MERLE;;MANER PAUL MICHAEL;;MILLER JAMES HENRY;;SPINNLER GERARD EUGENE,,https://lens.org/065-510-104-648-61X,Granted Patent,no,0,0,18,18,0,B09C1/002;;B09C1/10;;B09C2101/00;;E21B43/00;;E21B43/30;;Y10S210/908;;E21B43/00;;E21B43/30;;B09C1/002;;B09C1/10;;B09C2101/00;;Y10S210/908,B09C1/00;;B09C1/10;;E21B43/00;;E21B43/30,,0,0,,,,EXPIRED
318,US,B2,US 8711288 B2,026-601-211-942-231,2014-04-29,2014,US 51671806 A,2006-09-07,US 51671806 A;;US 73934900 A;;US 17119999 P,1999-12-15,Digital IF demodulator for video applications,"An integrated communications system. A substrate having a receiver disposed on the substrate for converting a received signal to an IF signal, a digital IF demodulator disposed on the substrate and coupled to the receiver for converting the IF signal to a demodulated baseband signal, and a transmitter disposed on the substrate operating in cooperation with the receiver to establish a two way communications path.",VORENKAMP PIETER;;WAKAYAMA MYLES H;;JAFFE STEVEN;;CARR FRANK;;VENES ARNOLDUS;;KINGET PETER R;;MARZ DANIEL J;;NGUYEN THINH;;BROADCOM CORP,VORENKAMP PIETER;;WAKAYAMA MYLES H;;JAFFE STEVEN;;CARR FRANK;;VENES ARNOLDUS;;KINGET PETER R;;MARZ DANIEL J;;NGUYEN THINH,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM CORPORATION (2001-10-04),https://lens.org/026-601-211-942-231,Granted Patent,yes,18,2,4,75,0,H04N5/455;;H04N5/455;;H03D7/16;;H03D7/16;;H03J3/18;;H03J3/18;;H04N5/44;;H04N5/44,H04N5/44;;H03D7/16;;H03J3/18;;H04N5/455,348/725;;348/678;;348/726,1,1,026-846-020-924-87X,10.1109/iscas.1988.15316,"Poole, S., Surace, G., Singh, B., Dyer, N., ""A CMOS Subscriber Line Audio Processing Circuit Including Adaptive Balance,"" IEEE International Symposium on Circuits and Systems, Finland, Espoo, vol. 2 of 3, Jun. 7-9, 1988, pp. 1931-1934.",INACTIVE
319,US,B2,US 10683242 B2,191-393-196-589-423,2020-06-16,2020,US 201615749278 A,2016-08-04,US 201615749278 A;;US 201562211410 P;;US 2016/0045563 W,2015-08-28,"Thixotropic suspension agent for plant nutrients or animal feed supplements: composition, method of making, and use thereof","A composition, in the form of an aqueous suspension. The composition comprises at least one form of attapulgite present in a solid weight fraction (SWF) amount ranging from 0.065% to 0.30%. The composition comprises kaolin present in a percent solids by weight (w/w %) amount ranging from 0.80% to 2.80%. The composition comprises one or more main plant nutrients or major animal mineral nutrient supplements. In the composition, the total percent solids by weight (w/w %) amount in the composition ranges from 45% to 90%. Although usable for other purposes, the composition is usable as a fertilizer. Although makeable in other ways, the composition is makeable by mixing the ingredients with agitation sufficient enough to form an aqueous suspension.",ACTIVE MINERALS INT LLC,FELDMAN STEVEN B;;CARR JR JEFFERY;;LYMAN MATTHEW J;;KITCHENS JOHN;;FUHRMANN LUKE;;PURCELL JR ROBERT J;;PARKER DENNIS,ACTIVE MINERALS INTERNATIONAL LLC (2018-10-16),https://lens.org/191-393-196-589-423,Granted Patent,yes,4,0,9,9,0,A01C21/005;;C05D5/00;;C05D5/00;;C05B9/00;;C05B9/00;;C05D9/02;;C05D9/02;;C05F11/02;;C05F11/02;;C05G1/00;;C05G1/00;;C05G5/27;;C05G5/27,C05D5/00;;A01C21/00;;C05B9/00;;C05D9/02;;C05F11/02;;C05G1/00;;C05G5/20,,8,0,,,"BASF. “Attagel Rheology modifiers”. <http://www.toshin-kasei.co.jp/basf%20attapulgite.pdf> Aug. 28, 2016.;;USDA. “Attapulgite Handling/Processing”. <https://www.ams.usda.gov/sites/default/files/media/Attapulgite%20TR.pdf> Feb. 21, 2017.;;International Search Report and Written Opinion for corresponding International PCT Application No. PCT/US2016/045563, dated Nov. 18, 2016, pp. 1-17.;;Examination Report in AU Application No. 2016317298, dated Jun. 4, 2018.;;Examination Report in NZ Application No. 739020, dated Jun. 22, 2018.;;Search Report in TW Application No. 105125516, dated Mar. 17, 2017.;;Examination Decision of Allowing a Patent in TW Application No. 105125516, dated Aug. 2, 2018.;;Examination Notice in TW Application No. 105125516, dated Nov. 13, 2017.",ACTIVE
320,US,A1,US 2019/0023623 A1,083-260-672-000-17X,2019-01-24,2019,US 201615749278 A,2016-08-04,US 201615749278 A;;US 201562211410 P;;US 2016/0045563 W,2015-08-28,"THIXOTROPIC SUSPENSION AGENT FOR PLANT NUTRIENTS OR ANIMAL FEED SUPPLEMENTS: COMPOSITION, METHOD OF MAKING, AND USE THEREOF","A composition, in the form of an aqueous suspension. The composition comprises at least one form of attapulgite present in a solid weight fraction (SWF) amount ranging from 0.065% to 0.30%. The composition comprises kaolin present in a percent solids by weight (w/w %) amount ranging from 0.80% to 2.80%. The composition comprises one or more main plant nutrients or major animal mineral nutrient supplements. In the composition, the total percent solids by weight (w/w %) amount in the composition ranges from 45% to 90%. Although usable for other purposes, the composition is usable as a fertilizer. Although makeable in other ways, the composition is makeable by mixing the ingredients with agitation sufficient enough to form an aqueous suspension.",ACTIVE MINERALS INT LLC,FELDMAN STEVEN B;;CARR JR JEFFERY;;LYMAN MATTHEW J;;KITCHENS JOHN;;FUHRMANN LUKE;;PURCELL JR ROBERT J;;PARKER DENNIS,ACTIVE MINERALS INTERNATIONAL LLC (2018-10-16),https://lens.org/083-260-672-000-17X,Patent Application,yes,0,1,9,9,0,A01C21/005;;C05D5/00;;C05D5/00;;C05B9/00;;C05B9/00;;C05D9/02;;C05D9/02;;C05F11/02;;C05F11/02;;C05G1/00;;C05G1/00;;C05G5/27;;C05G5/27,C05D5/00;;A01C21/00;;C05G3/00,,0,0,,,,ACTIVE
321,US,B2,US 7106388 B2,191-688-782-276-938,2006-09-12,2006,US 73934900 A,2000-12-15,US 73934900 A;;US 17119999 P,1999-12-15,Digital IF demodulator for video applications,"An integrated communications system. A substrate having a receiver disposed on the substrate for converting a received signal to an IF signal, a digital IF demodulator disposed on the substrate and coupled to the receiver for converting the IF signal to a demodulated baseband signal, and a transmitter disposed on the substrate operating in cooperation with the receiver to establish a two way communications path.",BROADCOM CORP,VORENKAMP PIETER;;WAKAYAMA MYLES H;;JAFFE STEVEN;;CARR FRANK;;VENES ARNOLDUS;;KINGET PETER R;;MARZ DANIEL J;;NGUYEN THINH,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;BROADCOM CORPORATION (2001-10-04),https://lens.org/191-688-782-276-938,Granted Patent,yes,11,44,4,75,0,H04N5/455;;H04N5/455;;H03D7/16;;H03D7/16;;H03J3/18;;H03J3/18;;H04N5/44;;H04N5/44,H04N5/455;;H03D7/16;;H03J3/18,348/726;;348/725;;348/731;;348/735,1,1,026-846-020-924-87X,10.1109/iscas.1988.15316,"Poole, S., Surace, G., Singh, B., Dyer, N., ""A CMOS Subscriber Line Audio Processing Circuit Including Adaptive Balance,"" IEEE International Symposium on Circuits and Systems, Finland, Espoo, vol. 2 of 3, Jun. 7-9, 1988, pp. 1931-1934.",EXPIRED
322,WO,A1,WO 2017/039943 A1,173-765-759-081-271,2017-03-09,2017,US 2016/0045563 W,2016-08-04,US 201562211410 P,2015-08-28,"THIXOTROPIC SUSPENSION AGENT FOR PLANT NUTRIENTS OR ANIMAL FEED SUPPLEMENTS: COMPOSITION, METHOD OF MAKING, AND USE THEREOF","A composition, in the form of an aqueous suspension. The composition comprises at least one form of attapulgite present in a solid weight fraction (SWF) amount ranging from 0.065% to 0.30%. The composition comprises kaolin present in a percent solids by weight (w/w%) amount ranging from 0.80% to 2.80%. The composition comprises one or more main plant nutrients or major animal mineral nutrient supplements. In the composition, the total percent solids by weight (w/w%) amount in the composition ranges from 45% to 90%. Although usable for other purposes, the composition is usable as a fertilizer. Although makeable in other ways, the composition is makeable by mixing the ingredients with agitation sufficient enough to form an aqueous suspension.",ACTIVE MINERALS INT LLC,FELDMAN STEVEN B;;CARR JEFFERY;;LYMAN MATTHEW J;;KITCHENS JOHN;;FUHRMANN LUKE;;PURCELL JR ROBERT J;;PARKER DENNIS C,,https://lens.org/173-765-759-081-271,Patent Application,yes,3,8,9,9,0,A01C21/005;;C05D5/00;;C05D5/00;;C05B9/00;;C05B9/00;;C05D9/02;;C05D9/02;;C05F11/02;;C05F11/02;;C05G1/00;;C05G1/00;;C05G5/27;;C05G5/27,C05B9/00;;C05F11/02;;C05G1/00;;C05G3/00,,0,0,,,,PENDING
323,US,A1,US 2007/0105504 A1,018-017-111-128-387,2007-05-10,2007,US 51671806 A,2006-09-07,US 51671806 A;;US 73934900 A;;US 17119999 P,1999-12-15,Digital IF demodulator for video applications,"An integrated communications system. A substrate having a receiver disposed on the substrate for converting a received signal to an IF signal, a digital IF demodulator disposed on the substrate and coupled to the receiver for converting the IF signal to a demodulated baseband signal, and a transmitter disposed on the substrate operating in cooperation with the receiver to establish a two way communications path.",BROADCOM CORP,VORENKAMP PIETER;;WAKAYAMA MYLES H;;JAFFE STEVEN;;CARR FRANK;;VENES ARNOLDUS;;KINGET PETER R;;MARZ DANIEL J;;NGUYEN THINH,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;BROADCOM CORPORATION (2001-10-04),https://lens.org/018-017-111-128-387,Patent Application,yes,18,56,4,75,0,H04N5/455;;H04N5/455;;H03D7/16;;H03D7/16;;H03J3/18;;H03J3/18;;H04N5/44;;H04N5/44,H04B1/38;;H03D7/16;;H03J3/18;;H04N5/455,455/73,0,0,,,,EXPIRED
324,US,A1,US 2022/0062394 A1,150-479-179-397-753,2022-03-03,2022,US 201917414480 A,2019-12-12,US 201917414480 A;;US 201862780832 P;;US 201962820042 P;;US 2019/0066104 W,2018-12-17,METHODS FOR IDENTIFYING NEOANTIGENS,"Disclosed herein are polypeptides and compositions comprising one or more neoantigens, methods of identifying neoantigens, and methods for preparing a neoantigen for an immunogenic pharmaceutical composition. The neoantigen can be specific to a subject that has a cancer, disease, or other disorder.",BROAD INST INC;;MASSACHUSETTS INST TECHNOLOGY;;MASSACHUSETTS GEN HOSPITAL;;DANA FARBER CANCER INST INC,OUSPENSKAIA TAMARA;;LAW TRAVIS;;REGEV AVIV;;CARR STEVEN;;CLAUSER KARL;;KLAEGER SUSAN;;HAOCHEN NIR;;WU CATHERINE J;;KESKIN DERIN,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2020-03-05);;DANA-FARBER CANCER INSTITUTE INC (2020-01-30);;THE BROAD INSTITUTE INC (2020-03-03);;THE GENERAL HOSPITAL CORPORATION (2020-03-05),https://lens.org/150-479-179-397-753,Patent Application,yes,0,1,3,3,0,A61K39/0011;;G01N33/56972;;C12Q1/6869;;A61K39/0005;;A61K45/06;;C12Q1/6869;;G01N33/6848,A61K39/00;;A61K45/06;;C12Q1/6869;;G01N33/68,,0,0,,,,PENDING
325,MX,A,MX 2018002527 A,098-875-209-211-632,2018-05-30,2018,MX 2018002527 A,2016-08-04,US 201562211410 P;;US 2016/0045563 W,2015-08-28,"THIXOTROPIC SUSPENSION AGENT FOR PLANT NUTRIENTS OR ANIMAL FEED SUPPLEMENTS: COMPOSITION, METHOD OF MAKING, AND USE THEREOF.","A composition, in the form of an aqueous suspension. The composition comprises at least one form of attapulgite present in a solid weight fraction (SWF) amount ranging from 0.065% to 0.30%. The composition comprises kaolin present in a percent solids by weight (w/w%) amount ranging from 0.80% to 2.80%. The composition comprises one or more main plant nutrients or major animal mineral nutrient supplements. In the composition, the total percent solids by weight (w/w%) amount in the composition ranges from 45% to 90%. Although usable for other purposes, the composition is usable as a fertilizer. Although makeable in other ways, the composition is makeable by mixing the ingredients with agitation sufficient enough to form an aqueous suspension.",ACTIVE MINERALS INT LLC,MATTHEW J LYMAN;;STEVEN B FELDMAN;;JEFFERY CARR;;JOHN KITCHENS;;LUKE FUHRMANN;;ROBERT J PURCELL JR;;DENNIS C PARKER,,https://lens.org/098-875-209-211-632,Patent Application,no,0,0,9,9,0,A01C21/005;;C05D5/00;;C05D5/00;;C05B9/00;;C05B9/00;;C05D9/02;;C05D9/02;;C05F11/02;;C05F11/02;;C05G1/00;;C05G1/00;;C05G5/27;;C05G5/27,C05B9/00;;C05F11/02;;C05G1/00;;C05G3/00,,0,0,,,,PENDING
326,US,A1,US 2002/0047942 A1,134-981-729-877-860,2002-04-25,2002,US 73934900 A,2000-12-15,US 73934900 A;;US 17119999 P,1999-12-15,Digital IF demodulator for video applications,"
   An integrated communications system. A substrate having a receiver disposed on the substrate for converting a received signal to an IF signal, a digital IF demodulator disposed on the substrate and coupled to the receiver for converting the IF signal to a demodulated baseband signal, and a transmitter disposed on the substrate operating in cooperation with the receiver to establish a two way communications path. 
",VORENKAMP PIETER;;WAKAYAMA MYLES H.;;JAFFE STEVEN;;CARR FRANK;;VENES ARNOLDUS;;KINGET PETER R.;;MARZ DANIEL J.;;NGUYEN THINH,VORENKAMP PIETER;;WAKAYAMA MYLES H;;JAFFE STEVEN;;CARR FRANK;;VENES ARNOLDUS;;KINGET PETER R;;MARZ DANIEL J;;NGUYEN THINH,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2017-01-20);;BROADCOM CORPORATION (2001-10-04),https://lens.org/134-981-729-877-860,Patent Application,yes,3,93,4,75,0,H04N5/455;;H04N5/455;;H03D7/16;;H03D7/16;;H03J3/18;;H03J3/18;;H04N5/44;;H04N5/44,H03D7/16;;H03J3/18;;H04N5/455,348/731;;348/725,0,0,,,,EXPIRED
327,US,A1,US 2022/0088180 A1,159-146-467-591-931,2022-03-24,2022,US 202117463429 A,2021-08-31,US 202117463429 A;;US 202063072898 P;;US 202163186742 P,2020-08-31,IMMUNOGENIC COMPOSITIONS AND USE THEREOF,"Immunogenic compositions comprising one or more polypeptides, wherein the one or more polypeptides: is capable of binding to Major Histocompatibility Complex (MHC) class I, and is derived from one or more proteins of SARS-CoV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.",BROAD INST INC;;HARVARD COLLEGE;;MASSACHUSETTS GEN HOSPITAL;;UNIV BOSTON,SABETI PARDIS;;WEINGARTEN-GABBAY SHIRA;;KLAEGER SUSAN;;ABELIN JENN;;SAEED MOHSAN;;HACOHEN NIR;;SARKIZOVA SIRANUSH;;CARR STEVEN;;CLAUSER KARL,HOWARD HUGHES MEDICAL INSTITUTE (2020-09-16);;TRUSTEES OF BOSTON UNIVERSITY (2021-11-10);;PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2021-10-04);;THE BROAD INSTITUTE INC (2021-10-04);;THE GENERAL HOSPITAL CORPORATION (2022-10-23),https://lens.org/159-146-467-591-931,Patent Application,yes,0,1,1,1,239,A61P31/14;;G01N2333/165;;G01N33/56983;;G01N2333/70539;;G01N2500/04;;G01N2500/10;;C12N2770/20034;;A61K39/12;;A61K2039/572;;A61K39/215;;A61K45/06;;A61P31/14;;G01N2800/26;;G01N33/6818;;A61K2039/53;;G01N2333/165;;G01N33/56983,A61K39/215;;A61K45/06;;A61P31/14;;G01N33/569;;G01N33/68,,2,2,147-569-128-559-661;;014-246-026-307-632,pmc7314509;;32595358;;10.3906/biy-2006-1;;pmc7387808;;32728199;;10.1038/s41423-020-0514-8,"TopuzoĞullari M, Acar T, Pelİt Arayici P, UÇar B, UĞurel E, Abamor EŞ, ArasoĞlu T, Turgut-Balik D, Derman S. An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19. Turk J Biol. 2020 Jun 21;44(3):215-227. (Year: 2020);;Jiang HW, Zhang HN, Meng QF, Xie J, Li Y, Chen H, Zheng YX, Wang XN, Qi H, Zhang J, Wang PH, Han ZG, Tao SC. SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. Cell Mol Immunol. 2020 Sep;17(9):998-1000. doi: 10.1038/s41423-020-0514-8. Epub 2020 Jul 29. (Year: 2020)",PENDING
328,US,A1,US 2022/0407005 A1,009-909-423-436-159,2022-12-22,2022,US 202117353098 A,2021-06-21,US 202117353098 A,2021-06-21,PHASE CHANGE MEMORY CELL GALVANIC CORROSION PREVENTION,A method for forming a phase-change memory cell includes depositing a metal layer over a wafer such that the metal layer covers connection structures of the wafer. The method further includes removing a portion of the metal layer such that the connection structures of the wafer remain covered by a remaining portion of the metal layer. The method further includes forming a phase-change memory stack on a stack area of the remaining portion of the metal layer. The method further includes removing the remaining portion of the metal layer except in the stack area.,IBM,OK INJO;;SAULNIER NICOLE;;BREW KEVIN W;;MCDERMOTT STEVEN MICHAEL;;CLEVENGER LAWRENCE A;;AMANAPU HARI PRASAD;;CARR ADRA;;BHOSALE PRASAD,INTERNATIONAL BUSINESS MACHINES CORPORATION (2021-06-07),https://lens.org/009-909-423-436-159,Patent Application,yes,1,0,2,2,0,H10B63/80;;H10N70/231;;H10N70/801;;H10N70/826;;H10N70/8828;;H10N70/063;;H10N70/063;;H10N70/231;;H10N70/826;;H10N70/8413;;H10N70/8828,H01L45/00,,0,0,,,,ACTIVE
329,US,A1,US 2016/0378637 A1,155-245-169-625-740,2016-12-29,2016,US 201514748601 A,2015-06-24,US 201514748601 A,2015-06-24,MULTI-TENANT AWARE DEBUGGING METHODS AND SYSTEMS,"Methods and systems are provided for debugging application code in an on-demand multi-tenant database system. One exemplary method involves an application server receiving a request associated with application code in a database from a client device via a network, verifying that debugging associated with the request does not violate a debugging utilization criterion, and after verifying that debugging associated with the request does not violate the debugging utilization criterion, accessing the application code in the database in conjunction with the request.",SALESFORCE COM INC,GAMBLE CHRISTOPHER DAVID;;WIDJAJA JONATHAN;;KAPLAN JOSH;;CARR KEVIN;;BOILEN MICHAEL;;LIPKE NATHAN EDWARD;;CHEN NICHOLAS CHUN YUAN;;TAMM STEVEN,SALESFORCE.COM INC (2015-06-21),https://lens.org/155-245-169-625-740,Patent Application,yes,6,17,2,2,0,G06F11/362;;G06F11/362;;G06F2201/80;;G06F2201/80;;G06F2201/81;;G06F2201/81,G06F11/36;;G06F17/30,,0,0,,,,ACTIVE
330,US,B2,US 10296440 B2,113-273-935-275-415,2019-05-21,2019,US 201514748601 A,2015-06-24,US 201514748601 A,2015-06-24,Multi-tenant aware debugging methods and systems,"Methods and systems are provided for debugging application code in an on-demand multi-tenant database system. One exemplary method involves an application server receiving a request associated with application code in a database from a client device via a network, verifying that debugging associated with the request does not violate a debugging utilization criterion, and after verifying that debugging associated with the request does not violate the debugging utilization criterion, accessing the application code in the database in conjunction with the request.",SALESFORCE COM INC,GAMBLE CHRISTOPHER DAVID;;WIDJAJA JONATHAN;;KAPLAN JOSH;;CARR KEVIN;;BOILEN MICHAEL;;LIPKE NATHAN EDWARD;;CHEN NICHOLAS CHUN YUAN;;TAMM STEVEN,SALESFORCE.COM INC (2015-06-21),https://lens.org/113-273-935-275-415,Granted Patent,yes,157,8,2,2,0,G06F11/362;;G06F11/362;;G06F2201/80;;G06F2201/80;;G06F2201/81;;G06F2201/81,G06F11/36,,0,0,,,,ACTIVE
331,US,A1,US 2004/0243921 A1,006-338-017-046-563,2004-12-02,2004,US 44919803 A,2003-05-30,US 44919803 A,2003-05-30,Methods and systems for synchronizing document elements,"
   A method for linking Document Object Model (DOM) elements using link attributes is provided. The method includes maintaining a plurality of DOM documents, linking at least one element in a first DOM document to at least one element in a second DOM document, revising an element in the first DOM document, and synchronizing the linked element in the second DOM document with the revised element in the first DOM document. 
",CARR STEVEN PAUL;;ROBERTSON DAVID MICHAEL;;SAGE PETE WILLIAM;;MATHUR SUNIL;;TUTAK WES ARTHUR;;CHARCHUK RUSSELL FREDRICK;;HANSON DANIEL JAMES,CARR STEVEN PAUL;;ROBERTSON DAVID MICHAEL;;SAGE PETE WILLIAM;;MATHUR SUNIL;;TUTAK WES ARTHUR;;CHARCHUK RUSSELL FREDRICK;;HANSON DANIEL JAMES,GE FANUC AUTOMATION NORTH AMERICA INC (2003-05-23),https://lens.org/006-338-017-046-563,Patent Application,yes,13,55,1,1,0,G06F16/94;;G06F16/94,G06F17/00;;G06F17/30,7155;;X71553,0,0,,,,DISCONTINUED
332,US,B2,US 11800817 B2,108-186-479-129-169,2023-10-24,2023,US 202117353098 A,2021-06-21,US 202117353098 A,2021-06-21,Phase change memory cell galvanic corrosion prevention,A method for forming a phase-change memory cell includes depositing a metal layer over a wafer such that the metal layer covers connection structures of the wafer. The method further includes removing a portion of the metal layer such that the connection structures of the wafer remain covered by a remaining portion of the metal layer. The method further includes forming a phase-change memory stack on a stack area of the remaining portion of the metal layer. The method further includes removing the remaining portion of the metal layer except in the stack area.,IBM,OK INJO;;SAULNIER NICOLE;;BREW KEVIN W;;MCDERMOTT STEVEN MICHAEL;;CLEVENGER LAWRENCE A;;AMANAPU HARI PRASAD;;CARR ADRA;;BHOSALE PRASAD,INTERNATIONAL BUSINESS MACHINES CORPORATION (2021-06-07),https://lens.org/108-186-479-129-169,Granted Patent,yes,12,0,2,2,0,H10B63/80;;H10N70/231;;H10N70/801;;H10N70/826;;H10N70/8828;;H10N70/063;;H10N70/063;;H10N70/231;;H10N70/826;;H10N70/8413;;H10N70/8828,H10N70/00;;H10N70/20,,2,0,,,"Anonymous, “Method and Structure for Creating a Heater with an Inverse Taper Angle for Phase-Change Memory (PCM) Mushroom Cell,” an IP.com Prior Art Database Technical Disclosure, IP.com IPCOM000260076D, Oct. 18, 2019, 6 pgs.;;Anonymous, “Phase Change Memory Cell with Plural Nano Heaters,” an IP.com Prior Art Database Technical Disclosure, IP.com IPCOM000263592D, Sep. 15, 2020, 16 pgs.",ACTIVE
333,HU,T2,HU E055409 T2,002-475-788-334-702,2021-11-29,2021,HU E14820969 A,2014-11-20,US 201361908195 P;;US 201462038870 P,2013-11-25,VACCINATION ASSEMBLY FOR DELIVERING VACCINE TO AVIAN PULLETS,,ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/002-475-788-334-702,Amended Patent,no,0,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,PENDING
334,CN,A,CN 105705115 A,103-911-258-857-274,2016-06-22,2016,CN 201480060597 A,2014-11-20,US 201361908195 P;;US 201462038870 P;;US 2014/0066574 W,2013-11-25,"Vaccination system for delivering vaccine to avian pullets, and associated methods, devices, and assemblies","The invention provides a vaccination system for delivering a vaccine to avian pullets, and associated methods, devices, and assemblies. Such a system includes a vaccine delivery assembly configured to perform a vaccine delivery procedure for delivering a vaccine substance to the avian pullets. A plurality of positioning devices is provided, with each positioning device receiving an avian pullet for presentation to the vaccine delivery assembly. Each positioning device is transported to individually mate with the vaccine delivery assembly to deliver the vaccine substance during the vaccine delivery procedure. Associated methods, devices, and assemblies are also provided.",ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/103-911-258-857-274,Patent Application,no,9,5,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D7/00,,0,0,,,,ACTIVE
335,DE,T2,DE 3873899 T2,109-741-245-127-378,1993-02-25,1993,DE 3873899 T,1988-12-07,US 13781187 A,1987-12-28,ZUSAMMENGESETZTER ARTIKEL FUER DIE CHROMATOGRAPHIE.,,MINNESOTA MINING & MFG,HAGEN DONALD F MINNESOTA MININ;;ST MARY STEVEN J MINNESOTA MIN;;ERREDE LOUIS A MINNESOTA MININ;;CARR PETER W MINNESOTA MINING,,https://lens.org/109-741-245-127-378,Granted Patent,no,0,0,13,16,0,B01J20/28028;;B01J20/28033;;Y10S435/803;;Y10T428/249986;;Y10T428/249954;;Y10T428/249986;;Y10T428/249954;;B01J20/28028;;B01J20/28033;;Y10S435/803,B01J20/281;;B01D15/08;;B01J20/28;;B01J20/285;;G01N30/88;;G01N30/92,,0,0,,,,EXPIRED
336,EP,A1,EP 3906890 A1,008-361-670-928-989,2021-11-10,2021,EP 21180496 A,2014-11-20,US 201361908195 P;;US 201462038870 P;;EP 14820969 A;;US 2014/0066574 W,2013-11-25,VACCINATION ASSEMBLY FOR DELIVERING VACCINE TO AVIAN PULLETS,"A vaccination system for delivering a vaccine substance to avian pullets is provided. Such a system includes a vaccine delivery assembly configured to perform a vaccine delivery procedure for delivering a vaccine substance to the avian pullets. A plurality of positioning devices is provided, with each positioning device receiving an avian pullet for presentation to the vaccine delivery assembly. Each positioning device is transported to individually mate with the vaccine delivery assembly to deliver the vaccine substance during the vaccine delivery procedure. Associated methods, devices, and assemblies are also provided.
",ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/008-361-670-928-989,Patent Application,yes,10,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,ACTIVE
337,CN,C,CN 100498428 C,076-984-796-030-960,2009-06-10,2009,CN 200610121270 A,2001-10-30,US 69827000 A,2000-10-30,Wide field spherical lenses and protective eyewear,,SOLA INT HOLDINGS,ALAN MORRIS MICHAEL;;MAURICE PERROTT COLIN;;STEVEN SPRATT RAY;;LAWRENCE CARR DAVID;;BRANDON YIP;;BRIAN ADAMS;;PARAIC BEGLEY;;SIMON BLACKER RICHARD,"KAER CAISI OPTICAL CO., LTD. (2014-08-06)",https://lens.org/076-984-796-030-960,Granted Patent,no,0,0,14,50,0,G02C7/10;;G02C7/02,G02C7/02;;G02B1/11;;G02C7/10,,0,0,,,,EXPIRED
338,US,A1,US 2010/0131856 A1,059-278-773-498-208,2010-05-27,2010,US 32424608 A,2008-11-26,US 32424608 A,2008-11-26,"Personalized, Online, Scientific Interface","An Internet-based personalized, online, scientific interface is described, operating from at least a proprietary web server connected to the Internet for sending display images produced at the web server from any software application to a client web browser. The interface is personalized and includes, in addition to providing a gateway to different information databases, a search function, an archiving function, a specific bookmark function, an access to uploaded abstracts, and a personalized area. The interface includes a tool for upload, creation, venue presentation, and highly interactive web delivery presentation of a scientific paper or a poster by an author, linked with an internal tool for reviewing, accepting, and grading submitted abstracts for review. Within the personalized page, the interface includes a management tool for all abstracts uploaded to the interface, a follow-up tool and a system for managing the academic currency associated with the uploaded presentations including the capacity to produce feedback report associated with comments and viewing statistics. A digital presentation system allows attendees to comment on specific slides of presentations, have live or deferred communications with the presenter, rate the presentation, and even archive part or all of the presentation in the interface for later retrieval.",KALBFLEISCH BRIAN JOSEPH;;CHANG PAUL JOSEPH;;DREW STEVEN THOMAS;;CARR CHRISTOPHER DANIEL;;PEDE DAVID RICHARD;;BASCO JOHN WILLIAM;;BASCO JAMES FRANCIS,KALBFLEISCH BRIAN JOSEPH;;CHANG PAUL JOSEPH;;DREW STEVEN THOMAS;;CARR CHRISTOPHER DANIEL;;PEDE DAVID RICHARD;;BASCO JOHN WILLIAM;;BASCO JAMES FRANCIS,RADIOLOGICAL SOCIETY OF NORTH AMERICA INC (2009-11-06),https://lens.org/059-278-773-498-208,Patent Application,yes,57,44,3,3,0,G06F16/954;;G06F16/954;;G06F16/9535;;G06F16/9535,G06F3/048;;G06F15/16;;G06F21/22,715/741;;715/745;;715/760,3,1,071-596-716-434-425,10.2214/ajr.05.1991;;16861514,"Gunnar Jurdzik Firefox Help - Tutorials: Bookmarks Wayback Machine archived date May 12, 2005 11 pages;;Mike Volodarksy IIS 7.0 Explore the Web Server for Windows Vista and Beyond Wyback Machine archived date Maye 1, 2008 15 pages;;Yam CS. Using Macromedia Flash for electronic presentations: a new alternative. AJR 2006;187:W207-W217",DISCONTINUED
339,GB,B,GB 2273612 B,078-486-876-377-535,1994-11-23,1994,GB 9401307 A,1994-01-24,GB 9103707 A;;US 49131490 A,1990-03-09,Igniter cable connector,,COOPER IND INC,ADAM LEROY B;;CANNADY STEVEN J;;CARR DARIN W;;MEEKS WILLIAM B;;RUNGE MICHAEL A;;SCHUEREN JAN R;;STRAUB STEPHEN W,,https://lens.org/078-486-876-377-535,Granted Patent,no,10,0,12,17,0,H01R13/2421;;H01R13/53;;H01R13/6276;;H01T13/04,H01R13/24;;H01R13/53;;H01R13/627;;H01T13/04,F1B BCAM          BCAM;;H2E ECCC          ECCCZ;;H2E ECCX          ECCX;;H2E EEPG          EEPG;;H2E EFBE          EFBE;;H2E E203          ECCCZ;;H2E E205          ECCCZ;;U1S S1839;;U1S S1950;;U1S S1987;;U1S S2073,0,0,,,,EXPIRED
340,WO,A3,WO 2010/062799 A3,158-341-019-095-341,2010-08-19,2010,US 2009/0064207 W,2009-11-12,US 32424608 A,2008-11-26,"PERSONALIZED, ONLINE, SCIENTIFIC INTERFACE","An Internet-based personalized, online, scientific interface is described, operating from at least a proprietary web server connected to the Internet for sending display images produced at the web server from any software application to a client web browser. The interface is personalized and includes, in addition to providing a gateway to different information databases, a search function, an archiving function, a specific bookmark function, an access to uploaded abstracts, and a personalized area. The interface includes a tool for upload, creation, venue presentation, and highly interactive web delivery presentation of a scientific paper or a poster by an author, linked with an internal tool for reviewing, accepting, and grading submitted abstracts for review. Within the personalized page, the interface includes a management tool for all abstracts uploaded to the interface, a follow-up tool and a system for managing the academic currency associated with the uploaded presentations including the capacity to produce feedback report associated with comments and viewing statistics. A digital presentation system allows attendees to comment on specific slides of presentations, have live or deferred communications with the presenter, rate the presentation, and even archive part or all of the presentation in the interface for later retrieval.",RADIOLOGICAL SOC OF NORTH AMER;;KALBFLEISCH BRIAN JOSEPH;;CHANG PAUL JOSEPH;;DREW STEVEN THOMAS;;CARR CHRISTOPHER DANIEL;;PEDE DAVID RICHARD;;BASCO JOHN WILLIAM;;BASCO JAMES FRANCIS,KALBFLEISCH BRIAN JOSEPH;;CHANG PAUL JOSEPH;;DREW STEVEN THOMAS;;CARR CHRISTOPHER DANIEL;;PEDE DAVID RICHARD;;BASCO JOHN WILLIAM;;BASCO JAMES FRANCIS,,https://lens.org/158-341-019-095-341,Search Report,yes,5,0,3,3,0,G06F16/954;;G06F16/954;;G06F16/9535;;G06F16/9535,G06Q50/00;;G06F3/00;;G06F15/16,,0,0,,,,PENDING
341,GB,A,GB 2277212 A,156-046-863-047-041,1994-10-19,1994,GB 9414007 A,1994-01-24,GB 9103707 A;;US 49131490 A,1990-03-09,Engine igniter and cable connector assembly,,COOPER IND INC,ADAM LEROY B;;CANNADY STEVEN J;;CARR DARIN W;;MEEKS WILLIAM B;;RUNGE MICHAEL A;;SCHUEREN JAN R;;STRAUB STEPHEN W,,https://lens.org/156-046-863-047-041,Patent Application,no,6,0,12,17,0,H01R13/2421;;H01R13/53;;H01R13/6276;;H01T13/04,H01R13/24;;H01R13/53;;H01R13/627;;H01T13/04,H2E ECCX          ECCX;;U1S S1839;;U1S S1950;;U1S S1987;;U1S S2073,0,0,,,,EXPIRED
342,EP,B1,EP 3906890 B1,164-225-491-639-84X,2024-03-06,2024,EP 21180496 A,2014-11-20,US 201361908195 P;;US 201462038870 P;;EP 14820969 A;;US 2014/0066574 W,2013-11-25,VACCINATION ASSEMBLY FOR DELIVERING VACCINE TO AVIAN PULLETS,,ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/164-225-491-639-84X,Granted Patent,yes,7,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,ACTIVE
343,GB,A,GB 2273612 A,004-763-397-035-480,1994-06-22,1994,GB 9401307 A,1994-01-24,GB 9103707 A;;US 49131490 A,1990-03-09,Engine igniter and cable connector assembly,"A cable connector 13 is secured to an adapter 12 receiving a spark igniter 11 or an igniter (181, Fig. 11) screwed directly into a turbine engine by a clamp assembly 14, a coupling nut (98, Fig. 7) or a quick release coupling (144, 195, and igniter about the abutting terminals 43 and 50. The terminal pin 49 is spring-loaded and is rotated during axial movement. The abutting terminal surfaces may take various forms (Figs. 8 and 9). <IMAGE>",COOPER IND INC,ADAM LEROY B;;CANNADY STEVEN J;;CARR DARIN W;;MEEKS WILLIAM B;;RUNGE MICHAEL A;;SCHUEREN JAN R;;STRAUB STEPHEN W,,https://lens.org/004-763-397-035-480,Patent Application,no,10,1,12,17,0,H01R13/2421;;H01R13/53;;H01R13/6276;;H01T13/04,H01R13/24;;H01R13/53;;H01R13/627;;H01T13/04,F1B BCAM          BCAM;;H2E ECCC          ECCCZ;;H2E ECCX          ECCX;;H2E EEPG          EEPG;;H2E EFBE          EFBE;;H2E E203          ECCCZ;;H2E E205          ECCCZ;;U1S S1839;;U1S S1950;;U1S S1987;;U1S S2073,0,0,,,,EXPIRED
344,GB,A,GB 2241739 A,006-860-515-486-256,1991-09-11,1991,GB 9103707 A,1991-02-22,US 49131490 A,1990-03-09,Engine igniter and cable connector assembly,"A cable connector 13 is secured to an adapter 12 receiving a spark igniter 11 or an igniter (181, Fig. 11) screwed directly into a turbine engine by a clamp assembly 14, a coupling nut (98. Fig. 7) or a quick release coupling (144, 195, Figs. 10 and 11) to compress a seal 84 between the connector and igniter about the abutting terminals 43 and 50. The terminal pin 49 is spring-loaded and is rotated during axial movement. The abutting terminal surfaces may take various forms (Figs. 8 and 9). <IMAGE>",COOPER IND INC,ADAM LEROY B;;CANNADY STEVEN J;;CARR DARIN W;;MEEKS WILLIAM B;;RUNGE MICHAEL A;;SCHUEREN JAN R;;STRAUB STEPHEN W,,https://lens.org/006-860-515-486-256,Patent Application,no,1,3,5,17,0,H01R13/2421;;H01R13/52;;H01R13/62;;H01R13/639;;H01T13/04;;H01R13/2421;;H01T13/04;;H01R13/639;;H01R13/62;;H01R13/52,F02C7/266;;H01R13/24;;H01R13/52;;H01R13/62;;H01R13/639;;H01T13/04,F1B BCAT          BCAZ;;F1B BCAV          BCAZ;;H2E ECCC          ECCCZ;;H2E ECCX          ECCX;;H2E EEPG          EEPG;;H2E EFBE          EFBE;;H2E E203          ECCCZ;;H2E E205          ECCCZ;;U1S S1839;;U1S S1950;;U1S S1987;;U1S S2073,0,0,,,,EXPIRED
345,US,A1,US 2004/0007530 A1,002-462-000-152-629,2004-01-15,2004,US 42823103 A,2003-05-02,US 42823103 A;;US 37745102 P,2002-05-03,High stability porous metal oxide spherules used for one-step antibody purifications,"
   The present invention describes the use of porous metal oxides for the preparative purification of antibodies and biomolecules within a range of particle physical characteristics. Typically, particles from 15 to 100 microns in average diameter with pores sizes ranging from 400 to 600 angstroms and surface areas from 10 to 50 square meters per gram, and pore volumes from 0.1 to 0.4 mL/gram can be used for purification processes. The metal oxide particles that fall within this range of physical properties show enhanced utility and greater chromatographic capacity for antibodies than materials oxide particles falling outside of this range. Metal oxides such as zirconia, titania and alumina can all be modified with a multi-Lewis base moiety such as an organophosphate ethylenediamine-N,N-tetra(methylenephosphonic) acid (EDTPA), to produce a bio-compatible purification media for, biomolecules. 
",MCNEFF CLAYTON V.;;CARR PETER W.;;RUPP STEVEN J.;;STOLL DWIGHT R.;;HAWKER DANIELLE R.;;ZIGAN LORINDA D.;;JOHNSON KERRY G.,MCNEFF CLAYTON V;;CARR PETER W;;RUPP STEVEN J;;STOLL DWIGHT R;;HAWKER DANIELLE R;;ZIGAN LORINDA D;;JOHNSON KERRY G,ZIRCHROM SEPARATIONS INC (2003-07-25),https://lens.org/002-462-000-152-629,Patent Application,yes,13,17,2,2,0,B01J20/28057;;B01J20/28057;;B01J20/28004;;B01J20/28004;;B01J20/28083;;B01J20/28083;;B01J20/28085;;B01J20/28085;;B01J20/286;;B01J20/286;;B01J20/3204;;B01J20/3204;;B01J20/3234;;B01J20/3234;;B01J20/3251;;B01J20/3251;;B01J20/3293;;B01J20/3293;;B01J39/17;;B01J39/17;;B01J39/26;;B01J39/26;;C07K1/16;;C07K1/16;;C07K16/065;;C07K16/065,B01J20/286;;B01J20/32;;B01J39/16;;B01J39/26;;C07K1/16;;C07K16/06,210/656;;210/198.2;;530/413;;530/417,0,0,,,,EXPIRED
346,MX,A,MX 2016006728 A,030-278-204-009-117,2016-09-06,2016,MX 2016006728 A,2014-11-20,US 201361908195 P;;US 201462038870 P;;US 2014/0066574 W,2013-11-25,"VACCINATION SYSTEM FOR DELIVERING VACCINE TO AVIAN PULLETS, AND ASSOCIATED METHODS, DEVICES, AND ASSEMBLIES.","A vaccination system for delivering a vaccine substance to avian pullets is provided. Such a system includes a vaccine delivery assembly configured to perform a vaccine delivery procedure for delivering a vaccine substance to the avian pullets. A plurality of positioning devices is provided, with each positioning device receiving an avian pullet for presentation to the vaccine delivery assembly. Each positioning device is transported to individually mate with the vaccine delivery assembly to deliver the vaccine substance during the vaccine delivery procedure. Associated methods, devices, and assemblies are also provided.",ZOETIS SERVICES LLC,WILLIAM DOUGLAS SAMSON;;MARCO GIOVANNI TRIVELLA;;RAYMOND JOHN NIEMCZURA;;DANIEL LEE KENNEDY;;DAVID ANDREW EICHENBERGER;;WILLIAM BRYAN CARR;;STEVEN ALLAN DUE,,https://lens.org/030-278-204-009-117,Patent Application,no,0,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,PENDING
347,WO,A3,WO 2015/077432 A3,033-988-087-150-941,2015-07-16,2015,US 2014/0066574 W,2014-11-20,US 201361908195 P;;US 201462038870 P,2013-11-25,"VACCINATION SYSTEM FOR DELIVERING VACCINE TO AVIAN PULLETS, AND ASSOCIATED METHODS, DEVICES, AND ASSEMBLIES","A vaccination system for delivering a vaccine substance to avian pullets is provided. Such a system includes a vaccine delivery assembly configured to perform a vaccine delivery procedure for delivering a vaccine substance to the avian pullets. A plurality of positioning devices is provided, with each positioning device receiving an avian pullet for presentation to the vaccine delivery assembly. Each positioning device is transported to individually mate with the vaccine delivery assembly to deliver the vaccine substance during the vaccine delivery procedure. Associated methods, devices, and assemblies are also provided.",ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/033-988-087-150-941,Search Report,yes,6,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,PENDING
348,GB,B,GB 2241739 B,055-866-098-660-923,1994-11-23,1994,GB 9103707 A,1991-02-22,US 49131490 A,1990-03-09,Igniter and cable connector assembly,,COOPER IND INC,ADAM LEROY B;;CANNADY STEVEN J;;CARR DARIN W;;MEEKS WILLIAM B;;RUNGE MICHAEL A;;SCHUEREN JAN R;;STRAUB STEPHEN W,,https://lens.org/055-866-098-660-923,Granted Patent,no,1,0,5,17,0,H01R13/2421;;H01R13/52;;H01R13/62;;H01R13/639;;H01T13/04;;H01R13/2421;;H01T13/04;;H01R13/639;;H01R13/62;;H01R13/52,F02C7/266;;H01R13/24;;H01R13/52;;H01R13/62;;H01R13/639;;H01T13/04,F1B BCAT          BCAZ;;F1B BCAV          BCAZ;;H2E ECCC          ECCCZ;;H2E ECCX          ECCX;;H2E EEPG          EEPG;;H2E EFBE          EFBE;;H2E E203          ECCCZ;;H2E E205          ECCCZ;;U1S S1839;;U1S S1950;;U1S S1987;;U1S S2073,0,0,,,,EXPIRED
349,GB,B,GB 2277127 B,061-319-414-079-36X,1995-01-04,1995,GB 9413907 A,1994-01-24,GB 9103707 A;;US 49131490 A,1990-03-09,Igniter construction,,COOPER IND INC,ADAM LEROY B;;CANNADY STEVEN J;;CARR DARIN W;;MEEKS WILLIAM B;;RUNGE MICHAEL A;;SCHUEREN JAN R;;STRAUB STEPHEN W,,https://lens.org/061-319-414-079-36X,Granted Patent,no,4,0,12,17,0,H01R13/2421;;H01R13/53;;H01R13/6276;;H01T13/04,H01R13/24;;H01R13/53;;H01R13/627;;H01T13/04,F1B BCAM          BCAM,0,0,,,,EXPIRED
350,WO,A2,WO 2010/062799 A2,089-235-037-137-330,2010-06-03,2010,US 2009/0064207 W,2009-11-12,US 32424608 A,2008-11-26,"PERSONALIZED, ONLINE, SCIENTIFIC INTERFACE","An Internet-based personalized, online, scientific interface is described, operating from at least a proprietary web server connected to the Internet for sending display images produced at the web server from any software application to a client web browser. The interface is personalized and includes, in addition to providing a gateway to different information databases, a search function, an archiving function, a specific bookmark function, an access to uploaded abstracts, and a personalized area. The interface includes a tool for upload, creation, venue presentation, and highly interactive web delivery presentation of a scientific paper or a poster by an author, linked with an internal tool for reviewing, accepting, and grading submitted abstracts for review. Within the personalized page, the interface includes a management tool for all abstracts uploaded to the interface, a follow-up tool and a system for managing the academic currency associated with the uploaded presentations including the capacity to produce feedback report associated with comments and viewing statistics. A digital presentation system allows attendees to comment on specific slides of presentations, have live or deferred communications with the presenter, rate the presentation, and even archive part or all of the presentation in the interface for later retrieval.",RADIOLOGICAL SOC OF NORTH AMER;;KALBFLEISCH BRIAN JOSEPH;;CHANG PAUL JOSEPH;;DREW STEVEN THOMAS;;CARR CHRISTOPHER DANIEL;;PEDE DAVID RICHARD;;BASCO JOHN WILLIAM;;BASCO JAMES FRANCIS,KALBFLEISCH BRIAN JOSEPH;;CHANG PAUL JOSEPH;;DREW STEVEN THOMAS;;CARR CHRISTOPHER DANIEL;;PEDE DAVID RICHARD;;BASCO JOHN WILLIAM;;BASCO JAMES FRANCIS,,https://lens.org/089-235-037-137-330,Patent Application,yes,0,1,3,3,0,G06F16/954;;G06F16/954;;G06F16/9535;;G06F16/9535,G06Q50/00;;G06F3/00;;G06F15/16,,0,0,,,,PENDING
351,WO,A2,WO 2015/077432 A2,178-940-305-896-991,2015-05-28,2015,US 2014/0066574 W,2014-11-20,US 201361908195 P;;US 201462038870 P,2013-11-25,"VACCINATION SYSTEM FOR DELIVERING VACCINE TO AVIAN PULLETS, AND ASSOCIATED METHODS, DEVICES, AND ASSEMBLIES","A vaccination system for delivering a vaccine substance to avian pullets is provided. Such a system includes a vaccine delivery assembly configured to perform a vaccine delivery procedure for delivering a vaccine substance to the avian pullets. A plurality of positioning devices is provided, with each positioning device receiving an avian pullet for presentation to the vaccine delivery assembly. Each positioning device is transported to individually mate with the vaccine delivery assembly to deliver the vaccine substance during the vaccine delivery procedure. Associated methods, devices, and assemblies are also provided.",ZOETIS LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/178-940-305-896-991,Patent Application,yes,3,3,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,PENDING
352,GB,B,GB 2277414 B,186-612-533-749-763,1995-01-25,1995,GB 9413807 A,1991-02-22,GB 9103707 A;;US 49131490 A,1990-03-09,Igniter and cable connector assembly,,COOPER IND INC,ADAM LEROY B;;CANNADY STEVEN J;;CARR DARIN W;;MEEKS WILLIAM B;;RUNGE MICHAEL A;;SCHUEREN JAN R;;STRAUB STEPHEN W,,https://lens.org/186-612-533-749-763,Granted Patent,no,2,0,12,17,0,H01R13/2421;;H01R13/53;;H01R13/6276;;H01T13/04,H01R13/24;;H01R13/53;;H01R13/627;;H01T13/04,H2E EHE           EHE;;U1S S1839;;U1S S1950;;U1S S1987;;U1S S2073,0,0,,,,EXPIRED
353,RU,C2,RU 2646626 C2,022-021-008-216-852,2018-03-06,2018,RU 2016117120 A,2014-11-20,US 201361908195 P;;US 201462038870 P;;US 2014/0066574 W,2013-11-25,"VACCINATION SYSTEM FOR DELIVERING VACCINE TO AVIAN PULLETS, AND ASSOCIATED METHODS, DEVICES, AND ASSEMBLIES","FIELD: veterinary science.SUBSTANCE: invention relates to veterinary science, in particular to a method, an assembly and a system for vaccinating avian pullets. Such a system includes a vaccine delivery assembly configured to perform a vaccine administration procedure for delivering a vaccine substance to the avian pullets. Vaccine administration unit has injecting devices configured to simultaneously administer different vaccines to individual locations of an avian pullet, wherein the vaccine administration unit is configured to position injection devices in proximity to the respective individual locations of an avian pullet. Positioning devices, each of which is configured to automatically and separately interface with a vaccine administration unit and adapted to receive an avian pullet and to feed an avian pullet to the unit for administering the vaccine for the vaccine administering procedure in a single position. In this case, each positioning device is configured to provide access to individual places for administering the vaccine, to ensure complete support and retention of the avian pullet in the posture reminiscent of her pose during a flight in which her wings are held together vertically above her back.EFFECT: use of the invention will allow one or more vaccines to be administered to the poultry in an efficient and high-performance manner.13 cl, 39 dwg",ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/022-021-008-216-852,Granted Patent,no,5,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,ACTIVE
354,EP,A2,EP 0323055 A2,058-034-127-213-119,1989-07-05,1989,EP 88311588 A,1988-12-07,US 13781187 A,1987-12-28,Composite cromatographic article.,"A composite chromatographic article comprising:
 a) a polytetrafluoroethylene fibril matrix, and b) a non-swellable sorptive particles enmeshed in said matrix, the ratio of non-swellable sorptive particles to polytetrafluoroethylene being in the range of 19:1 to 4: 1 by weight, said composite article having a net surface energy in the range of 20 to 300 milliNewtons per meter.   ",MINNESOTA MINING & MFG,HAGEN DONALD F MINNESOTA MININ;;ST MARY STEVEN J MINNESOTA MIN;;ERREDE LOUIS A MINNESOTA MININ;;CARR PETER W MINNESOTA MINING,,https://lens.org/058-034-127-213-119,Patent Application,yes,0,18,13,16,0,B01J20/28028;;B01J20/28033;;Y10S435/803;;Y10T428/249986;;Y10T428/249954;;Y10T428/249986;;Y10T428/249954;;B01J20/28028;;B01J20/28033;;Y10S435/803,B01J20/281;;B01D15/08;;B01J20/28;;B01J20/285;;G01N30/88;;G01N30/92,,0,0,,,,EXPIRED
355,US,B2,US 6846410 B2,114-447-100-889-391,2005-01-25,2005,US 42823103 A,2003-05-02,US 42823103 A;;US 37745102 P,2002-05-03,High stability porous metal oxide spherules used for one-step antibody purifications,"The present invention describes the use of porous metal oxides for the preparative purification of antibodies and biomolecules within a range of particle physical characteristics. Typically, particles from 15 to 100 microns in average diameter with pores sizes ranging from 400 to 600 angstroms and surface areas from 10 to 50 square meters per gram, and pore volumes from 0.1 to 0.4 mL/gram can be used for purification processes. The metal oxide particles that fall within this range of physical properties show enhanced utility and greater chromatographic capacity for antibodies than materials oxide particles falling outside of this range. Metal oxides such as zirconia, titania and alumina can all be modified with a multi-Lewis base moiety such as an organophosphate ethylenediamine-N,N-tetra(methylenephosphonic) acid (EDTPA), to produce a bio-compatible purification media for, biomolecules.",ZIRCHROM SEPARATIONS INC,MCNEFF CLAYTON V;;CARR PETER W;;RUPP STEVEN J;;STOLL DWIGHT R;;HAWKER DANIELLE R;;ZIGAN LORINDA D;;JOHNSON KERRY G,ZIRCHROM SEPARATIONS INC (2003-07-25),https://lens.org/114-447-100-889-391,Granted Patent,yes,14,23,2,2,0,B01J20/28057;;B01J20/28057;;B01J20/28004;;B01J20/28004;;B01J20/28083;;B01J20/28083;;B01J20/28085;;B01J20/28085;;B01J20/286;;B01J20/286;;B01J20/3204;;B01J20/3204;;B01J20/3234;;B01J20/3234;;B01J20/3251;;B01J20/3251;;B01J20/3293;;B01J20/3293;;B01J39/17;;B01J39/17;;B01J39/26;;B01J39/26;;C07K1/16;;C07K1/16;;C07K16/065;;C07K16/065,B01J20/286;;B01J20/32;;B01J39/16;;B01J39/26;;C07K1/16;;C07K16/06,210/198.2;;210/502.1;;210/635;;210/656;;502/401,21,18,026-517-126-751-586;;020-449-165-502-806;;121-742-975-319-071;;006-071-226-253-681;;043-764-541-193-256;;128-551-985-826-416;;074-422-720-693-728;;064-686-578-096-506;;016-699-363-669-700;;039-109-391-660-115;;024-256-403-628-362;;007-730-559-353-050;;003-289-275-461-113;;024-733-306-679-423;;072-883-631-840-449;;081-728-851-137-532;;005-771-848-934-300;;086-176-150-945-19X,3046429;;10.1021/ac00163a025;;7633592;;10.1016/0021-9673(95)00155-g;;10.1016/s0021-9673(01)90875-1;;1885689;;10.1016/s0021-9673(01)83988-1;;10.1016/0021-9673(95)00831-4;;10.1093/chromsci/20.5.203;;10.1016/s0021-9673(01)83376-8;;10.1016/s0021-9673(01)94709-0;;8450008;;10.1016/0021-9673(93)80510-f;;10.2116/analsci.4.671;;10.2116/analsci.5.485;;10.1016/s0021-9673(01)89308-0;;10.1016/s0021-9673(01)88938-x;;8130879;;10.1016/0021-9673(93)80284-f;;10.1016/0022-1902(58)80152-9;;2445822;;10.1016/0022-1759(87)90493-5;;10.1021/ac001008u;;11217783;;10.1016/0021-9673(95)00466-z;;7633593,"Barth, H. et al., ""Column Liquid Chromatography,"" Analytical Chemistry, vol. 60, pp. 387R-435R (1988).;;Clearfield, A. et al., ""New Inorganic Ion Exchangers,"" Ion Exchange and Solvent Extraction, Marinsky et al. eds., Marcel Dekker, New York, vol. 5, pp. 1-119 (1973).;;Sofer, G., ""Preparative chromatographic separations in pharmaceutical, diagnostic, and biotechnology industries: current and future trends,"" Journal of Chromatography A, vol. 707, pp. 23-28 (1995).;;Kopaciewicz, W. et al., Retention Model for High-Performance Ion-Exchange Chromatography, Journal of Chromatography, vol. 266, pp. 3-21 (1983).;;Yang, Y. et al., ""Coated hydrophilic polystyrene-based packing materials,"" Journal of Chromatography, vol. 544, pp. 233-247 (1991).;;Yang, Y. et al., ""Characterization of a novel stationary phase derived from a hydrophilic polystyrene-based resin for protein cation-exchange high-performance liquid chromatography,"" Journal of Chromatography A, vol. 723, pp. 1-10 (1996).;;Lee, D., ""Reversed-Phase HPLC from pH 1 to 13,"" Journal of Chromatographic Science, vol. 20, pp. 203-208 (1982).;;Dawkins, J. et al., ""Chromatographic Characteristics of Polymer-Based High-Performance Liquid Chromatography Packings,"" Journal of Chromatography, vol. 352, pp. 157-167 (1986).;;Bowers, L. et al., ""Solvent Strength Studies on Polystyrene-Divinylbenzene Columns,"" Journal of Chromatography, vol. 371, pp. 243-251 (1986).;;Varady, L. et al., ""Fimbriated stationary phases for proteins,"" Journal of Chromatography, vol. 631, pp. 107-114 (1993).;;Unger, K. et al., ""Oxide Stationary Phases,"" High Performance Liquid Chromatography, Brown et al. eds., Wiley, New York, Ch. 3, pp. 145-188 (1989).;;Kawahara, M. et al., ""Evaluation of New Ceramics as Column Packing Material for High Performance Liquid Chromatography,"" Analytical Sciences, vol. 4, pp. 671-673 (1988).;;Kawahara, M. et al., ""Titania and Zirconia as New Ceramic Column Packing Materials for High Performance Liquid Chromatography,"" Analytical Sciences, vol. 5, pp. 485-486 (1989).;;Kawahara, M. et al., Titania and zirconia: possible new ceramic microparticulates for high-performance liquid chromatography, Journal of Chromatography, vol. 515, pp. 149-158 (1990).;;Trudinger, U. et al., ""Porous zirconia and titania as packing materials for high-performance liquid chromatography,"" Journal of Chromatography, vol. 535, pp. 111-125 (1990).;;Nawrocki, J. et al., ""Chemistry of zirconia and its use in chromatography,"" Journal of Chromatography A, vol. 657, pp. 229-282 (1993).;;Amphlett, C. et al., ""Synthetic Inorganic Ion-Exchange Materials-II Hydrous Zirconium Oxide and Other Oxides,"" J. Inorg. Nucl. Chem., vol. 6, pp. 236-245 (1958).;;Amphlett, C. et al., ""Synthetic Inorganic Ion-Exchange Materials-I Zirconium Phosphate,"" J. Inorg. Nucl. Chem., vol. 6, pp. 220-235 (1958).;;Malm, B., ""A method suitable for the isolations of monoclonal antibodies from large volumes of serum-containing hybridoma cell culture supernatants,"" Journal of Immunological Methods, vol. 104, pp. 103-109 (1987).;;Jiang, Z. et al., ""Synthesis of Porous Titania Microspheres for HPLC Packings by Polymerization-Induced Colloid Aggregation (PICA),"" Analytical Chemistry, vol. 73, pp. 686-688 (2001).;;Jones C., et al., ""Current trends in molecular recognition and bioseparation,"" Journal of Chromatography A., vol. 707, pp. 3-22 (1995).",EXPIRED
356,WO,A1,WO 2010/093322 A1,007-855-673-670-032,2010-08-19,2010,SE 2010050161 W,2010-02-11,US 15254409 P,2009-02-13,METHODS FOR IDENTIFYING THERAPEUTIC AGENTS MODULATING ACTIVITY OF THE IGF2 REPRESSOR ZBED6,"The present invention relates to methods for identifying therapeutic agents capable of modulating the activity of the IGF2 repressor ZBED6 for use in growth promotion,wound healing, angiogenesis, inhibition of muscle wasting, and treatment of cancer,tumours and other malignancies, muscle atrophy, muscle dystrophy, neuropathy,osteoporosis, cachexia, diabetes, obesity, acromegaly, polycystic ovary syndrome, and retinopathy.",ANDERSSON LEIF BERTIL;;ANDERSSON GOERAN;;HJAELM GOERAN;;LINDBLAD-TOH KERSTIN;;CARR STEVEN A;;JAFFE JACOB D;;GNIRKE ANDREAS;;MIKKELSEN TARJEI S,ANDERSSON LEIF BERTIL;;ANDERSSON GOERAN;;HJAELM GOERAN;;LINDBLAD-TOH KERSTIN;;CARR STEVEN A;;JAFFE JACOB D;;GNIRKE ANDREAS;;MIKKELSEN TARJEI S,,https://lens.org/007-855-673-670-032,Patent Application,yes,0,1,1,1,9,A61K38/00;;A61P3/04;;A61P21/00;;C07K14/4703;;C12N15/113;;C12N2310/14;;C12N2320/11;;G01N2333/4704;;G01N2500/04,C07K14/47;;A61K38/17;;A61K48/00;;A61P3/04;;A61P21/00;;C07K14/65;;G01N33/68,,5,3,112-011-746-348-498;;000-588-901-917-108;;031-632-259-715-911,14574411;;10.1038/nature02064;;10.1017/s0016672304007098;;15678747;;20016685;;10.1371/journal.pbio.1000256;;pmc2780926,"VAN LAERE A-S: ""From QTL to QTN, Identification of a Quantitative Trait Nucleotide Influencing Muscle Development and Fat Deposition in Pig"", 26 January 2005 (2005-01-26), pages 26, XP003025664, Retrieved from the Internet <URL:http://diss-epsilon.slu.se:8080/archive/00000719/01/thesis4.pdf> [retrieved on 20100311];;VAN LAERE A-S. ET AL.: ""A regulatory mutation in IGF2 causes a major QTL effect on muscle growth in the pig"", NATURE, vol. 425, 2003, pages 832 - 836, XP002279572;;JUNGERIUS B.J. ET AL.: ""The IGF2-intron3-G3072A substitution explains a major imprinted QTL effect on backfat thickness in a Meishan x European white pig intercross"", GENET. RES. CAMB., vol. 84, 2004, pages 95 - 101, XP003025665;;MARKLJUNG ELLEN ET AL.: ""ZBED6, a Novel Transcription Factor Derived from a Domesticated DNA Transposon Regulates IGF2 Expression and Muscle Growth"", PLOS BIOL., vol. 7, no. 12, 2009, pages 1 - 13, XP003025666;;MARKLJUNG ELLEN: ""QTL Analysis in the Pig From the Identification of Quantitative Trait Loci to the Understanding of Molecular Mechanisms"", 20 February 2009 (2009-02-20), pages 36 - 44, XP003025667, Retrieved from the Internet <URL:http://uu.diva-portal.org/smash/record.jsf?pid=diva2:173250> [retrieved on 20100303]",PENDING
357,JP,A,JP 2019162486 A,028-251-069-584-52X,2019-09-26,2019,JP 2019102075 A,2019-05-31,US 201361908195 P;;US 201462038870 P,2013-11-25,"VACCINATION SYSTEM FOR DELIVERING VACCINE TO PULLETS, AND ASSOCIATED METHODS, DEVICES AND ASSEMBLIES","To provide a vaccination system for delivering a vaccine substance to pullets, and associated methods, devices and assemblies.SOLUTION: The system includes a vaccine delivery assembly configured to perform a vaccine delivery procedure for delivering a vaccine substance to the pullets. Each of multiple positioning devices 600 receives a pullet for presentation to the vaccine delivery assembly. Each positioning device is transported to individually mate with the vaccine delivery assembly to deliver the vaccine substance during the vaccine delivery procedure.SELECTED DRAWING: Figure 37",ZOETIS SERVICES LLC,WILLIAM DOUGLAS SAMSON;;MARCO GIOVANNI TRIVELLA;;RAYMOND JOHN NIEMCZURA;;DANIEL LEE KENNEDY;;DAVID ANDREW EICHENBERGER;;WILLIAM BRYAN CARR;;STEVEN ALLAN DUE,,https://lens.org/028-251-069-584-52X,Patent Application,no,6,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,ACTIVE
358,ES,T3,ES 2883291 T3,016-535-563-703-36X,2021-12-07,2021,ES 14820969 T,2014-11-20,US 201361908195 P;;US 201462038870 P;;US 2014/0066574 W,2013-11-25,"Sistema de vacunación para la administración de vacuna a polluelos y procedimientos, dispositivos y conjuntos asociados","Un conjunto de administración de vacunas (400), que comprende: un bastidor de administración de vacunas (402); un dispositivo de inyección de membrana de ala (410) acoplado operativamente con el bastidor de administración de vacuna (402) y que tiene un accionador de inyección de membrana de ala (463), estando configurado el dispositivo de inyección de membrana de ala (410) para administrar una primera sustancia de vacuna a al menos una membrana de ala de una polluelo aviar; un dispositivo de inyección intramuscular (430) acoplado operativamente con el bastidor de administración de vacuna (402) y que tiene un accionador de inyección intramuscular (461), estando configurado el dispositivo de inyección intramuscular (430) para administrar una segunda sustancia de vacuna a una pechuga del polluelo aviar; un dispositivo de inyección subcutánea (450) acoplado operativamente con el bastidor de administración de vacuna (402) y que tiene un accionador de inyector subcutáneo (462), estando adaptado el dispositivo de inyección subcutánea (450) para administrar una tercera sustancia de vacuna a un pliegue inguinal del polluelo aviar; un dispositivo de administración de pulverización (470) acoplado operativamente con el bastidor de administración de vacuna (402), estando adaptado el dispositivo de administración de pulverización (470) para administrar una cuarta sustancia de vacuna a una región facial del polluelo aviar, teniendo el dispositivo de administración de pulverización (470) un accionador (465) del dispositivo de pulverización y que está configurado para ser transportado cerca del área facial del polluelo aviar mediante una guía (466); y un accionador principal (460) configurado para mover el accionador de inyección de membrana de ala (463), el accionador de inyección intramuscular (461) y el accionador de inyector subcutáneo (462) a una posición que permite la inyección de una parte del cuerpo respectiva del polluelo aviar.",ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/016-535-563-703-36X,Granted Patent,no,0,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,ACTIVE
359,AU,B2,AU 2014/352984 B2,082-282-978-864-385,2019-03-07,2019,AU 2014/352984 A,2014-11-20,US 201361908195 P;;US 201462038870 P;;US 2014/0066574 W,2013-11-25,"Vaccination system for delivering vaccine to avian pullets, and associated methods, devices, and assemblies","A vaccination system for delivering a vaccine substance to avian pullets is provided. Such a system includes a vaccine delivery assembly configured to perform a vaccine delivery procedure for delivering a vaccine substance to the avian pullets. A plurality of positioning devices is provided, with each positioning device receiving an avian pullet for presentation to the vaccine delivery assembly. Each positioning device is transported to individually mate with the vaccine delivery assembly to deliver the vaccine substance during the vaccine delivery procedure. Associated methods, devices, and assemblies are also provided.",ZOETIS SERVICES LLC,CARR WILLIAM BRYAN;;DUE STEVEN ALLAN;;SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW,,https://lens.org/082-282-978-864-385,Granted Patent,no,4,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,ACTIVE
360,BR,B1,BR 112016010205 B1,110-198-086-417-565,2022-05-03,2022,BR 112016010205 A,2014-11-20,US 2014/0066574 W;;US 201361908195 P;;US 201462038870 P,2013-11-25,"Sistema de vacinação para aplicar vacina para frangas e métodos, dispositivos e montagens associadas","sistema de vacinação para aplicar vacina para frangas, e métodos, dispositivos e montagens associadas. a invenção diz respeito a um sistema de vacinação para aplicar uma substância de vacina para frangas. tal sistema inclui uma montagem de aplicação de vacina configurada para executar um procedimento de aplicação de vacina para aplicar uma substância de vacina para as frangas. vários dispositivos de posicionamento são proporcionados, com cada dispositivo de posicionamento recebendo uma franga para apresentação para a montagem de aplicação de vacina. cada dispositivo de posicionamento é transportado para individualmente se acoplar de forma correspondente com a montagem de aplicação de vacina para aplicar a substância de vacina durante o procedimento de aplicação de vacina. métodos, dispositivos e montagens associadas também são proporcionados.",ZOETIS SERVICES LLC,DANIEL LEE KENNEDY;;DAVID ANDREW EICHENBERGER;;MARCO GIOVANNI TRIVELLA;;RAYMOND JOHN NIEMCZURA;;STEVEN ALLAN DUE;;WILLIAM BRYAN CARR;;WILLIAM DOUGLAS SAMSON,ZOETIS SERVICES LLC (US) (2017-08-29),https://lens.org/110-198-086-417-565,Granted Patent,no,0,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,ACTIVE
361,DE,D1,DE 3873899 D1,082-627-621-391-352,1992-09-24,1992,DE 3873899 T,1988-12-07,US 13781187 A,1987-12-28,ZUSAMMENGESETZTER ARTIKEL FUER DIE CHROMATOGRAPHIE.,,MINNESOTA MINING & MFG,HAGEN DONALD F MINNESOTA MININ;;ST MARY STEVEN J MINNESOTA MIN;;ERREDE LOUIS A MINNESOTA MININ;;CARR PETER W MINNESOTA MINING,,https://lens.org/082-627-621-391-352,Granted Patent,no,0,0,13,16,0,B01J20/28028;;B01J20/28033;;Y10S435/803;;Y10T428/249986;;Y10T428/249954;;Y10T428/249986;;Y10T428/249954;;B01J20/28028;;B01J20/28033;;Y10S435/803,B01J20/281;;B01D15/08;;B01J20/28;;B01J20/285;;G01N30/88;;G01N30/92,,0,0,,,,EXPIRED
362,GB,A,GB 2277127 A,106-558-706-491-54X,1994-10-19,1994,GB 9413907 A,1994-01-24,GB 9103707 A;;US 49131490 A,1990-03-09,Igniter construction,,COOPER IND INC,ADAM LEROY B;;CANNADY STEVEN J;;CARR DARIN W;;MEEKS WILLIAM B;;RUNGE MICHAEL A;;SCHUEREN JAN R;;STRAUB STEPHEN W,,https://lens.org/106-558-706-491-54X,Patent Application,no,4,1,12,17,0,H01R13/2421;;H01R13/53;;H01R13/6276;;H01T13/04,H01R13/24;;H01R13/53;;H01R13/627;;H01T13/04,F1B BCAM          BCAM,0,0,,,,EXPIRED
363,BR,A2,BR 112016010205 A2,142-937-729-548-516,2017-08-08,2017,BR 112016010205 A,2014-11-20,US 2014/0066574 W;;US 201361908195 P;;US 201462038870 P,2013-11-25,"?sistema de vacinação para aplicar vacina para frangas e métodos, dispositivos e montagens associadas??","resumo ?sistema de vacinação para aplicar vacina para frangas, e métodos, dispositivos e montagens associadas?. a invenção diz respeito a um sistema de vacinação para aplicar uma substância de vacina para frangas. tal sistema inclui uma montagem de aplicação de vacina configurada para executar um procedimento de aplicação de vacina para aplicar uma substância de vacina para as frangas. vários dispositivos de posicionamento são proporcionados, com cada dispositivo de posicionamento recebendo uma franga para apresentação para a montagem de aplicação de vacina. cada dispositivo de posicionamento é transportado para individualmente se acoplar de forma correspondente com a montagem de aplicação de vacina para aplicar a substância de vacina durante o procedimento de aplicação de vacina. métodos, dispositivos e montagens associadas também são proporcionados.",ZOETIS SERVICES LLC,DANIEL LEE KENNEDY;;DAVID ANDREW EICHENBERGER;;MARCO GIOVANNI TRIVELLA;;RAYMOND JOHN NIEMCZURA;;STEVEN ALLAN DUE;;WILLIAM BRYAN CARR;;WILLIAM DOUGLAS SAMSON,ZOETIS SERVICES LLC (US) (2017-08-29),https://lens.org/142-937-729-548-516,Patent Application,no,0,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,ACTIVE
364,US,A1,US 2003/0056104 A1,063-597-129-674-920,2003-03-20,2003,US 23306902 A,2002-08-30,US 23306902 A;;US 93929801 A;;US 12750298 A;;US 7403498 A;;US 96769397 A;;US 61452196 A;;US 21528994 A;;US 57142200 A;;US 17276902 A;;US 15462102 A;;US 69446500 A;;US 17250602 A;;US 9459302 A;;US 15801599 P;;US 16367699 P;;US 35688102 P;;US 31685101 P;;US 32768701 P;;US 35265202 P,1994-03-17,Digitally watermarking checks and other value documents,"
   The present invention provides various techniques for encoding hidden information in checks and other security documents. The hidden information provides an authentication tool. In one implementation, we provide a method for encoding a security document with information. The security document includes a substrate having printing thereon. The information is hidden in the printing and corresponds to text or numbers conveyed by at least a portion of the printing. The method includes dividing the information into a plurality of payload sets, wherein each payload set includes a sub-set of the information, and encoding the payload sets across the substrate. The plurality of payload sets is concatenated in order to retrieve the information. 
",CARR J. SCOTT;;RHOADS GEOFFREY B.;;HEIN WILLIAM C.;;MILLER MARC D.;;HAWES JONATHAN L.;;ELOVITZ ANDREA NICOLE;;STEWART STEVEN W.,CARR J SCOTT;;RHOADS GEOFFREY B;;HEIN WILLIAM C;;MILLER MARC D;;HAWES JONATHAN L;;ELOVITZ ANDREA NICOLE;;STEWART STEVEN W,DIGIMARC CORPORATION (2002-12-07),https://lens.org/063-597-129-674-920,Patent Application,yes,4,69,1,1547,0,G07D7/005;;G07D7/005;;H04N1/32203;;H04N1/32203;;H04N2201/3235;;H04N2201/3235;;H04N2201/327;;H04N2201/327;;H04N2201/3271;;H04N2201/3271,H04L9/00,713/176,0,0,,,,DISCONTINUED
365,GB,A,GB 2277414 A,111-582-850-123-97X,1994-10-26,1994,GB 9413807 A,1991-02-22,GB 9103707 A;;US 49131490 A,1990-03-09,Igniter and cable connector assembly terminals,,COOPER IND INC,ADAM LEROY B;;CANNADY STEVEN J;;CARR DARIN W;;MEEKS WILLIAM B;;RUNGE MICHAEL A;;SCHUEREN JAN R;;STRAUB STEPHEN W,,https://lens.org/111-582-850-123-97X,Patent Application,no,2,1,12,17,0,H01R13/2421;;H01R13/53;;H01R13/6276;;H01T13/04,H01R13/24;;H01R13/53;;H01R13/627;;H01T13/04,H2E EHE           EHE;;U1S S1839;;U1S S1950;;U1S S1987;;U1S S2073,0,0,,,,EXPIRED
366,EP,B1,EP 3073959 B1,188-952-140-151-852,2021-06-30,2021,EP 14820969 A,2014-11-20,US 201361908195 P;;US 201462038870 P;;US 2014/0066574 W,2013-11-25,VACCINATION ASSEMBLY FOR DELIVERING VACCINE TO AVIAN PULLETS,,ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,ZOETIS SERVICES LLC (2017-08-02),https://lens.org/188-952-140-151-852,Granted Patent,yes,6,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,1,0,,,None,ACTIVE
367,CA,A1,CA 2929331 A1,004-430-587-263-93X,2015-05-28,2015,CA 2929331 A,2014-11-20,US 201361908195 P;;US 201462038870 P;;US 2014/0066574 W,2013-11-25,"VACCINATION SYSTEM FOR DELIVERING VACCINE TO AVIAN PULLETS, AND ASSOCIATED METHODS, DEVICES, AND ASSEMBLIES","A vaccination system for delivering a vaccine substance to avian pullets is provided. Such a system includes a vaccine delivery assembly configured to perform a vaccine delivery procedure for delivering a vaccine substance to the avian pullets. A plurality of positioning devices is provided, with each positioning device receiving an avian pullet for presentation to the vaccine delivery assembly. Each positioning device is transported to individually mate with the vaccine delivery assembly to deliver the vaccine substance during the vaccine delivery procedure. Associated methods, devices, and assemblies are also provided.",ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/004-430-587-263-93X,Patent Application,no,0,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,ACTIVE
368,GB,B,GB 2277212 B,009-225-261-016-786,1995-01-04,1995,GB 9414007 A,1994-01-24,GB 9103707 A;;US 49131490 A,1990-03-09,Igniter and cable connector assembly,,COOPER IND INC,ADAM LEROY B;;CANNADY STEVEN J;;CARR DARIN W;;MEEKS WILLIAM B;;RUNGE MICHAEL A;;SCHUEREN JAN R;;STRAUB STEPHEN W,,https://lens.org/009-225-261-016-786,Granted Patent,no,6,0,12,17,0,H01R13/2421;;H01R13/53;;H01R13/6276;;H01T13/04,H01R13/24;;H01R13/53;;H01R13/627;;H01T13/04,H2E ECCX          ECCX;;U1S S1839;;U1S S1950;;U1S S1987;;U1S S2073,0,0,,,,EXPIRED
369,EP,A2,EP 3073959 A2,079-138-174-918-718,2016-10-05,2016,EP 14820969 A,2014-11-20,US 201361908195 P;;US 201462038870 P;;US 2014/0066574 W,2013-11-25,"VACCINATION SYSTEM FOR DELIVERING VACCINE TO AVIAN PULLETS, AND ASSOCIATED METHODS, DEVICES, AND ASSEMBLIES",,ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,ZOETIS SERVICES LLC (2017-08-02),https://lens.org/079-138-174-918-718,Patent Application,yes,0,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,ACTIVE
370,CA,C,CA 2929331 C,049-067-883-112-414,2019-10-29,2019,CA 2929331 A,2014-11-20,US 201361908195 P;;US 201462038870 P;;US 2014/0066574 W,2013-11-25,"VACCINATION SYSTEM FOR DELIVERING VACCINE TO AVIAN PULLETS, AND ASSOCIATED METHODS, DEVICES, AND ASSEMBLIES","A vaccination system for delivering a vaccine substance to avian pullets is provided. Such a system includes a vaccine delivery assembly configured to perform a vaccine delivery procedure for delivering a vaccine substance to the avian pullets. A plurality of positioning devices is provided, with each positioning device receiving an avian pullet for presentation to the vaccine delivery assembly. Each positioning device is transported to individually mate with the vaccine delivery assembly to deliver the vaccine substance during the vaccine delivery procedure. Associated methods, devices, and assemblies are also provided.",ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/049-067-883-112-414,Granted Patent,no,0,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,ACTIVE
371,KR,A,KR 20160074660 A,058-633-626-911-821,2016-06-28,2016,KR 20167013566 A,2014-11-20,US 201361908195 P;;US 201462038870 P;;US 2014/0066574 W,2013-11-25,"VACCINATION SYSTEM FOR DELIVERING VACCINE TO AVIAN PULLETS, AND ASSOCIATED METHODS, DEVICES, AND ASSEMBLIES","조류 햇암탉(avian pullet)에 백신 물질을 전달하기 위한 백신접종 시스템이 제공된다. 이러한 시스템은 조류 햇암탉에 백신 물질을 전달하기 위한 백신 전달 절차를 행하도록 구성된 백신 전달 조립체를 포함한다. 복수의 위치결정 장치가 제공되며, 각각의 위치결정 장치는 상기 백신 전달 조립체에 제공을 위한 조류 햇암탉을 수용한다. 각각의 위치결정 장치는 상기 백신 전달 절차 동안에 상기 백신 물질을 전달하는 상기 백신 전달 조립체와 개별적으로 메이트되도록 이송된다. 관련된 방법, 장치 및 조립체가 또한 제공된다.",ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/058-633-626-911-821,Patent Application,no,0,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61B5/00;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00,,0,0,,,,ACTIVE
372,JP,A,JP 2021151471 A,075-366-104-988-63X,2021-09-30,2021,JP 2021037630 A,2021-03-09,JP 2019102075 A;;US 201361908195 P;;US 201462038870 P,2013-11-25,"VACCINATION SYSTEM FOR DELIVERING VACCINE TO PULLETS, AND ASSOCIATED METHODS, DEVICES AND ASSEMBLIES","To provide a vaccination system for delivering a vaccine substance to pullets.SOLUTION: A system includes a vaccine delivery assembly configured to perform a vaccine delivery procedure for delivering a vaccine substance to pullets. Multiple positioning devices 600 are provided each receiving a pullet for presentation to the vaccine delivery assembly. Each positioning device is transported to individually mate with the vaccine delivery assembly to deliver the vaccine substance during the vaccine delivery procedure. Associated methods, devices and assemblies are also provided.SELECTED DRAWING: Figure 37",ZOETIS SERVICES LLC,WILLIAM DOUGLAS SAMSON;;MARCO GIOVANNI TRIVELLA;;RAYMOND JOHN NIEMCZURA;;DANIEL LEE KENNEDY;;DAVID ANDREW EICHENBERGER;;WILLIAM BRYAN CARR;;STEVEN ALLAN DUE,,https://lens.org/075-366-104-988-63X,Patent Application,no,0,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,PENDING
373,PL,T3,PL 3073959 T3,106-908-241-504-01X,2021-12-13,2021,PL 14820969 T,2014-11-20,US 201361908195 P;;US 201462038870 P;;EP 14820969 A;;US 2014/0066574 W,2013-11-25,VACCINATION ASSEMBLY FOR DELIVERING VACCINE TO AVIAN PULLETS,,ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/106-908-241-504-01X,Patent Application,no,0,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D1/02,,0,0,,,,PENDING
374,UY,A,UY 35851 A,110-734-258-013-361,2015-06-30,2015,UY 35851 A,2014-11-24,US 201361908195 P;;US 201462038870 P,2013-11-25,"?SISTEMA DE VACUNACIÓN PARA LA ADMINISTRACIÓN DE VACUNA A POLLUELOS Y PROCEDIMIENTOS, DISPOSITIVOS Y CONJUNTOS ASOCIADOS?.","Sistema de vacunación para administración de sustancia de vacuna a polluelos aviares. Incluye un conjunto de administración de vacuna configurado para realizar un procedimiento de administración de vacuna para la administración de una sustancia de vacuna a polluelos aviares. Se proporciona una pluralidad de dispositivos de posicionamiento, con cada dispositivo de posicionamiento recibiendo un polluelo aviar para su presentación al conjunto de administración de vacuna. Cada dispositivo de posicionamiento es transportado para acoplarse individualmente con el conjunto de administración de vacuna y administrar la sustancia de vacuna durante dicho procedimiento. También se proporcionan procedimientos, dispositivos y conjuntos asociados.",ZOETIS LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;SR RAYMOND JOHN NIEMCZURA;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,,https://lens.org/110-734-258-013-361,Patent Application,no,0,0,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D7/00;;A01K13/00;;A01K37/00,,0,0,,,,ACTIVE
375,US,A1,US 2019/0346442 A1,112-792-036-511-97X,2019-11-14,2019,US 201716094786 A,2017-04-18,US 201716094786 A;;US 201662324228 P;;US 201662345556 P;;US 201762458954 P;;US 2017/0028122 W,2016-04-18,IMPROVED HLA EPITOPE PREDICTION,"Adaptive immune responses rely on the ability of cytotoxic T cells to identify and eliminate cells displaying disease-specific antigens on human leukocyte antigen (HLA) class I molecules. Investigations into antigen processing and display have immense implications in human health, disease and therapy. To extend understanding of the rules governing antigen processing and presentation, immunopurified peptides from B cells, each expressing a single HLA class I allele, were profiled using accurate mass, high-resolution liquid chromatography-mass spectrometry (LC-MS/MS). A resource dataset containing thousands of peptides bound to 28 distinct class I HLA-A, -B, and -C alleles was generated by implementing a novel allele-specific database search strategy. Applicants discovered new binding motifs, established the role of gene expression in peptide presentation and improved prediction of HLA-peptide binding by using these data to train machine-learning models. These streamlined experimental and analytic workflows enable direct identification and analysis of endogenously processed and presented antigens.",BROAD INST INC;;MASSACHUSETTS INST TECHNOLOGY;;PRESIDENT AND FELLOWS HARVARD COLLEGE;;DANA FARBER CANCER INST INC;;MASSACHUSETTS GEN HOSPITAL,CARR STEVEN A;;HACOHEN NIR;;WU CATHERINE J;;ABELIN JENNIFER G;;SARKIZOVA SIRANUSH;;KESKIN DERIN B;;CLAUSER KARL R;;ROONEY MICHAEL S,MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2017-12-01);;DANA-FARBER CANCER INSTITUTE INC (2017-05-03);;PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2017-12-01);;THE BROAD INSTITUTE INC (2017-03-29);;THE GENERAL HOSPITAL CORPORATION (2017-04-04),https://lens.org/112-792-036-511-97X,Patent Application,yes,0,16,5,5,0,A61K39/0011;;A61K2039/5158;;C12Q1/6881;;C12Q1/6886;;G01N33/56977;;G01N33/56977;;G01N2560/00;;G16B25/10;;G16B30/00;;G16B40/10,G01N33/569;;A61K39/00;;C12Q1/6881;;C12Q1/6886;;G16B25/10;;G16B30/00;;G16B40/10,,0,0,,,,PENDING
376,US,A,US 5283499 A,014-225-642-780-893,1994-02-01,1994,US 84996292 A,1992-03-12,US 84996292 A;;US 49131490 A,1990-03-09,Igniter and cable connector assembly,"An improved igniter and cable connector assembly for turbine engines. An igniter mounting adapter is secured to the engine. The igniter slides into a hole through the adapter and is retained by an enlarged head on the igniter. An annular seal is positioned around a high voltage terminal on the igniter head and a terminal on the cable connector is positioned against the igniter terminal. The cable connector is secured to the adapter, for example, by either a clamp assembly or a coupling nut or a quick release connector. As the cable connector is secured to the adapter, the seal is compressed between the igniter and connector insulators and, optionally, the connector terminal is rotated and pressed against the igniter terminal to establish a reliable electrical contact. The connector and igniter terminals preferably have mating conical or spherical surfaces, one of which may be an annular segment to provide an increased electrical contact area.",COOPER IND INC,ADAM LEROY B;;CANNADY STEVEN J;;CARR DARIN W;;MEEKS III WILLIAM B;;RUNGE MICHAEL A;;SCHUEREN JAN R;;STRAUB STEPHEN W,CHAMPION AEROSPACE LLC (2001-05-31);;COOPER INDUSTRIES INC (1992-03-20);;FEDERAL-MOGUL IGNITION COMPANY (1998-10-29),https://lens.org/014-225-642-780-893,Granted Patent,yes,9,36,5,17,0,H01R13/2421;;H01R13/52;;H01R13/62;;H01R13/639;;H01T13/04;;H01R13/2421;;H01T13/04;;H01R13/639;;H01R13/62;;H01R13/52,H01R13/24;;F02C7/266;;H01R13/52;;H01R13/62;;H01R13/639;;H01T13/04,H2E ECCC          ECCC203;;H2E ECCE          ECCE;;H2E ECCX          ECCX;;H2E EHF           EHF;;H2E E203          ECCC203;;U1S S1987;;U1S S2073,0,0,,,,EXPIRED
377,US,A1,US 2015/0148771 A1,050-877-885-863-801,2015-05-28,2015,US 201414543086 A,2014-11-17,US 201414543086 A;;US 201462038870 P;;US 201361908195 P,2013-11-25,"VACCINATION SYSTEM FOR DELIVERING VACCINE TO AVIAN PULLETS, AND ASSOCIATED METHODS, DEVICES, AND ASSEMBLIES","A vaccination system for delivering a vaccine substance to avian pullets is provided. Such a system includes a vaccine delivery assembly configured to perform a vaccine delivery procedure for delivering a vaccine substance to the avian pullets. A plurality of positioning devices is provided, with each positioning device receiving an avian pullet for presentation to the vaccine delivery assembly. Each positioning device is transported to individually mate with the vaccine delivery assembly to deliver the vaccine substance during the vaccine delivery procedure. Associated methods, devices, and assemblies are also provided.",ZOETIS LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA SR RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,ZOETIS SERVICES LLC (2015-04-26),https://lens.org/050-877-885-863-801,Patent Application,yes,32,5,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D3/00;;A61D7/00,604/500;;604/131,0,0,,,,ACTIVE
378,WO,A2,WO 2023/172913 A2,009-845-824-156-545,2023-09-14,2023,US 2023/0063863 W,2023-03-07,US 202263317402 P,2022-03-07,PROTEOGENOMIC MARKERS OF CHEMOTHERAPY RESISTANCE AND RESPONSE IN TRIPLE NEGATIVE BREAST CANCER,"Microscaled proteogenomics was deployed to probe the molecular basis for differential response to neoadjuvant carboplatin & taxotere combination chemotherapy for triple-negative breast cancer (TNBC). Proteomic analyses of pre-treatment biopsies uniquely revealed that metabolic pathways including oxidative phosphorylation, fatty acid metabolism and glycolysis were resistance-associated. Both proteomics and transcriptomics revealed that sensitivity was marked by elevation of DNA repair, E2F targets, G2M checkpoint, interferon-gamma response, and immune checkpoint components. Proteogenomic analyses of somatic copy number aberrations identified a resistance-associated 19q13.31-33 deletion where LIG1 , POLD1 and XRCC1 are located. In orthogonal datasets, LIG1 (DNA ligase I involved in lagging strand synthesis) gene deletion and/or low mRNA expression were associated with lack of pathological complete response and poor prognosis in TNBC, as well as selective carboplatin-resistance in TNBC patient-derived xenograft models. Low expression or LIG1 loss was also associated with higher chromosomal instability index (CIN) and poor prognosis in other cancer types, demonstrating that deletion of lagging- strand synthesis components has broad clinical significance.",BAYLOR COLLEGE MEDICINE;;BROAD INST INC;;MASSACHUSETTS GEN HOSPITAL,ANURAG MEENAKSHI;;ELLIS MATTHEW J;;ZHANG BING;;JAEHNIG ERIC;;TRAN-HUYNH ANH M;;SATPATHY SHANKHA;;CARR STEVEN;;KRUG KARSTEN;;GILLETTE MICHAEL A,,https://lens.org/009-845-824-156-545,Patent Application,yes,0,0,2,2,0,C12Q1/6886;;C12Q2600/158;;A61P35/00,C12Q1/6886;;A61K41/00,,0,0,,,,PENDING
379,AT,T1,AT E483689 T1,065-357-651-021-527,2010-10-15,2010,AT 04806258 T,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W,2003-12-23,PYRAZOLDERIVATE ALS MODULATOREN VON PROTEINKINASE,"The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between Rand NRRand a maximum chain length of 4 atoms extending between E and NRR, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NRRgroup and provided that the oxo group when present is located at a carbon atom a with respect to the NRRgroup; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; Ris an aryl or heteroaryl group; and R, R, Rand Rare as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS;;WOODHEAD STEVEN;;WYATT PAUL;;BOYLE ROBERT;;SORE HANNAH;;WALKER DAVID;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN,,https://lens.org/065-357-651-021-527,Granted Patent,no,0,0,12,52,0,,,,0,0,,,,ACTIVE
380,US,B2,US 10350041 B2,058-924-850-692-248,2019-07-16,2019,US 201414543086 A,2014-11-17,US 201414543086 A;;US 201462038870 P;;US 201361908195 P,2013-11-25,"Vaccination system for delivering vaccine to avian pullets, and associated methods, devices, and assemblies","A vaccination system for delivering a vaccine substance to avian pullets is provided. Such a system includes a vaccine delivery assembly configured to perform a vaccine delivery procedure for delivering a vaccine substance to the avian pullets. A plurality of positioning devices is provided, with each positioning device receiving an avian pullet for presentation to the vaccine delivery assembly. Each positioning device is transported to individually mate with the vaccine delivery assembly to deliver the vaccine substance during the vaccine delivery procedure. Associated methods, devices, and assemblies are also provided.",ZOETIS SERVICES LLC,SAMSON WILLIAM DOUGLAS;;TRIVELLA MARCO GIOVANNI;;NIEMCZURA SR RAYMOND JOHN;;KENNEDY DANIEL LEE;;EICHENBERGER DAVID ANDREW;;CARR WILLIAM BRYAN;;DUE STEVEN ALLAN,ZOETIS SERVICES LLC (2015-04-26),https://lens.org/058-924-850-692-248,Granted Patent,yes,51,7,30,31,0,A61D7/00;;A61D1/025;;A61B5/00;;A61D1/025;;A61D3/00;;A61D7/00;;A61D99/00;;B65G15/00;;B65G2201/02;;A61D1/02;;A61D1/025;;A61D3/00;;A61D7/00,A61D3/00;;A61D1/02;;A61D7/00,,1,0,,,"PCT International Search Report and the Written Opinion, International Application No. PCT/US2014/066574, dated Jun. 2, 2015.",ACTIVE
381,EP,A1,EP 3446119 A1,138-990-474-600-404,2019-02-27,2019,EP 17722542 A,2017-04-18,US 201662324228 P;;US 201662345556 P;;US 201762458954 P;;US 2017/0028122 W,2016-04-18,IMPROVED HLA EPITOPE PREDICTION,,BROAD INST INC;;MASSACHUSETTS INST TECHNOLOGY;;HARVARD COLLEGE;;DANA FARBER CANCER INST INC;;MASSACHUSETTS GEN HOSPITAL;;CARR STEVEN A;;HACOHEN NIR;;WU CATHERINE JU YING;;ABELIN JENNIFER G;;SARKIZOVA SIRANUSH;;KESKIN DERIN B;;CLAUSER KARL R;;ROONEY MICHAEL S,CARR STEVEN A;;HACOHEN NIR;;WU CATHERINE J;;ABELIN JENNIFER G;;SARKIZOVA SIRANUSH;;KESKIN DERIN B;;CLAUSER KARL R;;ROONEY MICHAEL S,"MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2019-09-11);;KESKIN, DERIN, B. (2019-09-11);;CLAUSER, KARL, R. (2019-09-11);;DANA-FARBER CANCER INSTITUTE, INC. (2019-09-11);;ROONEY, MICHAEL, S. (2019-09-11);;PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2019-09-11);;THE BROAD INSTITUTE, INC. (2019-09-11);;WU, CATHERINE, JU-YING (2019-09-11);;CARR, STEVEN A. (2019-09-11);;HACOHEN, NIR (2019-09-11);;ABELIN, JENNIFER, G. (2019-09-11);;THE GENERAL HOSPITAL CORPORATION (2019-09-11);;SARKIZOVA, SIRANUSH (2019-09-11)",https://lens.org/138-990-474-600-404,Patent Application,yes,0,0,5,5,0,G01N33/56977;;G16B25/10;;G16B40/10;;G16B30/00;;A61K39/0011;;A61K2039/5158;;C12Q1/6881;;C12Q1/6886;;G01N33/56977;;G01N2560/00,G01N33/569,,0,0,,,,PENDING
382,AR,A1,AR 099543 A1,190-135-447-638-368,2016-08-03,2016,AR P140104397 A,2014-11-21,US 201361908195 P,2013-11-25,"SISTEMA DE VACUNACIÓN PARA LA ADMINISTRACIÓN DE VACUNA A POLLUELOS Y PROCEDIMIENTOS, DISPOSITIVOS Y CONJUNTOS ASOCIADOS","Un sistema de vacunación para la administración de una sustancia de vacuna a polluelos aviares. Tal sistema incluye un conjunto de administración de vacuna configurado para realizar un procedimiento de administración de vacuna para la administración de una sustancia de vacuna a polluelos aviares. Una pluralidad de dispositivos de posicionamiento, con cada dispositivo de posicionamiento recibiendo un polluelo aviar para su presentación al conjunto de administración de vacuna. Cada dispositivo de posicionamiento es transportado para acoplarse individualmente con el conjunto de administración de vacuna y administrar la sustancia de vacuna durante el procedimiento de administración de vacuna. También procedimientos, dispositivos y conjuntos asociados.",ZOETIS LLC,STEVEN ALLAN DUE;;WILLIAM BRYAN CARR;;DAVID ANDREW EICHENBERGER;;DANIEL LEE KENNEDY;;RAYMOND JOHN NIEMCZURA SR;;MARCO GIOVANNI TRIVELLA;;WILLIAM DOUGLAS SAMSON,,https://lens.org/190-135-447-638-368,Patent Application,no,0,0,1,31,0,,A61D7/00;;A61D3/00,,0,0,,,,ACTIVE
383,WO,A3,WO 2023/172913 A3,199-003-645-352-566,2023-12-14,2023,US 2023/0063863 W,2023-03-07,US 202263317402 P,2022-03-07,PROTEOGENOMIC MARKERS OF CHEMOTHERAPY RESISTANCE AND RESPONSE IN TRIPLE NEGATIVE BREAST CANCER,"Microscaled proteogenomics was deployed to probe the molecular basis for differential response to neoadjuvant carboplatin & taxotere combination chemotherapy for triple-negative breast cancer (TNBC). Proteogenomic analyses of somatic copy number aberrations identified a resistance-associated 19q13.31-33 deletion where LIG1, POLD1 and XRCC1 are located, in orthogonal datasets, LIG1 (DNA ligase I involved in lagging strand synthesis) gene deletion and/or low mRNA expression were associated with lack of pathological complete response and poor prognosis in TNBC, as well as selective carboplatin-resistance in TNBC patient-derived xenograft models. Low expression or LIG1 loss was also associated with higher chromosomal instability index (CIN) and poor prognosis in other cancer types, demonstrating that deletion of lagging- strand synthesis components has broad clinical significance.",BAYLOR COLLEGE MEDICINE;;BROAD INST INC;;MASSACHUSETTS GEN HOSPITAL,ANURAG MEENAKSHI;;ELLIS MATTHEW J;;ZHANG BING;;JAEHNIG ERIC;;TRAN-HUYNH ANH M;;SATPATHY SHANKHA;;CARR STEVEN;;KRUG KARSTEN;;GILLETTE MICHAEL A,,https://lens.org/199-003-645-352-566,Search Report,yes,1,0,2,2,0,C12Q1/6886;;C12Q2600/158;;A61P35/00,C12Q1/6883;;C12Q1/6886,,2,2,008-733-849-881-070;;002-356-292-646-145,pmc8344016;;10.7150/thno.51456;;34373746;;pmc8064209;;10.18632/aging.202808;;33790054,"ALI REEM, ALABDULLAH MUSLIM, ALGETHAMI MASHAEL, ALBLIHY ADEL, MILIGY ISLAM, SHOQAFI AHMED, MESQUITA KATIA A., ABDEL-FATAH TAREK, C: ""Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers"", THERANOSTICS, IVYSPRING INTERNATIONAL PUBLISHER, AU, vol. 11, no. 17, 1 January 2021 (2021-01-01), AU , pages 8350 - 8361, XP093116294, ISSN: 1838-7640, DOI: 10.7150/thno.51456;;LI ET AL.: ""RIPK2 is an unfavorable prognosis marker and a potential therapeutic target in human kidney renal clear cell carcinoma"", AGING, vol. 13, no. 7, 31 March 2021 (2021-03-31), pages 10450 - 10467, XP055982293",PENDING
384,ZA,B,ZA 875128 B,146-804-889-026-801,1988-06-29,1988,ZA 875128 A,1987-07-14,US 89202786 A,1986-07-30,ANTIBIOTICS PRODUCED BY ACTINOMADURA PARVOSATA,,SMITHKLINE BECKMAN CORP,CARR STEVEN ALFRED;;STEVEN ALFRED CARR;;MUELLER LUCIANO;;LUCIANO MUELLER;;SHEARER MARCIA CATHRINE;;MARCIA CATHRINE SHEARER;;IV SIEGFRIED BENJAMIN CHRISTEN;;SIEGFRIED BENJAMIN CHRISTENSEN;;NISBET LOUIS JOSEPH;;LOUIS JOSEPH NISBET;;JEFFS PETER WALTER;;PETER WALTER JEFFS;;ROBERTS GERALD D;;GERALD D ROBERTS;;SITRIN ROBERT DAVID;;ROBERT DAVID SITRIN,,https://lens.org/146-804-889-026-801,Granted Patent,no,0,0,10,10,0,C07K9/008;;C12N1/00;;C12N1/205;;C12R2001/03,C12N1/20;;A61K35/74;;C07K7/64;;C07K9/00;;C07K14/195;;C07K14/41;;C12P21/02;;C12P21/04,,0,0,,,,EXPIRED
385,WO,A2,WO 2003/019449 A2,174-392-398-238-436,2003-03-06,2003,US 0227954 W,2002-08-30,US 31685101 P;;US 32768701 P;;US 35265202 P;;US 17276902 A;;US 17250602 A,2001-08-31,DIGITALLY WATERMARKING CHECKS AND OTHER VALUE DOCUMENTS,"A digital watermark (100) comprises of various techniques for encoding hidden information in checks and other security documents. The hidden information provides an authentication tool. Also including a method for encoding a security document with information. The security document comprises a substrate (102) having printing thereon. The information is hidden in the printing and corresponds to text or numbers conveyed by at least a portion of the printing. The method includes dividing the information into a plurality of playload sets, wherein each payload set includes a sub-set of the information, and encoding the payload sets acoss the substrate (102). The plurality of payload sets is concatenated in order to retrieve the information.",DIGIMARC CORP;;CARR J SCOTT;;RHOADS GEOFFREY B;;HIEN WILLIAM C III;;MILLER MARC D;;HAWES JONATHAN L;;ELOVITZ ANDREA NICOLE;;STEWART STEVEN W,CARR J SCOTT;;RHOADS GEOFFREY B;;HIEN WILLIAM C III;;MILLER MARC D;;HAWES JONATHAN L;;ELOVITZ ANDREA NICOLE;;STEWART STEVEN W,,https://lens.org/174-392-398-238-436,Patent Application,yes,0,0,2,1547,0,G06T1/0071;;G06T2201/0051;;G06T2201/0061,G06K9/00;;G06T1/00;;H04K1/00;;H04L9/00,,0,0,,,,PENDING
386,WO,A3,WO 2003/019449 A3,105-457-361-073-297,2003-05-30,2003,US 0227954 W,2002-08-30,US 31685101 P;;US 32768701 P;;US 35265202 P;;US 17276902 A;;US 17250602 A,2001-08-31,DIGITALLY WATERMARKING CHECKS AND OTHER VALUE DOCUMENTS,"A digital watermark (100) comprises of various techniques for encoding hidden information in checks and other security documents. The hidden information provides an authentication tool. Also including a method for encoding a security document with information. The security document comprises a substrate (102) having printing thereon. The information is hidden in the printing and corresponds to text or numbers conveyed by at least a portion of the printing. The method includes dividing the information into a plurality of playload sets, wherein each payload set includes a sub-set of the information, and encoding the payload sets acoss the substrate (102). The plurality of payload sets is concatenated in order to retrieve the information.",DIGIMARC CORP;;CARR J SCOTT;;RHOADS GEOFFREY B;;HIEN WILLIAM C III;;MILLER MARC D;;HAWES JONATHAN L;;ELOVITZ ANDREA NICOLE;;STEWART STEVEN W,CARR J SCOTT;;RHOADS GEOFFREY B;;HIEN WILLIAM C III;;MILLER MARC D;;HAWES JONATHAN L;;ELOVITZ ANDREA NICOLE;;STEWART STEVEN W,,https://lens.org/105-457-361-073-297,Search Report,yes,5,0,2,1547,0,G06T1/0071;;G06T2201/0051;;G06T2201/0061,G06K9/00;;G06T1/00;;H04K1/00;;H04L9/00,,0,0,,,,PENDING
387,AU,A1,AU 2017/254477 A1,125-534-433-715-124,2018-11-01,2018,AU 2017/254477 A,2017-04-18,US 201762458954 P;;US 201662324228 P;;US 201662345556 P;;US 2017/0028122 W,2016-04-18,Improved HLA epitope prediction,"Adaptive immune responses rely on the ability of cytotoxic T cells to identify and eliminate cells displaying disease-specific antigens on human leukocyte antigen (HLA) class I molecules. Investigations into antigen processing and display have immense implications in human health, disease and therapy. To extend understanding of the rules governing antigen processing and presentation, immunopurified peptides from B cells, each expressing a single HLA class I allele, were profiled using accurate mass, high-resolution liquid chromatography- mass spectrometry (LC-MS/MS). A resource dataset containing thousands of peptides bound to 28 distinct class I HLA-A, -B, and -C alleles was generated by implementing a novel allele-specific database search strategy. Applicants discovered new binding motifs, established the role of gene expression in peptide presentation and improved prediction of HLA-peptide binding by using these data to train machine-learning models. These streamlined experimental and analytic workflows enable direct identification and analysis of endogenously processed and presented antigens.",ABELIN JENNIFER G;;CARR STEVEN A;;CLAUSER KARL R;;DANA FARBER CANCER INST INC;;HACOHEN NIR;;KESKIN DERIN B;;MASSACHUSETTS INST TECHNOLOGY;;HARVARD COLLEGE;;ROONEY MICHAEL S;;SARKIZOVA SIRANUSH;;BROAD INST INC;;MASSACHUSETTS GEN HOSPITAL;;WU CATHERINE J,CARR STEVEN A;;HACOHEN NIR;;WU CATHERINE J;;ABELIN JENNIFER G;;SARKIZOVA SIRANUSH;;KESKIN DERIN B;;CLAUSER KARL R;;ROONEY MICHAEL S,,https://lens.org/125-534-433-715-124,Patent Application,no,0,0,5,5,0,A61K39/0011;;A61K2039/5158;;C12Q1/6881;;C12Q1/6886;;G01N33/56977;;G01N33/56977;;G01N2560/00;;G16B25/10;;G16B30/00;;G16B40/10,G01N33/569,,0,0,,,,DISCONTINUED
388,WO,A1,WO 2017/184590 A1,096-066-525-986-795,2017-10-26,2017,US 2017/0028122 W,2017-04-18,US 201662324228 P;;US 201662345556 P;;US 201762458954 P,2016-04-18,IMPROVED HLA EPITOPE PREDICTION,"Adaptive immune responses rely on the ability of cytotoxic T cells to identify and eliminate cells displaying disease-specific antigens on human leukocyte antigen (HLA) class I molecules. Investigations into antigen processing and display have immense implications in human health, disease and therapy. To extend understanding of the rules governing antigen processing and presentation, immunopurified peptides from B cells, each expressing a single HLA class I allele, were profiled using accurate mass, high-resolution liquid chromatography- mass spectrometry (LC-MS/MS). A resource dataset containing thousands of peptides bound to 28 distinct class I HLA-A, -B, and -C alleles was generated by implementing a novel allele-specific database search strategy. Applicants discovered new binding motifs, established the role of gene expression in peptide presentation and improved prediction of HLA-peptide binding by using these data to train machine-learning models. These streamlined experimental and analytic workflows enable direct identification and analysis of endogenously processed and presented antigens.",BROAD INST INC;;MASSACHUSETTS INST TECHNOLOGY;;HARVARD COLLEGE;;DANA FARBER CANCER INST INC;;THE GENARAL HOSPITAL CORP;;CARR STEVEN A;;HACOHEN NIR;;WU CATHERINE J;;ABELIN JENNIFER G;;SARKIZOVA SIRANUSH;;KESKIN DERIN B;;CLAUSER KARL R;;ROONEY MICHAEL S,CARR STEVEN A;;HACOHEN NIR;;WU CATHERINE J;;ABELIN JENNIFER G;;SARKIZOVA SIRANUSH;;KESKIN DERIN B;;CLAUSER KARL R;;ROONEY MICHAEL S,,https://lens.org/096-066-525-986-795,Patent Application,yes,209,71,5,5,50680,G01N33/56977;;G16B25/10;;G16B40/10;;G16B30/00;;A61K39/0011;;A61K2039/5158;;C12Q1/6881;;C12Q1/6886;;G01N33/56977;;G01N2560/00,G01N33/569,,245,196,056-937-846-565-908;;036-123-005-938-177;;099-030-093-573-974;;067-941-954-080-925;;055-534-430-991-476;;086-314-396-456-567;;020-080-307-999-663;;015-045-745-688-246;;090-505-728-893-752;;125-702-184-945-681;;113-227-143-558-84X;;056-072-812-092-997;;101-481-896-960-735;;055-015-731-698-797;;069-099-453-074-51X;;085-644-716-529-231;;032-119-106-438-65X;;109-665-410-830-20X;;090-169-482-807-577;;090-327-557-741-105;;095-849-513-154-961;;092-667-724-840-965;;086-660-693-292-847;;048-156-676-293-513;;105-571-956-647-527;;134-565-035-294-633;;048-419-629-020-848;;089-774-429-499-86X;;016-229-772-022-557;;079-889-760-145-612;;026-944-353-804-488;;017-216-732-209-839;;002-882-009-745-691;;040-345-923-870-253;;134-689-427-348-025;;004-724-173-477-122;;037-904-735-240-537;;120-176-283-549-095;;014-432-926-618-160;;093-423-744-136-655;;035-019-404-496-12X;;082-887-373-158-244;;040-277-381-986-160;;067-423-318-569-025;;125-645-965-899-165;;072-468-307-701-916;;132-216-675-405-508;;031-039-129-088-844;;020-178-335-962-88X;;066-916-220-868-595;;033-600-295-094-741;;022-225-349-299-937;;057-474-860-030-676;;009-372-903-326-197;;126-053-417-290-276;;046-843-081-365-102;;079-874-646-887-645;;072-983-585-843-582;;057-353-589-104-357;;024-392-972-050-341;;084-280-558-764-322;;028-333-567-010-894;;007-260-298-056-037;;003-264-306-643-657;;031-807-821-140-812;;059-400-780-458-227;;012-168-474-605-226;;151-747-107-866-762;;006-083-496-103-526;;065-427-040-070-857;;009-706-535-362-887;;001-738-886-327-915;;041-509-245-097-509;;064-133-645-690-020;;036-201-773-215-781;;028-696-271-645-551;;086-507-133-163-907;;063-131-302-295-146;;001-135-488-035-957;;001-135-488-035-957;;086-469-414-422-958;;015-839-900-804-759;;033-517-475-734-956;;004-528-067-817-471;;057-353-589-104-357;;041-737-949-940-597;;001-684-791-731-05X;;047-796-156-303-991;;134-789-844-003-392;;015-752-955-256-76X;;056-366-167-977-461;;015-005-537-927-250;;073-390-485-598-068;;067-768-558-783-008;;014-630-446-453-288;;000-426-165-109-927;;020-178-779-477-981;;104-877-511-857-009;;114-442-739-618-020;;114-700-871-180-280;;011-463-146-073-65X;;000-078-232-627-567;;020-781-137-201-736;;032-464-541-034-729;;089-310-781-933-578;;061-708-359-767-416;;024-311-781-677-427;;026-411-645-167-642;;007-261-999-134-784;;018-959-907-302-861;;006-381-297-836-722;;096-012-584-064-893;;001-634-188-074-328;;048-055-110-364-340;;114-442-739-618-020;;034-835-564-577-980;;125-237-538-945-224;;055-388-050-711-038;;013-223-611-540-656;;055-061-574-892-808;;064-682-744-872-69X;;135-277-134-797-957;;041-501-254-191-787;;087-286-239-620-774;;091-509-047-035-538;;042-913-591-104-522;;018-065-511-380-65X;;089-443-554-843-061;;063-009-450-995-217;;059-910-245-294-03X;;014-491-792-527-932;;129-580-616-064-283;;061-542-637-203-585;;095-894-960-349-974;;065-268-854-361-113;;077-295-491-167-117;;041-327-727-454-807;;005-198-548-268-394;;067-344-233-099-751;;090-522-587-795-474;;077-295-979-222-239;;089-839-991-684-282;;066-872-003-079-846;;014-188-174-852-197;;091-806-773-741-403;;009-939-788-857-914;;089-942-491-393-839;;004-992-481-487-884;;013-559-502-235-993;;037-780-185-187-88X;;029-373-120-748-203;;093-806-058-071-01X;;081-973-323-695-847;;124-408-451-056-317;;088-971-131-416-01X;;071-978-992-443-516;;079-902-257-271-084;;018-041-187-164-982;;002-955-370-415-401;;045-714-831-915-963;;112-871-461-451-205;;046-289-867-375-85X;;152-279-674-137-242;;113-118-416-348-870;;046-289-867-375-85X;;099-372-009-770-60X;;012-522-132-362-171;;103-736-007-949-11X;;019-202-837-544-006;;033-473-897-919-959;;020-366-451-479-738;;023-024-890-895-871;;002-085-775-109-916;;010-152-833-378-258;;020-579-657-226-196;;053-783-298-552-453;;057-165-601-966-358;;053-900-918-619-293;;076-543-057-824-958;;081-374-000-676-84X;;031-575-623-752-48X;;044-254-945-915-100;;001-889-138-393-421;;079-356-378-074-41X;;083-691-798-066-689;;119-887-125-221-540;;027-384-431-327-132;;036-234-477-464-944;;078-220-526-604-234;;101-481-896-960-735;;011-085-779-195-045;;006-024-654-347-578;;052-691-411-864-666;;033-060-549-025-363;;014-009-338-233-338;;014-009-338-233-338,10.2174/138161209789105180;;19860672;;19379493;;10.1186/1756-0500-2-61;;pmc2679046;;24880947;;10.1016/j.hoc.2014.02.008;;10.1016/j.jim.2011.09.010;;21986107;;pmc3134633;;10.1016/j.jim.2010.10.011;;21047511;;25717196;;pmc4481849;;10.1093/bioinformatics/btv123;;pmc2901998;;10.1038/nature09204;;20562859;;19615732;;019615732;;pmc2716422;;10.1016/j.cell.2009.04.042;;10.1093/intimm/dxg084;;12807816;;19948066;;pmc2790471;;10.1186/1471-2105-10-394;;2075190;;10.1093/protein/4.2.155;;26131937;;pmc4853910;;10.1038/nature14610;;24292625;;10.1126/science.1244851;;pmc4077049;;10.1074/mcp.m111.016857;;22505724;;pmc3418844;;26764012;;10.1074/mcp.m115.055780;;pmc4824864;;pmc4349985;;10.1074/mcp.m114.042812;;25576301;;26628741;;26483422;;10.1074/mcp.m115.052431;;pmc4762616;;10.1074/mcp.o115.052431;;19169245;;10.1038/nbt.1524;;pmc2753399;;pmc4744552;;10.4049/jimmunol.1501721;;26783342;;2936651;;10.1016/0378-1119(85)90022-8;;pmc386907;;3095831;;10.1073/pnas.83.21.8258;;18715801;;pmc6731373;;10.1016/j.smim.2008.07.003;;11325844;;pmc1266037;;10.1073/pnas.0500090102;;16247014;;22318521;;pmc3874809;;10.1038/nature10755;;10.1038/nature10803;;pmc3288744;;22318517;;20921459;;pmc3020702;;10.1200/jco.2010.28.6963;;10.3410/f.6040956.6344054;;25667941;;pmc4367481;;10.1002/mas.21406;;10.1016/j.ijpharm.2005.06.007;;16046256;;10.1073/pnas.1019266108;;21502532;;pmc3088639;;10.1021/ja00897a025;;10.1016/0196-8858(81)90046-4;;6260373;;10.1016/0092-8674(81)90282-8;;7636255;;10.4049/jimmunol.155.4.2039;;9550412;;10.4049/jimmunol.159.12.6112;;10.1016/s0065-308x(08)60152-9;;10050276;;11050940;;10.1016/s0065-3527(00)55001-5;;8690928;;10.1016/0022-1759(96)00035-x;;10547676;;10.1016/s0065-3527(08)60367-x;;pmc4395260;;25875117;;10.1371/journal.pone.0118803;;10.1073/pnas.91.21.9866;;7937907;;pmc44918;;9498786;;10.1126/science.270.5234.299;;7569980;;8265577;;10.1073/pnas.90.24.11478;;pmc48007;;23125444;;pmc3532831;;10.1093/infdis/jis670;;10.1128/jvi.66.5.2731-2739.1992;;1560523;;pmc241028;;1531369;;pmc240899;;10.1128/jvi.66.3.1635-1640.1992;;10.1128/jvi.63.5.2374-2378.1989;;2784836;;pmc250661;;pmc240569;;10.1128/jvi.65.5.2220-2224.1991;;1850008;;1727603;;10.1016/0042-6822(92)90082-z;;22777090;;pmc3495727;;10.4161/hv.21080;;10.1016/j.vaccine.2013.03.042;;pmc3755097;;23583893;;pmc346798;;10.1073/pnas.79.16.4927;;6289324;;10.1073/pnas.80.17.5364;;6310573;;pmc384256;;10.1073/pnas.79.23.7415;;pmc347350;;6296831;;pmc390012;;6580632;;10.1073/pnas.80.23.7155;;10.1038/302490a0;;6835382;;10.1099/0022-1317-68-10-2587;;2822841;;7616101;;10.1002/jlb.58.1.1;;10.1016/0264-410x(89)90266-1;;2609722;;10.1038/354520a0;;1758494;;6095272;;10.1073/pnas.81.22.7194;;pmc392104;;10.1073/pnas.83.20.7947;;3464010;;pmc386841;;17227690;;10.1016/j.vaccine.2006.11.066;;10.1016/j.vaccine.2009.09.033;;19925953;;4058585;;10.1038/317813a0;;10.1128/jvi.62.3.866-874.1988;;pmc253644;;3339716;;10.1038/330259a0;;3118219;;3184271;;pmc253556;;10.1128/jvi.62.12.4474-4480.1988;;pmc247729;;10.1128/jvi.63.2.600-606.1989;;2783466;;10.1016/0042-6822(90)90119-c;;2154895;;219640;;10.1006/viro.1998.9123;;9601507;;10.1006/viro.1998.9397;;9837798;;10.1128/jvi.76.16.8318-8334.2002;;pmc155139;;12134037;;pmc228399;;10.1128/jvi.77.19.10606-10622.2003;;12970445;;10.1016/0042-6822(90)90294-2;;2219722;;10.1016/0042-6822(92)90752-b;;1566575;;16731942;;pmc1472566;;10.1128/jvi.02108-05;;16731942;;pmc1472566;;10.1128/jvi.02108-05;;10.1099/vir.0.83018-0;;17698656;;10.1128/jvi.02216-07;;18184713;;pmc2258966;;10.2174/156652311795684731;;21453284;;8337851;;10.1006/viro.1993.1442;;7616101;;10.1002/jlb.58.1.1;;9603331;;10.1099/0022-1317-79-5-1159;;11393868;;11283352;;10.1126/science.1058915;;11739541;;10.4049/jimmunol.167.12.7180;;10.1128/jvi.77.12.7048-7057.2003;;12768024;;pmc156204;;15308364;;10.1016/j.vaccine.2004.02.025;;pmc404098;;10.1073/pnas.0401939101;;15096611;;10.1086/421266;;15227622;;15014500;;10.1038/nature02331;;15708987;;10.1128/jvi.79.5.2678-2688.2005;;pmc548443;;17900219;;10.1016/j.vaccine.2007.04.002;;17499893;;17434244;;10.1016/j.vaccine.2007.02.084;;10.1016/j.vaccine.2007.12.059;;18336966;;10.1073/pnas.0705191105;;18270165;;pmc2538878;;10.1200/jco.2004.08.083;;15169798;;10.1158/1078-0432.ccr-08-0668;;19010868;;10.1007/s10637-008-9187-3;;18931824;;10.1200/jco.2009.25.0597;;20100959;;pmc2834462;;20881001;;10.1158/1078-0432.ccr-10-2082;;20975327;;10.4161/hv.6.10.13144;;pmc9491320;;21069322;;10.1007/s00262-010-0935-9;;15242542;;10.1089/0889222041217428;;15325077;;10.1016/j.virusres.2004.04.008;;10.1073/pnas.0406381102;;15781866;;pmc555695;;18061316;;10.1016/j.vaccine.2007.08.066;;10.1016/j.vaccine.2006.09.090;;17113200;;10.4161/hv.9693;;19786840;;18393831;;10.2174/156652308784049363;;10.1002/eji.200939754;;pmc3044835;;20017188;;10.1073/pnas.0705191105;;18270165;;pmc2538878;;pmc2885029;;19008384;;10.1099/vir.0.2008/004440-0;;19944151;;pmc2814951;;10.1016/j.vaccine.2009.11.030;;pmc3196391;;10.1128/jvi.00788-11;;21775454;;10.1097/coh.0b013e32833d1e87;;20978379;;10.1016/s0952-7915(97)80104-5;;9287173;;10.1007/s002620000146;;11092617;;10873071;;10.4049/jimmunol.171.2.1094;;12847284;;pmc38060;;10.1073/pnas.93.21.11349;;8876138;;10.1200/jco.1999.17.1.332;;10458251;;10.1007/bf01641272;;2033387;;10.1099/0022-1317-72-5-1031;;20413326;;10.1016/j.smim.2010.03.004;;20693851;;pmc2922045;;10.1097/ppo.0b013e3181eaca65;;pmc3256967;;10.1084/jem.20111171;;22065672;;10.1016/s0264-410x(00)00498-9;;11257407;;10566139;;10.1111/j.1600-065x.1999.tb01326.x;;17908809;;10.1128/iai.00828-07;;pmc2168343;;10.4049/jimmunol.1300097;;23585680;;pmc3647383;;pmc3815523;;10.1021/cb400264n;;23683494;;10.1002/0471220574;;10.1213/00000539-194101000-00064;;16491401;;10.1007/s00262-006-0145-7;;9637761;;10.1006/cimm.1998.1283;;9554254;;10.1097/00002371-199611000-00005;;9041460;;pmc2660151;;19360120;;10.1371/journal.ppat.1000373;;16763660;;10.1038/nrd2059;;10477547;;pmc2195611;;10.1084/jem.190.5.617;;18499419;;10.1016/j.coi.2008.04.011;;pmc2538913;;17975151;;10.1158/1078-0432.ccr-07-0486;;10.1038/nature14567;;26040715;;10.1172/jci68395;;pmc3726168;;23867552;;pmc3846695;;23928481;;10.3791/50085;;19136947;;pmc2684978;;10.1038/nmat2357;;8977634;;10.1002/(sici)1097-0045(199612)29:6<371::aid-pros5>3.0.co;2-b;;10.1002/(sici)1097-0045(199612)29:6<371::aid-pros5>3.3.co;2-3;;9288186;;10.1002/(sici)1097-0045(19970901)32:4<272::aid-pros7>3.0.co;2-l;;20479115;;10.1084/jem.20100348;;pmc2882837;;10.1084/jem.20100223;;pmc2882835;;20479118;;10.1038/nm0810-854;;20689546;;1690918;;10.1126/science.1690918;;2856201;;12663709;;10.1200/jco.2003.06.100;;23159882;;10.1038/nbt.2436;;pmc21029;;9177197;;10.1073/pnas.94.12.6216;;10.1002/eji.200324804;;14991590;;10.1038/nri2216;;18097448;;10.1002/cncr.24988;;20187092;;16960692;;10.1007/s00262-006-0225-8;;10.1038/nri2216;;18097448;;16984371;;10.1111/j.1349-7006.2006.00272.x;;23307859;;10.1158/1078-0432.ccr-12-1630;;pmc3752683;;pmc3232304;;10.1002/ijc.26219;;21633954;;10.1158/1078-0432.ccr-07-5212;;18927310;;pmc2972555;;21050422;;10.1186/bcr2572;;10.1158/1078-0432.ccr-11-0184;;21586625;;21149254;;pmc3064599;;10.1093/neuonc/noq157;;pmc4533835;;10.1146/annurev-immunol-032713-120136;;24423116;;pmc6295668;;10.1126/science.aaa4967;;25838374;;22437939;;10.1038/nri3191;;pmc6292222;;10.1111/imr.12139;;24329794;;pmc3991306;;10.1182/blood-2014-01-551671;;24753538;;pmc4064331;;10.1056/nejmoa1106152;;pmc3236370;;22047558;;22047566;;10.1056/nejme1109971;;20506146;;pmc3290395;;10.1002/stem.433;;26183927;;10.1158/0008-5472.can-14-3321;;pmc5264497;;27068940;;10.1042/bst20150251;;26347741;;pmc4544156;;10.3389/fimmu.2015.00418;;pmc4350037;;10.1074/mcp.m114.044321;;25473088;;10.1074/mcp.m115.051300;;26100116;;pmc4563719;;10.1016/j.it.2014.01.002;;24566257;;pmc3986829;;10.1073/pnas.1321902111;;pmc4000780;;24715725;;21962745;;pmc3200450;;10.1016/j.it.2011.08.001;;23357871;;10.1371/journal.pcbi.1002884;;pmc3554532;;24292625;;10.1126/science.1244851;;pmc4077049;;10.1074/mcp.m500061-mcp200;;15958392;;10.1038/leu.2015.278;;26449664;;10.1007/s00251-005-0781-7;;15744535;;23203878;;pmc3531159;;10.1093/nar/gks1226;;10.1084/jem.20071985;;18299400;;pmc2275383;;10.1084/jem.20071985;;18299400;;pmc2275383,"FELIX KLUG ET AL: ""Characterization of MHC Ligands for Peptide Based Tumor Vaccination"", CURRENT PHARMACEUTICAL DESIGN, vol. 15, no. 28, 1 October 2009 (2009-10-01), pages 3221 - 3236, XP055006049, ISSN: 1381-6128, DOI: 10.2174/138161209789105180;;LATA SNEH ET AL: ""MHCBN 4.0: A database of MHC/TAP binding peptides and T-cell epitopes"", BMC RESEARCH NOTES, BIOMED CENTRAL LTD, GB, vol. 2, no. 1, 20 April 2009 (2009-04-20), pages 61, XP021052825, ISSN: 1756-0500, DOI: 10.1186/1756-0500-2-61;;OTT ET AL., HEMATOL. ONCOL. CLIN. N. AM., vol. 28, 2014, pages 559 - 569;;ZHANG ET AL.: ""Machine learning competition in immunology - Prediction of HLA class I binding peptides"", J IMMUNOL METHODS, vol. 374, 2011, pages 1;;LUNDEGAARD ET AL.: ""Prediction of epitopes using neural network based methods"", J IMMUNOL METHODS, vol. 374, 2011, pages 26, XP002739412, DOI: doi:10.1016/j.jim.2010.10.011;;TROLLE ET AL.: ""Automated benchmarking of peptide-MHC class I binding predictions"", BIOINFORMATICS, vol. 31, no. 13, 1 July 2015 (2015-07-01), pages 2174 - 2181;;BEHRENDS ET AL., NATURE, vol. 466, 2010, pages 68 - 76;;CHRISTIANSON ET AL., NAT. CELL BIOL., vol. 14, 2012, pages 93 - 105;;SOWA ET AL., CELL, vol. 138, 2009, pages 389 - 403;;SAXOVA ET AL., INT. IMMUNOL., vol. 15, 2003, pages 781 - 787;;KIM ET AL.: ""Derivation of an amino acid similarity matrix for peptide: MHC binding and its application as a Bayesian prior"", BMC BIOINFORMATICS, vol. 10, 2009, pages 1 - 11;;GURUPRASAD ET AL., PROTEIN ENG., vol. 4, 1990, pages 155 - 161;;KRONKE ET AL., NATURE, vol. 523, no. 7559, 2015;;KRONKE ET AL., SCIENCE, vol. 343, no. 6168, 2014;;UDESHI ET AL., MOLECULAR & CELLULAR PROTEOMICS, vol. 11, 2012, pages 148 - 159;;MOMMEN ET AL., MOL. CELL. PROTEOMICS MCP, vol. 15, 2016, pages 1412 - 1423;;BASSANI-STERNBERG ET AL., MOL. CELL. PROTEOMICS, vol. 14, 2015, pages 658 - 673;;CARON ET AL., MOL. CELL. PROTEOMICS, vol. 14, no. 12, 2015, pages 3105 - 3117;;FUSARO ET AL., NATURE BIOTECHNOLOGY, vol. 27, 2009, pages 190 - 198;;TROLLE ET AL., J. IMMUNOL., vol. 196, no. 4, 2016, pages 1480 - 1487;;""Molecular Cloning: A Laboratory Manual"", vol. 1-3, 1989, COLD SPRING HARBOR LABORATORY PRESS;;""Current Protocols in Molecular Biology"", 1992, GREENE PUBLISHING AND WILEY-INTERSCIENCE;;""Methods in Enzymology"", ACADEMIC PRESS, INC;;INNIS ET AL.: ""PCR Protocols: A Guide to Methods and Applications"", 1990, ACADEMIC PRESS;;M.J. MACPHERSON ET AL: ""PCR 2: A Practical Approach"", 1995;;HARLOW AND LANE: ""Antibodies, a Laboratory Manual"", 1988;;R.I. FRESHNEY: ""Animal Cell Culture"", 1987;;DAVIS, B. D. ET AL.: ""Microbiology"", 1980, HARPER & ROW, PUBLISHERS;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY, pages: 1418;;MARATEA ET AL., GENE, vol. 40, 1985, pages 39 - 46;;MURPHY ET AL., PROC. NAT'L. ACAD. SCI. USA, vol. 83, 1986, pages 8258 - 8262;;BUCKWALTER; SRIVASTAVA PK: ""It is the antigen(s), stupid"", SEMINARS IN IMMUNOLOGY, vol. 20, 2008, pages 296 - 300, XP025646569, DOI: doi:10.1016/j.smim.2008.07.003;;KARANIKAS ET AL.: ""High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival"", CANCER RES., vol. 61, 2001, pages 3718 - 3724, XP055111384;;LENNERZ ET AL.: ""The response of autologous T cells to a human melanoma is dominated by mutated neoantigens"", PROC NATL ACAD SCI U S A., vol. 102, 2005, pages 16013, XP002408502, DOI: doi:10.1073/pnas.0500090102;;MATSUSHITA ET AL.: ""Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting"", NATURE, vol. 482, 2012, pages 400, XP055355530, DOI: doi:10.1038/nature10755;;DUPAGE ET AL.: ""Expression of tumor-specific antigens underlies cancer immunoediting"", NATURE, vol. 482, 2012, pages 405;;SAMPSON ET AL.: ""Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma"", J CLIN ONCOL., vol. 28, 2010, pages 4722 - 4729, XP055111559, DOI: doi:10.1200/JCO.2010.28.6963;;MEDZIHRADSZKY KF; CHALKLEY RJ., MASS SPECTROM REV., vol. 34, no. 1, January 2015 (2015-01-01), pages 43 - 63;;G. GREGORIADIS ET AL., INT. J. PHARMACEUTICS, vol. 300, no. 1-2, pages 125 - 30;;T. LINDHOUT ET AL., PNAS, vol. 108, no. 18, 2011, pages 7397 - 7402;;MERRIFIELD RB: ""Solid phase peptide synthesis. I. The synthesis of a tetrapeptide"", J. AM. CHEM. SOC., vol. 85, 1963, pages 2149 - 2154, XP002257754, DOI: doi:10.1021/ja00897a025;;SAMBROOK ET AL.: ""Molecular Cloning, A Laboratory Manual"", 1989, COLD SPRING HARBOR LABORATORY;;SMITH; WATERMAN, ADVANCES IN APPLIED MATHEMATICS, vol. 2, 1981, pages 482 - 489;;ZOELLER ET AL., PROC. NAT'L. ACAD. SCI. USA, vol. 81, 1984, pages 5662 - 5066;;POUWELS ET AL.: ""Cloning Vectors: A Laboratory Manual"", 1985, ELSEVIER;;GLUZMAN, CELL, vol. 23, 1981, pages 175;;MOR ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 155, no. 4, 1995, pages 2039 - 2046;;LEITNER ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 159, no. 12, 1997, pages 6112 - 6119;;ALARCON ET AL., ADV. PARASITOL. ADVANCES IN PARASITOLOGY, vol. 42, 1999, pages 343 - 410;;ROBINSON ET AL., ADV. VIRUS RES. ADVANCES IN VIRUS RESEARCH, vol. 55, 2000, pages 1 - 74;;BOHM ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 193, no. 1, 1996, pages 29 - 40;;LEWIS ET AL.: ""Advances in Virus Research"", vol. 54, 1999, ACADEMIC PRESS, pages: 129 - 188;;WEINER ET AL., SCIENTIFIC AMERICAN, vol. 281, no. 1, 1999, pages 34 - 41;;SHAREI ET AL.: ""Ex Vivo Cytosolic Delivery of Functional Macromolecules to Immune Cells"", PLOS ONE, 13 April 2015 (2015-04-13);;SEDEGAH ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 91, no. 21, 1994, pages 9866 - 9870;;DAHESHIAET, THE JOURNAL OF IMMUNOLOGY, vol. 159, no. 4, 1997, pages 1945 - 1952;;CHEN ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 160, no. 5, 1998, pages 2425 - 2432;;SIZEMORE, SCIENCE, vol. 270, no. 5234, 1995, pages 299 - 302;;FYNAN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, no. 24, 1993, pages 11478 - 11482;;BADEN ET AL.: ""First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001"", J INFECT DIS., vol. 207, no. 2, 15 January 2013 (2013-01-15), pages 240 - 247, XP055190590, DOI: doi:10.1093/infdis/jis670;;BUCHSCHER ET AL., J. VIROL., vol. 66, 1992, pages 2731 - 2739;;JOHANN ET AL., J. VIROL., vol. 66, 1992, pages 1635 - 1640;;SOMMNERFELT ET AL., VIROL., vol. 176, 1990, pages 58 - 59;;WILSON ET AL., J. VIROL., vol. 63, 1998, pages 2374 - 2378;;MILLER ET AL., J. VIROL, vol. 65, 1991, pages 2220 - 2224;;BALAGAAN: ""J Gene Med"", vol. 8, 21 November 2005, WILEY INTERSCIENCE, pages: 275 - 285;;CHROBOCZEK, J.; BIEBER, F.; JACROT, B.: ""The Sequence of the Genome of Adenovirus Type 5 and Its Comparison with the Genome of Adenovirus Type 2"", VIROLOGY, vol. 186, 1992, pages 280 - 285, XP023049327, DOI: doi:10.1016/0042-6822(92)90082-Z;;VERARDIET, HUM VACCIN IMMUNOTHER, vol. 8, no. 7, July 2012 (2012-07-01), pages 961 - 70;;MOSS, VACCINE, vol. 31, no. 39, 2013, pages 4220 - 4222;;PANICALI, D, PROC. NATL. ACAD. SCI., vol. 79, 1982, pages 4927 - 493;;PANICALI D, PROC. NATL. ACAD. SCI., vol. 80, no. 17, 1983, pages 5364 - 5368;;MACKETT, M, PROC. NATL. ACAD. SCI., vol. 79, 1982, pages 7415 - 7419;;SMITH GL, PROC. NATL. ACAD. SCI., vol. 80, no. 23, 1983, pages 7155 - 7159;;SMITH GL., NATURE, vol. 302, 1983, pages 490 - 495;;SULLIVAN VJ., GEN. VIR., vol. 68, 1987, pages 2587 - 2598;;PERKUS M, JOURNAL OF LEUKOCYTE BIOLOGY, vol. 58, 1995, pages 1 - 13;;YILMA TD, VACCINE, vol. 7, 1989, pages 484 - 485;;BROCHIER B., NATURE, vol. 354, 1991, pages 520 - 522;;WIKTOR, TJ, PROC. NATL ACD. SCI., vol. 81, 1984, pages 7194 - 7198;;RUPPRECHT, CE., PROC. NATL ACD. SCI., vol. 83, 1986, pages 7947 - 7950;;POULET, H, VACCINE, vol. 25, July 2007 (2007-07-01), pages 5606 - 5612;;WEYER J., VACCINE, vol. 27, November 2009 (2009-11-01), pages 7198 - 7201;;BULLER, RM, NATURE, vol. 317, no. 6040, 1985, pages 813 - 815;;BULLER RM., J. VIROL., vol. 62, no. 3, 1988, pages 866 - 874;;FLEXNER, C., NATURE, vol. 330, no. 6145, 1987, pages 259 - 262;;SHIDA, H, J. VIROL., vol. 62, no. 12, 1988, pages 4474 - 4480;;KOTWAL, GJ., J. VIROL., vol. 63, no. 2, 1989, pages 600 - 606;;CHILD, SJ, VIROLOGY, vol. 174, no. 2, 1990, pages 625 - 629;;MAYR A, ZENTRALBL BAKTERIOL, vol. 167, no. 5,6, 1978, pages 375 - 379;;ANTOINE G, VIROLOGY, vol. 244, no. 2, 1998, pages 365 - 396;;WYATT, LS, VIROLOGY, vol. 251, no. 2, 1998, pages 334 - 342;;SANCHO, MC, J. VIROL., vol. 76, no. 16, 2002, pages 8313 - 8334;;GALLEGO-GOMEZ, JC., J. VIROL., vol. 77, no. 19, 2003, pages 10606 - 10622;;GOEBEL SJ., VIROLOGY, vol. 179, 1990, pages 247 - 266;;TARTAGLIA, J. VIROL., vol. 188, no. 1, 1992, pages 217 - 232;;NAJERA JL, J. VIROL., vol. 80, no. 12, 2006, pages 6033 - 6047;;NAJERA, JL, J. VIROL., vol. 80, 2006, pages 6033 - 6047;;GOMEZ, CE, J. GEN. VIROL., vol. 88, 2007, pages 2473 - 2478;;MOOIJ, P, JOUR. OF VIROL., vol. 82, 2008, pages 2975 - 2988;;GOMEZ, CE., CURR. GENE THER., vol. 11, 2011, pages 189 - 217;;COX,W., VIROLOGY, vol. 195, 1993, pages 845 - 850;;PERKUS, M., JOUR. OF LEUKOCYTE BIOLOGY, vol. 58, 1995, pages 1 - 13;;BLANCHARD TJ., J GEN VIROLOGY, vol. 79, no. 5, 1998, pages 1159 - 1167;;AMARA R, SCIENCE, vol. 292, 2001, pages 69 - 74;;HEL, Z., J. IMMUNOL., vol. 167, 2001, pages 7180 - 7189;;GHERARDI MM, J. VIROL., vol. 77, 2003, pages 7048 - 7057;;DIDIERLAURENT, A., VACCINE, vol. 22, 2004, pages 3395 - 3403;;BISSHT H., PROC. NAT. ACA. SCI., vol. 101, 2004, pages 6641 - 6646;;MCCURDY LH., CLIN. INF. DIS, vol. 38, 2004, pages 1749 - 1753;;EARL PL, NATURE, vol. 428, 2004, pages 182 - 185;;CHEN Z, J. VIROL., vol. 79, 2005, pages 2678 - 2688;;NAM JH., ACTA. VIROL., vol. 51, 2007, pages 125 - 130;;ANTONIS AF, VACCINE, vol. 25, 2007, pages 4818 - 4827;;B WEYER, J. VACCINE, vol. 25, 2007, pages 4213 - 4222;;FERRIER-REMBERT A, VACCINE, vol. 26, no. 14, 2008, pages 1794 - 1804;;CORBETT M, PROC. NATL. ACAD. SCI., vol. 105, no. 6, 2008, pages 2046 - 2051;;KAUFMAN HL., J. CLIN. ONCOL., vol. 22, 2004, pages 2122 - 2132;;AMATO, RJ., CLIN. CANCER RES., vol. 14, no. 22, 2008, pages 7504 - 7510;;DREICER R., INVEST NEW DRUGS, vol. 27, no. 4, 2009, pages 379 - 386;;KANTOFF PW., J. CLIN. ONCOL., vol. 28, 2010, pages 1099 - 1105;;AMATO RJ., J. CLIN. CAN. RES., vol. 16, no. 22, 2010, pages 5539 - 5547;;KIM, DW, HUM. VACCINE., vol. 6, 2010, pages 784 - 791;;OUDARD, S., CANCER IMMUNOL. IMMUNOTHER., vol. 60, 2011, pages 261 - 271;;WYATT, LS, AIDS RES. HUM. RETROVIRUSES, vol. 20, 2004, pages 645 - 653;;GOMEZ, CE, VIRUS RESEARCH, vol. 105, 2004, pages 11 - 22;;WEBSTER, DP, PROC. NATL. ACAD. SCI., vol. 102, no. 13, 2005, pages 4836 - 4841;;HUANG, X., VACCINE, vol. 25, 2007, pages 8874 - 8484;;GOMEZ, CE., VACCINE, vol. 25, 2007, pages 2863 - 2885;;ESTEBAN M., HUM. VACCINE, vol. 5, 2009, pages 867 - 871;;GOMEZ, CE., CURR. GENE THERAPY, vol. 8, no. 2, 2008, pages 97 - 120;;WHELAN, KT, PLOS ONE, vol. 4, no. 6, 2009, pages 5934;;SCRIBA, TJ., EUR. JOUR. IMMUNO., vol. 40, no. 1, 2010, pages 279 - 290;;CORBETT, M., PROC. NATL. ACAD. SCI., vol. 105, 2008, pages 2046 - 2051;;MIDGLEY, CM, J. GEN. VIROL., vol. 89, 2008, pages 2992 - 2997;;VON KREMPELHUBER, A, VACCINE, vol. 28, 2010, pages 1209 - 1216;;PERREAU, M., J. OF VIROL., October 2011 (2011-10-01), pages 9854 - 9862;;PANTALEO, G, CURR OPIN HIV-AIDS, vol. 5, 2010, pages 391 - 396;;ROLPH ET AL.: ""Recombinant viruses as vaccines and immunological tools"", CURR OPIN IMMUNOL, vol. 9, 1997, pages 517 - 524, XP004313548, DOI: doi:10.1016/S0952-7915(97)80104-5;;HORIG H. ET AL.: ""Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule"", CANCER IMMUNOL IMMUNOTHER, vol. 49, 2000, pages 504 - 514, XP002194114, DOI: doi:10.1007/s002620000146;;VON MEHREN M. ET AL.: ""Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas"", CLIN CANCER RES, vol. 6, 2000, pages 2219 - 2228, XP002327290;;MUSEY L. ET AL.: ""HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals"", J IMMUNOL, vol. 171, 2003, pages 1094 - 1101;;PAOLETTI E: ""Applications of pox virus vectors to vaccination: an update"", PROC NATL ACAD SCI U S A, vol. 93, 1996, pages 11349 - 11353, XP002135943, DOI: doi:10.1073/pnas.93.21.11349;;MARSHALL JL ET AL.: ""Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen."", J CLIN ONCOL, vol. 17, 1999, pages 332 - 337, XP001084702;;MAYR, A. ET AL., INFECTION, vol. 3, 1975, pages 6 - 14;;MEYER, H. ET AL., J. GEN. VIROL., vol. 72, 1991, pages 1031 - 1038;;MANDL ET AL., CANCER IMMUNOL IMMUNOTHER., vol. 61, no. 1, January 2012 (2012-01-01), pages 19 - 29;;SPEISER; ROMERO: ""Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity"", SEMINARS IN IMMUNOL, vol. 22, 2010, pages 144, XP027080489, DOI: doi:10.1016/j.smim.2010.03.004;;BHARDWAJ; GNJATIC: ""TLR AGONISTS: Are They Good Adjuvants?"", CANCER J., vol. 16, 2010, pages 382 - 391;;CASKEY ET AL.: ""Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans"", J EXP MED, vol. 208, 2011, pages 2357;;AUCOUTURIER ET AL., VACCINE, vol. 19, 2001, pages 2666 - 2672;;SCHNEIDER ET AL.: ""Induction of CD8+ T cells using heterologous prime-boost immunisation strategies"", IMMUNOLOGICAL REVIEWS, vol. 170, no. 1, August 1999 (1999-08-01), pages 29 - 38, XP000981910, DOI: doi:10.1111/j.1600-065X.1999.tb01326.x;;HUTCHINGS ET AL.: ""Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge"", INFECT IMMUN., vol. 75, no. 12, 1 October 2007 (2007-10-01), pages 5819 - 5826;;CONLON ET AL.: ""Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid"", JOURNAL OF IMMUNOLOGY, vol. 190, 2013, pages 5216 - 5225, XP055367377, DOI: doi:10.4049/jimmunol.1300097;;KIM ET AL., ANTICANCER FLAVONOIDS ARE MOUSE-SELECTIVE STING AGONISTS, vol. 8, 2013, pages 1396 - 1401;;R. LAROCK: ""Comprehensive Organic Transformations"", 1999, WILEY-VCH PUBLISHERS;;T.W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY AND SONS;;L. FIESER; M. FIESER: ""Fieser and Fieser's Reagents for Organic Synthesis"", 1999, JOHN WILEY AND SONS;;""Encyclopedia of Reagents for Organic Synthesis"", 1995, JOHN WILEY AND SONS;;""Goodman and Gilman's The Pharmacological Basis of Therapeutics"", 2005, MCGRAW-HILL;;""Remington: The Science and Practice of Pharmacy. 20th ed."", 2003, LIPPENCOTT WILLIAMS & WILKINS;;""Remington's Pharmaceutical Sciences. 21th ed."", 2005, MACK PUBLISHING COMPANY;;""Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. 9th ed."", 2011, LIPPINCOTT WILLIAMS & WILKINS;;""Transdermal Drug Delivery: Developmental Issues and Research Initiatives"", 1989, MARCEL DEKKER INC.;;BRUNSVIG P F ET AL., CANCER IMMUNOL IMMUNOTHER., vol. 55, no. 12, 2006, pages 1553 - 1564;;M. STAEHLER ET AL., ASCO MEETING, 2007;;DUPUIS M ET AL., CELL IMMUNOL., vol. 186, no. 1, 1998, pages 18 - 27;;ALLISON A C, DEV BIOL STAND., vol. 92, 1998, pages 3 - 11;;GABRILOVICH D I ET AL., J IMMUNOTHER EMPHASIS TUMOR IMMUNOL., no. 6, 1996, pages 414 - 418;;EISENBLATTER M; JASNY E ET AL.: ""Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques"", PLOS PATHOGENS, vol. 5, no. 4, April 2009 (2009-04-01);;ARTHUR M. KRIEG, NATURE REVIEWS, DRUG DISCOVERY, 5 June 2006 (2006-06-05), pages 471 - 484;;NISHIMURA ET AL.: ""Distinct role of antigen-specific T helper type 1 (TH1) and Th2 cells in tumor eradication in vivo"", J EX MED, vol. 190, 1999, pages 617 - 627;;KOBAYASHI ET AL., CURRENT OPINION IN IMMUNOLOGY, vol. 20, 2008, pages 221 - 227;;SLINGLUFF ET AL.: ""Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting"", CLINICAL CANCER RESEARCH, vol. 13, no. 21, 2007, pages 6386 - 6395, XP009144705, DOI: doi:10.1158/1078-0432.CCR-07-0486;;KREITER ET AL.: ""Mutant MHC Class II epitopes drive therapeutic immune responses to cancer"", NATURE, 2015;;CARRENO ET AL.: ""L-12p70-producing patient DC vaccine elicits Tel-polarized immunity"", JOURNAL OF CLINICAL INVESTIGATION, vol. 123, no. 8, 2013, pages 3383 - 3394, XP002770177, DOI: doi:10.1172/JCI68395;;ALI ET AL.: ""In situ regulation of DC subsets and T cells mediates tumor regression in mice"", CANCER IMMUNOTHERAPY, vol. 1, no. 8, 2009, pages 1 - 10, XP009165920, DOI: doi:10.1126/scitranslmed.3000359;;SABADO ET AL.: ""Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy"", J. VIS EXP., vol. 1, no. 78, August 2013 (2013-08-01);;ALI ET AL.: ""In situ regulation of DC subsets and T cells mediates tumor regression in mice"", CANCER IMMUNOTHERAPY, vol. 1, no. 8, pages 1 - 10;;ALI ET AL.: ""Infection-mimicking materials to program dendritic cells in situ"", NAT MATER, vol. 8, 2009, pages 151 - 158;;MURPHY ET AL., THE PROSTATE, vol. 29, 1996, pages 371 - 380;;TJUA ET AL., THE PROSTATE, vol. 32, 1997, pages 272 - 278;;BACHEM ET AL., J. EXP. MED., vol. 207, 2010, pages 1273 - 1281;;CROZAT ET AL., J. EXP. MED., vol. 207, 2010, pages 1283 - 1292;;GALLOIS; BHARDWAJ, NATURE MED, vol. 16, 2010, pages 854 - 856;;WOLFF ET AL., SCIENCE, vol. 247, 1990, pages 1465 - 1468;;MANNINO; GOULD-FOGERITE, BIOTECHNIQUES, vol. 6, no. 7, 1988, pages 682 - 691;;FEIGNER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413 - 7414;;HALABI ET AL., J CLIN ONCOL, vol. 21, 2003, pages 1232 - 1237;;PETSCH ET AL., NATURE BIOTECHNOLOGY, vol. 30, no. 12, 7 December 2012 (2012-12-07), pages 1210 - 1216;;SAMBROOK: ""Molecular Cloning: A Laboratory Manual"", 1989;;GAIT, OLIGONUCLEOTIDE SYNTHESIS, 1984;;FRESHNEY, ANIMAL CELL CULTURE, 1987;;WEI: ""Handbook of Experimental Immunology"", 1996, article ""Methods in Enzymology"";;MILLER; CALOS, GENE TRANSFER VECTORS FOR MAMMALIAN CELLS, 1987;;AUSUBEL, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 1987;;MULLIS, PCR: THE POLYMERASE CHAIN REACTION, 1994;;COLIGAN, CURRENT PROTOCOLS IN IMMUNOLOGY, 1991;;NOCENTINI ET AL., PROC NATL ACAD SCI USA, vol. 94, 1997, pages 6216 - 6221;;RONCHETTI ET AL., EUR J IMMUNOL, vol. 34, 2004, pages 613 - 622;;AVOGADRI ET AL., CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, 2011, pages 344;;PAGE, ANNUAL REVIEW OF MEDICINE, vol. 65, 2014, pages 27;;ZITVOGEL ET AL.: ""Immunological aspects of cancer chemotherapy"", NAT REV IMMUNOL., vol. 8, no. 1, January 2008 (2008-01-01), pages 59 - 73, XP055008389, DOI: doi:10.1038/nri2216;;PEREZ ET AL.: ""A new era in anticancer peptide vaccines"", CANCER, May 2010 (2010-05-01);;GHIRINGHELLI ET AL.: ""Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients"", CANCER IMMUNOL IMMUNOTHER, vol. 56, 2007, pages 641 - 648, XP019489789;;ZITVOGEL ET AL., NAT. REV. IMMUNOL., vol. 8, no. 1, 2008, pages 59 - 73;;ITOH ET AL.: ""Personalized peptide vaccines: A new therapeutic modality for cancer"", CANCER SCI, vol. 97, 2006, pages 970 - 976, XP002538826, DOI: doi:10.1111/j.1349-7006.2006.00272.x;;FREDERICK ET AL.: ""BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma"", CLIN CANCER RES., vol. 19, 2013, pages 1225 - 1231;;FARSACI ET AL.: ""Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy"", INT J CANCER, vol. 130, pages 1948 - 1959;;FINKE ET AL.: ""Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients"", CLIN CANCER RES, vol. 14, no. 20, 2008;;ALVAREZ: ""Present and future evolution of advanced breast cancer therapy"", BREAST CANCER RESEARCH, vol. 12, no. 2, 2010, pages S 1;;KYTE ET AL.: ""Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients"", CLIN CANCER RES, vol. 17, no. 13, 2011, XP002683221, DOI: doi:10.1158/1078-0432.CCR-11-0184;;SAMPSON ET AL.: ""Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma"", NEURO-ONCOLOGY, vol. 13, no. 3, 2011, pages 324 - 333;;MAUS ET AL.: ""Adoptive Immunotherapy for Cancer or Viruses"", ANNUAL REVIEW OF IMMUNOLOGY, vol. 32, 2014, pages 189 - 225;;ROSENBERG; RESTIFO: ""Adoptive cell transfer as personalized immunotherapy for human cancer"", SCIENCE, vol. 348, no. 6230, 2015, pages 62 - 68, XP055256712, DOI: doi:10.1126/science.aaa4967;;RESTIFO ET AL.: ""Adoptive immunotherapy for cancer: harnessing the T cell response"", NAT. REV. IMMUNOL., vol. 12, no. 4, 2015, pages 269 - 281, XP055034896, DOI: doi:10.1038/nri3191;;JENSON; RIDDELL: ""Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells"", IMMUNOL REV., vol. 257, no. 1, 2014, pages 127 - 144, XP055156740;;ZHOU ET AL., BLOOD, vol. 123/25, 2014, pages 3895 - 3905;;DI STASI ET AL., THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 365, 2011, pages 1673 - 1683;;SADELAIN M.: ""Eliminating Cells Gone Astray"", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 365, no. 18, 3 November 2011 (2011-11-03), pages 1735 - 1737;;RAMOS ET AL., STEM CELLS, vol. 28, no. 6, 2010, pages 1107 - 1115;;POIROT ET AL.: ""Multiplex genome edited T-cell manufacturing platform for ''off-the-shelf'' adoptive T-cell immunotherapies"", CANCER RES, vol. 75, no. 18, 2015, pages 3853, XP055221500, DOI: doi:10.1158/0008-5472.CAN-14-3321;;BONI, MURANSKI ET AL., BLOOD, vol. 112, no. 12, 1 December 2007 (2007-12-01), pages 4746 - 4754;;WATSON HA ET AL.: ""SHP-1: the next checkpoint target for cancer immunotherapy?"", BIOCHEM SOC TRANS., vol. 44, no. 2, 15 April 2016 (2016-04-15), pages 356 - 362;;LE MERCIER I ET AL.: ""Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators"", FRONT. IMMUNOL., vol. 6, 2015, pages 418;;EYERS ET AL., MOL CELLPROTEOMICS, vol. 10, no. 11, 2011;;MUNTEL ET AL., MOL. CELL. PROTEOMICS, vol. 14, 2015, pages 430 - 440;;SEARLE ET AL., MOL. CELL. PROTEOMICS, vol. 14, 2015, pages 2331 - 2340;;TROLLE ET AL., J. IMMUNOL., 2016;;ROCK ET AL., TRENDS IMMUNOL., vol. 35, 2014, pages 144 - 152;;BOURDETSKY ET AL., PROC. NATL. ACAD. SCI., vol. 111, 2014, pages E1591 - E1599;;YEWDELL, TRENDS IMMUNOL., vol. 32, 2011, pages 548 - 558;;KIM ET AL.: ""Positional Bias of MHC Class I Restricted T-Cell Epitopes in Viral Antigens Is Likely due to a Bias in Conservation"", PLOS COMPUT BIOL, vol. 9, 2013, pages EL002884;;KRONKE ET AL., SCIENCE, vol. 343, no. 6168, 2014, pages 301 - 305;;ISHIHAMA ET AL., MOL. CELL. PROTEOMICS, vol. 4, 2005, pages 1265 - 1272;;HAABETH, FRONTIERS IN IMMUNOLOGY, 2014;;HAABETH, LEUKEMIA, 2016;;KIM ET AL., BMC BIOINFORMATICS, vol. 10, 2009, pages 1 - 11;;SIDNEY ET AL.: ""Current Protocols in Immunology"", 2001, JOHN WILEY & SONS, INC.;;KE MIR ET AL., PROTEIN ENG., vol. 15, 2002, pages 287 - 296;;NIELSEN ET AL., IMMUNOGENETICS, vol. 57, 2005, pages 33 - 41;;OATES ET AL., NUCLEIC ACIDS RES., vol. 41, 2013, pages D508 - D516;;EICHMANN ET AL., TISSUE ANTIGENS, 2014, pages 84;;KENNETH MURPHY, CASEY WEAVER: ""JANEWAY'S IMMUNOBIOLOGY, 9th Edition"", 3 January 2016, GARLAND SCIENCE, TAYLOR & FRANCIS GROUP, LLC, article ""Chapter 4 : Antigen Recognition by B-Cell and T-Cell Receptors"", pages: 2pp, 156 - 157, XP055808498;;M-H FORTIER; CARON E; M-P HARDY; VOISIN G; LEMIEUX S; PERREAULT C; THIBAULT P: ""The MHC class I peptide repertoire is molded by the transcriptome"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 205, no. 3, 2008, pages 595 - 610, XP055006000;;M-H FORTIER; CARON E; M-P HARDY; VOISIN G; LEMIEUX S; PERREAULT C; THIBAULT P: ""The MHC class I peptide repertoire is molded by the transcriptome /Supplementary Material: Tables/"", JOURNAL OF EXPERIMENTAL MEDICINE, 2008, pages 1 - 18, XP055808502, Retrieved from the Internet <URL:https://cdn.rupress.org/rup/content_public/journal/jem/205/3/10.1084_jem.20071985/7/jem_20071985-sup-3.pdf?Expires=1623916766&Signature=w5GS8m2~D9NXfbVhZRVHTbA2qZm-0WL6Wbx8Vh7ceAQEcIkG50RFmdX1HmVZ6vUuPXgLRZsGuRwqmlQ~ApkY44BZuSIAJUe3OMqyMsKYTTYPUpuWLFKvym9~m00VToCCvgHblvXvivuOWFieR~uU-7PiZ4qwskLveO7OOUpch9S2YbggX08PNJ8-3jF4aH2rOOrmuuy1V13gSJwECzEjpvl~mex8sGYe3VfrZWk4u5FlGhZA48dmHYT~RcM7GkJJsTdCNBHfj1~vunop0fhIDHscfMP0FvUmsILuoP9vgIxS6CjH8t0TU4OM2POpKZDuF7PwoN2gyxf9Ll1pTDXAsQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA>",PENDING
389,ES,T3,ES 2354162 T3,159-610-425-946-155,2011-03-10,2011,ES 04806258 T,2004-12-23,US 53219903 P,2003-12-23,DERIVADOS DE PIRAZOL COMO MODULARES DE PROTEINA QUINASAS.,"Compuesto de fórmula (I): **(Ver fórmula)**NN H (I) o una sal, solvato, tautómero o N-óxido del mismo; donde A es un grupo enlazador de hibrocarburo saturado que contiene de 1 a 7 átomos de carbono, teniendo el grupo enlazador una longitud de cadena máxima de átomos que se extiende entre R1 y NR2R3 y una longitud de cadena máxima de 4 átomos que se extiende entre E y NR2R3, donde uno de los átomos de carbono del grupo enlazador puede opcionalmente remplazarse por un átomo de oxígeno o nitrógeno; y donde los átomos de carbono del grupo enlazador A pueden albergar opcionalmente uno o más sustituyentes seleccionados entre oxo, flúor e hidroxilo, con la condición de que cuando el grupo hidroxilo está presente no esté localizado en un átomo de carbono α con respecto al grupo NR2R3 y con la condición de que el grupo oxo, cuando está presente, esté localizado en un átomo de carbono α con respecto al grupo NR2R3; E es un grupo carbocíclico o heterocíclico monocíclico o bicíclico donde E no sustituido o tiene hasta 4 sustituyentes R8 seleccionados entre hidroxilo, oxo (cuando E es no aromático), cloro, bromo, trifluorometilo, ciano, hidrocarbiloxi(C1-4) e hidrocarbilo(C1-4) opcionalmente sustituido con alcoxi C1-2 o hidroxilo; R1 es un grupo arilo o heteroarilo no sustituido o alberga uno o más sustituyentes seleccionados entre hidroxilo; aciloxi(C1-4); flúor; cloro; bromo; trifluorometilo; ciano; CONH2; nitro; hidrocarbiloxi(C1-4) e hidrocarbilo(C1-4) cada uno opcionalmente sustituido con alcoxi(C1-2), carboxi o hidroxilo; acilamino(C1-4); benzoilamino; pirrolidincarbonilo; piperidincarbonilo; morfolincarbonilo; piperazincarbonilo; grupos heteroarilo y heteroariloxi de cinco y seis miembros que contienen uno o dos heteroátomos seleccionados entre N, O y S; fenilo; fenilalquilo(C1-4); fenilalcoxi(C1-4); heteroarilalquilo(C1-4); heteroarilalcoxi(C1-4) y fenoxi, donde los grupos heteroarilo, heteroariloxi, fenilo, fenilalquilo(C1-4), fenilalcoxi(C1-4), heteroarilalquilo(C1-4), heteroarilalcoxi(C1-4) y fenoxi están cada uno opcionalmente sustituido con 1, 2 ó 3 sustituyentes seleccionados entre aciloxi(C1-2), flúor, cloro, bromo, trifluorometilo, ciano, CONH2, hidrocarbiloxi(C1-2) e hidrocarbilo(C1-2) cada uno opcionalmente sustituido con metoxi o hidroxilo; R2 y R3 se seleccionan independientemente entre hidrógeno, hidrocarbilo(C1-4) y acilo(C1-4), donde los grupos hidrocarbilo y acilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados de entre flúor, hidroxilo, amino, metilamino, dimetilamino y metoxi; o R2 y R3, junto con el átomo de nitrógeno al que están unidos, forman un grupo cíclico seleccionado de entre un grupo imidazol y un grupo heterocíclico monocíclico saturado de 4-7 miembros en el anillo y que contiene opcionalmente un segundo miembro heteroatómico en el anillo seleccionado entre O y N; o uno de R2 y R3, junto con el átomo de nitrógeno al que están unidos y uno o más átomos del grupo enlazador A, forman un grupo heterocíclico monocíclico saturado de 4-7 miembros en el anillo y que contiene opcionalmente un segundo miembro heteroatómico en el anillo seleccionado entre O y N; o NR2R3 y el átomo de carbono del grupo enlazador A al que está unido juntos forman un grupo ciano; R4 se selecciona entre hidrógeno, halógeno, hidrocarbilo(C1-5) saturado, hidrocarbiloxi(C1-5) saturado, ciano y CF3; y R5 se selecciona entre hidrógeno, halógeno, hidrocarbilo(C1-5) saturado, hidrocarbiloxi(C1-5) saturado, ciano, CONH2, CONHR9, CF3, NH2, NHCOR9 o NHCONHR9; R9 es un grupo R9a o (CH2)R9a, donde R9a es un grupo monocíclico o bicíclico que puede ser carbocíclico o heterocíclico; estando el grupo carbocíclico o el grupo heterocíclico R9a opcionalmente sustituido con uno o más sustituyentes seleccionados de entre halógeno, hidroxilo, trifluorometilo, ciano, nitro, carboxi, amino, mono-o dihidrocarbilamino(C1-4); un grupo Ra-Rb donde Ra es un enlace, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc o NRcSO2; y Rb se selecciona entre hidrógeno, grupos heterocíclicos que tienen de 3 a 12 miembros en el anillo y un grupo hidrocarbilo(C1-8) opcionalmente sustituido con uno o más sustituyentes seleccionados entre hidroxilo, oxo, halógeno, ciano, nitro, carboxi, amino, mono-o di-hidrocarbilamino(C1-4), grupos carbocíclicos y heterocíclicos de 3 a 12 miembros en el anillo y donde uno o más átomos de carbono del grupo hidrocarbilo(C1-8) puede opcionalmente remplazarse por O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 o X1C(X2)X1; Rc se selecciona entre hidrógeno e hidrocarbilo(C1-4); y X1 es O,SoNRcy X2es =O,=So=NRc.",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,SAXTY GORDON;;BERDINI VALERIO;;VERDONK MARINUS;;COLLINS IAN;;WALKER DAVID;;DOWNHAM ROBERT;;WOODHEAD STEVEN;;BOYLE ROBERT;;SORE HANNAH;;WYATT PAUL;;CARR ROBIN,,https://lens.org/159-610-425-946-155,Granted Patent,no,0,0,1,52,0,,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,ACTIVE
390,CN,A,CN 101379058 A,028-572-131-137-307,2009-03-04,2009,CN 200580045026 A,2005-12-30,GB 2005005097 W;;GB 0428554 A;;GB 0428552 A;;US 64047504 P;;US 64059704 P,2004-12-30,"Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases","The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R', E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",ASTEX THERAPEUTICS LTD,VALERIO BERDINI;;GRAZIA CARR MARIA;;LIAM GILL ADRIAN;;STEVEN HOWARD;;FIGUEROA NAVARRO EVA;;GARY TREWARTHA;;CHARLES REES DAVID;;MLADEN VINKOVIC;;GRAHAM WYATT PAUL,,https://lens.org/028-572-131-137-307,Patent Application,no,0,3,3,30,0,,C07D403/04;;A61K31/4184;;A61P35/00;;C07D407/14;;C07D513/04,,0,0,,,,INACTIVE
391,CA,C,CA 2593993 C,014-177-097-592-964,2014-07-29,2014,CA 2593993 A,2005-12-30,GB 0428554 A;;GB 0428552 A;;US 64059704 P;;US 64047504 P;;GB 2005005097 W,2004-12-30,"PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES","The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R', E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,,https://lens.org/014-177-097-592-964,Granted Patent,no,0,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,C07D403/04;;A61K31/4184;;A61P35/00;;C07D407/14;;C07D513/04,,0,0,,,,INACTIVE
392,WO,A1,WO 2002/037169 A1,107-139-453-198-678,2002-05-10,2002,US 0142850 W,2001-10-30,US 69827000 A,2000-10-30,WIDE FIELD SPHERICAL LENSES AND PROTECTIVE EYEWEAR,"The present invention relates to novel ophthalmic lens elements (402, 404) and eyewear (400) having wide field of view, low distortion, improved astigmatism correction where required and enhanced eye protection properties. Series of lens elements have steeply curved spherical reference surfaces. The edged lenses of the series have approximately consistent aperture size, shape and hollow depth across a range of common prescriptions. Novel sunglasses, laser protection eyewear, and lens edgings, coatings, and frames are included in the invention.",SOLA INTERNATIONAL INC;;MORRIS MICHAEL ALAN;;PERROTT COLIN MAURICE;;EDWARDS SIMON J;;SPRATT RAY STEVEN;;CARR DAVID LAWRENCE;;YIP BRANDON;;ADAMS BRIAN;;BEGLEY PARAIC;;BLACKER RICHARD,MORRIS MICHAEL ALAN;;PERROTT COLIN MAURICE;;EDWARDS SIMON J;;SPRATT RAY STEVEN;;CARR DAVID LAWRENCE;;YIP BRANDON;;ADAMS BRIAN;;BEGLEY PARAIC;;BLACKER RICHARD,,https://lens.org/107-139-453-198-678,Patent Application,yes,5,7,14,50,0,G02C7/10;;G02C7/02,G02B1/11;;G02C7/02;;G02C7/10,,1,0,,,See also references of EP 1330676A4,PATENTED
393,CA,A1,CA 2593993 A1,120-791-909-080-650,2006-07-06,2006,CA 2593993 A,2005-12-30,GB 0428554 A;;GB 0428552 A;;US 64059704 P;;US 64047504 P;;GB 2005005097 W,2004-12-30,"PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES",,ASTEX THERAPEUTICS LTD,CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;VINKOVIC MLADEN;;NAVARRO EVA FIGUEROA;;HOWARD STEVEN;;BERDINI VALERIO;;TREWARTHA GARY;;REES DAVID CHARLES;;WYATT PAUL GRAHAM,,https://lens.org/120-791-909-080-650,Patent Application,no,0,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,A61K31/4184;;C07D403/04;;A61P35/00;;C07D407/14;;C07D513/04,,0,0,,,,INACTIVE
394,EP,A4,EP 1330676 A4,151-956-997-571-245,2006-10-25,2006,EP 01981901 A,2001-10-30,US 0142850 W;;US 69827000 A,2000-10-30,WIDE FIELD SPHERICAL LENSES AND PROTECTIVE EYEWEAR,,SOLA INTERNATIONAL INC;;MORIS MICHAEL ALAN,MORRIS MICHAEL ALAN;;PERROTT COLIN MAURICE;;EDWARDS SIMON J;;SPRATT RAY STEVEN;;CARR DAVID LAWRENCE;;YIP BRANDON;;ADAMS BRIAN;;BEGLEY PARAIC;;BLACKER RICHARD,,https://lens.org/151-956-997-571-245,Search Report,no,7,0,14,50,0,G02C7/02;;G02C7/10,G02B1/11;;G02C7/02;;G02C7/10,,1,0,,,See also references of WO 0237169A1,DISCONTINUED
395,EP,A1,EP 1833819 A1,058-635-161-983-401,2007-09-19,2007,EP 05823721 A,2005-12-30,GB 2005005097 W;;GB 0428554 A;;GB 0428552 A;;US 64059704 P;;US 64047504 P,2004-12-30,"PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES",,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,,https://lens.org/058-635-161-983-401,Patent Application,yes,0,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,A61K31/4184;;C07D403/04;;A61P35/00;;C07D407/14;;C07D513/04,,0,0,,,,DISCONTINUED
396,AU,A1,AU 2005/321091 A1,065-581-092-004-910,2006-07-06,2006,AU 2005/321091 A,2005-12-30,GB 0428552 A;;US 64047504 P;;US 64059704 P;;GB 0428554 A;;GB 2005005097 W,2004-12-30,"Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases",,ASTEX THERAPUTICS LTD,BERDINI VALERIO;;NAVARRO EVA FIGUEROA;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM;;HOWARD STEVEN;;GILL ADRIAN LIAM;;REES DAVID CHARLES;;CARR MARIA GRAZIA;;TREWARTHA GARY,,https://lens.org/065-581-092-004-910,Patent Application,no,0,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,C07D403/04;;A61K31/4184;;A61P35/00;;C07D407/14;;C07D513/04,,0,0,,,,INACTIVE
397,JP,A,JP 2009003464 A,127-452-898-410-21X,2009-01-08,2009,JP 2008192654 A,2008-07-25,US 69827000 A,2000-10-30,WIDE FIELD SPHERICAL LENS AND PROTECTIVE EYEWEAR,"<P>PROBLEM TO BE SOLVED: To provide a spectacle lens having a high vision characteristic. <P>SOLUTION: Lenses 28 and 30 can be generally expressed as a sphere or a spherical base, preferably, have a spherical surface, have a fixed radius less than 35 mm about all prescription values in a series, have a spherical back surface, and are expressed to include a reference sphere or be placed in a defined spherical shell. In each case, the radius of the reference sphere or the shell and lens during wearing are disposed so that the center of the reference sphere or the shell is positioned near or inside the rotation center of the eye. <P>COPYRIGHT: (C)2009,JPO&INPIT",SOLA INTERNATL INC,MORRIS MICHAEL ALAN;;PERROTT COLIN MAURICE;;EDWARDS SIMON J;;SPRATT RAY STEVEN;;CARR DAVID LAWRENCE;;YIP BRANDON;;ADAMS BRIAN;;BEGLEY PARAIC;;BLACKER RICHARD,,https://lens.org/127-452-898-410-21X,Patent Application,no,3,1,14,50,0,G02C7/10;;G02C7/02,G02C7/02;;G02B1/11;;G02B5/28;;G02C7/10,,0,0,,,,PENDING
398,US,B2,US 8778936 B2,165-060-340-314-11X,2014-07-15,2014,US 201113329952 A,2011-12-19,US 201113329952 A;;GB 0428552 A;;GB 0428554 A;;US 81303107 A;;GB 2005005097 W;;US 64059704 P;;US 64047504 P,2004-12-30,"Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases","The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R′, E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM;;ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,ASTEX THERAPEUTICS LIMITED (2008-03-14),https://lens.org/165-060-340-314-11X,Granted Patent,yes,84,2,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,A61K31/535,514/234.5,25,13,041-703-940-947-068;;029-742-983-481-795;;012-522-479-506-568;;041-999-952-766-040;;075-266-316-125-301;;150-531-382-227-747;;020-435-634-003-86X;;001-516-175-552-397;;012-522-479-506-568;;129-851-165-213-092;;137-556-656-441-725;;067-684-687-003-217;;007-199-701-352-072,9544425;;10.1023/a:1005960822365;;10.1126/science.286.5439.531;;10521349;;10.1002/bscb.19870960110;;6827558;;10.1021/jm00357a015;;10.1016/s0968-0896(01)00194-8;;11597481;;12482427;;10.1016/s0960-894x(02)00884-3;;10.1016/j.addr.2003.10.020;;14962582;;10.1016/s0169-409x(01)00097-7;;11325474;;10.1002/bscb.19870960110;;10.1016/j.ejca.2009.08.008;;19762228;;19104514;;10.1038/nrc2559;;10.1634/theoncologist.2009-0019;;19684075;;3567848;;10.1002/1097-0142(19870601)59:11<1853::aid-cncr2820591102>3.0.co;2-f,"Cancer and Metastasis Reviews (1998), 17(1), 91-106.;;Science (1999), vol. 286, 531-537.;;Essassi et al., Synthese et Hererocyclisation Des (Pyrazoly1-3-(5))-2 Benzimidazoles en Catalyse Par Transfert de Phase, Bull. Soc. Chim Belg. vol. 96, 1987, pp. 63-67.;;Blankley et al., Antihypertensive Activity of 6-Arylpyrido[2,3-d] Pyrimidim-7-Amine Derivatives. 2. 7-Acyl Amide Analogues, Journal of Medicinal Chemistry, vol. 26, No. 3, Mar. 1, 1983, pp. 403-411.;;Sarhan et al., Synthesis, Characterization and Reactions of 2-Deoxo-5-Deazaalloxazines, Bioorganic & Medicinal Chemistry, vol. 9, Jan. 1, 2001, pp. 2993-2998.;;Mesguiche et al., 4-Alkoxy-2,6-Diaminopyrimidine Derivatives. Inhibitors of Cyclin Dependent Kinases 1 and 2, Bioorganic & Medicinal Chemistry Letters, vol. 13, Jan. 1, 2003, pp. 217-222.;;Morissette et al., High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids, Advanced Drug Delivery Reviews, 2004, 56, pp. 275-300.;;Souillac et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, Encyclopedia of Controlled Drug Delivery, Wiley, 1999, pp. 212-227.;;Vippagunta et al., Crystalline solids, Advanced Drug Delivery Reviews, 2001, 48, pp. 3-26.;;International Search Report for PCT/GB2004/002824 (Apr. 7, 2005).;;GB Search Report for GB 0315657.7 (Oct. 28, 2003).;;GB Search Report for GB 0324919.0 (Feb. 25, 2004).;;European Supplementary Search Report for EP 04 743 172.1 (Jan. 27, 2009).;;GB Search Report for GB 0428552.4 (Mar. 23, 2005).;;GB Search Report for GB 0428554.0 (Mar. 23, 2005).;;International Search Report for PCT/GB/2005/005097 (Apr. 4, 2006).;;GB Search Report for GB 0526607.7 (May 19, 2006).;;International Search Report for PCT/GB2006/004954 (Jun. 6, 2007).;;Essassi et al., Synthese et Hererocyclisation Des (Pyrazolyl-3-(5))-2 Benzimidazoles en Catalyse Par Transfert de Phase, Bull. Soc. Chim Belg. vol. 96, 1987, pp. 63-67.;;Mukherjee, S., The Emperor of All Maladies-A Biography of Cancer, 2010, p. 80.;;Damia et al., Contemporary pre-clinical development of anticancer agents-What are the optimal preclinical models?, Eur. J. Cancer, 2009, 45, pp. 2768-2781.;;Zhang et al., Targeting cancer with small molecule kinase inhibitors, Nature Rev. Cancer., 2009, 9, pp. 28-39.;;Fojo, www.esmo.org (2011).;;Boss et al., Clinical Experience with Aurora Kinase Inhibitors: A Review, The Oncologist, 2009, 14, pp. 780-793.;;Evans et al., Prognostic Factors in Neuroblastoma, Cancer, 1987, 59, pp. 1853-1859.",INACTIVE
399,CA,A1,CA 2425157 A1,053-865-756-042-696,2002-05-10,2002,CA 2425157 A,2001-10-30,US 69827000 A;;US 0142850 W,2000-10-30,WIDE FIELD SPHERICAL LENSES AND PROTECTIVE EYEWEAR,"The present invention relates to novel ophthalmic lens elements (402, 404) a nd eyewear (400) having wide field of view, low distortion, improved astigmatis m correction where required and enhanced eye protection properties. Series of lens elements have steeply curved spherical reference surfaces. The edged lenses of the series have approximately consistent aperture size, shape and hollow depth across a range of common prescriptions. Novel sunglasses, laser protection eyewear, and lens edgings, coatings, and frames are included in t he invention.",SOLA INTERNATIONAL INC,SPRATT RAY STEVEN;;PERROTT COLIN MAURICE;;EDWARDS SIMON J;;BEGLEY PARAIC;;BLACKER RICHARD;;ADAMS BRIAN;;MORRIS MICHAEL ALAN;;YIP BRANDON;;CARR DAVID LAWRENCE,,https://lens.org/053-865-756-042-696,Patent Application,no,0,0,14,50,0,G02C7/10;;G02C7/02,G02B1/11;;G02C7/02;;G02C7/10,,0,0,,,,DISCONTINUED
400,NZ,A,NZ 555982 A,013-569-334-546-555,2011-01-28,2011,NZ 55598205 A,2005-12-30,GB 0428554 A;;GB 0428552 A;;US 64059704 P;;US 64047504 P;;GB 2005005097 W,2004-12-30,"Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases","Disclosed are benzimidazole derivatives as represented by the general formula (III) and pharmaceutical salts thereof (particularly the acetate, mesylate, ethanesulphonate, DL-Iactate, adipate, D-glucuronate, D-gluconate and hydrochloride salts); wherein E is a bond; R2 is H; R1 is a cycloalkyl group of 3 to 6 ring members, or a group CR6R7R8; R6 and R7 are each methyl; and R8 is selected from hydrogen, and methyl. Of particular importance is the compound 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea. Also disclosed are processes for the preparation of the above compounds, as well as their crystalline forms. Further disclosed is a pharmaceutical composition or a lyophilised formulation for use in the treatment of leukemia and particularly cancers such as breast cancer, ovarian cancer, colon cancer, prostate cancer, oesophageal cancer, squamous cancer, and non-small cell lung carcinomas.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,,https://lens.org/013-569-334-546-555,Patent Application,no,0,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,C07D403/04;;A61K31/4155;;A61K31/4184;;A61P35/00;;C07D231/40;;C07D235/18;;C07D407/14;;C07D513/04,,0,0,,,,DISCONTINUED
401,ES,T3,ES 2780185 T3,026-922-984-570-887,2020-08-24,2020,ES 12813604 T,2012-12-06,US 201213348015 A;;US 2012/0068313 W,2012-01-11,Matriz de antenas de ranura larga respaldada por cavidad de perfil bajo con circuladores integrados,"Una matriz de elementos radiantes que comprende: una placa base (103) que tiene una superficie que comprende una pluralidad de muescas (114) que se extienden a lo ancho de la placa base (103), y una pluralidad de cavidades de circuladores (116) inmediatamente por debajo, y separadas a lo largo de cada una de la pluralidad de muescas (114) una pluralidad de tiras conductoras (108) colocadas en una pluralidad de filas en la placa base (103) en donde cada tira conductora (108) está instalada contra la placa base de tal manera que un borde superior de la tira conductora (108) esté nivelada con un borde inferior de una de la pluralidad de muescas (114), y para todas las tiras conductoras (108) excepto aquellas en una fila inferior de la pluralidad de filas, un borde inferior de la tira conductora (108) está nivelada con un borde superior de una muesca adyacente, de tal manera que las muescas (114) y los bordes de las tiras conductoras adyacentes (108) forman una pluralidad de ranuras (205), y una pluralidad de circuladores con sondas integradas (107), cada uno de los circuladores con sondas integradas (107) siendo coplanar con la placa base (103) y estando asegurado entre una de las tiras conductoras (108) y la placa base en una de la pluralidad de cavidades de circuladores, en donde los circuladores con sondas integradas son dispuestos de tal manera que cada una de las sondas (107) se proyecta en la adyacente de la pluralidad de ranuras (205).",RAYTHEON CO,YACCARINO ROBERT G;;CARR JAMES A;;SAUER ROHN;;DAVEIGA THOMAS C;;CROCKETT JOHN A;;BRADSHAW STEVEN E;;HADDEN JOHN M;;WALKER LONNY RICHARD,,https://lens.org/026-922-984-570-887,Granted Patent,no,0,0,6,6,0,H01P1/387;;H01P1/387;;H01Q3/26;;H01Q3/26;;H01Q13/10;;H01Q13/10;;H01Q21/065;;H01Q21/065,H01Q3/26;;H01P1/387;;H01Q13/10;;H01Q21/06,,0,0,,,,ACTIVE
402,NO,L,NO 20073926 L,081-820-349-968-025,2007-10-01,2007,NO 20073926 A,2007-07-26,GB 0428552 A;;GB 0428554 A;;US 64047504 P;;US 64059704 P;;GB 2005005097 W,2004-12-30,"Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser","Foreliggende oppfinnelse tilveiebringer en forbindelse med formel (I): eller et salt, solvat, tautomer eller N-oksid derav, hvori M er valgt fra en gruppe D1 og en gruppe D2: og R1, E, A og X er som definert i kravene. Også tilveiebrakt er farmasøytiske sammensetninger som inneholder forbindelsene, fremgangsmåter for fremstilling av forbindelsene og anvendelse av forbindelsene ved profylakse eller behandling av en sykdomstilstand mediert av en CDK kinase, GSK-3 kinase eller Aurora kinase.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;WYATT PAUL GRAHAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;REWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN,,https://lens.org/081-820-349-968-025,Abstract,no,0,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,A61K31/4184;;C07D403/04;;A61P35/00;;C07D487/04,,0,0,,,,DISCONTINUED
403,TW,B,TW I427077 B,111-155-882-660-909,2014-02-21,2014,TW 94147642 A,2005-12-30,GB 0428552 A;;GB 0428554 A;;US 64047504 P;;US 64059704 P,2004-12-30,Pyrazole compound and use thereof and pharmaceutical composition containing the same,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,,https://lens.org/111-155-882-660-909,Granted Patent,no,1,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,,,0,0,,,,INACTIVE
404,BR,A,BR 0115063 A,158-095-745-945-91X,2004-02-03,2004,BR 0115063 A,2001-10-30,US 69827000 A;;US 0142850 W,2000-10-30,Lentes esféricas de campo amplo e óculos protetor,"""LENTES ESFéRICAS DE CAMPO AMPLO E óCULOS PROTETOR"". A presente invenção se relaciona a elementos de lente oftálmica (402, 404) e óculos (400) inéditos que têm um campo de visão amplo, distorção baixa, correção aprimorada de astigmatismo quando necessário, e propriedades aprimoradas de proteção ocular. Séries de elementos de lente têm superfícies de referência esféricas acentuadamente curvas. As lentes cortadas das séries têm tamanho de abertura, forma e profundidade oca aproximadamente consistentes através de uma faixa de prescrições comuns. óculos de sol, óculos de proteção para laser inéditos, e cortes, revestimentos, e armações são incluídos na invenção.",SOLA INTERNATIONAL INC,MORRIS MICHAEL ALAN;;PERROTT COLIN MAURICE;;EDWARDS SIMON J;;SPRATT RAY STEVEN;;CARR DAVID LAWRENCE;;YIP BRANDON;;ADAMS BRIAN;;BEGLEY PARAIC;;BLACKER RICHARD,,https://lens.org/158-095-745-945-91X,Patent Application,no,0,0,14,50,0,G02C7/10;;G02C7/02,G02B1/11;;G02C7/02;;G02C7/10,,0,0,,,,DISCONTINUED
405,US,A1,US 2008/0132495 A1,114-268-188-895-089,2008-06-05,2008,US 81303105 A,2005-12-30,US 81303105 A;;GB 0428552 A;;GB 0428554 A;;US 64059704 P;;US 64047504 P;;GB 2005005097 W,2004-12-30,"Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases","The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R′, E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,ASTEX THERAPEUTICS LIMITED (2008-03-14),https://lens.org/114-268-188-895-089,Patent Application,yes,17,42,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,A61K31/4184;;A61K31/454;;A61K31/496;;A61K31/5377;;A61K31/541;;A61P35/00;;A61P35/02;;C07D231/38;;C07D401/14;;C07D403/14;;C07D413/02;;C07D413/14;;C07D417/14;;C07D487/14,514/228.2;;514/233.2;;514/234.5;;514/254.06;;514/322;;514/394;;544/115;;544/131;;544/133;;544/139;;544/140;;544/247;;544/370;;544/58.4;;546/199;;548/306.1;;548/372.5,0,0,,,,INACTIVE
406,MX,A,MX 2007008008 A,136-498-174-958-01X,2007-11-12,2007,MX 2007008008 A,2005-12-30,GB 0428552 A;;GB 0428554 A;;US 64047504 P;;US 64059704 P;;GB 2005005097 W,2004-12-30,"PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES.","The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R', E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WYATT PAUL GRAHAM;;REES DAVID CHARLES;;VINKOVIC MLADEN,,https://lens.org/136-498-174-958-01X,Patent Application,no,0,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,A61K31/4184;;C07D403/04;;A61P35/00;;C07D407/14;;C07D513/04,,0,0,,,,ACTIVE
407,KR,A,KR 20070094639 A,138-307-950-030-766,2007-09-20,2007,KR 20077017527 A,2005-12-30,GB 0428552 A;;GB 0428554 A;;US 64047504 P;;US 64059704 P;;GB 2005005097 W,2004-12-30,"PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES","The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R', E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,,https://lens.org/138-307-950-030-766,Patent Application,no,0,1,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,C07D413/14;;A61K31/4184;;A61P35/00;;C07D513/04,,0,0,,,,INACTIVE
408,TW,A,TW 200635918 A,025-302-596-341-579,2006-10-16,2006,TW 94147642 A,2005-12-30,GB 0428552 A;;GB 0428554 A;;US 64047504 P;;US 64059704 P,2004-12-30,Pharmaceutical compounds,"The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is seiected from a group D1 and a group D2: and R1, E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,,https://lens.org/025-302-596-341-579,Patent of Addition,no,0,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,,,0,0,,,,INACTIVE
409,CN,B,CN 101379058 B,123-561-876-885-705,2014-06-04,2014,CN 200580045026 A,2005-12-30,GB 2005005097 W;;GB 0428554 A;;GB 0428552 A;;US 64047504 P;;US 64059704 P,2004-12-30,"Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases",,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;WYATT PAUL GRAHAM;;NAVARRO EVA FIGUEROA;;VINKOVIC MLADEN;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;REES DAVID CHARLES;;CARR MARIA GRAZIA,,https://lens.org/123-561-876-885-705,Granted Patent,no,0,0,3,30,0,,C07D403/04;;A61K31/4184;;A61P35/00;;C07D407/14;;C07D513/04,,0,0,,,,INACTIVE
410,ZA,B,ZA 200704980 B,000-284-988-183-027,2009-01-28,2009,ZA 200704980 A,2005-12-30,GB 0428552 A,2004-12-30,"Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases",,ASTEX THERAPEUTICS LTD,VALERIO BERDINI;;GRAZIA CARR MARIA;;LIAM GILL ADRIAN;;STEVEN HOWARD;;FIGUEROA NAVARRO EVA;;GARY TREWARTHA;;CHARLES REES DAVID;;MLADEN VINKOVIC;;GRAHAM WYATT PAUL,,https://lens.org/000-284-988-183-027,Granted Patent,no,0,0,2,30,0,,A61K/;;A61P/;;C07D/,,0,0,,,,ACTIVE
411,US,B2,US 8110573 B2,085-564-995-894-003,2012-02-07,2012,US 81303105 A,2005-12-30,US 81303105 A;;GB 0428552 A;;GB 0428554 A;;US 64059704 P;;US 64047504 P;;GB 2005005097 W,2004-12-30,"Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases","The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R′, E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM;;ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,ASTEX THERAPEUTICS LIMITED (2008-03-14),https://lens.org/085-564-995-894-003,Granted Patent,yes,75,8,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,A61K31/535;;C07D413/14,514/234.5;;544/139,16,6,012-522-479-506-568;;041-999-952-766-040;;075-266-316-125-301;;150-531-382-227-747;;020-435-634-003-86X;;001-516-175-552-397,10.1002/bscb.19870960110;;6827558;;10.1021/jm00357a015;;10.1016/s0968-0896(01)00194-8;;11597481;;12482427;;10.1016/s0960-894x(02)00884-3;;10.1016/j.addr.2003.10.020;;14962582;;10.1016/s0169-409x(01)00097-7;;11325474,"Essassi et al.: Synthese et Hererocyclisation Des (Pyrazolyl-3-(5))-2 Benzimidazoles en Catalyse Par Transfert de Phase, Bull. Soc. Chim. Belg. vol. 96, pp. 63-67, 1987.;;Blankley et al.: Antihypertensive Activity of 6-Arylpyrido[2,3-d] Pyrimidim-7-Amine Derivatives. 2. 7-Acyl Amide Analogues, Journal of Medicinal Chemistry, vol. 26, No. 3, Mar. 1, 1983, pp. 403-411.;;Abd El-Wareth A O Sarhan et al.: Synthesis, Characterization and Reactions of 2-Deoxo-5- Deazaalloxazines, Bioorganic & Medicinal Chemistry, vol. 9, Jan. 1, 2001, pp. 2993-2998.;;Mesguiche et al.: 4-Alkoxy-2,6-Diaminopyrimidine Derivatives: Inhibitors of Cyclin Dependent Kinases 1 and 2, Bioorganic & Medicinal Chemistry Letters, vol. 13, Jan. 1, 2003, pp. 217-222.;;GB search report GB 0315657.7 filed Jul. 3, 2003.;;GB search report GB 0324919.0 filed Oct. 24, 2003.;;International Search Report PCT/GB2004/002824 filed Jul. 5, 2004.;;GB search report GB 0428552.4 filed Dec. 30, 2004.;;GB search report GB 0428554.0 filed Dec. 30, 2004.;;International Search Report PCT/GB2005/005097 filed Dec. 30, 2005.;;GB search report GB 0526607.7 filed Dec. 30, 2005.;;International Search Report PCT/GB2006/004954 filed Dec. 29, 2006.;;European Supplementary Search report EP Application No. 04 743 172.1 (Jan. 27, 2009).;;Morissette et al., ""High-Throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids"", Advanced Drug Delivery Reviews, 2004, 56, 275-300.;;Souillac et al., ""Characterization of Delivery Systems, Differential Scanning Calorimetry"", Encyclopedia of Controlled Drug Delivery, Wiley, 1999, 212-227.;;Vippagunta et al., ""Crystalline Solids"", Advanced Drug Delivery Reviews, 2001, 48, 3-26.",INACTIVE
412,WO,A8,WO 2006/070195 A8,117-596-287-851-702,2006-08-24,2006,GB 2005005097 W,2005-12-30,GB 0428554 A;;GB 0428552 A;;US 64059704 P;;US 64047504 P,2004-12-30,"PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES","The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R', E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",ASTEX THERAPEUTICS LTD;;BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,,https://lens.org/117-596-287-851-702,Patent Application,no,0,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,C07D403/04;;A61K31/4184;;A61P35/00;;C07D407/14;;C07D513/04,,0,0,,,,PENDING
413,EP,A1,EP 1330676 A1,042-212-026-448-937,2003-07-30,2003,EP 01981901 A,2001-10-30,US 0142850 W;;US 69827000 A,2000-10-30,WIDE FIELD SPHERICAL LENSES AND PROTECTIVE EYEWEAR,,SOLA INTERNATIONAL INC;;MORIS MICHAEL ALAN,MORRIS MICHAEL ALAN;;PERROTT COLIN MAURICE;;EDWARDS SIMON J;;SPRATT RAY STEVEN;;CARR DAVID LAWRENCE;;YIP BRANDON;;ADAMS BRIAN;;BEGLEY PARAIC;;BLACKER RICHARD,,https://lens.org/042-212-026-448-937,Patent Application,yes,0,0,14,50,0,G02C7/10;;G02C7/02,G02B1/11;;G02C7/02;;G02C7/10,,0,0,,,,DISCONTINUED
414,AU,B2,AU 2005/321091 B2,036-822-957-394-325,2012-04-12,2012,AU 2005/321091 A,2005-12-30,GB 0428552 A;;US 64047504 P;;US 64059704 P;;GB 0428554 A;;GB 2005005097 W,2004-12-30,"Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases","The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R', E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;NAVARRO EVA FIGUEROA;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM;;HOWARD STEVEN;;GILL ADRIAN LIAM;;REES DAVID CHARLES;;CARR MARIA GRAZIA;;TREWARTHA GARY,,https://lens.org/036-822-957-394-325,Granted Patent,no,1,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,C07D403/04;;A61K31/4184;;A61P35/00;;C07D407/14;;C07D513/04,,0,0,,,,INACTIVE
415,WO,A1,WO 2006/070195 A1,065-913-534-800-358,2006-07-06,2006,GB 2005005097 W,2005-12-30,GB 0428554 A;;GB 0428552 A;;US 64059704 P;;US 64047504 P,2004-12-30,"PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASIS","The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R&apos;, E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",ASTEX THERAPEUTICS LTD;;BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,,https://lens.org/065-913-534-800-358,Patent Application,yes,5,31,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,A61K31/4184;;C07D403/04;;A61P35/00;;C07D407/14;;C07D513/04,,0,0,,,,PENDING
416,US,A1,US 2012/0190673 A1,128-873-111-277-040,2012-07-26,2012,US 201113329952 A,2011-12-19,US 201113329952 A;;GB 0428552 A;;GB 0428554 A;;US 81303107 A;;GB 2005005097 W;;US 64059704 P;;US 64047504 P,2004-12-30,"PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES","The invention provides a compound of the formula (I): or a salt, solvate, tautomer or N-oxide thereof, wherein M is selected from a group D1 and a group D2: and R′, E, A and X are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM;;ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,ASTEX THERAPEUTICS LIMITED (2008-03-14),https://lens.org/128-873-111-277-040,Patent Application,no,0,3,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,A61K31/496;;A61K31/5377;;A61K31/541;;A61P35/00;;C07D231/38;;C07D403/14;;C07D413/12;;C07D413/14;;C07D417/14;;C07D487/14;;C07D513/04,514/228.2;;514/234.5;;514/254.06;;514/232.5;;544/140;;548/372.5;;544/115;;514/234.2;;544/247;;544/133;;544/139;;544/370;;544/80;;544/131;;544/58.4,2,2,041-703-940-947-068;;029-742-983-481-795,9544425;;10.1023/a:1005960822365;;10.1126/science.286.5439.531;;10521349,"Cancer and Metastasis Reviews (1998), 17(1), 91-106.;;Science (1999), Vol. 286, 531-537.",INACTIVE
417,AU,A,AU 2002/013512 A,102-799-597-346-424,2002-05-15,2002,AU 2002/013512 A,2001-10-30,US 69827000 A;;US 0142850 W,2000-10-30,Wide field spherical lenses and protective eyewear,,SOLA INTERNAT INC;;MORRIS MICHAEL ALAN,MORRIS MICHAEL ALAN;;PERROTT COLIN MAURICE;;EDWARDS SIMON J;;SPRATT RAY STEVEN;;CARR DAVID LAWRENCE;;YIP BRANDON;;ADAMS BRIAN;;BEGLEY PARAIC;;BLACKER RICHARD,,https://lens.org/102-799-597-346-424,Patent Application,no,0,0,14,50,0,G02C7/10;;G02C7/02,G02B1/11;;G02C7/02;;G02C7/10,,0,0,,,,EXPIRED
418,WO,A9,WO 2002/037169 A9,113-585-659-015-635,2003-01-30,2003,US 0142850 W,2001-10-30,US 69827000 A,2000-10-30,WIDE FIELD SPHERICAL LENSES AND PROTECTIVE EYEWEAR,"The present invention relates to novel ophthalmic lens elements (402, 404) and eyewear (400) having wide field of view, low distortion, improved astigmatism correction where required and enhanced eye protection properties. Series of lens elements have steeply curved spherical reference surfaces. The edged lenses of the series have approximately consistent aperture size, shape and hollow depth across a range of common prescriptions. Novel sunglasses, laser protection eyewear, and lens edgings, coatings, and frames are included in the invention.",SOLA INTERNATIONAL INC;;MORRIS MICHAEL ALAN;;PERROTT COLIN MAURICE;;EDWARDS SIMON J;;SPRATT RAY STEVEN;;CARR DAVID LAWRENCE;;YIP BRANDON;;ADAMS BRIAN;;BEGLEY PARAIC;;BLACKER RICHARD,MORRIS MICHAEL ALAN;;PERROTT COLIN MAURICE;;EDWARDS SIMON J;;SPRATT RAY STEVEN;;CARR DAVID LAWRENCE;;YIP BRANDON;;ADAMS BRIAN;;BEGLEY PARAIC;;BLACKER RICHARD,,https://lens.org/113-585-659-015-635,Patent Application,no,0,0,14,50,0,G02C7/10;;G02C7/02,G02B1/11;;G02C7/02;;G02C7/10,,0,0,,,,PATENTED
419,EP,A1,EP 2395000 A1,122-643-089-109-910,2011-12-14,2011,EP 11180160 A,2005-12-30,EP 05823721 A;;GB 0428554 A;;GB 0428552 A;;US 64059704 P;;US 64047504 P,2004-12-30,"Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases","The invention provides a compound of the formula (I):
  
or a salt, solvate, tautomer or N-oxide thereof, 
wherein M is selected from a group D1 and a group D2:
  
  
and R 1 , E, A and X are as defined above. 
Also provided are pharmaceutical compositions containing the compounds, processes for making the compounds and the use of the compounds in the prophylaxis or treatment of a disease state mediated by a CDK kinase, GSK-3 kinase or Aurora kinase.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;NAVARRO EVA FIGUEROA;;TREWARTHA GARY;;REES DAVID CHARLES;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM,,https://lens.org/122-643-089-109-910,Patent Application,yes,38,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,A61K31/4184;;C07D403/04;;A61P35/00;;C07D407/14;;C07D513/04,,91,70,012-865-156-438-120;;001-661-891-531-467;;015-505-100-135-710;;051-255-997-632-880;;005-521-719-112-587;;032-279-363-704-157;;076-063-985-570-716;;068-327-833-456-435;;075-952-199-923-063;;009-033-647-751-621;;025-624-292-641-902;;051-098-750-980-596;;040-343-674-829-495;;023-475-764-350-339;;029-901-810-393-557;;007-838-854-537-973;;001-226-923-460-944;;002-515-903-844-18X;;028-122-953-422-563;;086-390-749-652-665;;066-013-401-674-717;;004-960-787-208-757;;036-451-583-862-453;;007-838-854-537-973;;160-341-123-989-355;;029-901-810-393-557;;022-498-296-482-829;;160-341-123-989-355;;083-182-706-995-400;;060-784-743-188-505;;005-383-821-091-791;;077-883-857-250-339;;052-908-745-194-978;;016-694-431-273-124;;131-678-430-028-96X;;004-960-787-208-757;;163-047-050-941-781;;028-122-953-422-563;;023-656-951-495-886;;042-163-039-479-494;;086-272-744-175-380;;061-272-775-060-941;;007-364-858-655-289;;000-820-736-344-337;;126-811-728-740-254;;024-966-947-509-122;;012-875-860-136-424;;077-365-619-775-156;;004-137-705-827-976;;077-295-491-167-117;;046-777-072-258-96X;;007-378-255-811-868;;075-596-410-145-597;;075-596-410-145-597;;124-153-998-836-964;;056-848-802-620-026;;110-712-435-087-04X;;056-848-802-620-026;;011-674-727-534-32X;;011-690-957-905-798;;050-476-538-810-273;;021-634-052-025-91X;;013-322-445-914-037;;143-158-089-688-29X;;037-370-591-087-508;;000-724-265-079-185;;019-078-987-150-365;;009-760-608-802-570;;027-745-118-667-14X;;007-421-226-677-859,7768349;;0007768349;;10.1096/fasebj.9.8.7768349;;10.1126/science.1862342;;0001862342;;1862342;;1322797;;10.1016/0092-8674(92)90166-a;;10.1016/0092-8674(93)90144-f;;8387896;;pmc395100;;8194527;;10.1002/j.1460-2075.1994.tb06519.x;;10424746;;10.1038/sj.bjc.6690539;;pmc2363083;;8996076;;10.3322/canjclin.47.1.5;;11114313;;10.1056/nejm200012143432402;;10.1182/blood.v92.10.3804;;10.1182/blood.v92.10.3804.422k36_3804_3816;;9808574;;11166196;;10.1016/s0962-8924(00)01880-8;;11413462;;10.1038/35048096;;10.1023/a:1023789416385;;12884918;;13678575;;10.1016/s0092-8674(03)00685-8;;10.1016/s0092-8674(03)00642-1;;13678582;;9771714;;10.1038/2496;;10232583;;12019169;;pmc1871005;;7573366;;10.1093/jnci/94.17.1320;;12208897;;10.1093/emboj/17.11.3052;;9606188;;pmc1170645;;10.1111/j.1349-7006.2000.tb00878.x;;11050471;;pmc5926256;;12684414;;10.1054/bjoc.2000.1684;;11259099;;pmc2363814;;10232583;;10.1074/jbc.274.11.7334;;10066797;;9771714;;10.1038/2496;;10.1093/jnci/91.13.1160;;10393726;;10.1074/jbc.274.11.7334;;10066797;;10511710;;10.1016/s0962-8924(99)01658-x;;10523496;;10.1242/jcs.112.21.3591;;12214247;;10.1038/sj.onc.1205775;;10.1002/cncr.11879;;14692019;;14522886;;10.3892/or.10.5.1275;;12883693;;12716366;;10.1046/j.1365-2141.2003.04311.x;;12684414;;12631597;;10.1093/jnci/94.17.1320;;12208897;;10.1124/mi.3.3.127;;14993419;;10.1016/s1535-6108(02)00235-0;;12559175;;14981513;;10.1038/nm1003;;10.1038/sj.onc.1208752;;16049526;;10.1002/jps.2600660104;;833720;;10.1080/00397917709409270;;10.1002/anie.196603851;;9002452;;10.1021/js9601896;;10.1093/acprof:oso/9780199573653.001.0001;;10.1021/jo01351a600;;10.1016/s0040-4039(00)94371-5;;10.1002/0471220574;;15002962;;10.1021/cc034046a;;12739949;;10.1021/cc0201041;;10.1023/b:pham.0000016235.32639.23;;15032302;;10.1023/b:pham.0000016235.32639.23;;15032302;;10.1074/jbc.m313407200;;14701826;;10.1038/nature02313;;14999283;;10.1038/ng1220;;12881723;;10.1038/nature02313;;14999283;;12183400;;15271856;;10.1093/carcin/bgh244;;10.1016/0076-6879(87)52071-7;;3657592;;10.1385/1-59259-760-2:077;;15064486;;10733493;;10.1016/s1525-1578(10)60494-1;;15096562;;pmc1867470;;14633913;;10.1373/clinchem.2003.024695;;10667604;;7805863;;10.1016/0014-5793(94)01298-9;;10559988;;010559988;;10.1038/15674;;12501191;;10.1021/bi0268910;;9692848;;10.1016/s0022-1759(98)00028-3,"HARDIE, G., HANKS, S.: ""The Protein Kinase Facts Book."", vol. I, II, 1995, ACADEMIC PRESS;;HANKS, S.K., HUNTER, T., FASEB J, vol. 9, 1995, pages 576 - 596;;KNIGHTON ET AL., SCIENCE, vol. 253, 1991, pages 407 - 414;;HILES ET AL., CELL, vol. 70, 1992, pages 419 - 429;;KUNZ ET AL., CELL, vol. 73, 1993, pages 585 - 596;;GARCIA-BUSTOS ET AL., EMBO J, vol. 13, 1994, pages 2352 - 2361;;BR. J. CANCER, vol. 80, no. 9, July 1999 (1999-07-01), pages 1427 - 1434;;PARKER SL, TONG T, BOLDEN S, WINGO PA, CANCER STATISTICS, 1997. CA. CANCER. J. CLIN., vol. 47, 1997, pages 5;;RAI KR, PETERSON B, ELIAS L, SHEPHERD L, HINES J, NELSON D, CHESON B, KOLITZ J, SCHIFFER CA: ""A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB SWOG, CTG/NCI-C and ECOG Inter-Group Study"", BLOOD, vol. 88, no. 1, 1996, pages 141A;;BYRD JC. ET AL.: ""Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53"", BLOOD, vol. 92, no. 10, 15 November 1998 (1998-11-15), pages 3804 - 3816;;ADAMS ET AL., TRENDS CELL BIOL., vol. 11, 2001, pages 49 - 54;;E. A. NIGG, NAT. REV. MOL. CELL BIOL., vol. 2, 2001, pages 21 - 32;;KATAYAMA H, BRINKLEY WR, SEN S: ""The Aurora kinases: role in cell transformation and tumorigenesis"", CANCER METASTASIS REV., vol. 22, no. 4, December 2003 (2003-12-01), pages 451 - 464, XP009022607, DOI: doi:10.1023/A:1023789416385;;PRIGENT ET AL., CELL, vol. 114, 2003, pages 531 - 535;;HIROTA ET AL., CELL, vol. 114, 2003, pages 585 - 598;;GIET ET AL., J CELL. SCI., vol. 112, 1999, pages 3591 - 3610;;ZHOU ET AL., NAT. GENET., vol. 20, 1998, pages 189 - 193;;TANAKA ET AL., CANCER RES., vol. 59, 1999, pages 2041 - 2044;;HAN ET AL., CANCER RES., vol. 62, 2002, pages 2890 - 2896;;ISOLA, AMERICAN JOURNAL OF PATHOLOGY, vol. 147, 1995, pages 905 - 911;;SEN ET AL., J NATL.CANCER INST, vol. 94, 2002, pages 1320 - 1329;;BISCHOFF ET AL., EMBO J., vol. 17, 1998, pages 3052 - 3065;;TAKAHASHI ET AL., JPN. J CANCER RES., vol. 91, 2000, pages 1007 - 1014;;GRITSKO ET AL., CLIN. CANCER RES., vol. 9, 2003, pages 1420 - 1426;;SAKAKUR ET AL., BRITISH JOURNAL OF CANCER, vol. 84, 2001, pages 824 - 831;;TANAKA ET AL., CANCER RESEARCH, vol. 59, 1999, pages 2041 - 2044;;KIMURA ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 7334 - 7340;;ZHOU ET AL., NATURE GENETICS, vol. 20, 1998, pages 189 - 193;;LI ET AL., CLIN CANCER RES., vol. 9, no. 3, 2003, pages 991 - 997;;KATAYAMA ET AL., GENE, vol. 244, pages 1 - 7;;KATAYAMA ET AL., J. NATL CANCER INST., vol. 91, 1999, pages 1160 - 1162;;KIMURA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 7334 - 7340;;TAKAHASHI ET AL., JPN J CANCER RES., vol. 91, 2001, pages 1007 - 1014;;BISCHOFF ET AL., TRENDS IN CELL BIOLOGY, vol. 9, 1999, pages 454 - 459;;GIET ET AL., JOURNAL OF CELL SCIENCE, vol. 112, 1999, pages 3591 - 3601;;DUTERTRE ET AL., ONCOGENE, vol. 21, 2002, pages 6175 - 6183;;ROYCE ME,ET AL.: ""STK15/Aurora-A expression in primary breast tumours is correlated with nuclear grade but not with prognosis"", CANCER, vol. 100, no. 1, 1 January 2004 (2004-01-01), pages 12 - 19;;MORENO-BUENO G, ET AL., CANCER RES., vol. 63, no. 18, 15 September 2003 (2003-09-15), pages 5697 - 5702;;REICHARDT ET AL., ONCOL REP., vol. 10, no. 5, September 2003 (2003-09-01), pages 1275 - 1279;;HAMADA ET AL., BR. J HAEMATOL., vol. 121, no. 3, May 2003 (2003-05-01), pages 439 - 447;;GRITSKO ET AL., CLIN CANCER RES., vol. 9, no. 4, April 2003 (2003-04-01), pages 1420 - 1426;;LI ET AL., CLIN. CANCER RES., vol. 9, no. 3, March 2003 (2003-03-01), pages 991 - 997;;J NATL. CANCER INST., vol. 94, no. 17, 4 September 2002 (2002-09-04), pages 1320 - 1329;;DUTERTRE S. AND PRIGENT C.: ""Aurora-A overexpression leads to override of the microtubule-kinetochore attachment checkpoint"", MOL. INTERV., vol. 3, no. 3, May 2003 (2003-05-01), pages 127 - 130;;ANAND S, PENRHYN-LOWE S, VENKITARAMAN AR.: ""Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol"", CANCER CELL, vol. 3, no. 1, January 2003 (2003-01-01), pages 51 - 62, XP009026392, DOI: doi:10.1016/S1535-6108(02)00235-0;;HARRINGTON ET AL., NAT MED., vol. 10, no. 3, March 2004 (2004-03-01), pages 262 - 267;;ANDREWS, ONCOGENE, vol. 24, 2005, pages 5005 - 5015;;""Pharmaceutical Salts: Properties, Selection, and Use"", August 2002, pages: 388;;BERGE ET AL.: ""Pharmaceutically Acceptable Salts"", J PHARM. SCI., vol. 66, 1977, pages 1 - 19;;JERRY MARCH: ""Advanced Organic Chemistry"", WILEY INTERSCIENCE;;L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514;;JERRY MARCH: ""Advanced Organic Chemistry"", 1992, JOHN WILEY & SONS, pages: 109 - 114;;CAHN, INGOLD, PRELOG, ANGEW. CHEM. INT. ED ENGL., vol. 5, 1966, pages 385 - 415;;""Pharmaceutical Salts: Properties, Selection, and Use"", August 2002, HARDCOVER, pages: 388;;HANCOCK ET AL., J PHARM. SCI., vol. 86, 1997, pages 1;;C. GIACOVAZZO, H. L. MONACO, D. VITERBO, F. SCORDARI, G. GILLI, G. ZANOTTI, M. CATTI: ""Fundamentals of Crystallography"", 1992, OXFORD UNIVERSITY PRESS;;HALL, ALLEN, BROWN, ACTA CRYST., vol. A47, 1991, pages 655 - 685, Retrieved from the Internet <URL:http://www.iucr.ac.uk/iucr-top/cif/home.html>;;RON JENKINS, ROBERT L. SNYDER: ""Introduction to X-ray Powder Diffraction"", 1996, JOHN WILEY & SONS;;SHEEHAN ET AL., J AMER. CHEM SOC., vol. 77, 1955, pages 1067;;SHEEHAN ET AL., J ORG. CHEM., vol. 26, 1961, pages 2525;;L. A. CARPINO, J AMER. CHEM. SOC., vol. 115, 1993, pages 4397;;CASTRO ET AL., TETRAHEDRON LETTERS, vol. 31, 1990, pages 205;;KONIG, CHEM. BER., vol. 103, no. 708, pages 2024 - 2034;;T. GREEN, P. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY AND SONS;;ROSENTRETER U, HUBER U.: ""Optimal fraction collecting in preparative LC/MS"", J COMB CHEM., vol. 6, no. 2, 2004, pages 159 - 164;;LEISTER W, STRAUSS K, WISNOSKI D, ZHAO Z, LINDSLEY C.: ""Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries"", J COMB CHEM., vol. 5, no. 3, 2003, pages 322 - 329, XP001198955, DOI: doi:10.1021/cc0201041;;P. HEINRICH STAHL ET AL.: ""Handbook of Pharmaceutical Salts: Properties, Selection, and Use"", WILEY-VCH;;""Crystallization Technology Handbook"", 2001;;R. G. STRICKLY: ""Solubilizing Excipients in oral and injectable formulations"", PHARMACEUTICAL RESEARCH, vol. 21, no. 2, 2004, pages 201 - 230;;""Solubilizing excipients in oral and injectable formulations"", PHARMACEUTICAL RESEARCH, vol. 21, no. 2, 2004, pages 201 - 230;;""Remington's Pharmaceutical Sciences"", MACK PUBLISHING COMPANY;;HARWELL RM, MULL BB, PORTER DC, KEYOMARSI K., J BIOL CHEM., vol. 279, no. 13, 26 March 2004 (2004-03-26), pages 12695 - 12705;;RAJAGOPALAN H, JALLEPALLI PV, RAGO C, VELCULESCU VE, KINZLER KW, VOGELSTEIN B, LENGAUER C., NATURE, vol. 428, no. 6978, 4 March 2004 (2004-03-04), pages 77 - 81;;EWART-TOLAND ET AL., NAT GENET., vol. 34, no. 4, August 2003 (2003-08-01), pages 403 - 412;;RAJAGOPALAN ET AL., NATURE, vol. 428, no. 6978, 4 March 2004 (2004-03-04), pages 77 - 81;;SPRUCK ET AL., CANCER RES., vol. 62, no. 16, 15 August 2002 (2002-08-15), pages 4535 - 4539;;SUN ET AL., CARCINOGENESIS, vol. 25, no. 11, 2004, pages 2225 - 2230;;""Current Protocols in Molecular Biology"", 2004, JOHN WILEY & SONS INC.;;""PCR Protocols: a guide to methods and applications"", 1990, ACADEMIC PRESS;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;ANGERER, METH. ENZYMOL., vol. 152, 1987, pages 649;;""Current Protocols in Molecular Biology"", 2004, JOHN WILEY & SONS INC;;JOHN M. S. BARTLETT: ""Molecular Diagnosis of Cancer, Methods and Protocols"", March 2004, article ""Fluorescence In Situ Hybridization: Technical Overview"", pages: 077 - 088;;YATABE ET AL., BLOOD, vol. 95, no. 7, 1 April 2000 (2000-04-01), pages 2253 - 2261;;JONES ET AL., J MOL DIAGN., vol. 6, no. 2, May 2004 (2004-05-01), pages 84 - 89;;HOWE ET AL., CLIN CHEM., vol. 50, no. 1, January 2004 (2004-01-01), pages 80 - 87;;HARWELL ET AL., CANCER RES, vol. 60, 2000, pages 481 - 489;;HELLMICH ET AL., FEBS LETT, vol. 356, 1994, pages 317 - 321;;BROWN ET AL., NAT. CELL BIOL., vol. 1, 1999, pages 438 - 443;;LOWE, E.D. ET AL., BIOCHEMISTRY, vol. 41, 2002, pages 15625 - 15634;;NOCIARI, M. M, SHALEV, A., BENIAS, P., RUSSO, C., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 213, 1998, pages 157 - 167",DISCONTINUED
420,EP,B1,EP 2803111 B1,050-896-041-141-132,2020-01-22,2020,EP 12813604 A,2012-12-06,US 201213348015 A;;US 2012/0068313 W,2012-01-11,LOW PROFILE CAVITY BACKED LONG SLOT ARRAY ANTENNA WITH INTEGRATED CIRCULATORS,,RAYTHEON CO,YACCARINO ROBERT G;;CARR JAMES A;;SAUER ROHN;;DAVEIGA THOMAS C;;CROCKETT JOHN A JR;;BRADSHAW STEVEN E;;HADDEN JOHN M;;WALKER LONNY RICHARD,,https://lens.org/050-896-041-141-132,Granted Patent,yes,8,0,6,6,0,H01P1/387;;H01Q3/26;;H01Q13/10;;H01Q21/065;;H01P1/387;;H01Q13/10;;H01Q21/065;;H01Q3/26,H01Q3/26;;H01P1/387;;H01Q13/10;;H01Q21/06,,0,0,,,,ACTIVE
421,US,A1,US 2005/0031781 A1,048-746-056-465-185,2005-02-10,2005,US 63388803 A,2003-08-04,US 63388803 A,2003-08-04,"Aluminizing slurry compositions free of hexavalent chromium, and related methods and articles","A slurry coating composition is described, which is very useful for enriching the surface region of a metal-based substrate with aluminum. The composition includes colloidal silica and particles of an aluminum-based powder, and is substantially free of hexavalent chromium. The slurry may include colloidal silica and an alloy of aluminum and silicon. Alternatively, the slurry includes colloidal silica, aluminum or aluminum-silicon, and an organic stabilizer such as glycerol. The slurry exhibits good thermal and chemical stability for extended periods of time, making it very useful for industrial applications. Related methods and articles are also described.",KOOL LAWRENCE BERNARD;;GIGLIOTTI MICHAEL FRANCIS;;RUTKOWSKI STEPHEN FRANCIS;;SVEC PAUL STEVEN;;KOGAN ANATOLI;;DIDOMIZIO RICHARD;;NOEL BRIAN STEPHEN;;CARR DAVID;;THOMPSON WILLIAM RANDALL,KOOL LAWRENCE BERNARD;;GIGLIOTTI MICHAEL FRANCIS;;RUTKOWSKI STEPHEN FRANCIS;;SVEC PAUL STEVEN;;KOGAN ANATOLI;;DIDOMIZIO RICHARD;;NOEL BRIAN STEPHEN;;CARR DAVID;;THOMPSON WILLIAM RANDALL,GENERAL ELECTRIC COMPANY (2003-08-19),https://lens.org/048-746-056-465-185,Patent Application,yes,5,22,8,11,0,C23C10/18;;C23C10/30;;Y10T428/12063;;Y10T428/1275;;Y10T428/12063;;Y10T428/1275;;C23C10/30;;C23C10/18,C09D1/00;;F01D5/28;;C09D5/10;;C09D7/12;;C09D17/00;;C23C10/18;;C23C10/30;;C23C24/08;;F02C7/00,42724;;428/652;;428/553;;416/241;;427/421.1;;427/429;;427/430.1;;427/428.01,0,0,,,,EXPIRED
422,US,B1,US 6682193 B1,172-640-862-642-967,2004-01-27,2004,US 69827000 A,2000-10-30,US 69827000 A;;AU 1929/099010 W;;US 65849600 A;;US 22300698 A,1998-12-30,Wide field spherical lenses and protective eyewear,"
    The present invention relates to novel ophthalmic lens elements and eyewear having wide field of view, low distortion, improved astigmatism correction where required and enhanced eye protection properties. Series of lens elements have steeply curved spherical reference surfaces. The edged lenses of the series have approximately consistent aperture size, shape and hollow depth across a range of common prescriptions. Novel sunglasses, laser protective eyewear, and lens edgings, coatings and frames are included in the invention. 
",SOLA INT HOLDINGS,MORRIS MICHAEL ALAN;;PERROTT COLIN MAURICE;;EDWARDS SIMON J;;SPRATT RAY STEVEN;;CARR DAVID LAWRENCE;;YIP BRANDON;;ADAMS BRIAN;;BEGLEY PARAIC;;BLACKER RICHARD SIMON,CARL ZEISS VISION AUSTRALIA HOLDINGS LTD (2006-07-10);;SOLA INTERNATIONAL HOLDING LTD (2000-11-15),https://lens.org/172-640-862-642-967,Granted Patent,yes,101,16,3,50,0,B29D11/00009;;B29D11/00009;;B29C45/561;;B29C45/561;;B29L2011/0016;;B29L2011/0016;;G02C7/02;;G02C7/02,B29C45/56;;B29D11/00;;G02C7/02,351/163;;351/44;;351/158;;351/159;;351/174,11,1,044-739-393-092-331,10.21236/ada234592,"M. Jalie, The Principles of Ophthalmic Lenses, 1994, pp. 1-27, 30-33, 151-152, 422-441, and 462-468 (publisher: The Association of British Dispensing Opticians).;;H.A. Macleod, Thin-Film Optical Filters, 1969, pp. 230-233,314-357 (publishers: McGraw-Hill Publishing Company and IOP Publishing Ltd.).;;Jeffrey M. Kingsbury, et al., Process for Molding Thermoplastic Lenses and, Steeply Curved and/or Thin Lenses Produced Thereby, copending patent application Ser. No. 09/658,496 filed Sep. 8, 2000.;;Jeffrey M. Kingsbury, et al., Molding Method for Manufacturing Thin Thermoplastic Lenses, copending patent application Ser. No. 09/277,035 filed Mar. 25, 1999.;;Greenhouse Grown Products, Inc.; Whatever Your Passion . . . ; Flyer (C)2000/2001.;;J. K. Crosley et al.; Visual and Field-of-View Evaluation of the M-43 Protective Mask with Prescription Eyepieces; U.S. Army Aeromedical Research Laboratory (USAARL) Report No. 91-13; Mar. 1991; cover and pp. 4-5.;;R. M. Wildzunas et al.; Visual Performance Effects and User Acceptance of the M43A1 Aviation Protective Mask Frontserts; U.S. Army Aeromedical Research Laboratory (USAARL) Report No. 96-07; Jan. 1996; cover and p. 1137.;;R. R. Levine et al.; Visual Performance of Contact Lens-Corrected Ametropic Aviators with the M-43 Protective Mask; U.S. Army Aeromedical Research laboratory (USAARL) Report No. 90-12; May 1990; cover and p. 5.;;Material at http://www.ilcdover.com/products/CBSysMasks/M43.htm and two photographs, 1996 (the Writting Pages Provided).;;N. R. Brletich et al.,; Worldwide NBC Mask Handbook; Defense Technical Information Center, Alexandria, VA; Sep. 1992; first three cover pages and pp. 389-393.;;Photographs and drawings of the ""Apache Helicopter"" lenses as described in the Supplemental Information Disclosure Statement, 1985.",EXPIRED
423,EP,A2,EP 0255256 A2,078-431-958-874-22X,1988-02-03,1988,EP 87306193 A,1987-07-14,US 89202786 A,1986-07-30,Antibiotics produced by actinomadura parvosata.,"This invention relates to a new microorganism Actinomadura parvosata. This invention also relates to a new glycopeptide antibiotic and its biologically functional components and derivatives produced by this new mlcro- organism, to the processes for the preparation thereof, and to pharmaceutical compositions containing the antibiotic or its bioactive components or derivatives. This invention further relates to animal feed premixes and compositions containing the antibiotic or its bioactive components or derivatives and to a process for enhancing feed utilization efficiency and promoting growth in animals.",SMITHKLINE BECKMAN CORP,CARR STEVEN ALFRED;;MUELLER LUCIANO;;SHEARER MARCIA CATHRINE;;CHRISTENSEN IV SIEGFRIED BENJA;;NISBET LOUIS JOSEPH;;SITRIN ROBERT DAVID;;JEFFS PETER WALTER;;ROBERTS GERALD D,,https://lens.org/078-431-958-874-22X,Patent Application,yes,0,4,10,10,0,C07K9/008;;C12N1/00;;C12N1/205;;C12R2001/03,C12N1/20;;A61K35/74;;C07K7/64;;C07K9/00;;C07K14/195;;C07K14/41;;C12P21/02;;C12P21/04,,0,0,,,,DISCONTINUED
424,CN,A,CN 116323665 A,081-860-542-508-465,2023-06-23,2023,CN 202180038994 A,2021-05-28,US 202063032508 P;;US 2021/0034852 W,2020-05-29,Anti-CD200R1 antibodies and methods of use thereof,"The present disclosure provides binding proteins, such as antibodies and antigen binding fragments, that specifically bind to the human CD200R1 receptor protein (hu-CD200R1) and are capable of reducing, inhibiting and/or completely blocking immunomodulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using antibodies (and compositions thereof) to treat diseases and conditions responsive to reducing, inhibiting, and/or blocking immunomodulatory function or activity mediated by binding of CD200 to CD200R1.",23 & ME INC,CHEN YAN;;FENNO JAMES B;;FOO-KELLY GRAHAM;;HUANG YI-MIN;;CHUNG WEI-JUNG;;CARR ERIC E;;RAE CHRIS;;PITTS STEVEN J;;SHOFF LAETITIA,,https://lens.org/081-860-542-508-465,Patent Application,no,0,0,20,20,0,C07K16/2803;;C07K2317/92;;A61K2039/505;;C07K2317/76;;A61K2039/572;;C07K2317/24;;A61P35/00;;C07K2317/94;;C07K2317/73;;C07K2317/35;;C07K2317/33;;A61K2039/54;;A61K2039/545;;C07K16/2803;;C07K2317/24;;A61P35/00;;C07K2317/76;;C07K2317/33;;A61K2039/54;;C07K2317/34;;A61K2039/572;;A61K2039/505;;C07K2317/94;;C07K2317/73;;C07K2317/92;;C07K2317/35;;A61K2039/545;;C07K16/2803;;A61P35/00;;A61K2039/505;;A61K2039/54;;A61K2039/545;;A61K2039/572;;C07K2317/73;;C07K2317/94;;C07K2317/76;;C07K2317/92;;C07K2317/33;;C07K2317/34;;C07K2317/24;;A61P35/00;;A61K2039/505;;C07K16/2803;;C07K2317/34;;C07K2317/76;;C07K2317/92,C07K16/28;;A61K39/395;;A61K45/06;;A61P35/00;;A61P35/02;;C12N5/10;;C12N15/13;;C12N15/85;;C12P21/00,,0,0,,,,PENDING
425,EP,A1,EP 2803111 A1,107-094-728-155-399,2014-11-19,2014,EP 12813604 A,2012-12-06,US 201213348015 A;;US 2012/0068313 W,2012-01-11,LOW PROFILE CAVITY BACKED LONG SLOT ARRAY ANTENNA WITH INTEGRATED CIRCULATORS,,RAYTHEON CO,YACCARINO ROBERT G;;CARR JAMES A;;SAUER ROHN;;DAVEIGA THOMAS C;;CROCKETT JOHN A JR;;BRADSHAW STEVEN E;;HADDEN JOHN M;;WALKER LONNY RICHARD,,https://lens.org/107-094-728-155-399,Patent Application,yes,0,1,6,6,0,H01P1/387;;H01P1/387;;H01Q3/26;;H01Q3/26;;H01Q13/10;;H01Q13/10;;H01Q21/065;;H01Q21/065,H01P1/387;;H01P5/107;;H01Q3/26;;H01Q13/10;;H01Q21/06,,1,0,,,See references of WO 2013106144A1,ACTIVE
426,DK,A,DK 363587 A,006-840-076-272-708,1988-01-31,1988,DK 363587 A,1987-07-13,US 89202786 A,1986-07-30,ANTIBIOTIKA OG FREMSTILLING HERAF UNDER ANVENDELSEAF ACTINOMADURA PARVOSATA,,SMITHKLINE BECKMAN CORP,CARR STEVEN ALFRED;;CHRISTENSEN IV SIEGFRIED BENJA;;JEFFS PETER WALTER;;MUELLER LUCIANO;;NISBET LOUIS JOSEPH;;ROBERTS GERALD D;;SHEARER MARCIA CATHRINE;;SITRIN ROBERT DAVID,,https://lens.org/006-840-076-272-708,Patent Application,no,0,0,10,10,0,C07K9/008;;C12N1/00;;C12N1/205;;C12R2001/03,C12N1/20;;A61K35/74;;C07K7/64;;C07K9/00;;C07K14/195;;C07K14/41;;C12P21/02;;C12P21/04,,0,0,,,,DISCONTINUED
427,DK,D0,DK 363587 D0,039-046-631-658-802,1987-07-13,1987,DK 363587 A,1987-07-13,US 89202786 A,1986-07-30,ANTIBIOTIKA OG FREMSTILLING HERAF UNDER ANVENDELSEAF ACTINOMADURA PARVOSATA,,SMITHKLINE BECKMAN CORP,CARR STEVEN ALFRED;;CHRISTENSEN IV SIEGFRIED BENJA;;JEFFS PETER WALTER;;MUELLER LUCIANO;;NISBET LOUIS JOSEPH;;ROBERTS GERALD D;;SHEARER MARCIA CATHRINE;;SITRIN ROBERT DAVID,,https://lens.org/039-046-631-658-802,Patent Application,no,0,0,10,10,0,C07K9/008;;C12N1/00;;C12N1/205;;C12R2001/03,C12N1/20;;A61K35/74;;C07K7/64;;C07K9/00;;C07K14/195;;C07K14/41;;C12P21/02;;C12P21/04,,0,0,,,,DISCONTINUED
428,BR,A2,BR PI0519759 A2,153-947-329-698-556,2009-03-10,2009,BR PI0519759 A,2005-12-30,GB 0428554 A;;GB 0428552 A;;US 64059704 P;;US 64047504 P;;GB 2005005097 W,2004-12-30,composiÇÕes farmacÊuticas,"COMPOSIÇÕES FARMACÊUTICAS. A invenção fornece um composto da fórmula (I): ou um sal, solvato, tautômero ou N-óxido deste, em que M é selecionado de um grupo D1 e um grupo D2: em que R¹, E, A e X são tais como definidos nas reivindicações. São também fornecidas composições farmacêuticas que contêm os compostos, processos para a produção dos compostos e o emprego dos compostos na profilaxia ou tratamento de um estado de doença mediado por uma cinase CDK, cinase GSK-3 ou Aurora cinase.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;GILL ADRIAN LIAM;;HOWARD STEVEN J;;TREWARTHA GARY;;VINKOVIC MLADEN;;WYATT PAUL GRAHAM;;FIGUEROA NAVARRO EVA;;REES DAVID CHARLES,,https://lens.org/153-947-329-698-556,Patent Application,no,0,0,25,30,0,C07D401/14;;C07D403/04;;C07D403/14;;C07D405/14;;C07D407/14;;C07D413/14;;C07D487/04;;C07D513/04;;A61P35/00;;A61P35/02;;A61P43/00;;C07D413/14;;C07D513/04;;A61K31/4184;;C07D401/14;;C07D513/04;;C07D403/04;;C07D413/14;;C07D487/04;;C07D403/14;;C07D407/14;;C07D405/14,C07D403/04;;A61K31/4184;;A61P35/00;;C07D407/14;;C07D513/04,,0,0,,,,DISCONTINUED
429,AU,A1,AU 2007/203670 A1,061-394-359-713-830,2007-08-23,2007,AU 2007/203670 A,2007-08-03,AU 2002/213512 A;;US 69827000 A,2000-10-30,Wide field spherical lenses and protective eyewear,,SOLA INT INC,BLACKER RICHARD SIMON;;BEGLEY PARAIC;;PERROTT COLIN MAURICE;;SPRATT RAY STEVEN;;YIP BRANDON;;MORRIS MICHAEL ALAN;;ADAMS BRIAN;;CARR DAVID LAWRENCE;;EDWARDS SIMON JOHN,,https://lens.org/061-394-359-713-830,Patent Application,no,0,1,14,50,0,G02C7/10;;G02C7/02,G02C7/02;;G02B1/11;;G02C7/10,,0,0,,,,DISCONTINUED
430,WO,A1,WO 2013/106144 A1,155-501-161-353-103,2013-07-18,2013,US 2012/0068313 W,2012-12-06,US 201213348015 A,2012-01-11,LOW PROFILE CAVITY BACKED LONG SLOT ARRAY ANTENNA WITH INTEGRATED CIRCULATORS,"The present invention relates to active electronically scanned array antennas. A thin, low cost design is provided by coupling electromagnetic energy into periodically driven long slots (205) using circulators with integrated probes (107). The long slots (205) are formed as grooves (114) in a conductive base plate (103), each groove (114) bracketed on both sides by conductive strips (108). The circulators with integrated probes (107) are installed between the conductive strips (108) and the base plate (103), to reduce fabrication costs of the machined parts and to facilitate the making of connections between the circulators and the antenna electronics. The probes (128) protrude partway into the slots (205) and provide coupling to waves propagating in free space.",RAYTHEON CO,YACCARINO ROBERT G;;CARR JAMES A;;SAUER ROHN;;DAVEIGA THOMAS C;;CROCKETT JOHN A JR;;BRADSHAW STEVEN E;;HADDEN JOHN M;;WALKER LONNY RICHARD,,https://lens.org/155-501-161-353-103,Patent Application,yes,12,0,6,6,0,H01P1/387;;H01Q3/26;;H01Q13/10;;H01Q21/065;;H01P1/387;;H01Q13/10;;H01Q21/065;;H01Q3/26,H01P1/387;;H01P5/107;;H01Q3/26;;H01Q13/10;;H01Q21/06,,0,0,,,,PENDING
431,PT,A,PT 85322 A,075-202-427-880-622,1987-08-01,1987,PT 8532287 A,1987-07-14,US 89202786 A,1986-07-30,ANTIBIOTICS PRODUCED BY ACTINOMADURA PARVOSATA,,SMITHKLINE BECKMAN CORP,CARR STEVEN ALFRED;;IV SIEGFRIED BENJAMIN CHRISTEN;;JEFFS PETER WALTER;;MUELLER LUCIANO;;ROBERTS GERALD D;;SHEARER MARCIA CATHERINE;;SITRIN ROBERT DAVID;;NISBET LOUIS JOSEPH,,https://lens.org/075-202-427-880-622,Patent Application,no,0,0,10,10,0,C07K9/008;;C12N1/00;;C12N1/205;;C12R2001/03,C12N1/20;;A61K35/74;;C07K7/64;;C07K9/00;;C07K14/195;;C07K14/41;;C12P21/02;;C12P21/04,,0,0,,,,EXPIRED
432,AU,A,AU 1987/075776 A,152-275-108-224-474,1988-02-04,1988,AU 1987/075776 A,1987-07-17,US 89202786 A,1986-07-30,GLYCOPEPTIDE ANTIBIOTICS FROM ACTINOMADURA PARVOSATA,,SMITHKLINE BECKMAN CORP,CARR STEVEN ALFRED;;MUELLER LUCIANO;;NISBET LOUIS JOSEPH;;ROBERTS GERALD D;;SHEARER MARCIA CATHRINE;;SITRIN ROBERT DAVID;;IV SIEGFRIED BENJAMIN CHRISTEN;;JEFFS PETER WALTER,,https://lens.org/152-275-108-224-474,Patent Application,no,0,0,10,10,0,C07K9/008;;C12N1/00;;C12N1/205;;C12R2001/03,C12N1/20;;A61K35/74;;C07K7/64;;C07K9/00;;C07K14/195;;C07K14/41;;C12P21/02;;C12P21/04,,0,0,,,,DISCONTINUED
433,PT,B,PT 85322 B,003-016-842-771-326,1989-10-09,1989,PT 8532287 A,1987-07-14,US 89202786 A,1986-07-30,ANTIBIOTICS PRODUCED BY ACTINOMADURA PARVOSATA,,SMITHKLINE BECKMAN CORP,CARR STEVEN ALFRED;;IV SIEGFRIED BENJAMIN CHRISTEN;;JEFFS PETER WALTER;;MUELLER LUCIANO;;ROBERTS GERALD D;;SHEARER MARCIA CATHERINE;;SITRIN ROBERT DAVID;;NISBET LOUIS JOSEPH,,https://lens.org/003-016-842-771-326,Granted Patent,no,0,0,10,10,0,C07K9/008;;C12N1/00;;C12N1/205;;C12R2001/03,C12N1/20;;A61K35/74;;C07K7/64;;C07K9/00;;C07K14/195;;C07K14/41;;C12P21/02;;C12P21/04,,0,0,,,,EXPIRED
434,EP,A3,EP 0255256 A3,039-058-952-515-739,1988-07-27,1988,EP 87306193 A,1987-07-14,US 89202786 A,1986-07-30,ANTIBIOTICS PRODUCED BY ACTINOMADURA PARVOSATA,"This invention relates to a new microorganism Actinomadura parvosata. This invention also relates to a new glycopeptide antibiotic and its biologically functional components and derivatives produced by this new mlcro- organism, to the processes for the preparation thereof, and to pharmaceutical compositions containing the antibiotic or its bioactive components or derivatives. This invention further relates to animal feed premixes and compositions containing the antibiotic or its bioactive components or derivatives and to a process for enhancing feed utilization efficiency and promoting growth in animals.",SMITHKLINE BECKMAN CORPORATION,"CARR, STEVEN ALFRED;;MUELLER, LUCIANO;;SHEARER, MARCIA CATHRINE;;CHRISTENSEN IV, SIEGFRIED BENJAMIN;;NISBET, LOUIS JOSEPH;;SITRIN, ROBERT DAVID;;JEFFS, PETER WALTER;;ROBERTS, GERALD D.",,https://lens.org/039-058-952-515-739,Search Report,yes,5,0,10,10,0,C07K9/008;;C12N1/00;;C12N1/205;;C12R2001/03,C12N1/20;;A61K35/74;;C07K7/64;;C07K9/00;;C07K14/195;;C07K14/41;;C12P21/02;;C12P21/04,,1,0,,,"THE CHEMISTRY OF THE AMINO GROUP, 1968, page 114, Interscience Publishers a Division of John Wiley & Sons, London, GB; ""The N-C bond""",DISCONTINUED
435,US,B2,US 8717243 B2,146-298-675-696-907,2014-05-06,2014,US 201213348015 A,2012-01-11,US 201213348015 A,2012-01-11,Low profile cavity backed long slot array antenna with integrated circulators,"The present invention relates to active electronically scanned array antennas. A thin, low cost design is provided by coupling electromagnetic energy into periodically driven long slots ( 205 ) using circulators with integrated probes ( 107 ). The long slots ( 205 ) are formed as grooves ( 114 ) in a conductive base plate ( 103 ), each groove ( 114 ) bracketed on both sides by conductive strips ( 108 ). The circulators with integrated probes ( 107 ) are installed between the conductive strips ( 108 ) and the base plate ( 103 ), to reduce fabrication costs of the machined parts and to facilitate the making of connections between the circulators and the antenna electronics. The probes ( 128 ) protrude partway into the slots ( 205 ) and provide coupling to waves propagating in free space.",YACCARINO ROBERT G;;CARR JAMES A;;SAUER ROHN;;DAVEIGA THOMAS C;;CROCKETT JR JOHN A;;BRADSHAW STEVEN E;;HADDEN IV JOHN M;;WALKER LONNY RICHARD;;RAYTHEON CO,YACCARINO ROBERT G;;CARR JAMES A;;SAUER ROHN;;DAVEIGA THOMAS C;;CROCKETT JR JOHN A;;BRADSHAW STEVEN E;;HADDEN IV JOHN M;;WALKER LONNY RICHARD,RAYTHEON COMPANY (2012-01-06),https://lens.org/146-298-675-696-907,Granted Patent,yes,21,5,6,6,0,H01P1/387;;H01P1/387;;H01Q3/26;;H01Q3/26;;H01Q13/10;;H01Q13/10;;H01Q21/065;;H01Q21/065,H01Q1/00,343/787,3,0,,,"Written Opinion of the International Searching Authority for International Application No. PCT/US2012/068313, filed Dec. 6, 2012, Written Opinion of the International Searching Authority mailed Mar. 1, 2013 (5 pgs).;;International Search Report for International Application No. PCT/US2012/068313, filed Dec. 6, 2012, International Search Report dated Feb. 22, 2013 and mailed Mar. 1, 2013 (4 pgs.);;Declaration of co-inventor, John A. Crockett, Jr., pertaining to U.S. Appl. No. 13/348,015; Declaration dated Mar. 8, 2012, 2 pages.",ACTIVE
436,EP,B1,EP 0323055 B1,056-078-023-025-027,1992-08-19,1992,EP 88311588 A,1988-12-07,US 13781187 A,1987-12-28,COMPOSITE CROMATOGRAPHIC ARTICLE,,MINNESOTA MINING AND MANUFACTURING COMPANY,"HAGEN, DONALD F. MINNESOTA MINING AND;;ST. MARY, STEVEN J. MINNESOTA MINING AND;;ERREDE, LOUIS A. MINNESOTA MINING AND;;CARR, PETER W. MINNESOTA MINING AND",,https://lens.org/056-078-023-025-027,Granted Patent,yes,5,0,13,16,0,B01J20/28028;;B01J20/28033;;Y10S435/803;;Y10T428/249986;;Y10T428/249954;;Y10T428/249986;;Y10T428/249954;;B01J20/28028;;B01J20/28033;;Y10S435/803,B01J20/281;;B01D15/08;;B01J20/28;;B01J20/285;;G01N30/88;;G01N30/92,,0,0,,,,EXPIRED
437,EP,A3,EP 0323055 A3,149-801-530-215-548,1989-08-02,1989,EP 88311588 A,1988-12-07,US 13781187 A,1987-12-28,COMPOSITION CHROMATOGRAPHIC ARTICLE,"A composite chromatographic article comprising:
 a) a polytetrafluoroethylene fibril matrix, and b) a non-swellable sorptive particles enmeshed in said matrix, the ratio of non-swellable sorptive particles to polytetrafluoroethylene being in the range of 19:1 to 4: 1 by weight, said composite article having a net surface energy in the range of 20 to 300 milliNewtons per meter.",MINNESOTA MINING AND MANUFACTURING COMPANY,"HAGEN, DONALD F. MINNESOTA MINING AND;;ST. MARY, STEVEN J. MINNESOTA MINING AND;;ERREDE, LOUIS A. MINNESOTA MINING AND;;CARR, PETER W. MINNESOTA MINING AND",,https://lens.org/149-801-530-215-548,Search Report,yes,5,0,13,16,0,B01J20/28028;;B01J20/28033;;Y10S435/803;;Y10T428/249986;;Y10T428/249954;;Y10T428/249986;;Y10T428/249954;;B01J20/28028;;B01J20/28033;;Y10S435/803,B01J20/281;;B01D15/08;;B01J20/28;;B01J20/285;;G01N30/88;;G01N30/92,,0,0,,,,EXPIRED
438,US,B2,US 7270852 B2,061-250-060-899-391,2007-09-18,2007,US 63388803 A,2003-08-04,US 63388803 A,2003-08-04,"Aluminizing slurry compositions free of hexavalent chromium, and related methods and articles","A slurry coating composition is described, which is very useful for enriching the surface region of a metal-based substrate with aluminum. The composition includes colloidal silica and particles of an aluminum-based powder, and is substantially free of hexavalent chromium. The slurry may include colloidal silica and an alloy of aluminum and silicon. Alternatively, the slurry includes colloidal silica, aluminum or aluminum-silicon, and an organic stabilizer such as glycerol. The slurry exhibits good thermal and chemical stability for extended periods of time, making it very useful for industrial applications. Related methods and articles are also described.",GEN ELECTRIC,KOOL LAWRENCE BERNARD;;GIGLIOTTI JR MICHAEL FRANCIS;;RUTKOWSKI STEPHEN FRANCIS;;SVEC PAUL STEVEN;;KOGAN ANATOLI;;DIDOMIZIO RICHARD;;NOEL BRIAN STEPHEN;;CARR DAVID;;THOMPSON WILLIAM RANDALL,GENERAL ELECTRIC COMPANY (2003-08-19),https://lens.org/061-250-060-899-391,Granted Patent,yes,18,16,8,11,0,C23C10/18;;C23C10/30;;Y10T428/12063;;Y10T428/1275;;Y10T428/12063;;Y10T428/1275;;C23C10/30;;C23C10/18,C09D1/00;;B05D5/00;;C09D5/10;;F01D5/28;;C09D7/12;;C09D17/00;;C23C10/18;;C23C10/30;;C23C24/08;;F02C7/00,427/383.1;;427/379;;427/380;;427/383.7;;427/240;;427/427;;427/429;;427/436;;427/428.01,1,0,,,"Search Report Dated Dec. 22, 2004.",INACTIVE
439,ES,T3,ES 2034268 T3,132-228-437-637-66X,1993-04-01,1993,ES 88311588 T,1988-12-07,US 13781187 A,1987-12-28,ARTICULO CROMATOGRAFICO DE COMPOSICION.,"Un artículo cromatográfico de material compuesto que comprende: a) una matriz fibrilar de politetra uoroetileno, y b) partículas sorbentes no hinchables embebidas en dicha matriz, estando la relación de partículas sorbentes no hinchables a politetrafluoroetileno en el intervalo de 19:1 a 4:1 en peso, teniendo dicho artículo de material compuesto una energía supercial neta en el intervalo de 20 hasta 300 milinewtones por metro.",MINNESOTA MINING AND MANUFACTURING COMPANY,"HAGEN, DONALD F. MINNESOTA MINING AND;;ST. MARY, STEVEN J. MINNESOTA MINING AND;;ERREDE, LOUIS A. MINNESOTA MINING AND;;CARR, PETER W. MINNESOTA MINING AND",,https://lens.org/132-228-437-637-66X,Granted Patent,no,0,0,13,16,0,B01J20/28028;;B01J20/28033;;Y10S435/803;;Y10T428/249986;;Y10T428/249954;;Y10T428/249986;;Y10T428/249954;;B01J20/28028;;B01J20/28033;;Y10S435/803,B01J20/281;;B01D15/08;;B01J20/28;;B01J20/285;;G01N30/88;;G01N30/92,,0,0,,,,EXPIRED
440,US,B2,US 7896962 B2,126-817-275-431-009,2011-03-01,2011,US 84063507 A,2007-08-17,US 84063507 A;;US 63388803 A,2003-08-04,"Aluminizing slurry compositions free of hexavalent chromium, and related methods and articles","A slurry coating composition is described, which is very useful for enriching the surface region of a metal-based substrate with aluminum. The composition includes colloidal silica and particles of an aluminum-based powder, and is substantially free of hexavalent chromium. The slurry may include colloidal silica and an alloy of aluminum and silicon. Alternatively, the slurry includes colloidal silica, aluminum or aluminum-silicon, and an organic stabilizer such as glycerol. The slurry exhibits good thermal and chemical stability for extended periods of time, making it very useful for industrial applications. Related methods and articles are also described.",GEN ELECTRIC,KOOL LAWRENCE BERNARD;;GIGLIOTTI JR MICHAEL FRANCIS;;RUTKOWSKI STEPHEN FRANCIS;;SVEC PAUL STEVEN;;KOGAN ANATOLI;;DIDOMIZIO RICHARD;;NOEL BRIAN STEPHEN;;CARR DAVID;;THOMPSON WILLIAM RANDALL,,https://lens.org/126-817-275-431-009,Granted Patent,yes,24,7,8,11,0,C23C10/18;;C23C10/30;;Y10T428/12063;;Y10T428/1275;;Y10T428/12063;;Y10T428/1275;;C23C10/30;;C23C10/18,C09D1/00;;C04B12/04;;C09D5/10;;F01D5/28;;C09D7/12;;C09D17/00;;C23C10/18;;C23C10/30;;C23C24/08;;F02C7/00,106/600;;106/603,4,0,,,"JP 02000026979 A (Fuji et al.) Jan. 25, 2000 abstract only.;;JP 02004359811 A (Kaneko) Dec. 2004 abstract only.;;JP 3636203 B1 (Yuken Kogyo Co. LTD) Apr. 2005 abstract only.;;PL 154952 (Kielska et al.) Oct. 1991 abstract only.",EXPIRED
441,EP,B1,EP 1505176 B1,148-523-827-995-713,2011-10-05,2011,EP 04254571 A,2004-07-30,US 63388803 A,2003-08-04,"Aluminizing slurry compositions free of hexavalent chromium, and related methods and articles",,GEN ELECTRIC,KOOL LAWRENCE BERNARD;;RUTKOWSKI STEPHEN FRANCIS;;KOGAN ANATOLI;;GIGLIOTTI JR MICHAEL FRANCIS X;;SVEC PAUL STEVEN;;DIDOMIZIO RICHARD;;NOEL BRIAN STEPHEN;;THOMPSON WILLIAM RANDALL;;CARR DAVID,,https://lens.org/148-523-827-995-713,Granted Patent,yes,3,2,8,11,0,C23C10/18;;C23C10/30;;Y10T428/12063;;Y10T428/1275;;Y10T428/12063;;Y10T428/1275;;C23C10/30;;C23C10/18,C23C22/74;;F01D5/28;;C09D1/00;;C09D5/10;;C09D7/12;;C09D17/00;;C23C10/18;;C23C10/30;;C23C24/08;;F02C7/00,,0,0,,,,ACTIVE
442,US,A1,US 2013/0176186 A1,005-760-791-092-603,2013-07-11,2013,US 201213348015 A,2012-01-11,US 201213348015 A,2012-01-11,LOW PROFILE CAVITY BACKED LONG SLOT ARRAY ANTENNA WITH INTEGRATED CIRCULATORS,"The present invention relates to active electronically scanned array antennas. A thin, low cost design is provided by coupling electromagnetic energy into periodically driven long slots ( 205 ) using circulators with integrated probes ( 107 ). The long slots ( 205 ) are formed as grooves ( 114 ) in a conductive base plate ( 103 ), each groove ( 114 ) bracketed on both sides by conductive strips ( 108 ). The circulators with integrated probes ( 107 ) are installed between the conductive strips ( 108 ) and the base plate ( 103 ), to reduce fabrication costs of the machined parts and to facilitate the making of connections between the circulators and the antenna electronics. The probes ( 128 ) protrude partway into the slots ( 205 ) and provide coupling to waves propagating in free space.",YACCARINO ROBERT G;;CARR JAMES A;;SAUER ROHN;;DA VEIGA THOMAS C;;CROCKETT JR JOHN A;;BRADSHAW STEVEN E;;HADDEN IV JOHN M;;WALKER LONNY RICHARD,YACCARINO ROBERT G;;CARR JAMES A;;SAUER ROHN;;DA VEIGA THOMAS C;;CROCKETT JR JOHN A;;BRADSHAW STEVEN E;;HADDEN IV JOHN M;;WALKER LONNY RICHARD,RAYTHEON COMPANY (2012-01-06),https://lens.org/005-760-791-092-603,Patent Application,yes,5,17,6,6,0,H01P1/387;;H01P1/387;;H01Q3/26;;H01Q3/26;;H01Q13/10;;H01Q13/10;;H01Q21/065;;H01Q21/065,H01Q1/00;;H01Q1/50,343/787,0,0,,,,ACTIVE
443,JP,A,JP 2005068556 A,093-705-556-678-145,2005-03-17,2005,JP 2004226291 A,2004-08-03,US 63388803 A,2003-08-04,"ALUMINIZING SLURRY COMPOSITION FREE OF HEXAVALENT CHROMIUM, AND RELATED METHOD AND ARTICLE","<P>PROBLEM TO BE SOLVED: To provide a slurry coating composition very useful for enriching the surface region of a metal-based substrate with aluminum. <P>SOLUTION: The composition includes colloidal silica and particles of an aluminum-based powder, and is substantially free of hexavalent chromium. The slurry may include colloidal silica and an alloy of aluminum and silicon. Alternatively, the slurry includes colloidal silica, aluminum or aluminum-silicon, and an organic stabilizer such as glycerol. The slurry exhibits good thermal and chemical stability for extended periods of time, making it very useful for industrial applications. Related methods and articles are also provided. <P>COPYRIGHT: (C)2005,JPO&NCIPI",GEN ELECTRIC,KOOL LAWRENCE BERNARD;;GIGLIOTTI JR MICHAEL FRANCIS X;;RUTKOWSKI STEPHEN FRANCIS;;SVEC PAUL STEVEN;;KOGAN ANATOLI;;DIDOMIZIO RICHARD;;NOEL BRIAN STEPHEN;;CARR DAVID;;THOMPSON WILLIAM RANDALL,,https://lens.org/093-705-556-678-145,Patent Application,no,3,7,8,11,0,C23C10/18;;C23C10/30;;Y10T428/12063;;Y10T428/1275;;Y10T428/12063;;Y10T428/1275;;C23C10/30;;C23C10/18,C09D1/00;;C09D5/10;;C09D7/12;;C09D17/00;;C23C10/18;;C23C10/30;;C23C24/08;;F02C7/00;;F01D5/28,,0,0,,,,INACTIVE
444,EP,A1,EP 1505176 A1,109-504-725-596-342,2005-02-09,2005,EP 04254571 A,2004-07-30,US 63388803 A,2003-08-04,"Aluminizing slurry compositions free of hexavalent chromium, and related methods and articles","A slurry coating composition is described, which is very useful for enriching the surface region of a metal-based substrate with aluminum. The composition includes colloidal silica and particles of an aluminum-based powder, and is substantially free of hexavalent chromium. The slurry may include colloidal silica and an alloy of aluminum and silicon. Alternatively, the slurry includes colloidal silica, aluminum or aluminum-silicon, and an organic stabilizer such as glycerol. The slurry exhibits good thermal and chemical stability for extended periods of time, making it very useful for industrial applications. Related methods and articles are also described.",GEN ELECTRIC,KOOL LAWRENCE BERNARD;;RUTKOWSKI STEPHEN FRANCIS;;KOGAN ANATOLI;;GIGLIOTTI JR MICHAEL FRANCIS X;;SVEC PAUL STEVEN;;DIDOMIZIO RICHARD;;NOEL BRIAN STEPHEN;;THOMPSON WILLIAM RANDALL;;CARR DAVID,,https://lens.org/109-504-725-596-342,Patent Application,yes,3,18,8,11,0,C23C10/18;;C23C10/30;;Y10T428/12063;;Y10T428/1275;;Y10T428/12063;;Y10T428/1275;;C23C10/30;;C23C10/18,C09D1/00;;C09D5/10;;F01D5/28;;C09D7/12;;C09D17/00;;C23C10/18;;C23C10/30;;C23C24/08;;F02C7/00,,0,0,,,,ACTIVE
445,US,S,US D0735246 S,095-424-149-137-677,2015-07-28,2015,US 201329461247 F,2013-07-19,US 201329461247 F,2013-07-19,Work vehicle body,,DEERE & CO,MILLER GREGORY G;;GUILLORY CHRISTOPHER L;;SHETLER JESSICA L;;HUNSTAD DAVID J;;BLASEN STEVEN T;;CARR ROBERT T;;WARD THOMAS H;;LONIAK JACOB R;;KRIEGER JOHN W,DEERE & COMPANY (2013-07-11);;DESIGNWORKS/USA INC (2013-07-16),https://lens.org/095-424-149-137-677,Design Right,no,0,0,2,2,0,,,1503;;D15/28,0,0,,,,ACTIVE
446,CO,A2,CO 7030958 A2,153-220-093-726-110,2014-08-21,2014,CO 14116814 A,2014-05-30,GB 201118876 A;;US 201161554415 P;;US 201261645283 P,2011-11-01,"Compuestos sustituidos de bencilamina, su uso en medicina, y en particular en el tratamiento de la infección del virús de la hepatitis c (vch)",,ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;BESONG GILBERT;;CARR MARIA GRAZIA;;HISCOCK STEVEN DOUGLAS;;O BRIEN MICHAEL ALISTAIR;;REES DAVID CHARLES;;SAALAU-BETHELL SUSANE MARIA;;THOMPSON NEIL THOMAS,,https://lens.org/153-220-093-726-110,Patent Application,no,0,0,16,16,0,C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C233/18;;C07C233/25;;C07C235/46;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07C243/34;;C07C251/48;;C07C255/24;;C07C255/29;;C07C255/37;;C07C255/46;;C07C255/54;;C07C259/06;;C07C271/12;;C07C275/36;;C07C311/04;;C07C311/08;;C07C311/29;;C07C317/22;;C07C323/25;;C07D205/04;;C07D207/14;;C07D207/335;;C07D209/08;;C07D209/14;;C07D209/44;;C07D211/26;;C07D211/56;;C07D211/70;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/73;;C07D213/74;;C07D213/75;;C07D213/81;;C07D213/84;;C07D217/02;;C07D231/12;;C07D233/24;;C07D233/64;;C07D237/14;;C07D239/34;;C07D239/42;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07D263/32;;C07D265/36;;C07D271/10;;C07D277/68;;C07D285/13;;C07D295/02;;C07D295/027;;C07D295/185;;C07D295/192;;C07D305/06;;C07D305/08;;C07D307/14;;C07D307/22;;C07D307/79;;C07D309/06;;C07D309/12;;C07D309/14;;C07D319/18;;C07D513/04;;C07C2601/16;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C2601/04;;C07B2200/05;;C07B2200/05;;C07C255/46;;C07C255/54;;C07D213/73;;C07D213/74;;C07D213/75;;C07C259/06;;C07D213/81;;C07D309/06;;C07D213/84;;C07D309/12;;C07D309/14;;C07C271/12;;C07D217/02;;C07C275/36;;C07D319/18;;C07D231/12;;C07D233/24;;C07D233/64;;C07C311/04;;C07C311/08;;C07C311/29;;C07D237/14;;C07C317/22;;C07D239/34;;C07D239/42;;C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C323/25;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07C233/18;;C07C233/25;;C07D263/32;;C07C235/46;;C07D205/04;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07D265/36;;C07D207/14;;C07D271/10;;C07C243/34;;C07D207/335;;C07C251/48;;C07D209/08;;C07D209/14;;C07D277/68;;C07C255/24;;C07D209/44;;C07D513/04;;C07C255/29;;C07C255/37;;C07D285/13;;C07D295/02;;C07D211/26;;C07D211/56;;C07D211/70;;C07D295/185;;C07D295/192;;C07D213/38;;C07D213/64;;C07D305/06;;C07D305/08;;C07D213/65;;C07D213/68;;C07D307/14;;C07D307/22;;C07D307/79;;C07C313/06;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;C07D295/027;;A61P31/12;;A61P31/14;;A61P43/00;;C07D239/42;;C07C217/58;;C07D211/70;;C07C237/08;;C07D209/08;;C07D207/335;;C07C255/37;;C07C255/29;;C07C237/06;;C07D285/13;;C07D513/04;;C07D265/36;;C07D295/02;;C07D305/08;;C07D213/81;;C07D263/32;;C07D243/14;;C07C235/46;;C07C237/10;;C07C255/46;;C07C259/06;;C07C271/12;;C07C251/48;;C07C255/54;;C07C255/24;;C07D305/06;;C07B2200/05;;C07D237/14;;C07D307/14;;C07D213/73;;C07D209/14;;C07C275/36;;C07D295/192;;C07C225/12;;C07D239/34;;C07C323/25;;C07D211/26;;C07C217/60;;C07C233/25;;C07D277/68;;C07D271/10;;C07D309/12;;C07D319/18;;C07C217/90;;C07D241/18;;C07D213/64;;C07D233/24;;C07C311/08;;C07D211/56;;C07D231/12;;C07D241/20;;C07C311/29;;C07D213/65;;C07C217/62;;C07D217/02;;C07D213/68;;C07D213/38;;C07D213/74;;C07D213/75;;C07C237/04;;C07D307/22;;C07D233/64;;C07C317/22;;C07D309/06;;C07D309/14;;C07D241/24;;C07D207/14;;C07D307/79;;C07C311/04;;C07D205/04;;C07C243/34;;C07C233/18;;C07C237/12;;C07D209/44;;C07D295/185;;C07D213/84;;C07C313/06;;C07C2601/04;;C07C2601/08;;C07C2601/16;;C07C2601/14;;C07C2601/02;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;A61K45/06;;C07C217/74;;C07C237/20;;C07D295/027,C07D209/14,,0,0,,,,PENDING
447,US,S,US D0734369 S,097-293-226-813-09X,2015-07-14,2015,US 201329461243 F,2013-07-19,US 201329461243 F,2013-07-19,Work vehicle cabin,,DEERE & CO,MILLER GREGORY G;;GUILLORY CHRISTOPHER L;;SHETLER JESSICA L;;HUNSTAD DAVID J;;BLASEN STEVEN T;;CARR ROBERT T;;WARD THOMAS H;;LONIAK JACOB R;;KRIEGER JOHN W,DEERE & COMPANY (2013-07-11);;DESIGNWORKS/USA INC (2013-07-16),https://lens.org/097-293-226-813-09X,Design Right,no,0,2,2,2,0,,,1503;;D15/30,0,0,,,,ACTIVE
448,US,S,US D0707727 S,140-345-019-513-528,2014-06-24,2014,US 201329461245 F,2013-07-19,US 201329461245 F,2013-07-19,Work vehicle body,,DEERE & CO,MILLER GREGORY G;;GUILLORY CHRISTOPHER L;;SHETLER JESSICA L;;HUNSTAD DAVID J;;BLASEN STEVEN T;;CARR ROBERT T;;WARD THOMAS H;;LONIAK JACOB R;;KRIEGER JOHN W,DEERE & COMPANY (2013-07-11);;DESIGNWORKS/USA INC (2013-07-16),https://lens.org/140-345-019-513-528,Design Right,no,0,4,2,2,0,,,1503;;D15/28,0,0,,,,ACTIVE
449,NZ,A,NZ 547696 A,133-056-734-868-286,2009-12-24,2009,NZ 54769604 A,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W,2003-12-23,Pyrazole derivatives as protein kinase modulators,"Disclosed are pyrazole derivative compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the specification. Also disclosed are pharmaceutical compositions containing these compounds, methods for preparing these compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/133-056-734-868-286,Patent Application,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/415;;C07D231/12;;C07D401/10;;C07D413/10,,0,0,,,,DISCONTINUED
450,DE,D1,DE 602004029501 D1,188-486-443-184-47X,2010-11-18,2010,DE 602004029501 T,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W,2003-12-23,PYRAZOLDERIVATE ALS MODULATOREN VON PROTEINKINASE,,ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR,,https://lens.org/188-486-443-184-47X,Granted Patent,no,0,0,12,52,0,,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,ACTIVE
451,US,A1,US 2007/0135477 A1,081-096-279-437-178,2007-06-14,2007,US 56416604 A,2004-07-05,US 56416604 A;;GB 0315657 A;;GB 0324919 A;;US 48468503 P;;US 51437403 P;;GB 2004002824 W,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,"The invention provides compounds of the formula (1): The compounds have activity against cyclin depdenent kinases, glycogen synthase kinase and Auroa kinases and are therefore useful to treat cancer and viral diseases.",ASTEX THERAPEUCTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL A;;CARR MARIA G;;EARLY THERESA R;;NAVARRO EVA F;;GILL ADRIAN L;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON J;;WOODHEAD ANDREW J;;WYATT PAUL,ASTEX THERAPEUTICS LTD (2006-06-16),https://lens.org/081-096-279-437-178,Patent Application,yes,16,19,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4745;;A61K31/00;;A61K31/4184;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,514/303;;514/394;;514/397;;514/406;;548/306.1,0,0,,,,INACTIVE
452,DE,T1,DE 353599 T1,055-537-049-461-859,1990-07-05,1990,DE 89113698 T,1989-07-25,US 22664188 A,1988-08-01,VERFAHREN ZUR HERSTELLUNG VON BIS(AMINOPROPYL)ALIPHATISCHEN GLYCOLEN.,,"AIR PRODUCTS AND CHEMICALS, INC., ALLENTOWN, PA., US","VAN COURT CARR, RICHARD, ALLENTOWN, PA 18104, US;;JOHNSON, THOMAS ALBERT, OREFIELD, PA 18069, US;;GALATON, STEVEN MARC, DOYLESTOWN, PA 18901, US;;ALBANESE, THOMAS ARCHIE, ALLENTOWN, PA 18103, US",,https://lens.org/055-537-049-461-859,Granted Patent,no,0,0,5,5,0,C07C213/02;;C07C213/06;;C07C217/08;;C07C253/34;;C07C217/08;;C07C253/34;;C07C213/06;;C07C213/02,C07C213/02;;C07C213/06;;C07C217/08;;C07C253/34,,0,0,,,,EXPIRED
453,PT,E,PT 1648426 E,030-695-227-949-002,2014-03-07,2014,PT 04743172 T,2004-07-05,GB 0315657 A;;GB 0324919 A;;US 48468503 P;;US 51437403 P,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;NAVARRO EVA FIGUEROA;;O'BRIEN MICHAEL ALISTAIR;;EARLY THERESA RACHEL;;GILL ADRIAN LIAM;;HOWARD STEVEN;;WYATT PAUL,,https://lens.org/030-695-227-949-002,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
454,US,A1,US 2014/0271662 A1,034-517-989-398-589,2014-09-18,2014,US 201414180440 A,2014-02-14,US 201414180440 A;;GB 0329617 A;;US 201213536174 A;;US 59678807 A;;GB 2004005464 W;;US 53219903 P;;US 57784304 P,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,"The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R 1 and NR 2 R 3 and a maximum chain length of 4 atoms extending between E and NR 2 R 3 , wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the NR 2 R 3 group and provided that the oxo group when present is located at a carbon atom α with respect to the NR 2 R 3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group;R 1 is an aryl or heteroaryl group; andR 2 , R 3 , R 4 and R 5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (2010-03-29);;ASTEX THERAPEUTICS LIMITED (2010-03-29);;CANCER RESEARCH TECHNOLOGY LIMITED (2010-03-12),https://lens.org/034-517-989-398-589,Patent Application,yes,5,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/5377;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K45/06;;C07D231/12;;C07D401/10;;C07D403/10;;C07D413/10,424/152.1;;514/406;;514/326;;514/236.5;;514/254.05;;514/210.2;;514/397;;514/255.05,3,3,026-856-766-952-702;;050-511-023-328-286;;046-707-787-993-630,10.1126/scisignal.122re4;;18523239;;20153226;;10.1016/j.jmgm.2010.01.007;;10.1038/5587;;9930872,"""Pharmacological PKA Inhibition: All May Not Be What It Seems"" by Murray, Sci. Signal. 1, re4 (2008).;;""A comprehensive structure-activity analysis of protein kinase B-alpha (Akt1) inhibitors"" by Ajmani et al., J. Molec. Graph. Model. 28, 683-94 (2010).;;""An essential part for Rho-associated kinase in the transcellular invasion of tumor cells"" by Itoh et al., Nature Med. 5, 221-25 (1999).",INACTIVE
455,CN,B,CN 1922148 B,183-902-583-328-146,2012-03-21,2012,CN 200480042037 A,2004-12-23,GB 2004005464 W;;GB 0329617 A;;US 53219903 P;;US 57784304 P,2003-12-23,Pyrazole derivatives as protein kinase modulators,"The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R<l >and NR<2>R<3> and a maximum chain length of 4 atoms extending between E and NR<2>R<3>, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR<2>R<3> group and provided that the oxo group when present is located at a carbon atom a with respect to the NR<2>R<3> group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R<l> is an aryl or heteroaryl group; and R<2>, R<3>, R<4> and R<5> are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD;;CANCER RES TECHNOLOGY CO LTD;;CANCER RES INST HOFFMANN LA ROCHE,GORDON SAXTY;;VALERIO BERDINI;;GRAHAM WYATT PAUL;;WINTER WALKER DAVID;;GEORGE BOYLE ROBERT;;ROBERT DOWNHAM;;FIONA SORE HANNAH;;IAN COLLINS;;LEENDERT VERDONK MARINUS;;JOHN WOODHEAD STEVEN;;ELLIS CARR ROBIN ARTHUR,,https://lens.org/183-902-583-328-146,Granted Patent,no,0,0,12,52,0,,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,INACTIVE
456,SI,T1,SI 1706385 T1,193-904-019-579-093,2011-01-31,2011,SI 200431571 T,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W;;EP 04806258 A,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,,ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/193-904-019-579-093,Granted Patent,no,0,0,12,52,0,,C07D231/00;;A61K31/00;;A61P37/00;;C07D401/00;;C07D413/00,,0,0,,,,ACTIVE
457,HK,A1,HK 1097543 A1,051-725-072-201-003,2007-06-29,2007,HK 07103603 A,2007-04-03,GB 2004005464 W;;GB 0329617 A;;US 53219903 P;;US 57784304 P,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,,ASTEX THERAPEUTICS LTD;;CANCER RESEARCH TECHNOLOGY LIMITED;;THE INSTITUTE OF CANCER RESEARCH,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/051-725-072-201-003,Patent Application,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K/;;A61K31/415;;A61P/;;C07D/;;C07D231/12;;C07D401/10;;C07D413/10,,0,0,,,,DISCONTINUED
458,CA,A1,CA 2548374 A1,066-058-148-407-154,2005-07-07,2005,CA 2548374 A,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,"The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between Rl and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in th e linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or mor e substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; Rl is an aryl or heteroaryl group; and R2 , R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds a nd their use as anticancer agents.",CANCER RES INST ROYAL;;ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD,VERDONK MARINUS LEENDERT;;SAXTY GORDON;;WOODHEAD STEVEN JOHN;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS;;BERDINI VALERIO;;SORE HANNAH FIONA;;BOYLE ROBERT GEORGE;;WALKER DAVID WINTER;;WYATT PAUL GRAHAM,,https://lens.org/066-058-148-407-154,Patent Application,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/415;;C07D231/12;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,INACTIVE
459,UY,A1,UY 28946 A1,119-468-617-367-398,2006-01-31,2006,UY 28946 A,2005-06-08,US 57784304 P;;GB 2004005464 W;;US 53219903 P;;GB 0329617 A,2003-12-23,"COMPUESTOS DE ARIL-Y HETEROARIL-ALQUILANINA QUE CONTIENEN PIRAZOL, COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS Y NUEVOS PRODUCTOS QUÍMICOS INTERMEDIOS","La invención proporciona compuestos de la fórmula (I) que presentan actividad inhibidora de la proteína quinasa B: en donde A, E, R1, R2, R3, R4 y R5 son como se definen en las reivindicaciones. También se propocionan composiciones farmacéuticas que contienen los compuestos, métodos para preparar los compuestos y su uso como agentes anticancerígenos.",ASTEX TECHNOLOGY LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,VALERIO BERDINI;;GORDON SAXTY;;LEENDERT VERDONIK MARINUS;;JOHN WOODHEAD STEVEN;;GRAHAM WYATT PAUL;;GEORGE BOYLE ROBERT;;FIONA SORE HANNAH;;WINTER WALKER DAVID;;ROBERT DOWNHAM;;ELLIS CARR ROBIN ARTHUR;;IAN COLLINS,,https://lens.org/119-468-617-367-398,Patent Application,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/00;;A61K31/415;;C07D231/12;;C07D401/10;;C07D413/10,,0,0,,,,DISCONTINUED
460,US,A1,US 2016/0250187 A1,144-809-216-564-066,2016-09-01,2016,US 201615010831 A,2016-01-29,US 201615010831 A;;GB 0329617 A;;US 201414180440 A;;US 201213536174 A;;US 59678807 A;;GB 2004005464 W;;US 53219903 P;;US 57784304 P,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,"The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R 1 and NR 2 R 3 and a maximum chain length of 4 atoms extending between E and NR 2 R 3 , wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the NR 2 R 3 group and provided that the oxo group when present is located at a carbon atom α with respect to the NR 2 R 3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R 1 is an aryl or heteroaryl group; and R 2 , R 3 , R 4 and R 5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD;;THE INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL;;CANCER RES TECH LTD,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (2010-03-29);;ASTEX THERAPEUTICS LIMITED (2010-03-29);;CANCER RESEARCH TECHNOLOGY LIMITED (2010-03-12),https://lens.org/144-809-216-564-066,Patent Application,yes,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/415;;A61K9/00;;A61K9/20;;A61K9/48;;A61K31/4155;;A61K31/4178;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K31/551;;A61K45/06;;C07D231/12;;C07D401/10;;C07D413/10,,0,0,,,,DISCONTINUED
461,US,B2,US 8691806 B2,041-886-052-299-706,2014-04-08,2014,US 201213536174 A,2012-06-28,US 201213536174 A;;GB 0329617 A;;US 59678807 A;;GB 2004005464 W;;US 53219903 P;;US 57784304 P,2003-12-23,Pyrazole derivatives as protein kinase modulators,"The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS;;ASTEX THERAPEUTICS LTD;;CANCER RES INST ROYAL;;CANCER REC TECH LTD,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (2010-03-29);;ASTEX THERAPEUTICS LIMITED (2010-03-29);;CANCER RESEARCH TECHNOLOGY LIMITED (2010-03-12),https://lens.org/041-886-052-299-706,Granted Patent,yes,73,2,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/397;;A61K31/415;;C07D231/12;;C07D401/10;;C07D413/10,514/210.2;;514/406;;514/326;;548/377.1;;548/373.1;;548/356.1;;548/100,16,10,020-344-400-405-766;;077-109-648-971-807;;028-567-007-131-606;;055-878-581-670-29X;;050-511-023-328-286;;026-856-766-952-702;;078-846-071-783-225;;035-444-077-928-497;;041-703-940-947-068;;029-742-983-481-795,10.1016/j.bbapap.2003.11.029;;15023366;;10.1016/s0163-7258(02)00193-6;;12191616;;10.2174/1568026053507714;;15853641;;10.1016/s0040-4039(00)89682-3;;20153226;;10.1016/j.jmgm.2010.01.007;;10.1126/scisignal.122re4;;18523239;;10.1093/annonc/mdh145;;15033673;;22781553;;10.1158/1078-0432.ccr-11-3313;;9544425;;10.1023/a:1005960822365;;10.1126/science.286.5439.531;;10521349,"Taylor, S.S. et al., PKA: a portrait of protein kinase dynamics, Biochemica et Biophysica, 1697, 2004, pp. 259-269.;;Hill, Michelle M. et al., Inhibition of protein kinase B/Akt: implications for cancer therapy, Pharmacology & Therapeutics, 93, 2002, pp. 243-251.;;Barnett, Stanley F. et al., The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation, Current Topics in Medicinal Chemistry, 5, 2005, pp. 109-125.;;Nagarajan, K. et al., Mechanism of Formation of p-Substituted Products in Displacement Reactions on alpha-Chlorodiphenylacetamides, Tetrahedron Letters, No. 22, 1968, pp. 2717-2720.;;Simig, Gyula et al., Single Electron Transfer Inititated Thermal Reactions of Arylmethyl Halides, X, Acta Chimica Hungarica, 118(4), 1985, pp. 309-314.;;Ajmani Subhash et al., A comprehensive structure-activity analysis of protein kinase B-alpha (Akt1) inhibitors, Journal of Molecular Graphics and Modelling, 28(7), 2010, pp. 683-694.;;Murray Andrew J., Pharmacological PKA Inhibition: All May Not Be What It Seems, Science Signaling, Jun. 3, 2008,vol. 1, issue 22, pp. 1-6.;;Dorwald, Florencio Zaragoza, Side Reactions in Organic Synthesis, Wiley-VCH, 2005, p. 1 and preface.;;Drewry et al. CAS 143 229871 (2005).;;Schrijvers et al., Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study, Annals of Oncology, vol. 15, 638-645, 2004.;;Yap et al.; AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity; Clin Cancer Re; Jul. 15, 2012; 18(14).;;Marshall, Chris; Effective inhibition of actomyosin contractility by a new series of Rho-kinase inhibitors blocks multiple modes of melanoma cell migration and metastasis; PowerPoint Presentation at Antitumoral Targets Upstream and Downstream of RAS GTPases Meeting; Santander, Spain; Oct. 8-9, 2012.;;Lala & Orucevic, Role of nitric oxide in tumor progression: Lessons from experimental tumors, Cancer and Metastasis Reviews 1998 17(1) 91-106.;;Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, Science (1999) vol. 286 531-537.;;Cancer online retrieved Jul. 6, 2007 retrieved from the internet http://www.nlm.nih.gov/medlineplus/cancer.html.;;Cancer online retrieved Jul. 6, 2007 retrieved from the internet http://en.wikipedia.org/wiki/Cancer.",INACTIVE
462,AU,A1,AU 2004/253338 A1,120-923-083-010-85X,2005-01-13,2005,AU 2004/253338 A,2004-07-05,US 48468503 P;;GB 0315657 A;;US 51437403 P;;GB 0324919 A;;GB 2004002824 W,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,,ASTEX TECHNOLOGY LTD,TREWARTHA GARY;;O'BRIEN MICHAEL ALISTAIR;;GILL ADRIAN LIAM;;EARLY THERESA RACHEL;;WOODHEAD ANDREW JAMES;;BERDINI VALERIO;;WOOLFORD ALISON JO-ANNE;;HOWARD STEVEN;;WYATT PAUL;;NAVARRO EVA FIGUEROA;;CARR MARIA GRAZIA,ASTEX THERAPUETICS LIMITED (2006-02-02),https://lens.org/120-923-083-010-85X,Patent Application,no,0,2,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,INACTIVE
463,ES,T3,ES 2443995 T3,167-068-475-077-878,2014-02-21,2014,ES 04743172 T,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;GB 2004002824 W,2003-07-03,Derivados de bencimidazol y sus usos como inhibidores de proteína quinasas,"Un compuesto de fórmula (VII): o una sal, N-óxido o solvato del mismo; donde A es -(CH2)m-(B)n-; donde m es 0 o 1, n es 1 y B es C>=O o NRg(C>=O); Ra es hidrógeno; R1d es un grupo R1 donde R1 es hidrógeno, un grupo carbocíclico o heterocíclico que tiene de 3 a 12 miembrosen el anillo, o un grupo hidrocarbilo C1-8 opcionalmente sustituido; donde los sustituyentes opcionales para el C1-8 grupo hidrocarbilo se seleccionan entre hidroxi, oxo, alcoxi,carboxi, halógeno, ciano, nitro, amino, mono- o di-hidrocarbilamino C1-4, y grupos carbocíclicos y heterocíclicosmonocíclicos o bicíclicos que tienen de 3 a 12 miembros en el anillo; y, donde los grupos carbocíclicos y heterocíclicos en cada caso están sin sustituir o sustituidos con uno o másgrupos sustituyentes R10 seleccionados entre halógeno, hidroxi, trifluorometilo, ciano, nitro, carboxi, amino,mono- o di-hidrocarbilamino C1-4, grupos carbocíclicos y heterocíclicos que tienen de 3 a 12 miembros en elanillo; un grupo Ra-Rb donde Ra es un enlace, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc oNRcSO2; y Rb se selecciona entre hidrógeno, grupos carbocíclicos y heterocíclicos que tienen de 3 a 12 miembros en elanillo, y un grupo hidrocarbilo C1-8 opcionalmente sustituido con uno o más sustituyentes seleccionados entrehidroxi, oxo, halógeno, ciano, nitro, carboxi, amino, mono- o di-hidrocarbilamino C1-4, grupos carbocíclicos yheterocíclicos que tienen de 3 a 12 miembros en el anillo y donde uno o más átomos de carbono del grupohidrocarbilo C1-8 pueden estar opcionalmente reemplazados con O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 oX1C(X2)X1; o dos grupos adyacentes R10, junto con los átomos de carbono o heteroátomos a los que estánunidos pueden formar un anillo de heteroarilo de 5 miembros o un anillo carbocíclico o heterocíclico no aromáticode 5 o 6 miembros, donde los grupos heteroarilo y heterocíclico mencionados contienen hasta 3 miembros en elanillo que son heteroátomos seleccionados entre N, O y S; Rc se selecciona entre hidrógeno e hidrocarbilo C1-4; y X1 es O, S o NRc y X2 es >=O, >=S o >=NRc; y con la condición de que cuando el grupo sustituyente R10 comprende o incluye un grupo carbocíclico oheterocíclico, el grupo carbocíclico o heterocíclico mencionado puede estar sin sustituir o puede estar sustituido en símismo con uno o más grupos sustituyentes adicionales R10 y donde (a) dichos grupos sustituyentes adicionales R10incluyen grupos carbocíclicos o heterocíclicos, que no están en sí mismos sustituidos adicionalmente; o (b) lossustituyentes adicionales mencionados no incluyen grupos carbocíclicos o heterocíclicos pero se seleccionan de otromodo entre los grupos que se han indicado anteriormente en la definición de R10.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,,https://lens.org/167-068-475-077-878,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
464,EP,A1,EP 1706385 A1,189-869-129-018-38X,2006-10-04,2006,EP 04806258 A,2004-12-23,GB 2004005464 W;;GB 0329617 A;;US 53219903 P;;US 57784304 P,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,,ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/189-869-129-018-38X,Patent Application,yes,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,ACTIVE
465,EP,A2,EP 1648426 A2,106-778-950-048-608,2006-04-26,2006,EP 04743172 A,2004-07-05,GB 2004002824 W;;GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,,https://lens.org/106-778-950-048-608,Patent Application,yes,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
466,SA,B1,SA 05260179 B1,185-380-236-352-528,2009-06-14,2009,SA 05260179 A,2005-06-22,US 57784304 P,2004-06-08,Pyrazole-containing aryl-and heteroaryl-alkylamine compounds that inhibit or modulate the activity of proten kinase A (PKA) and protein kinase B (PKB),"The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX TECH LTD,COLLINS IAN;;WAY PAUL GRAHAM;;SAXTY GORDON;;WALKER DAVID WINTER;;BOYLE ROBERT GEORGE;;DOWFD-[P ROBERT;;CARR ROBIN ARTHUR;;WOODHEAD STEVEN JOHN;;BERDINI VALERIO;;VERDONK MARINUS LEENDERT;;SORE HANNAH FIONA,,https://lens.org/185-380-236-352-528,Granted Patent,no,0,0,5,52,0,,,,0,0,,,,ACTIVE
467,CY,T1,CY 1111493 T1,020-325-649-166-373,2015-08-05,2015,CY 111100002 T,2011-01-03,EP 04806258 A;;GB 0329617 A;;US 53219903 P;;US 57784304 P,2003-12-23,ΠΑΡΑΓΩΓΑ ΠΥΡΑΖΟΛΙΟΥ ΩΣ ΤΡΟΠΟΠΟΙΗΤΕΣ ΠΡΩΤΕΪΝΟΚΙΝΑΣΗΣ,"Η εφεύρεση δίδει ενώσεις του τύπου I, που έχουν δραστικότητα αναστολής της πρωτεϊνοκινάσης Β· όπου το Α είναι μία ομάδα συνδέτη κεκορεσμένου υδρογονάνθρακα, που περιέχει 1 έως 7 άτομα άνθρακα, όπου η ομάδα συνδέτη έχει ένα μέγιστο μήκος αλυσίδας 5 ατόμων, τα οποία εκτείνονται μεταξύ των R1 και NR2R3 και ένα μέγιστο μήκος αλυσίδας 4 ατόμων, που εκτείνεται μεταξύ του Ε και NR2R3, όπου το ένα από τα άτομα άνθρακα εις την συνδετική ομάδα μπορεί ενδεχομένως να έχει αντικατασταθεί από ένα άτομο οξυγόνου ή αζώτου· και όπου τα άτομα άνθρακα της συνδετικής ομάδας Α μπορούν ενδεχομένως να φέρουν έναν ή περισσότερους υποκατάστατες, που επιλέγονται από οξο, φθόριο και υδροξυ, υπό τον όρο ότι η υδροξυ ομάδα, όταν υπάρχει, δεν είναι τοποθετημένη σε άτομο άνθρακα a σε σχέση ως προς την ομάδα NR2R3 και υπό τον όρο ότι η οξο ομάδα, όταν υπάρχει, είναι τοποθετημένη σε ένα άτομο άνθρακα a σε σχέση με την ομάδα NR2R3 · το Ε είναι μία μονοκυκλική ή δικυκλική καρβοκυκλική ή ετεροκυκλική ομάδα · το R1 είναι μία αρυλ ή ετεροαρυλ ομάδα · και τα R2, R3, R4 και R5 είναι όπως ορίζεται εις τις αξιώσεις. Επίσης δίδονται φαρμακευτικές συνθέσεις, που περιέχουν τις ενώσεις, μεθόδους για την παρασκευή των ενώσεων και χρήση αυτών ως αντικαρκινικών παραγόντων.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/020-325-649-166-373,Granted Patent,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,ACTIVE
468,AU,C1,AU 2004/303602 C1,157-143-287-453-674,2009-05-28,2009,AU 2004/303602 A,2004-12-23,US 53219903 P;;GB 0329617 A;;US 57784304 P;;GB 2004005464 W,2003-12-23,Pyrazole derivatives as protein kinase modulators,,ASTEX THERAPEUTICS LTD;;CANCER RESEARCH TECH LTD;;THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL,COLLINS IAN;;DOWNHAM ROBERT;;BERDINI VALERIO;;WYATT PAUL GRAHAM;;CARR ROBIN ARTHUR ELLIS;;WOODHEAD STEVEN JOHN;;SORE HANNAH FIONA;;BOYLE ROBERT GEORGE;;VERDONK MARINUS LEENDERT;;WALKER DAVID WINTER;;SAXTY GORDON,,https://lens.org/157-143-287-453-674,Amended Patent,no,1,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/415;;C07D231/12;;C07D401/10;;C07D413/10,,0,0,,,,INACTIVE
469,PL,T3,PL 1648426 T3,175-131-977-578-84X,2014-05-30,2014,PL 04743172 T,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;EP 04743172 A;;GB 2004002824 W,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,,https://lens.org/175-131-977-578-84X,Patent Application,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,PENDING
470,DK,T3,DK 1648426 T3,184-198-072-646-556,2014-02-10,2014,DK 04743172 T,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;GB 2004002824 W,2003-07-03,BENZIMIDAZOLDERIVATER OG ANVENDELSE HERAF SOM PROTEINKINASEINHIBITORER,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,,https://lens.org/184-198-072-646-556,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
471,US,B2,US 8247576 B2,014-617-807-774-305,2012-08-21,2012,US 59678804 A,2004-12-23,US 59678804 A;;GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W,2003-12-23,Pyrazole derivatives as protein kinase modulators,"The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R 1 and NR 2 R 3 and a maximum chain length of 4 atoms extending between E and NR 2 R 3 , wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR 2 R 3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR 2 R 3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R 1 is an aryl or heteroaryl group; and R 2 , R 3 , R 4 and R 5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS;;ASTEX THERAPEUTICS LTD;;CANCER RES INST ROYAL;;CANCER REC TECH LTD,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (2010-03-29);;ASTEX THERAPEUTICS LIMITED (2010-03-29);;CANCER RESEARCH TECHNOLOGY LIMITED (2010-03-12),https://lens.org/014-617-807-774-305,Granted Patent,yes,59,5,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/415;;C07D231/12;;C07D401/10;;C07D413/10,548/377.1;;548/373.1;;548/356.1;;548/100,11,9,050-511-023-328-286;;026-856-766-952-702;;010-040-048-846-785;;020-344-400-405-766;;077-109-648-971-807;;028-567-007-131-606;;055-878-581-670-29X;;050-511-023-328-286;;026-856-766-952-702,20153226;;10.1016/j.jmgm.2010.01.007;;10.1126/scisignal.122re4;;18523239;;10.1002/352760426x.ch1;;10.1016/j.bbapap.2003.11.029;;15023366;;10.1016/s0163-7258(02)00193-6;;12191616;;10.2174/1568026053507714;;15853641;;10.1016/s0040-4039(00)89682-3;;20153226;;10.1016/j.jmgm.2010.01.007;;10.1126/scisignal.122re4;;18523239,"""A comprehensive structure-activity analysis of protein kinase B-alpha (Akt1) inhibitors"" by Ajmani et al., J. Molec. Graph. Model. 28, 683-94 (2010).;;""Pharmacological PKA Inhibition: All May Not Be What It Seems"" by Murray, Sci. Signal. 1, re4 (2008).;;""Organic Synthesis: General Remarks"" in Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design by Dorwald, Wiley-VCH (Weinheim, Germany), Preface and p. 1 (2005).;;Taylor, S.S. et al., PKA: a portrait of protein kinase dynamics, Biochemica et Biophysica, 1697, 2004, pp. 259-269.;;Hill, Michelle M. et al., Inhibition of protein kinase B/Akt: implications for cancer therapy, Pharmacology & Therapeutics, 93, 2002, pp. 243-251.;;Barnett, Stanley F. et al., The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation, Current Topics in Medicinal Chemistry, 5, 2005, pp. 109-125.;;Nagarajan, K. et al., Mechanism of Formation of p-Substituted Products in Displacement Reactions on Chlorodiphenylacetamides, Tetrahedron Letters, No. 22, 1968, pp. 2717-2720.;;Simig, Gyula et al., Single Electron Transfer Inititated Thermal Reactions of Arylmethyl Halides, X, Acta Chimica Hungarica, 118(4), 1985, pp. 309-314.;;Ajmani Subhash et al., A Comprehensive structure-activity analysis of protein kinase B-alpha (Akt1) inhibitors, Journal of Molecular Graphics and Modelling, 28(7), 2010, pp. 683-694.;;Murray Andrew J., Pharmacological PKA Inhibition: All May Not Be What It Seems, Science Signaling, Jun. 3, 2008, pp. 1-6.;;Dorwald, Florencio Zaragoza, Side Reactions in Organic Synthesis, Wiley-VCH, 2005, p. 1 and preface.",INACTIVE
472,CA,A1,CA 2531050 A1,092-824-521-970-483,2005-01-13,2005,CA 2531050 A,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;GB 2004002824 W,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS,"The invention provides compounds having activity as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinases for use in the treatment of disease states and conditions such as cancer that are mediated by the kinases. The compounds have the general formula (I). Also included within formula (I) are the salts, solvates and N-oxides of the compounds.",ASTEX THERAPEUTICS LTD,TREWARTHA GARY;;WYATT PAUL;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;O'BRIEN MICHAEL ALISTAIR;;GILL ADRIAN LIAM;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;CARR MARIA GRAZIA;;HOWARD STEVEN;;BERDINI VALERIO,,https://lens.org/092-824-521-970-483,Patent Application,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,INACTIVE
473,KR,A,KR 20060130621 A,170-773-439-187-115,2006-12-19,2006,KR 20067014742 A,2004-12-23,GB 2004005464 W;;GB 0329617 A;;US 53219903 P;;US 57784304 P,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,"(I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between Rl and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2 R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; Rl is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD;;CANCER RES INST;;CANCER REC TECH LTD,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/170-773-439-187-115,Patent Application,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/12;;A61K31/415;;C07D401/04;;C07D401/10;;C07D413/10,,0,0,,,,INACTIVE
474,US,A1,US 2013/0005702 A1,015-828-978-870-701,2013-01-03,2013,US 201213536174 A,2012-06-28,US 201213536174 A;;GB 0329617 A;;US 59678807 A;;GB 2004005464 W;;US 53219903 P;;US 57784304 P,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,"The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL;;BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNA FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNA FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (2010-03-29);;ASTEX THERAPEUTICS LIMITED (2010-03-12);;CANCER RESEARCH TECHNOLOGY LIMITED (2010-03-12),https://lens.org/015-828-978-870-701,Patent Application,yes,5,5,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/415;;A61K31/4155;;A61K31/4439;;A61K31/451;;A61K31/5377;;A61K31/551;;A61P35/00;;C07D231/12;;C07D401/10;;C07D403/10;;C07D413/10;;C12N5/09,514/210.2;;548/377.1;;514/406;;546/211;;514/326;;546/275.4;;514/341;;544/140;;514/236.5;;540/575;;514/218;;435/375,0,0,,,,INACTIVE
475,UA,C2,UA 90461 C2,091-026-201-217-633,2010-05-11,2010,UA A200608166 A,2004-12-23,GB 0329617 A,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,"The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between Rand NRRand a maximum chain length of 4 atoms extending between E and NRR, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NRRgroup and provided that the oxo group when present is located at a carbon atom a with respect to the NRRgroup; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; Ris an aryl or heteroaryl group; and R, R, Rand Rare as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/091-026-201-217-633,Limited Patent,no,0,0,12,52,0,,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,EXPIRED
476,MY,A,MY 144464 A,108-961-231-975-729,2011-09-30,2011,MY PI20052573 A,2005-06-07,US 57784304 P;;GB 2004005464 W,2004-06-08,PYRAZOLE DERIVATIVES AS PROTIEN KINASE MODULATORS,"THE INVENTION PROVIDES COMPOUNDS OF THE FORMULA (Ι) HAVING PROTEIN KINASE B INHIBITING ACTIVITY: WHEREIN A IS A SATURATED HYDROCARBON LINKER GROUP CONTAINING FROM 1 TO 7 CARBON ATOMS, THE LINKER GROUP HAVING A MAXIMUM CHAIN LENGTH OF 5 ATOMS EXTENDING BETWEEN R¹ AND NR²R³ AND A MAXIMUM CHAIN LENGTH OF 4 ATOMS EXTENDING BETWEEN E AND NR²R³, WHEREIN ONE OF THE CARBON ATOMS IN THE LINKER GROUP MAY OPTIONALLY BE REPLACED BY AN OXYGEN OR NITROGEN ATOM; AND WHEREIN THE CARBON ATOMS OF THE LINKER GROUP A MAY OPTIONALLY BEAR ONE OR MORE SUBSTITUENTS SELECTED FROM OXO, FLUORINE AND HYDROXY, PROVIDED THAT THE HYDROXY GROUP WHEN PRESENT IS NOT LOCATED AT A CARBON ATOM A WITH RESPECT TO THE NR²R³ GROUP AND PROVIDED THAT THE OXO GROUP WHEN PRESENT IS LOCATED AT A CARBON ATOM A WITH RESPECT TO THE NR²R³ GROUP; E IS A MONOCYCLIC OR BICYCLIC CARBOCYCLIC OR HETEROCYCLIC GROUP; R1 IS AN ARYL OR HETEROARYL GROUP; AND R², R³, R⁴ AND R⁵ ARE AS DEFINED IN THE CLAIMS. ALSO PROVIDED ARE PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS, METHODS FOR PREPARING THE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS.",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;CARR ROBIN ARTHUR ELLIS;;COLLINS IAN;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;DOWNHAM ROBERT,,https://lens.org/108-961-231-975-729,Granted Patent,no,0,0,5,52,0,,A61K31/415,,0,0,,,,ACTIVE
477,ZA,B,ZA 200600050 B,109-225-732-041-423,2007-03-28,2007,ZA 200600050 A,2004-07-05,GB 0315657 A,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,,ASTEX THERAPEUTICS LTD,VALERIO BERDINI;;ALISTAIR O'BRIEN MICHAEL;;GRAZIA CARR MARIA;;RACHEL EARLY THERESA;;FIGUEROA NAVARRO EVA;;LIAM GILL ADRIAN;;STEVEN HOWARD;;GARY TREWARTHA;;JO-ANNE WOOLFORD ALISON;;JAMES WOODHEAD ANDREW;;PAUL WYATT,,https://lens.org/109-225-732-041-423,Granted Patent,no,0,0,8,48,0,A61K31/00;;A61K31/00;;A61K31/4184;;A61K31/4184;;A61P1/00;;A61P11/00;;A61P13/08;;A61P15/00;;A61P17/00;;A61P25/28;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/02;;A61P43/00;;C07D401/14;;C07D401/14;;C07D403/04;;C07D403/04;;C07D405/14;;C07D405/14;;C07D409/14;;C07D409/14;;C07D413/14;;C07D413/14,A61K/;;A61K31/00;;A61K31/4184;;A61P/;;A61P31/10;;A61P35/00;;C07D/,,0,0,,,,ACTIVE
478,TW,A,TW 200602046 A,162-772-768-508-464,2006-01-16,2006,TW 94118996 A,2005-06-08,US 57784304 P;;GB 2004005464 W,2004-06-08,Pharmaceutical compounds,"The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R1 is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX TECHNOLOGY LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS;;COLLINS IAN,,https://lens.org/162-772-768-508-464,Patent of Addition,no,0,0,5,52,0,,,,0,0,,,,INACTIVE
479,CA,C,CA 2531050 C,022-082-426-586-951,2013-04-09,2013,CA 2531050 A,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;GB 2004002824 W,2003-07-03,PHARMACEUTICAL COMPOUNDS,"The invention provides compounds having activity as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinases for use in the treatment of disease states and conditions such as cancer that are mediated by the kinases. The compounds have the general formula (I). Also included within formula (I) are the salts, solvates and N-oxides of the compounds.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,,https://lens.org/022-082-426-586-951,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,C07D403/04;;A61K31/00;;A61K31/4184;;A61K31/4439;;A61K31/517;;A61K31/519;;A61K31/5377;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D487/04;;C07D513/04,,0,0,,,,INACTIVE
480,BR,A,BR PI0418078 A,020-103-994-643-536,2007-04-17,2007,BR PI0418078 A,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W,2003-12-23,"composto ou um seu sal, solvato, tautÈmero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteìna quinase b e medida pela proteìna quinase a, para tratar uma doença ou condição, para inibir uma proteìna quinase b e uma proteìna quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamìfero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto","""COMPOSTO OU UM SEU SAL, SOLVATO, TAUTÈMERO OU NóXIDO, USO DE UM COMPOSTO, MéTODOS PARA A PROFILAXIA OU TRATAMENTO DE UM ESTADO OU CONDIçãO DOENTIA MEDIADA PELA PROTEìNA QUINASE B E MEDIADA PELA PROTEìNA QUINASE A, PARA TRATAR UMA DOENçA OU CONDIçãO, PARA INIBIR UMA PROTEìNA QUINASE B E UMA PROTEìNA QUINASE A, PARA MODULAR UM PROCESSO CELULAR, PARA TRATAR UM DISTúRBIO IMUNE EM UM MAMìFERO E PARA INDUZIR APOPTOSE EM UMA CéLULA CANCEROSA, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTOS"". A invenção provê compostos de Fórmula: tendo atividade inibidora da proteina quinase B: em que A é um grupo ligador de hidrocarboneto saturado, contendo de 1 a 7 átomos de carbono, o grupo ligador tendo um comprimento de cadeia máximo de 5 átomos, estendendo-se entre R¬ 1¬ e NR¬ 2¬R¬ 3¬ e um comprimento máximo de cadela de 4 átomos, estendendo-se entre E e NR¬ 2¬R¬ 3¬, em que um dos átomos de carbono do grupo ligador pode opcionalmente ser substituído com um átomo de oxigênio ou nitrogênio; e em que os átomos de carbono do grupo ligador A podem opcionalmente conter um ou mais substituintes selecionados de oxo, flúor e hidróxi, desde que o grupo hidróxi, quando presente, não seja localizado em um átomo de carbono com respeito ao grupo NR¬ 2¬R¬ 3¬ e desde que o grupo oxo, quando presente, seja localizado em um átomo de carbono com respeito ao grupo NR¬ 2¬R¬ 3¬; E é um grupo monocíclico ou bicíclico carbocíclico ou heterocíclico; R¬ 1¬ é um grupo arila ou heteroarila; e R¬ 2¬, R¬ 3¬, R¬ 4¬ e R¬ 5¬ são como definidos nas reivindicações. São também providas composições farmacêuticas contendo os compostos, métodos para preparar os compostos e seu uso como agentes anti-câncer.",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORG;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/020-103-994-643-536,Patent Application,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,DISCONTINUED
481,AU,B2,AU 2004/253338 B2,124-443-058-193-677,2010-02-18,2010,AU 2004/253338 A,2004-07-05,US 48468503 P;;GB 0315657 A;;US 51437403 P;;GB 0324919 A;;GB 2004002824 W,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,,ASTEX THERAPEUTICS LTD,TREWARTHA GARY;;O'BRIEN MICHAEL ALISTAIR;;GILL ADRIAN LIAM;;EARLY THERESA RACHEL;;WOODHEAD ANDREW JAMES;;BERDINI VALERIO;;WOOLFORD ALISON JO-ANNE;;HOWARD STEVEN;;WYATT PAUL;;NAVARRO EVA FIGUEROA;;CARR MARIA GRAZIA,ASTEX THERAPUETICS LIMITED (2006-02-02),https://lens.org/124-443-058-193-677,Granted Patent,no,1,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/00;;A61K31/4184;;A61P25/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P37/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,INACTIVE
482,KR,A,KR 20060082847 A,158-025-179-236-321,2006-07-19,2006,KR 20067000119 A,2004-07-05,GB 2004002824 W;;GB 0315657 A;;GB 0324919 A;;US 48468503 P;;US 51437403 P,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS,"The invention provides compounds having activity as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinases for use in the treatment of disease states and conditions such as cancer that are mediated by the kinases. The compounds have the general formula (I). Also included within formula (I) are the salts, solvates and N-oxides of the compounds.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,,https://lens.org/158-025-179-236-321,Patent Application,no,0,0,7,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D403/04;;A61K31/4155;;A61K31/4184,A61K31/4155;;A61K31/00;;A61K31/4184;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,INACTIVE
483,US,B2,US 9283226 B2,154-629-372-982-600,2016-03-15,2016,US 201414180440 A,2014-02-14,US 201414180440 A;;GB 0329617 A;;US 201213536174 A;;US 59678807 A;;GB 2004005464 W;;US 53219903 P;;US 57784304 P,2003-12-23,Pyrazole derivatives as protein kinase modulators,"The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R 1 and NR 2 R 3 and a maximum chain length of 4 atoms extending between E and NR 2 R 3 , wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the NR 2 R 3 group and provided that the oxo group when present is located at a carbon atom α with respect to the NR 2 R 3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group;R 1 is an aryl or heteroaryl group; andR 2 , R 3 , R 4 and R 5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD;;CANCER RES INST ROYAL;;CANCER REC TECH LTD;;ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (2010-03-29);;ASTEX THERAPEUTICS LIMITED (2010-03-12);;CANCER RESEARCH TECHNOLOGY LIMITED (2010-03-12),https://lens.org/154-629-372-982-600,Granted Patent,yes,75,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10,,19,13,026-856-766-952-702;;050-511-023-328-286;;046-707-787-993-630;;020-344-400-405-766;;077-109-648-971-807;;028-567-007-131-606;;055-878-581-670-29X;;050-511-023-328-286;;026-856-766-952-702;;078-846-071-783-225;;035-444-077-928-497;;041-703-940-947-068;;029-742-983-481-795,10.1126/scisignal.122re4;;18523239;;20153226;;10.1016/j.jmgm.2010.01.007;;10.1038/5587;;9930872;;10.1016/j.bbapap.2003.11.029;;15023366;;10.1016/s0163-7258(02)00193-6;;12191616;;10.2174/1568026053507714;;15853641;;10.1016/s0040-4039(00)89682-3;;20153226;;10.1016/j.jmgm.2010.01.007;;10.1126/scisignal.122re4;;18523239;;10.1093/annonc/mdh145;;15033673;;22781553;;10.1158/1078-0432.ccr-11-3313;;9544425;;10.1023/a:1005960822365;;10.1126/science.286.5439.531;;10521349,"""Pharmacological PKA Inhibition: All May Not Be What It Seems"" by Murray, Sci. Signal. 1, re4 (2008).;;""A comprehensive structure-activity analysis of protein kinase B-alpha (Akt1) inhibitors"" by Ajmani et al., J. Molec. Graph. Model. 28, 683-94 (2010).;;""An essential part for Rho-associated kinase in the transcellular invasion of tumor cells"" by Itoh et al., Nature Med. 5, 221-25 (1999).;;Taylor, S.S. et al., PKA: a portrait of protein kinase dynamics, Biochemica et Biophysica, 1697, 2004, pp. 259-269.;;Hill, Michelle M. et al., Inhibition of protein kinase B/Akt: implications for cancer therapy, Pharmacology & Therapeutics, 93, 2002, pp. 243-251.;;Barnett, Stanley F. et al., The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress Towards Target Validation, Current Topics in Medicinal Chemistry, 5, 2005, pp. 109-125.;;Nagarajan, K. et al., Mechanism of Formation of p-Substituted Products in Displacement Reactions on alpha-Chlorodiphenylacetamides, Tetrahedron Letters, No. 22, 1968, pp. 2717-2720.;;Simig, Gyula et al., Single Electron Transfer Inititated Thermal Reactions of Arylmethyl Halides, X, Acta Chimica Hungarica, 118(4), 1985, pp. 309-314.;;Ajmani Subhash et al., A comprehensive structure-activity analysis of protein kinase B-alpha (Aktl) inhibitors, Journal of Molecular Graphics and Modelling, 28(7), 2010, pp. 683-694.;;Murray Andrew J., Pharmacological PKA Inhibition: All May Not Be What It Seems, Science Signaling, Jun. 3, 2008,vol. 1, issue 22, pp. 1-6.;;Dorwald, Florencio Zaragoza, Side Reactions in Organic Synthesis, Wiley-VCH, 2005, p. 1 and preface.;;Drewry et al. CAS 143 229871 (2005).;;Schrijvers et al., Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study, Annals of Oncology, vol. 15, 638-645, 2004.;;Yap et al.; AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity; Clin Cancer Re; Jul. 15, 2012; 18(14).;;Marshall, Chris; Effective inhibition of actomyosin contractility by a new series of Rho-kinase inhibitors blocks multiple modes of melanoma cell migration and metastasis; PowerPoint Presentation at Antitumoral Targets Upstream and Downstream of RAS GTPases Meeting; Santander, Spain; Oct. 8-9, 2012.;;Lala & Orucevic, Role of nitric oxide in tumor progression: Lessons from experimental tumors, Cancer and Metastasis Reviews 1998 17(1) 91-106.;;Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, Science (1999) vol. 286 531-537.;;Cancer online retrieved Jul. 6, 2007 retrieved from the internet http://www.nlm.nih.gov/medlineplus/cancer.html.;;Cancer online retrieved Jul. 6, 2007 retrieved from the internet http://en.wikipedia.org/wiki/Cancer.",INACTIVE
484,AU,B2,AU 2004/303602 B2,186-826-472-890-598,2008-12-18,2008,AU 2004/303602 A,2004-12-23,US 53219903 P;;GB 0329617 A;;US 57784304 P;;GB 2004005464 W,2003-12-23,Pyrazole derivatives as protein kinase modulators,,CANCER REC TECH LTD;;ASTEX THERAPEUTICS LTD;;CANCER RES INST ROYAL,COLLINS IAN;;DOWNHAM ROBERT;;BERDINI VALERIO;;WYATT PAUL GRAHAM;;CARR ROBIN ARTHUR ELLIS;;WOODHEAD STEVEN JOHN;;SORE HANNAH FIONA;;BOYLE ROBERT GEORGE;;VERDONK MARINUS LEENDERT;;WALKER DAVID WINTER;;SAXTY GORDON,,https://lens.org/186-826-472-890-598,Granted Patent,no,1,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/415;;C07D231/12;;C07D401/10;;C07D413/10,,0,0,,,,INACTIVE
485,DK,T3,DK 1706385 T3,018-003-494-630-536,2011-01-10,2011,DK 04806258 T,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W,2003-12-23,Pyrazol-derivater som proteinkinasemodulatorer,,ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/018-003-494-630-536,Granted Patent,no,0,0,12,52,0,,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,ACTIVE
486,WO,A1,WO 2005/061463 A1,039-013-757-446-783,2005-07-07,2005,GB 2004005464 W,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,"The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between Rl and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; Rl is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX TECHNOLOGY LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL;;BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/039-013-757-446-783,Patent Application,yes,2,107,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/415;;C07D231/12;;C07D401/10;;C07D413/10,,0,0,,,,PENDING
487,CN,A,CN 104114537 A,089-971-379-223-816,2014-10-22,2014,CN 201280065744 A,2012-10-31,EP 2012071560 W;;GB 201118876 A;;US 201161554415 P;;US 201261645283 P,2011-11-01,"Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection","The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R0 is hydrogen or C1-2 alkyl; R1a is selected from CONH2; CO2H; an optionally substituted acyclic C1-8 hydrocarbon group; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R2 is selected from hydrogen and a group R2a; R2a is selected from an optionally substituted acyclic d-8 hydrocarbon group; an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1 or 2 ring members are heteroatom ring members selected from O, N and S; and an optionally substituted bicyclic heterocyclic group of 9 or 10 ring members, of which 1 or 2 ring members are nitrogen atoms; wherein at least one of R1 and R2 is other than hydrogen; R3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0, 1, 2 or 3 heteroatom ring members selected from N, O and S; R4a is selected from halogen; cyano; C1-4 alkyl optionally substituted with one or more fluorine atoms; C1-4 alkoxy optionally substituted with one or more fluorine atoms; hydroxy-C1-4 alkyl; and C1-2 alkoxy-C1-4 alkyl; R5 is selected from hydrogen and a substituent R5a; and R5a is selected from C1-2 alkyl optionally substituted with one or more fluorine atoms; C1-3 alkoxy optionally substituted with one or more fluorine atoms; halogen; cyclopropyl; cyano; and amino, The compounds have activity against hepatitis C virus and can be used in the prevention or treatment of hepatitis C viral infections.",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;BESONG GILBERT EBAI;;CARR MARIA GRAZIA;;HISCOCK STEVEN DOUGLAS;;O&#039;;BRIEN MICHAEL ALISTAIR;;REES DAVID CHARLES;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA,,https://lens.org/089-971-379-223-816,Patent Application,no,4,1,16,16,0,C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C233/18;;C07C233/25;;C07C235/46;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07C243/34;;C07C251/48;;C07C255/24;;C07C255/29;;C07C255/37;;C07C255/46;;C07C255/54;;C07C259/06;;C07C271/12;;C07C275/36;;C07C311/04;;C07C311/08;;C07C311/29;;C07C317/22;;C07C323/25;;C07D205/04;;C07D207/14;;C07D207/335;;C07D209/08;;C07D209/14;;C07D209/44;;C07D211/26;;C07D211/56;;C07D211/70;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/73;;C07D213/74;;C07D213/75;;C07D213/81;;C07D213/84;;C07D217/02;;C07D231/12;;C07D233/24;;C07D233/64;;C07D237/14;;C07D239/34;;C07D239/42;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07D263/32;;C07D265/36;;C07D271/10;;C07D277/68;;C07D285/13;;C07D295/02;;C07D295/027;;C07D295/185;;C07D295/192;;C07D305/06;;C07D305/08;;C07D307/14;;C07D307/22;;C07D307/79;;C07D309/06;;C07D309/12;;C07D309/14;;C07D319/18;;C07D513/04;;C07C2601/16;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C2601/04;;C07B2200/05;;C07B2200/05;;C07C255/46;;C07C255/54;;C07D213/73;;C07D213/74;;C07D213/75;;C07C259/06;;C07D213/81;;C07D309/06;;C07D213/84;;C07D309/12;;C07D309/14;;C07C271/12;;C07D217/02;;C07C275/36;;C07D319/18;;C07D231/12;;C07D233/24;;C07D233/64;;C07C311/04;;C07C311/08;;C07C311/29;;C07D237/14;;C07C317/22;;C07D239/34;;C07D239/42;;C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C323/25;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07C233/18;;C07C233/25;;C07D263/32;;C07C235/46;;C07D205/04;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07D265/36;;C07D207/14;;C07D271/10;;C07C243/34;;C07D207/335;;C07C251/48;;C07D209/08;;C07D209/14;;C07D277/68;;C07C255/24;;C07D209/44;;C07D513/04;;C07C255/29;;C07C255/37;;C07D285/13;;C07D295/02;;C07D211/26;;C07D211/56;;C07D211/70;;C07D295/185;;C07D295/192;;C07D213/38;;C07D213/64;;C07D305/06;;C07D305/08;;C07D213/65;;C07D213/68;;C07D307/14;;C07D307/22;;C07D307/79;;C07C313/06;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;C07D295/027;;A61P31/12;;A61P31/14;;A61P43/00;;C07D239/42;;C07C217/58;;C07D211/70;;C07C237/08;;C07D209/08;;C07D207/335;;C07C255/37;;C07C255/29;;C07C237/06;;C07D285/13;;C07D513/04;;C07D265/36;;C07D295/02;;C07D305/08;;C07D213/81;;C07D263/32;;C07D243/14;;C07C235/46;;C07C237/10;;C07C255/46;;C07C259/06;;C07C271/12;;C07C251/48;;C07C255/54;;C07C255/24;;C07D305/06;;C07B2200/05;;C07D237/14;;C07D307/14;;C07D213/73;;C07D209/14;;C07C275/36;;C07D295/192;;C07C225/12;;C07D239/34;;C07C323/25;;C07D211/26;;C07C217/60;;C07C233/25;;C07D277/68;;C07D271/10;;C07D309/12;;C07D319/18;;C07C217/90;;C07D241/18;;C07D213/64;;C07D233/24;;C07C311/08;;C07D211/56;;C07D231/12;;C07D241/20;;C07C311/29;;C07D213/65;;C07C217/62;;C07D217/02;;C07D213/68;;C07D213/38;;C07D213/74;;C07D213/75;;C07C237/04;;C07D307/22;;C07D233/64;;C07C317/22;;C07D309/06;;C07D309/14;;C07D241/24;;C07D207/14;;C07D307/79;;C07C311/04;;C07D205/04;;C07C243/34;;C07C233/18;;C07C237/12;;C07D209/44;;C07D295/185;;C07D213/84;;C07C313/06;;C07C2601/04;;C07C2601/08;;C07C2601/16;;C07C2601/14;;C07C2601/02;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;A61K45/06;;C07C217/74;;C07C237/20;;C07D295/027,C07D209/14;;A61K31/137;;A61K31/415;;A61K31/4164;;A61K31/44;;A61P31/12;;C07C217/58;;C07D213/75;;C07D231/12;;C07D233/24;;C07D233/64;;C07D295/02;;C07D305/06;;C07D305/08;;C07D309/14,,1,1,092-196-354-877-585,16621574;;10.1016/j.bmc.2006.03.042,"KATRIN GROEBKE ZBINDEN, ET AL.: ""Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity"", 《BIOORGANIC & MEDICINAL CHEMISTRY》, vol. 14, 18 April 2006 (2006-04-18), pages 5357 - 5369",DISCONTINUED
488,RS,B,RS 51546 B,140-834-722-037-401,2011-06-30,2011,RS P20100532 A,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,"Jedinjenje formule (I):ili njegova so, solvat, tautomer ili N-oksid;u kome, A je zasićena ugljovodonična linker grupa koja sadrži od 1 do 7 atoma ugljenika, pri čemu linker grupa ima maksimalnu dužinu lanca od 5 atoma koji se pruža između R1 i NR2R3 i maksimalnu dužinu lanca od 4 atoma koji se pruža između E i NR2R3, pri čemu jedan od atoma ugljenika u linker grupi mogu biti izborno zamenjeni atomom kiseonika ili azota; i pri čemu atomi ugljenika linker grupe A mogu izborno da nose jedan ili više supstituenata koji su izabrani od okso, fluora i hidroksida, uz uslov da se hidroksi grupa kada je prisutna ne nalazi na atomu ugljenika α u odnosu na NR2R3 grupu i uz uslov da se okso grupa kada je prisutna nalazi na atomu ugljenika α u odnosu na NR2R3 grupu;E je monociklična, biciklična karbociklična ili heterociklična grupa u kojoj, E je nesupstituisan ili ima do 4 supstituenta R8 izabrana iz grupe koju čine hidroksi, okso (kada je E nearomatičan), hlor, brom, trifluorometil, cijano, C1-4 hidrokarbiloksi i C1-4 hidrokarbil izborno supstituisan sa C1-2 alkoksi ili hidroksil;R1 je aril ili heteroaril grupa koja je nesupstituisana ili nosi jedan ili više supstituenata koji su izabrani iz grupe koju čine hidroksi; C1-4 aciloksi; fluor; hlor; brom; trifluorometil; cijano; CONH2; nitro; C1-4 hidrokarbiloksi i C1-4 hidrokarbil, pri čemu je svaki od njih izborno supstituisan sa C1-2 alkoksi, karboksi ili hidroksi; C1-4 acilamino; benzoilamino; pirolidinokarbonil; piperidinokarbonil; morfolinokarbonil; piperazinokarbonil; pet i šesto-člane heteroaril i heteroariloksi grupe koje sadrže jedan ili dva heteroatoma izabrana od N, O i S; fenil; fenil-C1-4alkil; fenil- C1-4 alkoksi; heteroaril- C1-4 alkil; heteroaril- C1-4 alkoksi i fenoksi, pri čemu su svaka od heteroaril, heteroariloksi, fenil, fenil- C1-4 alkil, fenil- C1-4 alkoksi, heteroaril-C1-4 alkil, heteroaril-C1-4 alkoksi i fenoksi grupa izborno supstituisana sa 1, 2 ili 3 supstituenata koji su izabrani iz grupe koju čine C1-2 aciloksi, fluor, hlor, brom, trifluorometil, cijano, CONH2, C1-2 hidrokarbiloksi i C1-2 hidrokarbil, gde je svaki od njih izborno supstituisan sa metoksi ili hidroksil;R2 i R3 nezabvisno su izabrani iz grupe koju čine vodonik, C1-4 hidrokarbil i C1-4 acil, pri čemu su hidrokarbil i acil grupe izborno supstituisane sa jednim ili više supstituenata koji su izabrani iz grupe koju čine fluor, hidroksi, amino, metilamino, dimetilamino i metoksi;ili R2 i R3 zajedno sa atomom azota za koji su vezani formiraju cikličnu grupu koja je izabrana od imidazol grupe i zasićene monociklične heterociklične grupe koja ima 4-7 članova u prstenu i izborno sadrži drugi heteroatom kao član prstena izabran od O i N;ili jedan od R",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/140-834-722-037-401,Granted Patent,no,0,0,12,52,0,,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,ACTIVE
489,US,B2,US 7977477 B2,156-115-927-776-670,2011-07-12,2011,US 56416604 A,2004-07-05,US 56416604 A;;GB 0315657 A;;GB 0324919 A;;US 48468503 P;;US 51437403 P;;GB 2004002824 W,2003-07-03,Benzimidazole derivatives and their use as protein kinase inhibitors,"The invention provides compounds of the formula (I): The compounds have activity against cyclin dependent kinases, glycogen synthase kinase and Auroa kinases and are therefore useful to treat cancer and viral diseases.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,ASTEX THERAPEUTICS LTD (2006-06-16),https://lens.org/156-115-927-776-670,Granted Patent,yes,63,29,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/5377;;A61K31/00;;A61K31/4184;;A61P31/10;;A61P35/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14,544/140;;548/306.1;;514/234.5;;514/394,21,8,001-516-175-552-397;;012-522-479-506-568;;041-999-952-766-040;;075-266-316-125-301;;150-531-382-227-747;;012-522-479-506-568;;020-435-634-003-86X;;001-516-175-552-397,10.1016/s0169-409x(01)00097-7;;11325474;;10.1002/bscb.19870960110;;6827558;;10.1021/jm00357a015;;10.1016/s0968-0896(01)00194-8;;11597481;;12482427;;10.1016/s0960-894x(02)00884-3;;10.1002/bscb.19870960110;;10.1016/j.addr.2003.10.020;;14962582;;10.1016/s0169-409x(01)00097-7;;11325474,"CA Registry No. 518987-01-4, entered in the Registry file on STN CAS Online May 22, 2003.;;Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227.;;Vippagunta et al., Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26.;;Essassi et al.: Synthese et Hererocyclisation Des (Pyrazolyl-3-(5))-2 Benzimidazoles en Catalyse Par Transfert de Phase, Bull. Soc. Chim. Belg. vol. 96, pp. 63-67, 1987.;;International Search Report for WO 2005/002552 (PCT/GB2004/002824 filed Jul. 5, 2004).;;Blankley et al.: Antihypertensive Activity of 6-Arylpyrido[2,3-d] Pyrimidim-7-Amine Derivatives. 2. 7-Acyl Amide Analogues, Journal of Medicinal Chemistry, vol. 26, No. 3, Mar. 1, 1983, pp. 403-411.;;Abd El-Wareth A O Sarhan et al.: Synthesis, Characterization and Reactions of 2-Deoxo-5-Deazaalloxazines, Bioorganic & Medicinal Chemistry, vol. 9, Jan. 1, 2001, pp. 2993-2998.;;Mesguiche et al.: 4-Alkoxy-2,6-Diaminopyrimidine Derivatives: Inhibitors of Cyclin Dependent Kinases 1 and 2, Bioorganic & Medicinal Chemistry Letters, vol. 13, Jan. 1, 2003, pp. 217-222.;;GB search report GB 0315657.7 filed Jul. 3, 2003.;;GB search report GB 0324919.0 filed Oct. 24, 2003.;;European Supplementary Search report EP Application No. 04 743 172.1, Sep. 19, 2008.;;GB search report GB 0428552.4 filed Dec. 30, 2004.;;GB search report GB 0428554.0 filed Dec. 30, 2004.;;International Search Report PCT/GB2005/005097 filed Mar. 28, 2006.;;GB search report GB 0526607.7 filed Dec. 30, 2005.;;International Search Report PCT/GB2006/004954 filed May 14, 2007.;;Essassi E M et al., ""Synthese Et Hererocyclisation Des (Pyrazolyl-3(5))-2 Benzimidazoles En Catalyse Par Transfert De Phase"" Bulletin Des Societes Chimiques Belges, 96(1), 63-67 (1987).;;International Search Report from priority application WO 2005/002552 published Jan. 13, 2005.;;Morissette et al., ""High-throughput crystallization: polymorphs, salts, co-crytsals and solvates of pharmaceutical solids"", Advanced Drug Delivery Reviews, 2004, 56, 275-300.;;Souillac et al., ""Characterization of Delivery Systems, Differential Scanning Calorimetry"", Encyclopedia of Controlled Drug Delivery, Wiley, 1999, 212-227.;;Vippagunta et al., ""Crystalline solids"", Advanced Drug Delivery Reviews, 2001, 48, 3-26.",INACTIVE
490,EP,B1,EP 1648426 B1,185-094-562-210-755,2014-01-08,2014,EP 04743172 A,2004-07-05,GB 2004002824 W;;GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,,https://lens.org/185-094-562-210-755,Granted Patent,yes,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,1,1,036-221-587-466-999,19143567;;10.1021/jm800984v,"HOWARD S. ET AL.: ""Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent Aurora kinase activity"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, no. 3, 2009, pages 379 - 388, XP055086933, DOI: doi:10.1021/jm800984v",ACTIVE
491,MX,A,MX PA06007326 A,039-621-574-255-625,2007-01-26,2007,MX PA06007326 A,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS.,"(I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between Rl and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; Rl is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;WYATT PAUL GRAHAM;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/039-621-574-255-625,Patent Application,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/12;;A61K31/00;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,ACTIVE
492,PT,E,PT 1706385 E,074-140-082-348-077,2010-12-22,2010,PT 04806258 T,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,,CANCER REC TECH LTD;;ASTEX THERAPEUTICS LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/074-140-082-348-077,Granted Patent,no,0,0,12,52,0,,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,ACTIVE
493,WO,A2,WO 2005/002552 A2,108-786-522-702-645,2005-01-13,2005,GB 2004002824 W,2004-07-05,GB 0315657 A;;GB 0324919 A;;US 48468503 P;;US 51437403 P,2003-07-03,PHARMACEUTICAL COMPOUNDS,"The invention provides compounds having activity as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinases for use in the treatment of disease states and conditions such as cancer that are mediated by the kinases. The compounds have the general formula (I). Also included within formula (I) are the salts, solvates and N-oxides of the compounds.",ASTEX TECHNOLOGY LTD;;BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,,https://lens.org/108-786-522-702-645,Patent Application,yes,27,136,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/00;;A61K31/4184;;A61P31/10;;A61P35/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14,,74,55,012-865-156-438-120;;001-661-891-531-467;;015-505-100-135-710;;051-255-997-632-880;;005-521-719-112-587;;009-033-647-751-621;;025-624-292-641-902;;051-098-750-980-596;;040-343-674-829-495;;023-475-764-350-339;;060-784-743-188-505;;029-901-810-393-557;;007-838-854-537-973;;001-226-923-460-944;;002-515-903-844-18X;;028-122-953-422-563;;086-390-749-652-665;;066-013-401-674-717;;004-960-787-208-757;;036-451-583-862-453;;007-838-854-537-973;;160-341-123-989-355;;029-901-810-393-557;;022-498-296-482-829;;160-341-123-989-355;;083-182-706-995-400;;060-784-743-188-505;;005-383-821-091-791;;077-883-857-250-339;;052-908-745-194-978;;016-694-431-273-124;;131-678-430-028-96X;;004-960-787-208-757;;028-122-953-422-563;;023-656-951-495-886;;042-163-039-479-494;;086-272-744-175-380;;007-364-858-655-289;;000-820-736-344-337;;126-811-728-740-254;;077-365-619-775-156;;004-137-705-827-976;;111-610-126-227-490;;077-295-491-167-117;;046-777-072-258-96X;;007-378-255-811-868;;110-712-435-087-04X;;050-476-538-810-273;;021-634-052-025-91X;;124-153-998-836-964;;056-848-802-620-026;;019-078-987-150-365;;009-760-608-802-570;;027-745-118-667-14X;;007-421-226-677-859,7768349;;0007768349;;10.1096/fasebj.9.8.7768349;;10.1126/science.1862342;;0001862342;;1862342;;1322797;;10.1016/0092-8674(92)90166-a;;10.1016/0092-8674(93)90144-f;;8387896;;pmc395100;;8194527;;10.1002/j.1460-2075.1994.tb06519.x;;11166196;;10.1016/s0962-8924(00)01880-8;;11413462;;10.1038/35048096;;10.1023/a:1023789416385;;12884918;;13678575;;10.1016/s0092-8674(03)00685-8;;10.1016/s0092-8674(03)00642-1;;13678582;;10523496;;10.1242/jcs.112.21.3591;;9771714;;10.1038/2496;;10232583;;12019169;;pmc1871005;;7573366;;10.1093/jnci/94.17.1320;;12208897;;10.1093/emboj/17.11.3052;;9606188;;pmc1170645;;10.1111/j.1349-7006.2000.tb00878.x;;11050471;;pmc5926256;;12684414;;10.1054/bjoc.2000.1684;;11259099;;pmc2363814;;10232583;;10.1074/jbc.274.11.7334;;10066797;;9771714;;10.1038/2496;;10.1093/jnci/91.13.1160;;10393726;;10.1074/jbc.274.11.7334;;10066797;;10511710;;10.1016/s0962-8924(99)01658-x;;10523496;;10.1242/jcs.112.21.3591;;12214247;;10.1038/sj.onc.1205775;;10.1002/cncr.11879;;14692019;;14522886;;10.3892/or.10.5.1275;;12883693;;12716366;;10.1046/j.1365-2141.2003.04311.x;;12684414;;10.1093/jnci/94.17.1320;;12208897;;10.1124/mi.3.3.127;;14993419;;10.1016/s1535-6108(02)00235-0;;12559175;;14981513;;10.1038/nm1003;;10.1002/jps.2600660104;;833720;;10.1080/00397917709409270;;10.1002/anie.196603851;;10.1021/jo01351a600;;10.1016/s0040-4039(00)94371-5;;10.1007/bf00808679;;10.1002/0471220574;;15002962;;10.1021/cc034046a;;12739949;;10.1021/cc0201041;;10.1038/ng1220;;12881723;;10.1016/0076-6879(87)52071-7;;3657592;;10.1385/1-59259-760-2:077;;15064486;;10.1074/jbc.m313407200;;14701826;;10.1038/nature02313;;14999283;;7805863;;10.1016/0014-5793(94)01298-9;;10559988;;010559988;;10.1038/15674;;12501191;;10.1021/bi0268910;;9692848;;10.1016/s0022-1759(98)00028-3,"HARDIE, G., HANKS, S.: ""The Protein Kinase Facts Book. I and II"", 1995, ACADEMIC PRESS;;HANKS, S.K., HUNTER, T., FASEB J., vol. 9, 1995, pages 576 - 596;;KNIGHTON ET AL., SCIENCE, vol. 253, 1991, pages 407 - 414;;HILES ET AL., CELL, vol. 70, 1992, pages 419 - 429;;KUNZ ET AL., CELL, vol. 73, 1993, pages 585 - 596;;GARCIA-BUSTOS ET AL., EMBO J, vol. 13, 1994, pages 2352 - 2361;;ADAMS ET AL., TRENDS CELL BIOL., vol. 11, 2001, pages 49 - 54;;E. A. NIGG, NAT. REV. MOL. CELL BIOL., vol. 2, 2001, pages 21 - 32;;KATAYAMA H, BRINKLEY WR, SEN S.: ""The Aurora kinases: role in cell transformation and tumorigenesis"", CANCER METASTASIS REV., vol. 22, no. 4, December 2003 (2003-12-01), pages 451 - 64, XP009022607, DOI: doi:10.1023/A:1023789416385;;PRIGENT ET AL., CELL, vol. 114, 2003, pages 531 - 535;;HIROTA ET AL., CELL, vol. 114, 2003, pages 585 - 598;;GIET ET AL., J. CELL. SCI., vol. 112, 1999, pages 3591 - 361;;ZHOU ET AL., NAT. GENET., vol. 20, 1998, pages 189 - 193;;TANAKA ET AL., CANCER RES., vol. 59, 1999, pages 2041 - 2044;;HAN ET AL., CANCER RES., vol. 62, 2002, pages 2890 - 2896;;ISOLA, AMERICAN JOURNAL OF PATHOLOGY, vol. 147, 1995, pages 905 - 911;;SEN ET AL., J. NATL.CANCER INST, vol. 94, 2002, pages 1320 - 1329;;BISCHOFF ET AL., EMBO J., vol. 17, 1998, pages 3052 - 3065;;TAKAHASHI ET AL., JPN. J. CANCER RES., vol. 91, 2000, pages 1007 - 1014;;GRITSKO ET AL., CLIN. CANCER RES., vol. 9, 2003, pages 1420 - 1426;;SAKAKURA ET AL., BRITISH JOURNAL OF CANCER, vol. 84, 2001, pages 824 - 831;;TANAKA ET AL., CANCER RESEARCH, vol. 59, 1999, pages 2041 - 2044;;KIMURA ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 7334 - 7340;;ZHOU ET AL., NATURE GENETICS, vol. 20, 1998, pages 189 - 193;;LI ET AL., CLIN CANCER RES., vol. 9, no. 3, 2003, pages 991 - 7;;KATAYAMA ET AL., GENE, vol. 244, pages 1 - 7;;KATAYAMA ET AL., J. NATL CANCER INST., vol. 91, 1999, pages 1160 - 1162;;KIMURA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 7334 - 7340;;TAKAHASHI ET AL., JPN J. CANCER RES., vol. 91, 2001, pages 1007 - 1014;;BISCHOFF ET AL., TRENDS IN CELL BIOLOGY, vol. 9, 1999, pages 454 - 459;;GIET ET AL., JOURNAL OF CELL SCIENCE, vol. 112, 1999, pages 3591 - 3601;;DUTERTRE ET AL., ONCOGENE, vol. 21, 2002, pages 6175 - 6183;;ROYCE ME, XIA W, SAHIN AA, KATAYAMA H, JOHNSTON DA, HORTOBAGYI G, SEN S, HUNG MC: ""STK15/Aurora-A expression in primary breast tumours is correlated with nuclear grade but not with prognosis"", CANCER., vol. 100, no. 1, 1 January 2004 (2004-01-01), pages 12 - 9;;MORENO-BUENO G, SANCHEZ-ESTEVEZ C, CASSIA R, RODRIGUEZ-PERALES S, DIAZ-URIARTE R, DOMINGUEZ 0, HARDISSON D, ANDUJAR M, PRAT J, MAT, CANCER RES., vol. 63, no. 18, 15 September 2003 (2003-09-15), pages 5697 - 702;;REICHARDT ET AL., ONCOL REP., vol. 10, no. 5, September 2003 (2003-09-01), pages 1275 - 9;;HAMADA ET AL., BR. J. HAEMATOL., vol. 121, no. 3, May 2003 (2003-05-01), pages 439 - 47;;GRITSKO ET AL., CLIN CANCER RES., vol. 9, no. 4, April 2003 (2003-04-01), pages 1420 - 6;;LI ET AL., CLIN. CANCER RES., vol. 9, no. 3, March 2003 (2003-03-01), pages 991 - 7;;J. NATL. CANCER INST., vol. 94, no. 17, 4 September 2002 (2002-09-04), pages 1320 - 9;;DUTERTRE S, PRIGENT C.: ""Aurora-A overexpression leads to override of the microtubule-kinetochore attachment checkpoint"", MOL. INTERV., vol. 3, no. 3, May 2003 (2003-05-01), pages 127 - 30;;ANAND S, PENRHYN-LOWE S, VENKITARAMAN AR.: ""Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol"", CANCER CELL., vol. 3, no. 1, January 2003 (2003-01-01), pages 51 - 62, XP009026392, DOI: doi:10.1016/S1535-6108(02)00235-0;;HARRINGTON ET AL., NAT MED., vol. 10, no. 3, March 2004 (2004-03-01), pages 262 - 7;;BERGE ET AL.: ""Pharmaceutically Acceptable Salts"", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;JERRY MARCH: ""Advanced Organic Chemistry"", WILEY INTERSCIENCE;;L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514;;JERRY MARCH: ""Advanced Organic Chemistry"", 1992, JOHN WILEY & SONS, pages: 109 - 114;;CAHN, INGOLD, PRELOG, ANGEW. CHEM. INT. ED. ENGL., vol. 5, 1966, pages 385 - 415;;SHEEHAN ET AL., J. AMER. CHEM SOC., vol. 77, 1955, pages 1067;;SHEEHAN ET AL., J. ORG. CHEM., vol. 26, 1961, pages 2525;;L. A. CARPINO, J. AMER. CHEM. SOC., vol. 115, 1993, pages 4397;;CASTRO ET AL., TETRAHEDRON LETTERS, vol. 31, 1990, pages 205;;KONIG ET AL., CHEM. BER., vol. 103, no. 708, pages 2024 - 2034;;""Fiesers'Reagentsfor Organic Synthesis"", vol. 1-17, JOHN WILEY;;""Organic Syntheses"", vol. 1-8, 1995, JOHN WILEY;;JACHAK ET AL., MONTASH. CHEM., vol. 124, no. 2, 1993, pages 199 - 207;;SCHMIDT, HELV. CHIM. ACTA., vol. 39, 1956, pages 986 - 991;;HELV. CHIM. ACTA., vol. 41, 1958, pages 306 - 309;;T. GREEN, P. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY AND SONS;;ROSENTRETER U, HUBER U.: ""Optimal fraction collecting in preparative LC/MS"", J COMB CHEM., vol. 6, no. 2, 2004, pages 159 - 64;;LEISTER W, STRAUSS K, WISNOSKI D, ZHAO Z, LINDSLEY C.: ""Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries"", J COMB CHEM., vol. 5, no. 3, 2003, pages 322 - 9, XP001198955, DOI: doi:10.1021/cc0201041;;""Remington's Pharmaceutical Sciences"", MACK PUBLISHING COMPANY;;EWART-TOLAND ET AL., NAT GENET., vol. 34, no. 4, August 2003 (2003-08-01), pages 403 - 12;;""Current Protocols in Molecular Biology"", 2004, JOHN WILEY & SONS INC.;;""PCR Protocols: a guide to methods and applications"", 1990, ACADEMIC PRESS;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;ANGERER, METH. ENZYMOL., vol. 152, 1987, pages 649;;""Current Protocols in Molecular Biology"", 2004, JOHN WILEY & SONS INC;;JOHN M. S. BARTLETT: ""Molecular Diagnosis of Cancer, Methods and Protocols"", March 2004, article ""Fluorescence In Situ Hybridization: Technical Overview"", pages: 077 - 088;;HARWELL RM, MULL BB, PORTER DC, KEYOMARSI K., J BIOL CHEM., vol. 279, no. 13, 26 March 2004 (2004-03-26), pages 12695 - 705;;RAJAGOPALAN H, JALLEPALLI PV, RAGO C, VELCULESCU VE, KINZLER KW, VOGELSTEIN B, LENGAUER C., NATURE, vol. 428, no. 6978, 4 March 2004 (2004-03-04), pages 77 - 81;;HELLMICH ET AL., FEBS LETT, vol. 356, 1994, pages 317 - 21;;BROWN ET AL., NAT. CELL BIOL., vol. 1, 1999, pages 438 - 443;;LOWE, E.D. ET AL., BIOCHEMISTRY, vol. 41, 2002, pages 15625 - 15634;;NOCIARI, M. M, SHALEV, A., BENIAS, P., RUSSO, C., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 213, 1998, pages 157 - 167",PENDING
494,AU,A1,AU 2004/303602 A1,120-504-331-659-281,2005-07-07,2005,AU 2004/303602 A,2004-12-23,US 53219903 P;;GB 0329617 A;;US 57784304 P;;GB 2004005464 W,2003-12-23,Pyrazole derivatives as protein kinase modulators,,CANCER REC TECH LTD;;ASTEX THERAPEUTICS LTD;;CANCER RES INST ROYAL,COLLINS IAN;;DOWNHAM ROBERT;;BERDINI VALERIO;;WYATT PAUL GRAHAM;;CARR ROBIN ARTHUR ELLIS;;WOODHEAD STEVEN JOHN;;SORE HANNAH FIONA;;BOYLE ROBERT GEORGE;;VERDONK MARINUS LEENDERT;;WALKER DAVID WINTER;;SAXTY GORDON,,https://lens.org/120-504-331-659-281,Patent Application,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/12;;A61K31/415;;C07D401/10;;C07D413/10,,0,0,,,,INACTIVE
495,AR,A1,AR 049437 A1,039-282-619-790-346,2006-08-02,2006,AR P050102341 A,2005-06-08,US 57784304 P;;GB 2004005464 W,2004-06-08,DERIVADOS DE PIRAZOLES COMO MODULADORES DE PROTEINA QUINASA,"Compuestos de formula (1) con actividad inhibidora de proteína quinasa B, composiciones farmacéuticas que contienen los compuestos, métodos para preparar los compuestos y su uso como agentes anticancerosos. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), o una sal, solvato, tautomero o N-oxido del mismo; donde A es un grupo conector hidrocarburo saturado que contiene entre 1 y 7 átomos de carbono, donde el grupo conector que se extiende entre R1 y NR2R3 tiene una longitud máxima de cadena de 5 átomos y el que se extiende entre E y NR2R3 tiene una longitud máxima de cadena de 4 átomos, donde uno de los átomos de carbono en el grupo conector se puede reemplazar opcionalmente por un átomo de oxígeno o de nitrogeno; y donde los átomos de carbono del grupo conector A pueden llevar opcionalmente uno o más sustituyentes que se seleccionan entre oxo, fluor e hidroxi, siempre y cuando, cuando esté presente, el grupo hidroxi no esté localizado en un átomo de carbono a con respecto al grupo NR2R3 y siempre y cuando, si está presente, el grupo oxo esté localizado en un átomo de carbono a con respecto al grupo NR2R3; E es un grupo carbocíclico monocíclico o bicíclico o heterocíclico; R1 es un grupo arilo o heteroarilo; R2 y R3 se seleccionan de manera independiente entre hidrogeno, hidrocarbilo C1-4 y acilo C1-4 donde las unidades hidrocarbilo y acilo están sustituidas opcionalmente con uno o más sustituyentes que se seleccionan entre fluor, hidroxi, amino, metilamino, dimetilamino y metoxi; o R2 y R3 junto con el átomo de nitrogeno al que están unidos forman un grupo cíclico que se selecciona entre un grupo imidazol y un grupo monocíclico heterocíclico saturado con 4-7 miembros en el anillo y que opcionalmente contienen un segundo miembro heteroátomo en el anillo que se selecciona entre O y N; o uno de R2 y R3 junto con el átomo de nitrogeno al que están unidos y uno o más átomos del grupo conector A forman un grupo monocíclico heterocíclico saturado con 4-7 miembros en el anillo y que opcionalmente contienen un segundo miembro heteroátomo en el anillo que se selecciona entre O y N; o NR2R3 y el átomo de carbono del grupo conector A al cual está unido forman juntos un grupo ciano; R4 se selecciona entre hidrogeno, halogeno, hidrocarbilo saturado C1-5, hidrocarbiloxi saturado C1-5, ciano, y CF3; y R5 se selecciona entre hidrogeno, halogeno, hidrocarbilo saturado C1-5, hidrocarbiloxi saturado C1-5, ciano, CONH2, CONHR9, CF3, NH2, NHCOR9 o NHCONHR9; R9 es un grupo R9a o (CH2)R9a, donde R9a es un grupo monocíclico o bicíclico que puede ser carbocíclico o heterocíclico; el grupo carbocíclico o heterocíclico R9 está sustituido opcionalmente con uno o más sustituyentes que se seleccionan entre halogeno, hidroxi, trifluorometilo, ciano, nitro, carboxi, amino, mono- o di-hidrocarbilamino C1-4; un grupo Ra-Rb donde Ra es un anion, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc o NRcSO2; y Rb se selecciona entre hidrogeno, grupos heterocíclicos con entre 3 y 12 miembros en el anillo, y un grupo hidrocarbilo C1-8 sustituido opcionalmente con uno o más sustituyentes que se seleccionan entre hidroxi, oxo, halogeno, ciano, nitro, carboxi, amino, mono- o di-hidrocarbilamino C1-4, grupos carbocíclicos y heterocíclicos con entre 3 y 12 miembros en el anillo y donde uno o más átomos de carbono del grupo hidrocarbilo C1-8 se pueden reemplazar opcionalmente por O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 o X1C(X2)X1; Rc se selecciona entre hidrogeno e hidrocarbilo C1-4; y X1 es O, S o NRc y X2 es =O, =S o =NRc.",ASTEX TECHNOLOGY LTD;;CANCER RES INST ROYAL;;CANCER REC TECH LTD,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS;;COLLINS IAN,,https://lens.org/039-282-619-790-346,Patent Application,no,0,0,5,52,0,,,,0,0,,,,ACTIVE
496,BR,A8,BR PI0418078 A8,093-447-415-339-079,2018-01-02,2018,BR PI0418078 A,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W,2003-12-23,"composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto","""composto ou um seu sal, solvato, tautômero ou nóxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um compostos"". a invenção provê compostos de fórmula: tendo atividade inibidora da proteina quinase b: em que a é um grupo ligador de hidrocarboneto saturado, contendo de 1 a 7 átomos de carbono, o grupo ligador tendo um comprimento de cadeia máximo de 5 átomos, estendendo-se entre r^ 1^ e nr^ 2^r^ 3^ e um comprimento máximo de cadela de 4 átomos, estendendo-se entre e e nr^ 2^r^ 3^, em que um dos átomos de carbono do grupo ligador pode opcionalmente ser substituído com um átomo de oxigênio ou nitrogênio; e em que os átomos de carbono do grupo ligador a podem opcionalmente conter um ou mais substituintes selecionados de oxo, flúor e hidróxi, desde que o grupo hidróxi, quando presente, não seja localizado em um átomo de carbono com respeito ao grupo nr^ 2^r^ 3^ e desde que o grupo oxo, quando presente, seja localizado em um átomo de carbono com respeito ao grupo nr^ 2^r^ 3^; e é um grupo monocíclico ou bicíclico carbocíclico ou heterocíclico; r^ 1^ é um grupo arila ou heteroarila; e r^ 2^, r^ 3^, r^ 4^ e r^ 5^ são como definidos nas reivindicações. são também providas composições farmacêuticas contendo os compostos, métodos para preparar os compostos e seu uso como agentes anti-câncer.",ASTEX THERAPEUTICS LTD;;CANCER RESEARCH TECH LTD;;THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL,DAVID WINTER WALKER;;GORDON SAXTY;;HANNAH FIONA SORE;;IAN COLLINS;;MARINUS LEENDERT VERDONK;;PAUL GRAHAM WYATT;;ROBERT DOWNHAM;;ROBERT GEORG BOYLE;;ROBIN ARTHUR ELLIS CARR;;STEVEN JOHN WOODHEAD;;VALERIO BERDINI,,https://lens.org/093-447-415-339-079,Patent Application,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,DISCONTINUED
497,NZ,A,NZ 543959 A,148-273-251-866-492,2009-08-28,2009,NZ 54395904 A,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;GB 2004002824 W,2003-07-03,Benzimidazole derivatives and their use as protein kinase inhibitors,"Disclosed is a compound of formula (IV), or a salt, N-oxide, or solvate thereof, where A is NH(C=O), O(C=O), or C=O, and wherein the other substituents are as described in the specification. Also disclosed is a method of synthesis for the compound. Also disclosed is the use of the compound for treating a condition mediated by a cyclin dependent kinase, glycogen synthase kinase, or Aurora kinase, such as: carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, or skin; a hematopoietic tumour of lymphoid lineage; a hematopoietic tumour of myeloid lineage; thyroid follicular cancer; a tumour of mesenchymal origin; a tumour of the central or peripheral nervous system; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoctanthoma; thyroid follicular cancer; Kaposi's sarcoma; a hematopoietic tumour of lymphoid lineage selected from leukemia, acute lymphocytic leukemia, B-celllymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy celf lymphoma, and Burkett's lymphoma; a hematopoietic tumour of myeloid lineage selected from acute and chronic myelogenous leukemias, myelodysplastic syndrome, and promyelocytic leukemia; cancer selected from breast cancer, ovarian cancer, colon cancer, prostate cancer, oesophageal cancer, squamous cancer, non-small cen lung carcinomas, breast cancer, bladder cancer, colorectal cancer, pancreatic cancer, ovarian cancer, non-Hodgkin's lymphoma, gliomas and non-endometrioid endometrial carcinomas.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,"ASTEX THERAPEUTICS LIMITED, GB (2007-07-27)",https://lens.org/148-273-251-866-492,Patent Application,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,DISCONTINUED
498,ZA,B,ZA 200605127 B,000-512-983-504-428,2010-07-28,2010,ZA 200605127 A,2006-06-21,GB 0329617 A,2003-12-23,Pyrazole derivatives as protein kinase modulators,,ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;VERDONK MARINUS LEENDERT;;WYATT PAUL GRAHAM;;SORE HANNAH FIONA;;COLLINS IAN;;CARR ROBIN ARTHUR ELLIS;;SAXTY GORDON;;WOODHEAD STEVEN JOHN;;BOYLE ROBERT GEORGE;;WALKER DAVID WINTER;;DOWNHAM ROBERT,,https://lens.org/000-512-983-504-428,Granted Patent,no,0,0,12,52,0,,A61K/;;A61P/;;C07D/,,0,0,,,,ACTIVE
499,NO,L,NO 20062633 L,005-431-335-605-56X,2006-07-20,2006,NO 20062633 A,2006-06-08,GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W,2003-12-23,Pyrazolderivater som proteinkinasemodulatorer,"Oppfinnelsen tilveiebringer forbindelser med formel (I) som har proteinkinase B-inhiberende aktivitet: hvor A er en mettet hydrokarbon-koblingsgruppe som inneholder fra 1 til 7 karbonatomer, hvor koblingsgruppen har en maksimal kjedelengde på 5 atomer mellom R1 og NR2R3 og en maksimal kjedelengde på 4 atomer mellom E og NR2R3, hvor ett av karbonatomene i koblingsgruppen eventuelt kan være erstattet med et oksygen- eller nitrogenatom; og hvor karbonatomene i koblingsgruppe A eventuelt kan bære én eller flere substituenter valgt fra okso, fluor og hydroksy, forutsatt at hydroksygruppen, når den er til stede, ikke er plassert på et karbonatom a med hensyn til NR2R3-gruppen, og forutsatt at oksogruppen, når den er til stede, er plassert på et karbonatom a med hensyn til NR2R3-gruppen; E er en monocyklisk eller bicyklisk, karbocyklisk eller heterocyklisk gruppe; R1 er en aryl- eller heteroarylgruppe; og R2, R3, R4 og R5 er som definert i kravene. Det tilveiebringes også farmasøytiske preparater som inneholder i forbindelsene, metoder for fremstilling av forbindelsene og anvendelsen av dem som antikreft-midler.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/005-431-335-605-56X,Abstract,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/415;;C07D231/12;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,DISCONTINUED
500,PL,T3,PL 1706385 T3,011-603-400-835-800,2011-03-31,2011,PL 04806258 T,2004-12-23,US 57784304 P;;US 53219903 P;;GB 0329617 A;;EP 04806258 A;;GB 2004005464 W,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,,ASTEX THERAPEUTICS LTD;;CANCER RESEARCH TECH LTD;;THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/011-603-400-835-800,Patent Application,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,PENDING
501,EP,A1,EP 2228369 A1,092-093-523-957-788,2010-09-15,2010,EP 10168024 A,2004-12-23,EP 04806258 A;;GB 0329617 A;;US 53219903 P;;US 57784304 P,2003-12-23,Pyrazole derivatives as protein kinase modulators,"The invention provides compounds of the formula (I) having protein kinase B inhibiting activity:
  
wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R 1  and NR 2 R 3  and a maximum chain length of 4 atoms extending between E and NR 2 R 3 , wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the NR 2 R 3  group and provided that the oxo group when present is located at a carbon atom α with respect to the NR 2 R 3  group; 
E is a monocyclic or bicyclic carbocyclic or heterocyclic group; 
R 1  is an aryl or heteroaryl group; and 
R 2 , R 3 , R 4  and R 5  are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD;;INST OF CANCER RES THE ROYAL C;;CANCER REC TECH LTD,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/092-093-523-957-788,Patent Application,yes,17,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,41,30,012-865-156-438-120;;001-661-891-531-467;;015-505-100-135-710;;051-255-997-632-880;;005-521-719-112-587;;067-349-350-491-296;;178-340-551-087-939;;020-041-421-299-132;;018-672-359-903-923;;057-056-042-997-883;;138-591-868-049-039;;082-081-444-251-372;;026-436-397-568-332;;011-872-340-996-607;;064-318-868-677-967;;047-839-678-077-853;;000-820-736-344-337;;126-811-728-740-254;;064-792-862-161-861;;077-365-619-775-156;;004-137-705-827-976;;000-232-807-137-917;;055-378-956-750-333;;050-476-538-810-273;;076-498-753-486-817;;001-730-207-519-469;;110-103-452-436-092;;049-219-274-603-971;;022-542-326-366-85X;;059-619-888-764-046,7768349;;0007768349;;10.1096/fasebj.9.8.7768349;;10.1126/science.1862342;;0001862342;;1862342;;1322797;;10.1016/0092-8674(92)90166-a;;10.1016/0092-8674(93)90144-f;;8387896;;pmc395100;;8194527;;10.1002/j.1460-2075.1994.tb06519.x;;9288767;;9371490;;10.1002/ijc.2910640412;;7657393;;10.1073/pnas.93.8.3636;;8622988;;pmc39663;;10.1038/sj.onc.1203598;;10822383;;10.1073/pnas.84.14.5034;;pmc305241;;3037531;;03037531;;11485901;;pmc1850562;;10.1016/s0002-9440(10)61714-2;;10419456;;10.1074/jbc.274.31.21528;;10.1096/fasebj.12.10.855;;9657525;;10.1016/s1043-2760(01)00560-4;;11854015;;12171565;;10.2174/1568026023393318;;10.1080/00397917709409270;;10.1002/anie.196603851;;10.1021/cr00039a007;;10.1021/jo01351a600;;10.1016/s0040-4039(00)94371-5;;15267229;;10.1021/jm049856v;;10.1016/s0957-4166(03)00175-7;;10.1016/0076-6879(87)52071-7;;3657592;;10.1021/ja00348a037;;12182580;;10.1021/ol0262688;;10.1021/jm000228x;;11052793;;10.1021/ol034060w;;12688710;;10.1128/mcb.19.7.5061;;10373555;;pmc84347;;10.1038/nsb870;;12434148,"HANKS, S.K.; HUNTER, T., FASEB J., vol. 9, 1995, pages 576 - 596;;KNIGHTON ET AL., SCIENCE, vol. 253, 1991, pages 407 - 414;;HILES ET AL., CELL, vol. 70, 1992, pages 419 - 429;;KUNZ ET AL., CELL, vol. 73, 1993, pages 585 - 596;;GARCIA-BUSTOS ET AL., EMBO J., vol. 13, 1994, pages 2352 - 2361;;GULDBERG ET AL., CANCER RESEARCH, vol. 57, 1997, pages 3660 - 3663;;CAIRNS ET AL., CANCER RESEARCH, vol. 57, 1997, pages 4997;;BELLACOSA ET AL., INT. J. CANCER, vol. 64, 1995, pages 280 - 285;;CHENG ET AL., PNAS, vol. 93, 1996, pages 3636 - 3641;;YUAN ET AL., ONCOGENE, vol. 19, 2000, pages 2324 - 2330;;STAAL, PNAS, vol. 84, 1987, pages 5034 - 5037;;SUN ET AL., AM. J. PATHOL., vol. 159, 2001, pages 431 - 437;;NAKATANI ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 21528 - 21532;;AANDAHL, E. M.; AUKRUST, P.; SKALHEGG, B. S.; MIILLER, F.; FROLAND, S. S.; HANSSON, V.; TASKEN, K.: ""Protein kinase A type I antagonist restores immune responses ofT cells from HIV-infected patients"", FASEB J., vol. 12, 1998, pages 855 - 862, XP002529929;;""Kinase A and human diseases"", TRENDS ENDROCRI. METAB., vol. 13, 2002, pages 50 - 52;;LI, Q.; ZHU, G-D., CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 2, 2002, pages 939 - 971;;PROTEIN KINASE A AND HUMAN DISEASE, vol. 968, 2002;;L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514;;CAHN: ""Ingold & Prelog"", ANGEW. CHEM. INT. ED. ENGL., vol. 5, 1966, pages 385 - 415;;N. MIYAURA; A. SUZUKI, CHEM. REV., vol. 95, 1995, pages 2457;;SHEEHAN ET AL., J. AMER. CHEM SOC., vol. 77, 1955, pages 1067;;SHEEHAN ET AL., J. ORG. CHEM., vol. 26, 1961, pages 2525;;CASTRO ET AL., TETRAHEDRON LETTERS, vol. 31, 1990, pages 205;;L. A. CARPINO, J. AMER. CHEM. SOC., vol. 115, 1993, pages 4397;;KONIG ET AL., CHEM. BER., vol. 103, no. 708, pages 2024 - 2034;;DESS, D.B.; MARTIN, J.C., J. ORG. SOC., vol. 48, 1983, pages 4155;;ORGANIC SYNTHESES, vol. 77, pages 141;;JERRY MARCH, ADVANCED ORGANIC CHEMISTRY, pages 534 - 542;;J. MED. CHEM., vol. 47, 2004, pages 3924 - 3926;;TETRAHEDRON: ASYMMETRY, vol. 14, 2003, pages 1309 - 1316;;ANGERER, METH. ENZYMOL., vol. 152, 1987, pages 649;;ALDRICH, vol. 52, pages 505 - 7;;J. AMER. CHEM. SOC., vol. 105, 1983, pages 3183 - 3188;;ORGANIC LETTERS, vol. 4, no. 17, 2002, pages 2885 - 2888;;TETRAHEDRON ASYMMETRY, vol. 14, 2003, pages 1309 - 1316;;J. CHEM. SOC., PERKIN TRANS, vol. 1, 2000, pages 3444 - 3450;;J. MEDICINAL CHEM., vol. 43, no. 21, 2000, pages 3878 - 3894;;ORGANIC LETTERS, vol. 5, no. 8, 2003, pages 1167 - 1169;;ZHONGGUO YAOWU HUAXUE ZAZHI, vol. 12, no. 3, 2002, pages 125 - 129;;ANDJELKOVIC ET AL., MOL. CELL. BIOL., vol. 19, 1999, pages 5061 - 5072;;YANG ET AL., NATURE STRUCTURAL BIOLOGY, vol. 9, 2002, pages 940 - 944",DISCONTINUED
502,EP,B1,EP 1706385 B1,119-009-082-257-033,2010-10-06,2010,EP 04806258 A,2004-12-23,GB 2004005464 W;;GB 0329617 A;;US 53219903 P;;US 57784304 P,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,,ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/119-009-082-257-033,Granted Patent,yes,2,3,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,ACTIVE
503,US,A1,US 2011/0144080 A1,047-710-175-792-161,2011-06-16,2011,US 59678804 A,2004-12-23,US 59678804 A;;GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,"The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R 1 and NR 2 R 3 and a maximum chain length of 4 atoms extending between E and NR 2 R 3 , wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR 2 R 3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR 2 R 3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; R 1 is an aryl or heteroaryl group; and R 2 , R 3 , R 4 and R 5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNA FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (2010-03-29);;ASTEX THERAPEUTICS LIMITED (2010-03-29);;CANCER RESEARCH TECHNOLOGY LIMITED (2010-03-12),https://lens.org/047-710-175-792-161,Patent Application,yes,9,8,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,A61K31/415;;A61K31/4155;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K31/551;;A61P35/00;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/14;;C07D403/10;;C07D413/10,514/210.2;;548/375.1;;514/406;;546/211;;514/326;;546/275.4;;514/341;;544/140;;514/236.5;;548/364.1;;548/365.1;;544/371;;514/254.05;;544/405;;514/255.05;;540/575;;514/218;;546/194;;514/318,0,0,,,,INACTIVE
504,WO,A3,WO 2005/002552 A3,060-749-996-285-780,2005-06-16,2005,GB 2004002824 W,2004-07-05,GB 0315657 A;;GB 0324919 A;;US 48468503 P;;US 51437403 P,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS,"The invention provides compounds having activity as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinases for use in the treatment of disease states and conditions such as cancer that are mediated by the kinases. The compounds have the general formula (I). Also included within formula (I) are the salts, solvates and N-oxides of the compounds.",ASTEX TECHNOLOGY LTD;;BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,,https://lens.org/060-749-996-285-780,Search Report,yes,2,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/00;;A61K31/4184;;A61P31/10;;A61P35/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14,,1,1,012-522-479-506-568,10.1002/bscb.19870960110,"ESSASSI E M ET AL: ""SYNTHESE ET HEREROCYCLISATION DES (PYRAZOLYL-3(5))-2 BENZIMIDAZOLES EN CATALYSE PAR TRANSFERT DE PHASE"", BULLETIN DES SOCIETES CHIMIQUES BELGES, XX, XX, vol. 96, no. 1, 1987, pages 63 - 67, XP008005414, ISSN: 0037-9646",PENDING
505,HR,T1,HR P20100675 T1,066-023-236-079-808,2011-01-31,2011,HR P20100675 T,2010-12-07,US 53219903 P;;GB 0329617 A;;GB 2004005464 W;;US 57784304 P,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,"Spoj formule (I): (I) ili njegova sol, solvat, tautomer ili N-oksid; naznacen time sto je A zasicena ugljikovodicna vezna skupina koja sadrzi 1 do 7 atoma ugljika, ta vezna skupina ima najvecu duljinu lanca od 5 atoma koji se pruzaju izmedu R1 i NR2R3 i najvecu duljinu lanca od 4 atoma koji se pruzaju izmedu E i NR2R3, gdje jedan od atoma ugljika u veznoj skupini moze po izboru biti zamijenjen atomom kisika ili dusika; i gdje atomi ugljika vezne skupine A mogu po izboru imati jedan ili vise supstituenata izabranih izmedu okso, fluora i hidroksi, uz uvjet da se hidroksilna skupina, kada je prisutna, ne nalazi na α atomu ugljika u odnosu na NR2R3 skupinu i uz uvjet da se okso skupina, kada je prisutna, nalazi na α atomu ugljika u odnosu na NR2R3 skupinu; E je monociklicka ili biciklicka karbociklicka ili heterociklicka skupina pri cemu E nije supstituiran ili ima do 4 supstituenta R8 izabrana izmedu hidroksi, okso (kada E nije aromatski), klor, brom, trifluorometil, cijano, C1-4 hidrokarbiloksi i C1-4 hidrokarbil po izboru supstituiran s C1-2 alkoksi ili hidroksil; R1 je arilna ili heteroarilna skupina koja nije supstituirana ili ima jedan ili vise supstituenata izabranih izmedu hidroksi; C1-4 aciloksi; fluor; klor; brom; trifluorometil; cijano; CONH2; nitro; C1-4 hidrokarbiloksi i C1-4 hidrokarbil od kojih svaki moze po izboru biti supstituiran s C1-2 alkoksi, karboksi ili hidroksi; C1-4 acilamino; benzoilamino; pirolidinokarbonil; piperidinokarbonil; morfolinokarbonil; piperazinokarbonil; petero- i sesteroclane heteroarilne i heteroariloksi skupine sadrze jedan ili dva heteroatoma izabrana izmedu N, O i S; fenil; fenil C1-4 alkil; fenil-C1-4 alkoksi; heteroaril-C1-4 alkil; heteroaril-C1-4 alkoksi i fenoksi, gdje su skupine heteroaril, heteroariloksi, fenil, fenil C1-4 alkil, fenil-C1-4 alkoksi, heteroaril C1-4 alkil, heteroaril-C1-4 alkoksi i fenoksi svaka po izboru supstituirane s 1, 2 ili 3 supstituenta izabrana izmedu C1-2 aciloksi, fluor, klor, brom, trifluorometil, cijano, CONH2, C1-2 hidrokarbiloksi i C1-2 hidrokarbil od kojih je svaki po izboru supstituiran sa metoksi ili hidroksil; R2 i R3 su nezavisno jedan od drugog izabrani izmedu vodika, C1-4 hidrokarbil i C1-4 acil gdje hidrokarbilni i acilni dijelovi mogu po izboru biti supstituirani jednim ili s vise supstituenta izabrana izmedu fluor, hidroksi, amino, metilamino, dimetilamino i metoksi; ili R2 i R3 zajedno s atomom dusika, na koji su vezani, tvore ciklicku skupinu izabranu izmedu imidazolske skupine i zasicene monociklicke heterociklicke skupine s 4-7 clanova prstena i koja po izboru sadrzi drugi heteroatomni clan prstena izabran izmedu O i N; ili jedan od R2 i R3 zajedno s atomom dusika, na koji su vezani, i s jednim ili vise atoma iz vezne skupine A tvore zasicenu monociklicku heterociklicku skupinu s 4-7 clanova prstena i koja po izboru sadrzi drugi heteroatomni clan prstena izabran izmedu O i N; ili NR2R3 i atom ugljika vezne skupine A na koji je spojen, zajedno tvor",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/066-023-236-079-808,Granted Patent,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,ACTIVE
506,CN,B,CN 1845734 B,088-426-386-537-776,2011-06-22,2011,CN 200480024928 A,2004-07-05,GB 2004002824 W;;GB 0315657 A;;GB 0324919 A;;US 48468503 P;;US 51437403 P,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,"The invention provides compounds having activity as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinases for use in the treatment of disease states and conditions such as cancer that are mediated by the kinases. The compounds have the general formula (I); Also included within formula (I) are the salts, solvates and N-oxides of the compounds.",ASTEX THERAPEUTICS LTD,VALERIO BERDINI;;STEVEN HOWARD;;ANNE WOOLFORD ALISON JO;;JAMES WOODHEAD ANDREW;;GRAZIA CARR MARIA;;LIAM GILL ADRIAN;;FIGUEROA NAVARRO EVA;;ALISTAIR O'BRIEN MICHAEL;;RACHEL EARLY THERESA;;GARY TREWARTHA;;PAUL WYATT,,https://lens.org/088-426-386-537-776,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,INACTIVE
507,CY,T1,CY 1114846 T1,030-487-205-552-825,2016-12-14,2016,CY 141100070 T,2014-01-28,EP 04743172 A;;GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A,2003-07-03,ΠΑΡΑΓΩΓΑ BENZIMIDAZOLE ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΣΑΝ ΚΑΤΑΣΤΟΛΕΩΝ KINΑΣΩΝ (KINASES) ΠΡΩΤΕΪΝΗΣ,"Η εφεύρεση παρέχει ενώσεις που έχουν δραστικότητα σαν καταστολείς των κινασών (kinases) που εξαρτώνται από την κυκλίνη (cyclin), κινασών (kinases)-3 συνθάσης (synthase) γλυκογόνου και κινασών (kinases) Aurora, για χρήση στην θεραπεία καταστάσεων ασθενειών και παθήσεων όπως ο καρκίνος με την μεσολάβηση κινασών (kinases). Οι συνθέσεις έχουν τον γενικό τύπο (I), όπου το Χ είναι CR5 ή Ν, το Α είναι ένας δεσμός ή -(CH2)m-(B)n-, το Β είναι C=O, NRg(C=O) ή O(C=O), το Rg είναι υδρογόνο ή C1-4 υδροκαρβύλιο προαιρετικά αντικατεστημένο με hydroxy ή C1-4 alcoxy, το m είναι 0, 1 ή 2, το n είναι 0 ή 1, το R0 είναι υδρογόνο ή, μαζί με το NRg όταν υπάρχει, σχηματίζει μία καρβοκυκλική ομάδα -(CH2)P- όπου το 1p είναι 2 μέχρι 4, το R1 είναι υδρογόνο, μία καρβοκυκλική ομάδα ή έτερο-κυκλική ομάδα που έχει από 3 μέχρι 12 μέλη δακτυλίου, ή μία προαιρετικά αντικατεστημένη ομάδα C1-8 υδροκαρβυλίου, το R2 είναι υδρογόνο, αλογόνο, methoxy, ή μία ομάδα C1-4 υδροκαρβυλίου, προαιρετικά αντικατεστημένη με αλογόνο, υδροξύλιο ή methoxy, τα R3 και R4, μαζί με τα άτομα του άνθρακα στα οποία είναι προσαρτημένα σχηματίζουν ένα προαιρετικά αντικατεστημένο συγχωνευμένο καρβοκυκλικό ή έτερο-κυκλικό δακτύλιο που έχει από 5 μέχρι 7 μέλη δακτυλίου από τα οποία 3 μπορεί να είναι έτερο-άτομα που επιλέγονται από Ν, Ο και S, το R5 είναι υδρογόνο, μία ομάδα R2 ή μία ομάδα R10, όπου το R10 επιλέγεται από αλογόνο, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- ή di-hydrocarbylamino C1-4, από καρβοκυκλικές ή έτερο-κυκλικές ομάδες που έχουν από 3 μέχρι 12 μέλη δακτυλίου, μία ομάδα Ra-Rb, όπου το Ra είναι ένας δεσμός, Ο, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRC, SO2NRc ή NRcSO2 και το Rb επιλέγεται από υδρογόνο, από καρβοκυκλικές και έτερο-κυκλικές ομάδες που έχουν από 3 μέχρι 12 μέλη δακτυλίου, και μία ομάδα C1-8 υδροκαρβυλίου προαιρετικά αντικατεστημένη με ένα ή περισσότερους παράγοντες αντικατάστασης που επιλέγονται από hydroxy, oxo, αλογόνο, cyano, nitro, carboxy, amino, mono- ή di-hydrocarbylamino C1-4, καρβοκυκλικές και έτερο-κυκλικές ομάδες που έχουν από 3 μέχρι 12 μέλη δακτυλίου, όπου ένα ή περισσότερα άτομα άνθρακα της ομάδας C1-8 υδροκαρβυλίου μπορεί να είναι προαιρετικά αντικατεστημένα με Ο, S, SO, SO2, NRC, Χ1C(Χ2), C(X2)X1 or X1C(X2)X1, το Rc επιλέγεται από υδρογόνο και C1-4 υδροκαρβύλιο και το Χ1 είναι Ο, S ή NRC και το Χ2 είναι =O, =S ή =NRC. Επίσης περιλαμβάνονται στον τύπο (I) τα άλατα, οι ενώσεις διαλύτη με διαλυμένη ουσία και τα Ν-οξείδια των ενώσεων.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,,https://lens.org/030-487-205-552-825,Granted Patent,no,0,0,7,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D403/04;;A61K31/4155;;A61K31/4184,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
508,ME,B,ME 01934 B,038-402-055-402-025,2011-06-30,2011,ME P53210 A,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P;;EP 04806258 A;;GB 2004005464 W,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,,SAXTY GORDON;;THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL;;CANCER RESEARCH TECH LTD,BERDINI VALERIO;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SAXTY GORDON,,https://lens.org/038-402-055-402-025,Granted Patent,no,0,0,12,52,0,,A61K31/415;;C07D231/12;;C07D401/10;;C07D413/10,,0,0,,,,ACTIVE
509,TW,B,TW I363622 B,052-460-757-461-073,2012-05-11,2012,TW 94118996 A,2005-06-08,US 57784304 P;;GB 2004005464 W,2004-06-08,Pharmaceutical compounds,,ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS;;COLLINS IAN,,https://lens.org/052-460-757-461-073,Granted Patent,no,0,0,5,52,0,,,,0,0,,,,INACTIVE
510,CA,C,CA 2548374 C,111-875-293-119-722,2014-05-27,2014,CA 2548374 A,2004-12-23,GB 0329617 A;;US 53219903 P;;US 57784304 P;;GB 2004005464 W,2003-12-23,PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS,"The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between Rl and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the inker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; Rl is an aryl or heteroaryl group; and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL,BERDINI VALERIO;;SAXTY GORDON;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;WYATT PAUL GRAHAM;;BOYLE ROBERT GEORGE;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DOWNHAM ROBERT;;CARR ROBIN ARTHUR ELLIS,,https://lens.org/111-875-293-119-722,Granted Patent,no,0,0,32,52,0,C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P1/04;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P35/02;;A61P3/04;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/12;;C07D401/10;;C07D401/04;;C07D231/12;;C07D401/04;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D403/12;;C07D405/04;;C07D413/10;;A61K31/415;;A61K31/4155;;A61K31/4178;;A61K31/454;;A61K31/496;;A61K31/497;;A61K31/5377;;A61K45/06;;A61K9/0019;;A61K9/20;;A61K9/48;;A61K31/4439;;A61K31/4545;;A61K31/551,C07D231/12;;A61K31/415;;A61P37/02;;C07D401/10;;C07D413/10,,0,0,,,,INACTIVE
511,HK,A1,HK 1087925 A1,142-018-208-122-846,2006-10-27,2006,HK 06108214 A,2006-07-24,GB 2004002824 W;;GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,,https://lens.org/142-018-208-122-846,Patent Application,no,0,0,7,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D403/04;;A61K31/4155;;A61K31/4184,A61K/;;A61K31/00;;A61K31/4184;;A61P/;;C07D/;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,DISCONTINUED
512,AU,A1,AU 2012/331185 A1,072-360-109-967-671,2014-04-10,2014,AU 2012/331185 A,2012-10-31,GB 201118876 A;;US 201261645283 P;;US 201161554415 P;;EP 2012071560 W,2011-11-01,"Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis C virus (HCV) infection","The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;BESONG GILBERT EBAI;;CARR MARIA GRAZIA;;HISCOCK STEVEN DOUGLAS;;O'BRIEN MICHAEL ALISTAIR;;REES DAVID CHARLES;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS,,https://lens.org/072-360-109-967-671,Patent Application,no,0,0,16,16,0,C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C233/18;;C07C233/25;;C07C235/46;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07C243/34;;C07C251/48;;C07C255/24;;C07C255/29;;C07C255/37;;C07C255/46;;C07C255/54;;C07C259/06;;C07C271/12;;C07C275/36;;C07C311/04;;C07C311/08;;C07C311/29;;C07C317/22;;C07C323/25;;C07D205/04;;C07D207/14;;C07D207/335;;C07D209/08;;C07D209/14;;C07D209/44;;C07D211/26;;C07D211/56;;C07D211/70;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/73;;C07D213/74;;C07D213/75;;C07D213/81;;C07D213/84;;C07D217/02;;C07D231/12;;C07D233/24;;C07D233/64;;C07D237/14;;C07D239/34;;C07D239/42;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07D263/32;;C07D265/36;;C07D271/10;;C07D277/68;;C07D285/13;;C07D295/02;;C07D295/027;;C07D295/185;;C07D295/192;;C07D305/06;;C07D305/08;;C07D307/14;;C07D307/22;;C07D307/79;;C07D309/06;;C07D309/12;;C07D309/14;;C07D319/18;;C07D513/04;;C07C2601/16;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C2601/04;;C07B2200/05;;C07B2200/05;;C07C255/46;;C07C255/54;;C07D213/73;;C07D213/74;;C07D213/75;;C07C259/06;;C07D213/81;;C07D309/06;;C07D213/84;;C07D309/12;;C07D309/14;;C07C271/12;;C07D217/02;;C07C275/36;;C07D319/18;;C07D231/12;;C07D233/24;;C07D233/64;;C07C311/04;;C07C311/08;;C07C311/29;;C07D237/14;;C07C317/22;;C07D239/34;;C07D239/42;;C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C323/25;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07C233/18;;C07C233/25;;C07D263/32;;C07C235/46;;C07D205/04;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07D265/36;;C07D207/14;;C07D271/10;;C07C243/34;;C07D207/335;;C07C251/48;;C07D209/08;;C07D209/14;;C07D277/68;;C07C255/24;;C07D209/44;;C07D513/04;;C07C255/29;;C07C255/37;;C07D285/13;;C07D295/02;;C07D211/26;;C07D211/56;;C07D211/70;;C07D295/185;;C07D295/192;;C07D213/38;;C07D213/64;;C07D305/06;;C07D305/08;;C07D213/65;;C07D213/68;;C07D307/14;;C07D307/22;;C07D307/79;;C07C313/06;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;C07D295/027;;A61P31/12;;A61P31/14;;A61P43/00;;C07D239/42;;C07C217/58;;C07D211/70;;C07C237/08;;C07D209/08;;C07D207/335;;C07C255/37;;C07C255/29;;C07C237/06;;C07D285/13;;C07D513/04;;C07D265/36;;C07D295/02;;C07D305/08;;C07D213/81;;C07D263/32;;C07D243/14;;C07C235/46;;C07C237/10;;C07C255/46;;C07C259/06;;C07C271/12;;C07C251/48;;C07C255/54;;C07C255/24;;C07D305/06;;C07B2200/05;;C07D237/14;;C07D307/14;;C07D213/73;;C07D209/14;;C07C275/36;;C07D295/192;;C07C225/12;;C07D239/34;;C07C323/25;;C07D211/26;;C07C217/60;;C07C233/25;;C07D277/68;;C07D271/10;;C07D309/12;;C07D319/18;;C07C217/90;;C07D241/18;;C07D213/64;;C07D233/24;;C07C311/08;;C07D211/56;;C07D231/12;;C07D241/20;;C07C311/29;;C07D213/65;;C07C217/62;;C07D217/02;;C07D213/68;;C07D213/38;;C07D213/74;;C07D213/75;;C07C237/04;;C07D307/22;;C07D233/64;;C07C317/22;;C07D309/06;;C07D309/14;;C07D241/24;;C07D207/14;;C07D307/79;;C07C311/04;;C07D205/04;;C07C243/34;;C07C233/18;;C07C237/12;;C07D209/44;;C07D295/185;;C07D213/84;;C07C313/06;;C07C2601/04;;C07C2601/08;;C07C2601/16;;C07C2601/14;;C07C2601/02;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;A61K45/06;;C07C217/74;;C07C237/20;;C07D295/027,C07D209/14;;A61K31/137;;A61K31/415;;A61K31/4164;;A61K31/44;;A61P31/12;;C07C217/58;;C07D213/75;;C07D231/12;;C07D233/24;;C07D233/64;;C07D295/02;;C07D305/06;;C07D305/08;;C07D309/14,,0,0,,,,DISCONTINUED
513,CA,A1,CA 2853006 A1,072-364-109-709-865,2013-05-10,2013,CA 2853006 A,2012-10-31,GB 201118876 A;;US 201161554415 P;;US 201261645283 P;;EP 2012071560 W,2011-11-01,"SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION","The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R0 is hydrogen or C1-2 alkyl; R1a is selected from CONH2; CO2H; an optionally substituted acyclic C1-8 hydrocarbon group; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R2 is selected from hydrogen and a group R2a; R2a is selected from an optionally substituted acyclic d-8 hydrocarbon group; an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1 or 2 ring members are heteroatom ring members selected from O, N and S; and an optionally substituted bicyclic heterocyclic group of 9 or 10 ring members, of which 1 or 2 ring members are nitrogen atoms; wherein at least one of R1 and R2 is other than hydrogen; R3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0, 1, 2 or 3 heteroatom ring members selected from N, O and S; R4a is selected from halogen; cyano; C1-4 alkyl optionally substituted with one or more fluorine atoms; C1-4 alkoxy optionally substituted with one or more fluorine atoms; hydroxy-C1-4 alkyl; and C1-2 alkoxy-C1-4 alkyl; R5 is selected from hydrogen and a substituent R5a; and R5a is selected from C1-2 alkyl optionally substituted with one or more fluorine atoms; C1-3 alkoxy optionally substituted with one or more fluorine atoms; halogen; cyclopropyl; cyano; and amino, The compounds have activity against hepatitis C virus and can be used in the prevention or treatment of hepatitis C viral infections.",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;BESONG GILBERT EBAI;;CARR MARIA GRAZIA;;HISCOCK STEVEN DOUGLAS;;O'BRIEN MICHAEL ALISTAIR;;REES DAVID CHARLES;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS,,https://lens.org/072-364-109-709-865,Patent Application,no,0,0,16,16,0,C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C233/18;;C07C233/25;;C07C235/46;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07C243/34;;C07C251/48;;C07C255/24;;C07C255/29;;C07C255/37;;C07C255/46;;C07C255/54;;C07C259/06;;C07C271/12;;C07C275/36;;C07C311/04;;C07C311/08;;C07C311/29;;C07C317/22;;C07C323/25;;C07D205/04;;C07D207/14;;C07D207/335;;C07D209/08;;C07D209/14;;C07D209/44;;C07D211/26;;C07D211/56;;C07D211/70;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/73;;C07D213/74;;C07D213/75;;C07D213/81;;C07D213/84;;C07D217/02;;C07D231/12;;C07D233/24;;C07D233/64;;C07D237/14;;C07D239/34;;C07D239/42;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07D263/32;;C07D265/36;;C07D271/10;;C07D277/68;;C07D285/13;;C07D295/02;;C07D295/027;;C07D295/185;;C07D295/192;;C07D305/06;;C07D305/08;;C07D307/14;;C07D307/22;;C07D307/79;;C07D309/06;;C07D309/12;;C07D309/14;;C07D319/18;;C07D513/04;;C07C2601/16;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C2601/04;;C07B2200/05;;C07B2200/05;;C07C255/46;;C07C255/54;;C07D213/73;;C07D213/74;;C07D213/75;;C07C259/06;;C07D213/81;;C07D309/06;;C07D213/84;;C07D309/12;;C07D309/14;;C07C271/12;;C07D217/02;;C07C275/36;;C07D319/18;;C07D231/12;;C07D233/24;;C07D233/64;;C07C311/04;;C07C311/08;;C07C311/29;;C07D237/14;;C07C317/22;;C07D239/34;;C07D239/42;;C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C323/25;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07C233/18;;C07C233/25;;C07D263/32;;C07C235/46;;C07D205/04;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07D265/36;;C07D207/14;;C07D271/10;;C07C243/34;;C07D207/335;;C07C251/48;;C07D209/08;;C07D209/14;;C07D277/68;;C07C255/24;;C07D209/44;;C07D513/04;;C07C255/29;;C07C255/37;;C07D285/13;;C07D295/02;;C07D211/26;;C07D211/56;;C07D211/70;;C07D295/185;;C07D295/192;;C07D213/38;;C07D213/64;;C07D305/06;;C07D305/08;;C07D213/65;;C07D213/68;;C07D307/14;;C07D307/22;;C07D307/79;;C07C313/06;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;C07D295/027;;A61P31/12;;A61P31/14;;A61P43/00;;C07D239/42;;C07C217/58;;C07D211/70;;C07C237/08;;C07D209/08;;C07D207/335;;C07C255/37;;C07C255/29;;C07C237/06;;C07D285/13;;C07D513/04;;C07D265/36;;C07D295/02;;C07D305/08;;C07D213/81;;C07D263/32;;C07D243/14;;C07C235/46;;C07C237/10;;C07C255/46;;C07C259/06;;C07C271/12;;C07C251/48;;C07C255/54;;C07C255/24;;C07D305/06;;C07B2200/05;;C07D237/14;;C07D307/14;;C07D213/73;;C07D209/14;;C07C275/36;;C07D295/192;;C07C225/12;;C07D239/34;;C07C323/25;;C07D211/26;;C07C217/60;;C07C233/25;;C07D277/68;;C07D271/10;;C07D309/12;;C07D319/18;;C07C217/90;;C07D241/18;;C07D213/64;;C07D233/24;;C07C311/08;;C07D211/56;;C07D231/12;;C07D241/20;;C07C311/29;;C07D213/65;;C07C217/62;;C07D217/02;;C07D213/68;;C07D213/38;;C07D213/74;;C07D213/75;;C07C237/04;;C07D307/22;;C07D233/64;;C07C317/22;;C07D309/06;;C07D309/14;;C07D241/24;;C07D207/14;;C07D307/79;;C07C311/04;;C07D205/04;;C07C243/34;;C07C233/18;;C07C237/12;;C07D209/44;;C07D295/185;;C07D213/84;;C07C313/06;;C07C2601/04;;C07C2601/08;;C07C2601/16;;C07C2601/14;;C07C2601/02;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;A61K45/06;;C07C217/74;;C07C237/20;;C07D295/027,C07D209/14;;A61K31/137;;A61K31/415;;A61K31/4164;;A61K31/44;;A61P31/12;;C07C217/58;;C07D213/75;;C07D231/12;;C07D233/24;;C07D233/64;;C07D295/02;;C07D305/06;;C07D305/08;;C07D309/14,,0,0,,,,DISCONTINUED
514,SG,A,SG 11201400874Q A,187-412-016-362-835,2014-08-28,2014,SG 11201400874Q A,2012-10-31,GB 201118876 A;;US 201161554415 P;;US 201261645283 P;;EP 2012071560 W,2011-11-01,"SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION",,ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;BESONG GILBERT EBAI;;CARR MARIA GRAZIA;;HISCOCK STEVEN DOUGLAS;;O'BRIEN MICHAEL ALISTAIR;;REES DAVID CHARLES;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS,,https://lens.org/187-412-016-362-835,Unknown,no,0,0,16,16,0,C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C233/18;;C07C233/25;;C07C235/46;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07C243/34;;C07C251/48;;C07C255/24;;C07C255/29;;C07C255/37;;C07C255/46;;C07C255/54;;C07C259/06;;C07C271/12;;C07C275/36;;C07C311/04;;C07C311/08;;C07C311/29;;C07C317/22;;C07C323/25;;C07D205/04;;C07D207/14;;C07D207/335;;C07D209/08;;C07D209/14;;C07D209/44;;C07D211/26;;C07D211/56;;C07D211/70;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/73;;C07D213/74;;C07D213/75;;C07D213/81;;C07D213/84;;C07D217/02;;C07D231/12;;C07D233/24;;C07D233/64;;C07D237/14;;C07D239/34;;C07D239/42;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07D263/32;;C07D265/36;;C07D271/10;;C07D277/68;;C07D285/13;;C07D295/02;;C07D295/027;;C07D295/185;;C07D295/192;;C07D305/06;;C07D305/08;;C07D307/14;;C07D307/22;;C07D307/79;;C07D309/06;;C07D309/12;;C07D309/14;;C07D319/18;;C07D513/04;;C07C2601/16;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C2601/04;;C07B2200/05;;C07B2200/05;;C07C255/46;;C07C255/54;;C07D213/73;;C07D213/74;;C07D213/75;;C07C259/06;;C07D213/81;;C07D309/06;;C07D213/84;;C07D309/12;;C07D309/14;;C07C271/12;;C07D217/02;;C07C275/36;;C07D319/18;;C07D231/12;;C07D233/24;;C07D233/64;;C07C311/04;;C07C311/08;;C07C311/29;;C07D237/14;;C07C317/22;;C07D239/34;;C07D239/42;;C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C323/25;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07C233/18;;C07C233/25;;C07D263/32;;C07C235/46;;C07D205/04;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07D265/36;;C07D207/14;;C07D271/10;;C07C243/34;;C07D207/335;;C07C251/48;;C07D209/08;;C07D209/14;;C07D277/68;;C07C255/24;;C07D209/44;;C07D513/04;;C07C255/29;;C07C255/37;;C07D285/13;;C07D295/02;;C07D211/26;;C07D211/56;;C07D211/70;;C07D295/185;;C07D295/192;;C07D213/38;;C07D213/64;;C07D305/06;;C07D305/08;;C07D213/65;;C07D213/68;;C07D307/14;;C07D307/22;;C07D307/79;;C07C313/06;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;C07D295/027;;A61P31/12;;A61P31/14;;A61P43/00;;C07D239/42;;C07C217/58;;C07D211/70;;C07C237/08;;C07D209/08;;C07D207/335;;C07C255/37;;C07C255/29;;C07C237/06;;C07D285/13;;C07D513/04;;C07D265/36;;C07D295/02;;C07D305/08;;C07D213/81;;C07D263/32;;C07D243/14;;C07C235/46;;C07C237/10;;C07C255/46;;C07C259/06;;C07C271/12;;C07C251/48;;C07C255/54;;C07C255/24;;C07D305/06;;C07B2200/05;;C07D237/14;;C07D307/14;;C07D213/73;;C07D209/14;;C07C275/36;;C07D295/192;;C07C225/12;;C07D239/34;;C07C323/25;;C07D211/26;;C07C217/60;;C07C233/25;;C07D277/68;;C07D271/10;;C07D309/12;;C07D319/18;;C07C217/90;;C07D241/18;;C07D213/64;;C07D233/24;;C07C311/08;;C07D211/56;;C07D231/12;;C07D241/20;;C07C311/29;;C07D213/65;;C07C217/62;;C07D217/02;;C07D213/68;;C07D213/38;;C07D213/74;;C07D213/75;;C07C237/04;;C07D307/22;;C07D233/64;;C07C317/22;;C07D309/06;;C07D309/14;;C07D241/24;;C07D207/14;;C07D307/79;;C07C311/04;;C07D205/04;;C07C243/34;;C07C233/18;;C07C237/12;;C07D209/44;;C07D295/185;;C07D213/84;;C07C313/06;;C07C2601/04;;C07C2601/08;;C07C2601/16;;C07C2601/14;;C07C2601/02;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;A61K45/06;;C07C217/74;;C07C237/20;;C07D295/027,C07D209/14;;A61K31/137;;A61K31/415;;A61K31/4164;;A61K31/44;;A61P31/12;;C07C217/58;;C07D213/75;;C07D231/12;;C07D233/24;;C07D233/64;;C07D295/02;;C07D305/06;;C07D305/08;;C07D309/14,,0,0,,,,PENDING
515,SI,T1,SI 2305250 T1,007-851-807-520-171,2014-06-30,2014,SI 200432146 T,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;EP 10195498 A,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/007-851-807-520-171,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/00;;A61K31/00;;A61K31/4184;;A61P31/00;;A61P31/10;;A61P35/00;;A61P35/00;;C07D401/14;;C07D403/00;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
516,CY,T1,CY 1115093 T1,071-151-217-524-782,2016-12-14,2016,CY 141100311 T,2014-04-28,EP 10195498 A;;GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A,2003-07-03,ΠΑΡΑΓΩΓΑ BENZIMIDAZOLE ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΣΑΝ ΚΑΤΑΣΤΟΛΕΩΝ ΚΙΝΑΣΩΝ (KINASES) ΠΡΩΤΕΪΝΗΣ,"Ένας συνδυασμός που περιλαμβάνει: (i) μία ένωση του τύπου (VII), ή ένα άλας, Ν-οξείδιο ή ένωση διαλύτη με διαλυμένη ουσία αυτού, και (ii) ένα ή περισσότερους άλλους θεραπευτικούς παράγοντες.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/071-151-217-524-782,Granted Patent,no,0,0,7,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D403/04;;A61K31/4155;;A61K31/4184,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
517,HK,A1,HK 1201262 A1,161-422-766-015-686,2015-08-28,2015,HK 15101749 A,2015-02-17,EP 2012071560 W;;GB 201118876 A;;US 201161554415 P;;US 201261645283 P,2011-11-01,"SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION (HCV)",,ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;BESONG GILBERT EBAI;;CARR MARIA GRAZIA;;HISCOCK STEVEN DOUGLAS;;OBRIEN MICHAEL ALISTAIR;;REES DAVID CHARLES;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS,,https://lens.org/161-422-766-015-686,Patent Application,no,0,0,16,16,0,C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C233/18;;C07C233/25;;C07C235/46;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07C243/34;;C07C251/48;;C07C255/24;;C07C255/29;;C07C255/37;;C07C255/46;;C07C255/54;;C07C259/06;;C07C271/12;;C07C275/36;;C07C311/04;;C07C311/08;;C07C311/29;;C07C317/22;;C07C323/25;;C07D205/04;;C07D207/14;;C07D207/335;;C07D209/08;;C07D209/14;;C07D209/44;;C07D211/26;;C07D211/56;;C07D211/70;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/73;;C07D213/74;;C07D213/75;;C07D213/81;;C07D213/84;;C07D217/02;;C07D231/12;;C07D233/24;;C07D233/64;;C07D237/14;;C07D239/34;;C07D239/42;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07D263/32;;C07D265/36;;C07D271/10;;C07D277/68;;C07D285/13;;C07D295/02;;C07D295/027;;C07D295/185;;C07D295/192;;C07D305/06;;C07D305/08;;C07D307/14;;C07D307/22;;C07D307/79;;C07D309/06;;C07D309/12;;C07D309/14;;C07D319/18;;C07D513/04;;C07C2601/16;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C2601/04;;C07B2200/05;;C07B2200/05;;C07C255/46;;C07C255/54;;C07D213/73;;C07D213/74;;C07D213/75;;C07C259/06;;C07D213/81;;C07D309/06;;C07D213/84;;C07D309/12;;C07D309/14;;C07C271/12;;C07D217/02;;C07C275/36;;C07D319/18;;C07D231/12;;C07D233/24;;C07D233/64;;C07C311/04;;C07C311/08;;C07C311/29;;C07D237/14;;C07C317/22;;C07D239/34;;C07D239/42;;C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C323/25;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07C233/18;;C07C233/25;;C07D263/32;;C07C235/46;;C07D205/04;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07D265/36;;C07D207/14;;C07D271/10;;C07C243/34;;C07D207/335;;C07C251/48;;C07D209/08;;C07D209/14;;C07D277/68;;C07C255/24;;C07D209/44;;C07D513/04;;C07C255/29;;C07C255/37;;C07D285/13;;C07D295/02;;C07D211/26;;C07D211/56;;C07D211/70;;C07D295/185;;C07D295/192;;C07D213/38;;C07D213/64;;C07D305/06;;C07D305/08;;C07D213/65;;C07D213/68;;C07D307/14;;C07D307/22;;C07D307/79;;C07C313/06;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;C07D295/027;;A61P31/12;;A61P31/14;;A61P43/00;;C07D239/42;;C07C217/58;;C07D211/70;;C07C237/08;;C07D209/08;;C07D207/335;;C07C255/37;;C07C255/29;;C07C237/06;;C07D285/13;;C07D513/04;;C07D265/36;;C07D295/02;;C07D305/08;;C07D213/81;;C07D263/32;;C07D243/14;;C07C235/46;;C07C237/10;;C07C255/46;;C07C259/06;;C07C271/12;;C07C251/48;;C07C255/54;;C07C255/24;;C07D305/06;;C07B2200/05;;C07D237/14;;C07D307/14;;C07D213/73;;C07D209/14;;C07C275/36;;C07D295/192;;C07C225/12;;C07D239/34;;C07C323/25;;C07D211/26;;C07C217/60;;C07C233/25;;C07D277/68;;C07D271/10;;C07D309/12;;C07D319/18;;C07C217/90;;C07D241/18;;C07D213/64;;C07D233/24;;C07C311/08;;C07D211/56;;C07D231/12;;C07D241/20;;C07C311/29;;C07D213/65;;C07C217/62;;C07D217/02;;C07D213/68;;C07D213/38;;C07D213/74;;C07D213/75;;C07C237/04;;C07D307/22;;C07D233/64;;C07C317/22;;C07D309/06;;C07D309/14;;C07D241/24;;C07D207/14;;C07D307/79;;C07C311/04;;C07D205/04;;C07C243/34;;C07C233/18;;C07C237/12;;C07D209/44;;C07D295/185;;C07D213/84;;C07C313/06;;C07C2601/04;;C07C2601/08;;C07C2601/16;;C07C2601/14;;C07C2601/02;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;A61K45/06;;C07C217/74;;C07C237/20;;C07D295/027,C07D/;;A61K/;;A61P/;;C07C/,,0,0,,,,PENDING
518,US,A1,US 2014/0288040 A1,088-968-384-332-511,2014-09-25,2014,US 201214355780 A,2012-10-31,US 201214355780 A;;GB 201118876 A;;US 201161554415 P;;US 201261645283 P;;EP 2012071560 W,2011-11-01,"SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION","The invention provides compounds of the formula (6): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R 0 is hydrogen or C 1-2 alkyl;R 1a is selected from CONH 2 ; CO 2 H; an optionally substituted acyclic C 1-8 hydrocarbon group; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S;R 2 is selected from hydrogen and a group R 2a ;R 2a is selected from an optionally substituted acyclic C 1-8 hydrocarbon group; an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1 or 2 ring members are heteroatom ring members selected from O, N and S; and an optionally substituted bicyclic heterocyclic group of 9 or 10 ring members, of which 1 or 2 ring members are nitrogen atoms; wherein at least one of R 1 and R 2 is other than hydrogen;R 3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0, 1, 2 or 3 heteroatom ring members selected from N, O and S;R 4a is selected from halogen; cyano; C 1-4 alkyl optionally substituted with one or more fluorine atoms; C 1-4 alkoxy optionally substituted with one or more fluorine atoms; hydroxy-C 1-4 alkyl; and C 1-2 alkoxy-C 1-4 alkyl;R 5 is selected from hydrogen and a substituent R 5a ; andR 5a is selected from C 1-2 alkyl optionally substituted with one or more fluorine atoms; C 1-3 alkoxy optionally substituted with one or more fluorine atoms; halogen; cyclopropyl; cyano; and amino. The compounds have activity against hepatitis C virus and can be used in the prevention or treatment of hepatitis C viral infections.",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;BESONG GILBERT EBAI;;CARR MARIA GRAZIA;;HISCOCK STEVEN DOUGLAS;;O'BRIEN MICHAEL ALISTAIR;;REES DAVID CHARLES;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS,,https://lens.org/088-968-384-332-511,Patent Application,yes,2,1,16,16,0,C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C233/18;;C07C233/25;;C07C235/46;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07C243/34;;C07C251/48;;C07C255/24;;C07C255/29;;C07C255/37;;C07C255/46;;C07C255/54;;C07C259/06;;C07C271/12;;C07C275/36;;C07C311/04;;C07C311/08;;C07C311/29;;C07C317/22;;C07C323/25;;C07D205/04;;C07D207/14;;C07D207/335;;C07D209/08;;C07D209/14;;C07D209/44;;C07D211/26;;C07D211/56;;C07D211/70;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/73;;C07D213/74;;C07D213/75;;C07D213/81;;C07D213/84;;C07D217/02;;C07D231/12;;C07D233/24;;C07D233/64;;C07D237/14;;C07D239/34;;C07D239/42;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07D263/32;;C07D265/36;;C07D271/10;;C07D277/68;;C07D285/13;;C07D295/02;;C07D295/027;;C07D295/185;;C07D295/192;;C07D305/06;;C07D305/08;;C07D307/14;;C07D307/22;;C07D307/79;;C07D309/06;;C07D309/12;;C07D309/14;;C07D319/18;;C07D513/04;;C07C2601/16;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C2601/04;;C07B2200/05;;C07B2200/05;;C07C255/46;;C07C255/54;;C07D213/73;;C07D213/74;;C07D213/75;;C07C259/06;;C07D213/81;;C07D309/06;;C07D213/84;;C07D309/12;;C07D309/14;;C07C271/12;;C07D217/02;;C07C275/36;;C07D319/18;;C07D231/12;;C07D233/24;;C07D233/64;;C07C311/04;;C07C311/08;;C07C311/29;;C07D237/14;;C07C317/22;;C07D239/34;;C07D239/42;;C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C323/25;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07C233/18;;C07C233/25;;C07D263/32;;C07C235/46;;C07D205/04;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07D265/36;;C07D207/14;;C07D271/10;;C07C243/34;;C07D207/335;;C07C251/48;;C07D209/08;;C07D209/14;;C07D277/68;;C07C255/24;;C07D209/44;;C07D513/04;;C07C255/29;;C07C255/37;;C07D285/13;;C07D295/02;;C07D211/26;;C07D211/56;;C07D211/70;;C07D295/185;;C07D295/192;;C07D213/38;;C07D213/64;;C07D305/06;;C07D305/08;;C07D213/65;;C07D213/68;;C07D307/14;;C07D307/22;;C07D307/79;;C07C313/06;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;C07D295/027;;A61P31/12;;A61P31/14;;A61P43/00;;C07D239/42;;C07C217/58;;C07D211/70;;C07C237/08;;C07D209/08;;C07D207/335;;C07C255/37;;C07C255/29;;C07C237/06;;C07D285/13;;C07D513/04;;C07D265/36;;C07D295/02;;C07D305/08;;C07D213/81;;C07D263/32;;C07D243/14;;C07C235/46;;C07C237/10;;C07C255/46;;C07C259/06;;C07C271/12;;C07C251/48;;C07C255/54;;C07C255/24;;C07D305/06;;C07B2200/05;;C07D237/14;;C07D307/14;;C07D213/73;;C07D209/14;;C07C275/36;;C07D295/192;;C07C225/12;;C07D239/34;;C07C323/25;;C07D211/26;;C07C217/60;;C07C233/25;;C07D277/68;;C07D271/10;;C07D309/12;;C07D319/18;;C07C217/90;;C07D241/18;;C07D213/64;;C07D233/24;;C07C311/08;;C07D211/56;;C07D231/12;;C07D241/20;;C07C311/29;;C07D213/65;;C07C217/62;;C07D217/02;;C07D213/68;;C07D213/38;;C07D213/74;;C07D213/75;;C07C237/04;;C07D307/22;;C07D233/64;;C07C317/22;;C07D309/06;;C07D309/14;;C07D241/24;;C07D207/14;;C07D307/79;;C07C311/04;;C07D205/04;;C07C243/34;;C07C233/18;;C07C237/12;;C07D209/44;;C07D295/185;;C07D213/84;;C07C313/06;;C07C2601/04;;C07C2601/08;;C07C2601/16;;C07C2601/14;;C07C2601/02;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;A61K45/06;;C07C217/74;;C07C237/20;;C07D295/027,A61K31/505;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K45/06;;C07C217/58;;C07C217/74;;C07C237/20;;C07D211/70;;C07D239/42;;C07D295/027,514/210.01;;564/430;;514/655;;564/306;;544/332;;514/275;;564/165;;514/620;;546/333;;514/357;;546/232;;514/331;;546/223;;514/329,0,0,,,,DISCONTINUED
519,PL,T3,PL 2305250 T3,040-164-634-812-281,2014-07-31,2014,PL 10195498 T,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;EP 10195498 A;;EP 04743172 A,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/040-164-634-812-281,Patent Application,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,PENDING
520,DK,T3,DK 2305250 T3,102-372-605-294-327,2014-04-22,2014,DK 10195498 T,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;EP 04743172 A,2003-07-03,BENZIMIDAZOLDERIVATER OG ANVENDELSE HERAF SOM PROTEINKINASEINHIBITORER,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;HOWARD STEVEN;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM;;O'BRIEN MICHAEL ALISTAIR;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;TREWARTHA GARY,,https://lens.org/102-372-605-294-327,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
521,KR,A,KR 20140102199 A,169-695-628-035-19X,2014-08-21,2014,KR 20147014847 A,2012-10-31,GB 201118876 A;;US 201161554415 P;;US 201261645283 P;;EP 2012071560 W,2011-11-01,"SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION",,ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;BESONG GILBERT EBAI;;CARR MARIA GRAZIA;;HISCOCK STEVEN DOUGLAS;;O'BRIEN MICHAEL ALISTAIR;;REES DAVID CHARLES;;SAALAU BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS,,https://lens.org/169-695-628-035-19X,Patent Application,no,0,0,16,16,0,C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C233/18;;C07C233/25;;C07C235/46;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07C243/34;;C07C251/48;;C07C255/24;;C07C255/29;;C07C255/37;;C07C255/46;;C07C255/54;;C07C259/06;;C07C271/12;;C07C275/36;;C07C311/04;;C07C311/08;;C07C311/29;;C07C317/22;;C07C323/25;;C07D205/04;;C07D207/14;;C07D207/335;;C07D209/08;;C07D209/14;;C07D209/44;;C07D211/26;;C07D211/56;;C07D211/70;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/73;;C07D213/74;;C07D213/75;;C07D213/81;;C07D213/84;;C07D217/02;;C07D231/12;;C07D233/24;;C07D233/64;;C07D237/14;;C07D239/34;;C07D239/42;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07D263/32;;C07D265/36;;C07D271/10;;C07D277/68;;C07D285/13;;C07D295/02;;C07D295/027;;C07D295/185;;C07D295/192;;C07D305/06;;C07D305/08;;C07D307/14;;C07D307/22;;C07D307/79;;C07D309/06;;C07D309/12;;C07D309/14;;C07D319/18;;C07D513/04;;C07C2601/16;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C2601/04;;C07B2200/05;;C07B2200/05;;C07C255/46;;C07C255/54;;C07D213/73;;C07D213/74;;C07D213/75;;C07C259/06;;C07D213/81;;C07D309/06;;C07D213/84;;C07D309/12;;C07D309/14;;C07C271/12;;C07D217/02;;C07C275/36;;C07D319/18;;C07D231/12;;C07D233/24;;C07D233/64;;C07C311/04;;C07C311/08;;C07C311/29;;C07D237/14;;C07C317/22;;C07D239/34;;C07D239/42;;C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C323/25;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07C233/18;;C07C233/25;;C07D263/32;;C07C235/46;;C07D205/04;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07D265/36;;C07D207/14;;C07D271/10;;C07C243/34;;C07D207/335;;C07C251/48;;C07D209/08;;C07D209/14;;C07D277/68;;C07C255/24;;C07D209/44;;C07D513/04;;C07C255/29;;C07C255/37;;C07D285/13;;C07D295/02;;C07D211/26;;C07D211/56;;C07D211/70;;C07D295/185;;C07D295/192;;C07D213/38;;C07D213/64;;C07D305/06;;C07D305/08;;C07D213/65;;C07D213/68;;C07D307/14;;C07D307/22;;C07D307/79;;C07C313/06;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;C07D295/027;;A61P31/12;;A61P31/14;;A61P43/00;;C07D239/42;;C07C217/58;;C07D211/70;;C07C237/08;;C07D209/08;;C07D207/335;;C07C255/37;;C07C255/29;;C07C237/06;;C07D285/13;;C07D513/04;;C07D265/36;;C07D295/02;;C07D305/08;;C07D213/81;;C07D263/32;;C07D243/14;;C07C235/46;;C07C237/10;;C07C255/46;;C07C259/06;;C07C271/12;;C07C251/48;;C07C255/54;;C07C255/24;;C07D305/06;;C07B2200/05;;C07D237/14;;C07D307/14;;C07D213/73;;C07D209/14;;C07C275/36;;C07D295/192;;C07C225/12;;C07D239/34;;C07C323/25;;C07D211/26;;C07C217/60;;C07C233/25;;C07D277/68;;C07D271/10;;C07D309/12;;C07D319/18;;C07C217/90;;C07D241/18;;C07D213/64;;C07D233/24;;C07C311/08;;C07D211/56;;C07D231/12;;C07D241/20;;C07C311/29;;C07D213/65;;C07C217/62;;C07D217/02;;C07D213/68;;C07D213/38;;C07D213/74;;C07D213/75;;C07C237/04;;C07D307/22;;C07D233/64;;C07C317/22;;C07D309/06;;C07D309/14;;C07D241/24;;C07D207/14;;C07D307/79;;C07C311/04;;C07D205/04;;C07C243/34;;C07C233/18;;C07C237/12;;C07D209/44;;C07D295/185;;C07D213/84;;C07C313/06;;C07C2601/04;;C07C2601/08;;C07C2601/16;;C07C2601/14;;C07C2601/02;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;A61K45/06;;C07C217/74;;C07C237/20;;C07D295/027,A61K31/137;;C07C217/58;;A61K31/44;;A61P31/12;;C07D209/14;;C07D213/75,,0,0,,,,DISCONTINUED
522,ZA,B,ZA 201403852 B,068-993-280-478-937,2017-08-30,2017,ZA 201403852 A,2014-05-27,GB 201118876 A;;US 201161554415 P;;US 201261645283 P;;EP 2012071560 W,2011-11-01,"SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION",,ASTEX THERAPEUTICS LTD,BESONG GILBERT EBAI;;WOODHEAD ANDREW JAMES;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;SAALAU-BETHELL SUSANNE MARIA;;REES DAVID CHARLES;;O'BRIEN MICHAEL ALISTAIR;;HISCOCK STEVEN DOUGLAS;;CHESSARI GIANNI;;CARR MARIA GRAZIA,,https://lens.org/068-993-280-478-937,Granted Patent,no,0,0,16,16,0,C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C233/18;;C07C233/25;;C07C235/46;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07C243/34;;C07C251/48;;C07C255/24;;C07C255/29;;C07C255/37;;C07C255/46;;C07C255/54;;C07C259/06;;C07C271/12;;C07C275/36;;C07C311/04;;C07C311/08;;C07C311/29;;C07C317/22;;C07C323/25;;C07D205/04;;C07D207/14;;C07D207/335;;C07D209/08;;C07D209/14;;C07D209/44;;C07D211/26;;C07D211/56;;C07D211/70;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/73;;C07D213/74;;C07D213/75;;C07D213/81;;C07D213/84;;C07D217/02;;C07D231/12;;C07D233/24;;C07D233/64;;C07D237/14;;C07D239/34;;C07D239/42;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07D263/32;;C07D265/36;;C07D271/10;;C07D277/68;;C07D285/13;;C07D295/02;;C07D295/027;;C07D295/185;;C07D295/192;;C07D305/06;;C07D305/08;;C07D307/14;;C07D307/22;;C07D307/79;;C07D309/06;;C07D309/12;;C07D309/14;;C07D319/18;;C07D513/04;;C07C2601/16;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C2601/04;;C07B2200/05;;C07B2200/05;;C07C255/46;;C07C255/54;;C07D213/73;;C07D213/74;;C07D213/75;;C07C259/06;;C07D213/81;;C07D309/06;;C07D213/84;;C07D309/12;;C07D309/14;;C07C271/12;;C07D217/02;;C07C275/36;;C07D319/18;;C07D231/12;;C07D233/24;;C07D233/64;;C07C311/04;;C07C311/08;;C07C311/29;;C07D237/14;;C07C317/22;;C07D239/34;;C07D239/42;;C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C323/25;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07C233/18;;C07C233/25;;C07D263/32;;C07C235/46;;C07D205/04;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07D265/36;;C07D207/14;;C07D271/10;;C07C243/34;;C07D207/335;;C07C251/48;;C07D209/08;;C07D209/14;;C07D277/68;;C07C255/24;;C07D209/44;;C07D513/04;;C07C255/29;;C07C255/37;;C07D285/13;;C07D295/02;;C07D211/26;;C07D211/56;;C07D211/70;;C07D295/185;;C07D295/192;;C07D213/38;;C07D213/64;;C07D305/06;;C07D305/08;;C07D213/65;;C07D213/68;;C07D307/14;;C07D307/22;;C07D307/79;;C07C313/06;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;C07D295/027;;A61P31/12;;A61P31/14;;A61P43/00;;C07D239/42;;C07C217/58;;C07D211/70;;C07C237/08;;C07D209/08;;C07D207/335;;C07C255/37;;C07C255/29;;C07C237/06;;C07D285/13;;C07D513/04;;C07D265/36;;C07D295/02;;C07D305/08;;C07D213/81;;C07D263/32;;C07D243/14;;C07C235/46;;C07C237/10;;C07C255/46;;C07C259/06;;C07C271/12;;C07C251/48;;C07C255/54;;C07C255/24;;C07D305/06;;C07B2200/05;;C07D237/14;;C07D307/14;;C07D213/73;;C07D209/14;;C07C275/36;;C07D295/192;;C07C225/12;;C07D239/34;;C07C323/25;;C07D211/26;;C07C217/60;;C07C233/25;;C07D277/68;;C07D271/10;;C07D309/12;;C07D319/18;;C07C217/90;;C07D241/18;;C07D213/64;;C07D233/24;;C07C311/08;;C07D211/56;;C07D231/12;;C07D241/20;;C07C311/29;;C07D213/65;;C07C217/62;;C07D217/02;;C07D213/68;;C07D213/38;;C07D213/74;;C07D213/75;;C07C237/04;;C07D307/22;;C07D233/64;;C07C317/22;;C07D309/06;;C07D309/14;;C07D241/24;;C07D207/14;;C07D307/79;;C07C311/04;;C07D205/04;;C07C243/34;;C07C233/18;;C07C237/12;;C07D209/44;;C07D295/185;;C07D213/84;;C07C313/06;;C07C2601/04;;C07C2601/08;;C07C2601/16;;C07C2601/14;;C07C2601/02;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;A61K45/06;;C07C217/74;;C07C237/20;;C07D295/027,,,0,0,,,,ACTIVE
523,ES,T3,ES 2457466 T3,111-812-157-418-236,2014-04-25,2014,ES 10195498 T,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A,2003-07-03,Derivados de bencimidazol y sus usos como inhibidores de proteína quinasas,"Una combinación que comprende: (i) un compuesto de fórmula (VII): o una sal, N-óxido o solvato del mismo; donde A es -(CH2)m-(B)n-; donde m es 0 o 1, n es 1 y B es C>=O o NRg(C>=O); Rg es hidrógeno; R1d es un grupo R1 donde R1 es hidrógeno, un grupo carbocíclico o heterocíclico que tiene de 3 a 12 miembros en el anillo, o un grupo hidrocarbilo C1-8 opcionalmente sustituido; donde los sustituyentes opcionales para el grupo hidrocarbilo C1-8 se seleccionan entre hidroxi, oxo, alcoxi, carboxi, halógeno, ciano, nitro, amino, mono- o di-hidrocarbilamino C1-4, y grupos carbocíclicos y heterocíclicos monocíclicos o bicíclicos que tienen de 3 a 12 miembros en el anillo; y, donde los grupos carbocíclicos y heterocíclicos en cada caso están sin sustituir o sustituidos con uno o más grupos sustituyentes R10 seleccionados entre halógeno, hidroxi, trifluorometilo, ciano, nitro, carboxi, amino, mono- o di-hidrocarbilamino C1-4, grupos carbocíclicos y heterocíclicos que tienen de 3 a 12 miembros en el anillo; un grupo Ra-Rb donde Ra es un enlace, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc o NRcSO2; y Rb se selecciona entre hidrógeno, grupos carbocíclicos y heterocíclicos que tienen de 3 a 12 miembros en el anillo, y un grupo hidrocarbilo C1-8 opcionalmente sustituido con uno o más sustituyentes seleccionados entre hidroxi, oxo, halógeno, ciano, nitro, carboxi, amino, mono- o di-hidrocarbilamino C1-4, grupos carbocíclicos y heterocíclicos que tienen de 3 a 12 miembros en el anillo y donde uno o más átomos de carbono del grupo hidrocarbilo C1-8 pueden estar opcionalmente reemplazados con O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 o X1C(X2)X1; o dos grupos adyacentes R10, junto con los átomos de carbono o heteroátomos a los que están unidos pueden formar un anillo de heteroarilo de 5 miembros o un anillo carbocíclico o heterocíclico no aromático de 5 o 6 miembros, donde los grupos heteroarilo y heterocíclico mencionados contienen hasta 3 miembros en el anillo que son heteroátomos seleccionados entre N, O y S; Rc se selecciona entre hidrógeno e hidrocarbilo C1-4; y X1 es O, S o NRc y X2 es >=O, >=S o >=NRc; y con la condición de que cuando el grupo sustituyente R10 comprende o incluye un grupo carbocíclico o heterocíclico, el grupo carbocíclico o heterocíclico mencionado puede estar sin sustituir o puede estar sustituido en sí mismo con uno o más grupos sustituyentes adicionales R10 y donde (a) dichos grupos sustituyentes adicionales R10 incluyen grupos carbocíclicos o heterocíclicos, que no están en sí mismos sustituidos adicionalmente; o (b) los sustituyentes adicionales mencionados no incluyen grupos carbocíclicos o heterocíclicos pero se seleccionan de otro modo entre los grupos que se han indicado anteriormente en la definición de R10, y (ii) uno u otros agentes terapéuticos más.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/111-812-157-418-236,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
524,TW,A,TW 200524598 A,044-496-601-382-445,2005-08-01,2005,TW 93120042 A,2004-07-02,GB 0315657 A;;US 48468503 P;;GB 0324919 A;;US 51437403 P,2003-07-03,Pharmaceutical compounds,"The invention provides compounds, known and novel, for use as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinases, and for use in the treatment of cancer. The compounds have the general formula (I): , or a salt, N-oxide or solvate thereof; wherein X is CR5 or N; A is a bond or -(CH2)m-(B)n-; B is C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; m is 0, 1 or 2; n is 0 or 1; R0 is hydrogen or, together with NRg when present, forms a group -(CH2)p- wherein p is 2 to 4; R1 is hydrogen, a carbocyclic or heterocyclic group having from 3 to 12 ring members, or an optionally substituted C1-8 hydrocarbyl group; R2 is hydrogen, halogen, methoxy, or a C1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or methoxy; R3 and R4 together with the carbon atoms to which they are attached form an optionally substituted fused carbocyclic or heterocyclic ring having from 5 to 7 ring members of which up to 3 can be heteroatoms selected from N, O and S; and R5 is hydrogen, a group R2 or a group R10 wherein R10 is selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group Ra-Rb wherein Ra is a bond, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2; and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; Rc is selected from hydrogen and C1-4 hydrocarbyl; and X1 is O, S or NRc and X2 is =O, =S or =NRc.",ASTEX TECHNOLOGY LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/044-496-601-382-445,Patent of Addition,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/00;;A61K31/4184;;A61P31/10;;A61P35/00;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,INACTIVE
525,WO,A1,WO 2013/064538 A1,143-518-919-772-674,2013-05-10,2013,EP 2012071560 W,2012-10-31,GB 201118876 A;;US 201161554415 P;;US 201261645283 P,2011-11-01,"SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION","The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R 0 is hydrogen or C 1-2 alkyl; R 1a is selected from CONH 2 ; CO 2 H; an optionally substituted acyclic C 1-8 hydrocarbon group; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R 2 is selected from hydrogen and a group R 2a ; R 2a is selected from an optionally substituted acyclic d-8 hydrocarbon group; an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1 or 2 ring members are heteroatom ring members selected from O, N and S; and an optionally substituted bicyclic heterocyclic group of 9 or 10 ring members, of which 1 or 2 ring members are nitrogen atoms; wherein at least one of R 1 and R 2 is other than hydrogen; R 3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0, 1, 2 or 3 heteroatom ring members selected from N, O and S; R 4a is selected from halogen; cyano; C 1-4 alkyl optionally substituted with one or more fluorine atoms; C 1-4 alkoxy optionally substituted with one or more fluorine atoms; hydroxy-C 1-4 alkyl; and C 1-2 alkoxy-C 1-4 alkyl; R 5 is selected from hydrogen and a substituent R 5a ; and R 5a is selected from C 1-2 alkyl optionally substituted with one or more fluorine atoms; C 1-3 alkoxy optionally substituted with one or more fluorine atoms; halogen; cyclopropyl; cyano; and amino, The compounds have activity against hepatitis C virus and can be used in the prevention or treatment of hepatitis C viral infections.",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;BESONG GILBERT EBAI;;CARR MARIA GRAZIA;;HISCOCK STEVEN DOUGLAS;;O'BRIEN MICHAEL ALISTAIR;;REES DAVID CHARLES;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS,,https://lens.org/143-518-919-772-674,Patent Application,yes,4,5,16,16,5,C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C233/18;;C07C233/25;;C07C235/46;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07C243/34;;C07C251/48;;C07C255/24;;C07C255/29;;C07C255/37;;C07C255/46;;C07C255/54;;C07C259/06;;C07C271/12;;C07C275/36;;C07C311/04;;C07C311/08;;C07C311/29;;C07C317/22;;C07C323/25;;C07D205/04;;C07D207/14;;C07D207/335;;C07D209/08;;C07D209/14;;C07D209/44;;C07D211/26;;C07D211/56;;C07D211/70;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/73;;C07D213/74;;C07D213/75;;C07D213/81;;C07D213/84;;C07D217/02;;C07D231/12;;C07D233/24;;C07D233/64;;C07D237/14;;C07D239/34;;C07D239/42;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07D263/32;;C07D265/36;;C07D271/10;;C07D277/68;;C07D285/13;;C07D295/02;;C07D295/027;;C07D295/185;;C07D295/192;;C07D305/06;;C07D305/08;;C07D307/14;;C07D307/22;;C07D307/79;;C07D309/06;;C07D309/12;;C07D309/14;;C07D319/18;;C07D513/04;;C07C2601/16;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C2601/04;;C07B2200/05;;C07B2200/05;;C07C255/46;;C07C255/54;;C07D213/73;;C07D213/74;;C07D213/75;;C07C259/06;;C07D213/81;;C07D309/06;;C07D213/84;;C07D309/12;;C07D309/14;;C07C271/12;;C07D217/02;;C07C275/36;;C07D319/18;;C07D231/12;;C07D233/24;;C07D233/64;;C07C311/04;;C07C311/08;;C07C311/29;;C07D237/14;;C07C317/22;;C07D239/34;;C07D239/42;;C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C323/25;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07C233/18;;C07C233/25;;C07D263/32;;C07C235/46;;C07D205/04;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07D265/36;;C07D207/14;;C07D271/10;;C07C243/34;;C07D207/335;;C07C251/48;;C07D209/08;;C07D209/14;;C07D277/68;;C07C255/24;;C07D209/44;;C07D513/04;;C07C255/29;;C07C255/37;;C07D285/13;;C07D295/02;;C07D211/26;;C07D211/56;;C07D211/70;;C07D295/185;;C07D295/192;;C07D213/38;;C07D213/64;;C07D305/06;;C07D305/08;;C07D213/65;;C07D213/68;;C07D307/14;;C07D307/22;;C07D307/79;;C07C313/06;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;C07D295/027;;A61P31/12;;A61P31/14;;A61P43/00;;C07D239/42;;C07C217/58;;C07D211/70;;C07C237/08;;C07D209/08;;C07D207/335;;C07C255/37;;C07C255/29;;C07C237/06;;C07D285/13;;C07D513/04;;C07D265/36;;C07D295/02;;C07D305/08;;C07D213/81;;C07D263/32;;C07D243/14;;C07C235/46;;C07C237/10;;C07C255/46;;C07C259/06;;C07C271/12;;C07C251/48;;C07C255/54;;C07C255/24;;C07D305/06;;C07B2200/05;;C07D237/14;;C07D307/14;;C07D213/73;;C07D209/14;;C07C275/36;;C07D295/192;;C07C225/12;;C07D239/34;;C07C323/25;;C07D211/26;;C07C217/60;;C07C233/25;;C07D277/68;;C07D271/10;;C07D309/12;;C07D319/18;;C07C217/90;;C07D241/18;;C07D213/64;;C07D233/24;;C07C311/08;;C07D211/56;;C07D231/12;;C07D241/20;;C07C311/29;;C07D213/65;;C07C217/62;;C07D217/02;;C07D213/68;;C07D213/38;;C07D213/74;;C07D213/75;;C07C237/04;;C07D307/22;;C07D233/64;;C07C317/22;;C07D309/06;;C07D309/14;;C07D241/24;;C07D207/14;;C07D307/79;;C07C311/04;;C07D205/04;;C07C243/34;;C07C233/18;;C07C237/12;;C07D209/44;;C07D295/185;;C07D213/84;;C07C313/06;;C07C2601/04;;C07C2601/08;;C07C2601/16;;C07C2601/14;;C07C2601/02;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;A61K45/06;;C07C217/74;;C07C237/20;;C07D295/027,C07D209/14;;A61K31/137;;A61K31/415;;A61K31/4164;;A61K31/44;;A61P31/12;;C07C217/58;;C07D213/75;;C07D231/12;;C07D233/24;;C07D233/64;;C07D295/02;;C07D305/06;;C07D305/08;;C07D309/14,,56,38,092-196-354-877-585;;017-347-015-881-243;;005-874-534-835-432;;045-415-706-073-517;;021-678-328-638-835;;045-804-232-391-319;;006-016-453-414-156;;152-983-672-513-485;;082-584-678-375-006;;107-578-170-220-753;;088-253-767-481-857;;141-771-777-785-977;;005-465-843-126-210;;001-213-758-138-077;;075-343-369-666-407;;096-631-839-313-189;;016-163-077-184-387;;030-285-531-359-849;;099-722-627-848-58X;;001-413-720-748-124;;071-434-763-452-86X;;032-511-500-330-440;;135-227-601-946-03X;;007-364-858-655-289;;000-820-736-344-337;;126-811-728-740-254;;041-878-720-663-623;;024-966-947-509-122;;077-295-491-167-117;;077-295-491-167-117;;046-777-072-258-96X;;007-378-255-811-868;;075-596-410-145-597;;003-656-629-895-712;;015-714-720-040-924;;180-914-831-542-651;;010-867-772-881-309;;075-553-717-843-39X,16621574;;10.1016/j.bmc.2006.03.042;;23023261;;10.1038/nchembio.1081;;pmc3480716;;15521006;;10.1053/j.gastro.2004.07.020;;9136797;;10.1016/s0002-9610(96)00384-4;;11870384;;10.1053/jhep.2002.31773;;10.1038/nature04083;;16107838;;10.1099/0022-1317-74-11-2391;;8245854;;10.1099/0022-1317-78-1-45;;9010284;;10.1099/0022-1317-75-5-1053;;8176367;;19684573;;10.1038/nature08309;;20621700;;10.1053/j.gastro.2010.05.079;;10.1053/j.gastro.2007.02.037;;17484874;;10.1586/14787210.6.4.463;;18662114;;20942646;;10.1086/656774;;10.1053/j.gastro.2009.11.055;;20006612;;10.2174/187152606776056706;;16787300;;10.3410/f.1046522.496495;;17004721;;10.1021/jm060325b.s001;;10.1021/jm060325b;;17556358;;10.1074/jbc.m610207200;;10.1021/jm060173k;;17444623;;10.21775/cimb.009.001;;17263143;;pmc3571657;;10.1074/jbc.m805460200;;19010782;;pmc2629105;;pmc3126282;;10.1128/jvi.02130-10;;21325413;;22814430;;pmc3467334;;10.1016/j.virusres.2012.07.007;;10.1002/jps.2600660104;;833720;;10.1080/00397917709409270;;10.1002/anie.196603851;;10.1002/crat.2170280318;;9002452;;10.1021/js9601896;;10.1002/0471220574;;10.1002/0471220574;;15002962;;10.1021/cc034046a;;12739949;;10.1021/cc0201041;;10.1023/b:pham.0000016235.32639.23;;15032302;;10.1016/s0168-3659(03)00241-4;;12932648;;10.1002/jps.2600600902;;4935981;;10.1002/0470055529;;12415250;;10.1038/nrd942;;15178332;;10.1016/j.febslet.2004.04.072,"DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 3 March 2011 (2011-03-03), WALTER, HARALD ET AL: ""N-alkoxy pyrazolecarboxamide derivatives as microbiocides and their preparation and use"", XP002693247, retrieved from STN Database accession no. 2011:266858;;DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 5 September 2009 (2009-09-05), ONO, NAOYA ET AL: ""Preparation of N-heterocyclylalkylbenzenesulfonamide derivatives as inhibitor of binding of Edg-1 (endothelial differentiation gene receptor type-1, S1P1)"", XP002693248, retrieved from STN Database accession no. 2009:139916;;DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1982, UEDA, IKUO ET AL: ""Phenylalkanoic acid derivatives and pharmaceutical compositions containing them"", XP002693249, retrieved from STN Database accession no. 1982:6400;;ZBINDEN K G ET AL: ""Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity"", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 14, no. 15, 1 August 2006 (2006-08-01), pages 5357 - 5369, XP025133433, ISSN: 0968-0896, [retrieved on 20060801], DOI: 10.1016/J.BMC.2006.03.042;;SAALAU-BETHELL SUSANNE M ET AL: ""Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function"", NATURE CHEMICAL BIOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 8, no. 11, 1 November 2012 (2012-11-01), pages 920 - 925, XP008160588, ISSN: 1552-4450, [retrieved on 20120930], DOI: 10.1038/NCHEMBIO.1081;;DAVILA, J.A. ET AL., GASTROENTEROLOGY, vol. 127, 2004, pages 1372 - 1380;;LIU, C.L.; FAN, S.T., AM. J. SURG., vol. 173, 1997, pages 358 - 365;;GARCIA-RETORTILLO, M. ET AL., HEPATOLOGY, vol. 35, 2002, pages 680 - 687;;BROWN, R.S., NATURE, vol. 436, 2005, pages 973 - 978;;SIMMONDS ET AL., J GEN VIROL, vol. 74, 1993, pages 2391 - 2399;;LAMBALLERIE ET AL., J GEN VIROL, vol. 78, 1997, pages 45 - 51;;SIMMONDS ET AL., J GEN VIROL, vol. 75, 1994, pages 1053 - 1061;;GE ET AL., NATURE, vol. 461, 2009, pages 399 - 401;;MANGIA ET AL., GASTROENTEROLOGY, vol. 139, no. 3, 2010, pages 821 - 7;;SARRAZIN, C. ET AL., GASTROENTEROLOGY, vol. 132, 2007, pages 1767 - 1777;;KIM, A.Y.; TIMM, J., EXPERT REV ANTI INFECT THER., vol. 6, 2008, pages 463 - 478;;LE POGAM, S. ET AL., J. INFECT DIS., vol. 202, 2010, pages 1510 - 9;;SARRAZIN, C.; ZEUZEM, S, GASTROENTEROLOGY, vol. 138, 2010, pages 447 - 462;;LIN, C. ET AL., INFECT DISORD DRUG TARGETS, vol. 6, 2006, pages 3 - 16;;VENKATRAMAN, S. ET AL., J. MED. CHEM., vol. 49, 2006, pages 6074 - 6086;;ZHOU, Y. ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 22619 - 22628;;PRONGAY, A.J. ET AL., J. MED. CHEM., vol. 50, 2007, pages 2310 - 2318;;HEZODE, C. ET AL., N. ENGL. J. MED., vol. 360, 2009, pages 1839 - 49;;FRICK, D.N., CURR. ISSUES MOL. BIOL., vol. 9, 2007, pages 1 - 20;;SEREBROV, V. ET AL., J. BIOL. CHEM., vol. 284, no. 4, 2009, pages 2512 - 21;;SWAN T.; KAPLAN, K., HEPATITIS C DRUG DEVELOPMENT GOES FROM PONY RIDE TO ROCKET LAUNCH- THE PIPELINE REPORT 2012, 2012, Retrieved from the Internet <URL:http://www.pipelinereport.org/toc/HCV>;;MAGA, G. ET AL., BIOCHEM., vol. 44, 2005, pages 9637 - 44;;DING, S.C. ET AL., J. VIROL., vol. 85, no. 9, 2011, pages 4343 - 4353;;VAUGHAN, R. ET AL., VIRUS RESEARCH, vol. 169, no. 1, 2012, pages 80 - 90;;JHOTI ET AL., NATURE CHEMICAL BIOLOGY, 2012;;""Pharmaceutical Salts: Properties, Selection, and Use"", August 2002, pages: 388;;BERGE ET AL.: ""Pharmaceutically Acceptable Salts"", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;ALBINI, A.; PIETRA, S.: ""Heterocyclic N-Oxides"", 1991, CRC PRESS, pages: 31;;L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514;;JERRY MARCH: ""Advanced Organic Chemistry"", 1992, JOHN WILEY & SONS, pages: 109 - 114;;CAHN; INGOLD; PRELOG, ANGEW. CHEM. INT. ED. ENGL., vol. 5, 1966, pages 385 - 415;;BRYN ET AL.: ""Solid-State Chemistry of Drugs"", 1999, SSCI, INC OF WEST LAFAYETTE;;C. GIACOVAZZO; H. L. MONACO; D. VITERBO; F. SCORDARI; G. GIIII; G. ZANOTTI; M. CATTI: ""Fundamentals of Crystallography"", 1992, INTERNATIONAL UNION OF CRYSTALLOGRAPHY/OXFORD UNIVERSITY PRESS;;HANCOCK ET AL., J. PHARM. SCI., vol. 86, 1997, pages 1;;GREENE; WUTS: ""Protective Groups in Organic Synthesis"", WILEY INTERSCIENCE;;JERRY MARCH: ""Advanced Organic Chemistry"", 1992, JOHN WILEY & SONS;;""Organic Syntheses"", vol. 1-8, 1995, JOHN WILEY;;""Fiesers' Reagents for Organic Synthesis"", vol. 1-17, JOHN WILEY;;T. GREEN; P. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY AND SONS;;ROSENTRETER U; HUBER U: ""Optimal fraction collecting in preparative LC/MS"", J COMB CHEM., vol. 6, no. 2, 2004, pages 159 - 64;;LEISTER W; STRAUSS K; WISNOSKI D; ZHAO Z; LINDSLEY C: ""Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries"", J COMB CHEM., vol. 5, no. 3, 2003, pages 322 - 9, XP001198955, DOI: doi:10.1021/cc0201041;;""Remington's Pharmaceutical Sciences"", MACK PUBLISHING COMPANY;;R. G. STRICKLY: ""Solubilizing Excipients in oral and injectable formulations"", PHARMACEUTICAL RESEARCH, vol. 21, no. 2, 2004, pages 201 - 230;;""Nanoparticle Technology for Drug Delivery"", 13 March 2006, INFORMA HEALTHCARE;;J. CONTROL. RELEASE, vol. 91, no. 1-2, 2003, pages 167 - 172;;SINHA ET AL., MOL. CANCER THER., vol. 5, 1 August 2006 (2006-08-01), pages 1909;;CHIOU; RIEGELMAN, J. PHARM. SCI., vol. 60, 1971, pages 1281 - 1300;;SNYDER L. R.; DOLAN J. W.: ""High-Performance Gradient Elution The Practical Application of the Linear-Solvent-Strength Model"", 2007, WILEY;;BEESLEY T. E.; SCOTT R.P.W.: ""Chiral Chromatography"", 1998, WILEY;;BARTENSCHLAGER, R.: ""Hepatitis C replicons: potential role for drug development"", NATURE REV. DRUG DISCOV., vol. 1, 2002, pages 911 - 916, XP003014571, DOI: doi:10.1038/nrd942;;BOGUSZEWKA-CHACHULSKA, FEBS LETTERS, vol. 567, 2004, pages 253 - 258",PENDING
526,MX,A,MX 2014005229 A,101-138-274-457-90X,2015-07-06,2015,MX 2014005229 A,2012-10-31,GB 201118876 A;;US 201161554415 P;;US 201261645283 P;;EP 2012071560 W,2011-11-01,"SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION.","The invention provides compounds of the formula (I): or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF or nitrogen; and R0 is hydrogen or C1-2 alkyl; R1a is selected from CONH2; CO2H; an optionally substituted acyclic C1-8 hydrocarbon group; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R2 is selected from hydrogen and a group R2a; R2a is selected from an optionally substituted acyclic d-8 hydrocarbon group; an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1 or 2 ring members are heteroatom ring members selected from O, N and S; and an optionally substituted bicyclic heterocyclic group of 9 or 10 ring members, of which 1 or 2 ring members are nitrogen atoms; wherein at least one of R1 and R2 is other than hydrogen; R3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0, 1, 2 or 3 heteroatom ring members selected from N, O and S; R4a is selected from halogen; cyano; C1-4 alkyl optionally substituted with one or more fluorine atoms; C1-4 alkoxy optionally substituted with one or more fluorine atoms; hydroxy-C1-4 alkyl; and C1-2 alkoxy-C1-4 alkyl; R5 is selected from hydrogen and a substituent R5a; and R5a is selected from C1-2 alkyl optionally substituted with one or more fluorine atoms; C1-3 alkoxy optionally substituted with one or more fluorine atoms; halogen; cyclopropyl; cyano; and amino, The compounds have activity against hepatitis C virus and can be used in the prevention or treatment of hepatitis C viral infections.",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;BESONG GILBERT EBAI;;CARR MARIA GRAZIA;;HISCOCK STEVEN DOUGLAS;;O'BRIEN MICHAEL ALISTAIR;;REES DAVID CHARLES;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS,,https://lens.org/101-138-274-457-90X,Patent Application,no,0,0,16,16,0,C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C233/18;;C07C233/25;;C07C235/46;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07C243/34;;C07C251/48;;C07C255/24;;C07C255/29;;C07C255/37;;C07C255/46;;C07C255/54;;C07C259/06;;C07C271/12;;C07C275/36;;C07C311/04;;C07C311/08;;C07C311/29;;C07C317/22;;C07C323/25;;C07D205/04;;C07D207/14;;C07D207/335;;C07D209/08;;C07D209/14;;C07D209/44;;C07D211/26;;C07D211/56;;C07D211/70;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/73;;C07D213/74;;C07D213/75;;C07D213/81;;C07D213/84;;C07D217/02;;C07D231/12;;C07D233/24;;C07D233/64;;C07D237/14;;C07D239/34;;C07D239/42;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07D263/32;;C07D265/36;;C07D271/10;;C07D277/68;;C07D285/13;;C07D295/02;;C07D295/027;;C07D295/185;;C07D295/192;;C07D305/06;;C07D305/08;;C07D307/14;;C07D307/22;;C07D307/79;;C07D309/06;;C07D309/12;;C07D309/14;;C07D319/18;;C07D513/04;;C07C2601/16;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C2601/04;;C07B2200/05;;C07B2200/05;;C07C255/46;;C07C255/54;;C07D213/73;;C07D213/74;;C07D213/75;;C07C259/06;;C07D213/81;;C07D309/06;;C07D213/84;;C07D309/12;;C07D309/14;;C07C271/12;;C07D217/02;;C07C275/36;;C07D319/18;;C07D231/12;;C07D233/24;;C07D233/64;;C07C311/04;;C07C311/08;;C07C311/29;;C07D237/14;;C07C317/22;;C07D239/34;;C07D239/42;;C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C323/25;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07C233/18;;C07C233/25;;C07D263/32;;C07C235/46;;C07D205/04;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07D265/36;;C07D207/14;;C07D271/10;;C07C243/34;;C07D207/335;;C07C251/48;;C07D209/08;;C07D209/14;;C07D277/68;;C07C255/24;;C07D209/44;;C07D513/04;;C07C255/29;;C07C255/37;;C07D285/13;;C07D295/02;;C07D211/26;;C07D211/56;;C07D211/70;;C07D295/185;;C07D295/192;;C07D213/38;;C07D213/64;;C07D305/06;;C07D305/08;;C07D213/65;;C07D213/68;;C07D307/14;;C07D307/22;;C07D307/79;;C07C313/06;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;C07D295/027;;A61P31/12;;A61P31/14;;A61P43/00;;C07D239/42;;C07C217/58;;C07D211/70;;C07C237/08;;C07D209/08;;C07D207/335;;C07C255/37;;C07C255/29;;C07C237/06;;C07D285/13;;C07D513/04;;C07D265/36;;C07D295/02;;C07D305/08;;C07D213/81;;C07D263/32;;C07D243/14;;C07C235/46;;C07C237/10;;C07C255/46;;C07C259/06;;C07C271/12;;C07C251/48;;C07C255/54;;C07C255/24;;C07D305/06;;C07B2200/05;;C07D237/14;;C07D307/14;;C07D213/73;;C07D209/14;;C07C275/36;;C07D295/192;;C07C225/12;;C07D239/34;;C07C323/25;;C07D211/26;;C07C217/60;;C07C233/25;;C07D277/68;;C07D271/10;;C07D309/12;;C07D319/18;;C07C217/90;;C07D241/18;;C07D213/64;;C07D233/24;;C07C311/08;;C07D211/56;;C07D231/12;;C07D241/20;;C07C311/29;;C07D213/65;;C07C217/62;;C07D217/02;;C07D213/68;;C07D213/38;;C07D213/74;;C07D213/75;;C07C237/04;;C07D307/22;;C07D233/64;;C07C317/22;;C07D309/06;;C07D309/14;;C07D241/24;;C07D207/14;;C07D307/79;;C07C311/04;;C07D205/04;;C07C243/34;;C07C233/18;;C07C237/12;;C07D209/44;;C07D295/185;;C07D213/84;;C07C313/06;;C07C2601/04;;C07C2601/08;;C07C2601/16;;C07C2601/14;;C07C2601/02;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;A61K45/06;;C07C217/74;;C07C237/20;;C07D295/027,C07D209/14;;A61K31/137;;A61K31/415;;A61K31/4164;;A61K31/44;;A61P31/12;;C07C217/58;;C07D213/75;;C07D231/12;;C07D233/24;;C07D233/64;;C07D295/02;;C07D305/06;;C07D305/08;;C07D309/14,,0,0,,,,PENDING
527,PT,E,PT 2305250 E,196-766-902-705-163,2014-05-19,2014,PT 10195498 T,2004-07-05,GB 0315657 A;;GB 0324919 A;;US 48468503 P;;US 51437403 P,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;WYATT PAUL GRAHAM;;CARR MARIA GRAZIA;;WOODHEAD ANDREW JAMES;;HOWARD STEVEN;;O'BRIEN MICHAEL ALISTAIR;;EARLY THERESA RACHEL;;GILL ADRIAN LIAM;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;NAVARRO EVA FIGUEROA,,https://lens.org/196-766-902-705-163,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
528,EP,B1,EP 2305250 B1,096-108-768-301-60X,2014-03-26,2014,EP 10195498 A,2004-07-05,EP 04743172 A;;GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/096-108-768-301-60X,Granted Patent,yes,1,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,1,0,,,"ESSASSI E M ET AL: ""SYNTHESE ET HEREROCYCLISATION DES (PYRAZOLYL-3(5))-2 BENZIMIDAZOLES EN CATALYSE PAR TRANSFERT DE PHASE"", BULLETIN DES SOCIETES CHIMIQUES BELGES, XX, XX, vol. 96, no. 1, 1987, pages 63-67, XP008005414, ISSN: 0037-9646",ACTIVE
529,US,A1,US 2014/0010892 A1,154-875-441-050-289,2014-01-09,2014,US 201313902325 A,2013-05-24,US 201313902325 A;;GB 0315657 A;;GB 0324919 A;;US 201113116121 A;;US 56416604 A;;GB 2004002824 W;;US 51437403 P;;US 48468503 P,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS,"The invention provides compounds of the formula (I): The compounds have activity against cyclin dependent kinases, glycogen synthase kinase and Aurora kinases and are therefore useful to treat cancer and viral diseases.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,ASTEX THERAPEUTICS LIMITED (2006-06-16),https://lens.org/154-875-441-050-289,Patent Application,yes,1,4,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/5377;;A61K31/00;;A61K31/4184;;A61K45/06;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D471/04;;C07D513/04,424/649;;514/234.5;;544/139;;544/119;;514/233.2;;544/121;;544/130;;544/137;;514/234.8;;544/131;;544/133;;544/122,1,1,069-466-469-920-604,10.3816/clm.2002.n.008;;12141952,"""Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia"" by Schmitt et al., Clin. Lymphoma 3, 26-35 (PubMed Abstract) (2002).",DISCONTINUED
530,US,A1,US 2011/0224203 A1,179-359-332-559-787,2011-09-15,2011,US 201113116121 A,2011-05-26,US 201113116121 A;;GB 0315657 A;;GB 0324919 A;;US 56416604 A;;GB 2004002824 W;;US 51437403 P;;US 48468503 P,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS,"The invention provides compounds of the formula (I): The compounds have activity against cyclin dependent kinases, glycogen synthase kinase and Aurora kinases and are therefore useful to treat cancer and viral diseases.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,ASTEX THERAPEUTICS LIMITED (2006-06-16),https://lens.org/179-359-332-559-787,Patent Application,yes,22,10,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/5377;;A61K31/00;;A61K31/4184;;A61P31/10;;A61P35/00;;A61P35/02;;A61P35/04;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14,514/232.5;;514/234.5,6,4,129-851-165-213-092;;137-556-656-441-725;;067-684-687-003-217;;007-199-701-352-072,10.1016/j.ejca.2009.08.008;;19762228;;19104514;;10.1038/nrc2559;;10.1634/theoncologist.2009-0019;;19684075;;3567848;;10.1002/1097-0142(19870601)59:11<1853::aid-cncr2820591102>3.0.co;2-f,"""The Emperor of All Maladies: A Biography of Cancer"" by Murkherjee, Scribner (New York), p. 80 (2010).;;""Contemporary pre-clinical development of anticancer agents - What are the optimal preclinical models?"" by Damia et al., Eur. J. Cancer 45, 2768-81 (2009).;;""Targeting cancer with small molecule kinase inhibitors"" by Zhang et al., Nature Rev. Cancer 9, 28-39 (2009).;;""What Went Wrong with Aurora Kinase Inhibitors"" by Fojo, retrieved from www.emso.org (2011).;;""Clinical Experience with Aurora Kinase Inhibitors: A Review"" by Boss et al., The Oncologist 14, 780-93 (2009).;;""Prognostic Factors in Neuroblastoma"" by Evans et al., Cancer 59, 1853-59 (1987).",DISCONTINUED
531,EP,A1,EP 2773613 A1,051-777-253-889-518,2014-09-10,2014,EP 12791446 A,2012-10-31,GB 201118876 A;;US 201161554415 P;;US 201261645283 P;;EP 2012071560 W,2011-11-01,"SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION",,ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;CHESSARI GIANNI;;BESONG GILBERT EBAI;;CARR MARIA GRAZIA;;HISCOCK STEVEN DOUGLAS;;O'BRIEN MICHAEL ALISTAIR;;REES DAVID CHARLES;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS,,https://lens.org/051-777-253-889-518,Patent Application,yes,0,0,16,16,0,C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C233/18;;C07C233/25;;C07C235/46;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07C243/34;;C07C251/48;;C07C255/24;;C07C255/29;;C07C255/37;;C07C255/46;;C07C255/54;;C07C259/06;;C07C271/12;;C07C275/36;;C07C311/04;;C07C311/08;;C07C311/29;;C07C317/22;;C07C323/25;;C07D205/04;;C07D207/14;;C07D207/335;;C07D209/08;;C07D209/14;;C07D209/44;;C07D211/26;;C07D211/56;;C07D211/70;;C07D213/38;;C07D213/64;;C07D213/65;;C07D213/68;;C07D213/73;;C07D213/74;;C07D213/75;;C07D213/81;;C07D213/84;;C07D217/02;;C07D231/12;;C07D233/24;;C07D233/64;;C07D237/14;;C07D239/34;;C07D239/42;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07D263/32;;C07D265/36;;C07D271/10;;C07D277/68;;C07D285/13;;C07D295/02;;C07D295/027;;C07D295/185;;C07D295/192;;C07D305/06;;C07D305/08;;C07D307/14;;C07D307/22;;C07D307/79;;C07D309/06;;C07D309/12;;C07D309/14;;C07D319/18;;C07D513/04;;C07C2601/16;;C07C2601/02;;C07C2601/08;;C07C2601/14;;C07C2601/04;;C07B2200/05;;C07B2200/05;;C07C255/46;;C07C255/54;;C07D213/73;;C07D213/74;;C07D213/75;;C07C259/06;;C07D213/81;;C07D309/06;;C07D213/84;;C07D309/12;;C07D309/14;;C07C271/12;;C07D217/02;;C07C275/36;;C07D319/18;;C07D231/12;;C07D233/24;;C07D233/64;;C07C311/04;;C07C311/08;;C07C311/29;;C07D237/14;;C07C317/22;;C07D239/34;;C07D239/42;;C07C217/58;;C07C217/60;;C07C217/62;;C07C217/90;;C07C225/12;;C07C323/25;;C07D241/18;;C07D241/20;;C07D241/24;;C07D243/14;;C07C233/18;;C07C233/25;;C07D263/32;;C07C235/46;;C07D205/04;;C07C237/04;;C07C237/06;;C07C237/08;;C07C237/10;;C07C237/12;;C07D265/36;;C07D207/14;;C07D271/10;;C07C243/34;;C07D207/335;;C07C251/48;;C07D209/08;;C07D209/14;;C07D277/68;;C07C255/24;;C07D209/44;;C07D513/04;;C07C255/29;;C07C255/37;;C07D285/13;;C07D295/02;;C07D211/26;;C07D211/56;;C07D211/70;;C07D295/185;;C07D295/192;;C07D213/38;;C07D213/64;;C07D305/06;;C07D305/08;;C07D213/65;;C07D213/68;;C07D307/14;;C07D307/22;;C07D307/79;;C07C313/06;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/16;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;C07D295/027;;A61P31/12;;A61P31/14;;A61P43/00;;C07D239/42;;C07C217/58;;C07D211/70;;C07C237/08;;C07D209/08;;C07D207/335;;C07C255/37;;C07C255/29;;C07C237/06;;C07D285/13;;C07D513/04;;C07D265/36;;C07D295/02;;C07D305/08;;C07D213/81;;C07D263/32;;C07D243/14;;C07C235/46;;C07C237/10;;C07C255/46;;C07C259/06;;C07C271/12;;C07C251/48;;C07C255/54;;C07C255/24;;C07D305/06;;C07B2200/05;;C07D237/14;;C07D307/14;;C07D213/73;;C07D209/14;;C07C275/36;;C07D295/192;;C07C225/12;;C07D239/34;;C07C323/25;;C07D211/26;;C07C217/60;;C07C233/25;;C07D277/68;;C07D271/10;;C07D309/12;;C07D319/18;;C07C217/90;;C07D241/18;;C07D213/64;;C07D233/24;;C07C311/08;;C07D211/56;;C07D231/12;;C07D241/20;;C07C311/29;;C07D213/65;;C07C217/62;;C07D217/02;;C07D213/68;;C07D213/38;;C07D213/74;;C07D213/75;;C07C237/04;;C07D307/22;;C07D233/64;;C07C317/22;;C07D309/06;;C07D309/14;;C07D241/24;;C07D207/14;;C07D307/79;;C07C311/04;;C07D205/04;;C07C243/34;;C07C233/18;;C07C237/12;;C07D209/44;;C07D295/185;;C07D213/84;;C07C313/06;;C07C2601/04;;C07C2601/08;;C07C2601/16;;C07C2601/14;;C07C2601/02;;A61K31/135;;A61K31/137;;A61K31/165;;A61K31/397;;A61K31/4409;;A61K31/4462;;A61K31/4465;;A61K31/505;;A61K45/06;;C07C217/74;;C07C237/20;;C07D295/027,C07D209/14;;A61K31/137;;A61K31/415;;A61K31/4164;;A61K31/44;;A61P31/12;;C07C217/58;;C07D213/75;;C07D231/12;;C07D233/24;;C07D233/64;;C07D295/02;;C07D305/06;;C07D305/08;;C07D309/14,,0,0,,,,DISCONTINUED
532,EP,A1,EP 2305250 A1,090-236-287-148-008,2011-04-06,2011,EP 10195498 A,2004-07-05,EP 04743172 A;;GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A,2003-07-03,Benzimidazole derivatives and their use as protein kinases inhibitors,"A combination comprising: 
(i) a compound of the formula (VII):
  
or a salt, N-oxide or solvate thereof; 
and 
(ii) one or more other therapeutic agents.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANN;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/090-236-287-148-008,Patent Application,yes,28,7,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/4184;;A61K31/00;;A61P31/10;;A61P35/00;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14,,75,55,012-522-479-506-568;;012-865-156-438-120;;001-661-891-531-467;;015-505-100-135-710;;051-255-997-632-880;;005-521-719-112-587;;009-033-647-751-621;;025-624-292-641-902;;051-098-750-980-596;;040-343-674-829-495;;023-475-764-350-339;;060-784-743-188-505;;029-901-810-393-557;;007-838-854-537-973;;001-226-923-460-944;;002-515-903-844-18X;;028-122-953-422-563;;086-390-749-652-665;;066-013-401-674-717;;004-960-787-208-757;;036-451-583-862-453;;007-838-854-537-973;;160-341-123-989-355;;029-901-810-393-557;;022-498-296-482-829;;160-341-123-989-355;;083-182-706-995-400;;060-784-743-188-505;;005-383-821-091-791;;077-883-857-250-339;;052-908-745-194-978;;016-694-431-273-124;;004-960-787-208-757;;028-122-953-422-563;;023-656-951-495-886;;042-163-039-479-494;;086-272-744-175-380;;007-364-858-655-289;;000-820-736-344-337;;126-811-728-740-254;;077-365-619-775-156;;004-137-705-827-976;;111-610-126-227-490;;077-295-491-167-117;;046-777-072-258-96X;;007-378-255-811-868;;110-712-435-087-04X;;050-476-538-810-273;;021-634-052-025-91X;;124-153-998-836-964;;056-848-802-620-026;;019-078-987-150-365;;009-760-608-802-570;;027-745-118-667-14X;;007-421-226-677-859,10.1002/bscb.19870960110;;7768349;;0007768349;;10.1096/fasebj.9.8.7768349;;10.1126/science.1862342;;0001862342;;1862342;;1322797;;10.1016/0092-8674(92)90166-a;;10.1016/0092-8674(93)90144-f;;8387896;;pmc395100;;8194527;;10.1002/j.1460-2075.1994.tb06519.x;;11166196;;10.1016/s0962-8924(00)01880-8;;11413462;;10.1038/35048096;;10.1023/a:1023789416385;;12884918;;13678575;;10.1016/s0092-8674(03)00685-8;;10.1016/s0092-8674(03)00642-1;;13678582;;10523496;;10.1242/jcs.112.21.3591;;9771714;;10.1038/2496;;10232583;;12019169;;pmc1871005;;7573366;;10.1093/jnci/94.17.1320;;12208897;;10.1093/emboj/17.11.3052;;9606188;;pmc1170645;;10.1111/j.1349-7006.2000.tb00878.x;;11050471;;pmc5926256;;12684414;;10.1054/bjoc.2000.1684;;11259099;;pmc2363814;;10232583;;10.1074/jbc.274.11.7334;;10066797;;9771714;;10.1038/2496;;10.1093/jnci/91.13.1160;;10393726;;10.1074/jbc.274.11.7334;;10066797;;10511710;;10.1016/s0962-8924(99)01658-x;;10523496;;10.1242/jcs.112.21.3591;;12214247;;10.1038/sj.onc.1205775;;10.1002/cncr.11879;;14692019;;14522886;;10.3892/or.10.5.1275;;12883693;;12684414;;10.1093/jnci/94.17.1320;;12208897;;10.1124/mi.3.3.127;;14993419;;10.1016/s1535-6108(02)00235-0;;12559175;;14981513;;10.1038/nm1003;;10.1002/jps.2600660104;;833720;;10.1080/00397917709409270;;10.1002/anie.196603851;;10.1021/jo01351a600;;10.1016/s0040-4039(00)94371-5;;10.1007/bf00808679;;10.1002/0471220574;;15002962;;10.1021/cc034046a;;12739949;;10.1021/cc0201041;;10.1038/ng1220;;12881723;;10.1016/0076-6879(87)52071-7;;3657592;;10.1385/1-59259-760-2:077;;15064486;;10.1074/jbc.m313407200;;14701826;;10.1038/nature02313;;14999283;;7805863;;10.1016/0014-5793(94)01298-9;;10559988;;010559988;;10.1038/15674;;12501191;;10.1021/bi0268910;;9692848;;10.1016/s0022-1759(98)00028-3,"ESSASSI E M ET AL: ""SYNTHESE ET HEREROCYCLISATION DES (PYRAZOLYL-3(5))-2 BENZIMIDAZOLES EN CATALYSE PAR TRANSFERT DE PHASE"", BULLETIN DES SOCIETES CHIMIQUES BELGES, XX, XX, vol. 96, no. 1, 1987, pages 63 - 67, XP008005414, ISSN: 0037-9646;;HARDIE, G.; HANKS, S.: ""The Protein Kinase Facts Book"", vol. I, II, 1995, ACADEMIC PRESS;;HANKS, S.K.; HUNTER, T., FASEB J., vol. 9, 1995, pages 576 - 596;;KNIGHTON ET AL., SCIENCE, vol. 253, 1991, pages 407 - 414;;HILES ET AL., CELL, vol. 70, 1992, pages 419 - 429;;KUNZ ET AL., CELL, vol. 73, 1993, pages 585 - 596;;GARCIA-BUSTOS ET AL., EMBO J, vol. 13, 1994, pages 2352 - 2361;;ADAMS ET AL., TRENDS CELL BIOL., vol. 11, 2001, pages 49 - 54;;E. A. NIGG, NAT. REV. MOL. CELL BIOL., vol. 2, 2001, pages 21 - 32;;KATAYAMA H; BRINKLEY WR; SEN S.: ""The Aurora kinases: role in cell transformation and tumorigenesis"", CANCER METASTASIS REV., vol. 22, no. 4, December 2003 (2003-12-01), pages 451 - 64;;PRIGENT ET AL., CELL, vol. 114, 2003, pages 531 - 535;;HIROTA ET AL., CELL, vol. 114, 2003, pages 585 - 598;;GIET ET AL., J. CELL. SCI., vol. 112, 1999, pages 3591 - 361;;ZHOU ET AL., NAT. GENET., vol. 20, 1998, pages 189 - 193;;TANAKA ET AL., CANCER RES., vol. 59, 1999, pages 2041 - 2044;;HAN ET AL., CANCER RES., vol. 62, 2002, pages 2890 - 2896;;ISOLA, AMERICAN JOURNAL OF PATHOLOGY, vol. 147, 1995, pages 905 - 911;;SEN ET AL., J. NATL. CANCER INST, vol. 94, 2002, pages 1320 - 1329;;BISCHOFF ET AL., EMBO J., vol. 17, 1998, pages 3052 - 3065;;TAKAHASHI ET AL., JPN. J. CANCER RES., vol. 91, 2000, pages 1007 - 1014;;GRITSKO ET AL., CLIN. CANCER RES., vol. 9, 2003, pages 1420 - 1426;;SAKAKURA ET AL., BRITISH JOURNAL OF CANCER, vol. 84, 2001, pages 824 - 831;;TANAKA ET AL., CANCER RESEARCH, vol. 59, 1999, pages 2041 - 2044;;KIMURA ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 7334 - 7340;;ZHOU ET AL., NATURE GENETICS, vol. 20, 1998, pages 189 - 193;;LI ET AL., CLIN CANCER RES., vol. 9, no. 3, 2003, pages 991 - 7;;KATAYAMA ET AL., GENE, vol. 244, pages 1 - 7;;KATAYAMA ET AL., J. NATL CANCER INST., vol. 91, 1999, pages 1160 - 1162;;KIMURA ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 7334 - 7340;;TAKAHASHI ET AL., JPN J. CANCER RES., vol. 91, 2001, pages 1007 - 1014;;BISCHOFF ET AL., TRENDS IN CELL BIOLOGY, vol. 9, 1999, pages 454 - 459;;GIET ET AL., JOURNAL OF CELL SCIENCE, vol. 112, 1999, pages 3591 - 3601;;DUTERTRE ET AL., ONCOGENE, vol. 21, 2002, pages 6175 - 6183;;ROYCE ME; XIA W; SAHIN AA; KATAYAMA H; JOHNSTON DA; HORTOBAGYI G; SEN S; HUNG MC: ""STK15/Aurora-A expression in primary breast tumours is correlated with nuclear grade but not with prognosis"", CANCER, vol. 100, no. 1, 1 January 2004 (2004-01-01), pages 12 - 9;;MORENO-BUENO G; SANCHEZ-ESTEVEZ C; CASSIA R; RODRIGUEZ-PERALES S; DIAZ-URIARTE R; DOMINGUEZ 0; HARDISSON D; ANDUJAR M; PRAT J; MAT, CANCER RES., vol. 63, no. 18, 15 September 2003 (2003-09-15), pages 5697 - 702;;REICHARDT ET AL., ONCOL REP., vol. 10, no. 5, September 2003 (2003-09-01), pages 1275 - 9;;HAMADA ET AL., BR. J. HAEMATOL., vol. L21, no. 3, May 2003 (2003-05-01), pages 439 - 47;;GRITSKO ET AL., CLIN CANCER RES., vol. 9, no. 4, April 2003 (2003-04-01), pages 1420 - 6;;LI ET AL., CLIN. CANCER RES., vol. 9, no. 3, March 2003 (2003-03-01), pages 991 - 7;;J NATL. CANCER INST., vol. 94, no. 17, 4 September 2002 (2002-09-04), pages 1320 - 9;;DUTERTRE S; PRIGENT C.: ""Aurora-A overexpression leads to override of the microtubule-kinetochore attachment checkpoint"", MOL. INTERV., vol. 3, no. 3, May 2003 (2003-05-01), pages 127 - 30;;ANAND S; PENRHYN-LOWE S; VENKITARAMAN AR: ""Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol"", CANCER CELL., vol. 3, no. 1, January 2003 (2003-01-01), pages 51 - 62;;HARRINGTON ET AL., NAT MED., vol. 10, no. 3, March 2004 (2004-03-01), pages 262 - 7;;BERGE ET AL.: ""Pharmaceutically Acceptable Salts"", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;JERRY MARCH: ""Advanced Organic Chemistry"", WILEY INTERSCIENCE;;L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514;;JERRY MARCH: ""Advanced Organic Chemistry"", 1992, JOHN WILEY & SONS, pages: 109 - 114;;CAHN, INGOLD; PRELOG, ANGEW. CHEM. INT. ED. ENGL., vol. 5, 1966, pages 385 - 415;;SHEEHAN ET AL., J. AMER. CHEM SOC., vol. 77, 1955, pages 1067;;SHEEHAN ET AL., J. ORG. CHEM., vol. 26, 1961, pages 2525;;L. A. CARPINO, J. AMER. CHEM. SOC., vol. 115, 1993, pages 4397;;CASTRO ET AL., TETRAHEDRON LETTERS, vol. 31, 1990, pages 205;;KONIG ET AL., CHEM. BER., vol. 103, no. 708, pages 2024 - 2034;;""Fiesers'Reagentsfor Organic Synthesis"", vol. 1-17, JOHN WILEY;;""Organic Syntheses"", vol. 1-8, 1995, JOHN WILEY;;JACHAK ET AL., MONTASH. CHEM., vol. 124, no. 2, 1993, pages 199 - 207;;SCHMIDT, HELV. CHIM. ACTA., vol. 39, 1956, pages 986 - 991;;HELV. CHIM. ACTA., vol. 41, 1958, pages 306 - 309;;T. GREEN; P. WUTS: ""Protective Groups in Organic Synthesis"", 1999, JOHN WILEY AND SONS;;ROSENTRETER U; HUBER U.: ""Optimal fraction collecting in preparative LC/MS"", J COMB CHEM., vol. 6, no. 2, 2004, pages 159 - 64;;LEISTER W; STRAUSS K; WISNOSKI D; ZHAO Z; LINDSLEY C.: ""Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries"", J COMB CHEM., vol. 5, no. 3, 2003, pages 322 - 9;;""Remington's Pharmaceutical Sciences"", MACK PUBLISHING COMPANY;;EWART-TOLAND ET AL., NAT GENET., vol. 34, no. 4, August 2003 (2003-08-01), pages 403 - 12;;""Current Protocols in Molecular Biology"", 2004, JOHN WILEY & SONS INC.;;""PCR Protocols: a guide to methods and applications"", 1990, ACADEMIC PRESS;;SAMBROOK ET AL.: ""Molecular Cloning: A Laboratory Manual"", 2001, COLD SPRING HARBOR LABORATORY PRESS;;ANGERER, METH. ENZYMOL., vol. 152, 1987, pages 649;;""Current Protocols in Molecular Biology"", 2004, JOHN WILEY & SONS INC;;JOHN M. S. BARTLETT: ""Molecular Diagnosis of Cancer, Methods and Protocols"", March 2004, article ""Fluorescence In Situ Hybridization: Technical Overview"", pages: 077 - 088;;HARWELL RM; MULL BB; PORTER DC; KEYOMARSI K., J BIOL CHEM., vol. 279, no. 13, 26 March 2004 (2004-03-26), pages 12695 - 705;;RAJAGOPALAN H; JALLEPALLI PV; RAGO C; VELCULESCU VE; KINZLER KW; VOGELSTEIN B; LENGAUER C., NATURE, vol. 428, no. 6978, 4 March 2004 (2004-03-04), pages 77 - 81;;HELLMICH ET AL., FEBS LETT, vol. 356, 1994, pages 317 - 21;;BROWN ET AL., NAT. CELL BIOL., vol. 1, 1999, pages 438 - 443;;LOWE, E.D. ET AL., BIOCHEMISTRY, vol. 41, 2002, pages 15625 - 15634;;NOCIARI, M. M; SHALEV, A.; BENIAS, P.; RUSSO, C., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 213, 1998, pages 157 - 167",ACTIVE
533,TW,B,TW I372050 B,098-902-300-757-098,2012-09-11,2012,TW 93120042 A,2004-07-02,GB 0315657 A;;US 48468503 P;;GB 0324919 A;;US 51437403 P,2003-07-03,(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL GRAHAM,,https://lens.org/098-902-300-757-098,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/00,,0,0,,,,INACTIVE
534,US,A1,US 2010/0160324 A1,098-124-196-619-577,2010-06-24,2010,US 81316705 A,2005-12-30,US 81316705 A;;GB 0428528 A;;US 64047404 P;;GB 2005005102 W,2004-12-30,"PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES","The invention provides a compound of the formula (I): for use in medicine: or salts or tautomers or N-oxides or solvates thereof; wherein R 1 is an optionally substituted heterocyclic group having from 3 to 12 ring members provided that the cyclic group joined to the pyrazole contains at least one heteroatom selected from N, O or S; A is a bond or —Y—(B) n —; B is C═O, NR g (C═O) or O(C═O) wherein R g is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; n is 0 or 1; Y is a bond or an alkylene chain of 1,2 or 3 carbon atoms in length; R 2 is hydrogen; halogen; C 1-4 alkoxy (e.g. methoxy); or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy); R 3 is selected from optionally substituted carbocyclic and heterocyclic groups having from 3 to 12 ring members or an optionally substituted C 1-8 hydrocarbyl group; with the proviso that R 1 is not formula (II): where X, R 3′ and R 4′ are defined in the claims.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;DAVIES NICHOLAS GARETH MORSE;;GILL ADRIAN LIAM;;NAVARRO EVA FIGUEROA;;HOWARD STEVEN;;TREWARTHA GARY;;WOODHEAD ANDREW JAMES;;WOOLFORD ALISON JO-ANNE;;WYATT PAUL GRAHAM,ASTEX THERAPEUTICS LIMITED (2007-11-06),https://lens.org/098-124-196-619-577,Patent Application,yes,0,6,4,5,0,A61P25/28;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/02;;A61P43/00;;C07D407/14;;C07D407/14;;C07D231/40;;C07D231/40;;C07D401/04;;C07D401/04;;C07D401/14;;C07D401/14;;C07D403/04;;C07D403/04;;C07D405/04;;C07D405/04;;C07D405/14;;C07D405/14;;C07D413/04;;C07D413/04;;C07D417/04;;C07D417/04;;C07D471/04;;C07D471/04,C07D403/04;;A61K31/415;;A61K31/4155;;A61K31/4196;;A61K31/422;;A61K31/4245;;A61K31/427;;A61K31/4353;;A61K31/4439;;A61K31/496;;A61K31/497;;A61K31/5377;;A61P25/28;;A61P35/04;;C07D231/10;;C07D249/12;;C07D401/04;;C07D413/04;;C07D417/04;;C07D471/04,514/236.2;;514/254.05;;514/255.05;;514/300;;514/341;;514/364;;514/365;;514/374;;514/383;;514/397;;514/404;;544/140;;544/371;;544/405;;546/121;;546/275.4;;548/143;;548/204;;548/236;;548/263.2;;548/312.4;;548/364.7;;548/365.4;;548/372.1,0,0,,,,DISCONTINUED
535,WO,A1,WO 2006/070198 A1,131-671-166-254-746,2006-07-06,2006,GB 2005005102 W,2005-12-30,GB 0428528 A;;US 64047404 P,2004-12-30,"PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES","The invention provides a compound of the formula (I): for use in medicine: or salts or tautomers or N-oxides or solvates thereof; wherein R1 is an optionally substituted heterocyclic group having from 3 to 12 ring members provided that the cyclic group joined to the pyrazole contains at least one heteroatom selected from N, O or S; A is a bond or -Y-(B)n-; B is C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; n is 0 or 1; Y is a bond or an alkylene chain of 1,2 or 3 carbon atoms in length; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from optionally substituted carbocyclic and heterocyclic groups having from 3 to 12 ring members or an optionally substituted C1-8 hydrocarbyl group; with the proviso that R1 is not formula (II): where X, R3&rsquo; and R4&rsquo; are defined in the claims.",ASTEX THERAPEUTICS LTD;;BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;DAVIES NICHOLAS GARETH MORSE;;GILL ADRIAN LIAM;;NAVARRO EVA FIGUEROA;;HOWARD STEVEN;;TREWARTHA GARY;;WOODHEAD ANDREW JAMES;;WOOLFORD ALISON JO-ANNE;;WYATT PAUL GRAHAM,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;DAVIES NICHOLAS GARETH MORSE;;GILL ADRIAN LIAM;;NAVARRO EVA FIGUEROA;;HOWARD STEVEN;;TREWARTHA GARY;;WOODHEAD ANDREW JAMES;;WOOLFORD ALISON JO-ANNE;;WYATT PAUL GRAHAM,,https://lens.org/131-671-166-254-746,Patent Application,yes,5,134,4,5,0,A61P25/28;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/02;;A61P43/00;;C07D407/14;;C07D407/14;;C07D231/40;;C07D231/40;;C07D401/04;;C07D401/04;;C07D401/14;;C07D401/14;;C07D403/04;;C07D403/04;;C07D405/04;;C07D405/04;;C07D405/14;;C07D405/14;;C07D413/04;;C07D413/04;;C07D417/04;;C07D417/04;;C07D471/04;;C07D471/04,C07D401/04;;A61K31/4155;;A61K31/422;;A61K31/427;;A61P35/00;;C07D401/14;;C07D403/04;;C07D413/04;;C07D417/04;;C07D471/04,,1,0,,,"DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002375954, retrieved from STN accession no. 1977:535189 Database accession no. 87:135189",PENDING
536,EP,A1,EP 1836188 A1,022-729-422-757-172,2007-09-26,2007,EP 05823522 A,2005-12-30,GB 2005005102 W;;GB 0428528 A;;US 64047404 P,2004-12-30,"PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES",,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;DAVIES NICHOLAS GARETH MORSE;;GILL ADRIAN LIAM;;NAVARRO EVA FIGUEROA;;HOWARD STEVEN;;TREWARTHA GARY;;WOODHEAD ANDREW JAMES;;WOOLFORD ALISON JO-ANNE;;WYATT PAUL GRAHAM,,https://lens.org/022-729-422-757-172,Patent Application,yes,0,0,4,5,0,A61P25/28;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/02;;A61P43/00;;C07D407/14;;C07D407/14;;C07D231/40;;C07D231/40;;C07D401/04;;C07D401/04;;C07D401/14;;C07D401/14;;C07D403/04;;C07D403/04;;C07D405/04;;C07D405/04;;C07D405/14;;C07D405/14;;C07D413/04;;C07D413/04;;C07D417/04;;C07D417/04;;C07D471/04;;C07D471/04,C07D401/04;;A61K31/4155;;A61K31/422;;A61K31/427;;A61P35/00;;C07D401/14;;C07D403/04;;C07D413/04;;C07D417/04;;C07D471/04,,1,0,,,See references of WO 2006070198A1,DISCONTINUED
537,SI,T1,SI 1648426 T1,097-841-760-000-923,2014-04-30,2014,SI 200432125 T,2004-07-05,GB 0315657 A;;US 48468503 P;;US 51437403 P;;GB 0324919 A;;GB 2004002824 W;;EP 04743172 A,2003-07-03,BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO CAMBRIDGE SCIENCE PARK;;O'BRIEN MICHAEL ALISTAIR;;CARR MARIA GRAZIA;;EARLY THERESA RACHEL;;NAVARRO EVA FIGUEROA;;GILL ADRIAN LIAM;;HOWARD STEVEN;;TREWARTHA GARY;;WOOLFORD ALISON JO-ANNE;;WOODHEAD ANDREW JAMES;;WYATT PAUL,,https://lens.org/097-841-760-000-923,Granted Patent,no,0,0,32,48,0,A61K31/00;;A61K31/4184;;C07D401/14;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;A61P25/00;;A61P31/00;;A61P31/10;;A61P31/12;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/00;;A61P37/02;;A61P43/00;;C07D403/04;;C07D405/14;;C07D409/14;;C07D413/14;;C07D401/14;;A61K31/00;;A61K31/4184;;A61K31/5377;;A61K45/06;;C07D471/04;;C07D513/04,A61K31/00;;A61K31/00;;A61K31/4184;;A61P31/00;;A61P31/10;;A61P35/00;;A61P35/00;;C07D401/14;;C07D403/00;;C07D405/14;;C07D409/14;;C07D413/14,,0,0,,,,ACTIVE
538,US,A1,US 2021/0322405 A1,125-339-455-364-675,2021-10-21,2021,US 202117231273 A,2021-04-15,US 202117231273 A;;US 202063010214 P,2020-04-15,COMPOSITIONS AND METHODS FOR TREATING CANCER,"The present disclosure provides for compositions and methods of treating cancer. In some embodiments, PTPN11 is targeted with and anti-PTPN11 drug, such as a Shp2 inhibitor (e.g., SHP099). In some embodiments, other upregulated, hyperphosphorylated, or hyperacetylated target proteins are inhibited or targeted.",UNIV WASHINGTON;;THE GENERAL HOSPITAL CORP D/B/A MASSACHUSETTS GENERAL HOSPITAL;;BROAD INST INC;;BATTELLE MEMORIAL INSTITUTE,DING LI;;CAO SONG;;WU YIGE;;KARPOVA ALLA;;WANG LIANG-BO;;CHHEDA MILAN;;CHEN FENG;;GOVINDAN RAMASWAMY;;KIM ALBERT;;GILLETTE MICHAEL;;CARR STEVEN;;SATPATHY SHANKHA;;LIU TAO;;RODLAND KARIN D;;SMITH RICHARD D,WASHINGTON UNIVERSITY (2021-04-20);;BATTELLE MEMORIAL INSTITUTE (2020-10-06);;THE BROAD INSTITUTE INC (2020-06-12);;THE GENERAL HOSPITAL CORPORATION (2020-11-18),https://lens.org/125-339-455-364-675,Patent Application,yes,2,3,1,1,0,A61P35/00;;A61K45/00;;G01N2800/52;;G01N2800/7028;;A61K31/497;;A61P35/00;;A61K45/06;;A61K31/685;;A61K31/702;;A61K31/4985,A61K31/497;;A61K31/4985;;A61K31/685;;A61K31/702;;A61K45/06;;A61P35/00,,4,4,029-694-790-547-774;;011-003-602-165-498;;038-481-305-777-005;;048-976-725-852-38X,pmc6170706;;30045908;;10.1158/2159-8290.cd-18-0444;;23343958;;10.1097/pai.0b013e31827da3f9;;26365186;;10.1016/j.celrep.2015.08.037;;10.1016/j.cell.2007.11.025;;18083107,"Fedele, Cancer Discov. 2018 October, 8(10) 1237-1249. (Year: 2018);;Chunlan, Applied Immunohistochemistry & Molecular Morphology 21(5):p 386-394, October 2013 (Year: 2013);;Prahallad, Cell Reports, Volume 12, Issue 12, 29 September 2015, Pages 1978-1985. (Year: 2015);;Rikova et al., (Cell 131, 1190–1203, December 14, 2007) (Year: 2007)",PENDING
539,US,A1,US 2014/0359508 A1,073-599-478-145-113,2014-12-04,2014,US 201313904872 A,2013-05-29,US 201313904872 A,2013-05-29,GRAPHICAL USER INTERFACE WITH DIAL CONTROL FOR A PARAMETER,"A graphical user interface for a computer includes a dial control. The control can be implemented, for example, as a touch-based, pointer-based, pen-based and/or keyboard-based mechanism. The dial control is intended for manipulating a large range of values, such as a menu of items from which a user makes a selection, or a range of continuous or discrete values. A dial control can replace other control types such as a slider, drop down menu or text field. The graphical elements of the dial control include one or more displayed rings and a handle for each ring. Inside the ring, or in another area adjacent the ring, a value can be displayed. The ring can be manipulated by the user to change the value selected by the dial control. In the case of multiple rings, each ring can be manipulated independently.",MICROSOFT CORP,OTERO DIAZ ANA LILIA;;CANAN RAMONA;;SOEGIONO ORRY;;LIU YANG;;SMITH BENJAMIN;;MEHTA KSHITIJ;;MCNEIL MEGHAN;;CARR WILLIAM;;JORDAN BEDE;;BISHOP JESSE;;MAHMOOD HAMID;;ABRAHAMS STEVEN;;WEST JEFF;;EBERSOL GEOFFREY T;;KOTHARI SUSMITHA,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2013-05-29),https://lens.org/073-599-478-145-113,Patent Application,yes,8,28,3,3,0,G06F3/04847;;G06F3/04847;;G06F3/0482;;G06F3/0482;;G06F3/04883;;G06F3/04883,G06F3/0484,715/771,0,0,,,,ACTIVE
540,AR,A1,AR 088596 A1,183-613-864-638-748,2014-06-18,2014,AR P120104076 A,2012-10-31,GB 201118874 A;;GB 201118875 A;;US 201161554237 P;;US 201161554421 P;;US 201261625925 P,2011-11-01,COMPUESTOS DE BENCILAMINA SUSTITUIDOS,"La presente provee compuestos que son útiles en el tratamiento de infecciones por virus de hepatitis C (HCV). Reivindicación 1: Un compuesto, caracterizado porque es de la fórmula (1), o una sal, N-óxido, tautómero o estereoisómero del mismo, donde: A es CH o nitrógeno; E es CH o nitrógeno; R¹ se selecciona entre: un grupo hidrocarbonado acíclico C₁₋₈ opcionalmente sustituido con uno o dos sustituyentes R⁶, donde un átomo de carbono del grupo hidrocarbonado acíclico C₁₋₈ puede reemplazarse opcionalmente por un heteroátomo o un grupo seleccionado entre O, S, NRᶜ, S(O) y SO₂, o dos átomos de carbono adyacentes del grupo hidrocarbonado acíclico C₁₋₈ pueden reemplazarse opcionalmente por un grupo seleccionado entre CONRᶜ, NRᶜCO, NRᶜSO₂ y SO₂NRᶜ con la condición de que en cada caso exista al menos un átomo de carbono del grupo hidrocarbonado acíclico C₁₋₈; y un grupo carbocíclico o heterocíclico monocíclico de entre 3 y 7 miembros del anillo, de los cuales 0, 1, 2, 3 ó 4 son heteroátomos como miembros del anillo seleccionados entre O, N y S, donde el grupo carbocíclico o heterocíclico está opcionalmente sustituido con uno o dos sustituyentes R⁷ᵃ; R² se selecciona entre hidrógeno y un grupo X-R⁸; X es un grupo alcandiilo C₁₋₈ donde un átomo de carbono del grupo alcandiilo C₁₋₈ puede estar unido opcionalmente a una unidad -CH₂-CH₂- para formar un grupo ciclopropan-1,1-diilo o dos átomos de carbono adyacentes del grupo alcandiilo C₁₋₈ pueden estar unidos opcionalmente a una unidad -(CH₂)ₙ, donde n es entre 1 y 5, para formar un grupo cicloalcan C₃₋₇-1,2-diilo; R³ es un anillo carbocíclico o heterocíclico monocíclico o bicíclico de entre 3 y 10 miembros que contiene 0, 1, 2 ó 3 heteroátomos como miembros del anillo seleccionados entre N, O y S, y que está opcionalmente sustituido con uno o más sustituyentes R¹³; R⁴ se selecciona entre hidrógeno y un sustituyente R⁴ᵃ; R⁴ᵃ se selecciona entre halógeno; ciano; alquilo C₁₋₄ opcionalmente sustituido con uno o más átomos de flúor; alcoxi C₁₋₄ opcionalmente sustituido con uno o más átomos de flúor; hidroxi-alquilo C₁₋₄; y alcoxi C₁₋₂-alquilo C₁₋₄; R⁵ se selecciona entre hidrógeno y un sustituyente R⁵ᵃ; R⁵ᵃ se selecciona entre alquilo C₁₋₂ opcionalmente sustituido con uno o más átomos de flúor; alcoxi C₁₋₃ opcionalmente sustituido con uno o más átomos de flúor; halógeno; ciclopropilo; y ciano; R⁶ se selecciona entre hidroxi; flúor; carbamoilo; mono- o di-alquil C₁₋₄carbamoilo; nitro; amino; mono- o di-alquil C₁₋₄amino; un grupo carbocíclico o heterocíclico monocíclico de entre 3 y 7 miembros del anillo, de los cuales 0, 1 ó 2 son heteroátomos como miembros del anillo seleccionados entre O, N y S, donde el grupo carbocíclico o heterocíclico está opcionalmente sustituido con uno o dos sustituyentes R⁷ᵇ; R⁷ᵃ y R⁷ᵇ se seleccionan en forma independiente entre sí entre (=O); (=S); amino; halógeno; ciano; hidroxi; alquilo C₁₋₄; hidroxi-alquilo C₁₋₄; amino-alquilo C₁₋₄; mono- y di-alquil C₁₋₄amino-alquilo C₁₋₄; R⁸ se selecciona entre un grupo hidroxi y C(=O)NR¹⁰R¹¹; con la condición de que cuando R⁸ es hidroxi, existen al menos dos átomos de carbono en línea entre el grupo hidroxi y el átomo de nitrógeno al cual X está unido; R¹⁰ se selecciona entre hidrógeno y alquilo C₁₋₄; R¹¹ se selecciona entre hidrógeno; amino-alquilo C₂₋₄ y hidroxi-alquilo C₂₋₄; R¹³ se selecciona entre halógeno; ciano; (=O); (=S); nitro; CH=NOH; y un grupo Rᵃ-Rᵇ; Rᵃ es una unión, O, CO, X¹C(X²), C(X²)X¹, X¹C(X²)X¹, S, SO, SO₂, NRᶜ, o NRᶜSO₂; Rᵇ es hidrógeno; un grupo cíclico Rᵈ; o un grupo hidrocarbonado acíclico C₁₋₈ opcionalmente sustituido con uno o más sustituyentes seleccionados entre hidroxi, oxo, halógeno, ciano, nitro, carboxi, amino, mono- o di-alquil C₁₋₄amino, y un grupo cíclico Rᵈ; donde uno o dos pero no todos los átomos de carbono del grupo hidrocarbonado acíclico C₁₋₈ pueden reemplazarse opcionalmente por O, S, SO, SO₂, NRᶜ, X¹C(X²), C(X²)X¹ o X¹C(X²)X¹; SO₂NRᶜ o NRᶜSO₂; el grupo cíclico Rᵈ es un grupo carbocíclico o heterocíclico monocíclico con entre 3 y 7 miembros del anillo, de los cuales 0, 1, 2 ó 3 son heteroátomos como miembros del anillo seleccionados entre O, N y S y formas oxidadas de los mismos, donde el grupo carbocíclico o heterocíclico está opcionalmente sustituido con uno o más sustituyentes seleccionados entre R¹⁴; R¹⁴ se selecciona entre oxo; halógeno; ciano; y Rᵃ-Rᵉ; Rᵉ es hidrógeno o un grupo hidrocarbonado acíclico C₁₋₈ opcionalmente sustituido con uno o más sustituyentes seleccionados entre fenilo; hidroxi; oxo; halógeno; ciano; carboxi; amino; mono- o di-alquil C₁₋₄amino; donde uno o dos pero no todos los átomos de carbono del grupo hidrocarbonado acíclico C₁₋₈ pueden reemplazarse opcionalmente por O, S, SO, SO₂, NRᶜ, X¹C(X²), C(X²)X¹ o X¹C(X²)X¹; SO₂NRᶜ o NRᶜSO₂; X¹ es O ó NRᶜ; X² es =O ó NRᶜ; y Rᶜ es hidrógeno o alquilo C₁₋₄; pero excluyendo los compuestos 1-(3-benzoilfenil)-etilamina y 1-(3-furan-2-oilcarbonilfenil)-etilamina.",ASTEX THERAPEUTICS LTD,CHRISTOPHER CHARLES FREDERICK HAMLETT;;GILBERT EBAI BESONG;;ANDREW JAMES WOODHEAD;;GIANNI CHESSARI;;STEVEN DOUGLAS HISCOCK;;DAVID NORTON;;SUSANNE MARIA SAALAU-BETHELL;;NEIL THOMAS THOMPSON;;HENDRIKA MARIA GERARDA WILLEMS;;MARIA GRAZIA CARR;;ALESSIA MILLEMAGGI,,https://lens.org/183-613-864-638-748,Patent Application,no,0,0,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,C07D213/50;;A61K31/44;;A61K31/495;;A61P31/14;;C07D213/63;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D239/26;;C07D241/20;;C07D265/34;;C07D405/06;;C07D409/06,,0,0,,,,DISCONTINUED
541,TW,A,TW 201329025 A,061-135-012-952-123,2013-07-16,2013,TW 101138655 A,2012-10-19,GB 201118874 A;;GB 201118875 A;;US 201161554237 P;;US 201161554421 P;;US 201261625925 P,2011-11-01,Pharmaceutical compounds,"The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): or a salt, N-oxide, tautomer or stereoisomer thereof, wherein A is CH or N; E is CH or N; R1 is selected from: an optionally substituted acyclic C1-8 hydrocarbon group wherein one carbon atom of the acyclic C1-8 hydrocarbon group may optionally be replaced by O, S, NRc, S(O) or SO2, or two adjacent carbon atoms of the acyclic C1-8 hydrocarbon group may optionally be replaced by CONRc, NRcCO, NRcSO2 or SO2NRc provided that in each case at least one carbon atom of the acyclic C1-8 hydrocarbon group remains; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R2 is hydrogen or X-R8; X is a C1-8 alkanediyl group wherein one carbon atom of the C1-8 alkanediyl group may optionally be bonded to a -CH2-CH2- moiety to form a cyclopropane-1, 1-diyl group or two adjacent carbon atoms of the C1-8 alkanediyl group may optionally be bonded to a -(CH2)n moiety, where n is 1 to 5, to form a C3-7-cycloalkane-1, 2-diyl group; R3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0-3 heteroatom ring members selected from N, O and S; R4 is hydrogen or R4a wherein R4a is halogen; cyano; C1-4 alkyl; fluoro-1-4 alkyl; C1-4 alkoxy; fluoro-C1-4 alkoxy; hydroxy-C1-4 alkyl; or C1-2 alkoxy-C1-4 alkyl; R5 is hydrogen or R5a wherein R5a is selected from C1-2 alkyl optionally substituted with fluorine; C1-3 alkoxy optionally substituted with fluorine; halogen; cyclopropyl; and cyano; R8 is hydroxy or C(=O)NR10R11; provided that when R8 is hydroxy, there are at least two carbon atoms in line between the hydroxy group and the nitrogen atom to which X is attached; R10 is hydrogen or C1-4 alkyl; and R11 is hydrogen; amino-C2-4 alkyl or hydroxy-C2-4 alkyl; but excluding the compounds 1-(3-benzoylphenyl)-ethylamine and 1-(3-furan-2-oylcarbonylphenyl)-ethylamine.",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;BESONG GILBERT EBAI;;CARR MARIA GRAZIA;;CHESSARI GIANNI;;HISCOCK STEVEN DOUGLAS;;MILLEMAGGI ALESSIA;;NORTON DAVID;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS,,https://lens.org/061-135-012-952-123,Patent of Addition,no,0,1,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,A61K31/165;;C07C237/06;;A61K31/44;;A61P31/14;;C07D213/73,,0,0,,,,PENDING
542,WO,A1,WO 2014/193453 A1,025-150-513-862-556,2014-12-04,2014,US 2013/0061061 W,2013-09-20,US 201313904872 A,2013-05-29,GRAPHICAL USER INTERFACE WITH DIAL CONTROL FOR A PARAMETER,"A graphical user interface for a computer includes a dial control. The control can be implemented, for example, as a touch-based, pointer-based, pen-based and/or keyboard-based mechanism. The dial control is intended for manipulating a large range of values, such as a menu of items from which a user makes a selection, or a range of continuous or discrete values. A dial control can replace other control types such as a slider, drop down menu or text field. The graphical elements of the dial control include one or more displayed rings and a handle for each ring. Inside the ring, or in another area adjacent the ring, a value can be displayed. The ring can be manipulated by the user to change the value selected by the dial control. In the case of multiple rings, each ring can be manipulated independently.",MICROSOFT CORP,OTERO DIAZ ANA LILIA;;CANAN RAMONA;;SOEGIONO ORRY;;LIU YANG;;SMITH BENJAMIN;;MEHTA KSHITIJ;;MCNEIL MEGHAN;;CARR WILLIAM;;JORDAN BEDE;;BISHOP JESSE;;MAHMOOD HAMID;;ABRAHAMS STEVEN;;WEST JEFF;;EBERSOL GEOFFREY T;;KOTHARI SUSMITHA,,https://lens.org/025-150-513-862-556,Patent Application,yes,5,1,3,3,0,G06F3/0482;;G06F3/04883;;G06F3/04847;;G06F3/04847;;G06F3/0482;;G06F3/04883,G06F3/0484;;G06F3/0482;;G06F3/0488,,0,0,,,,PENDING
543,US,A1,US 2015/0051199 A1,133-947-503-757-051,2015-02-19,2015,US 201214355786 A,2012-10-31,US 201214355786 A;;GB 201118874 A;;GB 201118875 A;;US 201161554237 P;;US 201161554421 P;;US 201261625925 P;;EP 2012071573 W,2011-11-01,PHARMACEUTICAL COMPOUNDS,"The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): or a salt, N-oxide, tautomer or stereoisomer thereof, wherein A is CH or N; E is CH or N; R 1 is selected from:an optionally substituted acyclic C 1-8 hydrocarbon group wherein one carbon atom of the acyclic C 1-8 hydrocarbon group may optionally be replaced by O, S, NR c , S(O) or SO 2 , or two adjacent carbon atoms of the acyclic C 1-8 hydrocarbon group may optionally be replaced by CONR c , NR c CO, NR c SO 2 or SO 2 NR c provided that in each case at least one carbon atom of the acyclic C 1-8 hydrocarbon group remains; andan optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S;R 2 is hydrogen or X—R 8 ;X is a C 1-8 alkanediyl group wherein one carbon atom of the C 1-8 alkanediyl group may optionally be bonded to a —CH 2 —CH 2 — moiety to form a cyclopropane-1,1-diyl group or two adjacent carbon atoms of the C 1-8 alkanediyl group may optionally be bonded to a —(CH 2 ) n moiety, where n is 1 to 5, to form a C 3-7 -cycloalkane-1,2-diyl group;R 3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0-3 heteroatom ring members selected from N, O and S;R 4 is hydrogen or R 4a wherein R 4a is halogen; cyano; C 1-4 alkyl; fluoro- 1-4 alkyl; C 1-4 alkoxy; fluoro-C 1-4 alkoxy; hydroxy-C 1-4 alkyl; or C 1-2 alkoxy-C 1-4 alkyl;R 5 is hydrogen or R 5a wherein R 5a is selected from C 1-2 alkyl optionally substituted with fluorine; C 1-3 alkoxy optionally substituted with fluorine; halogen; cyclopropyl; and cyano;R 8 is hydroxy or C(═O)NR 10 R 11 ; provided that when R 8 is hydroxy, there are at least two carbon atoms in line between the hydroxy group and the nitrogen atom to which X is attached;R 10 is hydrogen or C 1-4 alkyl; andR 11 is hydrogen; amino-C 2-4 alkyl or hydroxy-C 2-4 alkyl;but excluding the compounds 1-(3-benzoylphenyl)-ethylamine and 1-(3-furan-2-oylcarbonylphenyl)-ethylamine.",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;BESONG GILBERT EBAI;;CHESSARI GIANNI;;CARR MARIA GRAZIA;;MILLEMAGGI ALESSIA;;NORTON DAVID;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;HISCOCK STEVEN DOUGLAS,ASTEX THERAPEUTICS LIMITED (2012-10-14),https://lens.org/133-947-503-757-051,Patent Application,yes,0,9,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,A61K31/138;;C07C225/16;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07C255/58;;C07D213/50;;C07D213/65;;C07D213/73;;C07D239/26;;C07D241/20;;C07D261/08;;C07D275/02;;C07D498/04,514/230.5;;546/310;;514/352;;546/315;;514/355;;544/407;;514/255.06;;564/323;;514/648;;558/415;;514/524;;544/335;;514/256;;548/214;;514/372;;546/298;;514/350;;548/248;;514/378;;544/105,0,0,,,,INACTIVE
544,US,B2,US 9594493 B2,185-577-024-403-281,2017-03-14,2017,US 201313904872 A,2013-05-29,US 201313904872 A,2013-05-29,Graphical user interface with dial control for a parameter,"A graphical user interface for a computer includes a dial control. The control can be implemented, for example, as a touch-based, pointer-based, pen-based and/or keyboard-based mechanism. The dial control is intended for manipulating a large range of values, such as a menu of items from which a user makes a selection, or a range of continuous or discrete values. A dial control can replace other control types such as a slider, drop down menu or text field. The graphical elements of the dial control include one or more displayed rings and a handle for each ring. Inside the ring, or in another area adjacent the ring, a value can be displayed. The ring can be manipulated by the user to change the value selected by the dial control. In the case of multiple rings, each ring can be manipulated independently.",MICROSOFT CORP;;MICROSOFT TECHNOLOGY LICENSING LLC,OTERO DIAZ ANA LILIA;;CANAN RAMONA;;SOEGIONO ORRY;;LIU YANG;;SMITH BENJAMIN;;MEHTA KSHITIJ;;MCNEIL MEGHAN;;CARR WILLIAM;;JORDAN BEDE;;BISHOP JESSE;;MAHMOOD HAMID;;ABRAHAMS STEVEN;;WEST JEFF;;EBERSOL GEOFFREY T;;KOTHARI SUSMITHA,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2013-05-29),https://lens.org/185-577-024-403-281,Granted Patent,yes,20,10,3,3,0,G06F3/04847;;G06F3/04847;;G06F3/0482;;G06F3/0482;;G06F3/04883;;G06F3/04883,G06F3/0484;;G06F3/0482;;G06F3/0488,,2,1,083-386-829-333-348,10.1145/1029632.1029641,"""International Search Report & Written Opinion for PCT Patent Application No. PCT/US2013/061061"", Mailed Date: Dec. 4, 2013, Filed Date: Sep. 20, 2013, 12 Pages.;;Smith, et al., ""The Radial Scroll Tool: Scrolling Support for Stylus- or Touch-Based Document Navigation"", Retrieved at >, In Proceedings of 17th Annual ACM Symposium on User Interface Software and Technology, Oct. 27, 2004, pp. 4.",ACTIVE
545,US,B2,US 9145354 B2,178-337-860-934-313,2015-09-29,2015,US 201214355786 A,2012-10-31,US 201214355786 A;;GB 201118874 A;;GB 201118875 A;;US 201161554237 P;;US 201161554421 P;;US 201261625925 P;;EP 2012071573 W,2011-11-01,Pharmaceutical compounds,"The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): or a salt, N-oxide, tautomer or stereoisomer thereof, wherein A is CH or N; E is CH or N; R 1 is selected from: an optionally substituted acyclic C 1-8 hydrocarbon group wherein one carbon atom of the acyclic C 1-8 hydrocarbon group may optionally be replaced by O, S, NR c , S(O) or SO 2 , or two adjacent carbon atoms of the acyclic C 1-8 hydrocarbon group may optionally be replaced by CONR c , NR c CO, NR c SO 2 or SO 2 NR c provided that in each case at least one carbon atom of the acyclic C 1-8 hydrocarbon group remains; andan optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S;R 2 is hydrogen or X—R 8 ;X is a C 1-8 alkanediyl group wherein one carbon atom of the C 1-8 alkanediyl group may optionally be bonded to a —CH 2 —CH 2 — moiety to form a cyclopropane-1,1-diyl group or two adjacent carbon atoms of the C 1-8 alkanediyl group may optionally be bonded to a —(CH 2 ) n moiety, where n is 1 to 5, to form a C 3-7 -cycloalkane-1,2-diyl group;R 3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0-3 heteroatom ring members selected from N, O and S;R 4 is hydrogen or R 4a wherein R 4a is halogen; cyano; C 1-4 alkyl; fluoro- 1-4 alkyl; C 1-4 alkoxy; fluoro-C 1-4 alkoxy; hydroxy-C 1-4 alkyl; or C 1-2 alkoxy-C 1-4 alkyl;R 5 is hydrogen or R 5a wherein R 5a is selected from C 1-2 alkyl optionally substituted with fluorine; C 1-3 alkoxy optionally substituted with fluorine; halogen; cyclopropyl; and cyano;R 8 is hydroxy or C(═O)NR 10 R 11 ; provided that when R 8 is hydroxy, there are at least two carbon atoms in line between the hydroxy group and the nitrogen atom to which X is attached;R 10 is hydrogen or C 1-4 alkyl; andR 11 is hydrogen; amino-C 2-4 alkyl or hydroxy-C 2-4 alkyl;but excluding the compounds 1-(3-benzoylphenyl)-ethylamine and 1-(3-furan-2-oylcarbonylphenyl)-ethylamine.",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;BESONG GILBERT EBAI;;CHESSARI GIANNI;;CARR MARIA GRAZIA;;MILLEMAGGI ALESSIA;;NORTON DAVID;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;HISCOCK STEVEN DOUGLAS,ASTEX THERAPEUTICS LIMITED (2012-10-14),https://lens.org/178-337-860-934-313,Granted Patent,yes,41,0,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,C07C225/16;;A61K9/00;;A61K9/19;;A61K9/20;;A61K9/48;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;A61K47/10;;A61K47/26;;C07C221/00;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C253/30;;C07C255/58;;C07C313/06;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D275/02;;C07D277/28;;C07D401/04;;C07D498/04,,4,0,,,"International Search Report on PCT/EP2012/071753 dated Oct. 21, 2013.;;European Search Report on EP2634185 dated Jun. 21, 2013.;;Database Registry, Chemical Abstracts Service, XP002690955, Accession No. 1259674-97-9, (Jan. 18, 2011).;;Database Registry, Chemical Abstracts Service, XP002690954, Accession No. 1259916-62-5, (Jan. 19, 2011).",INACTIVE
546,EP,A1,EP 2773615 A1,165-743-631-217-881,2014-09-10,2014,EP 12798621 A,2012-10-31,GB 201118874 A;;GB 201118875 A;;US 201161554237 P;;US 201161554421 P;;US 201261625925 P;;EP 2012071573 W,2011-11-01,PHARMACEUTICAL COMPOUNDS,,ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;HAMLETT CHRISTOPHER CHARLES FREDERICK HAMLETT;;BESONG GILBERT EBAI;;CHESSARI GIANNI;;CARR MARIA GRAZIA;;MILLEMAGGI ALESSIA;;NORTON DAVID;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;HISCOCK STEVEN DOUGLAS,,https://lens.org/165-743-631-217-881,Patent Application,yes,0,0,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28,,0,0,,,,DISCONTINUED
547,WO,A1,WO 2013/064543 A1,041-592-181-615-61X,2013-05-10,2013,EP 2012071573 W,2012-10-31,GB 201118874 A;;GB 201118875 A;;US 201161554237 P;;US 201161554421 P;;US 201261625925 P,2011-11-01,PHARMACEUTICAL COMPOUNDS,"The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): or a salt, N-oxide, tautomer or stereoisomer thereof, wherein A is CH or N; E is CH or N; R 1 is selected from: an optionally substituted acyclic C 1-8 hydrocarbon group wherein one carbon atom of the acyclic C 1-8 hydrocarbon group may optionally be replaced by O, S, NRC, S(O) or SO 2 , or two adjacent carbon atoms of the acyclic d-β hydrocarbon group may optionally be replaced by CONR c , NR c CO, NR c SO 2 or SO 2 NR c provided that in each case at least one carbon atom of the acyclic C 1-8 hydrocarbon group remains; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R 2 is hydrogen or X-R 8 ; X is a C 1-8 alkanediyl group wherein one carbon atom of the C 1-8 alkanediyl group may optionally be bonded to a -CH 2 -CH 2 - moiety to form a cyclopropane-1,1-diyl group or two adjacent carbon atoms of the C 1-8 alkanediyl group may optionally be bonded to a -(CH 2 ) n moiety, where n is 1 to 5, to form a C 3-7 -cycloalkane-1,2-diyl group; R 3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0-3 heteroatom ring members selected from N, O and S; R 4 is hydrogen or R 43 wherein R 43 is halogen; cyano; C 1-4 alkyl; fluoro-1.4 alkyl; C 1-4 alkoxy; fluoro-C 1-4 alkoxy; hydroxy-C 1-4 alkyl; or C 1-2 alkoxy-C 1-4 alkyl; R 5 is hydrogen or R 53 wherein R 53 is selected from C 1-2 alkyl optionally substituted with fluorine; C 1-3 alkoxy optionally substituted with fluorine; halogen; cyclopropyl; and cyano; R 8 is hydroxy or C(=O)NR 10 R 11 ; provided that when R8 is hydroxy, there are at least two carbon atoms in line between the hydroxy group and the nitrogen atom to which X is attached; R 10 is hydrogen or C 1-4 alkyl; and R 11 is hydrogen; amino-C 2-4 alkyl or hydroxy-C 2-4 alkyl; but excluding the compounds 1-(3-benzoylphenyl)-ethylamine and 1-(3-furan-2-oylcarbonylphenyl)-ethylamine.",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;HAMLETT CHRISTOPHER CHARLES FREDERICK HAMLETT;;BESONG GILBERT EBAI;;CHESSARI GIANNI;;CARR MARIA GRAZIA;;MILLEMAGGI ALESSIA;;NORTON DAVID;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;HISCOCK STEVEN DOUGLAS,,https://lens.org/041-592-181-615-61X,Patent Application,yes,2,2,18,20,3,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,C07D213/64;;C07D213/50;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28,,56,38,005-874-534-835-432;;045-415-706-073-517;;021-678-328-638-835;;045-804-232-391-319;;006-016-453-414-156;;152-983-672-513-485;;082-584-678-375-006;;107-578-170-220-753;;088-253-767-481-857;;141-771-777-785-977;;005-465-843-126-210;;001-213-758-138-077;;075-343-369-666-407;;096-631-839-313-189;;016-163-077-184-387;;030-285-531-359-849;;099-722-627-848-58X;;001-413-720-748-124;;071-434-763-452-86X;;032-511-500-330-440;;135-227-601-946-03X;;017-347-015-881-243;;007-364-858-655-289;;000-820-736-344-337;;126-811-728-740-254;;012-875-860-136-424;;024-966-947-509-122;;077-365-619-775-156;;004-137-705-827-976;;075-596-410-145-597;;003-656-629-895-712;;015-714-720-040-924;;046-777-072-258-96X;;007-378-255-811-868;;180-914-831-542-651;;069-791-648-230-325;;010-867-772-881-309;;075-553-717-843-39X,15521006;;10.1053/j.gastro.2004.07.020;;9136797;;10.1016/s0002-9610(96)00384-4;;11870384;;10.1053/jhep.2002.31773;;10.1038/nature04083;;16107838;;10.1099/0022-1317-74-11-2391;;8245854;;10.1099/0022-1317-78-1-45;;9010284;;10.1099/0022-1317-75-5-1053;;8176367;;19684573;;10.1038/nature08309;;20621700;;10.1053/j.gastro.2010.05.079;;10.1053/j.gastro.2007.02.037;;17484874;;10.1586/14787210.6.4.463;;18662114;;20942646;;10.1086/656774;;10.1053/j.gastro.2009.11.055;;20006612;;10.2174/187152606776056706;;16787300;;10.3410/f.1046522.496495;;17004721;;10.1021/jm060325b.s001;;10.1021/jm060325b;;17556358;;10.1074/jbc.m610207200;;10.1021/jm060173k;;17444623;;10.21775/cimb.009.001;;17263143;;pmc3571657;;10.1074/jbc.m805460200;;19010782;;pmc2629105;;pmc3126282;;10.1128/jvi.02130-10;;21325413;;22814430;;pmc3467334;;10.1016/j.virusres.2012.07.007;;23023261;;10.1038/nchembio.1081;;pmc3480716;;10.1002/jps.2600660104;;833720;;10.1080/00397917709409270;;10.1002/anie.196603851;;10.1093/acprof:oso/9780199573653.001.0001;;9002452;;10.1021/js9601896;;10.1021/jo01351a600;;10.1016/s0040-4039(00)94371-5;;10.1023/b:pham.0000016235.32639.23;;15032302;;10.1016/s0168-3659(03)00241-4;;12932648;;10.1002/jps.2600600902;;4935981;;15002962;;10.1021/cc034046a;;12739949;;10.1021/cc0201041;;10.1002/0470055529;;10.1021/ol901955y;;19807115;;12415250;;10.1038/nrd942;;15178332;;10.1016/j.febslet.2004.04.072,"DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 19 January 2011 (2011-01-19), XP002690954, retrieved from STN Database accession no. 1259916-62-5;;DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 January 2011 (2011-01-18), XP002690955, retrieved from STN Database accession no. 1259674-97-9;;DAVILA, J.A. ET AL., GASTROENTEROLOGY, vol. 127, 2004, pages 1372 - 1380;;LIU, C.L.; FAN, S.T., AM. J. SURG., vol. 173, 1997, pages 358 - 365;;HEPATOLOGY, vol. 35, 2002, pages 680 - 687;;BROWN, R.S., NATURE, vol. 436, 2005, pages 973 - 978;;SIMMONDS ET AL., J GEN VIROL, vol. 74, 1993, pages 2391 - 2399;;LAMBALLERIE ET AL., J GEN VIROL, vol. 78, 1997, pages 45 - 51;;SIMMONDS ET AL., J GEN VIROL, vol. 75, 1994, pages 1053 - 1061;;GE ET AL., NATURE, vol. 461, 2009, pages 399 - 401;;MANGIA ET AL., GASTROENTEROLOGY, vol. 139, no. 3, 2010, pages 821 - 7;;SARRAZIN, C. ET AL., GASTROENTEROLOGY, vol. 132, 2007, pages 1767 - 1777;;KIM, A.Y.; TIMM, J., EXPERT REV ANTI INFECT THER., vol. 6, 2008, pages 463 - 478;;LE POGAM, S. ET AL., J. INFECT DIS., vol. 202, 2010, pages 1510 - 9;;ZEUZEM, S, GASTROENTEROLOGY, vol. 138, 2010, pages 447 - 462;;LIN, C. ET AL., INFECT DISORD DRUG TARGETS, vol. 6, 2006, pages 3 - 16;;VENKATRAMAN, S. ET AL., J. MED. CHEM., vol. 49, 2006, pages 6074 - 6086;;ZHOU, Y. ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 22619 - 22628;;PRONGAY, A.J. ET AL., J. MED. CHEM., vol. 50, 2007, pages 2310 - 2318;;HEZODE, C. ET AL., N. ENGL. J. MED., vol. 360, 2009, pages 1839 - 49;;FRICK, D.N., CURR. ISSUES MOL. BIOL., vol. 9, 2007, pages 1 - 20;;SEREBROV, V. ET AL., J. BIOL CHEM., vol. 284, no. 4, 2009, pages 2512 - 21;;MAGA, G. ET AL., BIOCHEM., vol. 44, 2005, pages 9637 - 44;;DING, S.C. ET AL., J. VIROL., vol. 85, no. 9, 2011, pages 4343 - 4353;;VAUGHAN, R. ET AL., VIRUS RESEARCH, vol. 169, no. 1, 2012, pages 80 - 90;;JHOTI ET AL., NATURE CHEMICAL BIOLOGY, vol. 8, no. 11, 2012, pages 920 - 925;;JERRY MARCH: ""Advanced Organic Chemistry"", 1992, WILEY INTERSCIENCE, pages: 131 - 133;;""Pharmaceutical Salts: Properties, Selection, and Use"", August 2002, HARDCOVER, pages: 388;;BERGE ET AL.: ""Pharmaceutically Acceptable Salts"", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;ALBINI, A.; PIETRA, S.: ""Heterocyclic N-Oxides"", 1991, CRC PRESS, pages: 31;;L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514;;JERRY MARCH: ""Advanced Organic Chemistry"", 1992, JOHN WILEY & SONS, pages: 109 - 114;;CAHN; INGOLD; PRELOG, ANGEW. CHEM. INT ED. ENGL., vol. 5, 1966, pages 385 - 415;;BRYN ET AL.: ""Solid-State Chemistry of Drugs"", 1999, SSCI, INC OF WEST LAFAYETTE;;C. GIACOVAZZO; H. L. MONACO; D. VITERBO; F. SCORDARI; G. GILLI; G. ZANOTTI; M. CATTI: ""Fundamentals of Crystallography"", 1992, INTERNATIONAL UNION OF CRYSTALLOGRAPHY/OXFORD UNIVERSITY PRESS;;HANCOCK ET AL., J. PHARM. SCI., vol. 86, 1997, pages 1;;SHEEHAN ET AL., J. AMER. CHEM SOC., vol. 77, 1955, pages 1067;;SHEEHAN ET AL., J. ORG. CHEM., vol. 26, 1961, pages 2525;;CASTRO ET AL., TETRAHEDRON LETTERS, vol. 31, 1990, pages 205;;L. A. CARPINO, J. AMER. CHEM. SOC., vol. 115, 1993, pages 4397;;KONIG ET AL., CHEM. BER., vol. 103, no. 708, pages 2024 - 2034;;J COMB CHEM., vol. 5, no. 3, 2003, pages 322 - 9;;JHOTI ET AL., NATURE CHEMICAL BIOLOGY, 2012;;""Remington's Pharmaceutical Sciences"", MACK PUBLISHING COMPANY;;R. G. STRICKLY: ""Solubilizing Excipients in oral and injectable formulations"", PHARMACEUTICAL RESEARCH, vol. 21, no. 2, 2004, pages 201 - 230;;""Nanoparticle Technology for Drug Delivery"", 13 March 2006, INFORMA HEALTHCARE;;J. CONTROL. RELEASE, vol. 91, no. 1-2, 2003, pages 167 - 172;;SINHA ET AL., MOL. CANCER THER., vol. 5, 1 August 2006 (2006-08-01), pages 1909;;CHIOU; RIEGELMAN, J. PHARM. SCI., vol. 60, 1971, pages 1281 - 1300;;ROSENTRETER U; HUBER U.: ""Optimal fraction collecting in preparative LC/MS"", J COMB CHEM., vol. 6, no. 2, 2004, pages 159 - 64;;LEISTER W; STRAUSS K; WISNOSKI D; ZHAO Z; LINDSLEY C.: ""Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries"", J COMB CHEM., vol. 5, no. 3, 2003, pages 322 - 9, XP001198955, DOI: doi:10.1021/cc0201041;;SNYDER L. R.; DOLAN J. W.: ""High-Performance Gradient Elution The Practical Application of the Linear-Solvent-Strength Model"", 2007, WILEY;;BEESLEY T. E.; SCOTT R.P.W.: ""Chiral Chromatography"", 1998, WILEY;;ORGANIC LETTERS, vol. 11, no. 21, 2009, pages 4882 - 4885;;NATURE REV. DRUG DISCOV., vol. 1, 2002, pages 911 - 916;;BOGUSZEWKA-CHACHULSKA, FEBS LETTERS, vol. 567, 2004, pages 253 - 258",PENDING
548,CA,A1,CA 2853008 A1,091-485-745-936-372,2013-05-10,2013,CA 2853008 A,2012-10-31,GB 201118874 A;;GB 201118875 A;;US 201161554237 P;;US 201161554421 P;;US 201261625925 P;;EP 2012071573 W,2011-11-01,PHARMACEUTICAL COMPOUNDS,"The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): or a salt, N-oxide, tautomer or stereoisomer thereof, wherein A is CH or N; E is CH or N; R1 is selected from: an optionally substituted acyclic C1-8 hydrocarbon group wherein one carbon atom of the acyclic C1-8 hydrocarbon group may optionally be replaced by O, S, NRC, S(O) or SO2, or two adjacent carbon atoms of the acyclic d-ß hydrocarbon group may optionally be replaced by CONRc, NRcCO, NRcSO2 or SO2NRc provided that in each case at least one carbon atom of the acyclic C1-8 hydrocarbon group remains; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R2 is hydrogen or X-R8; X is a C1-8 alkanediyl group wherein one carbon atom of the C1-8 alkanediyl group may optionally be bonded to a -CH2-CH2- moiety to form a cyclopropane-1,1-diyl group or two adjacent carbon atoms of the C1-8 alkanediyl group may optionally be bonded to a -(CH2)n moiety, where n is 1 to 5, to form a C3-7-cycloalkane-1,2-diyl group; R3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0-3 heteroatom ring members selected from N, O and S; R4 is hydrogen or R43 wherein R43 is halogen; cyano; C1-4 alkyl; fluoro-1.4 alkyl; C1-4 alkoxy; fluoro-C1-4 alkoxy; hydroxy-C1-4 alkyl; or C1-2 alkoxy-C1-4 alkyl; R5 is hydrogen or R53 wherein R53 is selected from C1-2 alkyl optionally substituted with fluorine; C1-3 alkoxy optionally substituted with fluorine; halogen; cyclopropyl; and cyano; R8 is hydroxy or C(=O)NR10R11; provided that when R8 is hydroxy, there are at least two carbon atoms in line between the hydroxy group and the nitrogen atom to which X is attached; R10 is hydrogen or C1-4 alkyl; and R11 is hydrogen; amino-C2-4 alkyl or hydroxy-C2-4 alkyl; but excluding the compounds 1-(3-benzoylphenyl)-ethylamine and 1-(3-furan-2-oylcarbonylphenyl)-ethylamine.",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;HAMLETT CHRISTOPHER CHARLES FREDERICK HAMLETT;;BESONG GILBERT EBAI;;CHESSARI GIANNI;;CARR MARIA GRAZIA;;MILLEMAGGI ALESSIA;;NORTON DAVID;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;HISCOCK STEVEN DOUGLAS,,https://lens.org/091-485-745-936-372,Patent Application,no,0,1,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28,,0,0,,,,DISCONTINUED
549,HK,A1,HK 1201534 A1,013-654-727-860-891,2015-09-04,2015,HK 15102129 A,2015-03-03,EP 2012071573 W;;GB 201118874 A;;GB 201118875 A;;US 201161554237 P;;US 201161554421 P;;US 201261625925 P,2011-11-01,PHARMACEUTICAL COMPOUNDS,,ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;HAMLETT CHRISTOPHER CHARLES FEDERICK HAMLETT;;BESONG GILBERT EBAI;;CHESSARI GIANNI;;CARR MARIA GRAZIA;;MILLEMAGGI ALESSIA;;NORTON DAVID;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;HISCOCK STEVEN DOUGLAS,,https://lens.org/013-654-727-860-891,Patent Application,no,0,0,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,C07D/,,0,0,,,,PENDING
550,CN,A,CN 104039766 A,071-235-111-683-505,2014-09-10,2014,CN 201280065417 A,2012-10-31,EP 2012071573 W;;GB 201118874 A;;GB 201118875 A;;US 201161554421 P;;US 201161554237 P;;US 201261625925 P,2011-11-01,Pharmaceutical compounds,"The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): or a salt, N-oxide, tautomer or stereoisomer thereof, wherein A is CH or N; E is CH or N; R1 is selected from: an optionally substituted acyclic C1-8 hydrocarbon group wherein one carbon atom of the acyclic C1-8 hydrocarbon group may optionally be replaced by O, S, NRC, S(O) or SO2, or two adjacent carbon atoms of the acyclic d-beta hydrocarbon group may optionally be replaced by CONRc, NRcCO, NRcSO2 or SO2NRc provided that in each case at least one carbon atom of the acyclic C1-8 hydrocarbon group remains; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R2 is hydrogen or X-R8; X is a C1-8 alkanediyl group wherein one carbon atom of the C1-8 alkanediyl group may optionally be bonded to a -CH2-CH2- moiety to form a cyclopropane-1,1-diyl group or two adjacent carbon atoms of the C1-8 alkanediyl group may optionally be bonded to a -(CH2)n moiety, where n is 1 to 5, to form a C3-7-cycloalkane-1,2-diyl group; R3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0-3 heteroatom ring members selected from N, O and S; R4 is hydrogen or R43 wherein R43 is halogen; cyano; C1-4 alkyl; fluoro-1.4 alkyl; C1-4 alkoxy; fluoro-C1-4 alkoxy; hydroxy-C1-4 alkyl; or C1-2 alkoxy-C1-4 alkyl; R5 is hydrogen or R53 wherein R53 is selected from C1-2 alkyl optionally substituted with fluorine; C1-3 alkoxy optionally substituted with fluorine; halogen; cyclopropyl; and cyano; R8 is hydroxy or C(=O)NR10R11; provided that when R8 is hydroxy, there are at least two carbon atoms in line between the hydroxy group and the nitrogen atom to which X is attached; R10 is hydrogen or C1-4 alkyl; and R11 is hydrogen; amino-C2-4 alkyl or hydroxy-C2-4 alkyl; but excluding the compounds 1-(3-benzoylphenyl)-ethylamine and 1-(3-furan-2-oylcarbonylphenyl)-ethylamine.",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;HAMLETT CHRISTOPHER CHARLES FREDERICK HAMLETT;;BESONG GILBERT EBAI;;CHESSARI GIANNI;;CARR MARIA GRAZIA;;MILLEMAGGI ALESSIA;;NORTON DAVID;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;HISCOCK STEVEN DOUGLAS,,https://lens.org/071-235-111-683-505,Patent Application,no,2,0,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28,,2,0,,,"王沙沙: ""《STN检索报告》"", 12 March 2015;;王沙沙: ""《STN检索报告》"", 12 March 2015, article ""STN检索报告""",DISCONTINUED
551,MX,A,MX 2014005228 A,079-381-936-593-770,2015-07-06,2015,MX 2014005228 A,2012-10-31,GB 201118874 A;;GB 201118875 A;;US 201161554237 P;;US 201161554421 P;;US 201261625925 P;;EP 2012071573 W,2011-11-01,PHARMACEUTICAL COMPOUNDS.,"The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): or a salt, N-oxide, tautomer or stereoisomer thereof, wherein A is CH or N; E is CH or N; R1 is selected from: an optionally substituted acyclic C1-8 hydrocarbon group wherein one carbon atom of the acyclic C1-8 hydrocarbon group may optionally be replaced by O, S, NRC, S(O) or SO2, or two adjacent carbon atoms of the acyclic d-Î² hydrocarbon group may optionally be replaced by CONRc, NRcCO, NRcSO2 or SO2NRc provided that in each case at least one carbon atom of the acyclic C1-8 hydrocarbon group remains; and an optionally substituted monocyclic carbocyclic or heterocyclic group of 3 to 7 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S; R2 is hydrogen or X-R8; X is a C1-8 alkanediyl group wherein one carbon atom of the C1-8 alkanediyl group may optionally be bonded to a -CH2-CH2- moiety to form a cyclopropane-1,1-diyl group or two adjacent carbon atoms of the C1-8 alkanediyl group may optionally be bonded to a -(CH2)n moiety, where n is 1 to 5, to form a C3-7-cycloalkane-1,2-diyl group; R3 is an optionally substituted 3- to 10-membered monocyclic or bicyclic carbocyclic or heterocyclic ring containing 0-3 heteroatom ring members selected from N, O and S; R4 is hydrogen or R43 wherein R43 is halogen; cyano; C1-4 alkyl; fluoro-1.4 alkyl; C1-4 alkoxy; fluoro-C1-4 alkoxy; hydroxy-C1-4 alkyl; or C1-2 alkoxy-C1-4 alkyl; R5 is hydrogen or R53 wherein R53 is selected from C1-2 alkyl optionally substituted with fluorine; C1-3 alkoxy optionally substituted with fluorine; halogen; cyclopropyl; and cyano; R8 is hydroxy or C(=O)NR10R11; provided that when R8 is hydroxy, there are at least two carbon atoms in line between the hydroxy group and the nitrogen atom to which X is attached; R10 is hydrogen or C1-4 alkyl; and R11 is hydrogen; amino-C2-4 alkyl or hydroxy-C2-4 alkyl; but excluding the compounds 1-(3-benzoylphenyl)-ethylamine and 1-(3-furan-2-oylcarbonylphenyl)-ethylamine.",ASTEX THERAPEUTICS LTD,NORTON DAVID;;WOODHEAD ANDREW JAMES;;HAMLETT CHRISTOPHER CHARLES FREDERICK HAMLETT;;BESONG GILBERT EBAI;;CHESSARI GIANNI;;CARR MARIA GRAZIA;;MILLEMAGGI ALESSIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;HISCOCK STEVEN DOUGLAS;;SAALAU-BETHELL SUSANNE MARIA,,https://lens.org/079-381-936-593-770,Patent Application,no,0,0,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28,,0,0,,,,PENDING
552,AU,A1,AU 2012/331190 A1,146-069-607-107-526,2014-04-10,2014,AU 2012/331190 A,2012-10-31,GB 201118874 A;;GB 201118875 A;;US 201161554421 P;;US 201261625925 P;;US 201161554237 P;;EP 2012071573 W,2011-11-01,Pharmaceutical compounds,"The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections. The compounds have the formula (1): or a salt, N-oxide, tautomer or stereoisomer thereof, wherein A is CH or N; E is CH or N; R",ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;HAMLETT CHRISTOPHER CHARLES FREDERICK HAMLETT;;BESONG GILBERT EBAI;;CHESSARI GIANNI;;CARR MARIA GRAZIA;;MILLEMAGGI ALESSIA;;NORTON DAVID;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;HISCOCK STEVEN DOUGLAS,,https://lens.org/146-069-607-107-526,Patent Application,no,0,0,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28,,0,0,,,,DISCONTINUED
553,KR,A,KR 20140102200 A,073-825-250-455-281,2014-08-21,2014,KR 20147014848 A,2012-10-31,GB 201118874 A;;GB 201118875 A;;US 201161554237 P;;US 201161554421 P;;US 201261625925 P;;EP 2012071573 W,2011-11-01,PHARMACEUTICAL COMPOUNDS,,ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;HAMLETT CHRISTOPHER CHARLES FREDERICK HAMLETT;;BESONG GILBERT EBAI;;CHESSARI GIANNI;;CARR MARIA GRAZIA;;MILLEMAGGI ALESSIA;;NORTON DAVID;;SAALAU BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;HISCOCK STEVEN DOUGLAS,,https://lens.org/073-825-250-455-281,Patent Application,no,0,0,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,C07D213/50;;A61K31/435;;C07D213/64;;C07D213/74;;C07D231/12,,0,0,,,,DISCONTINUED
554,ZA,B,ZA 201403832 B,194-338-288-484-415,2016-02-24,2016,ZA 201403832 A,2014-05-27,GB 201118874 A;;GB 201118875 A;;US 201161554237 P;;US 201161554421 P;;US 201261625925 P;;EP 2012071573 W,2011-11-01,PHARMACEUTICAL COMPOUNDS,,ASTEX THERAPEUTICS LTD,BESONG GILBERT EBAI;;WOODHEAD ANDREW JAMES;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;SAALAU-BETHELL SUSANNE MARIA;;NORTON DAVID;;MILLEMAGGI ALESSIA;;HISCOCK STEVEN DOUGLAS;;HAMLETT CHRISTOPHER CHARLES FREDERICK HAMLETT;;CHESSARI GIANNI;;CARR MARIA GRAZIA,,https://lens.org/194-338-288-484-415,Granted Patent,no,0,0,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,,,0,0,,,,ACTIVE
555,SG,A,SG 11201400872Y A,051-256-600-991-709,2014-08-28,2014,SG 11201400872Y A,2012-10-31,GB 201118874 A;;GB 201118875 A;;US 201161554237 P;;US 201161554421 P;;US 201261625925 P;;EP 2012071573 W,2011-11-01,PHARMACEUTICAL COMPOUNDS,,ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;HAMLETT CHRISTOPHER CHARLES FREDERICK HAMLETT;;BESONG GILBERT EBAI;;CHESSARI GIANNI;;CARR MARIA GRAZIA;;MILLEMAGGI ALESSIA;;NORTON DAVID;;SAALAU-BETHELL SUSANNE MARIA;;WILLEMS HENDRIKA MARIA GERARDA;;THOMPSON NEIL THOMAS;;HISCOCK STEVEN DOUGLAS,,https://lens.org/051-256-600-991-709,Unknown,no,0,0,18,20,0,C07C225/16;;C07C225/18;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;C07C255/58;;C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28;;C07D401/04;;C07D498/04;;C07C2601/02;;C07B2200/05;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C313/06;;C07C2601/02;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;C07D275/02;;C07C225/16;;A61P1/16;;A61P31/14;;A61P35/00;;A61P43/00;;C07C313/06;;C07D213/73;;C07D213/74;;C07C255/58;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D401/04;;C07D239/26;;C07D239/38;;C07C225/18;;C07D241/20;;C07D261/08;;C07D277/28;;C07D498/04;;C07D213/50;;C07D213/64;;C07D213/65;;C07B2200/05;;C07C225/22;;C07C229/38;;C07C237/06;;C07C237/10;;C07C237/24;;C07C237/30;;A61K9/0019;;A61K47/10;;A61K47/26;;A61K9/19;;A61K9/2018;;A61K9/4858;;C07C2601/02;;C07C225/16;;A61K31/138;;A61K31/277;;A61K31/42;;A61K31/425;;A61K31/44;;A61K31/4965;;A61K31/505;;A61K31/5383;;A61K45/06;;C07C221/00;;C07C253/30;;C07D275/02,C07D213/50;;C07D213/64;;C07D213/65;;C07D213/73;;C07D213/74;;C07D213/79;;C07D213/81;;C07D213/84;;C07D213/89;;C07D231/12;;C07D239/26;;C07D239/38;;C07D241/20;;C07D261/08;;C07D277/28,,0,0,,,,PENDING
556,LT,T,LT 2300465 T,017-297-581-621-590,2019-06-25,2019,LT 09761801 T,2009-06-12,GB 0810902 A;;US 6118408 P;;EP 2009057318 W,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA;;CONGREVE MILES;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE;;HAMLETT CHRISTOPHER;;MADIN ANDREW;;MURRAY CHRISTOPHER;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW;;WOODHEAD STEVEN;;FREYNE EDDY;;GOVAERTS TOM;;ANGIBAUD PATRICK;;WILLIAMS BRIAN,,https://lens.org/017-297-581-621-590,Unknown,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,PENDING
557,HU,T2,HU E045300 T2,081-971-497-934-781,2019-12-30,2019,HU E09761801 A,2009-06-12,GB 0810902 A;;US 6118408 P,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA;;CONGREVE MILES;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE;;HAMLETT CHRISTOPHER;;MADIN ANDREW;;MURRAY CHRISTOPHER;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW;;WOODHEAD STEVEN;;FREYNE EDDY;;GOVAERTS TOM;;ANGIBAUD PATRICK;;WILLIAMS BRIAN,,https://lens.org/081-971-497-934-781,Amended Patent,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,A61K31/53;;A61P35/00,,0,0,,,,PENDING
558,ES,T3,ES 2735979 T3,101-730-511-353-593,2019-12-23,2019,ES 09761801 T,2009-06-12,GB 0810902 A;;US 6118408 P;;EP 2009057318 W,2008-06-13,Derivados de la imidazopiridina como inhibidores de tirosina quinasas receptoras,"Un compuesto de fórmula (I):**Fórmula** en donde R1 representa hidrógeno y R2 representa alquilo C1-6 o haloalquilo C1-6; A es un grupo Ad que representa un grupo fenilo que puede estar opcionalmente sustituido con 1, 2 o 3 grupos Ra; R3 representa hidrógeno; R4 es un grupo R4c que se selecciona de cualquiera de (a)-(f) que representa: (a) piridazinilo opcionalmente sustituido con 1, 2 o 3 grupos Re, o 2, 3 o 4 grupos Rb; (b) pirazinilo opcionalmente sustituido con 1, 2 o 3 grupos Rb; (c) triazinilo opcionalmente sustituido con 1 o 2 grupos Rb; (d) pirimidin-2-ilo opcionalmente sustituido con 1, 2 o 3 grupos Rb; (e) pirimidin-4-ilo opcionalmente sustituido con 1, 2 o 3 grupos Rg o 2, 3 o 4 grupos Rb; (f) pirimidin-5-ilo opcionalmente sustituido con 1, 2 o 3 grupos Rp o 2, 3 o 4 grupos Rb; Rw, Rx, Ry y Rz representan independientemente hidrógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcanol C1-6, - COO alquilo C1-6, hidroxi, alcoxi C1-6, haloalquilo C1-6, -(CH2)n-O-alquilo C1-6, -CO-(CH2)n-alcoxi C1-6, alquilamino C1-6, -alquil C1-6-N(alquilo C1-6)2, alquilo C1-6-NH(alquilo C1-6), cicloalquilo C3-8 o cicloalquenilo C3-8 o cuando están unidos a un átomo de nitrógeno, Rw, Rx, Ry y Rz pueden formar un anillo; Ra representa grupos halógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, -ORx, - (CH2)n-O-alquilo C1-6, -O-(CH2)n-ORx, haloalquilo C1-6, haloalcoxi C1-6, alcanol C1-6, =O, =S, nitro, Si(Rx)4, -(CH2)s-CN, -S-Rx, -SO-Rx, -SO2-Rx, -CORx, -(CRxRy)s-COORz, -(CRxRy)s-CONRwRz, -(CH2)s-CONRxRy, -(CH2)s-NRxRy, -(CH2)s- NRxCORy, -(CH2)s-NRxSO2-Ry, -(CH2)s-NH-SO2-NRxRy, -OCONRxRy, -(CH2)s-NRxCO2Ry, -O-(CH2)n-NRxRy, -O-(CH2)s- CRxRy-(CH2)t-ORz o-(CH2)s-SO2NRxRy; Rb representa un grupo Ra o un grupo -Y-heterociclilo en donde dicho grupo heterociclilo puede estar opcionalmente sustituido con 1, 2 o 3 grupos Ra; Y representa un enlace, -CO-(CH2)s-, -(CRxRy)s-CO-, -COO-, -(CH2)n-(CRxRy)s-, -NRx-(CH2)s-, -( CH2)s-NRx-, -CONRx- , -NRxCO-, -SO2NRx-, -NRxSO2-, -NRxCONRy-, -NRxCSNRy-, -O-(CH2)s-, -(CH2)s-O-, -S-, -SO- o -(CH2)s-SO2-; Re representa halógeno, alquilo C2-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, -ORx, -(CH2)n- O-alquilo C1-6, -O-(CH2)n-ORx, haloalquilo C1-6, haloalcoxi C1-6, alcanol C1-6, =O, =S, nitro, Si(Rx)4, -(CH2)s-CN, -S-Rx, - SO-Rx, -SO2-Rx, -CORx, -(CRxRy)s-COORz, -(CRxRy)s-CONRwRz, -(CH2)s-CONRxRy, -(CH2)s-NRxRy, -(CH2)s-NRxCORy, -(CH2)s-NRxSO2-Ry, -(CH2)s-NH-SO2-NRxRy, -OCONRxRy, -(CH2)s-NRxCO2Ry, -O-(CH2)s-CRxRy-(CH2)t-ORz o grupos (CH2)s-SO2NRxRy, o un grupo -Y-heterociclilo en donde dicho grupo heterociclilo puede estar opcionalmente sustituido con 1, 2 o 3 grupos Ra; R9 representa grupos halógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, -ORx, - (CH2)n-O-alquilo C1-6, -O-(CH2)n-ORx, haloalquilo C1-6, haloalcoxi C1-5 6, alcanol C1-6, =O, =S, nitro, Si(Rx)4, -(CH2)s-CN, - S-Rx, -SO-Rx, -SO2-Rx, - CORx, -(CRxRy)s-COORz, -(CRxRy)s-CONRwRz, -(CH2)s-CONRxRy, -(CH2)s-NH alquilo C1-6, - (CH2)s-N(alquilo C1-6)2, -(CH2)n-NRxRy, -(CH2)s-NRxCORy, -(CH2)s-NRxSO2Ry, -(CH2)s-NH-SO2NRxRy, -OCONRxRy, - (CH2)s-NRxCO2Ry, -O-(CH2)s-CRxRy-(CH2)t-ORz o -(CH2)s-SO2NRxRy, o un grupo -Y-heterociclilo en donde dicho grupo heterociclilo puede estar opcionalmente sustituido con 1, 2 o 3 grupos Ra; Rp representa grupos halógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, cicloalquenilo C3-8, -ORx, - (CH2)n-O-alquilo C1-6, -O-(CH2)n-ORx, haloalquilo C1-6, haloalcoxi C1-6, alcanol C1-6, =O, =S, nitro, Si(Rx)4, -(CH2)s-CN, -S-Rx, -SO-Rx, -SO2-Rx, -CORx, -(CRxRy)s-COORz, -(CRxRy)s-CONRwRz, -(CH2)s-CONRxRy, -(CH2)s-NRxRy, -(CH2)s- NRxCORy, -(CH2)s-NRxSO2-Ry, -(CH2)s-NH-SO2-NRxRy, -OCONRxRy, -(CH2)s-NRxCO2Ry, -O-(CH2)s-CRxRy-(CH2)t-ORz o -(CH2)s-SO2NRxRy; un -Y- (grupo heterociclilo de 4 miembros) en donde dicho grupo heterociclilo de 4 miembros está sustituido con 1, 2 o 3 grupos Ra; o un -Y- (grupo heterociclilo de 5-10 miembros) en donde dicho grupo heterociclilo de 5-10 miembros puede estar opcionalmente sustituido con 1, 2 o 3 grupos Ra; n representa un número entero de 1-4; s y t representan independientemente un número entero de 0-4; o una sal o solvato o tautómero farmacéuticamente aceptable del mismo.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA;;CONGREVE MILES;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE;;HAMLETT CHRISTOPHER;;MADIN ANDREW;;MURRAY CHRISTOPHER;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW;;WOODHEAD STEVEN;;FREYNE EDDY;;GOVAERTS TOM;;ANGIBAUD PATRICK;;WILLIAMS BRIAN,,https://lens.org/101-730-511-353-593,Granted Patent,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,ACTIVE
559,MX,A,MX 2009006650 A,082-319-429-262-097,2009-08-20,2009,MX 2009006650 A,2007-12-20,GB 0625682 A;;US 87135506 P;;US 98263607 P;;US 98615007 P;;GB 2007050777 W,2006-12-21,SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY.,"The invention provides compounds of the formula (I) having PKA and PKB kinase inhibiting compounds of the formula (I): GP 1 J T 2 J N 4 R N H (I) or salts, solvates, tautomers or N-oxides thereof, wherein (1) GP is a group GP1: HET 2a a Q G (HNCO)f 7 (R )x N * (GP1) (2) GP is a group GP2: 10 (R )r O 2a a QG (CH2)w N V H N * (GP2) wherein HET is a monocyclic or bicyclic heterocyclic group containing up to 4 heteroatom ring members; the ring V is a monocyclic or bicyclic heteroaryl group of 5 to 10 ring members; and J1, J2, R4, R7, R10, Q2a, Ga, x, w and f are as defined in the claims.",ASTEX THERAPEUTICS LTD,LUKE RICHARD WILLIAM ARTHUR;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;MATUSIAK ZBIGNIEW STANLEY;;HAMLETT CHRISTOPHER;;MCHARDY TATIANA FARIA DA FONSECA;;CARR GREGORY RICHARD;;MORRIS JEFFREY JAMES;;CHEUNG KWAI MING,,https://lens.org/082-319-429-262-097,Patent Application,no,0,0,15,19,0,C07D473/34;;C07D487/04;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07D487/04;;C07D473/34;;A61K31/519;;C07D473/34;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00;;C07D471/04;;C07D473/34,,0,0,,,,DISCONTINUED
560,UY,A1,UY 30823 A1,038-321-784-196-087,2008-07-31,2008,UY 30823 A,2007-12-20,GB 0625682 A;;US 87135506 P;;US 98263607 P;;US 98615007 P,2006-12-21,PIPERIDINAS SUSTITUIDAS QUE CONTIENEN UNA FRACCION DE HETEROARILAMIDA O HETEROARILFENILO,"PIPERIDINAS SUSTITUIDAS QUE CONTIENEN UNA FRACCION DE HETEROARILAMIDA O HETEROARILFENILO La invencion proporciona compuestos de formula (I) que tienen compuestos inhibidores de la quinasa PKA y PKB de formula (I) : O sales, solvatos, tautomeros o N-oxidos de los mismos, donde (1) GP es un grupo GP1 (2) GP es un grupo GP 2 Donde HET es un grupo heterocíclico monocíclico o bicíclico que contiene hasta 4 miembros del anillo de heteroátomo; el anillo V es un grupo heteroarilo monociclito o bicíclico de a 5 a 10 miembros en el anillo ; y R7, R10, Q2a, Ga, x, w, y f son como se define en las reivindicaciones",CANCER RES INST ROYAL;;ASTEX THERAPEUTICS LTD;;CANCER RESARCH TECHNOLOGY LTD;;ASTRAZENECA AB,CARR GREGORY RICHARD;;MORRIS JEFFREY JAMES;;MATSUIAKZ ZBIGNIEW STANLEY;;CHEUNG KWAI MING;;HAMLETT CHRISTOPHER;;FONSECA TATIANA FARIA DA;;CALDWELL JOHN;;VERDONK MARINUS LEENDERT;;IAN COLLINS;;WINTER WALKER DAVID;;FIONA SORE HANNAH;;JOHN WOODHEAD STEVEN;;ARTHUR LUKE RICHARD WILLIAM,,https://lens.org/038-321-784-196-087,Patent Application,no,0,0,15,19,0,C07D473/34;;C07D487/04;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07D487/04;;C07D473/34;;A61K31/519;;C07D473/34;;C07D487/04,C07D473/00;;A61K31/52;;C07H19/16,,0,0,,,,DISCONTINUED
561,US,A1,US 2004/0049401 A1,197-827-607-823-098,2004-03-11,2004,US 37042103 A,2003-02-19,US 37042103 A;;US 35832102 P,2002-02-19,Security methods employing drivers licenses and other documents,"
   Driver's licenses and other security documents include one or more machine-readable features, each conveying plural bits of information. These features are used in a variety of ways to increase security, and/or to enhance functionality. In one embodiment, data encoded on a driver's license is used at airport check-in, to link to a state DMV database and obtain information by which the document, and its custodian, can be authenticated. In like fashion, a license can be used to authenticate a bearer and/or his/her age prior to the sale of alcohol or tobacco products. In other embodiments, different elements of a driver's license (e.g., the substrate, photo, text data, and machine-readable data) are logically bound together (e.g., interlinked through payloads conveyed by different machine-readable features) as a deterrent against counterfeiting. Driver's licenses can be similarly logically bound to personal checks and other documents. Many other arrangements are also disclosed. 
",CARR J. SCOTT;;DAVIS BRUCE L.;;DECKER STEPHEN K.;;HAWES JONATHAN L.;;HEIN WILLIAM C.;;LEVY KENNETH L.;;MUNDAY JOHN;;PERRY BURT W.;;SEDER PHILLIP ANDREW;;MEYER JOEL R.;;MCKINLEY TYLER J.;;BRUNK HUGH L.;;STEWART STEVEN W.,CARR J SCOTT;;DAVIS BRUCE L;;DECKER STEPHEN K;;HAWES JONATHAN L;;HEIN WILLIAM C;;LEVY KENNETH L;;MUNDAY JOHN;;PERRY BURT W;;SEDER PHILLIP ANDREW;;MEYER JOEL R;;MCKINLEY TYLER J;;BRUNK HUGH L;;STEWART STEVEN W,DIGIMARC CORPORATION (2003-10-04);;L-1 SECURE CREDENTIALING INC (2008-08-13),https://lens.org/197-827-607-823-098,Patent Application,yes,39,146,9,31,0,G06Q10/02;;G06Q50/265;;G07C2209/41;;G07C9/22;;G07C9/20;;G07C9/27;;G06Q10/02;;G07C2209/41;;G06Q50/265;;G07C9/20;;G07C9/22,G06Q10/02;;G06Q50/26;;G07C9/00,705/1,0,0,,,,DISCONTINUED
562,EC,A,EC SP099446 A,022-245-630-233-428,2009-09-29,2009,EC SP099446 A,2009-06-19,GB 0625682 A;;US 87135506 P;;US 98263607 P;;US 98615007 P,2006-12-21,PIPERIDINAS SUSTITUIDAS QUE CONTIENEN UNA UNIDAD HETEROARILAMIDA O HETEROARILFENILO,"La invención proporciona compuestos de fórmula I que tienen inhibidores de PKA y PKB quinasa de la fórmula (I): (I)o sales, solvatos, tautómeros o N-óxidos de los mismos, donde(1) GP es un grupo GP1: (GP1)(2) GP es un grupo GP2: (GP2)donde HET es un grupo heterocíclico monocíclico o bicíclico que contiene hasta 4 miembros del anillo que son heteroátomos; el anillo V es un grupo heteroarilo monocíclico o bicíclico con entre 5 y 10 miembros en el anillo; y J1, J2, R4, R7, R10, Q2a, Ga, x, w y f tienen los valores que se definen en las reivindicaciones.",ASTEX THERAPEUTICS LTD;;ASTRAZENECA AB;;INST CANCER RES ROYAL CANCER HOSPITAL;;CANCER RES TECH LTD,CALDWELL JOHN;;WOODHEAD STEVEN JOHN;;HAMLETT CHRISTOPHER;;VERDONK MARINUS;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;DA FONSECA MCHARDY TATIANA FARIA;;LUKE RICHARD WILLIAM ARTHUR;;MATUSIAK ZBIGNIEW STANLEY;;CARR GREGORY RICHARD;;MORRIS JEFFREY JAMES;;CHEUNG KWAI MING,,https://lens.org/022-245-630-233-428,Patent Application,no,0,0,15,19,0,C07D473/34;;C07D487/04;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07D487/04;;C07D473/34;;A61K31/519;;C07D473/34;;C07D487/04,A61K31/519;;A61P35/00;;C07D471/04;;C07D487/04,,0,0,,,,PENDING
563,BR,A2,BR PI0721124 A2,019-721-698-434-695,2014-03-04,2014,BR PI0721124 A,2007-12-20,GB 0625682 A;;US 87135506 P;;US 98263607 P;;US 98615007 P;;GB 2007050777 W,2006-12-21,"COMPOSTO, USO DO MESMO, MÉTODOS PARA A PROFILAXIA OU TRATAMENTO DE UM ESTADO OU CONDIÇÃO DE DOENÇA, PARA TRATAR UMA DOENÇA OU CONDIÇÃO, PARA INIBIR PROTEÍNA QUINASE, PARA MODULAR UM PROCESSO CELULAR, PARA ALIVIAR OU REDUZIR A INCIDÊNCIA DE UMA DOENÇA OU CONDIÇÃO, PARA A DIAGNOSE E TRATAMENTO DE UM ESTADO OU CONDIÇÃO DE DOENÇA E PARA MODULAR PROTEÍNA QUINASE B E/OU PROTEÍNA QUINASE A, E, COMPOSIÇÃO FARMACÊUTICA",,ASTEX THERAPEUTICS LTD;;INST CANCER RES ROYAL CANCER HOSPITAL;;CANCER RES TECH LTD;;ASTRAZENECA AB,WOODHEAD STEVEN JOHN;;HAMLETT CHRISTOPHER;;VERDONK MARINUS LEENDERT;;WALKER DAVID WINTER;;SORE HANNAH FIONA;;COLLINS IAN;;CALDWELL JOHN;;FARIA DA FONSECA MCHARDY TATIANA;;LUKE RICHARD WILLIAM ARTHUR;;MATUSIAK ZBIGNIEW STANLEY;;CARR GREGORY RICHARD;;MORRIS JEFFREY JAMES;;CHEUNG KWAI MING,,https://lens.org/019-721-698-434-695,Patent Application,no,0,0,15,19,0,C07D473/34;;C07D487/04;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07D487/04;;C07D473/34;;A61K31/519;;C07D473/34;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00;;C07D471/04;;C07D473/34,,0,0,,,,DISCONTINUED
564,US,A1,US 2010/0120798 A1,053-452-363-176-225,2010-05-13,2010,US 51999307 A,2007-12-20,US 51999307 A;;GB 0625682 A;;US 87135506 P;;US 98263607 P;;US 98615007 P;;GB 2007050777 W,2006-12-21,SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY,"The invention provides compounds of the formula (I) having PKA and PKB kinase inhibiting compounds of the formula (I): GP 1 J T 2 J N 4 R N H (I) or salts, solvates, tautomers or N-oxides thereof, wherein (1) GP is a group GP1: HET 2a a Q G (HNCO)f 7 (R)x N * (GP1) (2) GP is a group GP2: 10 (R)r O 2a a QG (CH2)w N V H N * (GP2) wherein HET is a monocyclic or bicyclic heterocyclic group containing up to 4 heteroatom ring members; the ring V is a monocyclic or bicyclic heteroaryl group of 5 to 10 ring members; and J1, J2, R4, R7, R10, Q2a, Ga, x, w and f are as defined in the claims",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;ASTRAZENECA AB;;CANCER RES INST,WOODHEAD STEVEN JOHN;;HAMLETT CHRISTOPHER;;VERDONK MARINUS LEENDERT;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;CHEUNG KWAI MING;;CALDWELL JOHN;;DA FONSECA MCHARDY TATIANA FARIA;;LUKE RICHARD WILLIAM ARTHUR;;MATUSIAK ZBIGNIEW STANLEY;;CARR GREGORY RICHARD;;MORRIS JEFFREY JAMES,THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (2009-07-29);;ASTRAZENECA AB (2009-07-29);;ASTEX THERAPEUTICS LIMITED (2009-07-29);;CANCER RESEARCH TECHNOLOGY LIMITED (2009-07-29),https://lens.org/053-452-363-176-225,Patent Application,yes,0,0,15,19,2,C07D473/34;;C07D487/04;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07D487/04;;C07D473/34;;A61K31/519;;C07D473/34;;C07D487/04,A61K31/522;;A61K31/52;;A61P9/00;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;C07D473/34,514/263.22;;514/265.1;;544/276;;544/277;;544/280,0,0,,,,DISCONTINUED
565,EP,A1,EP 2125820 A1,081-747-744-124-676,2009-12-02,2009,EP 07848737 A,2007-12-20,GB 2007050777 W;;GB 0625682 A;;US 87135506 P;;US 98263607 P;;US 98615007 P,2006-12-21,SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY,,ASTEX THERAPEUTICS LTD;;CANCER RES INST ROYAL;;CANCER RES CAMPAIGN TECH;;ASTRAZENECA AB,WOODHEAD STEVEN JOHN;;HAMLETT CHRISTOPHER;;VERDONK MARINUS LEENDERT;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;CALDWELL JOHN;;DA FONSECA MCHARDY TATIANA FARIA;;LUKE RICHARD WILLIAM ARTHUR;;MATUSIAK ZBIGNIEW STANLEY;;CARR GREGORY RICHARD;;MORRIS JEFFREY JAMES;;CHEUNG KWAI MING,,https://lens.org/081-747-744-124-676,Patent Application,yes,0,0,15,19,0,C07D473/34;;C07D487/04;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07D487/04;;C07D473/34;;A61K31/519;;C07D473/34;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00;;C07D471/04;;C07D473/34,,0,0,,,,DISCONTINUED
566,TW,A,TW 200833694 A,130-201-746-682-760,2008-08-16,2008,TW 96148757 A,2007-12-19,GB 0625682 A;;US 87135506 P;;US 98263607 P;;US 98615007 P,2006-12-21,Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety,"The inventin provides compounds of the formula (I) having PKA and PKB kinase inhibiting compounds of the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein (1) GP is a group GP1: (2) GP is a group GP2: wherein HET is a monocyclic or bicyclic heterocyclic group containing up to 4 heteroatom ring members; the ring V is a monocyclic or bicyclic heteroaryl group of 5 to 10 ring members; and R7, R10, Q2a, Ga, x, w and f are as defined in the claims.",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;CANCER RES INST ROYAL;;ASTRAZENECA AB,WOODHEAD STEVEN JOHN;;HAMLETT CHRISTOPHER;;VERDONK MARINUS LEENDERT;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;CHEUNG KWAI MING;;CALDWELL JOHN;;DA FONSECA MCHARDY TATIANA FARIA;;LUKE RICHARD WILLIAM ARTHUR;;MATUSIAK ZBIGNIEW STANLEY;;CARR GREGORY RICHARD;;MORRIS JEFFREY JAMES,,https://lens.org/130-201-746-682-760,Patent of Addition,no,0,0,15,19,0,C07D473/34;;C07D487/04;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07D487/04;;C07D473/34;;A61K31/519;;C07D473/34;;C07D487/04,C07D487/04;;A61K31/519;;A61K31/52;;A61P35/00;;C07D473/34,,0,0,,,,PENDING
567,CA,A1,CA 2476895 A1,167-008-500-043-422,2003-08-28,2003,CA 2476895 A,2003-02-19,US 35832102 P;;US 0305337 W,2002-02-19,SECURITY METHODS EMPLOYING DRIVERS LICENSES AND OTHER DOCUMENTS,"Driver's licenses and other security documents include one or more machine- readable features, each conveying plural bits of information. These features are used in a variety of ways to increase security, and/or to enhance functionality. In one embodiment, data encoded on a driver's license is used at airport check-in, to link to a state DMV database and obtain information by which the document, and its custodian, can be authenticated. In like fashion , a license can be used to authenticate a bearer and/or his/her age prior to t he sale of alcohol or tobacco products. In other embodiments, different element s of a driver's license (e.g., the substrate, photo, text data, and machine- readable data) are logically bound together (e.g., interlinked through payloads conveyed by different machine-readable features) as a deterrent against counterfeiting. Driver's licenses can be similarly logically bound t o personal checks and other documents. Many other arrangements are also disclosed.",DIGIMARC CORP,MUNDAY JOHN;;LEVY KENNETH L;;HEIN WILLIAM C III;;HAWES JONATHAN L;;DAVIS BRUCE L;;DECKER STEPHEN K;;PERRY BURT W;;CARR J SCOTT;;SEDER PHILLIP ANDREW;;MEYER JOEL R;;STEWART STEVEN W;;BRUNK HUGH L;;MCKINLEY TYLER J,,https://lens.org/167-008-500-043-422,Patent Application,no,0,0,9,31,0,G06Q10/02;;G06Q50/265;;G07C2209/41;;G07C9/22;;G07C9/20;;G07C9/27;;G06Q10/02;;G07C2209/41;;G06Q50/265;;G07C9/20;;G07C9/22,G06Q10/02;;G06Q50/26;;G07C9/00,,0,0,,,,DISCONTINUED
568,CA,A1,CA 2672841 A1,072-607-029-409-719,2008-06-26,2008,CA 2672841 A,2007-12-20,GB 0625682 A;;US 87135506 P;;US 98263607 P;;US 98615007 P;;GB 2007050777 W,2006-12-21,SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY,"The invention provides compounds of the formula (I) having PKA and PKB ki nase inhibiting compounds of the formula (I): GP 1 J T 2 J N 4 R N H (I) or salts, solvates, tautomers or N-oxides thereof, wherein (1) GP is a group GP 1: HET 2a a Q G (HNCO)f 7 (R )x N * (GP1) (2) GP is a group GP2: 10 (R )r O 2a a QG (CH2)w N V H N * (GP2) wherein HET is a monocyclic or bicyclic heter ocyclic group containing up to 4 heteroatom ring members; the ring V is a mo nocyclic or bicyclic heteroaryl group of 5 to 10 ring members; and J1, J2, R 4, R7, R10, Q2a, Ga, x, w and f are as defined in the claims",ASTEX THERAPEUTICS LTD;;CANCER REC TECH LTD;;ASTRAZENECA AB;;CANCER RES INST ROYAL,DA FONSECA MCHARDY TATIANA FARIA;;LUKE RICHARD WILLIAM ARTHUR;;MATUSIAK ZBIGNIEW STANLEY;;HAMLETT CHRISTOPHER;;MORRIS JEFFREY JAMES;;CARR GREGORY RICHARD;;SORE HANNAH FIONA;;CALDWELL JOHN;;COLLINS IAN;;WALKER DAVID WINTER;;VERDONK MARINUS LEENDERT;;CHEUNG KWAI MING;;WOODHEAD STEVEN JOHN,,https://lens.org/072-607-029-409-719,Patent Application,no,0,0,15,19,2,C07D473/34;;C07D487/04;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07D487/04;;C07D473/34;;A61K31/519;;C07D473/34;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00;;C07D471/04;;C07D473/34,,0,0,,,,DISCONTINUED
569,ZA,B,ZA 200904327 B,120-428-232-743-611,2010-06-30,2010,ZA 200904327 A,2009-06-19,GB 0625682 A,2006-12-21,Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety,,ASTEX THERAPEUTICS LTD;;INSTUTE OF CANCER RES;;ROYAL CANCER HOSPITAL;;CANCER REC TECH LTD;;ASTRAZENECA AB,WOODHEAD STEVEN JOHN;;VERDONK MARINUS LEENDERT;;WALKER DAVID WINTER;;CALDWELL JOHN;;LUKE RICHARD WILLIAM ARTHUR;;CARR GREGORY RICHARD;;CHEUNG KWAI MING;;HAMLETT CHRISTOPHER;;SORE HANNAH FIONA;;COLLINS IAN;;DA FONSECA MCHARDY TATIANA FARIA;;MATUSIAK ZBIGNIEW STANLEY;;MORRIS JEFFREY JAMES,,https://lens.org/120-428-232-743-611,Granted Patent,no,0,0,3,19,0,,A61K/;;A61P/;;C07D/,,0,0,,,,ACTIVE
570,US,A1,US 2009/0187435 A1,137-986-166-776-223,2009-07-23,2009,US 35290009 A,2009-01-13,US 35290009 A;;US 37042103 A;;US 35832102 P,2002-02-19,SECURITY METHODS EMPLOYING DRIVERS LICENSES AND OTHER DOCUMENTS,"Driver's licenses and other security documents include one or more machine-readable features, each conveying plural bits of information. These features are used in a variety of ways to increase security, and/or to enhance functionality. In one embodiment, data encoded on a driver's license is used at airport check-in, to link to a state DMV database and obtain information by which the document, and its custodian, can be authenticated. In like fashion, a license can be used to authenticate a bearer and/or his/her age prior to the sale of alcohol or tobacco products. In other embodiments, different elements of a driver's license (e.g., the substrate, photo, text data, and machine-readable data) are logically bound together (e.g., interlinked through payloads conveyed by different machine-readable features) as a deterrent against counterfeiting. Driver's licenses can be similarly logically bound to personal checks and other documents. Many other arrangements are also disclosed.",CARR J SCOTT;;DAVIS BRUCE L;;DECKER STEPHEN K;;HAWES JONATHAN L;;HEIN III WILLIAM C;;LEVY KENNETH L;;MUNDAY JOHN;;PERRY BURT W;;SEDER PHILIP ANDREW;;MEYER JOEL R;;MCKINLEY TYLER J;;BRUNK HUGH L;;STEWART STEVEN W,CARR J SCOTT;;DAVIS BRUCE L;;DECKER STEPHEN K;;HAWES JONATHAN L;;HEIN III WILLIAM C;;LEVY KENNETH L;;MUNDAY JOHN;;PERRY BURT W;;SEDER PHILIP ANDREW;;MEYER JOEL R;;MCKINLEY TYLER J;;BRUNK HUGH L;;STEWART STEVEN W,DIGIMARC CORPORATION (2003-10-04);;L-1 SECURE CREDENTIALING INC (2009-01-28),https://lens.org/137-986-166-776-223,Patent Application,yes,35,20,9,31,0,G06Q10/02;;G06Q50/265;;G07C2209/41;;G07C9/22;;G07C9/20;;G07C9/27;;G06Q10/02;;G07C2209/41;;G06Q50/265;;G07C9/20;;G07C9/22,G06F17/30;;G06K5/00;;G06Q10/02;;G06Q50/26;;G07C9/00,705/5;;235/382;;707/104.1;;X707E17044,0,0,,,,DISCONTINUED
571,NO,L,NO 20092341 L,083-448-745-059-581,2009-07-21,2009,NO 20092341 A,2009-06-18,GB 0625682 A;;US 87135506 P;;US 98263607 P;;US 98615007 P;;GB 2007050777 W,2006-12-21,Substituerte piperidiner inneholdende et heteroarylamid eller en heteroarylfenyl gruppe,"Oppfinnelsen tilveiebringer forbindelser med formel (I) som er PKA- og PKB-kinase-hemmende forbindelser med formel (I): eller salter, solvater, tautomerer eller N-oksider derav, hvor. (1) GP er en gruppe GP1:. (2) GP er en gruppe GP2:. hvor HET er en monocyklisk eller bicyklisk, heterocyklisk gruppe som inneholder opptil 4 ring-heteroatomer; ringen V er en monocyklisk eller bicyklisk heteroarylgruppe med 5 til 10 ledd i ringen; og,,,, R, Q, Ga, x, w og fer som definert i kravene.",CANCER RES INST ROYAL,LUKE RICHARD WILLIAM ARTHUR;;VERDONK MARINUS LEENDERT;;WOODHEAD STEVEN JOHN;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;HAMLETT CHRISTOPHER;;COLLINS IAN;;CHEUNG KWAI MING;;CALDWELL JOHN;;MCHARDY TATIANA FARIA DA FONSECA;;MATUSIAK ZBIGNIEW STANLEY;;CARR GREGORY RICHARD;;MORRIS JEFFREY JAMES,,https://lens.org/083-448-745-059-581,Abstract,no,0,0,15,19,0,C07D473/34;;C07D487/04;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07D487/04;;C07D473/34;;A61K31/519;;C07D473/34;;C07D487/04,C07D473/34;;A61K31/519;;A61P35/00;;C07D487/04,,0,0,,,,DISCONTINUED
572,WO,A1,WO 2008/075110 A1,059-681-836-952-042,2008-06-26,2008,GB 2007050777 W,2007-12-20,GB 0625682 A;;US 87135506 P;;US 98263607 P;;US 98615007 P,2006-12-21,SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY,"The invention provides compounds of the formula (I) having PKA and PKB kinase inhibiting compounds of the formula (I): GP 1 J T 2 J N 4 R N H (I) or salts, solvates, tautomers or N-oxides thereof, wherein (1) GP is a group GP1: HET 2a a Q G (HNCO)f 7 (R )x N * (GP1) (2) GP is a group GP2: 10 (R )r O 2a a QG (CH2)w N V H N * (GP2) wherein HET is a monocyclic or bicyclic heterocyclic group containing up to 4 heteroatom ring members; the ring V is a monocyclic or bicyclic heteroaryl group of 5 to 10 ring members; and J1, J2, R4, R7, R10, Q2a, Ga, x, w and f are as defined in the claims",ASTEX THERAPEUTICS LTD;;CANCER RES INST ROYAL;;CANCER REC TECH LTD;;ASTRAZENECA AB;;WOODHEAD STEVEN JOHN;;HAMLETT CHRISTOPHER;;VERDONK MARINUS LEENDERT;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;CALDWELL JOHN;;DA FONSECA MCHARDY TATIANA FAR;;LUKE RICHARD WILLIAM ARTHUR;;MATUSIAK ZBIGNIEW STANLEY;;CARR GREGORY RICHARD;;MORRIS JEFFREY JAMES;;CHEUNG KWAI MING,WOODHEAD STEVEN JOHN;;HAMLETT CHRISTOPHER;;VERDONK MARINUS LEENDERT;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;CALDWELL JOHN;;DA FONSECA MCHARDY TATIANA FAR;;LUKE RICHARD WILLIAM ARTHUR;;MATUSIAK ZBIGNIEW STANLEY;;CARR GREGORY RICHARD;;MORRIS JEFFREY JAMES;;CHEUNG KWAI MING,,https://lens.org/059-681-836-952-042,Patent Application,yes,6,25,15,19,0,C07D473/34;;C07D487/04;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07D487/04;;C07D473/34;;A61K31/519;;C07D473/34;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00;;C07D471/04;;C07D473/34,,0,0,,,,PENDING
573,AU,A1,AU 2007/335969 A1,088-682-906-279-006,2008-06-26,2008,AU 2007/335969 A,2007-12-20,GB 0625682 A;;US 98615007 P;;US 87135506 P;;US 98263607 P;;GB 2007050777 W,2006-12-21,Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety,,ASTEX THERAPEUTICS LTD;;ASTRAZENECA AB;;CANCER RESEARCH TECH LTD;;THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL,CHEUNG KWAI MING;;VERDONK MARINUS LEENDERT;;MATUSIAK ZBIGNIEW STANLEY;;COLLINS IAN;;WOODHEAD STEVEN JOHN;;MORRIS JEFFREY JAMES;;CALDWELL JOHN;;HAMLETT CHRISTOPHER;;MCHARDY TATIANA FARIA DA FONSECA;;LUKE RICHARD WILLIAM ARTHUR;;SORE HANNAH FIONA;;CARR GREGORY RICHARD;;WALKER DAVID WINTER,,https://lens.org/088-682-906-279-006,Patent Application,no,0,0,15,19,0,C07D473/34;;C07D487/04;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07D487/04;;C07D473/34;;A61K31/519;;C07D473/34;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00;;C07D471/04;;C07D473/34,,0,0,,,,DISCONTINUED
574,CN,A,CN 101627042 A,179-440-484-983-956,2010-01-13,2010,CN 200780050862 A,2007-12-20,GB 0625682 A,2006-12-21,Substituted piperidines containing a heteroarylamide or heteroarylphenyl moiety,"The invention provides compounds of the formula (I) having PKA and PKB kinase inhibiting compounds of the formula (I): GP 1 J T 2 J N 4 R N H (I) or salts, solvates, tautomers or N-oxides thereof, wherein (1) GP is a group GP1: HET 2a a Q G (HNCO)f 7 (R )x N * (GP1) (2) GP is a group GP2: 10 (R )r O 2a a QG (CH2)w N V H N * (GP2) wherein HET is a monocyclic or bicyclic heterocyclic group containing up to 4 heteroatom ring members; the ring V is a monocyclic or bicyclic heteroaryl group of 5 to 10 ring members; and J1, J2, R4, R7, R10, Q2a, Ga, x, w and f are as defined in the claims.",ASTEX THERAPEUTICS LTD,JOHN WOODHEAD STEVEN;;CHRISTOPHER HAMLETT;;LEENDERT VERDONK MARINUS;;FIONA SORE HANNAH;;WINTER WALKER DAVID;;IAN COLLINS;;JOHN CALDWELL;;FAR DA FONSECA MCHARDY TATIANA;;ARTHUR LUKE RICHARD WILLIAM;;STANLEY MATUSIAK ZBIGNIEW;;RICHARD CARR GREGORY;;JAMES MORRIS JEFFREY;;MING CHEUNG KWAI,,https://lens.org/179-440-484-983-956,Patent Application,no,0,2,3,19,0,,C07D487/04,,0,0,,,,DISCONTINUED
575,PE,A1,PE 20081680 A1,191-125-834-669-460,2008-12-18,2008,PE 2008000081 A,2008-01-02,GB 0625682 A;;US 87135506 P;;US 98263607 P;;US 98615007 P,2006-12-21,PIPERIDINAS SUSTITUIDAS QUE CONTIENEN UN COMPONENTE DE HETEROARILAMIDA O DE HETEROARILFENIL,"SE REFIERE A UN COMPUESTO DE FORMULA (I), DONDE GP ES UN GRUPO GP1; J1-J2 SON SELECCIONADOS DE N=CH, N=N, HN-C(O), ENTRE OTROS; f ES 0-1; x ES 0-3; T ES CH, N; HET ES UN GRUPO MONOCICLICO O BICICLICO QUE CONTIENE HASTA 4 HETEROATOMOS SUSTITUIDOS O NO; Q2a ES UN ENLACE, HIDROCARBONO ACICLICO DE 1-3 ATOMOS DE CARBONO; Ga ES CN, OH, ENTRE OTROS; R7 ES H, METOXI, TRIFLUOROMETIL, ENTRE OTROS. SON PRERIDOS: ACIDO 4-AMINO-1-(8-OXO-8,9-DIHIDRO-7H-PURIN-6-IL)-PIPERIDINA-4-CARBOXILICO[3-(4-METIL-PIRIDIN-3-IL)-FENIL]-AMIDA; (1-(5-CLORO-7H-PIRROLO[2,3-d]PIRIMIDINA-4-IL)-4-(3-(1-METIL-1H-PIRAZOL-4-IL)FENIL)PIPERIDIN-4-IL)METANAMINA; ENTRE OTROS. REFERIDA TAMBIEN A COMPOSICIONES FARMACEUTICAS Y UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES O MODULADORES DE LA CINASA PROTEICA B(QPB) Y/O CINASA PROTEICA A (QPA) UTILES EN EL TRATAMIENTO MEDIADAS POR QPB Y/O QPA",ASTEX THERAPEUTICS LTD;;CANCER RES INST ROYAL;;ASTRAZENECA AB,WOODHEAD STEVEN JOHN;;HAMLETT CHRISTOPHER;;VERDONK MARINUS LEENDERT;;SORE HANNAH FIONA;;WALKER DAVID WINTER;;COLLINS IAN;;CHEUNG KWAI MING;;CALDWELL JOHN;;DA FONSECA MCHARDY TATIANA FARIA;;LUKE RICHARD WILLIAM ARTHUR;;MATUSIAK ZBIGNIEW STANLEY;;CARR GREGORY RICHARD;;MORRIS JEFFREY JAMES,,https://lens.org/191-125-834-669-460,Patent Application,no,0,0,15,19,0,C07D473/34;;C07D487/04;;A61P11/06;;A61P25/00;;A61P29/00;;A61P35/00;;A61P37/00;;A61P43/00;;A61P9/00;;C07D487/04;;C07D473/34;;A61K31/519;;C07D473/34;;C07D487/04,A61K31/519;;A61K31/52;;C07D473/00;;C07H19/16,,0,0,,,,DISCONTINUED
576,US,A1,US 2008/0015116 A1,148-573-693-025-652,2008-01-17,2008,US 67750507 A,2007-02-21,US 67750507 A;;US 15493602 A;;US 76001001 A;;US 17555100 P;;US 21394700 P,2000-01-11,Integrated Systems and Methods for Diversity Generation and Screening,"Integrated systems and methods for diversity generation and screening are provided. The systems use common fluid and array handling components to provide nucleic acid diversification, transcription, translation, product screening and subsequent diversification reactions.",MAXYGEN INC,BASS STEVEN H;;DAVIS S C;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAUS;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN A;;CRAMERI ANDREAS;;STEMMER WILLEM P;;EMIG ROBIN;;LONGSCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,CODEXIS INC (2024-02-06);;CODEXIS MAYFLOWER HOLDINGS LLC (2010-10-28),https://lens.org/148-573-693-025-652,Patent Application,yes,99,18,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,C40B60/04;;G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,506/35,0,0,,,,EXPIRED
577,CA,A1,CA 2396320 A1,115-986-300-922-191,2001-07-19,2001,CA 2396320 A,2001-01-10,US 17555100 P;;US 21394700 P;;US 0101056 W,2000-01-11,INTEGRATED SYSTEMS AND METHODS FOR DIVERSITY GENERATION AND SCREENING,"Integrated systems and methods for diversity generation and screening are provided. The systems use common fluid and array handling components to provide nucleic acid diversification, transcription, translation, product screening and subsequent diversification reactions.",MAXYGEN INC,RAILLARD SUN AI;;BASS STEVEN H;;GIVER LORRAINE J;;GOLDMAN STANLEY;;CARR BRIAN;;DAVIS S CHRISTOPHER;;JENNE STEPHANE;;AFFHOLTER JOSEPH A;;GUSTAFSSON CLAES;;WELCH MARK;;CRAMERI ANDREAS;;PATTEN PHILLIP A;;EMIG ROBIN;;MINSHULL JEREMY;;LONGCHAMP PASCAL;;TOBIN MATTHEW;;STEMMER WILLEM P,,https://lens.org/115-986-300-922-191,Patent Application,no,0,1,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,,0,0,,,,DISCONTINUED
578,US,A1,US 2001/0039014 A1,113-882-183-225-944,2001-11-08,2001,US 76001001 A,2001-01-10,US 76001001 A;;US 17555100 P;;US 21394700 P,2000-01-11,Integrated systems and methods for diversity generation and screening,"
   Integrated systems and methods for diversity generation and screening are provided. The systems use common fluid and array handling components to provide nucleic acid diversification, transcription, translation, product screening and subsequent diversification reactions. 
",MAXYGEN INC,BASS STEVEN H;;DAVIS S CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAES;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,MAXYGEN INC (2001-04-03);;CODEXIS INC (2024-02-06);;CODEXIS MAYFLOWER HOLDINGS LLC (2010-10-28),https://lens.org/113-882-183-225-944,Patent Application,yes,42,212,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,435/6;;X702 2;;435/287.2,0,0,,,,DISCONTINUED
579,US,B2,US 7462469 B2,063-314-035-357-729,2008-12-09,2008,US 15493602 A,2002-05-23,US 15493602 A;;US 76001001 A;;US 17555100 P;;US 21394700 P,2000-01-11,Integrated system for diversity generation and screening,"Integrated systems and methods for diversity generation and screening are provided. The systems use common fluid and array handling components to provide nucleic acid diversification, transcription, translation, product screening and subsequent diversification reactions.",MAXYGEN INC,BASS STEVEN H;;DAVIS S CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAES;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,CODEXIS INC (2024-02-06);;CODEXIS MAYFLOWER HOLDINGS LLC (2010-10-28),https://lens.org/063-314-035-357-729,Granted Patent,yes,109,43,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,C12P19/34;;G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,435/91.2;;435/6;;435/91.1,45,41,069-081-028-661-451;;052-515-049-615-321;;076-857-393-695-376;;030-682-602-291-829;;041-686-146-430-131;;098-702-433-451-053;;024-369-171-979-227;;144-691-161-287-610;;094-087-374-443-020;;072-689-231-585-62X;;005-534-971-910-727;;017-122-411-657-318;;014-793-548-895-526;;034-553-838-798-25X;;025-834-245-974-873;;084-748-487-156-928;;008-668-626-323-479;;057-988-909-871-766;;049-427-119-219-60X;;049-917-149-198-776;;009-898-247-038-15X;;059-349-671-883-389;;008-006-631-989-07X;;016-467-427-627-620;;072-668-742-851-341;;111-715-011-111-624;;063-099-001-050-447;;040-482-527-661-995;;036-055-058-985-848;;027-719-371-280-548;;029-506-594-475-338;;056-304-474-559-637;;077-476-584-062-720;;023-130-578-604-418;;051-679-383-863-659;;061-754-589-503-35X;;009-992-889-537-648;;070-322-219-790-918;;028-312-552-297-631;;056-304-474-559-637;;028-312-552-297-631,10429246;;10.1038/11737;;10.1038/7003;;10096293;;11283594;;10.1038/86744;;7692403;;pmc310094;;10.1093/nar/21.18.4410;;7727111;;9630892;;10.1038/nbt0396-315;;8564822;;10.1038/nm0196-100;;9131621;;10.1038/nbt0597-436;;10.1038/34663;;9440693;;10.1006/jmbi.1996.0031;;8568883;;10359711;;10.1016/s1367-5931(99)80044-1;;10.1038/12884;;10471932;;9425664;;10.1016/s0958-1669(97)80127-9;;11283580;;10.1038/86681;;10.1073/pnas.91.22.10747;;7938023;;pmc45099;;10.1038/370389a0;;8047147;;7491501;;10.1126/science.270.5241.1510;;10.1038/nbt0695-549;;pmc20752;;9114019;;10.1073/pnas.94.9.4504;;pmc15083;;10.1073/pnas.96.1.11;;9874762;;10.1038/15095;;10545919;;pmc24609;;9144168;;10.1073/pnas.94.10.4937;;pmc24338;;10.1073/pnas.95.24.14130;;9826665;;10350066;;10.1016/s0014-5793(99)00475-5;;10.1128/jb.145.1.306-320.1981;;6450747;;pmc217274;;10.1016/s0958-1669(98)80042-6;;9821285;;9582111;;10.1126/science.280.5366.1046;;10397261;;10383126;;10388473;;10.1093/clinchem/45.7.982;;8994661;;10.2144/97221rr01;;9325094;;10.1006/jmbi.1997.1252;;9606143;;10.1006/abio.1998.2606;;9344407;;10.1006/abio.1997.2326;;9630890;;10.1038/nbt0396-303;;10.2144/99275rr01;;10572649;;10.1038/nbt0897-789;;9255796;;pmc217167;;6109711;;10.1128/jb.145.2.687-695.1981;;9223302;;10.1073/pnas.94.15.7997;;pmc21544;;9325094;;10.1006/jmbi.1997.1252;;9223302;;10.1073/pnas.94.15.7997;;pmc21544,"Chang, C., et al. (1999) ""Evolution of a cytokine using DNA family shuffling."" Nature Biotechnology 17:793-797.;;Christians, F.C. et al., (1999) ""Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling."" Nature Biotechnology 17:259-264.;;Coco et al., (2001) ""DNA shuffling method for generating highly recombined genes and evolved enzymes"" Nature Biotechnology vol. 19 pp. 354-359.;;Crameri et al., (1993) ""10(20)-Fold aptamer library amplification without gel purification,"" Nuc. Acids Res. 21(18):4410.;;Crameri, A. & Stemmer W.P.C. (1995) ""Combinatorial multiple cassette mutagenesis creates all the permutations of mutant and wildtype cassettes."" Biotechniques 18:194-195.;;Crameri, A. et al. (1996) ""Improved green fluorescent protein by molecular evolution using DNA shuffling."" Nature Biotechnology 14:315-319.;;Crameri, A. et al. (1996) ""Construction and evolution of antibody-phage libraries by DNA shuffling."" Nature Medicine 2:100-103.;;Crameri, A. et al., (1997) ""Molecular evolution of an arsenate detoxification pathway by DNA shuffling."" Nature Biotechnology 15:436-438.;;Crameri, A. et al., (1998) ""DNA shuffling of a family of genes from diverse species accelerates directed evolution."" Nature 391:288-291.;;Gates, C.M. et al., (1996) ""Affinity selective isolation of ligands from peptide libraries through display on a lac repressor headpiece dimer"". Journal of Molecular Biology 255:373-386.;;Minshull, J., Stemmer, W.P.C. (1999) ""Protein evolution by molecular breeding."" Current Opinion in Chemical Biology 3:284-290.;;Ness, J. et al., (1999) ""DNA Shuffling of subgenomic sequences of subtilisin."" Nature Biotechnology 17:893-896.;;Patten, P.A. et al., (1997) ""Application of DNA Shuffling to Pharmaceuticals and Vaccines."" Current Opinion in Biotechnology 8:724-733.;;Pelletier, Joelle N., (2001) ""A Rachitt for our toolbox"" Nature Biotechnology vol. 19, p. 314-315.;;Stemmer, W.P.C. (1994) ""DNA Shuffling by random fragmentation and reassemby: In vitro recombination for molecular evolution."" PNAS 91:10751.;;Stemmer, W.P.C. (1994) ""Rapid evolution of a protein in vitro by DNA shuffling."" Nature 370:389-391.;;Stemmer, W.P.C. (1995) ""The Evolution of Molecular Computation."" Science 270:1510.;;Stemmer, W.P.C. (1995) ""Searching Sequence Space."" Bio/Technology 13:549-553.;;Stemmer, W.P.C. (1996) ""Sexual PCR and Assembly PCR."" In: The Encyclopedia of Molecular Biology. VCH Publishers, New York. pp. 447-457.;;Stemmer, W.P.C. & Soong, N.W. (1999) ""Molecular breeding of viruses for targeting and other clinical properties."" Tumor Targeting 4:59-62.;;Zhang, J. et al., (1997) ""Directed evolution of an effective fucosidase from a galactosidase by DNA shuffling and screening."" Proceedings of the National Academy of Sciences, USA 94:4504-4509.;;Chou, H.P. et al (1999) ""A Microfabricated Device for Sizing and Sorting DNA Molecules."" Proc. Natl'l Acad. Sci. 96:11-113.;;DeSilva et al. (1998) ""Rapid Genotyping and Quantification on the LightCycler with Hybridization Probes"" Biochimica 2:12-15.;;DeSilva et al. (1998) ""The LightCycler-The Smartest Innovation for More Efficient PCR"" Biochemica 2:4-7.;;Fu, A.Y. et al (1999) ""A Microfabricated Fluorescence-Activated Cell Sorter,"" Nat. Biotechnol. 17:1109-1111.;;Hanes and Pluckthun (1997) ""In vitro Selection and Evolution of Functional Proteins by Using Ribosome Display."" Biochemistry 94:4937-4942.;;Hanes et al. (1988) ""Ribosome Display Efficiently Selects and Evolves High-Affinity Antibodies in vitro from Immune Libraries"" PNAS 95:14130-14135.;;Hanes et al. (1999) ""Comparison of E. coli and rabbit reticulocyte ribosome display systems"" FEBS Lett. 450(1-2): 105-10.;;Hays et al. (1981) ""Recombination of uracil-containing Lambda bacteriophages."" J. Bacteriol. 145(1):306-320.;;Jermutus et al. (1998) ""Recent advances in producing and selecting functional proteins by using cell-free translation"" Curr. Opin. Biotechnol. 9(5):534-48.;;Kopp et al. (1998) ""Chemical Amplification: Continuous flow PCR on a Chip"" Science 280:1046-1047.;;Kreuzer et al. (1999) ""LightCycler technology for the quantitation of bcr/ab1 fusion transcripts"" Cancer Research 59(13):3171-4.;;Laurendeau et al. (1999) ""Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcriptionPCR assay"" Clin Chem 59(12):2759-65.;;Laurendeau et al. (1999) ""TaqMan PCR-based gene dosage asay for predictive testing in Individuals from a cancer family with INK4 locus haploinsufficiency"" Clin Chem 45(7):982-6.;;Lindner et al. (1997) ""Specific Detection of His-tagged Proteins with Recombinant anti-His tag scFv-Phosphatase or scFv-phage fusions"" Biotechniques 22(1):140-149.;;Moore et al. (1997) ""Strategies for the in vitro evolution of protein function: enzyme evolution by random recombination of improved sequences"" Journal of Mol. Bio. 3:336-347.;;Muller et al. (1998) ""Tandem Immobilized Metal Ion Affinity Chromatography/Immunoaffinity purification of His-tagged proteins-evaluation of two anti-His-tag monoclonal antibodies"" Anal Biochem. 259(1):54-61.;;Nieba et al. (1997) ""BIACORE analysis of histadine-tagged proteins using a chelating NTA sensor chip."" Anal. Biochem 22(2):217-218.;;Tyagl and Kramer (1996). ""Molecular beacons: probes that fluoresce upon hybridization."" Nat Biotechnol 14, 303-308.;;Unger, M. et al (1999) ""Single Molecule Fluorescence Observed with Mercury Lamp Illumination,"" Biotechniques 27:1008-1013.;;Wang et al. (1997) ""Biocatalytic plastics as active and stable materials for biotransformations"" Nat Biotechnol 2:15(8):789-93.;;Warner et al. (1981) ""Synthesis and Metabolism of uracil-containing deoxyribonucleic acid in Escherichia coli"" J. Bacteriol. 145(2):687-695.;;Zhao et al. (1997) ""Functional and nonfunctional mutations distinguished by random recombination of homologous genes"" Proc. Natl. Acad. Sci. vol. 94:7997-8000.;;Moore, J.C., et al., J. Mol. Biol. (1997) 272:336-347.;;Zhao, H., et al., PNAS(USA) (1997) 94:7997-8000.",EXPIRED
580,US,A1,US 2003/0054383 A1,105-398-056-447-38X,2003-03-20,2003,US 15493602 A,2002-05-23,US 15493602 A;;US 76001001 A;;US 17555100 P;;US 21394700 P,2000-01-11,Integrated systems and methods for diversity generation and screening,"
   Integrated systems and methods for diversity generation and screening are provided. The systems use common fluid and array handling components to provide nucleic acid diversification, transcription, translation, product screening and subsequent diversification reactions. 
",MAXYGEN INC,BASS STEVEN H;;DAVIS S CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAES;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGSCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,CODEXIS INC (2024-02-06);;CODEXIS MAYFLOWER HOLDINGS LLC (2010-10-28),https://lens.org/105-398-056-447-38X,Patent Application,yes,81,15,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,435/6;;435/287.2;;X702 2,0,0,,,,EXPIRED
581,WO,A3,WO 2001/051663 A3,120-304-895-269-637,2002-06-13,2002,US 0101056 W,2001-01-10,US 17555100 P;;US 21394700 P,2000-01-11,INTEGRATED SYSTEMS AND METHODS FOR DIVERSITY GENERATION AND SCREENING,"Integrated systems and methods for diversity generation and screening are provided. The systems use common fluid and array handling components to provide nucleic acid diversification, transcription, translation, product screening and subsequent diversification reactions.",MAXYGEN INC;;BASS STEVEN H;;DAVIS S CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAES;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,BASS STEVEN H;;DAVIS S CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAES;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,,https://lens.org/120-304-895-269-637,Search Report,yes,11,0,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,,2,2,028-312-552-297-631;;056-304-474-559-637,9223302;;10.1073/pnas.94.15.7997;;pmc21544;;9325094;;10.1006/jmbi.1997.1252,"ZHAO H ET AL: ""FUNCTIONAL AND NONFUNCTIONAL MUTATIONS DISTINGUISHED BY RANDOM RECOMBINATION OF HOMOLOGOUS GENES"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 94, July 1997 (1997-07-01), pages 7997 - 8000, XP002916918, ISSN: 0027-8424;;MOORE J C ET AL: ""STRATEGIES FOR THE IN VITRO EVOLUTION OF PROTEIN FUNCTION: ENZYME EVOLUTION BY RANDOM RECOMBINATION OF IMPROVED SEQUENCES"", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 272, no. 3, 26 September 1997 (1997-09-26), pages 336 - 347, XP000892797, ISSN: 0022-2836",PENDING
582,SG,A1,SG 121902 A1,041-829-113-372-735,2006-05-26,2006,SG 200406111 A,2001-01-10,US 17555100 P;;US 21394700 P,2000-01-11,Integrated systems for diversity generation and screening,,MAXYGEN INC,BASS STEVEN H;;DAVIS S CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAES;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,,https://lens.org/041-829-113-372-735,Patent Application,no,0,0,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,,0,0,,,,PENDING
583,US,A1,US 2003/0054384 A1,149-138-461-118-964,2003-03-20,2003,US 15493902 A,2002-05-23,US 15493902 A;;US 76001001 A;;US 17555100 P;;US 21394700 P,2000-01-11,Integrated systems and methods for diversity generation and screening,"
   Integrated systems and methods for diversity generation and screening are provided. The systems use common fluid and array handling components to provide nucleic acid diversification, transcription, translation, product screening and subsequent diversification reactions. 
",MAXYGEN INC,BASS STEVEN H;;DAVIS S CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAUS;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGSCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,CODEXIS INC (2024-02-06),https://lens.org/149-138-461-118-964,Patent Application,yes,85,23,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,435/6;;435/287.2;;X702 2,0,0,,,,DISCONTINUED
584,EP,A2,EP 1276900 A2,118-341-535-205-059,2003-01-22,2003,EP 01902036 A,2001-01-10,US 0101056 W;;US 17555100 P;;US 21394700 P,2000-01-11,INTEGRATED SYSTEMS AND METHODS FOR DIVERSITY GENERATION AND SCREENING,,MAXYGEN INC,BASS STEVEN H;;DAVIS S CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAES;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,,https://lens.org/118-341-535-205-059,Patent Application,yes,0,0,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,,0,0,,,,DISCONTINUED
585,US,A1,US 2003/0064393 A1,172-724-825-882-556,2003-04-03,2003,US 15573902 A,2002-05-23,US 15573902 A;;US 76001001 A;;US 17555100 P;;US 21394700 P,2000-01-11,Integrated systems and methods for diversity generation and screening,"
   Integrated systems and methods for diversity generation and screening are provided. The systems use common fluid and array handling components to provide nucleic acid diversification, transcription, translation, product screening and subsequent diversification reactions. 
",MAXYGEN INC,BASS STEVEN H;;DAVIS S CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAES;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,CODEXIS INC (2024-02-06),https://lens.org/172-724-825-882-556,Patent Application,yes,44,41,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,435/6;;435/287.2;;X702 2,0,0,,,,DISCONTINUED
586,AU,A,AU 2001/027881 A,187-321-553-151-597,2001-07-24,2001,AU 2001/027881 A,2001-01-10,US 17555100 P;;US 21394700 P;;US 0101056 W,2000-01-11,Integrated systems and methods for diversity generation and screening,,MAXYGEN INC,BASS STEVEN H;;DAVIS S CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAES;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,,https://lens.org/187-321-553-151-597,Patent Application,no,0,0,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,,0,0,,,,PENDING
587,WO,A2,WO 2001/051663 A2,105-194-746-760-272,2001-07-19,2001,US 0101056 W,2001-01-10,US 17555100 P;;US 21394700 P,2000-01-11,INTEGRATED SYSTEMS AND METHODS FOR DIVERSITY GENERATION AND SCREENING,"Integrated systems and methods for diversity generation and screening are provided. The systems use common fluid and array handling components to provide nucleic acid diversification, transcription, translation, product screening and subsequent diversification reactions.",MAXYGEN INC;;BASS STEVEN H;;DAVIS S CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAES;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,BASS STEVEN H;;DAVIS S CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY;;WELCH MARK;;GUSTAFSSON CLAES;;CARR BRIAN;;JENNE STEPHANE;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,,https://lens.org/105-194-746-760-272,Patent Application,yes,0,18,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,,0,0,,,,PENDING
588,US,A1,US 2006/0129338 A1,045-965-350-949-78X,2006-06-15,2006,US 1024204 A,2004-12-10,US 1024204 A;;US 52875103 P,2003-12-11,Pipeline integrity management process,"A method for reducing the consequences and risks of failure in a hydrocarbon pipeline system includes identifying specific segments of pipelines the leakage of which could have an adverse impact on environment or safety, particularly in areas of high consequence, developing a baseline assessment plan for such segments by analyzing information including age, corrosion, and types of seams and joints and then establishing preventive and migitative measures including, where necessary, positioning emergency flow restricting devices in one or more pipeline segments.",TURLEY RICHARD D;;FEIGERT DEBRA S;;STECHSCHULTE DONALD J;;JONES J C;;JOHNSTON DENNIS C;;HUCKE DENNIS C;;GUINN GEORGE L;;MELAN BRYAN P;;JONES THOMAS A;;SCHMITS NINA M;;CARR DOUGLAS T;;PRICE RAYMOND W;;ROSS STEVEN T;;KENDRICK ANDREW W;;SIEBOLD DAVID E,TURLEY RICHARD D;;FEIGERT DEBRA S;;STECHSCHULTE DONALD J;;JONES J C;;JOHNSTON DENNIS C;;HUCKE DENNIS C;;GUINN GEORGE L;;MELAN BRYAN P;;JONES THOMAS A;;SCHMITS NINA M;;CARR DOUGLAS T;;PRICE RAYMOND W;;ROSS STEVEN T;;KENDRICK ANDREW W;;SIEBOLD DAVID E,MARATHON PETROLEUM COMPANY LLC (2004-03-13),https://lens.org/045-965-350-949-78X,Patent Application,yes,6,48,4,4,0,F17D5/00;;F17D5/00;;F17D5/02;;F17D5/02,G01F23/00;;E21B/,702/51,0,0,,,,INACTIVE
589,US,B2,US 7263465 B2,138-993-583-325-054,2007-08-28,2007,US 1024204 A,2004-12-10,US 1024204 A;;US 52875103 P,2003-12-11,Pipeline integrity management process,"A method for reducing the consequences and risks of failure in a hydrocarbon pipeline system includes identifying specific segments of pipelines the leakage of which could have an adverse impact on environment or safety, particularly in areas of high consequence, developing a baseline assessment plan for such segments by analyzing information including age, corrosion, and types of seams and joints and then establishing preventive and migitative measures including, where necessary, positioning emergency flow restricting devices in one or more pipeline segments.",MARATHON ASHLAND PETROLEUM LLC,TURLEY RICHARD D;;FEIGERT DEBRA S;;STECHSCHULTE DONALD J;;JONES J CHARLES;;JOHNSTON DENNIS C;;HUCKE DENNIS C;;GUINN GEORGE L;;MELAN BRYAN P;;JONES THOMAS A;;SCHMITS NINA M;;CARR DOUGLAS T;;PRICE RAYMOND W;;ROSS STEVEN T;;KENDRICK ANDREW W;;SIEBOLD DAVID E,MARATHON PETROLEUM COMPANY LLC (2004-03-13),https://lens.org/138-993-583-325-054,Granted Patent,yes,6,5,4,4,0,F17D5/00;;F17D5/00;;F17D5/02;;F17D5/02,G06F11/30;;E21B/,702/182,1,0,,,"Managing System Integrity for Hazardous Liquid Pipelines; American Petroleum Institute; API Standard 1160; First Edition, Nov. 2001.",INACTIVE
590,WO,A3,WO 2005/059294 A3,102-930-844-803-292,2006-08-31,2006,US 2004/0041563 W,2004-12-10,US 52875103 P,2003-12-11,PIPELINE INTEGRITY MANAGEMENT PROCESS,"A method for reducing the consequences and risks of failure in a hydrocarbon pipeline system includes identifying specific segments of pipelines the leakage of which could have an adverse impact on environment or safety, particularly in areas of high consequence, developing a baseline assessment plan for such segments by analyzing information including age, corrosion, and types of seams and joints and then establishing preventive and migitative measures including, where necessary, positioning emergency flow restricting devices in one or more pipeline segments.",MARATHON ASHLAND PETROLEUM LLC;;TURLEY RICHARD D;;FEIGERT DEBRA S;;STECHSCHULTE DONALD J;;JONES J CHARLES;;JOHNSTON DENNIS C;;HUCKE DENNIS C;;GUINN GEORGE L;;MELAN BRYAN P;;JONES THOMAS A;;SCHMITS NINA M;;CARR DOUGLAS T;;PRICE RAYMOND W;;ROSS STEVEN T;;KENDRICK ANDREW W;;SIEBOLD DAVID E,TURLEY RICHARD D;;FEIGERT DEBRA S;;STECHSCHULTE DONALD J;;JONES J CHARLES;;JOHNSTON DENNIS C;;HUCKE DENNIS C;;GUINN GEORGE L;;MELAN BRYAN P;;JONES THOMAS A;;SCHMITS NINA M;;CARR DOUGLAS T;;PRICE RAYMOND W;;ROSS STEVEN T;;KENDRICK ANDREW W;;SIEBOLD DAVID E,,https://lens.org/102-930-844-803-292,Search Report,yes,4,0,4,4,0,F17D5/00;;F17D5/00;;F17D5/02;;F17D5/02,G06Q99/00;;E21B/;;G21C7/36;;G21C17/00,,0,0,,,,PENDING
591,US,B2,US 8014961 B2,015-358-448-716-906,2011-09-06,2011,US 67750507 A,2007-02-21,US 67750507 A;;US 15493602 A;;US 76001001 A;;US 17555100 P;;US 21394700 P,2000-01-11,Integrated systems and methods for diversity generation and screening,"Integrated systems and methods for diversity generation and screening are provided. The systems use common fluid and array handling components to provide nucleic acid diversification, transcription, translation, product screening and subsequent diversification reactions.",CODEXIS MAYFLOWER HOLDINGS LLC,BASS STEVEN H;;DAVIS SIMON CHRISTOPHER;;PATTEN PHILLIP A;;TOBIN MATTHEW;;MINSHULL JEREMY S;;WELCH MARK;;GUSTAFSSON CLAUS;;CARR BRIAN;;JENNE STEPHAN J;;RAILLARD SUN AI;;CRAMERI ANDREAS;;STEMMER WILLEM P C;;EMIG ROBIN;;LONGCHAMP PASCAL;;GOLDMAN STANLEY;;GIVER LORRAINE J;;AFFHOLTER JOSEPH A,CODEXIS INC (2024-02-06);;CODEXIS MAYFLOWER HOLDINGS LLC (2010-10-28),https://lens.org/015-358-448-716-906,Granted Patent,yes,100,45,15,15,0,B01J19/0046;;B01J2219/00378;;B01J2219/00585;;B01J2219/00659;;B01J2219/00675;;B01J2219/00689;;B01J2219/00695;;B01J2219/007;;B01J2219/00722;;B82Y30/00;;C12N15/1027;;C12N15/1031;;C40B60/04;;G16B20/00;;Y02A90/10;;G16B20/50;;G16B20/20;;C12N15/1031;;B01J2219/00722;;B01J2219/00378;;B01J2219/00689;;C40B60/04;;B01J2219/00675;;C12N15/1027;;B01J2219/00695;;B82Y30/00;;B01J2219/007;;B01J2219/00585;;B01J19/0046;;B01J2219/00659;;G16B20/00;;Y02A90/10;;G16B20/20;;G16B20/50,G01N33/48;;G01N33/53;;C12M1/00;;C12N15/09;;C12N15/10;;C12Q1/68;;G01N37/00;;G16B20/20;;G16B20/50,702/20,47,42,015-740-103-303-249;;069-081-028-661-451;;052-515-049-615-321;;076-857-393-695-376;;030-682-602-291-829;;041-686-146-430-131;;098-702-433-451-053;;024-369-171-979-227;;144-691-161-287-610;;094-087-374-443-020;;072-689-231-585-62X;;005-534-971-910-727;;017-122-411-657-318;;014-793-548-895-526;;034-553-838-798-25X;;025-834-245-974-873;;084-748-487-156-928;;008-668-626-323-479;;057-988-909-871-766;;049-427-119-219-60X;;049-917-149-198-776;;009-898-247-038-15X;;059-349-671-883-389;;008-006-631-989-07X;;016-467-427-627-620;;072-668-742-851-341;;111-715-011-111-624;;063-099-001-050-447;;040-482-527-661-995;;036-055-058-985-848;;027-719-371-280-548;;029-506-594-475-338;;056-304-474-559-637;;077-476-584-062-720;;023-130-578-604-418;;051-679-383-863-659;;061-754-589-503-35X;;009-992-889-537-648;;070-322-219-790-918;;028-312-552-297-631;;056-304-474-559-637;;028-312-552-297-631,10.1093/nar/25.6.1307;;pmc146579;;9092645;;10429246;;10.1038/11737;;10.1038/7003;;10096293;;11283594;;10.1038/86744;;7692403;;pmc310094;;10.1093/nar/21.18.4410;;7727111;;9630892;;10.1038/nbt0396-315;;8564822;;10.1038/nm0196-100;;9131621;;10.1038/nbt0597-436;;10.1038/34663;;9440693;;10.1006/jmbi.1996.0031;;8568883;;10359711;;10.1016/s1367-5931(99)80044-1;;10.1038/12884;;10471932;;9425664;;10.1016/s0958-1669(97)80127-9;;11283580;;10.1038/86681;;10.1073/pnas.91.22.10747;;7938023;;pmc45099;;10.1038/370389a0;;8047147;;7491501;;10.1126/science.270.5241.1510;;10.1038/nbt0695-549;;pmc20752;;9114019;;10.1073/pnas.94.9.4504;;pmc15083;;10.1073/pnas.96.1.11;;9874762;;10.1038/15095;;10545919;;pmc24609;;9144168;;10.1073/pnas.94.10.4937;;pmc24338;;10.1073/pnas.95.24.14130;;9826665;;10350066;;10.1016/s0014-5793(99)00475-5;;10.1128/jb.145.1.306-320.1981;;6450747;;pmc217274;;10.1016/s0958-1669(98)80042-6;;9821285;;9582111;;10.1126/science.280.5366.1046;;10397261;;10383126;;10388473;;10.1093/clinchem/45.7.982;;8994661;;10.2144/97221rr01;;9325094;;10.1006/jmbi.1997.1252;;9606143;;10.1006/abio.1998.2606;;9344407;;10.1006/abio.1997.2326;;9630890;;10.1038/nbt0396-303;;10.2144/99275rr01;;10572649;;10.1038/nbt0897-789;;9255796;;pmc217167;;6109711;;10.1128/jb.145.2.687-695.1981;;9223302;;10.1073/pnas.94.15.7997;;pmc21544;;9325094;;10.1006/jmbi.1997.1252;;9223302;;10.1073/pnas.94.15.7997;;pmc21544,"Zhao et al., ""Optimization of DNA Shuffling for High Fidelity Recombination,"" Nucleic Acids Research (1997) vol. 25, No. 6, pp. 1307-1308.;;Sun, ""Modeling DNA Shuffling,"" Proceedings of the Second Annual International Conference on Computational Molecular Biology (1998) pp. 251-257.;;Chang, C., et al. (1999) ""Evolution of a cytokine using DNA family shuffling."" Nature Biotechnology 17:793-797.;;Christians, F.C. et al., (1999) ""Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling."" Nature Biotechnology 17:259-264.;;Coco et al., (2001) ""DNA shuffling method for generating highly recombined genes and evolved enzymes"" Nature Biotechnology vol. 19 pp. 354-359.;;Crameri et al., (1993) ""10(20)-Fold aptamer library amplification without gel purification,"" Nuc. Acids Res. 21(18):4410.;;Crameri, A. & Stemmer W.P.C. (1995) ""Combinatorial multiple cassette mutagenesis creates all the permutations of mutant and wildtype cassettes."" Biotechniques 18:194-195.;;Crameri, A, et al. (1996) ""Improved green fluorescent protein by molecular evolution using DNA shuffling."" Nature Biotechnology 14:315-319.;;Crameri, A. et al. (1996) ""Construction and evolution of antibody-phage libraries by DNA shuffling."" Nature Medicine 2:100-103.;;Crameri, A. et al., (1997) ""Molecular evolution of an arsenate detoxification pathway by DNA shuffling."" Nature Biotechnology 15:436-438.;;Crameri, A. et al., (1998) ""DNA shuffling of a family of genes from diverse species accelerates directed evolution."" Nature 391:288-291.;;Gates, C.M. et al., (1996) ""Affinity selective isolation of ligands from peptide libraries through display on a lac repressor headpiece dimer"". Journal of Molecular Biology 255:373-386.;;Minshull, J., Stemmer, W.P.C. (1999) ""Protein evolution by molecular breeding."" Current Opinion in Chemical Biology 3:284-290.;;Ness, J. et al., (1999) ""DNA shuffling of subgenominc sequences of subtilisin."" Nature Biotechnology 17:893-896.;;Patten, P.A. et al., (1997) ""Application of DNA Shuffling to Pharmaceuticals and Vaccines."" Current Opinion in Biotechnology 8:724-733.;;Pelletier, Joelle N., (2001) ""A Rachitt for our toolbox"" Nature Biotechnology vol. 19, p. 314-315.;;Stemmer, W.P.C. (1994) ""DNA Shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution."" PNAS 91:10751.;;Stemmer, W.P.C. (1994) ""Rapid evolution of a protein in vitro by DNA shuffling."" Nature 370:389-391.;;Stemmer, W.P.C. (1995) ""The Evolution of Molecular Computation."" Science 270:1510.;;Stemmer, W.P.C. (1995) ""Searching Sequence Space."" Bio/Technology 13:549-553.;;Stemmer, W.P.C. (1996) ""Sexual PCR and Assembly PCR."" In: The Encyclopedia of Molecular Biology. VCH Publishers, New York. pp. 447-457.;;Stemmer, W.P.C. & Soong, N. W. (1999) ""Molecular breeding of viruses for targeting and other clinical properties."" Tumor Targeting 4:59-62.;;Zhang, J. et al., (1997) ""Directed evolution of an effective fucosidase from a galactosidase by DNA shuffling and screening."" Proceedings of the National Academy of Sciences, USA 94:4504-4509.;;Chou, H.P. et al (1999) ""A Microfabricated Device for Sizing and Sorting DNA Molecules."" Proc. Nat'l Acad. Sci. 96:11-113.;;DeSilva et al. (1998) ""Rapid Genotyping and Quantification on the LightCycler with Hybridization Probes"" Biochimica 2:12-15.;;DeSilva et al. (1998) ""The LightCycler-The Smartest Innovation for More Efficient PCR"" Biochemica 2:4-7.;;Fu, A.Y. et al (1999) ""A Microfabricated Fluorescence-Activated Cell Sorter,"" Nat. Biotechnol. 17:1109-1111.;;Hanes and Pluckthun (1997) ""In vitro Selection and Evolution of Functional Proteins by Using Ribosome Display."" Biochemistry 94:4937-4942.;;Hanes et al. (1988) ""Ribosome Display Efficiently Selects and Evolves High-Affinity Antibodies in vitro from Immune Libraries"" PNAS 95:14130-14135.;;Hanes et al. (1999) ""Comparison of E. Coli and rabbit reticulocyte ribosome display systems"" FEBS Lett. 450(1-2):105-10.;;Hays et al. (1981) ""Recombination of uracil-containing Lambda bacteriophages."" J. Bacteriol. 145(1):306-320.;;Jermutus et al. (1998) ""Recent advances in producing and selecting functional proteins by using cell-free translation"" Curr. Opin. Biotechnol. 9(5):534-48.;;Kopp et al. (1998) ""Chemical Amplification: Continuous flow PCR on a Chip"" Science 280:1046-1047.;;Kreuzer et al. (1999) ""LightCycler technology for the quantitation of bcr/ab1 fusion transcripts"" Cancer Research 59(13):3171-4.;;Laurendeau et al. (1999) ""Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcriptionPCR assay"" Clin Chem 59(12):2759-65.;;Laurendeau et al. (1999) ""TaqMan PCR-based gene dosage asay for predictive testing in individuals from a cancer family with INK4 locus haploinsufficiency"" Clin Chem 45(7):982-6.;;Lindner et al. (1997) ""Specific Detection of His-tagged Proteins with Recombinant anti-His tag scFv-Phosphatase or scFv-phage fusions"" Biotechniques 22(1):140-149.;;Moore et al. (1997) ""Strategies for the in vitro evolution of protein function: enzyme evolution by random recombination of improved sequences"" Journal of Mol. Bio. 3:336-347.;;Muller et al. (1998) ""Tandem Immobilized Metal Ion Affinity Chromatography/Immunoaffinity purification of His-tagged proteins-evaluation of two anti-His-tag monoclonal antibodies"" Anal Biochem. 259(1):54-61.;;Nieba et al. (1997) ""BIACORE analysis of histadine-tagged proteins using a chelating NTA sensor chip."" Anal. Biochem 22(2):217-218.;;Tyagi and Kramer (1996) ""Molecular beacons: probes that fluoresce upon hybridization."" Nat Biotechnol 14, 303-308.;;Unger, M. et al (1999) ""Single Molecule Fluorescence Observed with Mercury Lamp Illumination,"" Biotechniques 27:1008-1013.;;Wang et al. (1997) ""Biocatalytic plastics as active and stable materials for biotransformations"" Nat Biotechnol 2:15(8):789-93.;;Warner et al. (1981) ""Synthesis and Metabolism of uracil-containing deoxyribonucleic acid in Escherichia coli"" J. Bacteriol. 145(2):687-695.;;Zhao et al. (1997) ""Functional and nonfunctional mutations distinguished by random recombination of homologous genes"" Proc. Natl. Acad. Sci. vol. 94:7997-8000.;;Moore, J.C., et al., J. Mol. Biol. (1997) 272:336-347.;;Zhao, H., et al., PNAS(USA) (1997) 94:7997-8000.",EXPIRED
592,WO,A2,WO 2005/059294 A2,160-312-793-557-292,2005-06-30,2005,US 2004/0041563 W,2004-12-10,US 52875103 P,2003-12-11,PIPELINE INTEGRITY MANAGEMENT PROCESS,"A method for reducing the consequences and risks of failure in a hydrocarbon pipeline system includes identifying specific segments of pipelines the leakage of which could have an adverse impact on environment or safety, particularly in areas of high consequence, developing a baseline assessment plan for such segments by analyzing information including age, corrosion, and types of seams and joints and then establishing preventive and migitative measures including, where necessary, positioning emergency flow restricting devices in one or more pipeline segments.",MARATHON ASHLAND PETROLEUM LLC;;TURLEY RICHARD D;;FEIGERT DEBRA S;;STECHSCHULTE DONALD J;;JONES J CHARLES;;JOHNSTON DENNIS C;;HUCKE DENNIS C;;GUINN GEORGE L;;MELAN BRYAN P;;JONES THOMAS A;;SCHMITS NINA M;;CARR DOUGLAS T;;PRICE RAYMOND W;;ROSS STEVEN T;;KENDRICK ANDREW W;;SIEBOLD DAVID E,TURLEY RICHARD D;;FEIGERT DEBRA S;;STECHSCHULTE DONALD J;;JONES J CHARLES;;JOHNSTON DENNIS C;;HUCKE DENNIS C;;GUINN GEORGE L;;MELAN BRYAN P;;JONES THOMAS A;;SCHMITS NINA M;;CARR DOUGLAS T;;PRICE RAYMOND W;;ROSS STEVEN T;;KENDRICK ANDREW W;;SIEBOLD DAVID E,,https://lens.org/160-312-793-557-292,Patent Application,yes,0,2,4,4,0,F17D5/00;;F17D5/00;;F17D5/02;;F17D5/02,E21B/,,0,0,,,,PENDING
593,CA,A1,CA 2727062 A1,055-249-177-079-025,2009-12-17,2009,CA 2727062 A,2009-06-12,GB 0810902 A;;US 6118408 P;;EP 2009057318 W,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES,"The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.",ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENE,,https://lens.org/055-249-177-079-025,Patent Application,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,DISCONTINUED
594,AU,B2,AU 2009/256584 B2,008-739-164-293-206,2014-06-12,2014,AU 2009/256584 A,2009-06-12,US 6118408 P;;GB 0810902 A;;EP 2009057318 W,2008-06-13,Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases,"The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.",ASTEX THERAPEUTICS LTD,FREYNE EDDY JEAN EDGARD;;WOODHEAD ANDREW JAMES;;CARR MARIA GRAZIA;;SAXTY GORDON;;BENNING RAJDEEP KAUR;;WOODHEAD STEVEN JOHN;;MADIN ANDREW;;ANGIBAUD PATRICK RENE;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;VICKERSTAFFE EMMA;;BERDINI VALERIO;;MURRAY CHRISTOPHER WILLIAM;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;GOVAERTS TOM CORNELIS HORTENSE;;GRIFFITHS-JONES CHARLOTTE MARY;;WILLIAMS BRIAN,,https://lens.org/008-739-164-293-206,Granted Patent,no,1,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,ACTIVE
595,CN,A,CN 102137859 A,123-130-358-390-150,2011-07-27,2011,CN 200980122215 A,2009-06-12,EP 2009057318 W;;GB 0810902 A;;US 6118408 P,2008-06-13,Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases,"The present invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.",ASTEX THERAPEUTICS LTD,VALERIO BERDINI;;GRAZIA CARR MARIA;;STUART CONGREVE MILES;;MARTYN FREDERICKSON;;MARY GRIFFITHS-JONES CHARLOTTE;;FREDERICK HAMLETT CHRISTOPHER CHARLES;;ANDREW MADIN;;WILLIAM MURRAY CHRISTOPHER;;KAUR BENNING RAJDEEP;;GORDON SAXTY;;EMMA VICKERSTAFFE;;JAMES WOODHEAD ANDREW;;JOHN WOODHEAD STEVEN;;EDGARD FREYNE EDDY JEAN;;HORTENSE GOVAERTS TOM CORNELIS;;RENE ANGIBAUD PATRICK;;JOHN WILLIAMS BRIAN,,https://lens.org/123-130-358-390-150,Patent Application,no,0,6,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,ACTIVE
596,EP,B1,EP 2300465 B1,104-465-964-417-515,2019-04-17,2019,EP 09761801 A,2009-06-12,EP 2009057318 W;;GB 0810902 A;;US 6118408 P,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENÉ;;WILLIAMS BRIAN JOHN,ASTEX THERAPEUTICS LIMITED (2015-09-30),https://lens.org/104-465-964-417-515,Granted Patent,yes,3,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,ACTIVE
597,AU,A1,AU 2009/256584 A1,039-100-059-160-02X,2009-12-17,2009,AU 2009/256584 A,2009-06-12,US 6118408 P;;GB 0810902 A;;EP 2009057318 W,2008-06-13,Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases,,ASTEX THERAPEUTICS LTD,FREYNE EDDY JEAN EDGARD;;WOODHEAD ANDREW JAMES;;CARR MARIA GRAZIA;;SAXTY GORDON;;BENNING RAJDEEP KAUR;;WOODHEAD STEVEN JOHN;;MADIN ANDREW;;ANGIBAUD PATRICK RENE;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;VICKERSTAFFE EMMA;;BERDINI VALERIO;;MURRAY CHRISTOPHER WILLIAM;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;GOVAERTS TOM CORNELIS HORTENSE;;GRIFFITHS-JONES CHARLOTTE MARY;;WILLIAMS BRIAN JOHN,,https://lens.org/039-100-059-160-02X,Patent Application,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,ACTIVE
598,HR,T1,HR P20191027 T1,164-989-488-817-596,2019-11-29,2019,HR P20191027 T,2019-06-07,GB 0810902 A;;US 6118408 P;;EP 09761801 A;;EP 2009057318 W,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENÉ;;WILLIAMS BRIAN JOHN,,https://lens.org/164-989-488-817-596,Granted Patent,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,ACTIVE
599,US,B2,US 8796244 B2,131-828-212-400-488,2014-08-05,2014,US 99775409 A,2009-06-12,US 99775409 A;;GB 0810902 A;;US 6118408 P;;EP 2009057318 W,2008-06-13,Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases,"The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.",BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENÉ;;WILLIAMS MARIAN;;ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WILLIAMS BRIAN JOHN;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENÉ,JANSSEN-CILAG (2009-09-02);;ASTEX THERAPEUTICS LTD (2009-09-09);;JANSSEN PHARMACEUTICA NV (2009-09-14),https://lens.org/131-828-212-400-488,Granted Patent,yes,99,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,A61K31/5025;;C07D413/02,514/127;;514/300;;544/144,41,23,020-435-634-003-86X;;049-005-881-813-07X;;109-819-869-147-841;;025-847-893-539-32X;;001-971-631-845-447;;048-606-470-549-224;;074-920-428-711-062;;111-588-566-784-17X;;066-624-719-841-936;;082-434-261-136-233;;064-765-456-762-289;;031-899-328-341-646;;018-567-451-052-506;;090-652-750-938-494;;010-445-137-845-210;;001-516-175-552-397;;035-613-305-055-523;;066-664-903-143-931;;007-364-858-655-289;;000-820-736-344-337;;050-476-538-810-273;;023-929-221-295-808;;007-042-809-826-481,10.1016/j.addr.2003.10.020;;14962582;;10.1023/b:jtan.0000032284.89029.06;;12852948;;10.1016/s0960-894x(03)00485-2;;17189692;;10.1016/j.bmcl.2006.12.018;;10.1016/b978-012744481-9/50017-9;;10.1016/s0960-894x(02)00525-5;;12217372;;10.1016/j.bmcl.2003.12.007;;15012992;;10.1002/chin.200312150;;10.1046/j.1471-4159.2000.0751520.x;;10987832;;9774334;;10.1093/emboj/17.20.5896;;pmc1170917;;10.1016/s0960-894x(97)00445-9;;10.1021/jm970367n;;9240345;;10.1016/j.ejmech.2007.02.006;;17433505;;12941325;;10.1016/s0960-894x(03)00638-3;;9139660;;10.1126/science.276.5314.955;;10.1016/s0169-409x(01)00097-7;;11325474;;10.1038/nrc2403;;18596824;;10.1021/jm9804681;;9876115;;10.1002/jps.2600660104;;833720;;10.1080/00397917709409270;;10.1016/0076-6879(87)52071-7;;3657592;;12657164;;10.1186/1471-2407-3-3;;pmc152639;;10.1002/(sici)1097-0215(19990420)84:2<101::aid-ijc2>3.0.co;2-5;;10096239,"Morissette et al., High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids, Advanced Drug Delivery Reviews 2004, 56, 275-300.;;Hamdi et al., Solvates of indomethacin. Journal of Thermal Analysis and Calorimetry 2004, 76, 985-1001.;;West, Anthony R., Solid state chemistry and its applications, Department of Chemistry, University of Aberdeen, 1988, pp. 358 and 365.;;Search Report for GB0625827.1 dated Apr. 25, 2007.;;Search Report for GB0719998.7 dated Nov. 12, 2007.;;Search Report for PCT/GB2007/004960 dated Sep. 22, 2008.;;Search Report for GB0625826.3 dated Apr. 25, 2007.;;Search Report for GB0720000.9 dated Nov. 12, 2007.;;Search Report for PCT/GB2007/004934 dated May 6, 2008.;;Search Report for GB0810902.7 dated Sep. 17, 2008.;;Search Report for PCT/EP2009/057318 dated Oct. 12, 2009.;;Search Report for GB0720038.9 dated Apr. 17, 2008.;;Search Report for PCT/GB2008/003439 dated Jan. 29, 2009.;;Search Report for GB0720041.3 dated Apr. 17, 2008.;;Search Report for PCT/GB2008/003418 dated Jan. 29, 2009.;;Search Report for GB0906472.6 dated Jul. 7, 2009.;;Search Report for PCT/GB2010/050617 dated Jul. 20, 2010.;;Search Report for GB0906470.0 dated Jul. 8, 2009.;;Search Report for PCT/GB2010/050618 dated Jul. 23, 2010.;;Bilodeau, Mark T. et al., Design and Synthesis of 1,5-Dairylbenzimidazoles as Inhibitors of the VEGF-Receptor KDR, Bioorganic & Medicinal Chemistry Letters 13, 2003, pp. 2485-2488.;;Clark, Michael P. et al., Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3), Bioorganic & Medicinal Chemistry Letters 17 (5), 2007, pp. 1250-1253.;;Wermuth, Camille G., Molecular Variations Based on Isosteric Replacements, The Practice of Medicinal Chemistry, 1996, pp. 203-237.;;Fraley, Mark E. et al., Synthesis and Initial SAR Studies of 3,6-Disubstituted Pyrazolo[1,5-alpha]pyrimidines: A New Class of KDR Kinase Inhibitors, Bioorganic & Medicinal Chemistry Letters 12, 2002, pp. 2767-2770.;;Wu, Zhicai et al., Design and Synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR, Bioorganic & Medicinal Chemistry Letters 14, 2004, pp. 909-912.;;Fraley, Mark E. et al., Optimization of a Pyrazolo[1,5-alpha]pyrimidine Class of KDR Kinase Inhibitors: Improvements in Physical Properties Enhance Cellular Activity and Pharmacokinetics, Bioorganic & Medicinal Chemistry Letters 12, 2002, pp. 3537-3541.;;Skaper, Stephen D. et al., The FGFR1 Inhibitor PD 173074 Selectively and Potently Antagonizes FGF-2 Neurotrophic and Neurotropic Effects, Journal of Neurochemistry, 2000, pp. 1520-1527.;;Mohammadi, Moosa et al., Crystal structure of an angiogenesis inhibitor bound to the FGR receptor tyrosine kinase domain, The EMBO Journal, vol. 17, No. 20, 1998, pp. 5896-5904.;;Connolly, Cleo J.C. et al., Discovery and Structure-Activity Studies of a Novel Series of Pyrido[2,3-d]Pyrimidine Tyrosine Kinase Inhibitors, Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 18, 1997, pp. 2415-2420.;;Hamby, James M. et al., Structure-Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors, J. Med. Chem, 40, 1997, pp. 2296-2303.;;Scribner, Andrew et al., Synthesis and biological activity of imidazopyridine anticoccidial agents: Part I, European Journal of Medicinal Chemistry 42, 2007, pp. 1334-1357.;;Anderson, Malcolm et al., Imidazo[1,2-alpha]pyridines: A Potent and Selective Class of Cyclin-Dependent Kinase Inhibitors Identified Through Structure-Based Hybridisation, Bioorganic & Medicinal Chemistry Letters 13, 2003, pp. 3021-3026.;;Mohammadi, Moosa et al., Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors, Science, 276, 1997, pp. 955-960.;;Dorwald, F. Zaragoza, Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.;;Vippagunta, Sudha R., et al., Crystalline solids, Advanced Drug Delivery Reviews 48, 2001, pp. 3-26.;;Ellis, Lee M. et al., ""VEGF-Targeted Therapy: Mechanisms of Anti-Tumour Activity"" Nature Reviews/Cancer, Aug. 2008, vol. 8, pp. 579-591.;;Palmer, Brian D., et al.""Structure-Activity Relationships for 1-Phenylbenzimidazoles as Selective ATP Site Inhibitors of the Platelet-Derived Growth Factor Receptor"" Journal of Medicinal Chemistry, 1998, 41 (27), pp. 5457-5465.;;Berge, Stephen M. et al. ""Pharmaceutical Salts"", Journal of Pharmaceutical Sciences, vol. 66, No. 1, 1977, pp. 1-19.;;Deady, Leslie W. ""Ring Nitrogen Oxidation of Amino Substituted Nitrogen Heterocycles with m-Chloroperbenzoic Acid"", Synthetic Communications, vol. 7(8), 1977, pp. 509-514.;;Angerer, Lynne M. et al. ""Demonstration of Tissue-Specific Gene Expression by in Situ Hybridization"", Methods in Enzymology; vol. 152, 1987, pp. 649-661.;;Deprimo, Samuel E, et al. ""Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification"", BMC Cancer, vol. 3, 2003; pp. 1-12.;;Orre, Maxine and Rogers, Peter A.W. ""VEGF, VEGFR-1, VEGFR-2, Microvessel Density and Endothelial Cell Proliferation in Tumours of the Ovary"", Int. J. Cancer (Prod. Oncol.), vol. 84(2), 1999, pp. 101-108.",ACTIVE
600,BR,B8,BR PI0915084 B8,011-356-132-911-575,2021-05-25,2021,BR PI0915084 A,2009-06-12,EP 2009057318 W;;GB 0810902 A;;US 6118408 P,2008-06-13,"composto, e, composição farmacêutica","composto, composição farmacêutica, e, uso de um composto a invenção refere-se a novos compostos de derivados heterocíclicos bicíclicos, a composições farmacêuticas compreendendo referidos compostos e ao uso de referidos compostos no tratamento de doenças, p. ex.câncer.",ASTEX THERAPEUTICS LTD,GORDON SAXTY;;ANDREW JAMES WOODHEAD;;ANDREW MADIN;;BRIAN JOHN WILLIAMS;;CHARLOTTE MARY GRIFFITHS-JONES;;CHRISTOPHER CHARLES FREDERICK HAMLETT;;CHRISTOPHER WILLIAM MURRAY;;EMMA VICKER-STAFFE;;EDDY JEAN EDGARD FREYNE;;MARIA GRAZIA CARR;;MARTYN FREDERICKSON;;MILES STUART CONGREVE;;PATRICK RENÉ ANGIBAUD;;RAJDEEP KAUR BENNING;;STEVEN JOHN WOODHEAD;;TOM CORNELIS HORTENSE GOVAERTS;;VALERIO BERDINI,,https://lens.org/011-356-132-911-575,Amended Patent,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,A61K31/53;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61P35/00;;C07D471/04;;C07D513/04,,0,0,,,,ACTIVE
601,KR,A,KR 20110017000 A,131-194-106-640-099,2011-02-18,2011,KR 20117000791 A,2009-06-12,GB 0810902 A;;US 6118408 P;;EP 2009057318 W,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENE;;WILLIAMS BRIAN JOHN,,https://lens.org/131-194-106-640-099,Patent Application,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61P35/00,,0,0,,,,ACTIVE
602,EP,A1,EP 2300465 A1,103-854-076-072-734,2011-03-30,2011,EP 09761801 A,2009-06-12,EP 2009057318 W;;GB 0810902 A;;US 6118408 P,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENE;;WILLIAMS BRIAN JOHN,ASTEX THERAPEUTICS LIMITED (2015-09-30),https://lens.org/103-854-076-072-734,Patent Application,yes,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,ACTIVE
603,WO,A1,WO 2009/150240 A1,170-507-159-544-403,2009-12-17,2009,EP 2009057318 W,2009-06-12,GB 0810902 A;;US 6118408 P,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES,"The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.",ASTEX THERAPEUTICS LTD;;BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENE,BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENE;;WILLIAMS BRIAN JOHN,,https://lens.org/170-507-159-544-403,Patent Application,yes,3,64,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,A61K31/437;;C07D471/04;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,PENDING
604,CN,B,CN 102137859 B,083-523-642-077-020,2015-07-01,2015,CN 200980122215 A,2009-06-12,EP 2009057318 W;;GB 0810902 A;;US 6118408 P,2008-06-13,Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENE;;WILLIAMS BRIAN JOHN,,https://lens.org/083-523-642-077-020,Granted Patent,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,ACTIVE
605,ZA,B,ZA 201008961 B,124-666-787-289-60X,2015-05-27,2015,ZA 201008961 A,2010-12-13,GB 0810902 A;;US 6118408 P;;EP 2009057318 W,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES,,ASTEX THERAPEUTICS LTD,WILLIAMS BRIAN JOHN;;BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENE,,https://lens.org/124-666-787-289-60X,Granted Patent,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,A61K/;;C07D/;;A61P/,,0,0,,,,ACTIVE
606,MX,A,MX 2010013743 A,147-854-489-884-526,2011-02-15,2011,MX 2010013743 A,2009-06-12,US 6118408 P;;GB 0810902 A;;EP 2009057318 W,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES.,"The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.",ASTEX THERAPEUTICS LTD,ANGIABAUD PATRICK RENE;;FREYNE EDDY JEAN EDGARD;;CONGREVE MILES STUART;;BERDINI VALERIO;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;CARR MARIA GRAZIA;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;SAXTY GORDON;;VICKERSTAFFE EMMA;;GRIFFITHS-JONES CHARLOTTE MARY;;FREDERICKSON MARTYN;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;BENNING RAJDEEP KAUR;;GOVAERTS TOM CORNELIS HORTENSE;;WILLIAMS BRIAN JOHN,,https://lens.org/147-854-489-884-526,Patent Application,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,ACTIVE
607,NZ,A,NZ 589781 A,037-957-442-486-428,2013-02-22,2013,NZ 58978109 A,2009-06-12,US 6118408 P;;GB 0810902 A;;EP 2009057318 W,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES,"589781 Disclosed herein are imidazo[1,2-a]pyridinyl containing urea compounds and the use thereof in the treatment of a disease mediated by FGFR kinase, such as cancer. Exemplary compounds include: 1-(3-{ 7-[5-(tetrahydrofuran-2-yl)-[1,3,4]thiadiazol-2-yl]imidazo[1,2-a]pyridin-3-yl} -phenyl)-3-(2,2,2-trifluoroethyl)urea, 1-[3-(7-pyridazin-3-ylimidazo[1,2-a]pyridin-3-yl)phenyl]-3-(2,2,2-trifluoroethyl)urea hydrochloride, N-methyl-2-[4-(3-{ 3-[3-(2,2,2-trifluoro-ethyl)-ureido]-phenyl} -imidazo[1,2-a]pyridin-7-yl)-pyrazol-1-yl]-isobutyramide, and 1-ethyl-3-{ 3-[7-(5-fluoro-6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyridin-3-yl]-phenyl} -urea.",ASTEX THERAPEUTICS LTD,WILLIAMS BRIAN JOHN;;BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENE,,https://lens.org/037-957-442-486-428,Patent Application,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,PENDING
608,BR,B1,BR PI0915084 B1,107-685-055-473-054,2020-02-11,2020,BR PI0915084 A,2009-06-12,EP 2009057318 W;;GB 0810902 A;;US 6118408 P,2008-06-13,"composto, e, composição farmacêutica","composto, e, composição farmacêutica a invenção refere-se a novos compostos de derivados heterocíclicos bicíclicos, a composições farmacêuticas compreendendo referidos compostos e ao uso de referidos compostos 5 no tratamento de doenças, p. ex. câncer.",ASTEX THERAPEUTICS LTD,ANDREW JAMES WOODHEAD;;ANDREW MADIN;;BRIAN JOHN WILLIAMS;;CHARLOTTE MARY GRIFFITHS - JONES;;CHRISTOPHER CHARLES FREDERICK HAMLETT;;CHRISTOPHER WILLIAM MURRAY;;EMMA VICKER - STAFFE;;EDDY JEAN EDGARD FREYNE;;GORDON SAXTY;;MARIA GRAZIA CARR;;MARTYN FREDERICKSON;;MILES STUART CONGREVE;;PATRICK RENÉ ANGIBAUD;;RAJDEEP KAUR BENNING;;STEVEN JOHN WOODHEAD;;TOM CORNELIS HORTENSE GOVAERTS;;VALERIO BERDINI,,https://lens.org/107-685-055-473-054,Granted Patent,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,A61K31/53;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61P35/00;;C07D471/04;;C07D513/04,,0,0,,,,ACTIVE
609,SI,T1,SI 2300465 T1,134-482-481-227-752,2019-08-30,2019,SI 200931974 T,2009-06-12,GB 0810902 A;;US 6118408 P;;EP 2009057318 W;;EP 09761801 A,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENE;;WILLIAMS BRIAN JOHN,,https://lens.org/134-482-481-227-752,Granted Patent,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/00;;A61K31/00;;A61P35/00;;C07D513/00,,0,0,,,,ACTIVE
610,BR,A2,BR PI0915084 A2,068-027-815-139-255,2015-10-27,2015,BR PI0915084 A,2009-06-12,EP 2009057318 W;;GB 0810902 A;;US 6118408 P,2008-06-13,"composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer",,ASTEX THERAPEUTICS LTD,WOODHEAD ANDREW JAMES;;MADIN ANDREW;;BRIAN JOHN WILLIAMS;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MURRAY CHRISTOPHER WILLIAM;;FREYNE EDDY JEAN EDGARD;;VICKER-STAFFE EMMA;;SAXTY GORDON;;CARR MARIA GRAZIA;;FREDERICKSON MARTYN;;CONGREVE MILES STUART;;ANGIBAUD PATRICK RENÉ;;BENNING RAJDEEP KAUR;;WOODHEAD STEVEN JOHN;;GOVAERTS TOM CORNELIS HORTENSE;;BERDINI VALERIO,,https://lens.org/068-027-815-139-255,Patent Application,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,A61K31/53;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61P35/00;;C07D471/04;;C07D513/04,,0,0,,,,ACTIVE
611,DK,T3,DK 2300465 T3,175-483-696-457-67X,2019-06-24,2019,DK 09761801 T,2009-06-12,GB 0810902 A;;US 6118408 P;;EP 2009057318 W,2008-06-13,IMIDAZOPYRIDINDERIVATER SOM HÆMMERE AF RECEPTORTYROSINKINASER,,ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WOODHEAD ANDREW JAMES;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENÉ;;MADIN ANDREW;;WOODHEAD STEVEN JOHN;;WILLIAMS BRIAN JOHN,,https://lens.org/175-483-696-457-67X,Granted Patent,no,0,0,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,C07D471/04;;A61K31/437;;A61K31/444;;A61K31/4545;;A61K31/496;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/53;;A61P35/00;;C07D513/04,,0,0,,,,ACTIVE
612,US,A1,US 2012/0208791 A1,181-677-754-025-692,2012-08-16,2012,US 99775409 A,2009-06-12,US 99775409 A;;GB 0810902 A;;US 6118408 P;;EP 2009057318 W,2008-06-13,IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES,"The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.",BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WILLIAMS BRIAN JOHN;;WILLIAMS MARIAN;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENE;;ASTEX THERAPEUTICS LTD,BERDINI VALERIO;;CARR MARIA GRAZIA;;CONGREVE MILES STUART;;FREDERICKSON MARTYN;;GRIFFITHS-JONES CHARLOTTE MARY;;HAMLETT CHRISTOPHER CHARLES FREDERICK;;MADIN ANDREW;;MURRAY CHRISTOPHER WILLIAM;;BENNING RAJDEEP KAUR;;SAXTY GORDON;;VICKERSTAFFE EMMA;;WILLIAMS BRIAN JOHN;;WILLIAMS MARIAN;;WOODHEAD ANDREW JAMES;;WOODHEAD STEVEN JOHN;;FREYNE EDDY JEAN EDGARD;;GOVAERTS TOM CORNELIS HORTENSE;;ANGIBAUD PATRICK RENE,JANSSEN-CILAG (2009-09-02);;ASTEX THERAPEUTICS LTD (2009-09-09);;JANSSEN PHARMACEUTICA NV (2009-09-14),https://lens.org/181-677-754-025-692,Patent Application,yes,0,3,31,31,0,C07D471/04;;C07D513/04;;A61P35/00;;A61P43/00;;C07D471/04;;A61K31/437;;C07D471/04;;C07D513/04,A61K31/437;;A61K31/501;;A61K31/506;;A61K31/53;;A61K31/5377;;A61P35/00;;C07D471/04;;C07D513/04,514/210.18;;546/121;;514/300;;544/238;;514/252.04;;514/252.02;;544/114;;514/233.2;;544/255;;544/333;;514/210.21;;544/182;;514/242;;514/252.18;;544/122;;544/127;;514/256,2,2,020-435-634-003-86X;;049-005-881-813-07X,10.1016/j.addr.2003.10.020;;14962582;;10.1023/b:jtan.0000032284.89029.06,"Morissette et al., High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids, Advanced Drug Delivery Reviews 2004, 56, 275-300;;Hamdi et al., Solvates of indomethacin. Journal of Thermal Analysis and Calorimetry 2004, 76, 985-1001",ACTIVE
